[
{
    "pk": 1, 
    "model": "er.evidencereview", 
    "fields": {
        "content": "<h1 id=\"erh-1f63a7a2-7eb8-4c7d-b68f-e742b0c448fe\">Introduction</h1>\n<p id=\"erb-0e4b22a6-6ce8-45c1-a953-f16b5fb462b0\">The revolutionary discovery of a striking, if temporary, effect that targeted inhibition of BRAF has on the clinical course of metastatic melanoma has spiked a new wave of research into molecular targets. In addition, it has raised a number of new questions: what are the mechanisms of both inherent and acquired resistance to BRAF inhibitors and the possible ways to overcome this resistance; how is the activating effect of BRAF inhibition on the MAPK pathway in cells with nonmutated BRAF avoided; how should melanoma tumors that have no activating mutations in BRAF, such as tumors with mutated NRAS or NF1, or tumors that are wild type for both BRAF and NRAS, be targeted; which targeted or nontargeted drug combinations should be pursued as determined by the molecular profile of each and every tumor; what is the future of combination targeted therapy and immunotherapy; and many more.</p>\n<p id=\"erb-c6bef2b1-4f42-42be-bb2b-490911acef68\">The mutational landscape of melanoma was examined in several large studies employing NGS (next-generation sequencing) and large-scale expression analyses of tumors. The mutation rate of melanoma, on average, exceeds those reported for other aggressive tumors, probably due to the involvement of ultraviolet (UV) radiation in the genesis of superficial cutaneous melanomas. Indeed, the rate of transversions characteristic of UV-induced lesions is much higher in melanoma than the rates of other nucleotide substitutions. The high rate of mutations in melanoma makes it particularly difficult to distinguish between causative (\"driver\") mutations and bystander (\"passenger\") mutations.</p>\n<p id=\"erb-3e5ffdfd-f72b-495e-adb4-21bdb0370ec5\">In one recent study <a class=\"rlc-reference\" data-ref-info=\"Berger MF, Hodis E, Heffernan TP, et al: Melanoma genome sequencing reveals frequent PREX2 mutations. Nature 485:502-6, 2012.\" href=\"#_ENREF_1\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22622578\"><sup>1</sup></a>, a wide range of point-mutation rates was observed: they were lowest in melanomas in which primaries arose on non-UV-exposed hairless skin of the extremities (3 and 14 mutations/megabase [Mb] of genome); intermediate in those originating from hair-bearing skin of the trunk (5-55 mutations/Mb); and highest in a patient with a documented history of chronic sun exposure (111 mutations/Mb). Uveal melanomas, tumors with generally poor prognosis, nevertheless have a fairly low mutation rate <a class=\"rlc-reference\" data-ref-info=\"Furney SJ, Pedersen M, Gentien D, et al: SF3B1 mutations are associated with alternative splicing in uveal melanoma. Cancer Discov, 2013.\" href=\"#_ENREF_2\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23861464\"><sup>2</sup></a>. Interestingly, melanomas that are wild type for both BRAF and NRAS have almost five times higher mutational loads than tumors where one of these oncogenes is mutated <a class=\"rlc-reference\" data-ref-info=\"Mar VJ, Wong SQ, Li J, et al: BRAF/NRAS wild-type melanomas have a high mutation load correlating with histological and molecular signatures of UV damage. Clin Cancer Res, 2013.\" href=\"#_ENREF_3\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23833303\"><sup>3</sup></a>.</p>\n<p id=\"erb-f0cbea73-6ed6-4eb6-ad22-4456396e14ef\">The different types of melanoma appear to have distinct sets of relevant somatogenic alterations (Tables <a href=\"#Table1\">1</a> and <a href=\"#Table2\">2</a>). Some of the difference could be attributed to the lack of UV involvement in pathogenesis of acral and mucosal melanomas. Uveal melanoma was recognized as distinct tumor for a long time, and it is reflected in predominance of driver mutations in G protein subunits rather then BRAF or NRAS mutations. Mutational analyses of mucosal melanoma concluded that this subtype shares with cutaneous melanoma relatively few mutations in specific genes, suggesting different mechanisms of carcinogenesis <a class=\"rlc-reference\" data-ref-info=\"Furney SJ, Turajlic S, Stamp G, et al: Genome sequencing of mucosal melanomas reveals that they are driven by distinct mechanisms from cutaneous melanoma. J Pathol 230:261-9, 2013.\" href=\"#_ENREF_4\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23620124\"><sup>4</sup></a>. The rare conjuctival melanoma apparently has a mutational landscape similar to cutaneous melanoma <a class=\"rlc-reference\" data-ref-info=\"Griewank KG, Westekemper H, Murali R, et al: Conjunctival Melanomas Harbor BRAF and NRAS Mutations and Copy Number Changes Similar to Cutaneous and Mucosal Melanomas. Clin Cancer Res 19:3143-3152, 2013.\" href=\"#_ENREF_5\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23633454\"><sup>5</sup></a>, pending confirmation from an analysis of a larger number of tumors.</p>\n<p id=\"erb-f2f9cfb7-2384-4a85-9340-8fc891271a64\">This paper describes genetic alterations that are known to occur in melanoma and information about their role in melanomagenesis, as well as their suitability as targets for therapeutic intervention. The latest information on molecular events underlying inherent or acquired resistance to targeted therapies is also included, along with immunotherapeutic approaches and prognostic methodologies.</p>\n<p id=\"erb-3821d319-941d-4af8-9899-e66726b4046a\">Multiple cellular pathways have been implicated in melanomagenesis, ranging from signal transduction to developmental and transcriptional pathways and cell cycle deregulation (<a href=\"#Table1\">Table 1</a>). The search for driver mutations in melanoma continues, with the previously identified subtypes involving BRAF, NRAS, KIT, GNAQ, and GNA11 expanded recently to include NF1 and telomerase<!-- MD  suggests including RAC\r\n --> (<a href=\"#Table2\">Table 2</a>). Together, these driver mutations are very likely to define the vast majority of molecular subtypes in melanoma and, eventually, the identified mutations in drivers will guide targeted therapy choices. However, for a number of reasons, such as oncogene-induced senescence (discussed below), driver mutations result in a frank tumorigenic phenotype only in the presence of \"supporting mutations\" that are also listed in Table 2 and described below. It is likely that these supporting mutations have to be targeted along with driver mutations to achieve durable responses. Finally, immunotherapies continue to play an important role in melanoma treatment strategies and are also described here.</p>\n<h3><a name=\"Table1\"></a>Table 1. Pathways Involved In Melanomagenesis</h3>\n<table border=\"1\" cellpadding=\"7\" cellspacing=\"0\" id=\"erb-02709731-4df3-4436-ad37-619c5cf5c169\" width=\"643\">\n<colgroup>\n<col width=\"191\"></col>\n<col width=\"154\"></col>\n<col width=\"256\"></col>\n</colgroup>\n<tbody>\n<tr valign=\"TOP\">\n<td height=\"23\" width=\"191\">\n<p><b>PATHWAY*</b></p>\n</td>\n<td width=\"154\">\n<p><b>COMPONENTS MUTATED/ACTIVATED</b></p>\n</td>\n<td width=\"256\">\n<p><b>TYPE OF ALTERATION</b></p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td rowspan=\"5\" width=\"191\">\n<p>\u00a0</p>\n<p>\u00a0</p>\n<p>Receptor tyrosine kinases</p>\n<p>\u00a0</p>\n</td>\n<td width=\"154\">\n<p>KIT</p>\n</td>\n<td width=\"256\">\n<p>Mutation/amplification</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"154\">\n<p>EGFR</p>\n</td>\n<td width=\"256\">\n<p>Activation</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"154\">\n<p>MET</p>\n</td>\n<td width=\"256\">\n<p>Activation; high level of ligand in stroma</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"154\">\n<p>ERBB4</p>\n</td>\n<td width=\"256\">\n<p>Mutation</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"154\">\n<p>FGFR</p>\n</td>\n<td width=\"256\">\n<p>Activation; high levels of ligands</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"191\">\n<p>Integrin adaptors/ECM signaling</p>\n</td>\n<td width=\"154\">\n<p>NEDD9/HEF</p>\n</td>\n<td width=\"256\">\n<p>Amplification</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td rowspan=\"3\" width=\"191\">\n<p>\u00a0</p>\n<p>RAS/RAF/MEK/ERK</p>\n</td>\n<td width=\"154\">\n<p>NRAS</p>\n</td>\n<td width=\"256\">\n<p>Mutation</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"154\">\n<p>BRAF</p>\n</td>\n<td width=\"256\">\n<p>Mutation</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"154\">\n<p>MEK1</p>\n</td>\n<td width=\"256\">\n<p>Mutation</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td rowspan=\"4\" width=\"191\">\n<p>\u00a0</p>\n<p>RAS/PI3K/PTEN/AKT/mTOR</p>\n</td>\n<td width=\"154\">\n<p>PIK3CA</p>\n</td>\n<td width=\"256\">\n<p>Mutation</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"154\">\n<p>PTEN</p>\n</td>\n<td width=\"256\">\n<p>Mutation</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"154\">\n<p>AKT1, AKT2</p>\n</td>\n<td width=\"256\">\n<p>Rare mutation</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"154\">\n<p>AKT3</p>\n</td>\n<td width=\"256\">\n<p>Amplification</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"191\">\n<p>NF1 (PI3K + MAPK pathways)</p>\n</td>\n<td width=\"154\">\n<p>NF1</p>\n</td>\n<td width=\"256\">\n<p>Mutation</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td rowspan=\"3\" width=\"191\">\n<p>\u00a0</p>\n<p>RHO/RAC/other MAPKs</p>\n</td>\n<td width=\"154\">\n<p>RAC</p>\n</td>\n<td width=\"256\">\n<p>Mutation</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"154\">\n<p>MAP3K5 &amp; MAP3K9</p>\n</td>\n<td width=\"256\">\n<p>Mutation</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"154\">\n<p>PREX</p>\n</td>\n<td width=\"256\">\n<p>Mutation</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td rowspan=\"2\" width=\"191\">\n<p>Glutamate receptors</p>\n</td>\n<td width=\"154\">\n<p>GRIN2A</p>\n</td>\n<td width=\"256\">\n<p>Mutation</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"154\">\n<p>GRM3</p>\n</td>\n<td width=\"256\">\n<p>Mutation</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td rowspan=\"2\" width=\"191\">\n<p>G proteins other than RAS, effectors of MAPK</p>\n</td>\n<td width=\"154\">\n<p>GNAQ</p>\n</td>\n<td width=\"256\">\n<p>Mutation</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"154\">\n<p>GNA11</p>\n</td>\n<td width=\"256\">\n<p>Mutation</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"191\">\n<p>Apoptosis</p>\n</td>\n<td width=\"154\">\n<p>BCL2A1</p>\n</td>\n<td width=\"256\">\n<p>Amplification</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"191\">\n<p>WNT/\uf062-catenin</p>\n</td>\n<td width=\"154\">\n<p>CTNNB1</p>\n</td>\n<td width=\"256\">\n<p>Mutation</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td rowspan=\"2\" width=\"191\">\n<p>CDK</p>\n</td>\n<td width=\"154\">\n<p>CDK4</p>\n</td>\n<td width=\"256\">\n<p>Mutation/amplification</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"154\">\n<p>CCND1</p>\n</td>\n<td width=\"256\">\n<p>Amplification</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td rowspan=\"2\" width=\"191\">\n<p>P53</p>\n</td>\n<td width=\"154\">\n<p>P14ARF (CDKN2A)</p>\n</td>\n<td width=\"256\">\n<p>Mutation/deletion</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"154\">\n<p>MDM4</p>\n</td>\n<td width=\"256\">\n<p>Amplification</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"191\">\n<p>RB1</p>\n</td>\n<td width=\"154\">\n<p>P116INK4A (CDKN2A)</p>\n</td>\n<td width=\"256\">\n<p>Mutation/deletion</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"191\">\n<p>MITF transcriptional program</p>\n</td>\n<td width=\"154\">\n<p>MITF</p>\n</td>\n<td width=\"256\">\n<p>Mutation/amplification</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"191\">\n<p>MYC transcriptional program</p>\n</td>\n<td width=\"154\">\n<p>MYC</p>\n</td>\n<td width=\"256\">\n<p>Amplification/overexpression</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"191\">\n<p>ETV1 transcriptional program</p>\n</td>\n<td width=\"154\">\n<p>ETV1</p>\n</td>\n<td width=\"256\">\n<p>Amplification</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"191\">\n<p>TERT</p>\n</td>\n<td width=\"154\">\n<p>Promoter region of catalytic subunit</p>\n</td>\n<td width=\"256\">\n<p>Mutation</p>\n</td>\n</tr>\n<tr>\n<td colspan=\"3\" valign=\"TOP\" width=\"629\">\n<p>* <i>The order of pathways in this Table has no relationship to their significance in melanoma; it is simply from the cell periphery to the nucleus.</i></p>\n<p>\u00a0</p>\n</td>\n</tr>\n</tbody>\n</table>\n<h1 id=\"erh-2869d8e5-6721-401b-81b8-f35a96487ad7\">Molecular subtypes</h1>\n<p id=\"erb-0d16e5de-d11d-486d-a28a-98572f1ecb2c\"><a href=\"#Table1\">Table 1</a> summarizes the molecular pathways involved in melanomagenesis, and <a href=\"#Table2\">Table 2</a> lists the known driver and additional mutations/alterations.</p>\n<h3><a name=\"Table2\"></a>Table\u00a02. Genes Known To Be Altered in Melanoma</h3>\n<table border=\"1\" cellpadding=\"7\" cellspacing=\"0\" id=\"erb-5b68f1b2-a05f-4d0f-83a5-8b4ae9a45126\" width=\"696\">\n<colgroup>\n<col width=\"106\"></col>\n<col width=\"120\"></col>\n<col width=\"104\"></col>\n<col width=\"98\"></col>\n<col width=\"84\"></col>\n<col width=\"100\"></col>\n</colgroup>\n<tbody>\n<tr valign=\"TOP\">\n<td height=\"15\" width=\"106\">\n<p><b>PRIMARY SUBTYPES</b></p>\n</td>\n<td width=\"120\">\n<p><b>PATHWAY </b></p>\n</td>\n<td width=\"104\">\n<p><b>ABERRATION</b></p>\n</td>\n<td width=\"98\">\n<p><b>FOUND IN TUMORS WITH\u2026</b></p>\n</td>\n<td width=\"84\">\n<p><b>FREQUENCY</b></p>\n</td>\n<td width=\"100\">\n<p><b>POSSIBLE THERAPIES</b></p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"106\">\n<p><a href=\"#BRAF\"><b>BRAF</b></a><a href=\"#BRAF\"><!-- Let's find out from Brian if jump links in text are possible - best to link to the sections below, from mention in table\r\n --></a></p>\n</td>\n<td width=\"120\">\n<p>MAPK</p>\n</td>\n<td width=\"104\">\n<p>Point mutation</p>\n</td>\n<td width=\"98\">\n<p>NRAS wild type</p>\n</td>\n<td width=\"84\">\n<p>50-60%</p>\n</td>\n<td width=\"100\">\n<p>BRAFi + MEKi</p>\n<p>BRAFi + EGFRi + AKTi</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"106\">\n<p><a href=\"#NRAS\"><b>NRAS</b></a></p>\n</td>\n<td width=\"120\">\n<p>MAPK, PI3K, RALGDS</p>\n</td>\n<td width=\"104\">\n<p>\u00a0</p>\n</td>\n<td width=\"98\">\n<p>BRAF wild type</p>\n</td>\n<td width=\"84\">\n<p>20-25%</p>\n</td>\n<td width=\"100\">\n<p>HMGCRi + CDKi</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td height=\"20\" width=\"106\">\n<p><a href=\"#KIT\"><b>KIT</b></a></p>\n</td>\n<td width=\"120\">\n<p>MAPK, PI3K</p>\n</td>\n<td width=\"104\">\n<p>Point mutation, amplification</p>\n</td>\n<td width=\"98\">\n<p>NRAS BRAF wild type mostly</p>\n</td>\n<td width=\"84\">\n<p>1% overall; 10% in in mucosal; 10% in acral</p>\n</td>\n<td width=\"100\">\n<p>Sunitinib, nilotinib, imatinib</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"106\">\n<p><a href=\"#GNAQ\"><b>GNAQ/GNA11</b></a></p>\n</td>\n<td width=\"120\">\n<p>G\u03b1(q) family of G protein \u03b1 subunits; MAPK activators</p>\n</td>\n<td width=\"104\">\n<p>Point mutation</p>\n</td>\n<td width=\"98\">\n<p>NRAS BRAF wild type</p>\n</td>\n<td width=\"84\">\n<p>1%; 40-50% each in uveal</p>\n</td>\n<td width=\"100\">\n<p>MEKi + PI3Ki, enzastaurin</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"106\">\n<p><b><a href=\"#MITF\">MITF</a>*</b></p>\n</td>\n<td width=\"120\">\n<p>Transcription, lineage, cell cycle</p>\n</td>\n<td width=\"104\">\n<p>Amplification</p>\n</td>\n<td width=\"98\">\n<p>ALL???</p>\n</td>\n<td width=\"84\">\n<p>20%</p>\n</td>\n<td width=\"100\">\n<p>HDACi</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td height=\"24\" width=\"106\">\n<p><b><a href=\"#NF1\">NF1</a>*</b></p>\n</td>\n<td width=\"120\">\n<p>MAPK, PI3K negative regulator of RAS</p>\n</td>\n<td width=\"104\">\n<p>Mutations, loss of expression</p>\n</td>\n<td width=\"98\">\n<p>BRAF, NRAS wild type, but also in mutated</p>\n</td>\n<td width=\"84\">\n<p>4% overall; 25% of BRAF, NRAS wild type</p>\n</td>\n<td width=\"100\">\n<p>MEKi + mTORi or PI3Ki</p>\n<p>\u00a0</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"106\">\n<p><a href=\"#TERT\">TERT</a>*</p>\n</td>\n<td width=\"120\">\n<p>Telomerase</p>\n</td>\n<td width=\"104\">\n<p>Mutations in the promoter of catalytic subunit</p>\n</td>\n<td width=\"98\">\n<p>ND</p>\n</td>\n<td width=\"84\">\n<p>70-80% overall;</p>\n<p>33% primary; 85% metastatic</p>\n</td>\n<td width=\"100\">\n<p>TERT inhibitors in preclinical</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"106\">\n<p><a href=\"#ERBB4\">ERBB4</a></p>\n</td>\n<td width=\"120\">\n<p>PI3K, MAPK</p>\n</td>\n<td width=\"104\">\n<p>Point mutation</p>\n</td>\n<td width=\"98\">\n<p>All types</p>\n</td>\n<td width=\"84\">\n<p>15-20%</p>\n</td>\n<td width=\"100\">\n<p>Lapatinib (ERBBi) + PI3Ki</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"106\">\n<p><a href=\"#MET\">MET</a></p>\n</td>\n<td width=\"120\">\n<p>PI3K, MAPK</p>\n</td>\n<td width=\"104\">\n<p>Activation by stromal HGF</p>\n</td>\n<td width=\"98\">\n<p>All types</p>\n</td>\n<td width=\"84\">\n<p>ND</p>\n</td>\n<td width=\"100\">\n<p>Cabozantinib?</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"106\">\n<p><a href=\"#AKT\">AKT3</a></p>\n</td>\n<td width=\"120\">\n<p>PI3K</p>\n</td>\n<td width=\"104\">\n<p>Amplification</p>\n</td>\n<td width=\"98\">\n<p>All types</p>\n</td>\n<td width=\"84\">\n<p>25%</p>\n</td>\n<td width=\"100\">\n<p>AKTi, PI3Ki, mTORi</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"106\">\n<p><a href=\"#PTEN\">PTEN</a></p>\n</td>\n<td width=\"120\">\n<p>PI3K</p>\n</td>\n<td width=\"104\">\n<p>Point mutation or deletions</p>\n</td>\n<td width=\"98\">\n<p>BRAF mutated; BRAF and NRAS wild type</p>\n</td>\n<td width=\"84\">\n<p>40-60%</p>\n</td>\n<td width=\"100\">\n<p>PI3Ki</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"106\">\n<p><a href=\"#MAGI\">MAGI</a></p>\n</td>\n<td width=\"120\">\n<p>PI3K; stabilizes PTEN</p>\n</td>\n<td width=\"104\">\n<p>--</p>\n</td>\n<td width=\"98\">\n<p>All types</p>\n</td>\n<td width=\"84\">\n<p>--</p>\n</td>\n<td width=\"100\">\n<p>PI3Ki</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"106\">\n<p><a href=\"#TACC\">TACC</a></p>\n</td>\n<td width=\"120\">\n<p>Possibly stimulates PI3K AURKA signaling</p>\n</td>\n<td width=\"104\">\n<p>--</p>\n</td>\n<td width=\"98\">\n<p>BRAF and NRAS mutated</p>\n</td>\n<td width=\"84\">\n<p>5%</p>\n</td>\n<td width=\"100\">\n<p>PI3Ki, AURKAi</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"106\">\n<p><a href=\"#PREX2\">PREX2</a></p>\n</td>\n<td width=\"120\">\n<p>RHO/RAC/MAPK; Rac exchange factor</p>\n</td>\n<td width=\"104\">\n<p>Point mutations</p>\n</td>\n<td width=\"98\">\n<p>BRAF or NRAS mutated</p>\n</td>\n<td width=\"84\">\n<p>14%</p>\n</td>\n<td width=\"100\">\n<p>--</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"106\">\n<p><a href=\"#RAC\">RAC1</a></p>\n</td>\n<td width=\"120\">\n<p>RHO/RAC/MAPK; Regulator of cell adhesion, invasion, migration</p>\n</td>\n<td width=\"104\">\n<p>Point mutations</p>\n</td>\n<td width=\"98\">\n<p>BRAF or NRAS mutated</p>\n</td>\n<td width=\"84\">\n<p>9% of sun exposed</p>\n</td>\n<td width=\"100\">\n<p>--</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"106\">\n<p><a href=\"#MAPK\">MAP2K1, MAP2K2</a></p>\n</td>\n<td width=\"120\">\n<p>MAPK (MEK1/2)</p>\n</td>\n<td width=\"104\">\n<p>Mutations</p>\n</td>\n<td width=\"98\">\n<p>BRAF mutated; BRAF, NRAF wild type</p>\n</td>\n<td width=\"84\">\n<p>5%</p>\n</td>\n<td width=\"100\">\n<p>ERKi</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"106\">\n<p><a href=\"#MAP3K5\">MAP3K5</a><a href=\"#MAP3K5\">, MAP3K9</a></p>\n</td>\n<td width=\"120\">\n<p>RHO/RAC/MAPK</p>\n</td>\n<td width=\"104\">\n<p>Mutations, loss of heterozygocity</p>\n</td>\n<td width=\"98\">\n<p>All types</p>\n</td>\n<td width=\"84\">\n<p>85% and 67%</p>\n</td>\n<td width=\"100\">\n<p>MEKi, ERKi</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"106\">\n<p>\u00a0</p>\n</td>\n<td width=\"120\">\n<p><a href=\"#MYC\">MYC</a></p>\n</td>\n<td width=\"104\">\n<p>Transcription</p>\n</td>\n<td width=\"98\">\n<p>Amplification</p>\n</td>\n<td width=\"84\">\n<p>All types</p>\n</td>\n<td width=\"100\">\n<p>20-40%</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"106\">\n<p><a href=\"#MYC\">MYC</a></p>\n</td>\n<td width=\"120\">\n<p>Transcription</p>\n</td>\n<td width=\"104\">\n<p>Amplification</p>\n</td>\n<td width=\"98\">\n<p>All types</p>\n</td>\n<td width=\"84\">\n<p>20-40%</p>\n</td>\n<td width=\"100\">\n<p>mTORi?<i> </i></p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"106\">\n<p><a href=\"file:///home/bri/Desktop/ETV1\">ETV1</a></p>\n</td>\n<td width=\"120\">\n<p>Transcription</p>\n</td>\n<td width=\"104\">\n<p>Amplification</p>\n</td>\n<td width=\"98\">\n<p>All types</p>\n</td>\n<td width=\"84\">\n<p>15%</p>\n</td>\n<td width=\"100\">\n<p>--</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"106\">\n<p><a href=\"#TP53\">TP53</a></p>\n</td>\n<td width=\"120\">\n<p>Cell cycle, apoptosis</p>\n</td>\n<td width=\"104\">\n<p>Point mutation</p>\n</td>\n<td width=\"98\">\n<p>All types</p>\n</td>\n<td width=\"84\">\n<p>10-20%</p>\n</td>\n<td width=\"100\">\n<p>--</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"106\">\n<p><a href=\"#MDM4\">MDM4</a></p>\n</td>\n<td width=\"120\">\n<p>Negative regulator of p53</p>\n</td>\n<td width=\"104\">\n<p>Overexpression</p>\n</td>\n<td width=\"98\">\n<p>All types</p>\n</td>\n<td width=\"84\">\n<p>65%</p>\n</td>\n<td width=\"100\">\n<p>--</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"106\">\n<p><a href=\"#CDKN2A\">CDKN2A</a>(P16INK4a, p14ARF)*</p>\n</td>\n<td width=\"120\">\n<p>Negative regulator of TP53 and RB</p>\n</td>\n<td width=\"104\">\n<p>Point mutation, deletion</p>\n</td>\n<td width=\"98\">\n<p>BRAF and NRAS mutated, KIT amplified</p>\n</td>\n<td width=\"84\">\n<p>30-40%</p>\n</td>\n<td width=\"100\">\n<p>--</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"106\">\n<p><a href=\"#BCL2\">BCL2, BCL2A1</a></p>\n</td>\n<td width=\"120\">\n<p>Suppression of apoptosis</p>\n</td>\n<td width=\"104\">\n<p>Elevated expression,</p>\n<p>amplification (BCL2A1)</p>\n</td>\n<td width=\"98\">\n<p>All types</p>\n</td>\n<td width=\"84\">\n<p>ND</p>\n<p>30% (BCL2A1)</p>\n</td>\n<td width=\"100\">\n<p>BH3 mimetics?</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"106\">\n<p><a href=\"#CCND1\">CCND1</a></p>\n</td>\n<td width=\"120\">\n<p>Cell cycle, G1/S cyclin</p>\n</td>\n<td width=\"104\">\n<p>Amplifications</p>\n</td>\n<td width=\"98\">\n<p>More frequent in BRAF, NRAS wild type</p>\n</td>\n<td width=\"84\">\n<p>11%</p>\n</td>\n<td width=\"100\">\n<p>CDKi?</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"106\">\n<p><a href=\"#CDK4\">CDK4</a>*</p>\n</td>\n<td width=\"120\">\n<p>Cell cycle, G1/S cyclin-dependent kinase</p>\n</td>\n<td width=\"104\">\n<p>Amplifications</p>\n</td>\n<td width=\"98\">\n<p>More frequent in BRAF, NRAS wild type</p>\n</td>\n<td width=\"84\">\n<p>3%</p>\n</td>\n<td width=\"100\">\n<p>Flavopiridol, selective CDKi</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"106\">\n<p><a href=\"#PPP6C\">PPP6C</a></p>\n</td>\n<td width=\"120\">\n<p>Catalytic unit of phosphatase, negative regulator of CCND1, Aurora</p>\n</td>\n<td width=\"104\">\n<p>Point mutations</p>\n</td>\n<td width=\"98\">\n<p>BRAF and NRAS mutated</p>\n</td>\n<td width=\"84\">\n<p>12% sun exposed</p>\n</td>\n<td width=\"100\">\n<p>AURKAi?</p>\n<p>CDKi?</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"106\">\n<p><a href=\"#STK19\">STK19</a></p>\n</td>\n<td width=\"120\">\n<p>Kinase; unknown function</p>\n</td>\n<td width=\"104\">\n<p>Point mutations</p>\n</td>\n<td width=\"98\">\n<p>BRAF and NRAS mutated</p>\n</td>\n<td width=\"84\">\n<p>5%</p>\n</td>\n<td width=\"100\">\n<p>--</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"106\">\n<p><a href=\"#SNX3\">SNX3</a></p>\n</td>\n<td width=\"120\">\n<p>Endosome protein sorting</p>\n</td>\n<td width=\"104\">\n<p>Point mutations</p>\n</td>\n<td width=\"98\">\n<p>BRAF mutated; BRAF,NRAS wild type</p>\n</td>\n<td width=\"84\">\n<p>7%</p>\n</td>\n<td width=\"100\">\n<p>--</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"106\">\n<p><a href=\"#GRIN2A\">GRIN2A</a></p>\n</td>\n<td width=\"120\">\n<p>Ionotropic glutamate-gated ion channel, NMDA binding</p>\n</td>\n<td width=\"104\">\n<p>--</p>\n</td>\n<td width=\"98\">\n<p>--</p>\n</td>\n<td width=\"84\">\n<p>25%</p>\n</td>\n<td width=\"100\">\n<p>--</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"106\">\n<p><a href=\"#GRM3\">GRM3</a></p>\n</td>\n<td width=\"120\">\n<p>Possibly accessory MAPK signaling</p>\n</td>\n<td width=\"104\">\n<p>Point mutations</p>\n</td>\n<td width=\"98\">\n<p>ND</p>\n</td>\n<td width=\"84\">\n<p>--</p>\n</td>\n<td width=\"100\">\n<p>--</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"106\">\n<p><a href=\"#TRRAP\">TRRAP</a></p>\n</td>\n<td width=\"120\">\n<p>Part of histone acetyltransferase complex</p>\n</td>\n<td width=\"104\">\n<p>Point mutations</p>\n</td>\n<td width=\"98\">\n<p>ND</p>\n</td>\n<td width=\"84\">\n<p>--</p>\n</td>\n<td width=\"100\">\n<p>--</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"106\">\n<p><a href=\"#ARID2\">ARID2</a></p>\n</td>\n<td width=\"120\">\n<p>SWI/SNF Chromatin remodeling, SWI/SNF complex</p>\n</td>\n<td width=\"104\">\n<p>Inactivating mutations</p>\n</td>\n<td width=\"98\">\n<p>BRAF, NRAS mutated</p>\n</td>\n<td width=\"84\">\n<p>7-9%</p>\n</td>\n<td width=\"100\">\n<p>--</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"106\">\n<p><a href=\"#BAP1\">BAP1</a></p>\n</td>\n<td width=\"120\">\n<p>BRCA1 DNA repair</p>\n</td>\n<td width=\"104\">\n<p>Inactivating mutations</p>\n</td>\n<td width=\"98\">\n<p>BRAF, NRAS wild type\u2014uveal</p>\n</td>\n<td width=\"84\">\n<p>1% overall, 84% uveal</p>\n</td>\n<td width=\"100\">\n<p>--</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"106\">\n<p><a href=\"#NEDD9\">NEDD9</a></p>\n</td>\n<td width=\"120\">\n<p>Integrin adaptor, promotes EMT and migration; metastasis</p>\n</td>\n<td width=\"104\">\n<p>Amplification</p>\n</td>\n<td width=\"98\">\n<p>Probably all</p>\n</td>\n<td width=\"84\">\n<p>50-60%</p>\n</td>\n<td width=\"100\">\n<p>--</p>\n</td>\n</tr>\n<tr>\n<td colspan=\"6\" height=\"116\" valign=\"TOP\" width=\"682\">\n<p><i><b>Bold font</b></i><i> of gene names indicates that these mutations are considered to be driver mutations based on presence in familial melanoma and/or high frequency of mutations is sporadic, even though experimental evidence of their precise role in melanomagenesi is not always available.</i></p>\n<p><i>* germline mutations in high-risk melanoma families; MC1R mutation is not listed. </i></p>\n<p><i>Not listed: rare mutations in HRAS, RAF1 and other oncogenes.</i></p>\n<p><i>Many of the data on the mutation frequency are based on relatively small sample tumor sizes and should be considered with caution.</i></p>\n</td>\n</tr>\n</tbody>\n</table>\n<p id=\"erb-7a3b9a7d-4480-4ec6-bbde-9c2778bf02d8\"><a name=\"BRAF\"></a> <b>BRAF</b></p>\n<p id=\"erb-ce9f76a8-c5e4-4551-9dd8-feda472f170b\">BRAF mutations (V600E in 70%-80% of all BRAF mutations in all cancers) occur early in melanomagenesis and are found in a high percentage of melanocytic nevi. Other mutations at the V600 position leading to alternate amino acid substitutions (V600K, V600D, V600R) account for another 5% to 15% of all BRAF mutations. Mutations in BRAF alone do not induce melanoma, and the high frequency of BRAF mutations in benign nevi supports this conclusion <a class=\"rlc-reference\" data-ref-info=\"Pollock PM, Harper UL, Hansen KS, et al: High frequency of BRAF mutations in nevi. Nat Genet 33:19-20, 2003.\" href=\"#_ENREF_6\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/12447372\"><sup>6</sup></a>. Moreover, expression of the BRAF mutations in preclinical models is associated with the phenomenon known as oncogene-induced senescence (OIS) <a class=\"rlc-reference\" data-ref-info=\"Michaloglou C, Vredeveld LC, Soengas MS, et al: BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 436:720-4, 2005.\" href=\"#_ENREF_7\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/16079850\"><sup>7</sup></a>, which results in a cell-cycle arrest in BRAFV600E-expressing cells. Additional genetic events in BRAF-mutant cells, such as deletion of CDKN2A or PTEN, are necessary to elicit a fully cancerous phenotype (reviewed by Flaherty, 2012 <a class=\"rlc-reference\" data-ref-info=\"Flaherty KT, Hodi FS, Fisher DE: From genes to drugs: targeted strategies for melanoma. Nat Rev Cancer 12:349-61, 2012.\" href=\"#_ENREF_8\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22475929\"><sup>8</sup></a>).</p>\n<p id=\"erb-f8ead44c-bff2-49c2-a996-276b0148d012\">Overall, about 50% of melanomas of all clinical types have mutations in BRAF. BRAF mutations are more frequent in melanomas that develop in intermittently sun-exposed skin and less so in acral and mucosal melanomas. BRAF mutations are not found in uveal melanomas. Mutations in BRAF and NRAS (~20% of melanomas of the same origin/location as BRAF-mutated melanomas) are almost always mutually exclusive. The V600E mutation in BRAF confers to this kinase the ability to activate MEK (the only known downstream target of BRAF) independent of RAS.</p>\n<p id=\"erb-c739d91f-58a7-4be5-bcf9-601eecc6d23c\">The reported results of trials with selective oral BRAF inhibitors showed efficacy in melanoma patients with BRAFV600E mutations <a class=\"rlc-reference\" data-ref-info=\"Flaherty KT, Puzanov I, Kim KB, et al: Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363:809-19, 2010.\" href=\"#_ENREF_9\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/20818844\"><sup>9</sup></a>. In addition, inhibition of MEK (the only known phosphorylation substrate of BRAF) is considered to be a valid therapeutic intervention for both BRAF- and NRAS-mutated melanoma. However, the success of BRAF inhibitors has not come without problems:</p>\n<ul>\n<li>\n<p>A significant minority of patients with mutant BRAF show no response to BRAF inhibition <a class=\"rlc-reference\" data-ref-info=\"Jordan EJ, Kelly CM: Vemurafenib for the treatment of melanoma. Expert Opin Pharmacother 13:2533-43, 2012.\" href=\"#_ENREF_10\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23094782\"><sup>10</sup></a>. Preclinical results suggest that this group has a variety of additional genomic somatic alterations that confer the resistance phenotype (discussed below).</p>\n</li>\n<li>\n<p>Most patients initially responding to BRAF inhibitors develop resistance to those inhibitors within a relatively short period of time (&lt;1 year).</p>\n</li>\n<li>\n<p>About 20% of BRAF inhibitor-treated patients developed cutaneous squamous cell carcinomas <a class=\"rlc-reference\" data-ref-info=\"Jordan EJ, Kelly CM: Vemurafenib for the treatment of melanoma. Expert Opin Pharmacother 13:2533-43, 2012.\" href=\"#_ENREF_10\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23094782\"><sup>10</sup></a>. Photodynamic therapy (PTD) was reported to be effective in treatment of these usually numerous tumors <a class=\"rlc-reference\" data-ref-info=\"Alloo A, Garibyan L, LeBoeuf N, et al: Photodynamic therapy for multiple eruptive keratoacanthomas associated with vemurafenib treatment for metastatic melanoma. Arch Dermatol 148:363-6, 2012.\" href=\"#_ENREF_11\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22431777\"><sup>11</sup></a>. Accelerated development of RAS-mutant leukemia in a patient treated with vemurafenib was also described <a class=\"rlc-reference\" data-ref-info=\"Callahan MK, Rampal R, Harding JJ, et al: Progression of RAS-mutant leukemia during RAF inhibitor treatment. N Engl J Med 367:2316-21, 2012.\" href=\"#_ENREF_12\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23134356\"><sup>12</sup></a>, raising concern about the development of squamous cell carcinoma (SCC) and other malignancies as a consequence of BRAF inhibition <a class=\"rlc-reference\" data-ref-info=\"Gibney GT, Messina JL, Fedorenko IV, et al: Paradoxical oncogenesis-the long-term effects of BRAF inhibition in melanoma. Nat Rev Clin Oncol, 2013.\" href=\"#_ENREF_13\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23712190\"><sup>13</sup></a>.</p>\n</li>\n<li>\n<p>Paradoxical effects of BRAFV600 inhibitors in activating wild-type BRAF and/or CRAF. The mechanism of this is thought to be due to conformational changes in wild-type BRAF protein induced by binding of the inhibitors promoting the formation of heterodimers with other RAF isoforms, leading to MEK activation <a class=\"rlc-reference\" data-ref-info=\"Poulikakos PI, Zhang C, Bollag G, et al: RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 464:427-30, 2010.\" href=\"#_ENREF_14\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/20179705\"><sup>14</sup></a>. This effect might trigger growth of new malignant melanoma tumors that have wild-type BRAF, but high expression of RAS-GTP, Akt, and cyclin D1 <sup><a class=\"rlc-reference\" data-ref-info=\"Dalle S, Poulalhon N, Debarbieux S, et al: Second primary melanomas under vemurafenib. Br J Dermatol, 2012.\" href=\"#_ENREF_15\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23066856\">15</a>,<a class=\"rlc-reference\" data-ref-info=\"Zimmer L, Hillen U, Livingstone E, et al: Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition. J Clin Oncol 30:2375-83, 2012.\" href=\"#_ENREF_16\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22614973\">16</a></sup>. A recent study provided a possible mechanism of activation of wild-type BRAF by inhibitors through a relief of inhibitory autophosphorylation <a class=\"rlc-reference\" data-ref-info=\"Holderfield M, Merritt H, Chan J, et al: RAF Inhibitors Activate the MAPK Pathway by Relieving Inhibitory Autophosphorylation. Cancer Cell 23:594-602, 2013.\" href=\"#_ENREF_17\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23680146\"><sup>17</sup></a>.</p>\n</li>\n</ul>\n<p id=\"erb-63373e0b-6424-4201-ae7b-bf6f18a4eafb\"><u>Treatment approaches to BRAF mutations</u></p>\n<p id=\"erb-2418ebde-7cd5-4eeb-aad8-814cbbcf66d0\">The U.S. Food and Drug Administration (FDA) approved the mutant BRAF inhibitor <a href=\"http://www.cancer.gov/drugdictionary?CdrID=528954\">vemurafenib</a>/Zelboraf in 2011. Another inhibitor, <a href=\"http://www.cancer.gov/drugdictionary?CdrID=641977\">dabrafenib</a>/Tafinlar, was approved in May 2013. Dabrafenib showed clinical responses in 59% of patients with V600E/K mutation, including 7% complete responders <a class=\"rlc-reference\" data-ref-info=\"Ascierto PA, Minor D, Ribas A, et al: Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic Melanoma. J Clin Oncol, 2013.\" href=\"#_ENREF_18\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23918947\"><sup>18</sup></a>. A newer inhibitor, <a href=\"http://www.cancer.gov/drugdictionary?CdrID=712549\">LGX818</a>, is in early stages of testing (<a href=\"http://www.cancercommons.org/researchers-clinicians/melanoma/melanoma-stats-page/#tabs2\">Supplemental Table 1</a>). New inhibitors are in development to eliminate the side effects associated with the paradoxical activation by vemurafenib of the ERK1/2 pathway in wild-type BRAF cells. PLX7904, a new \u201cparadox-breaking\u201d BRAF inhibitor, appears to inhibit ERK1/2 in BRAF-mutant cells without activating BRAF in BRAF wild-type cells <a class=\"rlc-reference\" data-ref-info=\"Le K, Blomain E, Rodeck U, et al: Selective RAF inhibitor impairs ERK1/2 phosphorylation and growth in mutant NRAS, vemurafenib-resistant melanoma cells. Pigment Cell Melanoma Res, 2013.\" href=\"#_ENREF_19\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23490205\"><sup>19</sup></a>. Dosing schedules with BRAF inhibitors were explored in a genetically engineered mouse model (GEMM), where intermittent inhibition of BRAF by vemurafenib works better than continuous treatment <a class=\"rlc-reference\" data-ref-info=\"Das Thakur M, Salangsang F, Landman AS, et al: Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature, 2013.\" href=\"#_ENREF_20\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23302800\"><sup>20</sup></a>. Intermittent dosing of vemurafenib has not yet been tested in clinical trials.</p>\n<p id=\"erb-8cae2532-fc08-4b77-8286-950c2966813e\">Inhibition of MEK has been explored in clinical trials for melanoma patients with mutant BRAF <sup><a class=\"rlc-reference\" data-ref-info=\"Falchook GS, Lewis KD, Infante JR, et al: Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol 13:782-9, 2012.\" href=\"#_ENREF_21\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22805292\">21</a>,<a class=\"rlc-reference\" data-ref-info=\"Flaherty KT, Robert C, Hersey P, et al: Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 367:107-14, 2012.\" href=\"#_ENREF_22\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22663011\">22</a></sup>. A phase III randomized trial comparing MEK inhibitor trametinib to chemotherapy showed a marked improvement in both progression free and overall survival (PFS and OS) in the trametinib arm <a class=\"rlc-reference\" data-ref-info=\"Flaherty KT, Robert C, Hersey P, et al: Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 367:107-14, 2012.\" href=\"#_ENREF_22\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22663011\"><sup>22</sup></a>. <!-- Cited in different style - why no footnote?\r\n --><!--  ink to zed trialsRK1/2 in BRAF s\r\nnounafter)\r\n possible - best to link to the sections below, from mention in tables 3&4icate tha\r\n -->Combination of <a href=\"http://www.cancer.gov/drugdictionary?CdrID=532294\">selumetinib</a>/AZD6244 with alkylating agent dacarbazine improved PFS in a randomized clinical trial <a class=\"rlc-reference\" data-ref-info=\"Robert C, Dummer R, Gutzmer R, et al: Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study. Lancet Oncol 14:733-40, 2013.\" href=\"#_ENREF_23\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23735514\"><sup>23</sup></a>. MEK inhibitor <a href=\"http://www.cancer.gov/drugdictionary?CdrID=599034\">trametinib</a> showed some clinical responses in BRAF-mutant patients that had undergone previous immune- or chemotherapy, but had no effect in patients who were previously treated with vemurafenib <a class=\"rlc-reference\" data-ref-info=\"Kim KB, Kefford R, Pavlick AC, et al: Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol 31:482-9, 2013.\" href=\"#_ENREF_24\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23248257\"><sup>24</sup></a>. This strongly indicates that mechanisms involved in development of resistance to mutant BRAF confer resistance to MEK inhibition as well. FDA approved trametinib/Mekinist for melanoma in May 2013.</p>\n<p id=\"erb-ef2c64bc-47e3-4d9f-aeda-0d9152add2f4\">Most importantly, it is increasingly clear that combination treatments, such as BRAF and MEK inhibition investigated in a recently reported clinical study <a class=\"rlc-reference\" data-ref-info=\"Flaherty KT, Infante JR, Daud A, et al: Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 367:1694-703, 2012.\" href=\"#_ENREF_25\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23020132\"><sup>25</sup></a>, have potential for a robust and lasting clinical response in the treatment of BRAF-mutant melanoma. Combination dabrafenib+trametinib trial responses were not only more numerous compared to dabrafenib alone, but also more durable. This combination is now being considered for approval by the FDA. BRAF inhibitors are explored in a number of clinical trials in combination with inhibitors of MEK, including four phase III trials (<a href=\"http://www.clinicaltrials.gov/ct2/show/NCT01689519\">NCT01689519</a>, <u><a href=\"http://clinicaltrials.gov/ct2/results?term=NCT01597908&amp;Search=Search\">NCT01597908</a>, <a href=\"http://clinicaltrials.gov/ct2/results?term=NCT01682083&amp;Search=Search\">NCT01682083</a>, <a href=\"http://clinicaltrials.gov/ct2/results?term=NCT01682083&amp;Search=Search\">NCT01682083</a>), </u> the first of which involves a new MEK inhibitor GDC-0973 or cobimetinib<u>. </u>Other early-phase combination trials with approved BRAF inhibitors explore addition of inhibitors of PI3K, AKT, CDK, HSP90, RTKs and other targets, as well as immunotherapy (<a href=\"http://www.cancercommons.org/researchers-clinicians/melanoma/melanoma-stats-page/#tabs3\">Supplemental Table 2</a>).</p>\n<p id=\"erb-57d18d6a-2baa-4160-93df-c2069c8a2a91\">Targeting ERK1/2, the kinases at the lower end of the MAPK cascade, <!-- Should we point to a general pathway map depicting these cascades (throughout), or is it too complex?  \r\n -->is an emerging therapeutic strategy, with several candidate drugs in preclinical development. ERK inhibitors have an important advantage of being potentially active in the setting of acquired resistance to inhibitors of BRAF or MEK <a class=\"rlc-reference\" data-ref-info=\"Morris EJ, Jha S, Restaino CR, et al: Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors. Cancer Discov 3:742-50, 2013.\" href=\"#_ENREF_26\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23614898\"><sup>26</sup></a>.</p>\n<p id=\"erb-7b669e2c-f30a-441b-90fa-a675dd659036\"><b>BRAF mutations other than V600</b></p>\n<p id=\"erb-df60f658-712c-4d30-a0fe-27c548fd57fa\">A number of BRAF mutants other than V600 were identified in human cancers <a class=\"rlc-reference\" data-ref-info=\"Davies H, Bignell GR, Cox C, et al: Mutations of the BRAF gene in human cancer. Nature 417:949-54, 2002.\" href=\"#_ENREF_27\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/12068308\"><sup>27</sup></a>. Some of these have a relatively low kinase activity compared to BRAFV600E <a class=\"rlc-reference\" data-ref-info=\"Wan PT, Garnett MJ, Roe SM, et al: Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116:855-67, 2004.\" href=\"#_ENREF_28\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/15035987\"><sup>28</sup></a>. Three mutants with low activity\u2014G469E, G466A, and N581S\u2014were shown to still activate ERK via a mechanism involving their ability to strongly activate CRAF<a class=\"rlc-reference\" data-ref-info=\"Wan PT, Garnett MJ, Roe SM, et al: Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116:855-67, 2004.\" href=\"#_ENREF_28\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/15035987\"><sup>28</sup></a>. The low-activity BRAF mutations G469E/D594G that signal through CRAF were later identified in a panel of melanoma cell lines <a class=\"rlc-reference\" data-ref-info=\"Smalley KS, Xiao M, Villanueva J, et al: CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations. Oncogene 28:85-94, 2009.\" href=\"#_ENREF_29\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/18794803\"><sup>29</sup></a>. Analysis of BRAF exon 15 in 49 tumors negative for BRAFV600 mutations, as well as other known driver mutations in KIT, NRAS, GNAQ, and GNA11, showed that two (4%) harbored L597 mutations and another two involved BRAF D594 and K601 mutations <a class=\"rlc-reference\" data-ref-info=\"Smalley KS, Xiao M, Villanueva J, et al: CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations. Oncogene 28:85-94, 2009.\" href=\"#_ENREF_29\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/18794803\"><sup>29</sup></a>.</p>\n<p id=\"erb-4ffc32e9-24d6-4073-82c2-ae0a8433ae31\">Melanomas with BRAF mutations other than V600 have not been specifically targeted in clinical trials. Kinase inhibitor <a href=\"http://www.cancer.gov/drugdictionary?CdrID=299013\">sorafenib</a> is a better inhibitor of CRAF than mutant BRAF; sorafenib induced apoptosis <i>in vitro</i> and in a xenograft model <i>in vivo</i> in tumors with G469E/D594G <a class=\"rlc-reference\" data-ref-info=\"Smalley KS, Xiao M, Villanueva J, et al: CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations. Oncogene 28:85-94, 2009.\" href=\"#_ENREF_29\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/18794803\"><sup>29</sup></a>. A patient with BRAF(L597S)-mutant metastatic melanoma responded significantly to treatment with the MEK inhibitor <a href=\"http://www.cancer.gov/drugdictionary?CdrID=651550\">TAK-733</a> <a class=\"rlc-reference\" data-ref-info=\"Dahlman KB, Xia J, Hutchinson K, et al: BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors. Cancer Discov 2:791-7, 2012.\" href=\"#_ENREF_30\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22798288\"><sup>30</sup></a>. Another patient with this mutation responded to trametinib in the phase I clinical trials mentioned above <a class=\"rlc-reference\" data-ref-info=\"Falchook GS, Lewis KD, Infante JR, et al: Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol 13:782-9, 2012.\" href=\"#_ENREF_21\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22805292\"><sup>21</sup></a>.</p>\n<p id=\"erb-b89a33da-c4c9-4634-9d85-364ff318989b\"><a name=\"NRAS\"></a> <b>NRAS</b></p>\n<p id=\"erb-c2dbe411-6d00-46ad-add7-8d61a8644774\">Approximately 20% of melanomas have mutations in the GTPase NRAS. NRAS and BRAF mutations are almost always mutually exclusive. Therapeutic approaches targeting mutant NRAS directly have not been successful. Combination treatments targeting the downstream effectors of NRAS remain a viable option.</p>\n<p id=\"erb-31ec429f-45a9-4a30-b4b3-7690826b659b\"><u>Potential treatment approaches to NRAS mutations</u></p>\n<p id=\"erb-7cc2f960-8afe-4af9-83b9-6cb80ad58496\">The pathways downstream of NRAS that could be targeted simultaneously in NRAS-mutant melanoma include, but are not limited to, MEK, PI3K/mTOR, and cell-cycle-related targets. PTEN abnormalities are rarely found in NRAS-mutant tumors <a class=\"rlc-reference\" data-ref-info=\"Hodis E, Watson IR, Kryukov GV, et al: A landscape of driver mutations in melanoma. Cell 150:251-63, 2012.\" href=\"#_ENREF_31\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22817889\"><sup>31</sup></a>. Monotherapy with the MEK inhibitor MEK162 showed limited partial responses (20%) in NRAS-mutant patients and represents the most active single-agent targeted therapy evaluated to date <a class=\"rlc-reference\" data-ref-info=\"Ascierto PA, Schadendorf D, Berking C, et al: MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol, 2013.\" href=\"#_ENREF_32\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23414587\"><sup>32</sup></a>. A recent study identified the basis of different activity of MEK inhibitors in BRAF versus KRAS mutant cancers. Unlike trametinib-like inhibitors that inhibit phosphorylated MEK and are effective in the setting of BRAFV600 mutants, the new class of inhibitors, like <a href=\"http://www.cancer.gov/drugdictionary?CdrID=673612\">GDC-0623</a>, inhibit feedback activation of MEK by RAF, and are therefore more efficacious in the setting of mutant KRAS <a class=\"rlc-reference\" data-ref-info=\"Hatzivassiliou G, Haling JR, Chen H, et al: Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers. Nature, 2013.\" href=\"#_ENREF_33\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23934108\"><sup>33</sup></a>. It is likely that GDC-0623, which is currently in a phase I clinical trial, might be efficacious in melanomas with mutant NRAS.</p>\n<p id=\"erb-5bdd1d01-c1f4-4533-b6a6-52e593018905\">Preclinical studies indicate several potential points of intervention:</p>\n<ul>\n<li>\n<p>NRAS-driven melanoma in genetically engineered mice responded only to the combination of MEK and PI3K/mTOR dual inhibitors out of 16 treatment combinations tested <a class=\"rlc-reference\" data-ref-info=\"Roberts PJ, Usary JE, Darr DB, et al: Combined PI3K/mTOR and MEK inhibition provides broad antitumor activity in faithful murine cancer models. Clin Cancer Res 18:5290-303, 2012.\" href=\"#_ENREF_34\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22872574\"><sup>34</sup></a>. Combined targeting of MEK and PI3K was superior to MEK and mTOR inhibition in NRAS-mutant melanoma cell lines and xenografts <a class=\"rlc-reference\" data-ref-info=\"Posch C, Moslehi H, Feeney L, et al: Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo. Proc Natl Acad Sci U S A, 2013.\" href=\"#_ENREF_35\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23431193\"><sup>35</sup></a>. A number of clinical trials examining this combination are ongoing (<a href=\"http://www.cancercommons.org/researchers-clinicians/melanoma/melanoma-stats-page/#tabs3\">Supplemental Table 2</a>).</p>\n</li>\n<li>\n<p>In an inducible model of NRAS-mutant melanoma, genetic ablation of NRAS triggered cell-cycle arrest and apoptosis, while pharmacological inhibition of MEK activated apoptosis, but not cell-cycle arrest. CDK4 was implicated as a key driver of these differences and combined pharmacological inhibition of MEK and CDK4 in vivo led to substantial synergy in therapeutic efficacy in a mouse model <a class=\"rlc-reference\" data-ref-info=\"Kwong LN, Costello JC, Liu H, et al: Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma. Nat Med 18:1503-10, 2012.\" href=\"#_ENREF_36\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22983396\"><sup>36</sup></a>. The phase I/II trial <a href=\"http://clinicaltrials.gov/show/NCT01781572\">NCT01781572</a> with MEK inhibitor MEK162 and CDK inhibitor <a href=\"http://www.cancer.gov/drugdictionary?CdrID=689330\">LEE011</a> for NRAS-mutant melanoma is ongoing.</p>\n</li>\n<li>\n<p>Sensitivity of NRAS-mutant cell lines to MEK inhibitors was shown to be associated with expression of AHR (aryl hydrocarbon receptor) <i>in vitro</i> <a class=\"rlc-reference\" data-ref-info=\"Barretina J, Caponigro G, Stransky N, et al: The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483:603-7, 2012.\" href=\"#_ENREF_37\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22460905\"><sup>37</sup></a>.</p>\n</li>\n<li>\n<p>A study of combinatorial drug interactions <i>in vitro</i> pinpointed the combination of simvastatin with a CDK inhibitor as the only fairly effective cytotoxic treatment for NRAS-mutated melanoma cell lines <a class=\"rlc-reference\" data-ref-info=\"Held MA, Langdon CG, Platt JT, et al: Genotype-selective combination therapies for melanoma identified by high-throughput drug screening. Cancer Discov 3:52-67, 2013.\" href=\"#_ENREF_38\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23239741\"><sup>38</sup></a>.</p>\n</li>\n</ul>\n<p id=\"erb-51453db9-3d17-4a11-9a0d-3f42dab813dd\">The combinations of inhibitors to\u00a0target NRAS-activated signaling through MEK and PI3K, MEK and AKT, MEK and PI3K/mTOR, as well as MEK and VEGF-receptor inhibition, are now in early phase clinical trials. Only a few trials specifically target melanomas with NRAS mutations, but a number of trials use combinations of agents or single agents that could have therapeutic benefits in this subgroup of melanoma. Single agents in phase I or early phase II trials include inhibitors of CDK (<a href=\"http://www.cancer.gov/drugdictionary?cdrid=454586\">PD0332991</a>, <a href=\"http://www.cancer.gov/drugdictionary?CdrID=612855\">d</a><a href=\"http://www.cancer.gov/drugdictionary?CdrID=612855\">inaciclib</a> , <a href=\"http://www.cancer.gov/drugdictionary?CdrID=706364\">LY2835219</a>, <a href=\"http://www.cancer.gov/drugdictionary?CdrID=684718\">BAY1000394</a>, <a href=\"http://www.cancer.gov/drugdictionary?CdrID=689330\">LEE011</a>), the Notch pathway (<a href=\"http://www.cancer.gov/drugdictionary?CdrID=662240\">RO4929097</a>), and Aurora kinase A (<a href=\"http://www.cancer.gov/drugdictionary?CdrID=561286\">MLN8237/alisertib</a>, <a href=\"http://www.cancer.gov/drugdictionary?CdrID=670668\">GSK1070916A</a>) (<a href=\"http://www.cancercommons.org/researchers-clinicians/melanoma/melanoma-stats-page/#tabs3\">Supplemental Table 2</a>).</p>\n<p id=\"erb-d9e0414a-3515-48c1-a417-809861afe389\"><a name=\"GNAQ\"></a> <b>GNAQ and GNA11</b></p>\n<p id=\"erb-d4ac2909-fd2b-450b-9226-05a71f5a24a3\">Activating mutations in GNAQ and GNA11, encoding members of the G\u03b1(q) family of G protein \u03b1 subunits, are driver oncogenes in uveal melanoma <sup><a class=\"rlc-reference\" data-ref-info=\"Van Raamsdonk CD, Bezrookove V, Green G, et al: Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature 457:599-602, 2009.\" href=\"#_ENREF_39\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/19078957\">39</a>,<a class=\"rlc-reference\" data-ref-info=\"Van Raamsdonk CD, Griewank KG, Crosby MB, et al: Mutations in GNA11 in uveal melanoma. N Engl J Med 363:2191-9, 2010.\" href=\"#_ENREF_40\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/21083380\">40</a></sup>. Mutations in GNAQ and GNA11 are mutually exclusive and are present in the vast majority of uveal melanomas <a class=\"rlc-reference\" data-ref-info=\"Daniels AB, Lee JE, MacConaill LE, et al: High throughput mass spectrometry-based mutation profiling of primary uveal melanoma. Invest Ophthalmol Vis Sci 53:6991-6, 2012.\" href=\"#_ENREF_41\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22977135\"><sup>41</sup></a>. GNA11 has a stronger association with metastatic uveal melanoma than GNAQ. Mutations in these GTP-binding proteins activate the MAPK pathway.</p>\n<p id=\"erb-e7273fec-770e-4d82-bd83-a43079ad7dd9\"><u>Potential treatment approaches to GNAQ and GNA11 mutations</u></p>\n<p id=\"erb-073e712d-e755-47c1-a91d-adb0b1d32394\">A randomized phase II clinical trial compared the MEK inhibitor <a href=\"http://www.cancer.gov/drugdictionary?CdrID=532294\">selumetinib</a> (AZD6244) with temozolomide (<a href=\"http://clinicaltrials.gov/ct2/show/NCT01143402\">NCT01143402</a>) with results showing superiority of selumetinib in terms of PFS and overall response rate (ORR), but not OS (J Clin Oncol 31, 2013 suppl; abstr CRA9003). <!-- Cited in different style\r\n -->GNAQ mutation promotes resistance <i>in vitro</i> to selumetinib, but the combination of selumetinib with the ATP-competitive mTOR inhibitor <a href=\"http://www.cancer.gov/drugdictionary?CdrID=612860\">AZD8055</a> might be more promising <a class=\"rlc-reference\" data-ref-info=\"Ho AL, Musi E, Ambrosini G, et al: Impact of combined mTOR and MEK inhibition in uveal melanoma is driven by tumor genotype. PLoS One 7:e40439, 2012.\" href=\"#_ENREF_42\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22808163\"><sup>42</sup></a>. A trial of the MTOR inhibitor <a href=\"http://www.cancer.gov/drugdictionary\">everolimus</a> and the somatostatin-receptor-activating peptide <a href=\"http://www.cancer.gov/drugdictionary?CdrID=540440\">pasireotide</a>/SOM232 is recruiting patients (<a href=\"http://clinicaltrials.gov/show/NCT01252251\">NCT01252251</a>).</p>\n<p id=\"erb-b09c5847-d0a1-4f7a-88d7-d0f3bf38b0fa\">Inhibition of both PI3K and MAPK, but neither of them singly, might also work in uveal melanoma as seen from <i>in vitro</i> experiments <a class=\"rlc-reference\" data-ref-info=\"Khalili JS, Yu X, Wang J, et al: Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner. Clin Cancer Res 18:4345-55, 2012.\" href=\"#_ENREF_43\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22733540\"><sup>43</sup></a>. No trials involving this combination are ongoing.</p>\n<p id=\"erb-88dcaf09-70a7-4cc8-a2de-554aaf2655d4\"><a href=\"http://www.cancer.gov/drugdictionary?CdrID=269069\">Enzastaurin</a> and <a href=\"http://www.cancer.gov/drugdictionary?CdrID=708113\">AEB071</a>, PKC inhibitors, have shown some activity against uveal melanoma cell lines <i>in vitro</i> <sup><a class=\"rlc-reference\" data-ref-info=\"Wu X, Li J, Zhu M, et al: Protein kinase C inhibitor AEB071 targets ocular melanoma harboring GNAQ mutations via effects on the PKC/Erk1/2 and PKC/NF-kappaB pathways. Mol Cancer Ther 11:1905-14, 2012.\" href=\"#_ENREF_44\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22653968\">44</a>,<a class=\"rlc-reference\" data-ref-info=\"Wu X, Zhu M, Fletcher JA, et al: The protein kinase C inhibitor enzastaurin exhibits antitumor activity against uveal melanoma. PLoS One 7:e29622, 2012.\" href=\"#_ENREF_45\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22253748\">45</a></sup>. PKC is involved in signal transduction from GNAQ to MEK. AEB071 is tested in a phase I clinical study <a href=\"http://clinicaltrials.gov/ct2/show/NCT01430416\">NCT01430416</a> as a single agent, and will be examined in combination with trametinib in <a href=\"http://clinicaltrials.gov/ct2/show/NCT01801358\">NCT01801358</a>.</p>\n<p id=\"erb-5a81201a-d4c1-40b8-91e8-b67d021c5671\">Recently, it was shown that the guanine nucleotide exchange factor Trio is involved in mitogenic signaling through GNAQ and GNA11. Trio is essential for activating Rho- and Rac-regulated signaling pathways acting on JNK and p38, thereby transducing proliferative signals from G\u03b1(q) to the nucleus independently of phospholipase C-\u03b2 <a class=\"rlc-reference\" data-ref-info=\"Vaque JP, Dorsam RT, Feng X, et al: A Genome-wide RNAi Screen Reveals a Trio-Regulated Rho GTPase Circuitry Transducing Mitogenic Signals Initiated by G Protein-Coupled Receptors. Mol Cell, 2012.\" href=\"#_ENREF_46\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23177739\"><sup>46</sup></a>. These findings might open new avenues for treatment of uveal melanoma.</p>\n<p id=\"erb-239f381e-e2cf-4c86-96ee-687621279c2e\"><a name=\"MITF\"></a> <b>MITF</b></p>\n<p id=\"erb-56aa8edf-0fb1-459e-bf3f-89273acbeb08\">Microphthalmia-associated transcription factor\u00a0MITF is a lineage survival oncogene, amplified in 20% of melanoma cases <a class=\"rlc-reference\" data-ref-info=\"Garraway LA, Widlund HR, Rubin MA, et al: Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 436:117-22, 2005.\" href=\"#_ENREF_47\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/16001072\"><sup>47</sup></a>; amplification of MITF is associated with a reduced 5-year survival. MITF is mutated in some familial melanomas <a class=\"rlc-reference\" data-ref-info=\"Yokoyama S, Woods SL, Boyle GM, et al: A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma. Nature 480:99-103, 2011.\" href=\"#_ENREF_48\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22080950\"><sup>48</sup></a>. The variant MITF(E318K) co-segregates with affected individuals in familial melanoma and is likely to be a gain-of-function (GOF) mutation. It abolishes a SUMO-ilation site on MITF that reportedly acts to inhibit transcriptional activity of MITF. Transcriptional targets of MITF have been identified and, besides a large number of lineage-specific transcripts, include genes related to regulation of cell cycle, among them CDK2 <a class=\"rlc-reference\" data-ref-info=\"Du J, Widlund HR, Horstmann MA, et al: Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF. Cancer Cell 6:565-76, 2004.\" href=\"#_ENREF_49\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/15607961\"><sup>49</sup></a>. Considering that MITF itself is currently not a druggable target, inhibition of CDK2 is a plausible aim in melanoma with MITF aberrations.</p>\n<p id=\"erb-d936ecae-262f-4c85-9b93-654d95c0afc3\">Other candidate targets in the MITF program include receptor tyrosine kinase TYRO3, which regulates expression of MITF in a SOX-10-dependent manner <a class=\"rlc-reference\" data-ref-info=\"Zhu S, Wurdak H, Wang Y, et al: A genomic screen identifies TYRO3 as a MITF regulator in melanoma. Proc Natl Acad Sci U S A 106:17025-30, 2009.\" href=\"#_ENREF_50\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/19805117\"><sup>50</sup></a>. Ubiquitin-specific protease 13 (USP13) was shown to be responsible for MITF deubiquitination and stabilization. USP13 is essential for melanoma growth <i>in vitro</i> and <i>in vivo</i> and might be another target in MITF-mutated melanoma <a class=\"rlc-reference\" data-ref-info=\"Zhao X, Fiske B, Kawakami A, et al: Regulation of MITF stability by the USP13 deubiquitinase. Nat Commun 2:414, 2011.\" href=\"#_ENREF_51\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/21811243\"><sup>51</sup></a>.</p>\n<p id=\"erb-9df14086-f884-4ed5-ae88-fa3e0d0a853a\">Hypoxia-inducible factor HIF1\uf061 was also reported to be a transcriptional target of MITF<a class=\"rlc-reference\" data-ref-info=\"Busca R, Berra E, Gaggioli C, et al: Hypoxia-inducible factor 1{alpha} is a new target of microphthalmia-associated transcription factor (MITF) in melanoma cells. J Cell Biol 170:49-59, 2005.\" href=\"#_ENREF_52\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/15983061\"><sup>52</sup></a>, and its expression is apparently stimulated by MITF with the well-known consequences of stimulating tumor survival, angiogenesis, and metastases. Paradoxically, expression of MITF itself is reduced under hypoxic conditions in normal melanocytes and melanoma via direct binding of transcription repressor DEC1, which is activated by HIF1\uf061 <a class=\"rlc-reference\" data-ref-info=\"Feige E, Yokoyama S, Levy C, et al: Hypoxia-induced transcriptional repression of the melanoma-associated oncogene MITF. Proc Natl Acad Sci U S A 108:E924-33, 2011.\" href=\"#_ENREF_53\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/21949374\"><sup>53</sup></a>. This suggests a negative feedback loop. A recent study implicated HIF1 factors in promoting melanoma invasion and metastases without affecting proliferation of the primary tumors <a class=\"rlc-reference\" data-ref-info=\"Hanna SC, Krishnan B, Bailey ST, et al: HIF1alpha and HIF2alpha independently activate SRC to promote melanoma metastases. J Clin Invest 123:2078-93, 2013.\" href=\"#_ENREF_54\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23563312\"><sup>54</sup></a>.</p>\n<p id=\"erb-3a7e7eb6-a743-4394-99f6-68afeb037026\">MITF is regulated by the transcription factor ATF2. Primary melanoma specimens that exhibit a high nuclear ATF2:MITF ratio were found to be associated with metastatic disease and poor prognosis <a class=\"rlc-reference\" data-ref-info=\"Shah M, Bhoumik A, Goel V, et al: A role for ATF2 in regulating MITF and melanoma development. PLoS Genet 6:e1001258, 2010.\" href=\"#_ENREF_55\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/21203491\"><sup>55</sup></a>. ATF2 control of melanoma development is mediated, in part, through its negative regulation of SOX10 and consequently, of MITF transcription. In human patients, virtually all congenital nevi and melanomas are SOX10 positive. SOX10 silencing in human melanoma cells suppresses neural crest stem cell properties, counteracts proliferation and cell survival, and completely abolishes <i>in vivo</i> tumor formation <a class=\"rlc-reference\" data-ref-info=\"Shakhova O, Zingg D, Schaefer SM, et al: Sox10 promotes the formation and maintenance of giant congenital naevi and melanoma. Nat Cell Biol 14:882-90, 2012.\" href=\"#_ENREF_56\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22772081\"><sup>56</sup></a>.</p>\n<p id=\"erb-19b230ba-e3a4-4fa4-bd4a-a2ab01105e0e\">SOX10, PAX3, and MITF participate in regulation of MET (HGF receptor), which is expressed at high levels in human melanoma <a class=\"rlc-reference\" data-ref-info=\"Puri N, Ahmed S, Janamanchi V, et al: c-Met is a potentially new therapeutic target for treatment of human melanoma. Clin Cancer Res 13:2246-53, 2007.\" href=\"#_ENREF_57\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/17404109\"><sup>57</sup></a>. MITF and PAX3 bind directly to the MET promoter; coexpression of these three proteins is found in melanoma biopsies <a class=\"rlc-reference\" data-ref-info=\"Mascarenhas JB, Littlejohn EL, Wolsky RJ, et al: PAX3 and SOX10 activate MET receptor expression in melanoma. Pigment Cell Melanoma Res 23:225-37, 2010.\" href=\"#_ENREF_58\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/20067553\"><sup>58</sup></a>.</p>\n<p id=\"erb-4593a26a-e92c-4995-97e5-d5794b5227a1\">PPAR-\u03b3 coactivators PGC-1\u03b1 and PGC-1\u03b2 are critical components of the melanogenic system governed by MITF. Melanomas with high expression of PGC-1\u03b1 exhibit increased expression of mitochondrial respiration complexes and increased oxidative phosphorylation <a class=\"rlc-reference\" data-ref-info=\"Vazquez F, Lim JH, Chim H, et al: PGC1alpha Expression Defines a Subset of Human Melanoma Tumors with Increased Mitochondrial Capacity and Resistance to Oxidative Stress. Cancer Cell, 2013.\" href=\"#_ENREF_59\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23416000\"><sup>59</sup></a>. The high MITF-high <!-- dual \"high\" listing okay?\r\n -->PGC-1\u03b1 expressing cells have an increased capacity to withstand oxidative stress, and, unlike PGC-1\u03b1 low cells, respond poorly to ROS-inducing agents such as PEITC or piperlongumine <a class=\"rlc-reference\" data-ref-info=\"Vazquez F, Lim JH, Chim H, et al: PGC1alpha Expression Defines a Subset of Human Melanoma Tumors with Increased Mitochondrial Capacity and Resistance to Oxidative Stress. Cancer Cell, 2013.\" href=\"#_ENREF_59\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23416000\"><sup>59</sup></a>. In addition, polymorphism studies reveal expression quantitative trait loci (eQTLs) in the PGC-1\u03b2 gene that correlate with protection from\u00a0melanoma\u00a0in humans <a class=\"rlc-reference\" data-ref-info=\"Shoag J, Haq R, Zhang M, et al: PGC-1 Coactivators Regulate MITF and the Tanning Response. Mol Cell, 2012.\" href=\"#_ENREF_60\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23201126\"><sup>60</sup></a>.</p>\n<p id=\"erb-147d6a53-f1be-433e-8ad0-6ad23a7e1d2d\">BCL2A1, a lineage-specific anti-apoptotic protein in the BCL2 family, is amplified and overexpressed in MITF-high melanomas, and confers resistance to BRAF inhibitor <a class=\"rlc-reference\" data-ref-info=\"Haq R, Yokoyama S, Hawryluk EB, et al: BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition. Proc Natl Acad Sci U S A 110:4321-6, 2013.\" href=\"#_ENREF_61\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23447565\"><sup>61</sup></a>. Suppression of BCL2A1 might have clinical benefit in this group of melanomas <a class=\"rlc-reference\" data-ref-info=\"Haq R, Yokoyama S, Hawryluk EB, et al: BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition. Proc Natl Acad Sci U S A 110:4321-6, 2013.\" href=\"#_ENREF_61\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23447565\"><sup>61</sup></a>.</p>\n<p id=\"erb-12f09655-0be6-4bfc-a835-e492f02b2ac8\">A recent paper proposed targeting of tyrosinase (MITF transcriptional target) by first inducing expression of MITF in melanoma cells using the well-known anti-folate drug methotrexate. The second step is to target the now high-MITF expressing cells with a designed pro-drug that is converted to a cytotoxic anti-folate drug by the MITF-induced tyrosinase <a class=\"rlc-reference\" data-ref-info=\"Saez-Ayala M, Montenegro MF, Sanchez-Del-Campo L, et al: Directed Phenotype Switching as an Effective Antimelanoma Strategy. Cancer Cell, 2013.\" href=\"#_ENREF_62\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23792190\"><sup>62</sup></a>. The death of thus targeted cells should then ensue as a consequence of dTTP depletion. There are many questions regarding the rationale and execution of this strategy, including how methotrexate induces MITF expression, how to reconcile the known oncogenic role of MITF in melanoma to further increase its expression, and how targeting DHFR\u2014a long explored target in cancer\u2014could overcome the acquired resistance long associated with methotrexate. The loss of tyrosinase expression in advanced amelanotic tumors would need to be considered as well.</p>\n<p id=\"erb-7b78a90c-bab1-4602-bb25-a4da2cd6296b\">The crystal structure of MITF was resolved recently, paving the way for the future targeting of MITF in melanoma and other cancers <a class=\"rlc-reference\" data-ref-info=\"Pogenberg V, Ogmundsdottir MH, Bergsteinsdottir K, et al: Restricted leucine zipper dimerization and specificity of DNA recognition of the melanocyte master regulator MITF. Genes Dev 26:2647-58, 2012.\" href=\"#_ENREF_63\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23207919\"><sup>63</sup></a>.</p>\n<p id=\"erb-c5ee4029-b2eb-4585-a0f5-33eba6287546\"><u>Potential treatment approaches to MITF amplification</u></p>\n<p id=\"erb-020e1f17-1cff-4a83-878a-76f126739c9d\">These findings on MITF-mediated pathways remain in the domain of preclinical research, although targeting MET receptor is feasible because MET inhibitors (<a href=\"http://www.cancer.gov/drugdictionary?CdrID=461103\">cabozantinib</a> <i>et al.</i>) are in clinical trials for cancers other than melanoma.<u> </u>For now, <a href=\"http://www.cancer.gov/drugdictionary?CdrID=530790\">panobinostat</a>/ LBH589 (HDAC inhibitor) is in early clinical testing in melanoma (<a href=\"http://clinicaltrials.gov/ct2/show/NCT01065467\">NCT01065467</a>), and also involves examining the effect of panobinostat on MITF expression. The rationale behind investigating HAD inhibitors is supported by a study demonstrating efficacy of the HDAC inhibitor in suppressing MITF expression <i>in vitro</i> and <i>in vivo</i> <a class=\"rlc-reference\" data-ref-info=\"Yokoyama S, Feige E, Poling LL, et al: Pharmacologic suppression of MITF expression via HDAC inhibitors in the melanocyte lineage. Pigment Cell Melanoma Res 21:457-63, 2008.\" href=\"#_ENREF_64\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/18627530\"><sup>64</sup></a>.</p>\n<p id=\"erb-d5adc7da-36c2-4855-8a09-3a2a879b7a2f\">A new study opened a possibility of targeting the nuclear translocation of ATF2 by inhibiting PKC\u03b5, which phosphorylates ATF2 and induces its transport to the nucleus. The two compounds found to promote cytoplasmic localization of ATF2 were identified in an image-based screen <a class=\"rlc-reference\" data-ref-info=\"Varsano T, Lau E, Feng Y, et al: Inhibition of Melanoma Growth by Small Molecules That Promote the Mitochondrial Localization of ATF2. Clin Cancer Res 19:2710-22, 2013.\" href=\"#_ENREF_65\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23589174\"><sup>65</sup></a>.</p>\n<p id=\"erb-d0bdf58d-ca6e-444f-8d18-afa26d180b73\"><a name=\"KIT\"></a> <b>KIT </b></p>\n<p id=\"erb-fa56fd3b-fc8a-4573-945d-22814431cb9f\">KIT is a receptor tyrosine kinase activated by binding of the cytokine stem cell factor (SCF); mutations and amplification of KIT are found in particular subsets of melanoma. KIT mutations activate signal-transduction pathways (MAPK and PI3K) that ultimately lead to cell proliferation. Mutations in KIT are found in mucosal, acral, and chronically sun-exposed skin melanomas <a class=\"rlc-reference\" data-ref-info=\"Curtin JA, Busam K, Pinkel D, et al: Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 24:4340-6, 2006.\" href=\"#_ENREF_66\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/16908931\"><sup>66</sup></a>. KIT mutations are rare in melanoma, but the availability of selective inhibitors for KIT has prompted interest in targeting this oncogene. These inhibitors\u2014imatinib, sunitinib, nilotinib, and dasatanib\u2014were developed for different cancers (chronic myeloid leukemia, gastrointestinal stromal tumors) and different kinases, but they showed activity against KIT. Approximately 70% of KIT mutations identified in melanoma are found in exon 11, most commonly L576P, and in the kinase domain in exon 13, most often K642E <a class=\"rlc-reference\" data-ref-info=\"Woodman SE, Davies MA: Targeting KIT in melanoma: a paradigm of molecular medicine and targeted therapeutics. Biochem Pharmacol 80:568-74, 2010.\" href=\"#_ENREF_67\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/20457136\"><sup>67</sup></a>. The majority of mutations of KIT found in melanoma also occur in other cancers that are responsive to KIT inhibitors.</p>\n<p id=\"erb-55232cfd-f792-46a3-8e93-78c9e8144cd3\"><u>Treatment approaches to KIT mutations</u></p>\n<p id=\"erb-c98c1930-4ffd-4eb7-96a0-25d314df8539\"><a name=\"BRIAN\"></a> Targeting KIT with <a href=\"http://www.cancer.gov/drugdictionary?CdrID=37862\">imatinib</a> has demonstrated remarkable efficacy in patients with gastrointestinal stromal tumors (GIST), but initial trials in\u00a0melanoma\u00a0were unsuccessful, clearly due to the absence of selection of patients with aberrations in KIT <a class=\"rlc-reference\" data-ref-info=\"Kim KB, Eton O, Davis DW, et al: Phase II trial of imatinib mesylate in patients with metastatic melanoma. Br J Cancer 99:734-40, 2008.\" href=\"#_ENREF_68\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/18728664\"><sup>68-70</sup></a>. Dasatinib was tested as a single agent in unselected melanoma patients and also showed poor response and high toxicity <a class=\"rlc-reference\" data-ref-info=\"Kluger HM, Dudek AZ, McCann C, et al: A phase 2 trial of dasatinib in advanced melanoma. Cancer 117:2202-8, 2011.\" href=\"#_ENREF_71\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/21523734\"><sup>71</sup></a>. Nevertheless, case reports continued to surface that demonstrated the efficacy of imatinib in melanoma patients with specific KIT genetic aberrations, such as mutation K642E <a class=\"rlc-reference\" data-ref-info=\"Lutzky J, Bauer J, Bastian BC: Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation. Pigment Cell Melanoma Res 21:492-3, 2008.\" href=\"#_ENREF_72\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/18510589\"><sup>72</sup></a> and a small duplication <a class=\"rlc-reference\" data-ref-info=\"Hodi FS, Friedlander P, Corless CL, et al: Major response to imatinib mesylate in KIT-mutated melanoma. J Clin Oncol 26:2046-51, 2008.\" href=\"#_ENREF_73\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/18421059\"><sup>73</sup></a>. Two patients whose melanomas harbored L576P responded to dasatinib <a class=\"rlc-reference\" data-ref-info=\"Woodman SE, Trent JC, Stemke-Hale K, et al: Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates. Mol Cancer Ther 8:2079-85, 2009.\" href=\"#_ENREF_74\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/19671763\"><sup>74</sup></a>. Even when alterations in KIT are present in tumors, not all are predictive of responses to kinase inhibitors. Overexpression of KIT in melanoma was found not to confer sensitivity to imatinib <a class=\"rlc-reference\" data-ref-info=\"Hofmann UB, Kauczok-Vetter CS, Houben R, et al: Overexpression of the KIT/SCF in uveal melanoma does not translate into clinical efficacy of imatinib mesylate. Clin Cancer Res 15:324-9, 2009.\" href=\"#_ENREF_75\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/19118061\"><sup>75</sup></a>. <a href=\"http://www.cancer.gov/drugdictionary?CdrID=299061\">Sunitinib malate</a> was tested in another trial; again, no correlation was observed between the degree of KIT expression and longer PFS or OS <a class=\"rlc-reference\" data-ref-info=\"Mahipal A, Tijani L, Chan K, et al: A pilot study of sunitinib malate in patients with metastatic uveal melanoma. Melanoma Res 22:440-6, 2012.\" href=\"#_ENREF_76\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23114504\"><sup>76</sup></a>.</p>\n<p id=\"erb-f1d4d650-64b8-4f27-a229-4baeb9ba4fb9\">Recently, trials of imatinib and <a href=\"http://www.cancer.gov/drugdictionary?CdrID=435988\">nilotinib</a> have shown promising results in trials where patients were selected for KIT mutations. Phase II trials of imatinib in melanoma produced only modest responses to treatment, but 9 of the 10 partial responses (PRs) were observed in patients with mutations in exons 11 or 13 <a class=\"rlc-reference\" data-ref-info=\"Guo J, Si L, Kong Y, et al: Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol 29:2904-9, 2011.\" href=\"#_ENREF_77\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/21690468\"><sup>77</sup></a>. Another phase II trial of imatinib in 28 patients with alterations in KIT produced durable responses in 16% of patients, predominantly in those with KIT mutations versus those with amplifications <a class=\"rlc-reference\" data-ref-info=\"Carvajal RD, Antonescu CR, Wolchok JD, et al: KIT as a therapeutic target in metastatic melanoma. JAMA 305:2327-34, 2011.\" href=\"#_ENREF_78\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/21642685\"><sup>78</sup></a>. Sunitinib induced responses in 3 out of 4 patients with KIT mutations in exons 11 and 13, but only in one out of six patients with KIT amplification <a class=\"rlc-reference\" data-ref-info=\"Minor DR, Kashani-Sabet M, Garrido M, et al: Sunitinib therapy for melanoma patients with KIT mutations. Clin Cancer Res 18:1457-63, 2012.\" href=\"#_ENREF_79\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22261812\"><sup>79</sup></a>. Preliminary results of a trial with <a href=\"http://www.cancer.gov/drugdictionary?CdrID=435988\">nilotinib</a> were published when it showed durable responses in patients with KIT mutations <a class=\"rlc-reference\" data-ref-info=\"Cho JH, Kim KM, Kwon M, et al: Nilotinib in patients with metastatic melanoma harboring KIT gene aberration. Invest New Drugs 30:2008-14, 2012.\" href=\"#_ENREF_80\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22068222\"><sup>80</sup></a>. A recent phase II trial of imatinib in selected patient population with mucosal, acral, or chronically sun-damaged melanoma concluded with an overall disease-control rate of 50%, but the responses were observed in 77% of patients with mutated KIT and only in 18% of those with amplified KIT. The best ORR was, respectively, 54% versus 0% <a class=\"rlc-reference\" data-ref-info=\"Hodi FS, Corless CL, Giobbie-Hurder A, et al: Imatinib for Melanomas Harboring Mutationally Activated or Amplified KIT Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin. J Clin Oncol, 2013.\" href=\"#_ENREF_81\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23775962\"><sup>81</sup></a>. Preexisting NRAS mutations conferred intrinsic resistance to imatinib <a class=\"rlc-reference\" data-ref-info=\"Hodi FS, Corless CL, Giobbie-Hurder A, et al: Imatinib for Melanomas Harboring Mutationally Activated or Amplified KIT Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin. J Clin Oncol, 2013.\" href=\"#_ENREF_81\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23775962\"><sup>81</sup></a> and to sunitinib (<a class=\"rlc-reference\" data-ref-info=\"Haarberg HE, Paraiso KH, Wood E, et al: Inhibition of Wee1, AKT and CDK4 underlies the efficacy of the HSP90 inhibitor XL888 in an in vivo model of NRAS mutant melanoma. Mol Cancer Ther, 2013.\" href=\"#_ENREF_175\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23538902\">Minor et al., 2012</a>) <!-- Citation style?\r\n -->in patients with KIT mutation. It is becoming clear that inhibitors of KIT should be used in selected patient populations whose tumors have KIT mutations in exon 11 and 13 but not where KIT is not mutated but amplified <a class=\"rlc-reference\" data-ref-info=\"Carvajal RD: Another Option in Our KIT of Effective Therapies for Advanced Melanoma. J Clin Oncol, 2013.\" href=\"#_ENREF_82\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23940226\"><sup>82</sup></a>.</p>\n<p id=\"erb-ac4c6160-a5ba-4382-a875-a192cdef848d\">At least 10 ongoing trials test the activity of the aforementioned inhibitors in KIT-mutated melanoma as single agents (<a href=\"http://www.cancercommons.org/researchers-clinicians/melanoma/melanoma-stats-page/#tabs3\">Supplemental Table 2</a>). Planned and ongoing trials include combinations of KIT inhibitors with other targeted drugs and immunotherapy. Trial <a href=\"http://clinicaltrials.gov/ct2/show/NCT01738139\">NCT01738139</a> recruits patients for the combination of imatinib with ipilimumab (an immunomodulatory antibody to CTLA4) in patients with various tumors that have somatic alterations of KIT.</p>\n<p id=\"erb-00ffdc40-98d4-4ebc-9a1a-3086be30a5ac\"><a name=\"NF1\"></a> <b>NF1/neurofibromin</b></p>\n<p id=\"erb-eef66596-3cd2-4b72-abd4-3d430f97b84c\">NF1 is a tumor suppressor regulating signaling from RAS; germline mutations in NF1 deregulate both PI3K and MAPK pathways and result in familial neurofibromatosis. Some neurofibromatosis patients with inactivation of NF1 develop melanomas. Moreover, NF1 expression is low in 47% of uveal melanomas <a class=\"rlc-reference\" data-ref-info=\"Johnson MR, Look AT, DeClue JE, et al: Inactivation of the NF1 gene in human melanoma and neuroblastoma cell lines without impaired regulation of GTP.Ras. Proc Natl Acad Sci U S A 90:5539-43, 1993.\" href=\"#_ENREF_83\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/8516298\"><sup>83</sup></a> and allelic losses are seen in other types of melanoma <a class=\"rlc-reference\" data-ref-info=\"Gutzmer R, Herbst RA, Mommert S, et al: Allelic loss at the neurofibromatosis type 1 (NF1) gene locus is frequent in desmoplastic neurotropic melanoma. Hum Genet 107:357-61, 2000.\" href=\"#_ENREF_84\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/11129335\"><sup>84</sup></a>. Mutations in NF1 are enriched in melanoma that have wild-type BRAF and NRAS (25% of those had NF1 mutations as reported by Hodis <a class=\"rlc-reference\" data-ref-info=\"Hodis E, Watson IR, Kryukov GV, et al: A landscape of driver mutations in melanoma. Cell 150:251-63, 2012.\" href=\"#_ENREF_31\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22817889\"><sup>31</sup></a>, albeit a relatively small number of patients was analyzed), suggesting that they could be considered as driver mutations in this subset that was, until now, not amenable to targeted therapy approaches. In addition, NF1 mutations or suppression occur in human melanomas that harbor concurrent BRAF mutations <sup><a class=\"rlc-reference\" data-ref-info=\"Hodis E, Watson IR, Kryukov GV, et al: A landscape of driver mutations in melanoma. Cell 150:251-63, 2012.\" href=\"#_ENREF_31\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22817889\">31</a>,<a class=\"rlc-reference\" data-ref-info=\"Maertens O, Johnson B, Hollstein P, et al: Elucidating distinct roles for NF1 in melanomagenesis. Cancer Discov, 2012.\" href=\"#_ENREF_85\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23171796\">85</a></sup>. Mutations in the NF1 cooperate with BRAF mutations in a mouse model of melanomagenesis by suppressing BRAF-induced senescence (OIS), promoting melanocyte hyperproliferation and enhancing melanoma development. Knockdown of NF1 <i>in vitro</i> promotes activation of both KRAS and CRAF.</p>\n<p id=\"erb-cc0d14ae-c5a8-45ea-87fa-4df69c8d8cd5\"><u>Potential treatment approaches to NFI mutations</u></p>\n<p id=\"erb-0228c2a0-fba1-40bc-80be-ceed4fa45fff\">In recent studies NF1 could be successfully targeted in mouse models with a combination of MEK and PI3K/mTOR inhibitors <a class=\"rlc-reference\" data-ref-info=\"Maertens O, Johnson B, Hollstein P, et al: Elucidating distinct roles for NF1 in melanomagenesis. Cancer Discov, 2012.\" href=\"#_ENREF_85\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23171796\"><sup>85</sup></a>; a combination of irreversible RAF inhibition and MEK inhibition was also effective <i>in vivo</i> <a class=\"rlc-reference\" data-ref-info=\"Whittaker SR, Theurillat JP, Van Allen E, et al: A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. Cancer Discov, 2013.\" href=\"#_ENREF_86\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23288408\"><sup>86</sup></a>.</p>\n<p id=\"erb-248e4516-a0cf-4aed-aa83-e89639717f8c\"><a name=\"TERT\"></a> <b>Telomerase</b></p>\n<p id=\"erb-abc25c8a-8bd1-4e9a-807f-aac2b693d397\">Two very recent studies\u2014one based on analysis of genomic alterations in a melanoma-prone family, the other based on analysis of the genomic sequence data from melanoma tumors\u2014have revealed new, frequent, and unexpected mutations in the regulatory regions of the catalytic subunit of telomerase <sup><a class=\"rlc-reference\" data-ref-info=\"Horn S, Figl A, Rachakonda PS, et al: TERT Promoter Mutations in Familial and Sporadic Melanoma. Science, 2013.\" href=\"#_ENREF_87\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23348503\">87</a>,<a class=\"rlc-reference\" data-ref-info=\"Huang FW, Hodis E, Xu MJ, et al: Highly Recurrent TERT Promoter Mutations in Human Melanoma. Science, 2013.\" href=\"#_ENREF_88\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23348506\">88</a></sup>. Mutations were found in 33% primary and 85% metastatic tumors in the first study versus 71% of all tumors in the second study. Mutations create a new binding motif for TCF/ETS transcription factors and result in an increased transcription from TERT promoter. Mutations in the promoter region of TERT are considered to be driver mutations because of their association with familial melanoma and high frequency in sporadic melanoma. TERT promoter mutations are not limited to melanoma, and were found in 16% of tumor cell lines from diverse cancers <a class=\"rlc-reference\" data-ref-info=\"Huang FW, Hodis E, Xu MJ, et al: Highly Recurrent TERT Promoter Mutations in Human Melanoma. Science, 2013.\" href=\"#_ENREF_88\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23348506\"><sup>88</sup></a>.</p>\n<p id=\"erb-d8f7b837-e8e0-4eba-9dcc-3535ae3bf84c\"><u>Potential treatment options to telomerase mutations</u></p>\n<p id=\"erb-838ebaae-c5b9-4471-984f-7f226db06ff7\">Telomerase inhibitor <a href=\"http://www.cancer.gov/drugdictionary?CdrID=447136\">imetelstat sodium</a>/GRN163L (antisense oligonucleotide) is trialed in breast cancer and a telomerase vaccine GV1001 in nonsmall cell lung cancer (NSCLC).</p>\n<p id=\"erb-9879baa1-652a-446a-8030-26b5d1148a14\"><b>Receptor tyrosine kinases and PI3K pathway</b></p>\n<p id=\"erb-ebf678ea-cdf6-4ce4-8589-b5f210d15c6e\">Activation of the PI3K pathway serves to overcome OIS that is associated with mutant BRAF. PTEN aberrations are often associated with the presence of BRAFV600E, and cooperate with mutant BRAF in a GEMM <a class=\"rlc-reference\" data-ref-info=\"Dankort D, Curley DP, Cartlidge RA, et al: Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet 41:544-52, 2009.\" href=\"#_ENREF_89\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/19282848\"><sup>89</sup></a>, most likely by overcoming OIS associated with mutant BRAF. In support of this notion, while BRAF mutations are present in both nevi and melanoma sections of contiguous nevi-melanoma biopsies, activation of PI3K (through loss of PTEN expression or activation of AKT3) was detected in the melanoma portions only <a class=\"rlc-reference\" data-ref-info=\"Vredeveld LC, Possik PA, Smit MA, et al: Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis. Genes Dev 26:1055-69, 2012.\" href=\"#_ENREF_90\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22549727\"><sup>90</sup></a>. This indicates that the AKT3/PI3K pathway is activated during progression to malignant melanoma, most likely as a means of overcoming OIS. PI3K pathway activation serves as a rate-limiting event and dual inhibition of PI3K/mutant BRAF eliminated cells resistant to BRAF inhibition <i>in vitro</i> <a class=\"rlc-reference\" data-ref-info=\"Vredeveld LC, Possik PA, Smit MA, et al: Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis. Genes Dev 26:1055-69, 2012.\" href=\"#_ENREF_90\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22549727\"><sup>90</sup></a>. Several mutations in different components of the PI3K pathway, from receptor tyrosine kinases (RTK) to PTEN and to AKT3, have been described.</p>\n<p id=\"erb-8a9fe700-5ea3-4229-a1a0-a816abd97f38\"><a name=\"ERBB4\"></a> <b>ERBB4.</b> Mutations in this tyrosine kinase receptor are<b> </b>found in 19% of melanomas, based on the results of targeted sequencing of the tyrosine kinase family in seven melanoma tumors <a class=\"rlc-reference\" data-ref-info=\"Prickett TD, Agrawal NS, Wei X, et al: Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4. Nat Genet 41:1127-32, 2009.\" href=\"#_ENREF_91\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/19718025\"><sup>91</sup></a>. The pattern of mutations, however, did not exhibit recurrent hot spots. Subsequent studies have reported either much lower incidence (2% of 271 tumors) of ERBB4 mutations in melanoma <a class=\"rlc-reference\" data-ref-info=\"Dutton-Regester K, Irwin D, Hunt P, et al: A high-throughput panel for identifying clinically relevant mutation profiles in melanoma. Mol Cancer Ther 11:888-97, 2012.\" href=\"#_ENREF_92\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22383533\"><sup>92</sup></a>, or lack of any in sampling of 117 tumors <a class=\"rlc-reference\" data-ref-info=\"Zhou QM, Li W, Guan YX, et al: The absence of the ERBB4 hotspot mutations in melanomas in patients from southern China. Chin J Cancer 32:410-4, 2013.\" href=\"#_ENREF_93\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23237222\"><sup>93</sup></a>. Nevertheless, <a href=\"http://www.cancer.gov/drugdictionary?CdrID=269659\">lapatinib</a>, a reversible inhibitor of EGFR, ERBB2, and other kinases is currently in a clinical trial for advanced melanoma with ERBB4 mutations (<a href=\"http://clinicaltrials.gov/ct2/results?term=NCT01264081&amp;Search=Search\">NCT01264081</a>).</p>\n<p id=\"erb-79724e00-ca39-4ee1-9937-da4ae749ca70\"><a name=\"MET\"></a> <b>MET.</b> Mutations in MET have not been described in melanoma, but there is strong evidence that this RTK is involved in melanoma growth and metastases (see below: WNT pathway and HGF expression in stroma). Copy number gains involving MET locus in melanomas were documented <a class=\"rlc-reference\" data-ref-info=\"Moore SR, Persons DL, Sosman JA, et al: Detection of copy number alterations in metastatic melanoma by a DNA fluorescence in situ hybridization probe panel and array comparative genomic hybridization: a southwest oncology group study (S9431). Clin Cancer Res 14:2927-35, 2008.\" href=\"#_ENREF_94\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/18483359\"><sup>94</sup></a>. SU11274, an inhibitor of MET, has shown significant activity in a xenograft model <a class=\"rlc-reference\" data-ref-info=\"Kenessey I, Keszthelyi M, Kramer Z, et al: Inhibition of c-Met with the specific small molecule tyrosine kinase inhibitor SU11274 decreases growth and metastasis formation of experimental human melanoma. Curr Cancer Drug Targets 10:332-42, 2010.\" href=\"#_ENREF_95\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/20370683\"><sup>95</sup></a>. <a href=\"http://www.cancer.gov/drugdictionary?CdrID=461103\">Cabozantinib</a>, an inhibitor of MET and other RTKs is in clinical trials for a variety of cancers with deregulated RTK signaling. In melanoma, cabozantinib will be trialed in combination with vemurafenib (<a href=\"http://clinicaltrials.gov/ct2/show/NCT01835184\">NCT01835184</a>).</p>\n<p id=\"erb-b6f2b62a-0c39-4682-bfe5-2f37e8deffa6\"><a name=\"MERTK\"></a> <b>MERTK.</b> MER, a receptor tyrosine kinase (RTK) sharing a family relationship with TYRO3 and AXL, was found to be expressed at increasing levels during progression from nevi to metastatic melanoma. Stimulation of MER with its ligand GAS6 leads to activation of MAPK, PI3K, and JAK/STAT pathways. Inhibition of MERTK with a synthetic compound UNC1062 inhibits invasion and induces apoptosis in melanoma cells in vitro <a class=\"rlc-reference\" data-ref-info=\"Schlegel J, Sambade MJ, Sather S, et al: MERTK receptor tyrosine kinase is a therapeutic target in melanoma. J Clin Invest, 2013.\" href=\"#_ENREF_96\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23585477\"><sup>96</sup></a>. MERTK and AXL are expressed alternatively in melanoma <a class=\"rlc-reference\" data-ref-info=\"Tworkoski KA, Platt JT, Bacchiocchi A, et al: MERTK controls melanoma cell migration and survival and differentially regulates cell behavior relative to AXL. Pigment Cell Melanoma Res, 2013.\" href=\"#_ENREF_97\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23617806\"><sup>97</sup></a>. MERTK-expressing melanoma cells are more proliferative than AXL-expressing cells, though the latter are more invasive <a class=\"rlc-reference\" data-ref-info=\"Tworkoski KA, Platt JT, Bacchiocchi A, et al: MERTK controls melanoma cell migration and survival and differentially regulates cell behavior relative to AXL. Pigment Cell Melanoma Res, 2013.\" href=\"#_ENREF_97\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23617806\"><sup>97</sup></a>.</p>\n<p id=\"erb-83e8396d-5364-4d5d-866c-87a848750c4e\"><a name=\"AKT\"></a> <b>AKT.</b> <!-- Mysterious capititalization vs. lowercase in this pargraph - Akt1 vs. AKT1 etc.  Throughout rest of manuscript there is no differentiation between gene and its product, etc.\r\n -->Deregulated Akt3 activity was shown to promote development of malignant melanoma; amplifications of Akt3 were detected in melanoma <a class=\"rlc-reference\" data-ref-info=\"Stahl JM, Sharma A, Cheung M, et al: Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res 64:7002-10, 2004.\" href=\"#_ENREF_98\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/15466193\"><sup>98</sup></a>. Alterations of AKT1 and AKT2 are rare, but genetic gain of Akt3 is seen in 25% of melanoma tumors. A screen of 137 melanomas and 65 cell lines identified an activating mutation E17A in AKT1 (one patient) and AKT3 (one patient and two cell lines), all with concurrent BRAF mutations <a class=\"rlc-reference\" data-ref-info=\"Davies MA, Stemke-Hale K, Tellez C, et al: A novel AKT3 mutation in melanoma tumours and cell lines. Br J Cancer 99:1265-8, 2008.\" href=\"#_ENREF_99\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/18813315\"><sup>99</sup></a>. High activity of AKT3 was shown to promote progression of BRAFV600E-positive nevi to melanoma <a class=\"rlc-reference\" data-ref-info=\"Cheung M, Sharma A, Madhunapantula SV, et al: Akt3 and mutant V600E B-Raf cooperate to promote early melanoma development. Cancer Res 68:3429-39, 2008.\" href=\"#_ENREF_100\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/18451171\"><sup>100</sup></a>. A trial combining <a href=\"http://www.cancer.gov/drugdictionary?CdrID=596332\">MK2206</a> (Akt inhibitor) in combination with <a href=\"http://www.cancer.gov/drugdictionary?CdrID=532294\">AZD6244</a> (the MEK inhibitor selumetinib) is in progress (<a href=\"http://clinicaltrials.gov/ct2/results?term=NCT01519427\">NCT01519427</a>).</p>\n<p id=\"erb-56cb8e54-3af5-4f91-88b0-da2a6a09d8e1\"><a name=\"PTEN\"></a><a name=\"MAGI\"></a> <b>PTEN</b> is a well-known tumor suppressor affected in approximately 25% to 30% of melanoma, most commonly via allelic loss and focal deletions <sup><a class=\"rlc-reference\" data-ref-info=\"Hodis E, Watson IR, Kryukov GV, et al: A landscape of driver mutations in melanoma. Cell 150:251-63, 2012.\" href=\"#_ENREF_31\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22817889\">31</a>,<a class=\"rlc-reference\" data-ref-info=\"Tsao H, Zhang X, Benoit E, et al: Identification of PTEN/MMAC1 alterations in uncultured melanomas and melanoma cell lines. Oncogene 16:3397-402, 1998.\" href=\"#_ENREF_101\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/9692547\">101</a></sup>. PTEN is also deregulated in melanoma via loss of ZEB2, a competitive endogenous RNA (ceRNA) <a class=\"rlc-reference\" data-ref-info=\"Karreth FA, Tay Y, Perna D, et al: In vivo identification of tumor- suppressive PTEN ceRNAs in an oncogenic BRAF-induced mouse model of melanoma. Cell 147:382-95, 2011.\" href=\"#_ENREF_102\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22000016\"><sup>102</sup></a>. In addition, disruptions of MAGI2, a protein that associates with and stabilizes PTEN, occur in melanoma <a class=\"rlc-reference\" data-ref-info=\"Berger MF, Hodis E, Heffernan TP, et al: Melanoma genome sequencing reveals frequent PREX2 mutations. Nature 485:502-6, 2012.\" href=\"#_ENREF_1\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22622578\"><sup>1</sup></a>. PTEN aberrations are often associated with the presence of BRAFV600E, and cooperate with mutant BRAF in a GEMM <a class=\"rlc-reference\" data-ref-info=\"Dankort D, Curley DP, Cartlidge RA, et al: Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet 41:544-52, 2009.\" href=\"#_ENREF_89\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/19282848\"><sup>89</sup></a>, most likely providing an OIS inhibitory function by activating the PI3K pathway. In this model, growth of melanoma could be inhibited by combined treatment with PD325901 (MEK inhibitor) and rapamycin (mTOR inhibitor). PTEN-inactivating aberrations are not associated with NRAS mutations, perhaps because the latter lead to activation of PI3K in the absence of this pathway's mutations. PTEN mutations and copy losses are associated with lower PFS in response to inhibition of mutant BRAF in patients <a class=\"rlc-reference\" data-ref-info=\"Nathanson KL, Martin AM, Wubbenhorst B, et al: Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor Dabrafenib (GSK2118436). Clin Cancer Res, 2013.\" href=\"#_ENREF_103\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23833299\"><sup>103</sup></a>. PTEN (or rather lack of PTEN) was shown to play a key role in the predisposition to melanoma in individuals carrying certain variants of melanocortin-1 receptor (MC1R). The mechanisms through which MC1R variants associated with red hair and fair skin predispose to melanoma were not understood until recently, when it was shown that wild-type but not variant MC1R protein associates with PTEN and protects it from degradation after UVB exposure. Disrupted MC1R-PTEN association was shown to be responsible for the oncogenic transformation promoted by MC1R variants in presence of BRAFV600E <a class=\"rlc-reference\" data-ref-info=\"Cao J, Wan L, Hacker E, et al: MC1R Is a Potent Regulator of PTEN after UV Exposure in Melanocytes. Mol Cell 51:409-22, 2013.\" href=\"#_ENREF_104\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23973372\"><sup>104</sup></a>.</p>\n<p id=\"erb-37473d55-6894-4c8d-b7ae-c9f7902953ec\"><b>Other PI3K pathway mutations.</b> Mutations in other PI3K pathways genes MTOR, IRS4, PIK3R1, PIK3R4, and PIK3R5 were detected in 17% of BRAFV600 and in 9% of NRAS-mutant tumors <a class=\"rlc-reference\" data-ref-info=\"Shull AY, Latham-Schwark A, Ramasamy P, et al: Novel somatic mutations to PI3K pathway genes in metastatic melanoma. PLoS One 7:e43369, 2012.\" href=\"#_ENREF_105\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22912864\"><sup>105</sup></a>, even though their functional significance remains to be determined.</p>\n<p id=\"erb-1f34f8cd-2472-4371-9d13-050f33474336\"><a name=\"MAPK\"></a> <b>MAPK pathway downstream of BRAF</b></p>\n<p id=\"erb-29b4e57e-47b2-4137-9d2f-391330b01d7d\"><b>MEK1 and MEK2</b>. Sequencing of seven melanoma cell lines and donor-matched germline cells found MAP2K1 and MAP2K2 (MEK1 and MEK2, respectively) mutations, resulting in constitutive ERK phosphorylation and higher resistance to MEK inhibitors. Screening of a larger cohort of melanoma tumors revealed the presence of recurring somatic MAP2K1 and MAP2K2 mutations at an overall frequency of 8% <a class=\"rlc-reference\" data-ref-info=\"Nikolaev SI, Rimoldi D, Iseli C, et al: Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma. Nat Genet 44:133-9, 2012.\" href=\"#_ENREF_106\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22197931\"><sup>106</sup></a>.</p>\n<p id=\"erb-c865b9c2-a395-4508-8b1d-b0e54c099b14\"><b>IQGAP1: a scaffold protein in MAPK pathway as a possible target.</b> There are new data indicating that it might be possible to target the MAPK pathway without direct inhibition of enzymatic activity of kinases in this pathway. It is well known that kinases usually depend on scaffold proteins that assemble signaling complexes. One of these scaffold proteins, IQGAP1 is essential for activity of ERK1/2, and disruption of IQGAP interaction with ERK using a small peptide inhibited RAS- or BRAF-driven tumorigenesis and even overcame resistance to vemurafenib <a class=\"rlc-reference\" data-ref-info=\"Jameson KL, Mazur PK, Zehnder AM, et al: IQGAP1 scaffold-kinase interaction blockade selectively targets RAS-MAP kinase-driven tumors. Nat Med, 2013.\" href=\"#_ENREF_107\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23603816\"><sup>107</sup></a>.</p>\n<p id=\"erb-2507e33a-dbf7-4d0f-bc64-f884083acf1b\"><a name=\"RAC\"></a> <b>RAC pathway.</b> RAC1 is a<b> </b>Rho GTPase, a GTP exchange protein known to affect the cell cytoskeleton and motility. Its role in conveying oncogenic signaling from mutant NRAS in melanoma was described (Li et al. <a class=\"rlc-reference\" data-ref-info=\"Li A, Ma Y, Jin M, et al: Activated mutant NRas(Q61K) drives aberrant melanocyte signaling, survival, and invasiveness via a Rac1-dependent mechanism. J Invest Dermatol 132:2610-21, 2012.\" href=\"#_ENREF_108\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22718121\"><sup>108</sup></a> and references therein). Recently P29S mutations in the conserved switch domain were described in melanoma, in 5% of tumors in the experimental set <sup><a class=\"rlc-reference\" data-ref-info=\"Hodis E, Watson IR, Kryukov GV, et al: A landscape of driver mutations in melanoma. Cell 150:251-63, 2012.\" href=\"#_ENREF_31\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22817889\">31</a>,<a class=\"rlc-reference\" data-ref-info=\"Krauthammer M, Kong Y, Ha BH, et al: Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat Genet 44:1006-14, 2012.\" href=\"#_ENREF_109\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22842228\">109</a></sup>, and their functional role <i>in vitro</i> was confirmed. Mutations were also found in other Rho family members\uf0beRAC2 (P29L), RHOT1 (P30L), and in CDC42 (G12D) \uf0bemaking RAC pathway a target of frequent hotspot mutation.</p>\n<p id=\"erb-8d5c6794-1a4e-4e2c-80c4-78c5b33f1e29\"><a name=\"MAP3K5\"></a> <b>MAP3K5 and MAP3K9</b>. These MAP3 kinases are directly downstream of Rac and Rho signaling activated by various stress signals. Mutations and the loss of heterozygosity of MAP3K5 and MAP3K9 in 85% and 67% of melanoma samples, respectively, suggest inactivation of these kinases. Indeed, mutants MAP3K5 I780F and MAP3K9 W333* variants had reduced kinase activity <i>in vitro</i>. Overexpression of these mutants reduced the phosphorylation of downstream MAP kinases, while siRNA-mediated depletion of MAP3K9 in melanoma cells led to increased cell viability after temozolomide treatment, suggesting that decreased MAP3K activity acts as a pro-survival adaptation <a class=\"rlc-reference\" data-ref-info=\"Stark MS, Woods SL, Gartside MG, et al: Frequent somatic mutations in MAP3K5 and MAP3K9 in metastatic melanoma identified by exome sequencing. Nat Genet 44:165-9, 2012.\" href=\"#_ENREF_110\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22197930\"><sup>110</sup></a>.</p>\n<p id=\"erb-dd32afd0-8356-42ff-888f-5f3af6c23a63\"><a name=\"PREX2\"></a> <b>PREX2.</b> Mutations of<b> </b>phosphatidylinositol-3,4,5-trisphosphate-dependent Rac exchange factor 2 were found in 14% of a cohort of 107 tumors <a class=\"rlc-reference\" data-ref-info=\"Berger MF, Hodis E, Heffernan TP, et al: Melanoma genome sequencing reveals frequent PREX2 mutations. Nature 485:502-6, 2012.\" href=\"#_ENREF_1\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22622578\"><sup>1</sup></a>. Functional studies <i>in vitro</i> have confirmed a role for PREX2 in melanomagenesis. Presence of mutations in three functional components of RAC pathways (Rho family proteins, MAP3K5 and MAP3K9, PREX2) strongly indicates involvement of RAC pathway in pathogenesis of melanoma.</p>\n<p id=\"erb-0e752c0a-d0ac-4b58-aa67-800530260f85\"><b>Cell cycle and apoptosis-related genes</b></p>\n<p id=\"erb-97e2927a-2e4d-4426-9288-a5aacc416c43\"><a name=\"CDK4\"></a><a name=\"CCND1\"></a> <b>CDK4</b>, a cell cycle G1/S kinase, and<b> </b>cyclin D1 (CCND1)<b>, </b>were shown to be amplified in melanoma <a class=\"rlc-reference\" data-ref-info=\"Muthusamy V, Hobbs C, Nogueira C, et al: Amplification of CDK4 and MDM2 in malignant melanoma. Genes Chromosomes Cancer 45:447-54, 2006.\" href=\"#_ENREF_111\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/16419059\"><sup>111</sup></a>. CDK4 mutations are associated with familial melanoma <a class=\"rlc-reference\" data-ref-info=\"Zuo L, Weger J, Yang Q, et al: Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nat Genet 12:97-9, 1996.\" href=\"#_ENREF_112\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/8528263\"><sup>112</sup></a>. In a clinical study of FOLFIRI (chemotherapeutic agent) with the nonselective CDK inhibitor flavopirodol in solid tumors, one melanoma patient had a complete response <a class=\"rlc-reference\" data-ref-info=\"Dickson MA, Shah MA, Rathkopf D, et al: A phase I clinical trial of FOLFIRI in combination with the pan-cyclin-dependent kinase (CDK) inhibitor flavopiridol. Cancer Chemother Pharmacol 66:1113-21, 2010.\" href=\"#_ENREF_113\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/20953860\"><sup>113</sup></a>. Targeted CDK inhibitors<u> </u>are in clinical development (<a href=\"http://www.cancer.gov/drugdictionary?cdrid=454586\">PD0332991</a>, <a href=\"http://www.cancer.gov/drugdictionary?CdrID=612855\">d</a><a href=\"http://www.cancer.gov/drugdictionary?CdrID=612855\">inaciclib</a>, <a href=\"http://www.cancer.gov/drugdictionary?CdrID=706364\">LY2835219</a>, <a href=\"http://www.cancer.gov/drugdictionary?CdrID=684718\">BAY1000394</a>, <a href=\"http://www.cancer.gov/drugdictionary?CdrID=689330\">LEE011</a>), and at least four of them are currently tested in trials for melanoma and other tumors (<a href=\"http://www.cancercommons.org/researchers-clinicians/melanoma/melanoma-stats-page/#tabs2\">Supplemental Tables 1 and 2</a>).</p>\n<p id=\"erb-8d3cee48-1465-47bf-9b5a-2bb6313a419f\"><a name=\"TP53\"></a> <b>TP53 pathway.</b> TP53 mutations are found in 19% of melanoma tumors <a class=\"rlc-reference\" data-ref-info=\"Hodis E, Watson IR, Kryukov GV, et al: A landscape of driver mutations in melanoma. Cell 150:251-63, 2012.\" href=\"#_ENREF_31\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22817889\"><sup>31</sup></a>, a frequency relatively low compared to other cancers, raising the possibility that melanomas uses alternative ways to overcome p53-mediated tumor suppression. Indeed, several alterations in genes affecting p53 activity have been discovered in melanoma. Among them are the long known mutations in p14ARF<a class=\"rlc-reference\" data-ref-info=\"Hussussian CJ, Struewing JP, Goldstein AM, et al: Germline p16 mutations in familial melanoma. Nat Genet 8:15-21, 1994.\" href=\"#_ENREF_114\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/7987387\"><sup>114</sup></a>, overexpression of MDM2 <a class=\"rlc-reference\" data-ref-info=\"Polsky D, Bastian BC, Hazan C, et al: HDM2 protein overexpression, but not gene amplification, is related to tumorigenesis of cutaneous melanoma. Cancer Res 61:7642-6, 2001.\" href=\"#_ENREF_115\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/11606406\"><sup>115</sup></a>, amplification of MDM4 in melanoma<a class=\"rlc-reference\" data-ref-info=\"Gembarska A, Luciani F, Fedele C, et al: MDM4 is a key therapeutic target in cutaneous melanoma. Nat Med, 2012.\" href=\"#_ENREF_116\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22820643\"><sup>116</sup></a>, elevated expression and the anti-apoptotic role of p53-related protein p63 <a class=\"rlc-reference\" data-ref-info=\"Matin RN, Chikh A, Law Pak Chong S, et al: p63 is an alternative p53 repressor in melanoma that confers chemoresistance and a poor prognosis. J Exp Med, 2013.\" href=\"#_ENREF_117\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23420876\"><sup>117</sup></a>, and increased expression of iASPP <a class=\"rlc-reference\" data-ref-info=\"Bergamaschi D, Samuels Y, Sullivan A, et al: iASPP preferentially binds p53 proline-rich region and modulates apoptotic function of codon 72-polymorphic p53. Nat Genet 38:1133-41, 2006.\" href=\"#_ENREF_118\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/16964264\"><sup>118</sup></a> \uf0beall of which act to inhibit the function of p53. This means that the rare \"p53 mutant subtype\" could now be expanded to a \"p53 pathway aberrations\" subtype.</p>\n<p id=\"erb-f49b36e6-6d5e-4e98-b0f7-3561b96cf1d2\"><a name=\"CDKN2A\"></a> <b>CDKN2A</b> locus is frequently deleted in melanoma of all primary subtypes <a class=\"rlc-reference\" data-ref-info=\"Kamb A, Gruis NA, Weaver-Feldhaus J, et al: A cell cycle regulator potentially involved in genesis of many tumor types. Science 264:436-40, 1994.\" href=\"#_ENREF_119\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/8153634\"><sup>119-121</sup></a>. Two tumor suppressors are encoded within this locus: p14ARF, which activates p53 through inhibition of its major negative regulator MDM2; and p16INK4a, a cyclin-dependent kinase inhibitor that activates retinoblastoma (RB) through negative regulation of CDK4. Loss of CDKN2A was reported to occur in 16% to 41% of sporadic melanoma and with a high frequency in familial melanoma <a class=\"rlc-reference\" data-ref-info=\"Hussussian CJ, Struewing JP, Goldstein AM, et al: Germline p16 mutations in familial melanoma. Nat Genet 8:15-21, 1994.\" href=\"#_ENREF_114\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/7987387\"><sup>114</sup></a>.</p>\n<p id=\"erb-cb25dde7-dc30-4592-906d-9b8373eef7b2\"><b>MDM2. </b>This protein binds to p53 and promotes its degradation and inactivation. MDM2 is considered to be the major negative regulator of p53. Recently, it has been reported that in a fraction of melanoma tumors MDM2 expression is upregulated owing to the silencing of a microRNA, miR-18b, that targets Mdm2 mRNA <a class=\"rlc-reference\" data-ref-info=\"Dar AA, Majid S, Rittsteuer C, et al: The role of miR-18b in MDM2-p53 pathway signaling and melanoma progression. J Natl Cancer Inst 105:433-42, 2013.\" href=\"#_ENREF_122\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23365201\"><sup>122</sup></a>. The authors suggest that targeted overexpression of miR-18b could be considered as a novel strategy for activation of the p53 pathway in melanoma.</p>\n<p id=\"erb-fd68e0cd-d3c2-4f6f-b7d9-e7f75e613a55\"><a name=\"MDM4\"></a> <b>MDM4</b>. In a recent study it was shown that MDM4, a negative regulator of p53, is upregulated in about 65% of melanomas, and that melanocyte-specific Mdm4 overexpression enhanced tumorigenesis in a mouse model of\u00a0melanoma\u00a0induced by\u00a0NRAS <a class=\"rlc-reference\" data-ref-info=\"Gembarska A, Luciani F, Fedele C, et al: MDM4 is a key therapeutic target in cutaneous melanoma. Nat Med, 2012.\" href=\"#_ENREF_116\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22820643\"><sup>116</sup></a>. <!-- Throughout, it seems there's inconsistent use of Nras vs NRAS, MDM4 vs. Mdm4 etc.  Let's discuss your usage.\r\n -->Inhibition of the MDM4-p53 interaction restored p53 function in\u00a0melanoma\u00a0cells, resulting in increased sensitivity to cytotoxic chemotherapy and to inhibitors of the BRAFV600E mutation. MDM4 could be a key determinant of impaired p53 function in human\u00a0melanoma\u00a0and a promising target for anti-melanoma combination therapy <a class=\"rlc-reference\" data-ref-info=\"Gembarska A, Luciani F, Fedele C, et al: MDM4 is a key therapeutic target in cutaneous melanoma. Nat Med, 2012.\" href=\"#_ENREF_116\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22820643\"><sup>116</sup></a>.</p>\n<p id=\"erb-1e63ec19-be6b-4e0d-9c05-5f02802eab63\"><u>Potential treatment</u> of melanoma harboring inactivated wild-type p53 would involve inhibition of CDK4, and MDM2-p53 and MDM4-p53 interactions. The MDM2-p53 interaction has attracted serious efforts to develop specific inhibitors, of which Nutlin analogues are the more advanced. The new generations of Nutlin-based drugs are in clinical studies for various solid tumors. Encouraging results were reported for one of them, <a href=\"http://www.asco.org/ASCOv2/Meetings/Abstracts?&amp;vmview=abst_detail_view&amp;confID=102&amp;abstractID=80576\">RG7112</a>, in early clinical testing for liposarcoma and other tumors <a class=\"rlc-reference\" data-ref-info=\"Ray-Coquard I, Blay JY, Italiano A, et al: Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study. Lancet Oncol 13:1133-40, 2012.\" href=\"#_ENREF_123\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23084521\"><sup>123</sup></a>. Nutlin3, an early prototype inhibitor of p53-MDM2 interaction, was shown to synergize with vemurafenib in inducing cell death in melanoma cell lines and inhibiting tumor growth <i>in vivo </i><a class=\"rlc-reference\" data-ref-info=\"Ji Z, Kumar R, Taylor M, et al: Vemurafenib Synergizes with Nutlin-3 to Deplete Survivin and Suppress Melanoma Viability and Tumor Growth. Clin Cancer Res, 2013.\" href=\"#_ENREF_124\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23812671\"><sup>124</sup></a>. An alternative approach under development is based on the use of stapled peptides against MDM2/MDM4, which exhibit high potency and selectivity <a class=\"rlc-reference\" data-ref-info=\"Brown CJ, Quah ST, Jong J, et al: Stapled peptides with improved potency and specificity that activate p53. ACS Chem Biol 8:506-12, 2013.\" href=\"#_ENREF_125\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23214419\"><sup>125</sup></a>. A potent inhibitor of MDM2 and MDMX interactions, ATSP-7041, reactivated TP53 function and inhibited tumor growth <i>in vitro</i> and <i>in vivo </i><a class=\"rlc-reference\" data-ref-info=\"Chang YS, Graves B, Guerlavais V, et al: Stapled alpha-helical peptide drug development: A potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy. Proc Natl Acad Sci U S A, 2013.\" href=\"#_ENREF_126\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23946421\"><sup>126</sup></a>.</p>\n<p id=\"erb-548bfbc1-9744-4042-a74b-0616a916d9c4\"><b>P63</b>,<b> </b>a protein related to p53, has been reported to have an anti-apoptotic role in melanoma, which is mediated through its interaction with p53. P63 is expressed at high levels in melanoma cell lines and clinical samples and prevents translocation of p53 to the nucleus <a class=\"rlc-reference\" data-ref-info=\"Matin RN, Chikh A, Law Pak Chong S, et al: p63 is an alternative p53 repressor in melanoma that confers chemoresistance and a poor prognosis. J Exp Med, 2013.\" href=\"#_ENREF_117\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23420876\"><sup>117</sup></a>. This study further expands the role of the aberrations of the p53 pathway in melanomagenesis.</p>\n<p id=\"erb-910e7562-3a16-4c73-b552-6b9718fb5096\"><b>iASPP</b> is a conserved ankyrin repeat protein that shuttles between nuclear and cytoplasmic compartments, and nuclear iASPP is found in proliferating cells. The nuclear iASPP was shown to inhibit the pro-apoptotic function of p53 <a class=\"rlc-reference\" data-ref-info=\"Bergamaschi D, Samuels Y, Sullivan A, et al: iASPP preferentially binds p53 proline-rich region and modulates apoptotic function of codon 72-polymorphic p53. Nat Genet 38:1133-41, 2006.\" href=\"#_ENREF_118\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/16964264\"><sup>118</sup></a>. High levels of nuclear iASPP were observed in metastatic melanoma versus primary melanoma <a class=\"rlc-reference\" data-ref-info=\"Lu M, Breyssens H, Salter V, et al: Restoring p53 Function in Human Melanoma Cells by Inhibiting MDM2 and Cyclin B1/CDK1-Phosphorylated Nuclear iASPP. Cancer Cell, 2013.\" href=\"#_ENREF_127\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23623661\"><sup>127</sup></a>. The researchers found that iASPP is phosphorylated by cyclin B/CDK1, which promotes its nuclear localization and binding to p53, inhibiting its pro-apoptotic function. Prevention of iASPP phosphorylation by CDK1 inhibitor or knock-down of iASPP induced apoptotic death in melanoma cell lines, which is further enhanced by Nutlin3 (inhibitor of p53-MDM2 interaction and degradation of p53). Furthermore, inhibition of BRAF with vemurafenib, or MEK with UO126, potentiated effects of Nutlin3 and cyclin B /CDK1 inhibition, inducing apoptosis of melanoma <i>in vitro</i> and <i>in vivo</i> <a class=\"rlc-reference\" data-ref-info=\"Lu M, Breyssens H, Salter V, et al: Restoring p53 Function in Human Melanoma Cells by Inhibiting MDM2 and Cyclin B1/CDK1-Phosphorylated Nuclear iASPP. Cancer Cell, 2013.\" href=\"#_ENREF_127\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23623661\"><sup>127</sup></a>. These findings indicate an alternative strategy for combining therapies that target MAPK pathway and cyclin B/CDK1 in wild-type p53 melanoma.</p>\n<p id=\"erb-d3a43b44-6467-4d2b-ac37-7c97a240c6b7\">\u00a0<b>NFkB</b>. As in many, many other tumors, the NFkB pathway is activated in melanoma, but systemic inhibition of NFkB might have catastrophic general adverse effects and toxicity. A new faucet <!-- facet or faucet?\r\n -->of NFkB activation was described recently in drug-treated melanoma cells that might acquire a senescent secretory phenotype; the latter results in a pro-inflammatory and pro-metastatic phenotype characterized by production of CCL-2. Activated NFkB and PARP-1 contribute to this phenomenon and could be involved in the therapeutic failure <a class=\"rlc-reference\" data-ref-info=\"Ohanna M, Giuliano S, Bonet C, et al: Senescent cells develop a PARP-1 and nuclear factor-{kappa}B-associated secretome (PNAS). Genes Dev 25:1245-61, 2011.\" href=\"#_ENREF_128\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/21646373\"><sup>128</sup></a>.</p>\n<p id=\"erb-0eb540fb-7aca-4928-a763-fe5f86feb587\"><a name=\"BCL2\"></a> <b>BCL2.</b> There is abundant literature that documents elevated BCL2 expression in melanoma and its contribution to melanoma and melanocyte cell survival. A member of this family, BCL2A1, was shown to be amplified in 30% of melanoma and contribute to resistance to BRAF inhibition <a class=\"rlc-reference\" data-ref-info=\"Haq R, Yokoyama S, Hawryluk EB, et al: BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition. Proc Natl Acad Sci U S A 110:4321-6, 2013.\" href=\"#_ENREF_61\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23447565\"><sup>61</sup></a> (see section \u201cIntrinsic Resistance to BRAF and MEK Inhibitors\u201d). Another member of BCL2 family, BCL2L12 is mutated in 4% of melanomas, but mutation is synonymous. mRNA from this mutated BCL2L12 is stable due to failure of targeting by specific miRNA and leads to higher levels of protein. BCL2L12 binds and inhibits tumor suppressor TP53 <a class=\"rlc-reference\" data-ref-info=\"Gartner JJ, Parker SC, Prickett TD, et al: Whole-genome sequencing identifies a recurrent functional synonymous mutation in melanoma. Proc Natl Acad Sci U S A 110:13481-6, 2013.\" href=\"#_ENREF_129\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23901115\"><sup>129</sup></a>.</p>\n<p id=\"erb-072257b9-814a-4a4e-a65d-9826eb9b1d8b\">Attempts to target BCL2 with antisense RNA in melanoma patients have not been successful. <a href=\"http://www.cancer.gov/drugdictionary?CdrID=504100\">Obatoclax</a>, a drug inhibiting interaction of BCL2 with pro-apoptotic proteins Bax and Bak, is in clinical trials for other malignancies. BH3 mimetics to inhibit function of anti-apoptotic proteins, such as BCL2 and BCL-xL, are still subjects of significant interest. One of them, ABT-737, resensitized both melanoma cell lines <i>in vitro</i> and tumors in the <i>in vivo</i> model to common chemotherapeutics (including the only FDA-approved chemotherapeutic for melanoma, dacarbazine), leading to marked BIM (Bcl-2-interacting mediator of cell death)<b> </b>-mediated apoptosis. ABT-737 may be a beneficial adjuvant therapy to improve melanoma response rates when conventional chemotherapy is the only option <a class=\"rlc-reference\" data-ref-info=\"Anvekar RA, Asciolla JJ, Lopez-Rivera E, et al: Sensitization to the mitochondrial pathway of apoptosis augments melanoma tumor cell responses to conventional chemotherapeutic regimens. Cell Death Dis 3:e420, 2012.\" href=\"#_ENREF_130\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23152056\"><sup>130</sup></a>.</p>\n<p id=\"erb-8d8315e8-afe0-45de-9ef0-3bc5e474bb11\"><b>\u03b2-catenin and WNT pathway</b></p>\n<p id=\"erb-e1285874-a599-4bd0-a8e4-ddd48d97e30c\">A number of reports have heavily implicated WNT signaling in melanoma progression and metastases. \u03b2-catenin fortifies the cadherin-based adhesion at the plasma membrane, but, when detached from cadherins, activates transcription of target genes, frequently with oncogenic consequences. Rare mutations in \uf062-catenin and in other members of the WNT signaling family were identified in malignant melanoma 10 years ago <a class=\"rlc-reference\" data-ref-info=\"Reifenberger J, Knobbe CB, Wolter M, et al: Molecular genetic analysis of malignant melanomas for aberrations of the WNT signaling pathway genes CTNNB1, APC, ICAT and BTRC. Int J Cancer 100:549-56, 2002.\" href=\"#_ENREF_131\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/12124804\"><sup>131</sup></a>. \uf062-catenin suppresses expression of p16INK and cooperates with NRAS in transformation to a frank melanoma <a class=\"rlc-reference\" data-ref-info=\"Delmas V, Beermann F, Martinozzi S, et al: Beta-catenin induces immortalization of melanocytes by suppressing p16INK4a expression and cooperates with N-Ras in melanoma development. Genes Dev 21:2923-35, 2007.\" href=\"#_ENREF_132\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/18006687\"><sup>132</sup></a>. WNT5a, in particular, by binding to the Frizzled4- LRP6 complex, activates ARF6 (guanosine triphosphatase adenosine diphosphate ribosylation factor 6), leading to displacement of \uf062-catenin from N-cadherin in melanoma. This stimulates signaling from \uf062-catenin and increases invasiveness <a class=\"rlc-reference\" data-ref-info=\"Grossmann AH, Yoo JH, Clancy J, et al: The Small GTPase ARF6 Stimulates beta-Catenin Transcriptional Activity During WNT5A-Mediated Melanoma Invasion and Metastasis. Sci Signal 6:ra14, 2013.\" href=\"#_ENREF_133\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23462101\"><sup>133</sup></a>.</p>\n<p id=\"erb-58103a4e-516e-49a5-bab2-2ddf8d1e1bac\">In a mouse melanoma model based on PTEN loss and BRAFV600E mutation, \uf062-catenin was shown to be a central mediator of metastases as well as a regulator of both MAPK and PI3K pathways. Recent findings established WNT signaling <!-- Wnt signaling vs. WNT/b-catenin signaling below.... etc with Wnt and WNT.\r\n -->as a metastasis regulator in\u00a0melanoma <a class=\"rlc-reference\" data-ref-info=\"Damsky WE, Curley DP, Santhanakrishnan M, et al: beta-catenin signaling controls metastasis in Braf-activated Pten-deficient melanomas. Cancer Cell 20:741-54, 2011.\" href=\"#_ENREF_134\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22172720\"><sup>134</sup></a>. Mutant BRAF signaling is thought to inhibit WNT/\uf062-catenin signaling. Endogenous \uf062-catenin was apparently required for the efficacy of PLX4720 <i>in vitro</i>; activation of WNT/\uf062-catenin signaling was found to enhance the anticancer activity of PLX4720 <i>in vitro</i> and <i>in vivo</i> <a class=\"rlc-reference\" data-ref-info=\"Biechele TL, Kulikauskas RM, Toroni RA, et al: Wnt/beta-catenin signaling and AXIN1 regulate apoptosis triggered by inhibition of the mutant kinase BRAFV600E in human melanoma. Sci Signal 5:ra3, 2012.\" href=\"#_ENREF_135\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22234612\"><sup>135</sup></a>.</p>\n<p id=\"erb-3094bab2-099a-4613-9efd-7df29395c6d4\">Negative regulation of WNT/\uf062-catenin signaling by MAPK pathway was confirmed in an additional study <a class=\"rlc-reference\" data-ref-info=\"Conrad WH, Swift RD, Biechele TL, et al: Regulating the response to targeted MEK inhibition in melanoma: enhancing apoptosis in NRAS- and BRAF-mutant melanoma cells with Wnt/beta-catenin activation. Cell Cycle 11:3724-30, 2012.\" href=\"#_ENREF_136\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22895053\"><sup>136</sup></a>. Treatment of BRAF-mutant and NRAS-mutant\u00a0melanoma\u00a0lines with WNT3A and the MEK inhibitor AZD6244 induces apoptosis. The susceptibility of BRAF- and NRAS-mutant lines to apoptosis correlated with negative regulation of\u00a0Wnt/\u03b2-catenin signaling by ERK/MAPK signaling and dynamic decreases in abundance of the downstream scaffolding protein, AXIN1 <a class=\"rlc-reference\" data-ref-info=\"Conrad WH, Swift RD, Biechele TL, et al: Regulating the response to targeted MEK inhibition in melanoma: enhancing apoptosis in NRAS- and BRAF-mutant melanoma cells with Wnt/beta-catenin activation. Cell Cycle 11:3724-30, 2012.\" href=\"#_ENREF_136\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22895053\"><sup>136</sup></a>. WNT inhibitors such as <a href=\"http://www.cancer.gov/drugdictionary?CdrID=696436\">PRI-724</a> (inhibitor of interaction between \uf062-catenin and CBP) and <a href=\"http://www.cancer.gov/drugdictionary?CdrID=734935\">OMP-54F28</a> (a fusion protein antagonistic to Fzd8) are starting to enter clinical testing in tumors other than melanoma.</p>\n<p id=\"erb-6659576e-f647-471c-b3e7-066f04447e15\"><b>Transcriptional factors in melanoma</b></p>\n<p id=\"erb-298b26b9-f61e-4c75-b154-23fce1deeaa5\"><a name=\"MYC\"></a> <b>MYC.</b> This universal oncogene and transcriptional master regulator is overexpressed or present at increased copy numbers in<b> </b>41% or more of melanoma tumors <a class=\"rlc-reference\" data-ref-info=\"Moore SR, Persons DL, Sosman JA, et al: Detection of copy number alterations in metastatic melanoma by a DNA fluorescence in situ hybridization probe panel and array comparative genomic hybridization: a southwest oncology group study (S9431). Clin Cancer Res 14:2927-35, 2008.\" href=\"#_ENREF_94\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/18483359\"><sup>94</sup></a>. It is currently considered not to be druggable.</p>\n<p id=\"erb-d5b7934b-9072-45ed-9279-a008e19d363f\"><a name=\"ETV1\"></a> <b>ETV1.</b> This transcription factor from the ETS family was implicated as an oncogene in melanoma and copy-gain numbers were found in 40% of cases examined, with amplification of ETV1 in 13% to18% of cases <a class=\"rlc-reference\" data-ref-info=\"Jane-Valbuena J, Widlund HR, Perner S, et al: An oncogenic role for ETV1 in melanoma. Cancer Res 70:2075-84, 2010.\" href=\"#_ENREF_137\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/20160028\"><sup>137</sup></a>.</p>\n<p id=\"erb-6f7778b4-4ecc-43e3-b35c-dc4e05eb0a36\"><b>Other significant genetic abnormalities in melanoma</b></p>\n<p id=\"erb-66dfcf6c-695a-4eb4-9125-e6640b3d8a0f\"><a name=\"NEDD9\"></a> <b>NEDD9</b>, an integrin adaptor protein related to P130CAS, and a member of a family implicated in pathogenesis of a variety of cancers, was identified as a bona fide melanoma metastasis gene in melanoma. NEDD9 enhanced invasion <i>in vitro</i> and metastasis <i>in vivo</i> of both normal and transformed melanocytes, and was frequently overexpressed in metastatic melanoma relative to primary melanoma <a class=\"rlc-reference\" data-ref-info=\"Kim M, Gans JD, Nogueira C, et al: Comparative oncogenomics identifies NEDD9 as a melanoma metastasis gene. Cell 125:1269-81, 2006.\" href=\"#_ENREF_138\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/16814714\"><sup>138</sup></a>. Fifty-seven percent of melanomas were found to have amplification of NEDD9 <a class=\"rlc-reference\" data-ref-info=\"Moore SR, Persons DL, Sosman JA, et al: Detection of copy number alterations in metastatic melanoma by a DNA fluorescence in situ hybridization probe panel and array comparative genomic hybridization: a southwest oncology group study (S9431). Clin Cancer Res 14:2927-35, 2008.\" href=\"#_ENREF_94\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/18483359\"><sup>94</sup></a>.</p>\n<p id=\"erb-ad5c7083-6e61-4f05-a094-668be826386c\"><a name=\"PPP6C\"></a> <b>PPP6C</b> is a serine-threonine phosphatase, mutated in 12% of sun-exposed melanomas exclusively with BRAF or NRAS mutations <sup><a class=\"rlc-reference\" data-ref-info=\"Hodis E, Watson IR, Kryukov GV, et al: A landscape of driver mutations in melanoma. Cell 150:251-63, 2012.\" href=\"#_ENREF_31\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22817889\">31</a>,<a class=\"rlc-reference\" data-ref-info=\"Krauthammer M, Kong Y, Ha BH, et al: Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat Genet 44:1006-14, 2012.\" href=\"#_ENREF_109\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22842228\">109</a></sup>. PPP6C is the catalytic unit of a phosphatase complex that negatively regulates activity of the mitotic Aurora kinase, a known oncogene. Most mutations map in the conserved domain that is involved in interaction with the regulatory subunit of the complex.</p>\n<p id=\"erb-281f6400-ece2-41bd-8a86-079197a63b18\"><a name=\"TACC\"></a> <b>TACC1</b> (transforming acidic coiled-coil containing protein 1) is mutated in 5% of an experimental set of 121. TACC1 is known to stimulate the PI3K and Ras pathways <!-- In table, it's RAS pathway; I think Ras is correct.\r\n -->and interact with Aurora kinase, which is notable considering that PPP6C mutations (above) also inactivate Aurora kinase <a class=\"rlc-reference\" data-ref-info=\"Hodis E, Watson IR, Kryukov GV, et al: A landscape of driver mutations in melanoma. Cell 150:251-63, 2012.\" href=\"#_ENREF_31\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22817889\"><sup>31</sup></a>. At least 16 Aurora kinase inhibitors are in clinical studies, of which two (<a href=\"http://www.cancer.gov/drugdictionary?CdrID=561286\">MLN8237/alisertib</a>, <a href=\"http://www.cancer.gov/drugdictionary?CdrID=670668\">GSK1070916A</a>) are investigated in melanoma (<a href=\"http://www.cancercommons.org/researchers-clinicians/melanoma/melanoma-stats-page/#tabs2\">Supplemental Tables 1 and 2</a>).</p>\n<p id=\"erb-bb450c96-e0d3-469e-bd47-393cd5010ff7\"><a name=\"BAP1\"></a> <b>BAP1</b> (BRCA1-associated protein-1/ubiquitin carboxy-terminal hydrolase) is involved in metastatic progression of ocular and cutaneous melanoma. BAP1 is a known tumor-suppressor gene. BAP1 mutations are frequently found in uveal melanoma <a class=\"rlc-reference\" data-ref-info=\"Harbour JW, Onken MD, Roberson ED, et al: Frequent mutation of BAP1 in metastasizing uveal melanomas. Science 330:1410-3, 2010.\" href=\"#_ENREF_139\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/21051595\"><sup>139</sup></a>. Germline BAP1 mutations have recently been associated with an increased risk of several cancers, including atypical melanocytic tumors <a class=\"rlc-reference\" data-ref-info=\"Wiesner T, Obenauf AC, Murali R, et al: Germline mutations in BAP1 predispose to melanocytic tumors. Nat Genet 43:1018-21, 2011.\" href=\"#_ENREF_140\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/21874003\"><sup>140</sup></a> and uveal melanoma <a class=\"rlc-reference\" data-ref-info=\"Njauw CN, Kim I, Piris A, et al: Germline BAP1 inactivation is preferentially associated with metastatic ocular melanoma and cutaneous-ocular melanoma families. PLoS One 7:e35295, 2012.\" href=\"#_ENREF_141\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22545102\"><sup>141</sup></a>. Uveal melanoma might be sensitive to <a href=\"http://www.cancer.gov/drugdictionary\">HDAC inhibitors</a> <a class=\"rlc-reference\" data-ref-info=\"Landreville S, Agapova OA, Matatall KA, et al: Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma. Clin Cancer Res 18:408-16, 2012.\" href=\"#_ENREF_142\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22038994\"><sup>142</sup></a>, and a clinical trial of HDAC inhibitor vorinostat/SAHA in uveal melanoma is ongoing (phase II <a href=\"http://clinicaltrials.gov/ct2/show/NCT01587352\">NCT01587352</a>).</p>\n<p id=\"erb-28e06d63-5c2f-403e-a1af-9e54ce7b16b3\"><b>SF3B1.</b> Codon 625 of the SF3B1 gene, encoding splicing factor 3B subunit 1, is consistently mutated in low-grade uveal melanomas with good prognosis <a class=\"rlc-reference\" data-ref-info=\"Harbour JW, Roberson ED, Anbunathan H, et al: Recurrent mutations at codon 625 of the splicing factor SF3B1 in uveal melanoma. Nat Genet 45:133-5, 2013.\" href=\"#_ENREF_143\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23313955\"><sup>143</sup></a>. Mutations of SF3B1 are associated with disomy 3 <a class=\"rlc-reference\" data-ref-info=\"Martin M, Masshofer L, Temming P, et al: Exome sequencing identifies recurrent somatic mutations in EIF1AX and SF3B1 in uveal melanoma with disomy 3. Nat Genet, 2013.\" href=\"#_ENREF_144\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23793026\"><sup>144</sup></a>, are mutually exclusive with BAP1 mutations and lead to aberrant splicing of transcripts of a number of genes <a class=\"rlc-reference\" data-ref-info=\"Furney SJ, Pedersen M, Gentien D, et al: SF3B1 mutations are associated with alternative splicing in uveal melanoma. Cancer Discov, 2013.\" href=\"#_ENREF_2\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23861464\"><sup>2</sup></a>.</p>\n<p id=\"erb-a6602eb0-c3c3-493b-8fcf-f35733f49233\"><a name=\"SNX31\"></a> <b>SNX31</b> was identified as one of the 11 new genes mutated in melanoma <a class=\"rlc-reference\" data-ref-info=\"Hodis E, Watson IR, Kryukov GV, et al: A landscape of driver mutations in melanoma. Cell 150:251-63, 2012.\" href=\"#_ENREF_31\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22817889\"><sup>31</sup></a>. It encodes a poorly characterized sorting nexin 31 protein. It could be a Ras effector protein that selectively binds GTP-loaded H-RAS <a class=\"rlc-reference\" data-ref-info=\"Ghai R, Mobli M, Norwood SJ, et al: Phox homology band 4.1/ezrin/radixin/moesin-like proteins function as molecular scaffolds that interact with cargo receptors and Ras GTPases. Proc Natl Acad Sci U S A 108:7763-8, 2011.\" href=\"#_ENREF_145\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/21512128\"><sup>145</sup></a>.</p>\n<p id=\"erb-137b4e60-95db-4bba-897d-7e60bd10d440\"><a name=\"STK19\"></a> <b>STK19.</b> A 5% mutation rate of this kinase gene with unknown functions is seen in melanoma <a class=\"rlc-reference\" data-ref-info=\"Hodis E, Watson IR, Kryukov GV, et al: A landscape of driver mutations in melanoma. Cell 150:251-63, 2012.\" href=\"#_ENREF_31\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22817889\"><sup>31</sup></a>.</p>\n<p id=\"erb-32566ff2-661e-4af8-b927-b6f18a470c6d\"><b>LKB1/STK11</b>. LKB1 might be a central kinase that integrates energy metabolism and tumor growth, in part through activation of the family of AMPK kinases. Germline mutations in LKB1 (STK11) are associated with the Peutz-Jeghers syndrome (PJS), which includes aberrant mucocutaneous pigmentation, and somatic LKB1 mutations, which occur in 10% of cutaneous melanoma <a class=\"rlc-reference\" data-ref-info=\"Forbes SA, Bindal N, Bamford S, et al: COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res 39:D945-50, 2011.\" href=\"#_ENREF_146\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/20952405\"><sup>146</sup></a>. Somatic inactivation of LKB1 with K-Ras activation in murine melanocytes led to highly metastatic melanoma with 100% penetrance. Downstream events of LKB1 inactivation, in addition to AMPK-related effects, included increased phosphorylation of the SRC family kinase YES, increased expression of WNT target genes, and expansion of a CD24(+) cell population in melanoma with increased metastatic behavior <i>in vitro</i> and <i>in vivo </i><a class=\"rlc-reference\" data-ref-info=\"Liu W, Monahan KB, Pfefferle AD, et al: LKB1/STK11 inactivation leads to expansion of a prometastatic tumor subpopulation in melanoma. Cancer Cell 21:751-64, 2012.\" href=\"#_ENREF_147\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22698401\"><sup>147</sup></a>. <a href=\"http://www.cancer.gov/drugdictionary?CdrID=315885\">Dasatinib</a>, an SRC inhibitor, was shown previously to exhibit a higher activity towards YES rather than SRC, and could be a promising treatment for LKB1-mutated melanoma <a class=\"rlc-reference\" data-ref-info=\"Liu W, Monahan KB, Pfefferle AD, et al: LKB1/STK11 inactivation leads to expansion of a prometastatic tumor subpopulation in melanoma. Cancer Cell 21:751-64, 2012.\" href=\"#_ENREF_147\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22698401\"><sup>147</sup></a>. <a href=\"http://www.cancer.gov/drugdictionary?CdrID=593641\">Metformin</a>, an indirect activator of AMPK, the downstream target of LKB1, is currently in a clinical trial in combination with vemurafenib (NCT01638676<!-- Link?\r\n -->).</p>\n<p id=\"erb-539cfd4f-2755-462b-9599-dc18fffc7aab\"><a name=\"ARID2\"></a> <b>ARID2 </b>is a component of the SWI/SNF chromatin-remodeling complex. Loss-of-function mutations were found in 7% of melanomas. Targeted search identified mutations in other members of the ARID family (ARID1B, ARID1A, SMARCA4), altogether amounting to 13% of the experimental set <a class=\"rlc-reference\" data-ref-info=\"Hodis E, Watson IR, Kryukov GV, et al: A landscape of driver mutations in melanoma. Cell 150:251-63, 2012.\" href=\"#_ENREF_31\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22817889\"><sup>31</sup></a>.</p>\n<p id=\"erb-50257ede-1f07-40c4-900a-94567efad325\"><a name=\"TRRAP\"></a> <b>TRRAP2</b>. Identified mutations occur in 4% of the melanoma set examined. TRRAP functions as part of a multiprotein coactivator complex possessing histone acetyltranferase activity that is central to the transcriptional activity of p53, c-Myc, and E2F1 <a class=\"rlc-reference\" data-ref-info=\"Wei X, Walia V, Lin JC, et al: Exome sequencing identifies GRIN2A as frequently mutated in melanoma. Nat Genet 43:442-6, 2011.\" href=\"#_ENREF_148\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/21499247\"><sup>148</sup></a>.</p>\n<p id=\"erb-74a95d24-41dc-467d-9cd3-2a22270d602a\"><a name=\"GRIN2A\"></a> <b>GRIN2A </b>encodes the glutamate N-methyl-D-aspartic acid (NMDA) receptor subunit \u03b5-1 that is part of the class of ionotropic glutamate receptors and bears the agonist binding site for glutamate. GRIN2A was found to be mutated in 25% of melanomas <a class=\"rlc-reference\" data-ref-info=\"Wei X, Walia V, Lin JC, et al: Exome sequencing identifies GRIN2A as frequently mutated in melanoma. Nat Genet 43:442-6, 2011.\" href=\"#_ENREF_148\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/21499247\"><sup>148</sup></a>; this was confirmed in another study <a class=\"rlc-reference\" data-ref-info=\"Stark MS, Woods SL, Gartside MG, et al: Frequent somatic mutations in MAP3K5 and MAP3K9 in metastatic melanoma identified by exome sequencing. Nat Genet 44:165-9, 2012.\" href=\"#_ENREF_110\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22197930\"><sup>110</sup></a>. Many mutations are missense or nonsense; therefore, it is unlikely to behave as a canonical oncogene.</p>\n<p id=\"erb-5869b252-4210-4b24-889d-190e07c649fd\"><a name=\"GRM3\"></a> <b>GRM3 </b>is a metabotropic glutamate receptor, a G-protein-coupled receptor (GPCR) that activates phospholipase C upon ligand binding. It was found to be mutated in melanoma through exome-capture analysis of GPCR genes <a class=\"rlc-reference\" data-ref-info=\"Prickett TD, Wei X, Cardenas-Navia I, et al: Exon capture analysis of G protein-coupled receptors identifies activating mutations in GRM3 in melanoma. Nat Genet 43:1119-26, 2011.\" href=\"#_ENREF_149\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/21946352\"><sup>149</sup></a>. Mutated GRM3 was shown to contribute to the proliferation and invasiveness of melanoma cells <i>in vitro</i> and induce an increased phosphorylation of MEK. AZD-6244, an inhibitor of MEK, was able to reduce cell proliferation by inducing apoptosis <i>in vitro</i>. There is some interest in using available inhibitors of glutamate release for treatment of melanoma, since one of them, <a href=\"http://www.cancer.gov/drugdictionary?CdrID=594943\">riluzole</a>, was shown to inhibit growth of melanoma cells <i>in vitro</i> and <i>in vivo</i> <a class=\"rlc-reference\" data-ref-info=\"Namkoong J, Shin SS, Lee HJ, et al: Metabotropic glutamate receptor 1 and glutamate signaling in human melanoma. Cancer Res 67:2298-305, 2007.\" href=\"#_ENREF_150\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/17332361\"><sup>150</sup></a>. Even though riluzole was shown to inhibit growth of cell lines expressing GRM1, a clinical trial is ongoing to explore the antitumor activity of riluzole in melanoma without prior analysis of GRM3 status.</p>\n<p id=\"erb-d116599e-26a2-4ad3-8bb9-dad4f3684fb0\"><b>Phosphoglycerate dehydrogenase PHGDH</b> serves to divert glycolytic carbon into serine and glycine metabolism in some cancer cells to supply the increased biosynthetic needs of transformed phenotype <a class=\"rlc-reference\" data-ref-info=\"Locasale JW, Grassian AR, Melman T, et al: Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. Nat Genet 43:869-74, 2011.\" href=\"#_ENREF_151\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/21804546\"><sup>151</sup></a>. The same study found that PHGDH is recurrently amplified in a genomic region of a focal copy number gain most commonly found in melanoma. PHGDH catalyzes the first step in the biosynthesis of serine and subsequent generation of nucleotides. Melanoma cell lines with amplified PHGDH had increased flux through the serine pathway. This pathway, as well as proliferation of cells with high PHGDH, was sensitive to short hairpin RNA (shRNA)-mediated knockdown of PHGDH <a class=\"rlc-reference\" data-ref-info=\"Locasale JW, Grassian AR, Melman T, et al: Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. Nat Genet 43:869-74, 2011.\" href=\"#_ENREF_151\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/21804546\"><sup>151</sup></a>.</p>\n<p id=\"erb-ed110c4e-0b8d-430a-b97f-dd04d5f459fe\"><b>WEE1.</b> Cell cycle regulatory kinase Wee1 is upregulated in melanoma and is associated with poor prognosis <a class=\"rlc-reference\" data-ref-info=\"Magnussen GI, Holm R, Emilsen E, et al: High expression of Wee1 is associated with poor disease-free survival in malignant melanoma: potential for targeted therapy. PLoS One 7:e38254, 2012.\" href=\"#_ENREF_152\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22719872\"><sup>152</sup></a>. Selective inhibitor of Wee1 <a href=\"http://www.cancer.gov/drugdictionary?CdrID=594147\">MK-1775</a> showed somewhat promising results as a single agent in previously treated patients with metastatic melanoma, but additional trials are not being conducted at this time.</p>\n<p id=\"erb-4646ca08-554a-4315-b2bd-3e32584ef8a7\"><b>NUAK2</b> (AMPK-related kinase). High levels of expression of NUAK2 were found in patients with acral melanoma and are associated with increased risk of relapse <a class=\"rlc-reference\" data-ref-info=\"Namiki T, Tanemura A, Valencia JC, et al: AMP kinase-related kinase NUAK2 affects tumor growth, migration, and clinical outcome of human melanoma. Proc Natl Acad Sci U S A 108:6597-602, 2011.\" href=\"#_ENREF_153\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/21460252\"><sup>153</sup></a>. NUAK2 knockdown suppresses melanoma cell growth <i>in vitro</i> and tumorigenicity <i>in vivo</i> and has been proposed as a new oncogene in acral melanoma.</p>\n<p id=\"erb-37090b04-274d-4c2e-81f4-04fd16907d33\"><b>Various noncoding RNAs and other epigenetic alterations</b></p>\n<p id=\"erb-5d7bc483-6997-476e-9125-34ee18086488\">A number of reports found significant roles for miRNA, ncRNA, or ceRNA in pathogenesis of melanoma; for example, ZEB2, a ceRNA for PTEN, upregulates expression of this tumor suppressor in melanoma. Abrogated ZEB2 cooperates with BRAFV600E to promote melanomagenesis <a class=\"rlc-reference\" data-ref-info=\"Karreth FA, Tay Y, Perna D, et al: In vivo identification of tumor- suppressive PTEN ceRNAs in an oncogenic BRAF-induced mouse model of melanoma. Cell 147:382-95, 2011.\" href=\"#_ENREF_102\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22000016\"><sup>102</sup></a>. ADAR1, a protein of the family known as adenosine deaminase acting on RNA, is substantially downregulated during metastatic progression of melanoma. ADAR1 was found to regulate expression of numerous miRNAs, as well as of the key miRNA processing protein DICER. Two miRNAS were implicated in silencing of ADAR1 itself (<a href=\"http://www.jci.org/articles/view/62980\">http://www.jci.org/articles/view/62980</a>). These findings reaffirm the significant contribution of epigenetic miRNA regulation to melanoma pathogenesis.</p>\n<p id=\"erb-957ba85d-cdd3-490c-93ae-3bd46a038329\">Strategies to inhibit or increase expression of ncRNAs in clinical setting are only beginning to emerge. A growing interest in epigenetic alterations such as chromatin remodeling, DNA methylation, and histone modification regarding their role in melanomagenesis, might lead to the identification of novel therapeutic targets (reviewed by van den Hurk<a class=\"rlc-reference\" data-ref-info=\"van den Hurk K, Niessen HE, Veeck J, et al: Genetics and epigenetics of cutaneous malignant melanoma: A concert out of tune. Biochim Biophys Acta 1826:89-102, 2012.\" href=\"#_ENREF_154\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22503822\"><sup>154</sup></a>).</p>\n<h1 id=\"erh-885f8fad-b845-4050-aef0-c4ea92f6c88a\">Intrinsic resistance to BRAF and MEK inhibitors</h1>\n<p id=\"erb-afe7c337-b1e5-4c18-8416-e2a883ef3c0b\">Resistance to BRAF inhibitors could be intrinsic (as in lack of response to selective BRAF inhibitors in patients with BRAF-mutated tumors) or acquired (development of resistance after treatment with BRAF or MEK inhibitors). Both are of the utmost concern. The current understanding of the origins of intrinsic resistance, as well as possible approaches to overcoming it, are addressed here (see <a href=\"#Table3\">Table 3</a>).</p>\n<p id=\"erb-28572f71-516c-451e-abd0-ec37e4f035cf\">It is well established that BRAF mutations play a role in melanomagenesis; however, without additional genetic alterations, tumor development is restricted by OIS. As described in the earlier section, and in Table 1, additional genetic alterations are present in BRAF-mutant tumors, some of which serve to overcome OIS, and could play a role in inherent resistance to mutant BRAF and MEK inhibitors. These two groups overlap, as could be expected. The necessity of targeting multiple signaling pathways to overcome drug resistance of aggressive melanoma was demonstrated <i>in vitro</i> <a class=\"rlc-reference\" data-ref-info=\"Smalley KS, Haass NK, Brafford PA, et al: Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Mol Cancer Ther 5:1136-44, 2006.\" href=\"#_ENREF_155\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/16731745\"><sup>155</sup></a>. Genomic analyses and the informed choice of combinatorial approaches analyzed in preclinical models are critical in selecting the right combination of targeted therapies in a personalized approach to melanoma treatment. In general, in addition to the MAPK pathway that is deregulated in most melanomas, the other targets might include any of the ones listed in <a href=\"#Table1\">Table 1</a>. Experimental evidence indicating involvement of several pathways/genes in inherent resistance to BRAF inhibition is cited below in Table 3.</p>\n<h3><a name=\"Table3\"></a>Table 3. Intrinsic Resistance to BRAF and MEK Inhibitors</h3>\n<table border=\"1\" cellpadding=\"7\" cellspacing=\"0\" id=\"erb-6269dc15-0dbb-41c4-8751-2a46e69ab1dc\" width=\"546\">\n<colgroup>\n<col width=\"208\"></col>\n<col width=\"202\"></col>\n<col width=\"94\"></col>\n</colgroup>\n<tbody>\n<tr valign=\"TOP\">\n<td width=\"208\">\n<p><b>MOLECULAR CHANGE</b></p>\n</td>\n<td width=\"202\">\n<p><b>CONFIRMED IN PATIENT BIOPSIES?</b></p>\n</td>\n<td width=\"94\">\n<p><b>DRUGS TO OVERCOME RESISTANCE</b></p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"208\">\n<p><b>Resistance to Vemurafenib </b></p>\n</td>\n<td width=\"202\">\n<p>\u00a0</p>\n</td>\n<td width=\"94\">\n<p>\u00a0</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"208\">\n<p>Loss of PTEN and consequent loss of BIM expression <sup><a class=\"rlc-reference\" data-ref-info=\"Paraiso KH, Xiang Y, Rebecca VW, et al: PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res 71:2750-60, 2011.\" href=\"#_ENREF_156\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/21317224\">156</a>,<a class=\"rlc-reference\" data-ref-info=\"Vredeveld LC, Possik PA, Smit MA, et al: Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis. Genes Dev 26:1055-69, 2012.\" href=\"#_ENREF_90\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22549727\">90</a>, <a class=\"rlc-reference\" data-ref-info=\"Nathanson KL, Martin AM, Wubbenhorst B, et al: Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor Dabrafenib (GSK2118436). Clin Cancer Res, 2013.\" href=\"#_ENREF_103\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23833299\">103</a></sup></p>\n</td>\n<td width=\"202\">\n<p>Yes</p>\n</td>\n<td width=\"94\">\n<p>PI3Ki + MEKi</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"208\">\n<p>NF1 mutation or loss of expression<sup><a class=\"rlc-reference\" data-ref-info=\"Maertens O, Johnson B, Hollstein P, et al: Elucidating distinct roles for NF1 in melanomagenesis. Cancer Discov, 2012.\" href=\"#_ENREF_85\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23171796\">85</a>, <a class=\"rlc-reference\" data-ref-info=\"Whittaker SR, Theurillat JP, Van Allen E, et al: A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. Cancer Discov, 2013.\" href=\"#_ENREF_86\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23288408\">86</a></sup></p>\n</td>\n<td width=\"202\">\n<p>Yes</p>\n</td>\n<td width=\"94\">\n<p>MEKi/mTORi</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"208\">\n<p>Activation of CDK pathway<sup><a class=\"rlc-reference\" data-ref-info=\"Smalley KS, Lioni M, Dalla Palma M, et al: Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas. Mol Cancer Ther 7:2876-83, 2008.\" href=\"#_ENREF_157\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/18790768\">157</a>, <a class=\"rlc-reference\" data-ref-info=\"Nathanson KL, Martin AM, Wubbenhorst B, et al: Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor Dabrafenib (GSK2118436). Clin Cancer Res, 2013.\" href=\"#_ENREF_103\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23833299\">103</a></sup></p>\n</td>\n<td width=\"202\">\n<p>No, in vitro only</p>\n</td>\n<td width=\"94\">\n<p>CDKi</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"208\">\n<p>Metabolic signature <a class=\"rlc-reference\" data-ref-info=\"McArthur GA, Puzanov I, Amaravadi R, et al: Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma. J Clin Oncol 30:1628-34, 2012.\" href=\"#_ENREF_158\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22454415\"><sup>158</sup></a></p>\n</td>\n<td width=\"202\">\n<p>Yes, high FDG uptake is associated with response to BRAFi</p>\n</td>\n<td width=\"94\">\n<p>\u00a0</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"208\">\n<p>MET and SRC signaling <a class=\"rlc-reference\" data-ref-info=\"Vergani E, Vallacchi V, Frigerio S, et al: Identification of MET and SRC activation in melanoma cell lines showing primary resistance to PLX4032. Neoplasia 13:1132-42, 2011.\" href=\"#_ENREF_159\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22241959\"><sup>159</sup></a></p>\n</td>\n<td width=\"202\">\n<p>Observed in patient-derived lines</p>\n</td>\n<td width=\"94\">\n<p>METi?</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"208\">\n<p>Production of HGF by stroma <a class=\"rlc-reference\" data-ref-info=\"Straussman R, Morikawa T, Shee K, et al: Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 487:500-4, 2012.\" href=\"#_ENREF_160\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22763439\"><sup>160</sup></a></p>\n</td>\n<td width=\"202\">\n<p>Yes</p>\n</td>\n<td width=\"94\">\n<p>METi?</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"208\">\n<p>Expression of antiapoptotic proteins, BCL2 and BCL2A1 <sup><a class=\"rlc-reference\" data-ref-info=\"Wroblewski D, Mijatov B, Mohana-Kumaran N, et al: The BH3-mimetic ABT-737 sensitizes human melanoma cells to apoptosis induced by selective BRAF inhibitors but does not reverse acquired resistance. Carcinogenesis, 2012.\" href=\"#_ENREF_161\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23087082\">161</a> <a class=\"rlc-reference\" data-ref-info=\"Haq R, Yokoyama S, Hawryluk EB, et al: BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition. Proc Natl Acad Sci U S A 110:4321-6, 2013.\" href=\"#_ENREF_61\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23447565\">61</a></sup></p>\n</td>\n<td width=\"202\">\n<p>Yes</p>\n</td>\n<td width=\"94\">\n<p>BH3 mimetics</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"208\">\n<p>Elevated expression of MITF and PGC1a <a class=\"rlc-reference\" data-ref-info=\"Haq R, Shoag J, Andreu-Perez P, et al: Oncogenic BRAF Regulates Oxidative Metabolism via PGC1alpha and MITF. Cancer Cell 23:302-15, 2013.\" href=\"#_ENREF_162\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23477830\"><sup>162</sup></a></p>\n</td>\n<td width=\"202\">\n<p>Yes</p>\n</td>\n<td width=\"94\">\n<p>OXPHOSi</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"208\">\n<p>Elevated expression of FOXD3 and ERBB3 <sup><a class=\"rlc-reference\" data-ref-info=\"Basile KJ, Abel EV, Aplin AE: Adaptive upregulation of FOXD3 and resistance to PLX4032/4720-induced cell death in mutant B-RAF melanoma cells. Oncogene 31:2471-9, 2012.\" href=\"#_ENREF_163\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/21996740\">163</a>, <a class=\"rlc-reference\" data-ref-info=\"Abel EV, Basile KJ, Kugel CH, 3rd, et al: Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3. J Clin Invest, 2013.\" href=\"#_ENREF_164\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23543055\">164</a></sup></p>\n</td>\n<td width=\"202\">\n<p>No</p>\n</td>\n<td width=\"94\">\n<p>ERBB2/3i</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"208\">\n<p>Expression of Hsp90 <a class=\"rlc-reference\" data-ref-info=\"Paraiso KH, Haarberg HE, Wood E, et al: The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms. Clin Cancer Res 18:2502-14, 2012.\" href=\"#_ENREF_165\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22351686\"><sup>165</sup></a></p>\n</td>\n<td width=\"202\">\n<p>No</p>\n</td>\n<td width=\"94\">\n<p>XL888, Hsp90i</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"208\">\n<p>Persistent activity of mTORC1 <a class=\"rlc-reference\" data-ref-info=\"Deng W, Gopal YN, Scott A, et al: Role and therapeutic potential of PI3K-mTOR signaling in de novo resistance to BRAF inhibition. Pigment Cell Melanoma Res 25:248-58, 2012.\" href=\"#_ENREF_166\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22171948\"><sup>166</sup></a>, <a class=\"rlc-reference\" data-ref-info=\"Corcoran RB, Rothenberg SM, Hata AN, et al: TORC1 Suppression Predicts Responsiveness to RAF and MEK Inhibition in BRAF-Mutant Melanoma. Sci Transl Med 5:196ra98, 2013.\" href=\"#_ENREF_167\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23903755\"><sup>167</sup></a></p>\n</td>\n<td width=\"202\">\n<p>Yes</p>\n</td>\n<td width=\"94\">\n<p>mTORi</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"208\">\n<p><b>Resistance to MEK Inhibitors </b></p>\n</td>\n<td width=\"202\">\n<p>\u00a0</p>\n</td>\n<td width=\"94\">\n<p>\u00a0</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"208\">\n<p>Signaling through TGF-\uf062/SMURF2/PAX3 and MITF <a class=\"rlc-reference\" data-ref-info=\"Smith MP, Ferguson J, Arozarena I, et al: Effect of SMURF2 Targeting on Susceptibility to MEK Inhibitors in Melanoma. J Natl Cancer Inst 105:33-46, 2013.\" href=\"#_ENREF_168\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23250956\"><sup>168</sup></a></p>\n</td>\n<td width=\"202\">\n<p>No</p>\n<p>\u00a0</p>\n</td>\n<td width=\"94\">\n<p>\u00a0</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"208\">\n<p>Downregulation of PTEN, activation of PI3K <a class=\"rlc-reference\" data-ref-info=\"Byron SA, Loch DC, Wellens CL, et al: Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status. Mol Cancer 11:75, 2012.\" href=\"#_ENREF_169\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23039341\"><sup>169</sup></a></p>\n</td>\n<td width=\"202\">\n<p>No</p>\n</td>\n<td width=\"94\">\n<p>PI3Ki + MEKi</p>\n</td>\n</tr>\n</tbody>\n</table>\n<p id=\"erb-d8b2489b-e981-4356-b3f5-444b02fd34ea\"><b>PI3K/AKT</b>. Mutations of the PI3K pathway are frequent in the BRAF-mutant setting. These have been shown to overcome BRAFV600E-induced OIS and contribute to inherent resistance to BRAF inhibitors <a class=\"rlc-reference\" data-ref-info=\"Vredeveld LC, Possik PA, Smit MA, et al: Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis. Genes Dev 26:1055-69, 2012.\" href=\"#_ENREF_90\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22549727\"><sup>90</sup></a>. In particular, loss of PTEN and consequent loss of expression of the pro-apoptotic BIM that is distantly regulated by PTEN were implicated in inherent resistance to BRAF inhibitor <i>in vitro</i> <a class=\"rlc-reference\" data-ref-info=\"Paraiso KH, Xiang Y, Rebecca VW, et al: PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res 71:2750-60, 2011.\" href=\"#_ENREF_156\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/21317224\"><sup>156</sup></a> and to dabrafenib in patients <a class=\"rlc-reference\" data-ref-info=\"Nathanson KL, Martin AM, Wubbenhorst B, et al: Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor Dabrafenib (GSK2118436). Clin Cancer Res, 2013.\" href=\"#_ENREF_103\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23833299\"><sup>103</sup></a>. PTEN-negative or AKT3-overexpressing melanomas do not undergo apoptosis in response to BRAF inhibition and do not upregulate pro-apoptotic protein BIM. PLX4720 was found to stimulate AKT signaling in the PTEN-, but not the PTEN+, cell lines. A clinical trial with inhibitors of both MAPK and PI3K showed promise in patients with various solid tumors <a class=\"rlc-reference\" data-ref-info=\"Shimizu T, Tolcher AW, Papadopoulos KP, et al: The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer. Clin Cancer Res 18:2316-25, 2012.\" href=\"#_ENREF_170\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22261800\"><sup>170</sup></a>.</p>\n<p id=\"erb-307987f0-c962-4af3-b1d9-64f67cf1a53f\">A recent study demonstrated an essential role for ERK-phosphorylated MEK1 (pT292) in membrane recruitment of PTEN and consequent negative regulation of AKT <a class=\"rlc-reference\" data-ref-info=\"Zmajkovicova K, Jesenberger V, Catalanotti F, et al: MEK1 Is Required for PTEN Membrane Recruitment, AKT Regulation, and the Maintenance of Peripheral Tolerance. Mol Cell 50:43-55, 2013.\" href=\"#_ENREF_171\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23453810\"><sup>171</sup></a>. Inhibition of BRAFV600-MEK1-ERK therefore might lead to the inhibition of the restraining role that this pathway has on activity of PI3K/AKT pathway via PTEN.</p>\n<p id=\"erb-584c2e95-20de-4f70-ae8c-9b3c2e070d6f\"><b>CDK4 pathway</b>. Increased cyclin D expression mediates inherent resistance to mutant BRAF inhibition <a class=\"rlc-reference\" data-ref-info=\"Smalley KS, Lioni M, Dalla Palma M, et al: Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas. Mol Cancer Ther 7:2876-83, 2008.\" href=\"#_ENREF_157\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/18790768\"><sup>157</sup></a>, and copy number changes in CDKN2A, CCND1 correlated with the shortened duration of PFS in patients treated with dabrafenib <a class=\"rlc-reference\" data-ref-info=\"Nathanson KL, Martin AM, Wubbenhorst B, et al: Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor Dabrafenib (GSK2118436). Clin Cancer Res, 2013.\" href=\"#_ENREF_103\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23833299\"><sup>103</sup></a>.</p>\n<p id=\"erb-e7c830b2-46df-4816-86cc-52660915f5c0\"><b>NF1 mutations</b>. In a mouse model, NF1 ablation decreases the sensitivity of NF1 wild-type melanoma cell lines to BRAF inhibitors, and NF1 is lost in tumors from patients following treatment with these agents. Nf1/BRAF-mutant tumors are resistant to BRAF inhibitors, but are sensitive to combined MEK/mTOR inhibition <a class=\"rlc-reference\" data-ref-info=\"Maertens O, Johnson B, Hollstein P, et al: Elucidating distinct roles for NF1 in melanomagenesis. Cancer Discov, 2012.\" href=\"#_ENREF_85\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23171796\"><sup>85</sup></a>. In another study, NF1 mutations were documented in BRAF-mutant tumor cells that were intrinsically resistant to BRAF inhibition, and in melanoma tumors from patients exhibiting resistance\u00a0to vemurafenib, thus demonstrating the clinical significance for NF1-driven\u00a0resistance\u00a0to RAF/MEK-targeted therapies <a class=\"rlc-reference\" data-ref-info=\"Whittaker SR, Theurillat JP, Van Allen E, et al: A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. Cancer Discov, 2013.\" href=\"#_ENREF_86\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23288408\"><sup>86</sup></a>.</p>\n<p id=\"erb-68cf2a34-e2a6-4a57-9dfe-3e4efc1e9ac8\"><b>MET and SRC.</b> The activation of MET and SRC signaling was detected in two patient-derived melanoma cell lines with BRAFV600E that were resistant to BRAF inhibitor PLX4032. MET or SRC, respectively, were targeted with siRNA or drugs in combination with PLX4032. This was effective in inhibiting cell growth and reducing cell invasion and migration, indicating a functional role for MET and SRC signaling in primary resistance to PLX4032 <a class=\"rlc-reference\" data-ref-info=\"Vergani E, Vallacchi V, Frigerio S, et al: Identification of MET and SRC activation in melanoma cell lines showing primary resistance to PLX4032. Neoplasia 13:1132-42, 2011.\" href=\"#_ENREF_159\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22241959\"><sup>159</sup></a>.</p>\n<p id=\"erb-192d69a2-f242-4731-94b0-947f0f712215\"><b>Metabolic signature of melanoma sensitive to mutant BRAF inhibition. </b>An interesting study could not find correlation between sensitivity to PLX4032 and genetic profiles in a panel of BRAF-mutant cell lines. However, the sensitive cell lines had a more profound inhibition of FDG uptake upon exposure to PLX4032 than resistant cell lines. This indicates that melanomas with a higher dependence on glycolysis might be more sensitive to mutant BRAF inhibition. This also indicates that FDG-PET could be useful in assessing sensitivity to BRAF inhibitors <a class=\"rlc-reference\" data-ref-info=\"Sondergaard JN, Nazarian R, Wang Q, et al: Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032. J Transl Med 8:39, 2010.\" href=\"#_ENREF_172\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/20406486\"><sup>172</sup></a>. Indeed, a clinical study that incorporated FDG-PET monitoring of responses to vemurafenib strongly indicated that there is a positive correlation between responses to therapy (PFS) and reduction in the uptake of FDG <a class=\"rlc-reference\" data-ref-info=\"McArthur GA, Puzanov I, Amaravadi R, et al: Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma. J Clin Oncol 30:1628-34, 2012.\" href=\"#_ENREF_158\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22454415\"><sup>158</sup></a>.</p>\n<p id=\"erb-982f66de-9ea7-4a2d-8144-a9a98fe7dc5b\"><b>MITF-PGC1</b>a<b> axis in resistance to BRAF inhibition</b>. Inhibition of BRAFV600 and, to a lesser extent of MEK, were found to induce expression of genes involved in citric acid cycle and oxidative phosphorylation (OXPHOS) in melanoma. Search for factors regulating OXPHOS revealed that PGC1a is upregulated in resistant melanoma lines <a class=\"rlc-reference\" data-ref-info=\"Haq R, Shoag J, Andreu-Perez P, et al: Oncogenic BRAF Regulates Oxidative Metabolism via PGC1alpha and MITF. Cancer Cell 23:302-15, 2013.\" href=\"#_ENREF_162\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23477830\"><sup>162</sup></a>. PGC1a, in turn, was found to be a direct transcriptional target of MITF <sup><a class=\"rlc-reference\" data-ref-info=\"Vazquez F, Lim JH, Chim H, et al: PGC1alpha Expression Defines a Subset of Human Melanoma Tumors with Increased Mitochondrial Capacity and Resistance to Oxidative Stress. Cancer Cell, 2013.\" href=\"#_ENREF_59\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23416000\">59</a>,<a class=\"rlc-reference\" data-ref-info=\"Haq R, Shoag J, Andreu-Perez P, et al: Oncogenic BRAF Regulates Oxidative Metabolism via PGC1alpha and MITF. Cancer Cell 23:302-15, 2013.\" href=\"#_ENREF_162\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23477830\">162</a></sup>. MITF expression and, as a consequence, PGC1a levels, are upregulated in melanoma lines and in tumors of patients treated with Vemurafenib. Inhibition of BRAF leads to inhibition of glycolytic pathway for ATP production, but MITF-expressing melanomas can undergo a bioenergetics adaptation via MITF-PGC1a-OXPHOS upregulation <a class=\"rlc-reference\" data-ref-info=\"Haq R, Shoag J, Andreu-Perez P, et al: Oncogenic BRAF Regulates Oxidative Metabolism via PGC1alpha and MITF. Cancer Cell 23:302-15, 2013.\" href=\"#_ENREF_162\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23477830\"><sup>162</sup></a>. The authors suggest targeting OXPHOS in this group of patients prior to use of MAPK inhibitors because lines selected to resistance to vemurafenib have elevated levels of PGC1a.</p>\n<p id=\"erb-e5e35ea6-896c-4daf-a01a-b8f08df0eab0\"><b>Tumor stroma influence.</b> An important study demonstrated production of HGF by stromal cells in patients with melanoma, which resulted in activation of the HGF receptor MET, reactivation of the MAPK and PI3K pathways, and resistance to BRAF <a class=\"rlc-reference\" data-ref-info=\"Straussman R, Morikawa T, Shee K, et al: Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 487:500-4, 2012.\" href=\"#_ENREF_160\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22763439\"><sup>160</sup></a>. Addition of growth factors was shown to rescue various tumor cells lines from killing by kinase inhibitors including vemurafenib in melanoma <a class=\"rlc-reference\" data-ref-info=\"Wilson TR, Fridlyand J, Yan Y, et al: Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 487:505-9, 2012.\" href=\"#_ENREF_173\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22763448\"><sup>173</sup></a>. High production of HGF was observed in the stroma samples from patients who had a poor response to the inhibition of mutant BRAF. In a cellular model, co-treatment with BRAF and HGF or MET inhibitors reversed drug resistance\u00a0<a class=\"rlc-reference\" data-ref-info=\"Straussman R, Morikawa T, Shee K, et al: Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 487:500-4, 2012.\" href=\"#_ENREF_160\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22763439\"><sup>160</sup></a>.</p>\n<p id=\"erb-e8913150-f47e-4957-83ca-05891cb5143e\"><b>BCL-2.</b> Inhibition of anti-apoptotic protein Bcl-2 might have a potential role in the future studies aimed to prevent the development of resistance to BRAF inhibition. The BH3 mimetic ABT-737 (inhibiting both Bcl2 and Bcl-xL) sensitizes human melanoma cells to apoptosis induced by selective BRAF inhibitors, but does not reverse acquired resistance <i>in vitro</i> <a class=\"rlc-reference\" data-ref-info=\"Wroblewski D, Mijatov B, Mohana-Kumaran N, et al: The BH3-mimetic ABT-737 sensitizes human melanoma cells to apoptosis induced by selective BRAF inhibitors but does not reverse acquired resistance. Carcinogenesis, 2012.\" href=\"#_ENREF_161\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23087082\"><sup>161</sup></a>.</p>\n<p id=\"erb-a1e06b5b-a9fe-4253-832d-0b5134a9f149\"><b>BCL2A1</b>. Amplification of one family member, BCL2A1 in 30% of melanoma, was shown to contribute to resistance to BRAF inhibition <a class=\"rlc-reference\" data-ref-info=\"Haq R, Yokoyama S, Hawryluk EB, et al: BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition. Proc Natl Acad Sci U S A 110:4321-6, 2013.\" href=\"#_ENREF_61\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23447565\"><sup>61</sup></a>. <!-- Construction of this sentence odd - not sure wherle comma goes - can you fix?\r\n -->BCL2A1 expression is apparently restricted to melanocytic lineage as it is indirectly controlled by MITF, and because of this its expression is limited to high-MITF-expressing melanomas. Obatoclax, inhibitor of the BCL family, helps to overcome the resistance of cell lines with amplified BCL2A1 to BRAF inhibition.</p>\n<p id=\"erb-5631fee9-0f29-4c30-8e02-e2ebab62e2a0\"><b>FOXD3-ERBB3</b>. Transcription factor FOXD3 was shown to be upregulated when mutant BRAF is inhibited in melanoma cell lines PGC1a <a class=\"rlc-reference\" data-ref-info=\"Basile KJ, Abel EV, Aplin AE: Adaptive upregulation of FOXD3 and resistance to PLX4032/4720-induced cell death in mutant B-RAF melanoma cells. Oncogene 31:2471-9, 2012.\" href=\"#_ENREF_163\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/21996740\"><sup>163</sup></a>. Subsequent work revealed that FOXD3 directly activates expression of ERBB3, which contributes to resistance to vemurafenib via activation of PI3K pathway, with involvement of ERBB2. The latter finding indicates a possibility of targeting ERBB2 alongside BRAF to overcome resistance <a class=\"rlc-reference\" data-ref-info=\"Abel EV, Basile KJ, Kugel CH, 3rd, et al: Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3. J Clin Invest, 2013.\" href=\"#_ENREF_164\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23543055\"><sup>164</sup></a>.</p>\n<p id=\"erb-60130f4e-e3e4-4b44-97f7-577e1a1be17a\"><strong>Chaperone Hsp90</strong> is required for the stability of several of the oncoproteins that mediate RAF inhibitor resistance. Inhibitors of Hsp90 may be effective in patients with intrinsic or acquired resistance to BRAF inhibition <a class=\"rlc-reference\" data-ref-info=\"Catalanotti F, Solit DB: Will Hsp90 inhibitors prove effective in BRAF-mutant melanomas? Clin Cancer Res 18:2420-2, 2012.\" href=\"#_ENREF_174\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22442059\"><sup>174</sup></a>. In lab studies, treatment of melanoma cells with XL888, the inhibitor of Hsp90, induced apoptosis more effectively than dual MEK/PI3K inhibition in several different models of resistance <a class=\"rlc-reference\" data-ref-info=\"Paraiso KH, Haarberg HE, Wood E, et al: The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms. Clin Cancer Res 18:2502-14, 2012.\" href=\"#_ENREF_165\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22351686\"><sup>165</sup></a>. Multiple proteins, including PDGFR\u03b2, COT, IGFR1, CRAF, ARAF, S6, cyclin D1, and AKT, were degraded as a result of inhibition of Hsp90, which led to the nuclear accumulation of FOXO3a, an increase in BIM expression, and the downregulation of Mcl-1. XL888 was effective against NRAS mutant melanoma cells in vitro and in xenografts, most likely by decreasing protein levels of AKT, CDK4, and WEE1<!-- Earlier Wee1 - okay?\r\n --> <a class=\"rlc-reference\" data-ref-info=\"Haarberg HE, Paraiso KH, Wood E, et al: Inhibition of Wee1, AKT and CDK4 underlies the efficacy of the HSP90 inhibitor XL888 in an in vivo model of NRAS mutant melanoma. Mol Cancer Ther, 2013.\" href=\"#_ENREF_175\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23538902\"><sup>175</sup></a>. <a href=\"http://www.cancer.gov/drugdictionary?CdrID=629922\">XL888</a> is now in clinical studies in combination with vemurafenib (NCT01657591). Another non-geldanamycin Hsp90 inhibitor, <a href=\"http://www.cancer.gov/drugdictionary?CdrID=598379\">STA-9090</a> (ganetispib), is also in clinical trials.</p>\n<p id=\"erb-f23716a5-5cbf-4405-a2bb-f1d715223c25\"><strong>mTORC1</strong>. Activity of mTORC1 after treatment of melanoma cells <i>in vitro</i> was found to be a faithful predictor of the response <a class=\"rlc-reference\" data-ref-info=\"Deng W, Gopal YN, Scott A, et al: Role and therapeutic potential of PI3K-mTOR signaling in de novo resistance to BRAF inhibition. Pigment Cell Melanoma Res 25:248-58, 2012.\" href=\"#_ENREF_166\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22171948\"><sup>166</sup></a>. Suppression of mTORC1 as seen from inhibited phosphorylation of the surrogate marker ribosomal s6 protein was highly predictive of death response to BRAF and MEK inhibitors. In patients, suppression of phospho-S6 was significantly associated with improved PFS <a class=\"rlc-reference\" data-ref-info=\"Corcoran RB, Rothenberg SM, Hata AN, et al: TORC1 Suppression Predicts Responsiveness to RAF and MEK Inhibition in BRAF-Mutant Melanoma. Sci Transl Med 5:196ra98, 2013.\" href=\"#_ENREF_167\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23903755\"><sup>167</sup></a>. Quantitation of p-S6 could serve as a biomarker to guide treatment of BRAF mutant melanoma. It also raises the possibility that simultaneous inhibition of mutant BRAF and PI3K or mTORC1 might be of clinical value. Several early-phase clinical trials examining MEK inhibitors with PI3K/mTOR inhibitors are recruiting patients.</p>\n<h1 id=\"erh-d0af1f47-8119-4057-beb9-bea7b3e46beb\"><b>Intrinsic resistance to MEK inhibitors</b></h1>\n<p id=\"erb-f0d2d93a-9883-49d2-adb8-0bc096059632\"><b>Signaling through TGF-\u03b2/SMURF2/PAX3 and MITF. </b> In an <i>in vitro</i> study, cells sensitive to MEK inhibition demonstrated increased transforming growth\u00a0factor\u00a0\u03b2 (TGF-\u03b2) signaling. Melanoma\u00a0cells resistant to the cytotoxic effects of MEK inhibitors counteracted TGF-\u03b2 signaling through overexpression of the E3 ubiquitin ligase SMURF2, which resulted in increased expression of the\u00a0transcription\u00a0factors PAX3 and\u00a0MITF. High\u00a0MITF\u00a0expression protected\u00a0melanoma\u00a0cells against MEK inhibitor cytotoxicity. The study also found increased SMURF2 expression in advanced stages of melanoma <a class=\"rlc-reference\" data-ref-info=\"Smith MP, Ferguson J, Arozarena I, et al: Effect of SMURF2 Targeting on Susceptibility to MEK Inhibitors in Melanoma. J Natl Cancer Inst 105:33-46, 2013.\" href=\"#_ENREF_168\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23250956\"><sup>168</sup></a>.</p>\n<p id=\"erb-fc2e7f2e-8696-4fca-b4b8-0d4c431508a2\">Activation of the <b>PI3K</b> pathway<b> </b>was seen as a factor in resistance of a panel of melanoma cell lines to novel MEK inhibitor E6201. The sensitivity of cell lines to MEK inhibition correlated with wild-type PTEN and mutant BRAF <a class=\"rlc-reference\" data-ref-info=\"Byron SA, Loch DC, Wellens CL, et al: Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status. Mol Cancer 11:75, 2012.\" href=\"#_ENREF_169\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23039341\"><sup>169</sup></a>.</p>\n<h1 id=\"erh-1790630e-e1a9-4921-a099-a554732ba516\">Acquired resistance to BRAF and MEK inhibitors</h1>\n<h3><a name=\"Table4\"></a>Table 4. Acquired Resistance to BRAF and MEK Inhibitors</h3>\n<table border=\"1\" cellpadding=\"7\" cellspacing=\"0\" id=\"erb-c4701a71-1ae7-4194-9643-389381125674\" width=\"618\">\n<colgroup>\n<col width=\"196\"></col>\n<col width=\"154\"></col>\n<col width=\"112\"></col>\n<col width=\"100\"></col>\n</colgroup>\n<tbody>\n<tr valign=\"TOP\">\n<td width=\"196\">\n<p><b>MOLECULAR CHANGE</b></p>\n</td>\n<td width=\"154\">\n<p><b>CONFIRMED IN PATIENT BIOPSIES?</b></p>\n</td>\n<td width=\"112\">\n<p align=\"CENTER\"><b>DRUGS TO ADD TO OVERCOME RESISTANCE</b></p>\n</td>\n<td width=\"100\">\n<p align=\"CENTER\"><b>PATHWAYS ACTIVATED</b></p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"196\">\n<p><b>Resistance to vemurafenib</b></p>\n</td>\n<td width=\"154\">\n<p>\u00a0</p>\n</td>\n<td width=\"112\">\n<p align=\"CENTER\">\u00a0</p>\n</td>\n<td width=\"100\">\n<p align=\"CENTER\">\u00a0</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"196\">\n<p>Expression of splicing variant of BRAF lacking exons 4-8 <a class=\"rlc-reference\" data-ref-info=\"Poulikakos PI, Persaud Y, Janakiraman M, et al: RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 480:387-90, 2011.\" href=\"#_ENREF_176\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22113612\"><sup>176</sup></a> <a class=\"rlc-reference\" data-ref-info=\"Romano E, Pradervand S, Paillusson A, et al: Identification of Multiple Mechanisms of Resistance to Vemurafenib in a Patient with BRAFV600E-Mutated Cutaneous Melanoma Successfully Rechallenged after Progression. Clin Cancer Res, 2013.\" href=\"#_ENREF_177\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23948972\"><sup>177</sup></a></p>\n</td>\n<td width=\"154\">\n<p>Yes, in 6/19 relapsed patients</p>\n</td>\n<td width=\"112\">\n<p align=\"CENTER\">\u00a0</p>\n</td>\n<td width=\"100\">\n<p align=\"CENTER\"><a class=\"rlc-reference\" data-ref-info=\"Poulikakos PI, Persaud Y, Janakiraman M, et al: RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 480:387-90, 2011.\" href=\"#_ENREF_176\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22113612\"><b>MAPK</b></a></p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"196\">\n<p>Amplification of BRAF <a class=\"rlc-reference\" data-ref-info=\"Shi H, Moriceau G, Kong X, et al: Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat Commun 3:724, 2012.\" href=\"#_ENREF_178\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22395615\"><sup>178</sup></a></p>\n</td>\n<td width=\"154\">\n<p>Yes, in 4/20 relapsed patients</p>\n</td>\n<td width=\"112\">\n<p align=\"CENTER\">\u00a0</p>\n</td>\n<td width=\"100\">\n<p align=\"CENTER\"><b>MAPK</b></p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"196\">\n<p>Activation of EGFR/SFK/STAT3 <a class=\"rlc-reference\" data-ref-info=\"Girotti MR, Pedersen M, Sanchez-Laorden B, et al: Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma. Cancer Discov, 2012.\" href=\"#_ENREF_179\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23242808\"><sup>179</sup></a></p>\n</td>\n<td width=\"154\">\n<p>Yes</p>\n</td>\n<td width=\"112\">\n<p align=\"CENTER\">EGFRi, SRKi</p>\n</td>\n<td width=\"100\">\n<p align=\"CENTER\"><b>RTK</b></p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"196\">\n<p>Activation of FGFR3-RAS pathway <a class=\"rlc-reference\" data-ref-info=\"Yadav V, Zhang X, Liu J, et al: Reactivation of mitogen-activated protein kinase (MAPK) pathway by FGF receptor 3 (FGFR3)/Ras mediates resistance to vemurafenib in human B-RAF V600E mutant melanoma. J Biol Chem 287:28087-98, 2012.\" href=\"#_ENREF_180\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22730329\"><sup>180</sup></a></p>\n</td>\n<td width=\"154\">\n<p><i>in vitro</i> only</p>\n</td>\n<td width=\"112\">\n<p align=\"CENTER\">FGFRi</p>\n</td>\n<td width=\"100\">\n<p align=\"CENTER\"><a class=\"rlc-reference\" data-ref-info=\"Girotti MR, Pedersen M, Sanchez-Laorden B, et al: Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma. Cancer Discov, 2012.\" href=\"#_ENREF_179\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23242808\"><b>RTK</b></a></p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"196\">\n<p>Activation of IGFR1-PIK3 pathway <a class=\"rlc-reference\" data-ref-info=\"Villanueva J, Vultur A, Lee JT, et al: Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 18:683-95, 2010.\" href=\"#_ENREF_181\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/21156289\"><sup>181</sup></a></p>\n</td>\n<td width=\"154\">\n<p>Yes</p>\n</td>\n<td width=\"112\">\n<p align=\"CENTER\">IGFRi</p>\n</td>\n<td width=\"100\">\n<p align=\"CENTER\"><a class=\"rlc-reference\" data-ref-info=\"Yadav V, Zhang X, Liu J, et al: Reactivation of mitogen-activated protein kinase (MAPK) pathway by FGF receptor 3 (FGFR3)/Ras mediates resistance to vemurafenib in human B-RAF V600E mutant melanoma. J Biol Chem 287:28087-98, 2012.\" href=\"#_ENREF_180\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22730329\"><b>RTK</b></a></p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"196\">\n<p>Activation of ERBB3 \u2013 AKT <sup><a class=\"rlc-reference\" data-ref-info=\"Fattore L, Marra E, Pisanu ME, et al: Activation of an early feedback survival loop involving phospho-ErbB3 is a general response of melanoma cells to RAF/MEK inhibition and is abrogated by anti-ErbB3 antibodies. J Transl Med 11:180, 2013.\" href=\"#_ENREF_182\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23890105\">182</a>, <a class=\"rlc-reference\" data-ref-info=\"Abel EV, Basile KJ, Kugel CH, 3rd, et al: Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3. J Clin Invest, 2013.\" href=\"#_ENREF_164\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23543055\">164</a></sup></p>\n</td>\n<td width=\"154\">\n<p><i>in vitro</i> only</p>\n</td>\n<td width=\"112\">\n<p align=\"CENTER\">HER3i, HER2i</p>\n</td>\n<td width=\"100\">\n<p align=\"CENTER\"><b>RTK</b></p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"196\">\n<p>Activation of PDGFR\uf062 <a class=\"rlc-reference\" data-ref-info=\"Nazarian R, Shi H, Wang Q, et al: Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468:973-7, 2010.\" href=\"#_ENREF_183\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/21107323\"><sup>183</sup></a></p>\n</td>\n<td width=\"154\">\n<p>Yes</p>\n</td>\n<td width=\"112\">\n<p align=\"CENTER\">RTKi</p>\n</td>\n<td width=\"100\">\n<p align=\"CENTER\"><b>RTK</b></p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"196\">\n<p>Loss or mutations in NF1 <sup><a class=\"rlc-reference\" data-ref-info=\"Maertens O, Johnson B, Hollstein P, et al: Elucidating distinct roles for NF1 in melanomagenesis. Cancer Discov, 2012.\" href=\"#_ENREF_85\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23171796\">85</a>,<a class=\"rlc-reference\" data-ref-info=\"Whittaker SR, Theurillat JP, Van Allen E, et al: A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. Cancer Discov, 2013.\" href=\"#_ENREF_86\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23288408\">86</a></sup></p>\n</td>\n<td width=\"154\">\n<p>Yes</p>\n</td>\n<td width=\"112\">\n<p align=\"CENTER\">MEKi + PI3Ki + RAFi</p>\n</td>\n<td width=\"100\">\n<p align=\"CENTER\"><b>RAS</b></p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"196\">\n<p>Mutation of NRAS <a class=\"rlc-reference\" data-ref-info=\"Nazarian R, Shi H, Wang Q, et al: Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468:973-7, 2010.\" href=\"#_ENREF_183\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/21107323\"><sup>183</sup></a> <a class=\"rlc-reference\" data-ref-info=\"Romano E, Pradervand S, Paillusson A, et al: Identification of Multiple Mechanisms of Resistance to Vemurafenib in a Patient with BRAFV600E-Mutated Cutaneous Melanoma Successfully Rechallenged after Progression. Clin Cancer Res, 2013.\" href=\"#_ENREF_177\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23948972\"><sup>177</sup></a></p>\n</td>\n<td width=\"154\">\n<p>Yes</p>\n</td>\n<td width=\"112\">\n<p align=\"CENTER\">MEKi?</p>\n</td>\n<td width=\"100\">\n<p align=\"CENTER\"><b>RAS</b></p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"196\">\n<p>Activation of MAP3K8/COT, ERK activating kinase independent of MEK <a class=\"rlc-reference\" data-ref-info=\"Johannessen CM, Boehm JS, Kim SY, et al: COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 468:968-72, 2010.\" href=\"#_ENREF_184\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/21107320\"><sup>184</sup></a></p>\n</td>\n<td width=\"154\">\n<p>Yes</p>\n</td>\n<td width=\"112\">\n<p align=\"CENTER\">\u00a0</p>\n</td>\n<td width=\"100\">\n<p align=\"CENTER\"><b>MAPK</b></p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"196\">\n<p>MEK1 mutations <a class=\"rlc-reference\" data-ref-info=\"Wagle N, Emery C, Berger MF, et al: Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol 29:3085-96, 2011.\" href=\"#_ENREF_185\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/21383288\"><sup>185</sup></a> <a class=\"rlc-reference\" data-ref-info=\"Trunzer K, Pavlick AC, Schuchter L, et al: Pharmacodynamic Effects and Mechanisms of Resistance to Vemurafenib in Patients With Metastatic Melanoma. J Clin Oncol, 2013.\" href=\"#_ENREF_186\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23569304\">186</a><sup>,</sup><a class=\"rlc-reference\" data-ref-info=\"Emery CM, Vijayendran KG, Zipser MC, et al: MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci U S A 106:20411-6, 2009.\" href=\"#_ENREF_187\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/19915144\">187</a></p>\n</td>\n<td width=\"154\">\n<p>Yes</p>\n</td>\n<td width=\"112\">\n<p align=\"CENTER\">\u00a0</p>\n</td>\n<td width=\"100\">\n<p align=\"CENTER\"><b>MAPK</b></p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"196\">\n<p>AKT3 <a class=\"rlc-reference\" data-ref-info=\"Shao Y, Aplin AE: Akt3-mediated resistance to apoptosis in B-RAF-targeted melanoma cells. Cancer Res 70:6670-81, 2010.\" href=\"#_ENREF_188\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/20647317\"><sup>188</sup></a></p>\n</td>\n<td width=\"154\">\n<p><i>in vitro</i> only</p>\n</td>\n<td width=\"112\">\n<p align=\"CENTER\">AKTi</p>\n</td>\n<td width=\"100\">\n<p align=\"CENTER\"><b>PI3K</b></p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"196\">\n<p>Activation of ERK independently of MEK through PI3K <a class=\"rlc-reference\" data-ref-info=\"Jiang CC, Lai F, Thorne RF, et al: MEK-independent survival of B-RAFV600E melanoma cells selected for resistance to apoptosis induced by the RAF inhibitor PLX4720. Clin Cancer Res 17:721-30, 2011.\" href=\"#_ENREF_189\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/21088259\"><sup>189</sup></a></p>\n</td>\n<td width=\"154\">\n<p><i>in vitro</i> only</p>\n</td>\n<td width=\"112\">\n<p align=\"CENTER\">PI3Ki</p>\n</td>\n<td width=\"100\">\n<p align=\"CENTER\"><b>PI3K</b></p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"196\">\n<p>Loss of expression of RND3 <a class=\"rlc-reference\" data-ref-info=\"Klein RM, Higgins PJ: A switch in RND3-RHOA signaling is critical for melanoma cell invasion following mutant-BRAF inhibition. Mol Cancer 10:114, 2011.\" href=\"#_ENREF_190\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/21917148\"><sup>190</sup></a></p>\n</td>\n<td width=\"154\">\n<p><i>in vitro</i> only</p>\n</td>\n<td width=\"112\">\n<p align=\"CENTER\">\u00a0</p>\n</td>\n<td width=\"100\">\n<p align=\"CENTER\"><b>RHO</b></p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"196\">\n<p>High levels of insulin receptor substrate 1 (IRS1) <a class=\"rlc-reference\" data-ref-info=\"Reuveni H, Flashner-Abramson E, Steiner L, et al: Therapeutic destruction of insulin receptor substrates for cancer treatment. Cancer Res 73:4383-94, 2013.\" href=\"#_ENREF_191\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23651636\"><sup>191</sup></a></p>\n</td>\n<td width=\"154\">\n<p><i>in vitro:</i> established and patient-derived cell lines</p>\n</td>\n<td width=\"112\">\n<p align=\"CENTER\">New IRS inhibitors in preclinical</p>\n</td>\n<td width=\"100\">\n<p align=\"CENTER\"><b>RTK</b></p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"196\">\n<p><b>Resistance to MEK inhibitors</b></p>\n</td>\n<td width=\"154\">\n<p>\u00a0</p>\n</td>\n<td width=\"112\">\n<p align=\"CENTER\">\u00a0</p>\n</td>\n<td width=\"100\">\n<p align=\"CENTER\">\u00a0</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"196\">\n<p>MEK1 mutation <a class=\"rlc-reference\" data-ref-info=\"Emery CM, Vijayendran KG, Zipser MC, et al: MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci U S A 106:20411-6, 2009.\" href=\"#_ENREF_187\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/19915144\"><sup>187</sup></a></p>\n</td>\n<td width=\"154\">\n<p>Yes</p>\n</td>\n<td width=\"112\">\n<p align=\"CENTER\">\u00a0</p>\n</td>\n<td width=\"100\">\n<p align=\"CENTER\"><b>MAPK</b></p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"196\">\n<p>Activation of PI3K/AKT</p>\n</td>\n<td width=\"154\">\n<p><i>in vitro</i> only</p>\n</td>\n<td width=\"112\">\n<p align=\"CENTER\">IGFRi, AKTi, mTORi</p>\n</td>\n<td width=\"100\">\n<p align=\"CENTER\"><b>PI3K</b></p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"196\">\n<p><b>Resistance to BRAF and MEK inhibitors</b></p>\n</td>\n<td width=\"154\">\n<p>\u00a0</p>\n</td>\n<td width=\"112\">\n<p align=\"CENTER\">\u00a0</p>\n</td>\n<td width=\"100\">\n<p align=\"CENTER\">\u00a0</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"196\">\n<p>Mutation in MEK2 and amplification of BRAF <a class=\"rlc-reference\" data-ref-info=\"Villanueva J, Infante JR, Krepler C, et al: Concurrent MEK2 Mutation and BRAF Amplification Confer Resistance to BRAF and MEK Inhibitors in Melanoma. Cell Rep, 2013.\" href=\"#_ENREF_192\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/24055054\"><sup>192</sup></a></p>\n</td>\n<td width=\"154\">\n<p>Yes</p>\n</td>\n<td width=\"112\">\n<p align=\"CENTER\">BRAFi + MEKi</p>\n<p align=\"CENTER\">+mTORi</p>\n</td>\n<td width=\"100\">\n<p align=\"CENTER\"><b>MAPK</b></p>\n</td>\n</tr>\n</tbody>\n</table>\n<p id=\"erb-8bc889b0-c044-45b7-a9b3-b2c6d6deb5bc\">Mechanistic studies have provided insights into the development of resistance through two major mechanisms: new mutations in the RAF-MAPK pathway itself and changes in other oncogenic pathways, mainly RAS and PI3K, that relieve melanoma cells from reliance on BRAF signaling <a class=\"rlc-reference\" data-ref-info=\"Sullivan RJ, Flaherty KT: Resistance to BRAF-targeted therapy in melanoma. Eur J Cancer, 2013.\" href=\"#_ENREF_193\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23290787\"><sup>193</sup></a>. Emergence of resistance in different tumors from the same patient could involve different mechanisms and genes <a class=\"rlc-reference\" data-ref-info=\"Romano E, Pradervand S, Paillusson A, et al: Identification of Multiple Mechanisms of Resistance to Vemurafenib in a Patient with BRAFV600E-Mutated Cutaneous Melanoma Successfully Rechallenged after Progression. Clin Cancer Res, 2013.\" href=\"#_ENREF_177\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23948972\"><sup>177</sup></a>.</p>\n<p id=\"erb-0e800264-886e-4544-a5a7-4cb54852bdec\">The identification of mechanisms of acquired resistance to BRAF inhibitors usually involves selection of surviving cells/clones from BRAF-mutant cell lines <i>in vitro</i> after treatment with a BRAF inhibitor and identification of newly acquired mutations or other somatic changes. Biopsies from relapsed patients are then analyzed for the presence of these <i>in vitro</i>\u2013identified changes. Alternatively, biopsies are subjected to massive sequencing for the identification of newly acquired mutations/aberrations. A clinical study that examined mechanisms of developing resistance to vemurafenib concluded that it resulted mainly from reactivation of MAPK signaling <a class=\"rlc-reference\" data-ref-info=\"Trunzer K, Pavlick AC, Schuchter L, et al: Pharmacodynamic Effects and Mechanisms of Resistance to Vemurafenib in Patients With Metastatic Melanoma. J Clin Oncol, 2013.\" href=\"#_ENREF_186\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23569304\"><sup>186</sup></a>. Based on findings described below, it appears that many of the confirmed mechanisms of resistance are indeed in this category, though activation of pathways \u201cparallel\u201d to BRAF-MAPK has been documented (<a href=\"#Table4\">Table 4</a>).</p>\n<p id=\"erb-f0996500-f62f-4395-8344-31f82dd8fda1\"><b>New aberrations in BRAF.</b> Unlike the experiences with other molecularly targeted therapies of oncogenic kinases, treatment with BRAFV600E inhibitors did not lead to the emergence of gatekeeper mutations in BRAF itself. However, amplification of mutant BRAF was detected in 4 of 20 patients who developed resistance to vemurafenib <a class=\"rlc-reference\" data-ref-info=\"Shi H, Moriceau G, Kong X, et al: Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat Commun 3:724, 2012.\" href=\"#_ENREF_178\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22395615\"><sup>178</sup></a>.</p>\n<p id=\"erb-0903eb56-1da2-4e31-be5c-efb15cec4a96\">Analysis of a subset of cells resistant to vemurafenib (PLX4032) <i>in vitro</i> detected the 61-kDa variant form of BRAFV600E, p61BRAFV600E, which lacks exons 4 to 8, a region that encompasses the RAS-binding domain. p61BRAFV600E shows enhanced dimerization in cells with low levels of RAS activation, as compared to full-length BRAFV600E that acts as a monomer. The p61BRAFV600E-splicing variants lacking the RAS-binding domain were identified in the tumors of 6 of 19 patients with acquired resistance to vemurafenib. These data determined a novel mechanism of acquired resistance in patients: expression of splicing isoforms of BRAFV600E that dimerize in a RAS-independent manner <a class=\"rlc-reference\" data-ref-info=\"Poulikakos PI, Persaud Y, Janakiraman M, et al: RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 480:387-90, 2011.\" href=\"#_ENREF_176\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22113612\"><sup>176</sup></a>.</p>\n<p id=\"erb-99548d8d-e6ea-41ac-baaa-2d1f935d01dc\"><b>Activation of signaling through RTKs</b></p>\n<p id=\"erb-c65359c3-f932-461a-a3c6-4f84673f7bb1\"><b>EGFR/SFK/STAT3.</b> BRAF inhibitor\u2013mediated activation of EGFR/SRC family kinase/STAT3 signaling was shown to mediate resistance in BRAF-mutant\u00a0melanoma cell lines and was confirmed in\u00a0patient biopsies. <i>In vitro</i> treatments with an EGFR inhibitor in combination with a BRAF inhibitor, or monotherapy with dasatinib, appeared to overcome this resistance and could deliver therapeutic efficacy in drug-resistant BRAF-mutant melanoma\u00a0patients <a class=\"rlc-reference\" data-ref-info=\"Girotti MR, Pedersen M, Sanchez-Laorden B, et al: Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma. Cancer Discov, 2012.\" href=\"#_ENREF_179\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23242808\"><sup>179</sup></a>.</p>\n<p id=\"erb-96f3781d-3083-472e-b24d-da86db4150b7\"><b>FGFR3-RAS.</b> Upregulation of FGFR3 signaling in selected vemurafenib-resistant cells was described <i>in vitro</i>. Signaling through FGFR3 activated the MAPK pathway through RAS, but these cells were still sensitive to inhibition of MEK or pan-RAF inhibition <a class=\"rlc-reference\" data-ref-info=\"Yadav V, Zhang X, Liu J, et al: Reactivation of mitogen-activated protein kinase (MAPK) pathway by FGF receptor 3 (FGFR3)/Ras mediates resistance to vemurafenib in human B-RAF V600E mutant melanoma. J Biol Chem 287:28087-98, 2012.\" href=\"#_ENREF_180\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22730329\"><sup>180</sup></a>.</p>\n<p id=\"erb-e2c6bd92-b956-4810-967a-4d6aab221cb5\"><b>IGF-1R/PI3K pathway. </b> Mutations in the IGF-1R/PI3K pathway were identified as another way for developing resistance to the BRAF inhibitor SB590885. IGF-1R/PI3K signaling was enhanced in resistant melanomas; combined treatment with IGF-1R/PI3K and MEK inhibitors induced death of BRAF inhibitor-resistant cells. Increased IGF-1R and pAKT levels in a post-relapse human tumor sample were consistent with the proposed role for IGF-1R/PI3K-dependent resistance to BRAF inhibitors <a class=\"rlc-reference\" data-ref-info=\"Villanueva J, Vultur A, Lee JT, et al: Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 18:683-95, 2010.\" href=\"#_ENREF_181\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/21156289\"><sup>181</sup></a>.</p>\n<p id=\"erb-1f89b788-7780-4165-b8e7-c3aa54cc1365\">Activation of PDGFR\uf062 signaling was shown to occur during selection for BRAF inhibitor resistance <i>in vitro</i>. The clones with PDGFR\uf062 activation were also resistant to MEK inhibition, implying that activation of PDGFR bypasses the tumor dependence on RAF signaling entirely <a class=\"rlc-reference\" data-ref-info=\"Nazarian R, Shi H, Wang Q, et al: Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468:973-7, 2010.\" href=\"#_ENREF_183\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/21107323\"><sup>183</sup></a>. These findings were validated in resistant tumors <a class=\"rlc-reference\" data-ref-info=\"Nazarian R, Shi H, Wang Q, et al: Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468:973-7, 2010.\" href=\"#_ENREF_183\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/21107323\"><sup>183</sup></a>.</p>\n<p id=\"erb-0ff6e5a1-dd3c-4f95-8d7d-d8239a601678\"><b>ERBB3 signaling.</b> Enhanced ERBB3 signaling promoted resistance to RAF pathway inhibitors in cultured melanoma cell lines and in mouse xenograft models <a class=\"rlc-reference\" data-ref-info=\"Abel EV, Basile KJ, Kugel CH, 3rd, et al: Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3. J Clin Invest, 2013.\" href=\"#_ENREF_164\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23543055\"><sup>164</sup></a>. ERBB3 was transcriptionally activated by FOXD3, and increased ERBB3 signaling was dependent on ERBB2. Targeting ERBB2 with lapatinib in combination with the BRAF inhibitor PLX4720 reduced tumor burden and extended latency of tumor regrowth in vivo versus PLX4720 alone. ERBB3 was shown to be the main RTK undergoing rapid hyperphosphorylation upon either treatment with a BRAF inhibitor or with a MEK inhibitor in another publication <a class=\"rlc-reference\" data-ref-info=\"Fattore L, Marra E, Pisanu ME, et al: Activation of an early feedback survival loop involving phospho-ErbB3 is a general response of melanoma cells to RAF/MEK inhibition and is abrogated by anti-ErbB3 antibodies. J Transl Med 11:180, 2013.\" href=\"#_ENREF_182\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23890105\"><sup>182</sup></a>. The mechanism of ERBB3 was traced to an autocrine loop that resulted in production of high levels of neuregulin by melanoma cells in response to MAPK pathway inhibition.</p>\n<p id=\"erb-09cafe12-16bd-4759-9504-110e786ff7bb\"><b>PDGFR</b><b>\uf062</b><b> activation</b>. Induction of PDGFR\uf062 RNA, protein, and tyrosine phosphorylation were detected in a cell line model of resistance to vemurafenib as well as in short-term cultures and patient-derived biopsies <a class=\"rlc-reference\" data-ref-info=\"Nazarian R, Shi H, Wang Q, et al: Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468:973-7, 2010.\" href=\"#_ENREF_183\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/21107323\"><sup>183</sup></a>.</p>\n<p id=\"erb-edeb2a21-15f4-4bab-a12e-42c51c5dce15\"><b>NF1</b> expression is lost in tumors from patients following treatment with BRAF and MEK inhibitors <a class=\"rlc-reference\" data-ref-info=\"Maertens O, Johnson B, Hollstein P, et al: Elucidating distinct roles for NF1 in melanomagenesis. Cancer Discov, 2012.\" href=\"#_ENREF_85\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23171796\"><sup>85</sup></a>. NF1 mutations were observed in melanoma tumors obtained from patients exhibiting resistance\u00a0to vemurafenib, as already mentioned. However, cells lacking\u00a0NF1\u00a0retained sensitivity to the irreversible RAF inhibitor AZ628 and an ERK inhibitor <a class=\"rlc-reference\" data-ref-info=\"Whittaker SR, Theurillat JP, Van Allen E, et al: A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. Cancer Discov, 2013.\" href=\"#_ENREF_86\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23288408\"><sup>86</sup></a>.</p>\n<p id=\"erb-0154e608-7aa2-4ec2-91f0-a935257234e5\"><b>NRAS.</b> Secondary mutations in NRAS<b> </b>were shown to confer resistance to PLX4032 <i>in vitro</i> <a class=\"rlc-reference\" data-ref-info=\"Nazarian R, Shi H, Wang Q, et al: Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468:973-7, 2010.\" href=\"#_ENREF_183\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/21107323\"><sup>183</sup></a>. These acquired changes were mutually exclusive with PDGFR\uf062 activation observed in the same study. In contrast to PDGFR-activated resistant cells, NRAS-mutated cells were sensitive to MEK inhibitors. Mutations of NRAS were also found in 4 out of 19 patients that developed resistance to PLX4032 <a class=\"rlc-reference\" data-ref-info=\"Nazarian R, Shi H, Wang Q, et al: Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468:973-7, 2010.\" href=\"#_ENREF_183\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/21107323\"><sup>183</sup></a>, and in additional patients in a clinical trial exploring mechanism of acquired resistance to vemurafenib <a class=\"rlc-reference\" data-ref-info=\"Trunzer K, Pavlick AC, Schuchter L, et al: Pharmacodynamic Effects and Mechanisms of Resistance to Vemurafenib in Patients With Metastatic Melanoma. J Clin Oncol, 2013.\" href=\"#_ENREF_186\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23569304\"><sup>186</sup></a>. New mutant BRAF inhibitors, such as PLX7904, have been explored <i>in vitro</i>. PLX7904 inhibits ERK1/2 activation in cells with mutant BRAF, but not in cells with wild-type BRAF <a class=\"rlc-reference\" data-ref-info=\"Le K, Blomain E, Rodeck U, et al: Selective RAF inhibitor impairs ERK1/2 phosphorylation and growth in mutant NRAS, vemurafenib-resistant melanoma cells. Pigment Cell Melanoma Res, 2013.\" href=\"#_ENREF_19\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23490205\"><sup>19</sup></a>. Promisingly, PLX 7904 inhibited ERK1/2 phosphorylation in mutant BRAF melanoma cells with acquired resistance to vemurafenib/PLX4720 that is mediated by a secondary mutation in NRAS.</p>\n<p id=\"erb-4c0fb62f-b5f8-45a5-bc36-bac351ee3539\"><b>AKT3.</b> Activation of AKT3 in response to BRAF inhibitor PLX4720 or BRAF siRNA was implicated in the resistance of primary three-dimensional cultures of melanoma cells to BRAFV600E inhibitors <a class=\"rlc-reference\" data-ref-info=\"Shao Y, Aplin AE: Akt3-mediated resistance to apoptosis in B-RAF-targeted melanoma cells. Cancer Res 70:6670-81, 2010.\" href=\"#_ENREF_188\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/20647317\"><sup>188</sup></a>.</p>\n<p id=\"erb-99d5ae0d-0812-4467-8906-826215054172\"><b>ERK</b> activation, independent of classical RAF/MEK/ERK pathways, was shown to occur in resistant lines with mutant BRAF. PI3K<b> </b>pathway activation could be responsible for ERK activity. Inhibition of either PIK3CA or ERK slowed the growth of these lines selected <i>in vitro</i> for resistance to PLX4720 <a class=\"rlc-reference\" data-ref-info=\"Jiang CC, Lai F, Thorne RF, et al: MEK-independent survival of B-RAFV600E melanoma cells selected for resistance to apoptosis induced by the RAF inhibitor PLX4720. Clin Cancer Res 17:721-30, 2011.\" href=\"#_ENREF_189\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/21088259\"><sup>189</sup></a>. Targeting ERK activation is a promising strategy to overcome resistance to BRAF and MEK inhibitors. A new ERK inhibitor, SCH772984, is active in nanomolar concentrations <i>in vitro</i> and inhibited tumor growth <i>in vivo</i>. More importantly, SCH772984 was able to overcome resistance to BRAF or MEK inhibition in cells and tumors that became resistant by acquiring mutations in NRAS or MEK1, respectively. SCH772984 was able to suppress growth of melanoma cells engineered to contain amplified BRAFV600E and even growth of melanoma lines selected for double resistance to BRAF and MEK inhibition <a class=\"rlc-reference\" data-ref-info=\"Morris EJ, Jha S, Restino CR, et al: Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. Cancer Discov, 2013.\" href=\"#_ENREF_194\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23614898\"><sup>194</sup></a>.</p>\n<p id=\"erb-ea4d73da-44e1-4178-9247-41f8449ceb6a\"><b>MAP3K8/COT.</b> In a massive functional kinome screening study, a kinase known as MAP3K8/COT was implicated in both inherent and acquired resistance to BRAFV600E inhibitors. COT is a MAPK independent of RAF and is expressed highly in inherently resistant melanoma or in cells from patients with acquired resistance. Its expression drives resistance to BRAF inhibitors <i>in vitro</i> and occurs in relapsing patient tumors <a class=\"rlc-reference\" data-ref-info=\"Johannessen CM, Boehm JS, Kim SY, et al: COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 468:968-72, 2010.\" href=\"#_ENREF_184\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/21107320\"><sup>184</sup></a>. COT-mediated resistance to a RAF inhibitor cannot be overcome by a MEK inhibitor, suggesting that activation of ERK in these tumors occurs outside of the classical RAF-MAPK-ERK pathway. COT might be a direct ERK phosphorylating kinase.</p>\n<p id=\"erb-6257e971-8375-41c2-b0fd-cf906819d405\"><b>MEK1</b> mutation C121S was identified in a patient treated with vemurafenib <a class=\"rlc-reference\" data-ref-info=\"Wagle N, Emery C, Berger MF, et al: Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol 29:3085-96, 2011.\" href=\"#_ENREF_185\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/21383288\"><sup>185</sup></a>. This mutation was shown to increase kinase activity of MEK1 and confer resistance to both BRAF and MEK inhibition. Two new mutations of MEK, E203K and Q56P, were found in tumors that developed resistance to vemurafenib <a class=\"rlc-reference\" data-ref-info=\"Trunzer K, Pavlick AC, Schuchter L, et al: Pharmacodynamic Effects and Mechanisms of Resistance to Vemurafenib in Patients With Metastatic Melanoma. J Clin Oncol, 2013.\" href=\"#_ENREF_186\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23569304\"><sup>186</sup></a>.</p>\n<p id=\"erb-1b90aaf2-bab3-4cb7-8256-168f945fb106\"><b>RND3.</b> An <i>in vitro</i> study with a single BRAF-mutant melanoma line showed that BRAF-inhibitor treatments were associated with reduced expression of RND3, an antagonist of RHOA activation, and elevated RHOA-dependent signaling. Restoration of RND3 expression or RHOA knockdown attenuated the migratory ability of residual cells without affecting overall cell survival <a class=\"rlc-reference\" data-ref-info=\"Klein RM, Higgins PJ: A switch in RND3-RHOA signaling is critical for melanoma cell invasion following mutant-BRAF inhibition. Mol Cancer 10:114, 2011.\" href=\"#_ENREF_190\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/21917148\"><sup>190</sup></a>.</p>\n<p id=\"erb-9370fa6a-524a-46bd-9080-616ee145fe5c\"><b>IRS1.</b> Insulin receptor substrates 1 and 2 (IRS1/2) mediate oncogenic signaling from IGF-1R and are upregulated in melanoma cell lines resistant to BRAF inhibitors or derived from patients that developed resistance to vemurafenib treatment. A new class of drugs that promote phosphorylation and degradation of IRS1/2 were also able to overcome acquired resistance to vemurafenib <i>in vitro</i> <a class=\"rlc-reference\" data-ref-info=\"Reuveni H, Flashner-Abramson E, Steiner L, et al: Therapeutic destruction of insulin receptor substrates for cancer treatment. Cancer Res 73:4383-94, 2013.\" href=\"#_ENREF_191\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23651636\"><sup>191</sup></a>.</p>\n<p id=\"erb-58763f49-7168-4acd-b1dc-f94069870552\"><b>Factors that mediate acquired resistance to MEK inhibitors (<a href=\"#Table4\">Table 4</a>)</b></p>\n<p id=\"erb-9ffd59e9-9fb3-4338-93f1-6da50337007f\">Similar to the adaptation of BRAF-mutant melanoma cells to BRAF inhibition, resistance to MEK inhibitors could involve multiple pathways. In a study of triple-negative breast cancer treated with a MEK inhibitor, it was found that inhibition of MEK, similar to inhibition of BRAFV600E in melanoma, induces a reprogramming of RTK activation <a class=\"rlc-reference\" data-ref-info=\"Duncan JS, Whittle MC, Nakamura K, et al: Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. Cell 149:307-21, 2012.\" href=\"#_ENREF_195\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22500798\"><sup>195</sup></a>. It is possible that activation of RTK when MEK is acutely inhibited is also involved in responses of melanoma to MEK inhibition, though this has not been shown yet.</p>\n<p id=\"erb-0e93d07a-d392-4844-beed-c1eb6da670d7\"><b>Mutations in MEK1 and MEK2. </b><i>De novo</i> mutations in MEK1 were strongly implicated in resistance to MEK inhibitor selumetinib/AZD6244, both in treated cell lines and in a metastatic tumor from a relapsed patient <a class=\"rlc-reference\" data-ref-info=\"Emery CM, Vijayendran KG, Zipser MC, et al: MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci U S A 106:20411-6, 2009.\" href=\"#_ENREF_187\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/19915144\"><sup>187</sup></a>. Mutations in selected lines resulted in constitutive ERK phosphorylation and higher resistance to MEK inhibitors, but also conferred cross-resistance to mutant BRAF inhibitor PLX4023. Variant MEK1(P124L) was identified in a resistant metastatic focus that emerged in a melanoma patient treated with selumetinib.</p>\n<p id=\"erb-176caa71-f1b5-44be-8e4f-6514c966b030\"><b>PI3K-AKT pathway</b>. A study <i>in vitro</i> has identified basal and treatment-induced activation of the PI3K-AKT pathway as a critical regulator of selumetinib sensitivity in BRAF-mutant cutaneous melanoma cells. Sensitive, but not resistant lines showed upregulation of PTEN expression by selumetinib. Combination of a MEK inhibitor with inhibitors of Akt, mTOR, or IGF1R was able to overcome resistance to MEK inhibitors <a class=\"rlc-reference\" data-ref-info=\"Gopal YN, Deng W, Woodman SE, et al: Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells. Cancer Res 70:8736-47, 2010.\" href=\"#_ENREF_196\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/20959481\"><sup>196</sup></a>.</p>\n<p id=\"erb-363747c7-2caf-4059-9785-0649b9bc2d14\"><b>Factors that mediate acquired resistance to BRAF and MEK inhibitors (<a href=\"#Table4\">Table 4</a>)</b></p>\n<p id=\"erb-2db3901c-9414-4d97-8a7a-8d2e5198c513\"><b>MEK2</b> mutation Q60P was identified in a patient that developed resistance to trametinib <a class=\"rlc-reference\" data-ref-info=\"Villanueva J, Infante JR, Krepler C, et al: Concurrent MEK2 Mutation and BRAF Amplification Confer Resistance to BRAF and MEK Inhibitors in Melanoma. Cell Rep, 2013.\" href=\"#_ENREF_192\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/24055054\"><sup>192</sup></a>. Interestingly, the patient\u2019s progression tumor also acquired amplification of BRAFV600E. A xenograft tumor derived from a second patient resistant to the combination of BRAF and MEK inhibitors contained identical changes. These cells were resistant to combination treatment with dabrafenib and trametinib, but responded when mTOR inhibitor was added <a class=\"rlc-reference\" data-ref-info=\"Villanueva J, Infante JR, Krepler C, et al: Concurrent MEK2 Mutation and BRAF Amplification Confer Resistance to BRAF and MEK Inhibitors in Melanoma. Cell Rep, 2013.\" href=\"#_ENREF_192\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/24055054\"><sup>192</sup></a>. The mechanisms of resistance to dual inhibition of MAPK pathway by vemurafenib or dabrafenib and trametinib are only beginning to emerge because relatively few patients were treated with this combination in the clinical trials.</p>\n<h1 id=\"erh-a4edbefd-752d-4839-bb51-0fd43b105df4\">Combinatorial Therapies</h1>\n<p id=\"erb-f9e66180-1eeb-4aee-b543-8a8f691525ce\">Inherent resistance, partial and low durability responses, and acquired resistance are major problems in the clinical development of targeted therapies. Recent results of clinical studies combining two targeted therapies have confirmed the long-held belief that combinatorial approaches have significant advantages over monotherapy <sup><a class=\"rlc-reference\" data-ref-info=\"Flaherty KT, Infante JR, Daud A, et al: Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 367:1694-703, 2012.\" href=\"#_ENREF_25\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23020132\">25</a>,<a class=\"rlc-reference\" data-ref-info=\"Shimizu T, Tolcher AW, Papadopoulos KP, et al: The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer. Clin Cancer Res 18:2316-25, 2012.\" href=\"#_ENREF_170\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22261800\">170</a></sup>.</p>\n<p id=\"erb-cce3f0b2-84f3-4c25-bc73-c91dc7972507\">Two recent publications examined possible synergistic interactions between targeted therapies. The first study<a class=\"rlc-reference\" data-ref-info=\"Roller DG, Axelrod M, Capaldo BJ, et al: Synthetic lethal screening with small-molecule inhibitors provides a pathway to rational combination therapies for melanoma. Mol Cancer Ther 11:2505-15, 2012.\" href=\"#_ENREF_197\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22962324\"><sup>197</sup></a> looked at synthetic, lethal, pairwise interactions of a library of 300 compounds in a panel of nine established melanoma cell lines. This study did not find synergistic interactions that were genotype-specific (BRAF, NRAS-mutant, or wild-type cell lines were screened). A synergistic interaction was found for just one combination, which was not genotype-related: sorafenib and the nonsteroidal anti-inflammatory drug (NSAID) diclofenac. Drug substitution experiments confirmed that the synergy is due to the combined effects on MAPK and cyclooxygenase (COX). The use of established cell lines in this study was a limiting factor.</p>\n<p id=\"erb-cc486c29-7d1c-4dc4-b3b7-cb81ccb641d6\">The second study\u00a0<a class=\"rlc-reference\" data-ref-info=\"Held MA, Langdon CG, Platt JT, et al: Genotype-selective combination therapies for melanoma identified by high-throughput drug screening. Cancer Discov 3:52-67, 2013.\" href=\"#_ENREF_38\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23239741\"><sup>38</sup></a> examined drug interactions between 150 small-molecule inhibitors in a panel of 28 early-passage cell lines from melanomas with mutations either in BRAF, NRAS, or neither. The authors first selected inhibitors that showed some activity in at least one group of cell lines, and proceeded to analyze the antiproliferative effects of all drugs pairwise (over 7,000 combinations). The single drug screen produced several drugs with activity in BRAF-mutant melanoma, some of them known (vemurafenib and MEK inhibitors), but also non-BRAF-targeted kinase inhibitors of SRC/ABL (bosutinib), FGFR (dovitinib), and EGFR (gefitinib). There were almost no drugs effective against NRAS-mutant lines, except 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR)\u2013inhibitor simvastatin, which indirectly blocked prenylation and membrane localization of RAS. Drug combination analysis showed that the most effective combination for BRAF-mutant lines was that of vemurafenib, EGFR, and AKT inhibitors, which was cytotoxic even in lines with primary resistance to vemurafenib or in lines selected for resistance to vemurafenib. NRAS-mutant lines were most sensitive to combination of the HMGCR inhibitor simvastatin and a nonspecific CDK inhibitor flavopiridol, which was in line with the previous studies highlighting the role of CDK activation in pathogenesis of NRAS driven melanoma <a class=\"rlc-reference\" data-ref-info=\"Kwong LN, Costello JC, Liu H, et al: Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma. Nat Med 18:1503-10, 2012.\" href=\"#_ENREF_36\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22983396\"><sup>36</sup></a>. Simvastatin was able to displace NRAS from the plasma membrane, thus exhibiting an inhibitory effect on its activity. These findings could be important in guiding future preclinical and clinical studies.</p>\n<p id=\"erb-f5c71d36-dbea-4346-a56a-32d7120f115f\">IMMUNOTHERAPY</p>\n<p id=\"erb-823083b6-9431-417c-87e9-1f4b5664de0e\">Malignant melanoma is a tumor extensively investigated as target for immunotherapy for reasons including its high immunogenic potential and the availability of tumor infiltrating lymphocytes (TILs) reactive against melanoma antigens <a class=\"rlc-reference\" data-ref-info=\"Kawakami Y, Eliyahu S, Delgado CH, et al: Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci U S A 91:3515-9, 1994.\" href=\"#_ENREF_198\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/8170938\"><sup>198</sup></a>. Earliest approaches had employed active immunization against the constantly growing repertoire of melanoma regression antigens <a class=\"rlc-reference\" data-ref-info=\"Slingluff CL, Jr., Petroni GR, Yamshchikov GV, et al: Immunologic and clinical outcomes of vaccination with a multiepitope melanoma peptide vaccine plus low-dose interleukin-2 administered either concurrently or on a delayed schedule. J Clin Oncol 22:4474-85, 2004.\" href=\"#_ENREF_199\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/15542798\"><sup>199</sup></a>, but enthusiasm subsided because of the very modest objective responses to immunization, mostly obtained for low volume disease <a class=\"rlc-reference\" data-ref-info=\"Rosenberg SA, Yang JC, Restifo NP: Cancer immunotherapy: moving beyond current vaccines. Nat Med 10:909-15, 2004.\" href=\"#_ENREF_200\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/15340416\"><sup>200</sup></a>. The puzzling question of why hasn\u2019t successful immunization, generating tumor-cognate lymphocytes, been yielding measurable tumor responses led to the recognition of the inhibitory role of immune check point modulators expressed on melanoma cells or on activated lymphocytes <sup><a class=\"rlc-reference\" data-ref-info=\"Spranger S, Spaapen RM, Zha Y, et al: Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells. Sci Transl Med 5:200ra116, 2013.\" href=\"#_ENREF_201\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23986400\">201</a>,<a class=\"rlc-reference\" data-ref-info=\"van Elsas A, Hurwitz AA, Allison JP: Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med 190:355-66, 1999.\" href=\"#_ENREF_202\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/10430624\">202</a></sup>. Understanding the role of costimulation opened a new era in the clinic and an intense search for additional targets for immunotherapies with improved efficacy to toxicity ratio.</p>\n<p id=\"erb-e4c96035-e1a1-483c-b8e5-6fe68ce774ce\">Interleukin-2 was the earliest immunotherapy for metastatic melanoma, approved by the FDA in 1998, followed by interferon-\u03b12b as an adjuvant therapy and ipilimumab (anti-CTLA-4 antibody) as therapy for advanced disease, approved by the U.S. Food and Drug Administration (FDA) for melanoma in March 2011. While the response rates to IL-2 and ipilimumab given as a single agent are in the range of 10% to 20% <sup><a class=\"rlc-reference\" data-ref-info=\"Atkins MB, Lotze MT, Dutcher JP, et al: High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 17:2105-16, 1999.\" href=\"#_ENREF_203\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/10561265\">203</a>,<a class=\"rlc-reference\" data-ref-info=\"Hodi FS, O'Day SJ, McDermott DF, et al: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711-23, 2010.\" href=\"#_ENREF_204\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/20525992\">204</a></sup>, when induced, responses to IL-2 and ipilimumab are typically long lasting and sometimes complete. In recent years, investigational agents have included adoptive T cell transfer, blocking antibodies against inhibitory immune molecules, stimulatory antibodies for immune cells, and immunization with distinct cancer cell antigens. Recently, interest in the role of mutated antigens being more immunogenic and therefore triggering a more robust immune response, has risen <a class=\"rlc-reference\" data-ref-info=\"Robbins PF, Lu YC, El-Gamil M, et al: Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med 19:747-52, 2013.\" href=\"#_ENREF_205\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23644516\"><sup>205</sup></a>. Identification and validation of biomarkers predictive of responses to immunotherapy is a rapidly developing field (reviewed by Ascierto et al. <a class=\"rlc-reference\" data-ref-info=\"Ascierto PA, Kalos M, Schaer DA, et al: Biomarkers for Immunostimulatory Monoclonal Antibodies in Combination Strategies for Melanoma and Other Tumor Types. Clin Cancer Res 19:1009-1020, 2013.\" href=\"#_ENREF_206\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23460532\"><sup>206</sup></a>). These might include a variety of tumor and tumor microenvironment\u2013specific alterations, the immune parameters of the individual patient. The mutational load of a tumor could be also a predictive factor, as it is plausible that highly mutated tumors are more immunogenic, therefore triggering a more robust immune response.</p>\n<p id=\"erb-27ade8df-9cb6-4f10-9074-45d57beb1425\">In light of the complexity of the immune response, it is very likely that combining immunotherapies will be necessary to induce better clinical responses, but even at this point it is clear that there is a life-prolonging effect of immunotherapy on many patients and a potential for cure.</p>\n<p id=\"erb-de5c7103-b647-49ae-902d-40d7493c5411\"><b>Immunomodulatory antibodies</b></p>\n<p id=\"erb-2f6e80bb-2a77-4bf5-8b0d-f445e62e1dc7\">The use of immune checkpoint inhibitors (antibodies that block proteins inhibiting immune response) has gained particular interest after approval of ipilimumab/anti-CTLA4 antibody for treatment of melanoma in 2011, and more so after the recent reports on the clinical efficacy of antibodies blocking PD-1. Table 5 shows some of the clinical trials with immune-system-targeting antibodies, which are described in more detail below.</p>\n<h3><a name=\"Table5\"></a>Table 5. Antibody-based immunotherapy of melanoma</h3>\n<table border=\"1\" cellpadding=\"7\" cellspacing=\"0\" id=\"erb-d65c659d-6353-46d2-b650-73d7256644ab\" width=\"655\">\n<colgroup>\n<col width=\"71\"></col>\n<col width=\"190\"></col>\n<col width=\"104\"></col>\n<col width=\"234\"></col>\n</colgroup>\n<tbody>\n<tr valign=\"TOP\">\n<td width=\"71\">\n<p lang=\"da-DK\"><b>Target</b></p>\n</td>\n<td width=\"190\">\n<p lang=\"da-DK\"><b>Desired effects</b></p>\n</td>\n<td width=\"104\">\n<p lang=\"da-DK\"><b>Antibodies </b></p>\n</td>\n<td width=\"234\">\n<p lang=\"da-DK\"><b>Trials</b></p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"71\">\n<p lang=\"da-DK\">CTLA-4</p>\n</td>\n<td width=\"190\">\n<p lang=\"da-DK\">Relieve the immune checkpoint</p>\n</td>\n<td width=\"104\">\n<p lang=\"da-DK\">Ipilimumab/Yervoy</p>\n</td>\n<td width=\"234\">\n<p lang=\"da-DK\">Approved</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"71\">\n<p lang=\"da-DK\">PD-1</p>\n</td>\n<td width=\"190\">\n<p lang=\"da-DK\">Relieve the immune checkpoint</p>\n</td>\n<td width=\"104\">\n<p lang=\"da-DK\">MDX-1106, CT-011, MK-3475</p>\n</td>\n<td width=\"234\">\n<p><a href=\"http://clinicaltrials.gov/ct2/results?term=NCT01024231&amp;Search=Search\">NCT01024231</a>, <a href=\"http://clinicaltrials.gov/ct2/results?term=NCT01176461&amp;Search=Search\">NCT01176461</a>, <a href=\"http://clinicaltrials.gov/ct2/results?term=NCT01721746&amp;Search=Search\">NCT01721746</a>, <a href=\"http://clinicaltrials.gov/ct2/results?term=NCT01621490&amp;Search=Search\">NCT01621490</a>, <a href=\"http://clinicaltrials.gov/ct2/results?term=NCT01721772&amp;Search=Search\">NCT01721772</a>, <a href=\"http://clinicaltrials.gov/ct2/results?term=NCT01783938&amp;Search=Search\">NCT01783938</a>, <a href=\"http://clinicaltrials.gov/ct2/results?term=NCT01714739&amp;Search=Search\">NCT01714739</a>, <a href=\"http://clinicaltrials.gov/ct2/results?term=NCT01435369&amp;Search=Search\">NCT01435369</a>, <a href=\"http://clinicaltrials.gov/ct2/results?term=NCT01295827&amp;Search=Search\">NCT01295827</a>,</p>\n<p><a href=\"http://clinicaltrials.gov/ct2/results?term=NCT01704287&amp;Search=Search\">NCT01704287</a></p>\n<p lang=\"da-DK\">\u00a0</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"71\">\n<p lang=\"da-DK\">PD-L1/B7-H1</p>\n</td>\n<td width=\"190\">\n<p lang=\"da-DK\">Relieve the immune checkpoint</p>\n</td>\n<td width=\"104\">\n<p lang=\"da-DK\">MDX-1105-01, MPDL3280A, MEDI4736</p>\n</td>\n<td width=\"234\">\n<p><a href=\"http://clinicaltrials.gov/ct2/results?term=NCT00729664&amp;Search=Search\">NCT00729664</a>, <a href=\"http://www.clinicaltrials.gov/ct2/show/NCT01633970\">NCT01633970</a>, <a href=\"http://clinicaltrials.gov/show/NCT01375842\">NCT01375842</a></p>\n<p><a href=\"http://clinicaltrials.gov/ct2/results?term=NCT01693562&amp;Search=Search\">NCT01693562</a></p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"71\">\n<p lang=\"da-DK\">4-1BB/CD137</p>\n</td>\n<td width=\"190\">\n<p lang=\"da-DK\">Stimulate T cells</p>\n</td>\n<td width=\"104\">\n<p lang=\"da-DK\">BMS-663513</p>\n</td>\n<td width=\"234\">\n<p><a href=\"http://clinicaltrials.gov/ct2/results?term=NCT01471210&amp;Search=Search\">NCT01471210</a></p>\n<p lang=\"da-DK\">\u00a0</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"71\">\n<p lang=\"da-DK\">CD40</p>\n</td>\n<td width=\"190\">\n<p lang=\"da-DK\">Stimulate T cells</p>\n</td>\n<td width=\"104\">\n<p lang=\"da-DK\">CP870,893</p>\n</td>\n<td width=\"234\">\n<p><a href=\"http://clinicaltrials.gov/ct2/results?term=NCT01103635&amp;Search=Search\">NCT01103635</a></p>\n<p lang=\"da-DK\">\u00a0</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"71\">\n<p lang=\"da-DK\">GITR</p>\n</td>\n<td width=\"190\">\n<p lang=\"da-DK\">Inhibit T regs</p>\n</td>\n<td width=\"104\">\n<p lang=\"da-DK\">TRX518</p>\n</td>\n<td width=\"234\">\n<p><a href=\"http://clinicaltrials.gov/ct2/results?term=NCT01239134&amp;Search=Search\">NCT01239134</a></p>\n<p lang=\"da-DK\">\u00a0</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"71\">\n<p lang=\"da-DK\">OX40/CD134</p>\n</td>\n<td width=\"190\">\n<p lang=\"da-DK\">Stimulate T cells</p>\n</td>\n<td width=\"104\">\n<p lang=\"da-DK\">Anti-OX40</p>\n</td>\n<td width=\"234\">\n<p><a href=\"http://clinicaltrials.gov/ct2/results?term=NCT01689870&amp;Search=Search\">NCT01689870</a></p>\n<p lang=\"da-DK\">\u00a0</p>\n</td>\n</tr>\n</tbody>\n</table>\n<p id=\"erb-f0e0c87c-1cde-4cc7-a0e4-f700c8f30dff\"><b>CTLA4 </b>is an inhibitory molecule expressed on T cells that is involved in the negative regulation of the T cell interaction with antigen-presenting dendritic cells (APCs). CTLA4 inhibits binding of CD28 on T cells to B7 proteins on APCs, thus weakening the costimulation of effector T cells. In addition, CTLA4 is expressed on regulatory T-cells (Treg), and the immune effects of anti-CTLA4 may be a combination of enhancing effector T-cell function while blocking Treg <a class=\"rlc-reference\" data-ref-info=\"Peggs KS, Quezada SA, Chambers CA, et al: Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med 206:1717-25, 2009.\" href=\"#_ENREF_207\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/19581407\"><sup>207</sup></a>. CTLA4 is also expressed on tumor cell lines <a class=\"rlc-reference\" data-ref-info=\"Contardi E, Palmisano GL, Tazzari PL, et al: CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction. Int J Cancer 117:538-50, 2005.\" href=\"#_ENREF_208\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/15912538\"><sup>208</sup></a> and in human melanoma <a class=\"rlc-reference\" data-ref-info=\"Shah KV, Chien AJ, Yee C, et al: CTLA-4 is a direct target of Wnt/beta-catenin signaling and is expressed in human melanoma tumors. J Invest Dermatol 128:2870-9, 2008.\" href=\"#_ENREF_209\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/18563180\"><sup>209</sup></a>; blockade of CTLA4 <i>in vitro</i> induces apoptosis of melanoma cells, indicating that CTLA4 might have non-immune functions. Available results from clinical trials indicate that the response rates to CTLA4 blockade with human monoclonal antibodies <a href=\"http://www.cancer.gov/drugdictionary?CdrID=38447\">ipilimumab</a> and <a href=\"http://www.cancer.gov/drugdictionary?CdrID=448620\">tremelimumab</a> are at most 18%, but overall survival is superior to what is seen with cytotoxic therapies. Significant immune toxicities were reported in a number of trials, and, interestingly, strong association of immune-related toxicities and\u00a0responses\u00a0were observed (reviewed by Flaherty et al. and Sapoznik et al. <sup><a class=\"rlc-reference\" data-ref-info=\"Flaherty KT, Hodi FS, Fisher DE: From genes to drugs: targeted strategies for melanoma. Nat Rev Cancer 12:349-61, 2012.\" href=\"#_ENREF_8\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22475929\">8</a>,<a class=\"rlc-reference\" data-ref-info=\"Sapoznik S, Hammer O, Ortenberg R, et al: Novel anti-melanoma immunotherapies: disarming tumor escape mechanisms. Clin Dev Immunol 2012:818214, 2012.\" href=\"#_ENREF_210\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22778766\">210</a></sup>).</p>\n<p id=\"erb-917d1447-9fea-4df9-afda-0bfcb6737dcd\">Potential markers that could predict response to ipilimumab are of obvious importance. Clinical trial <a href=\"http://clinicaltrials.gov/ct2/show/NCT00261365\">NCT00261365</a> incorporated investigation of a number of parameters in tumor biopsies pre- and post-treatment with ipilimumab. Significant associations were detected between clinical activity and high-baseline expression of FoxP3 and indoleamine 2,3-dioxygenase (IDO), and an increase in tumor-infiltrating lymphocytes (TILs) <a class=\"rlc-reference\" data-ref-info=\"Hamid O, Schmidt H, Nissan A, et al: A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. J Transl Med 9:204, 2011.\" href=\"#_ENREF_211\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22123319\"><sup>211</sup></a>. The immunosuppressive role of IDO in the context of immunotherapies was later shown in the B16 murine melanoma model <a class=\"rlc-reference\" data-ref-info=\"Holmgaard RB, Zamarin D, Munn DH, et al: Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. J Exp Med, 2013.\" href=\"#_ENREF_212\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23752227\"><sup>212</sup></a>. IDO catalyzes tryptophan degradation and inhibits T cell function. Inhibitors of IDO INCB024360 and 1-methyl-D-tryptophan are in several clinical trials for different malignancies, including a randomized phase \u00bd trial of combination of ipilimumab with INCB024360 (<a href=\"http://clinicaltrials.gov/ct2/show/NCT01604889\">NCT01604889</a>).</p>\n<p id=\"erb-875ab628-23c2-47e7-8d58-eb3a70f610cf\">Trials of ipilimumab and <a href=\"http://www.cancer.gov/drugdictionary?CdrID=42211\">gp100</a> peptide vaccine\u2014each as a single agent or in combination\u2014showed limited responses, but the responses were long lasting. Early-phase combination trials with ipilimumab include the following second agents: <a href=\"http://www.cancer.gov/drugdictionary\">bevacizumab</a>, high dose <a href=\"http://www.cancer.gov/drugdictionary?CdrID=462279\">interferon </a><a href=\"http://www.cancer.gov/drugdictionary?CdrID=462279\">\uf061</a><a href=\"http://www.cancer.gov/drugdictionary?CdrID=462279\">-2b</a>, <a href=\"http://www.cancer.gov/drugdictionary?CdrID=39756\">IL-2</a>, <a href=\"http://www.cancer.gov/drugdictionary?CdrID=40566\">GM-CSF</a>, <a href=\"http://www.cancer.gov/drugdictionary?CdrID=539733\">anti-PD-1 antibody</a> (see below), antibody to NK receptor KIR BMS-986015 (in patients with melanoma or other tumors), immunostimulatory cytokine IL-21, and even an oncolytic herpes simplex 1 virus (<a href=\"http://en.wikipedia.org/wiki/Talimogene_laherparepvec\">talimogene laherparepvec</a>/T-VEC) \u2014designed to replicate selectively in tumor cells and to express GM-CSF (the virus preparation is injectable directly into tumors) \u2014as well as a variety of chemotherapeutic agents and surgical/radiotherapy interventions (<a href=\"http://www.cancercommons.org/researchers-clinicians/melanoma/melanoma-stats-page/#tabs3\">Supplementary Table 2</a>). Reported results from trial <a href=\"http://clinicaltrials.gov/ct2/results?term=NCT01134614\">NCT01134614</a> combining ipilimumab with GM-CSF showed an increased OS in the combination arm (<a href=\"http://meetinglibrary.asco.org/content/109794-132\">ASCO abstract # CRA9007, 2013</a>).</p>\n<p id=\"erb-25bc6e98-1cac-45b0-a497-a3024998f4fa\"><b>PD-1</b>, like CTLA-4, is an inhibitory receptor; however, its expression is not limited to T cells and is found in B cells and some myeloid cells. The PD-1 ligands PD-L1 and PD-L2 have different expression patterns, with PD-L1 found on multiple normal and cancerous cells including melanoma tumors, where it provides, once bound by PD-1, peripheral tolerance to \"self\" antigens <a class=\"rlc-reference\" data-ref-info=\"Iwai Y, Ishida M, Tanaka Y, et al: Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A 99:12293-7, 2002.\" href=\"#_ENREF_213\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/12218188\"><sup>213</sup></a>. PD-L2 is expressed on APC cells, providing tolerance to orally administered antigens. Interactions between PD-1 and its ligands attenuate immune responses <a class=\"rlc-reference\" data-ref-info=\"Freeman GJ, Long AJ, Iwai Y, et al: Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 192:1027-34, 2000.\" href=\"#_ENREF_214\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/11015443\"><sup>214</sup></a>, and, in the context of cancer, serve to protect tumor cells from cytotoxic T cells. At the same time, PD-1 is expressed on CD8+ T cells in patients with metastatic melanoma\u2014particularly within the tumor microenvironment where they encounter chronic antigen exposure <a class=\"rlc-reference\" data-ref-info=\"Ahmadzadeh M, Johnson LA, Heemskerk B, et al: Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 114:1537-44, 2009.\" href=\"#_ENREF_215\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/19423728\"><sup>215</sup></a>, suggesting that the immune response to melanoma is inhibited under these circumstances.</p>\n<p id=\"erb-537b8e01-23e6-4505-9cd8-97da16fc116f\">Humanized antibodies to PD-1 and PD-L1 have been developed and tested in clinical trials for several cancers including melanoma. Anti-PD1 antibody <a href=\"http://www.cancer.gov/drugdictionary?CdrID=539733\">nivolumab</a> was well tolerated, and the maximum tolerated dose has not been reached <a class=\"rlc-reference\" data-ref-info=\"Topalian SL, Hodi FS, Brahmer JR, et al: Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443-54, 2012.\" href=\"#_ENREF_216\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22658127\"><sup>216</sup></a>. This study also found a strong correlation between pretreatment tumor expression of PD-L1 and responses, with a 36% response rate in patients whose tumors expressed PD-L1, and 0% in the PD-L1-negative group. However, a larger study of PD-L1 expression as a biomarker of response in solid tumors including melanoma reported that the correlation is not as solid as reported, because some patients with PD-L1 negative tumors had clinical responses to nivolumab (<a href=\"http://meetinglibrary.asco.org/content/113904-132\">http://meetinglibrary.asco.org/content/113904-132</a>). This may be because PD-L1 expression in the tumor is dynamic and is upregulated by factors such as the production of gamma interferon by infiltrating T cells. The better safety profile of PD-1 antibody versus CTLA-4 antibody is most likely due to the fact that the latter targets a peripheral interaction between T cells and tumor or APCs. Inhibition of PD-1 probably inhibits peripheral interactions as well, through PD-L2 on APCs, but it could be expected to act more locally at tumor sites by preventing inhibition of tumor-infiltrating PD-1-expressing T cells through interaction with PD-L1 on tumor cells.</p>\n<p id=\"erb-83120be2-c74b-4fe3-81c9-e8f2f6f6a96a\"><b>Clinical trials targeting PD-1/ PD-L1 interaction</b></p>\n<p id=\"erb-c64a70a1-fe95-4708-95c8-bee27b379874\">Results from an early-phase clinical trial with anti-PD1 antibody BMS-936558 (<a href=\"http://www.cancer.gov/drugdictionary?CdrID=539733\">MDX-1106</a>, ONO-4538, nivolumab) showed durable responses in 28% of patients with melanoma <a class=\"rlc-reference\" data-ref-info=\"Lipson EJ, Sharfman WH, Drake CG, et al: Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody. Clin Cancer Res 19:462-8, 2013.\" href=\"#_ENREF_217\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23169436\"><sup>217</sup></a>. Currently there are at least eight trials ongoing with MDX-1106 for melanoma.</p>\n<p id=\"erb-af58c21e-2e9f-48dc-bddf-81d553983d6e\">Two other anti-PD-1 antibodies (<a href=\"http://www.cancer.gov/drugdictionary?CdrID=573227\">CT-011</a>: CureTech Ltd. and MK-3475/<a href=\"http://www.cancer.gov/drugdictionary?CdrID=695789\">Lambrolizumab</a><a href=\"http://www.cancer.gov/drugdictionary?CdrID=695789\">lambrolizumab</a>: Merck) are also in clinical trials. Results of a clinical trial of lambrolizumab in advanced melanoma produced very promising results. Of 135 patients treated, 38% had durable responses as evaluated by RECIST. Remarkably, patients that have received ipilimumab prior to enrolling in this trial had a similar response rate. Importantly, lambrolizumab showed a favorable safety profile <a class=\"rlc-reference\" data-ref-info=\"Hamid O, Robert C, Daud A, et al: Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma. N Engl J Med, 2013.\" href=\"#_ENREF_218\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23724846\"><sup>218</sup></a>.</p>\n<p id=\"erb-30dd191a-b19f-431a-b5ab-a1cf8af10370\">An anti-PD-L1 antibody (<a href=\"http://www.cancer.gov/drugdictionary?CdrID=702758\">MPDL3280A</a>/BMS-936559/MDX-1105 is being tested as well. Preliminary results with anti-PD-L1 antibody showed significant tumor shrinkage in 21% of 140 patients who had a variety of cancers; 9 out of 52 melanoma patients had objective and durable <a class=\"rlc-reference\" data-ref-info=\"Brahmer JR, Tykodi SS, Chow LQ, et al: Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366:2455-65, 2012.\" href=\"#_ENREF_219\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22658128\"><sup>219</sup></a>.</p>\n<p id=\"erb-e9fa247c-e40d-4e7f-a8be-9f70c3b90dfb\">An important paper has shown that combining blockade of both immune checkpoints (PD-1 and CTLA4) is highly synergistic in rejection of melanoma tumors in an animal model through strong stimulation of effector T cells and IFN-g production <a class=\"rlc-reference\" data-ref-info=\"Curran MA, Montalvo W, Yagita H, et al: PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A 107:4275-80, 2010.\" href=\"#_ENREF_220\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/20160101\"><sup>220</sup></a>. Anti-PD-1/nivolumab/MK-3475 and anti-CTLA-4/Yervoy antibodies are being combined in clinical trials with the hope of synergistic effects (<a href=\"http://clinicaltrials.gov/ct2/show/NCT01024231?term=NCT01024231&amp;rank=1\">NCT01024231</a>). This combination treatment, when administered concurrently to 52 patients at a variety of dose levels, produced an objective response rate of 40% with 5 complete responses. The degree of observed tumor shrinkage was more than 80% for most of responding patients. In several patients in the study, tumors disappeared completely, as could be determined by imaging. Grade 3 or 4 adverse events related to therapy occurred in 53% of patients, but were generally reversible <a class=\"rlc-reference\" data-ref-info=\"Wolchok JD, Kluger H, Callahan MK, et al: Nivolumab plus Ipilimumab in Advanced Melanoma. N Engl J Med, 2013.\" href=\"#_ENREF_221\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23724867\"><sup>221</sup></a>. A randomized phase III trial <a href=\"http://clinicaltrials.gov/ct2/results?term=NCT01844505&amp;Search=Search\">NCT01844505</a> for ipilimumab <u>+</u> nivolumab with the endpoint of OS is recruiting melanoma patients. Phase II trial <a href=\"http://clinicaltrials.gov/ct2/results?term=NCT01783938\">NCT01783938</a> will explore sequential administration of nivolumab and ipilimumab.</p>\n<p id=\"erb-6abcc4f1-0b07-4d7a-97b4-8ccc59174e26\">In general, a concept is emerging that different immune checkpoints might have non-overlapping functions in immune escape; therefore, targeting more than one inhibitory molecule might be a general strategy for future approaches to immunotherapies. In addition to CTLA and PD-1/PD-L1, other proteins (LAG-3 and TIM-3) act as checkpoints. In addition, several proteins listed below are known to positively modulate T cells function. There are dozens of molecules now known to upregulate or downregulate immune responses and future trials evaluating agonists and antagonists of these molecules in combination may be promising.</p>\n<p id=\"erb-1293d806-5436-4805-96fe-ddb7b4fc04a1\"><b>4-1BB.</b> Also known as CD137, 4-1BB is a member of the TNF receptor superfamily, and is an activation-induced costimulatory molecule. Binding of 4-1BB by its ligand or antibody induces powerful CD8+ T-cell activation, IFN-\u03b3 production, and cytolytic activity. An agonistic antibody, <a href=\"http://www.cancer.gov/drugdictionary?CdrID=489120\">BMS-663513</a> (Bristol-Myers Squibb) was in clinical trials for melanoma and other tumors. Safety concerns caused suspension of the trial after several patients developed liver problems, including high-grade hepatitis. However, the antibody has promise in expanding the repertoire of functional CD8+ effector cells during T-cell expansion for autologous cell transfer (ACT). A recent study showed that addition of BMS-663513 to the expansion cultures of T cells isolated from metastases strongly increased the frequency and yield of CD8+ cells as well as their cytotoxic activity in vitro <a class=\"rlc-reference\" data-ref-info=\"Chacon JA, Wu RC, Sukhumalchandra P, et al: Co-Stimulation through 4-1BB/CD137 Improves the Expansion and Function of CD8(+) Melanoma Tumor-Infiltrating Lymphocytes for Adoptive T-Cell Therapy. PLoS One 8:e60031, 2013.\" href=\"#_ENREF_222\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23560068\"><sup>222</sup></a>.</p>\n<p id=\"erb-43588aca-3377-498f-8d41-3c4181b8eefc\"><b>GITR</b> is a co-stimulatory receptor expressed after T-cell activation that enhances T-cell function and survival. GITR also negatively affects regulatory T cells (Tregs), a specialized T-cell lineage that downregulates cellular immunity. A trial with anti-GITR antibody TRX-518 is ongoing (<a href=\"http://clinicaltrials.gov/ct2/show/NCT01239134\">NCT01239134</a>).</p>\n<p id=\"erb-7ad2a15c-2ab4-4c1c-b8b4-d1d24c4a806c\"><b>OX40</b> is not involved in effector T-cell activation, but rather, promotes T-cell survival and expansion. In a clinical study, based at the Portland Providence Medical Center in Oregon, patients received three infusions of the agonistic mouse anti-OX40 antibody within a week. The xenogeneic nature of the antibody precluded further treatments. Nine of 27 patients experienced minor tumor shrinkage, although none met RECIST (response evaluation criteria in solid tumors) criteria for objective responses.</p>\n<p id=\"erb-1b9c0c60-e3a3-4313-90b2-5121d3018589\"><b>CD40.</b> Unlike the co-stimulatory targets above, CD40 is expressed on APCs, while its ligand is expressed on T cells. Binding of the two acts as a powerful enhancer of APCs\u2019 ability to present antigens and activate T cells against foreign targets <a class=\"rlc-reference\" data-ref-info=\"Vonderheide RH, Flaherty KT, Khalil M, et al: Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clin Oncol 25:876-83, 2007.\" href=\"#_ENREF_223\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/17327609\"><sup>223</sup></a>. A number of cancer patients with diverse solid tumors have received infusions of agonistic antibody <a href=\"http://www.cancer.gov/drugdictionary?CdrID=588974\">CP870,893</a>, often in combination with conventional chemotherapy, making it difficult to evaluate the antibody contribution. In those given antibody alone some objective responses were observed, particularly in a few patients with melanoma. A surprising finding was that treatments did not increase numbers of TILs in the tumors. In a mouse model, antibody treatments induced an influx of macrophages into tumors, presumably with enhanced cytotoxic activities. A phase I trial <a href=\"http://clinicaltrials.gov/ct2/show/NCT01103635\">NCT01103635</a> combining CP870,893 with <a href=\"http://www.cancer.gov/drugdictionary?CdrID=448620\">tremelimumab</a> in melanoma and other tumors is ongoing. A dose escalation trial of CP870,893 is ongoing where antibody is combined with Oncovir poly IC:LC and NY-ESO-1/gp100 <a href=\"http://clinicaltrials.gov/ct2/show/NCT01008527\">NCT01008527</a>.</p>\n<p id=\"erb-93279be7-ac58-4175-b917-d55b09ed8bc8\"><b>CEACAM1</b> is a potential new target for the development of targeting antibodies. CEACAM1 is a carcinoembryonic, antigen-related adhesion molecule 1 from the IG superfamily whose expression is absent from normal melanocytes, but often found in melanomas, particularly those that are metastatic. CEACAM1 was shown to protect melanoma cells from T cells <i>in vitro</i>, and, moreover, its expression was found on T cells and NK cells from melanoma patients, presumably enabling a homotypic inhibitory interaction. A mouse antibody to CEACAM has no apparent effect on CEACAM1-expressing melanoma cells <i>in vitro</i>, but renders them susceptible to elimination by T cells <i>in vitro</i> and in an <i>in vivo</i> xenograft model. These findings provide a strong rationale for developing CEACAM1-based therapeutics for the treatment of metastatic melanoma <a class=\"rlc-reference\" data-ref-info=\"Sapoznik S, Hammer O, Ortenberg R, et al: Novel anti-melanoma immunotherapies: disarming tumor escape mechanisms. Clin Dev Immunol 2012:818214, 2012.\" href=\"#_ENREF_210\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22778766\"><sup>210</sup></a>.</p>\n<p id=\"erb-4601313c-3878-4164-8aab-b497e27115ea\"><b>Cytokines</b></p>\n<p id=\"erb-dcf15b3a-1e46-4e27-8785-6f6ea67e862c\">Interleukin-2 (IL-2), a protein produced primarily by CD4+ T-cells that activates and induces proliferation of natural killer (NK) cells, CD8+, and CD4+ T cells, is FDA-approved for the treatment of metastatic melanoma. This is due to the long, durable responses lasting over 10 years in a subset of patients. However, objective clinical responses to IL-2 alone are under 15% in most series, and the treatment is related to significant adverse reactions including pulmonary edema, hypotension, fever, and chills. In a randomized clinical trial for metastatic melanoma patients, IL-2 combined with a gp100 peptide vaccine doubled the clinical responses compared to those patients receiving IL-2 alone. The vaccine + IL-2 group also had increased progression-free survival (PFS), but only a trend towards improved overall survival <a class=\"rlc-reference\" data-ref-info=\"Schwartzentruber DJ, Lawson DH, Richards JM, et al: gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med 364:2119-27, 2011.\" href=\"#_ENREF_224\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/21631324\"><sup>224</sup></a>. Currently, a trial with IL-2 in combination with a MAGE vaccine containing an improved adjuvant is ongoing. One interesting small trial combined high-dose IL-2 with ipilimumab in 36 patients with metastatic melanoma <a class=\"rlc-reference\" data-ref-info=\"Prieto PA, Yang JC, Sherry RM, et al: CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin Cancer Res 18:2039-47, 2012.\" href=\"#_ENREF_225\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22271879\"><sup>225</sup></a>. The overall response rate of 25% was most notable because 6 of the 9 responders achieved CRs (CR rate 17%) and all were sustained beyond 6 years. This suggests that combining stimulatory cytokines with checkpoint blockade is a strategy worth further investigation.</p>\n<p id=\"erb-b087af16-6e14-4438-9d65-e81899886d02\">Interferon-alpha is FDA-approved for the treatment of stage III melanoma in the adjuvant setting. Interferon has been shown to increase relapse-free survival (RFS)\u2014but in most studies, not overall survival. Recently a weekly pegylated formulation was also FDA-approved for the same indication. Data suggests that patients with ulcerated primaries and microscopic compared to palpable nodal disease are subsets that may benefit most from interferon. Toxicities of interferon include immune hepatitis, fever, chills, and fatigue, and the recommended regimen includes one month of high-dose intravenous therapy followed by 11 months of subcutaneous injections.</p>\n<p id=\"erb-cbd24ae9-37ce-4c26-a00c-a93d9583fc17\">Cytokines under investigation for the treatment of metastatic melanoma include IL-21, which produced an ORR of 22.5% <a class=\"rlc-reference\" data-ref-info=\"Petrella TM, Tozer R, Belanger K, et al: Interleukin-21 has activity in patients with metastatic melanoma: a phase II study. J Clin Oncol 30:3396-401, 2012.\" href=\"#_ENREF_226\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22915661\"><sup>226</sup></a>, and is tested both alone and in phase I trials in combination with anti-CTLA4 (<a href=\"http://clinicaltrials.gov/ct2/show/NCT01489059?term=NCT01489059&amp;rank=1\">NCT01489059</a>) and anti-PD1 antibody (<a href=\"http://clinicaltrials.gov/ct2/show/NCT01629758\">NCT01629758</a>).</p>\n<p id=\"erb-d63dfac4-9ac0-4b82-ae2d-65042822be0c\"><b>Adoptive cell transfer</b></p>\n<p id=\"erb-1d22d4c7-1bdb-4994-aa70-7b3690421dfe\">Adoptive cell transfer (ACT) involves the selection of autologous lymphocytes with antitumor activity, their expansion/activation <i>ex vivo</i>, and their reinfusion into the patient, often in the context of lymphodepleting regimens to minimize endogenous immunosuppression (reviewed by Galluzzi et al. and Itzhaki et al.<sup><a class=\"rlc-reference\" data-ref-info=\"Galluzzi L, Vacchelli E, Eggermont A, et al: Trial Watch: Adoptive cell transfer immunotherapy. Oncoimmunology 1:306-315, 2012.\" href=\"#_ENREF_227\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22737606\">227</a>,<a class=\"rlc-reference\" data-ref-info=\"Itzhaki O, Levy D, Zikich D, et al: Adoptive T-cell transfer in melanoma. Immunotherapy 5:79-90, 2013.\" href=\"#_ENREF_228\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23256800\">228</a></sup>). T-cell-adoptive therapy for metastatic melanoma has been quite successful in achieving objective regressions in about 50% of patients <a class=\"rlc-reference\" data-ref-info=\"Rosenberg SA, Yang JC, Sherry RM, et al: Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 17:4550-7, 2011.\" href=\"#_ENREF_229\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/21498393\"><sup>229</sup></a> and produced durable complete regressions. Despite the clear therapeutic efficacy in some melanoma patients with ACT, there are a number of challenges for this approach to become widely accepted and FDA approved, including the complex methodology required to manufacture large numbers of T cells, which has restricted this therapy to a limited number of patients in a handful of centers. Increased utilization of this approach will require a simplification and improvement of the methods for T-cell expansion and a modification of the treatment regimen associated with decreased toxicity such as the use of lower doses of IL-2. Importantly, while it is clear that patients failing anti-CTLA4 can respond to ACT, future studies will determine whether the same is true for patients who fail anti-PD1 therapy.</p>\n<p id=\"erb-254eb6b2-7685-43f1-9f59-288c6b2195a2\">Different aspects of ACT are being examined, among them the role of cytokines such as IL-15 and T-cell-produced IL-9 in T-cell-based therapy <a class=\"rlc-reference\" data-ref-info=\"Purwar R, Schlapbach C, Xiao S, et al: Robust tumor immunity to melanoma mediated by interleukin-9-producing T cells. Nat Med, 2012.\" href=\"#_ENREF_230\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22772464\"><sup>230</sup></a>; concomitant low-dose IL-2 in patients treated with ACT <a class=\"rlc-reference\" data-ref-info=\"Ellebaek E, Iversen TZ, Junker N, et al: Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients. J Transl Med 10:169, 2012.\" href=\"#_ENREF_231\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22909342\"><sup>231</sup></a>; facilitation of the long-term engraftment of T cells by using the memory-T-cell population <sup><a class=\"rlc-reference\" data-ref-info=\"Hirschhorn-Cymerman D, Budhu S, Kitano S, et al: Induction of tumoricidal function in CD4+ T cells is associated with concomitant memory and terminally differentiated phenotype. J Exp Med 209:2113-26, 2012.\" href=\"#_ENREF_232\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23008334\">232</a>,<a class=\"rlc-reference\" data-ref-info=\"Wang A, Chandran S, Shah SA, et al: The stoichiometric production of IL-2 and IFN-gamma mRNA defines memory T cells that can self-renew after adoptive transfer in humans. Sci Transl Med 4:149ra120, 2012.\" href=\"#_ENREF_233\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22932225\">233</a></sup>; the basis for the relapses frequently observed after ACT immunotherapy, such as inflammation-induced, reversible loss of melanocytic antigens mediated by TNF-a <a class=\"rlc-reference\" data-ref-info=\"Landsberg J, Kohlmeyer J, Renn M, et al: Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation. Nature 490:412-6, 2012.\" href=\"#_ENREF_234\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23051752\"><sup>234</sup></a>; the immunosuppressive role of Tregs and myeloid-derived suppressor cells (MDSC) <a class=\"rlc-reference\" data-ref-info=\"Kodumudi KN, Weber A, Sarnaik AA, et al: Blockade of myeloid-derived suppressor cells after induction of lymphopenia improves adoptive T cell therapy in a murine model of melanoma. J Immunol 189:5147-54, 2012.\" href=\"#_ENREF_235\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23100512\"><sup>235</sup></a>; and the nature of the relevant tumor-rejection antigens being targeted.</p>\n<p id=\"erb-45030460-32a2-48b3-b6a1-747133dbf1af\">Analysis of the repertoire of T cells in the successful ACT treatments of three melanoma patients through exomic sequencing of tumors established a correlation between the ability of infused T cells to recognize specific mutated proteins present in tumors. Candidate mutated epitopes were identified using major histocompatibility complex\u2013binding algorithm for recognition by TILs <a class=\"rlc-reference\" data-ref-info=\"Robbins PF, Lu YC, El-Gamil M, et al: Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med 19:747-52, 2013.\" href=\"#_ENREF_205\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23644516\"><sup>205</sup></a>. In one patient successfully treated by ACT in a previous trial, the specific T cells recognizing a mutated epitope persisted in peripheral blood for over 5 years <a class=\"rlc-reference\" data-ref-info=\"Lu YC, Yao X, Li YF, et al: Mutated PPP1R3B Is Recognized by T Cells Used To Treat a Melanoma Patient Who Experienced a Durable Complete Tumor Regression. J Immunol 190:6034-42, 2013.\" href=\"#_ENREF_236\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23690473\"><sup>236</sup></a>.</p>\n<p id=\"erb-609713af-4a52-40ae-a23c-0d9c59e2b740\">A recent phase II clinical trial reported objective clinical responses in almost half of the 31 patients enrolled, with two complete remissions and a significant increase in PFS <a class=\"rlc-reference\" data-ref-info=\"Radvanyi LG, Bernatchez C, Zhang M, et al: Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. Clin Cancer Res 18:6758-70, 2012.\" href=\"#_ENREF_237\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23032743\"><sup>237</sup></a>. The study also analyzed characteristics of infused T cells associated with significant responses, and found significant correlations with a higher number of TIL infused: a higher proportion of CD8+ T cells in the infusion product; a more differentiated effector phenotype of the CD8+ population; and, unexpectedly, a higher frequency of CD8+ T cells co-expressing the negative co-stimulation molecule \"B- and T-lymphocyte attenuator\" (BTLA). A phase I/II trial is investigating the use of autologous TILs enriched for CD8 and engineered to secrete IL-12, which will be infused after patients undergo a myeloablative regimen of chemotherapy (<a href=\"http://clinicaltrials.gov/ct2/results?term=NCT+01236573\">NCT</a><a href=\"http://clinicaltrials.gov/ct2/results?term=NCT+01236573\"> </a><a href=\"http://clinicaltrials.gov/ct2/results?term=NCT+01236573\">01236573</a>). On the other hand, a randomized trial suggested that use of unselected young autologous T cells is preferable to enrichment for CD8+ cells because the latter are more laborious to prepare and did not offer a therapeutic advantage <a class=\"rlc-reference\" data-ref-info=\"Dudley ME, Gross CA, Somerville RP, et al: Randomized Selection Design Trial Evaluating CD8+-Enriched Versus Unselected Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy for Patients With Melanoma. J Clin Oncol 31:2152-9, 2013.\" href=\"#_ENREF_238\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23650429\"><sup>238</sup></a>.</p>\n<p id=\"erb-99d0d6e3-8556-481a-8feb-388584db20c8\">Failure of the infused CD8 cells to persist in the patients could be a major cause for the limited efficacy of TIL approaches to treatment. In a number of trials this was addressed by administration of IL-2 after infusion, or lymphodepletion prior to infusion. To increase the persistence of infused T cells in patients, an approach was tested to stimulate CD8+ cells <i>in vitro</i> with MART-1-presenting APCs in the presence of IL-2 and IL-15. These CTLs displayed a memory phenotype, both central and effector, trafficked successfully to the tumor sites, and produced a complete response in one of nine patients, as well as several partial responses and disease stabilization <a class=\"rlc-reference\" data-ref-info=\"Butler MO, Friedlander P, Milstein MI, et al: Establishment of antitumor memory in humans using in vitro-educated CD8+ T cells. Sci Transl Med 3:80ra34, 2011.\" href=\"#_ENREF_239\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/21525398\"><sup>239</sup></a>.</p>\n<p id=\"erb-db75d187-397b-4b54-bde4-634ef093d518\">Another approach to ACT therapy is to create tumor-reactive T-cell populations from PBL by retrovirally transducing them with chimeric antigen receptors (CAR) to tumor-associated antigens or natural T-cell receptors against antigens presented in the context of MHC. CAR-modified T cells do not depend on MHC-mediated antigen presentation, which is frequently dysfunctional in tumors. The steps and considerations in producing T cells with CARs and their advantages as well as pitfalls were recently reviewed <a class=\"rlc-reference\" data-ref-info=\"Kershaw MH, Westwood JA, Darcy PK: Gene-engineered T cells for cancer therapy. Nat Rev Cancer 13:525-41, 2013.\" href=\"#_ENREF_240\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23880905\"><sup>240</sup></a>. In melanoma, T cells redirected to recognize MART-1 have produced significant clinical responses (reviewed by Strauss <a class=\"rlc-reference\" data-ref-info=\"Stauss HJ, Morris EC: Immunotherapy with gene-modified T cells: limiting side effects provides new challenges. Gene Ther, 2013.\" href=\"#_ENREF_241\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23804078\"><sup>241</sup></a>). A tumor-testis antigen on melanoma and other tumors, NY-ESO-1, has been effectively targeted with an MHC-restricted T-cell receptor in another trial<a class=\"rlc-reference\" data-ref-info=\"Robbins PF, Morgan RA, Feldman SA, et al: Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol 29:917-24, 2011.\" href=\"#_ENREF_242\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/21282551\"><sup>242</sup></a>.</p>\n<p id=\"erb-cfb04485-e0a7-4d85-a7b5-3f3043575dcf\">Some remarkable responses were observed in individual patients treated with CD4+ T cells. For example, autologous transfer of expanded CD4+ T cells recognizing melanoma antigen NY-ESO-1 produced a complete and durable response in one patient trial <a class=\"rlc-reference\" data-ref-info=\"Hunder NN, Wallen H, Cao J, et al: Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med 358:2698-703, 2008.\" href=\"#_ENREF_243\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/18565862\"><sup>243</sup></a>. Recent findings indicate that CD4+ T cells could also contribute to the success of ACT by inducing tumor senescence through production of high levels of IFN-\uf067 and TNF <a class=\"rlc-reference\" data-ref-info=\"Braumuller H, Wieder T, Brenner E, et al: T-helper-1-cell cytokines drive cancer into senescence. Nature, 2013.\" href=\"#_ENREF_244\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23376950\"><sup>244</sup></a>.</p>\n<p id=\"erb-a91c5f17-805c-4fa0-9dde-712f245b0da6\"><b>Dendritic cell\u2013based immunotherapy.</b></p>\n<p id=\"erb-7c01ddf9-9268-4bdf-9442-a2403c41016e\">Dendritic cells (DCs) are the most potent-presenting cells in the immune system; clinical efforts to use DC to induce potent anti-melanoma immune responses have been ongoing for at least a decade <a class=\"rlc-reference\" data-ref-info=\"Palucka K, Banchereau J: Cancer immunotherapy via dendritic cells. Nat Rev Cancer 12:265-77, 2012.\" href=\"#_ENREF_245\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22437871\"><sup>245</sup></a>. However, as with most immunotherapies, the responses to DC-mediated vaccination have been unpredictable and variable.</p>\n<p id=\"erb-12d84f95-8931-4b00-94c4-807d09f84881\">Stimulation of anti-melanoma responses by DCs involves a number of steps that need better scientific understanding and clinical exploration. To arm DCs with the antigens needed to be presented to immune effector cells, DC are usually \u201cloaded\u201d with antigens expressed in tumors by incubation with the tumor antigens and an adjuvant <i>ex vivo</i>. This process induces maturation of DCs, which involves processing the antigens via proteasomal degradation and presenting them to T cells on a variety of MHC-family molecules. As so-called \u201cprofessional antigen presenting cells\u201d, DCs can present antigen to and efficiently co-stimulate both CD4+ cells and CD8+ cells. The T-helper cells could stimulate B-cell-based humoral responses, and killer T cells could have direct cytotoxic activity against antigen-presenting tumor cells. DCs can also react to as well as stimulate the components of the innate immune system such as NK cells and phagocytes. Yet other DC interactions can also induce regulatory T cells that dampen immune responses. Finally, DCs are also influenced by a large variety of soluble factors, many of which are abundant in the tumor microenvironment.</p>\n<p id=\"erb-9c55671a-249d-423f-a02f-4c43660fdbe4\">A number of variables remain to be fully explored in DC vaccination: the source of DCs, the optimal methods for maturation <i>ex vivo</i>, the route of introduction into patients, the ways to overcome the tumor-generated immunosuppressory activities, and more.</p>\n<p id=\"erb-026d6c02-e46c-47d6-b891-bcefc55bdc2e\">Clinical trials have explored DCs generated by different methods and injected by different routes in patients with metastatic melanoma (only a few are mentioned here). DCs can be isolated from peripheral blood and from Langerhans cells\u2014a subset of DCs present in skin\u2014or other sources (see below). For example, an early clinical trial that concluded in 1998 produced promising results. Patients were vaccinated with monocyte-derived DCs pulsed with tumor lysate or a mix of tumor-related peptides, and stimulated with GM-CSF and IL-4. Five of 16 patients had objective responses <a class=\"rlc-reference\" data-ref-info=\"Nestle FO, Alijagic S, Gilliet M, et al: Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 4:328-32, 1998.\" href=\"#_ENREF_246\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/9500607\"><sup>246</sup></a>. Monocyte-derived DCs were pulsed with a single tumor peptide from Mage-3A1 and a recall antigen in another study. Evaluation of immune responses showed that 8 of 11 patients had an expansion of Mage-3A1-recognizing CD8+ T cells, and 6 patients showed regression of some metastases, but no formal PRs or CRs were achieved <a class=\"rlc-reference\" data-ref-info=\"Thurner B, Haendle I, Roder C, et al: Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 190:1669-78, 1999.\" href=\"#_ENREF_247\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/10587357\"><sup>247</sup></a>. It was noted that some nonregressing tumors lacked Mage-3A1 expression and specific T cells.</p>\n<p id=\"erb-e5673e8d-57dc-4e7c-8b21-07a1a05221fb\">In a different approach, immature DCs were generated from CD34+ hematopoietic progenitor cells through stimulation with a predefined cytokine cocktail, and matured <i>in vitro</i> by pulsing with a pool of peptides derived from known melanoma antigens <a class=\"rlc-reference\" data-ref-info=\"Mackensen A, Herbst B, Chen JL, et al: Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34(+) hematopoietic progenitor cells. Int J Cancer 86:385-92, 2000.\" href=\"#_ENREF_248\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/10760827\"><sup>248</sup></a>. This study reported durable immune responses and perhaps one objective clinical response.</p>\n<p id=\"erb-9785c4ed-b003-47c5-9a76-a5d7eddf3800\">Langerhans cells were directly compared to monocyte-derived DCs in a clinical trial, and were found to be similar in terms of eliciting immune responses, but different in terms of the need for cytokine stimulation <a class=\"rlc-reference\" data-ref-info=\"Romano E, Rossi M, Ratzinger G, et al: Peptide-loaded Langerhans cells, despite increased IL15 secretion and T-cell activation in vitro, elicit antitumor T-cell responses comparable to peptide-loaded monocyte-derived dendritic cells in vivo. Clin Cancer Res 17:1984-97, 2011.\" href=\"#_ENREF_249\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/21355077\"><sup>249</sup></a>. The role of the route of injection was explored in a study that injected monocyte-derived, stimulated DCs either intranodally or intradermally. The latter produced very low percentages of cells surviving and migrating to lymph nodes <a class=\"rlc-reference\" data-ref-info=\"Verdijk P, Aarntzen EH, Lesterhuis WJ, et al: Limited amounts of dendritic cells migrate into the T-cell area of lymph nodes but have high immune activating potential in melanoma patients. Clin Cancer Res 15:2531-40, 2009.\" href=\"#_ENREF_250\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/19318472\"><sup>250</sup></a>, but the induced immune responses (stimulation of tumor-specific T cells) were superior in the patients receiving intradermal inoculation <a class=\"rlc-reference\" data-ref-info=\"Lesterhuis WJ, de Vries IJ, Schreibelt G, et al: Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients. Clin Cancer Res 17:5725-35, 2011.\" href=\"#_ENREF_251\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/21771874\"><sup>251</sup></a>.</p>\n<p id=\"erb-09a59a75-8f38-4418-9762-8611b4c26c7f\">Stimulation of DCs could be performed not only by exposing them to tumor antigens, but also by transfection of mRNA coding for the antigens <a class=\"rlc-reference\" data-ref-info=\"Mitchell DA, Nair SK: RNA-transfected dendritic cells in cancer immunotherapy. J Clin Invest 106:1065-9, 2000.\" href=\"#_ENREF_252\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/11067858\"><sup>252</sup></a>. The latter might have an advantage of longer exposure and correct processing of the antigens. Indeed, it was shown to produce strong immune responses after intranodal injection, inducing a broad repertoire of IFN-\u03b3 producing TAA-specific CD8+ and CD4+ T cells <a class=\"rlc-reference\" data-ref-info=\"Aarntzen EH, Schreibelt G, Bol K, et al: Vaccination with mRNA-electroporated dendritic cells induces robust tumor antigen-specific CD4+ and CD8+ T cells responses in stage III and IV melanoma patients. Clin Cancer Res 18:5460-70, 2012.\" href=\"#_ENREF_253\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22896657\"><sup>253</sup></a>. Stage III melanoma patients in this study also had significant immune responses.</p>\n<p id=\"erb-bbec9ffe-343a-4fe2-80a3-a13810e7e507\">A recent study reported a further significant improvement on DC maturation <i>ex vivo</i>. Mature DCs (used for vaccination) express a specific type of proteasomes, the immunoproteasomes (iPs) that are responsible for antigen processing in immune cells. However, tumor cells express constitutive proteasomes (cPs) that contain three different subunits. It was hypothesized that generating T cells against epitopes from one type of proteasome (iPs) might not result in recognition of epitopes generated by target cell proteasomes (cPs), preventing optimal recognition and immune attack of tumor cells. Therefore, the patient-derived DCs were transfected not only with the RNA for tumor antigens, but also with shRNA, which enforced the default use of only cPs in the DCs. Patients vaccinated with cPs-expressing DCs had lower levels of circulating melanoma cells and enhanced melanoma-directed T-cell-lytic activity, which was of a longer duration compared to patients in control arms of the study. Of the five patients vaccinated with cPs-expressing DCs, one had a complete response, and one had a partial response <a class=\"rlc-reference\" data-ref-info=\"Dannull J, Haley NR, Archer G, et al: Melanoma immunotherapy using mature DCs expressing the constitutive proteasome. J Clin Invest 123:3135-45, 2013.\" href=\"#_ENREF_254\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23934126\"><sup>254</sup></a>.</p>\n<p id=\"erb-a8c697ae-dcc4-414a-a647-0802c728b0f9\">Another important component of successful vaccination with DCs is their ability to stimulate CD8+ T cells, which requires production of IL-12-p70 by DCs, which, in turn, depends on stimulation of DCs by two signals: CD40 or TLR and INF-\uf067. A recent small clinical trial used DCs from peripheral blood mononuclear cells (PBMCs) of melanoma patients pulsed with gp100 peptides. In addition, maturation <i>in vitro</i> included stimulation of DCs from PBMCs with both CD40L and INF-\uf067. The study of seven patients showed a straightforward correlation between the clinical responses and levels of IL-12 produced by their DCs. The one patient with complete remission had the highest levels of IL-12. Moreover, the study has identified the deficiency in nonresponding patients as the inability to produce IL12 without additional stimulation with TLR agonist. Addition of poly I:C to the maturation protocol has rescued production of IL-12 by these DCs <i>in vitro</i> and improved the clinical outcomes <a class=\"rlc-reference\" data-ref-info=\"Carreno BM, Becker-Hapak M, Huang A, et al: IL-12p70-producing patient DC vaccine elicits Tc1-polarized immunity. J Clin Invest, 2013.\" href=\"#_ENREF_255\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23867552\"><sup>255</sup></a>.</p>\n<p id=\"erb-2ea746c1-2752-49b7-8cc6-5e16687d339b\">Although combination immunotherapies involving DCs and immunomodulatory antibodies may hold promise <a class=\"rlc-reference\" data-ref-info=\"Ribas A, Comin-Anduix B, Chmielowski B, et al: Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma. Clin Cancer Res 15:6267-76, 2009.\" href=\"#_ENREF_256\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/19789309\"><sup>256</sup></a>, overall clinical results with DC vaccines remain sporadic, anecdotal, and inconsistent. Clinical investigators continue to struggle with an overwhelming number of variables, reflecting the complicated biology and role of this immune cell.</p>\n<p id=\"erb-b28b107f-99d3-4d4e-bb6c-01fc5d6ec555\"><b>Adoptive transfer of natural killer cells</b>. NK cells are an essential part of the innate immune system and have been considered in immunotherapies of melanoma. NK cells in principle are able to recognize and destroy virally infected or malignant cells without a need for antecedent antigenic stimulation. However, their activity, as with other immune effector cells, also depends on balance of stimulatory or inhibitory factors. NK cells themselves are regulated by inhibitory receptors, one of which, KIR (killer-cell immunoglobulin-like receptors), is being targeted in a clinical trial with the antagonistic antibody BMS-986015 that is designed to block the inhibition by KIR of tumor-cell cytolysis.</p>\n<p id=\"erb-bc5a2fc9-1278-4cb0-84ca-bc05395bc8a8\">NK cells can be obtained from PBMC where they comprise 5% to 15 % of the lymphocyte population, expanded and activated <i>in vitro</i> and adoptively transferred. In fact lymphokine activated killer cells (LAK cells) given in large numbers 20 years ago were largely IL-2 activated NK cells <a class=\"rlc-reference\" data-ref-info=\"Rosenberg SA, Lotze MT, Yang JC, et al: Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst 85:622-32, 1993.\" href=\"#_ENREF_257\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/8468720\"><sup>257</sup></a>. These prior trials, as well as a more recent trial combining autologous NK transfer with preparative lymphodepletion, have not demonstrated benefit attributable to the NK cells <a class=\"rlc-reference\" data-ref-info=\"Parkhurst MR, Riley JP, Dudley ME, et al: Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression. Clin Cancer Res 17:6287-97, 2011.\" href=\"#_ENREF_258\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/21844012\"><sup>258</sup></a>. New strategies might include combination of NK transfer with immunomodulatory antibodies or even transfer of activated allogeneic NK cells <a class=\"rlc-reference\" data-ref-info=\"Besser MJ, Shoham T, Harari-Steinberg O, et al: Development of allogeneic NK cell adoptive transfer therapy in metastatic melanoma patients: in vitro preclinical optimization studies. PLoS One 8:e57922, 2013.\" href=\"#_ENREF_259\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23483943\"><sup>259</sup></a>. The cytokine-induced killer cells (CIKs), which can also be isolated from PBMCs, were recently characterized as a variant NK subtype that have a cytotoxic activity against autologous melanoma cells <a class=\"rlc-reference\" data-ref-info=\"Gammaitoni L, Giraudo L, Leuci V, et al: Effective Activity of Cytokine Induced Killer Cells against Autologous Metastatic Melanoma including Cells with Stemness Features. Clin Cancer Res, 2013.\" href=\"#_ENREF_260\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23794732\"><sup>260</sup></a>.</p>\n<p id=\"erb-734f3d55-e577-4b29-8584-c56319b8b1f4\"><b>Influence of targeted therapies on the responses to immune therapy</b></p>\n<p id=\"erb-264ec0d5-bd68-43d8-9394-4f2ca52a9a53\"><b>BRAF/MAPK signaling and TIL</b>. Activated BRAF/MAPK signaling was shown to be essential in the development of immune evasion in melanoma <a class=\"rlc-reference\" data-ref-info=\"Sumimoto H, Imabayashi F, Iwata T, et al: The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells. J Exp Med 203:1651-6, 2006.\" href=\"#_ENREF_261\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/16801397\"><sup>261</sup></a>. Prior to clinical development of BRAF and MEK inhibitors, it was shown that inhibition of the MAPK pathway leads to increased expression of melanocytic antigen expression, including MART-1, gp100, and tyrosinase; whereas enforced expression of mutant RAF downregulated expression of these antigens <a class=\"rlc-reference\" data-ref-info=\"Kono M, Dunn IS, Durda PJ, et al: Role of the mitogen-activated protein kinase signaling pathway in the regulation of human melanocytic antigen expression. Mol Cancer Res 4:779-92, 2006.\" href=\"#_ENREF_262\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/17050671\"><sup>262</sup></a>. Mutant BRAF induces expression of IL-1\uf061 in stroma, also leading to immune suppression <a class=\"rlc-reference\" data-ref-info=\"Khalili JS, Liu S, Rodriguez-Cruz TG, et al: Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma. Clin Cancer Res 18:5329-40, 2012.\" href=\"#_ENREF_263\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22850568\"><sup>263</sup></a>. In a mouse model, BRAFV600E induced expression of CCL2, an immunosuppressive chemokine, while PLX4720 treatment downregulated tumor CCL2 gene expression and increased numbers of CD8 TILs <a class=\"rlc-reference\" data-ref-info=\"Knight DA, Ngiow SF, Li M, et al: Host immunity contributes to the anti-melanoma activity of BRAF inhibitors. J Clin Invest 123:1371-81, 2013.\" href=\"#_ENREF_264\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23454771\"><sup>264</sup></a>.</p>\n<p id=\"erb-d149b695-d28d-4ded-a866-5528871d164b\">There were concerns that treatment with BRAF/MEK inhibitors might have a direct inhibitory effect on T-cell function and it was indeed shown later that treatment with MEK inhibitors, but not BRAFV600E inhibitors, impairs T-lymphocyte function <a class=\"rlc-reference\" data-ref-info=\"Boni A, Cogdill AP, Dang P, et al: Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res 70:5213-9, 2010.\" href=\"#_ENREF_265\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/20551059\"><sup>265</sup></a>.</p>\n<p id=\"erb-d93d4775-8175-4fca-bee2-321836b37444\">A number of subsequent reports have confirmed that inhibition of mutant BRAF could potentiate immune responses in melanoma, suggesting that blockade of immune checkpoints in combination with BRAF inhibitors could have clinical value. Treatment with BRAF inhibitors vemurafenib and dabrafenib resulted in markedly increased numbers of TILs in tumor biopsies obtained pre- and post-treatment in 15 patients <a class=\"rlc-reference\" data-ref-info=\"Wilmott JS, Long GV, Howle JR, et al: Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin Cancer Res 18:1386-94, 2012.\" href=\"#_ENREF_266\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22156613\"><sup>266</sup></a>. Another study found that dabrafenib has no detectable negative impact on existing systemic immunity or the <i>de novo</i> generation of tumor-specific T cells in patients <a class=\"rlc-reference\" data-ref-info=\"Hong DS, Vence L, Falchook G, et al: BRAF(V600) inhibitor GSK2118436 targeted inhibition of mutant BRAF in cancer patients does not impair overall immune competency. Clin Cancer Res 18:2326-35, 2012.\" href=\"#_ENREF_267\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22355009\"><sup>267</sup></a>.</p>\n<p id=\"erb-b60705c7-35fa-47f0-b063-6cdb5ad6feb6\">A single report claimed that selective BRAF inhibition decreases tumor-resident lymphocyte frequencies in a genetically engineered mouse (GEM) melanoma model; moreover, treatment with ipilimumab did not restore the numbers of TIL <a class=\"rlc-reference\" data-ref-info=\"Hooijkaas A, Gadiot J, Morrow M, et al: Selective BRAF inhibition decreases tumor-resident lymphocyte frequencies in a mouse model of human melanoma. Oncoimmunology 1:609-617, 2012.\" href=\"#_ENREF_268\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22934253\"><sup>268</sup></a>. Although GEM models are clearly helpful in studies of targeted therapies, their utility in the evaluation of immunotherapies is not clear. This is because it is likely that melanoma is immunogenic due to the large number of missense mutations inducing antigens that are recognized as \u201cforeign\u201d by the immune system, and many of the GEM models have very few mutations.</p>\n<p id=\"erb-1f0f9f9b-f0f4-4011-9064-2fffbd023970\">The latest reported analysis of biopsies taken before and after treatment with BRAF or BRAF+MEK inhibitors showed the following: enhancement of melanoma antigen expression, increase in CD8+ TILs, and decrease in immunosuppressive cytokines IL-6 and IL-8. Interestingly, inhibitory PD-1 was increased on T cells and its immunosuppressive ligand PDL1 was also increased with BRAF inhibition. This supports the hypothesis that targeting inhibitory immune interactions may be critical in augmenting responses to BRAF-targeted therapy in patients with melanoma <a class=\"rlc-reference\" data-ref-info=\"Frederick DT, Piris A, Cogdill AP, et al: BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma. Clin Cancer Res, 2013.\" href=\"#_ENREF_269\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23307859\"><sup>269</sup></a>.</p>\n<p id=\"erb-ddca8f46-e0d5-4740-8392-9a9c4a547446\"><b>Adoptive cell transfer therapy and targeted therapies</b>. Adoptive cell transfer therapy could also be of more benefit when combined with vemurafenib, as a mouse model suggests <a class=\"rlc-reference\" data-ref-info=\"Koya RC, Mok S, Otte N, et al: BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy. Cancer Res 72:3928-37, 2012.\" href=\"#_ENREF_270\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22693252\"><sup>270</sup></a>. In a recent study, vemurafenib increased MAPK signaling, <i>in vivo</i> cytotoxic activity, and intratumoral cytokine secretion by adoptively transferred cells (T cells genetically engineered to recognize tumor-expressing antigens). Another study reported that administration of PLX4720 significantly increased tumor infiltration of adoptively transferred T cells <i>in vivo</i> and enhanced their antitumor activity in a mouse model. Apparently, PLX4720 negatively affected expression of VEGF by tumor cells. Importantly, analysis of human melanoma biopsies before and during BRAF inhibitor treatment also showed downregulation of VEGF consistent with the preclinical murine model <a class=\"rlc-reference\" data-ref-info=\"Liu C, Peng W, Xu C, et al: BRAF Inhibition Increases Tumor Infiltration by T cells and Enhances the Antitumor Activity of Adoptive Immunotherapy in Mice. Clin Cancer Res 19:393-403, 2013.\" href=\"#_ENREF_271\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23204132\"><sup>271</sup></a>.</p>\n<p id=\"erb-a533c539-5734-43a3-8ce8-c725f6243f82\">An <i>in vitro</i> study analyzed effects of BRAF and MEK inhibition on function of dendritic cells (DC) <i>in vitro</i> and found that BRAF-mutant melanomas suppress immune function of dendritic cells. Inhibition of BRAF, but not MEK could reverse suppression of DC function. As has been reported for the effects of MEK inhibition on T cells <a class=\"rlc-reference\" data-ref-info=\"Boni A, Cogdill AP, Dang P, et al: Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res 70:5213-9, 2010.\" href=\"#_ENREF_265\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/20551059\"><sup>265</sup></a>, inhibition of MEK did negatively affect DC function and viability. Vemurafenib, but not MEK inhibitors, was therefore suggested as a preferable candidate for combination immunotherapy approaches in BRAF-mutant melanoma. <a class=\"rlc-reference\" data-ref-info=\"Ott PA, Henry T, Baranda SJ, et al: Inhibition of both BRAF and MEK in BRAF(V600E) mutant melanoma restores compromised dendritic cell (DC) function while having differential direct effects on DC properties. Cancer Immunol Immunother, 2013.\" href=\"#_ENREF_272\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23306863\"><sup>272</sup></a>.</p>\n<p id=\"erb-71e6a9bb-45b4-4a8a-8623-42e6ba355d06\">Another <i>in vitro</i> study examined how vemurafenib affects the ability of the TILs to recognize autologous BRAF(V600) mutant melanoma cell lines <i>in vitro</i> <a class=\"rlc-reference\" data-ref-info=\"Donia M, Fagone P, Nicoletti F, et al: BRAF inhibition improves tumor recognition by the immune system: Potential implications for combinatorial therapies against melanoma involving adoptive T-cell transfer. Oncoimmunology 1:1476-1483, 2012.\" href=\"#_ENREF_273\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23264894\"><sup>273</sup></a>. The results showed a significant increase in recognition of the inhibitor-treated melanoma cells, attributed to increased expression of MHC class I-associated proteins and heat-shock proteins.</p>\n<p id=\"erb-1ae76afc-a762-402d-b1f9-6a7b5c77b56a\">These studies in general provide a strong rationale for combination therapies involving BRAF inhibition with immunotherapies involving either antibodies to immunosuppressive molecules or adoptive cell transfer. Several trials are ongoing, but one has been closed for toxicity. The phase I trial of concurrent vemurafenib and ipilimumab (<a href=\"http://clinicaltrials.gov/ct2/results?term=NCT01400451&amp;Search=Search\">NCT01400451</a>) was closed in March 2013, due to dose-limiting liver toxicities <a class=\"rlc-reference\" data-ref-info=\"Ribas A, Hodi FS, Callahan M, et al: Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med 368:1365-6, 2013.\" href=\"#_ENREF_274\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23550685\"><sup>274</sup></a>. This highlights the need for careful evaluation of combination strategies, in particular because the drugs in this trial were approved, and had little overlap in terms of side effects. Other trials will evaluate combinations of vemurafenib and anti-PD-L1 antibody MPDL3280A (<a href=\"http://clinicaltrials.gov/ct2/results?term=NCT01656642&amp;Search=Search\">NCT01656642</a>), vemurafenib and HD-IL2 (<a href=\"http://clinicaltrials.gov/show/NCT01683188\">NCT01683188</a>), vemurafenib and adoptive cell transfer (<a href=\"http://clinicaltrials.gov/show/NCT01585415\">NCT01585415</a>), HD-IL2 + adoptive cell transfer + vemurafenib (<a href=\"http://clinicaltrials.gov/show/NCT01659151\">NCT01659151</a>), and more. Whether to give targeted therapy or immunotherapy first to patients with BRAF mutant melanoma remains an important clinical question. Patients with rapidly progressing disease may need to start with BRAF inhibitors since this treatment works quickly. On the other hand, if the disease is not rapidly progressing, beginning with immunotherapy makes sense due to the durability of response in some patients.</p>\n<p id=\"erb-a34486fe-9657-4c79-be5c-2db30d2eac9c\">Mutant BRAF and/or its inhibition are not expected to influence outcomes of all immune therapies. For example, a recent trial showed that treatment with IL-21 produced an overall response rate of 22.5% in melanoma and responses were not related to the status of BRAF <a class=\"rlc-reference\" data-ref-info=\"Petrella TM, Tozer R, Belanger K, et al: Interleukin-21 has activity in patients with metastatic melanoma: a phase II study. J Clin Oncol 30:3396-401, 2012.\" href=\"#_ENREF_226\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22915661\"><sup>226</sup></a>. Treatment with high-dose IL-2 was more effective in patients with NRAS mutations versus BRAF mutations or WT/WT tumors <a class=\"rlc-reference\" data-ref-info=\"Joseph RW, Sullivan RJ, Harrell R, et al: Correlation of NRAS mutations with clinical response to high-dose IL-2 in patients with advanced melanoma. J Immunother 35:66-72, 2012.\" href=\"#_ENREF_275\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22130161\"><sup>275</sup></a>.</p>\n<p id=\"erb-4a58fbb8-e0ac-4065-8444-937c6ebd1f5a\">Other melanoma-related pathways might also play a role in responses to immune therapy. Wnt/\uf062-catenin signaling might be involved in immunosuppression in melanoma, as high levels of nuclear \uf062-catenin in melanoma cells impaired maturation of DCs at least in part through increased production of IL-10 and inhibited IFN-\uf067 production by melanoma-specific CTLs <a class=\"rlc-reference\" data-ref-info=\"Yaguchi T, Goto Y, Kido K, et al: Immune suppression and resistance mediated by constitutive activation of Wnt/beta-catenin signaling in human melanoma cells. J Immunol 189:2110-7, 2012.\" href=\"#_ENREF_276\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22815287\"><sup>276</sup></a>. It is entirely possible and even likely that other oncogenic pathways in melanoma also mediate immune suppression in melanoma.</p>\n<p id=\"erb-9e5fa267-5536-4272-afab-a0f70b61f4af\"><b>Tumor microenvironment and immune responses</b></p>\n<p id=\"erb-b010b7df-1b63-4db6-a4d5-1eca0d83ff32\"><b>The role of B cells in immune responses in melanoma.</b> An extensive study measured humoral B-cell responses in melanoma patients, and concluded that on average melanoma patients have highly increased antibody responses against melanoma cells compared to healthy volunteers. Interestingly, the B-cell-mediated immune responses were significantly diminished in patients with metastatic melanoma versus primary disease <a class=\"rlc-reference\" data-ref-info=\"Gilbert AE, Karagiannis P, Dodev T, et al: Monitoring the systemic human memory B cell compartment of melanoma patients for anti-tumor IgG antibodies. PLoS One 6:e19330, 2011.\" href=\"#_ENREF_277\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/21559411\"><sup>277</sup></a>. The impaired B-cell functionality with loss of CD27+ (memory) cells was previously reported in metastatic melanoma <a class=\"rlc-reference\" data-ref-info=\"Carpenter EL, Mick R, Rech AJ, et al: Collapse of the CD27+ B-cell compartment associated with systemic plasmacytosis in patients with advanced melanoma and other cancers. Clin Cancer Res 15:4277-87, 2009.\" href=\"#_ENREF_278\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/19549767\"><sup>278</sup></a>.</p>\n<p id=\"erb-72aa5aad-00c5-42f8-bf01-d0f48af633eb\">Intratumoral IgG-producing B cells have been reported in melanoma, but their functional significance was largely unknown. A study published in March 2013 found a skewing of B cell repertoire in melanoma tumors, with highly increased numbers of IgG4-producing B cells relative to normal ratios. High IgG4/IgG total ratios are considered a limiting response by the immune system to contain immune activation. In melanoma, production of B cells secreting inhibitory IgG4 is stimulated by the tumor secreted IL-10 and IL-4. The tumor-specific IgG4 even inhibited IgG1-dependent tumor-cell killing through engagement of the Fc\u03b3RI effector mechanisms. Moreover, high circulating levels of IgG4 in serum of patients were associated with poor prognosis <a class=\"rlc-reference\" data-ref-info=\"Karagiannis P, Gilbert AE, Josephs DH, et al: IgG4 subclass antibodies impair antitumor immunity in melanoma. J Clin Invest, 2013.\" href=\"#_ENREF_279\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23454746\"><sup>279</sup></a>.</p>\n<p id=\"erb-0f97d5b8-b866-46e9-ac51-a7dedd30b3c7\"><b>Immune cell infiltrates in melanoma</b>. The presence of lymph node\u2013like structures in solid tumors has been recognized relatively recently, and is considered to have a prognostic value, in particular as related to immune therapy <a class=\"rlc-reference\" data-ref-info=\"Jochems C, Schlom J: Tumor-infiltrating immune cells and prognosis: the potential link between conventional cancer therapy and immunity. Exp Biol Med (Maywood) 236:567-79, 2011.\" href=\"#_ENREF_280\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/21486861\"><sup>280</sup></a>. It was suggested that the presence of these lymphoid structures could be due to locally tumor-produced chemokines, and could be useful in selection of patients for whom immunotherapies might work best. Moreover, a particular 12-chemokine signature produced by tumors was identified by expression profiling, and was shown to be predictive of the formation of these lymph node\u2013like structures. The hope is that this expression signature might be used for selection of patients for whom long-lasting responses to immunotherapy are possible <a class=\"rlc-reference\" data-ref-info=\"Messina JL, Fenstermacher DA, Eschrich S, et al: 12-Chemokine gene signature identifies lymph node-like structures in melanoma: potential for patient selection for immunotherapy? Sci Rep 2:765, 2012.\" href=\"#_ENREF_281\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23097687\"><sup>281</sup></a>. However, the subset of melanoma tumors characterized by the presence of T-cell infiltrates show activation of three immunosuppressive markers: indoleamine-2,3-dioxygenase (IDO), PD-L1, and FoxP3+ regulatory T cells (Tregs). Moreover, expression of these actually was shown to be secondary to the infiltration of CD8+ T cells, implying that the immune system rather than the tumor initiates the creation of immunosuppressive environment <a class=\"rlc-reference\" data-ref-info=\"Spranger S, Spaapen RM, Zha Y, et al: Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells. Sci Transl Med 5:200ra116, 2013.\" href=\"#_ENREF_201\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23986400\"><sup>201</sup></a>. Nevertheless, these findings still support the notion that tumors with CD8+ T-cell infiltrates could benefit from treatments with immune-modulatory antibodies.</p>\n<h1 id=\"erh-27f0edbc-2f21-4059-bf29-4c1b1fd718db\">Metabolism and Autophagy\u00a0as Targets in Melanoma Therapy</h1>\n<p id=\"erb-33c355e4-ef04-4f7a-85e9-34a94a20a7d9\">There have been few attempts to target melanoma metabolism with the exception of several known metabolic preferences listed below. However, recent discoveries, such as high levels of OXPHOS (oxidative phosphorylation) in highly aggressive melanoma mediated by elevated expression of PGC-1a <a class=\"rlc-reference\" data-ref-info=\"Vazquez F, Lim JH, Chim H, et al: PGC1alpha Expression Defines a Subset of Human Melanoma Tumors with Increased Mitochondrial Capacity and Resistance to Oxidative Stress. Cancer Cell, 2013.\" href=\"#_ENREF_59\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23416000\"><sup>59</sup></a>, might prompt more interest in targeting melanoma metabolism. For many years, serum lactate dehydrogenase (LDH) levels were used as a predictive factor to identify melanoma patients with worsened prognosis, and they presumably are indicative of the high glycolytic character of tumors, though the energy requirements of melanoma might be fulfilled through a more complex relationship between glycolysis and OXPHOS <a class=\"rlc-reference\" data-ref-info=\"Sonveaux P, Vegran F, Schroeder T, et al: Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J Clin Invest 118:3930-42, 2008.\" href=\"#_ENREF_282\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/19033663\"><sup>282</sup></a>. The OXPHOS inhibitor elesclomol in combination with paclitaxel was clinically tested in a randomized trial in unselected patients. The study was terminated due to increased death in patients with high LDH receiving paclitaxel alone <a class=\"rlc-reference\" data-ref-info=\"O'Day SJ, Eggermont AM, Chiarion-Sileni V, et al: Final Results of Phase III SYMMETRY Study: Randomized, Double-Blind Trial of Elesclomol Plus Paclitaxel Versus Paclitaxel Alone As Treatment for Chemotherapy-Naive Patients With Advanced Melanoma. J Clin Oncol, 2013.\" href=\"#_ENREF_283\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23401447\"><sup>283</sup></a>. However, the study revealed a statistically significant increase in PFS in patients with normal serum levels of LDH receiving elesclomol, that is, a group of patients with tumors that rely on OXPHOS.</p>\n<p id=\"erb-447034fc-cd27-4330-87c7-c5f752c220ad\">Regarding the possible effects of metabolic preferences of melanoma tumors on the efficacy of targeted therapy, it is of interest that mutant BRAF inhibition might be more efficacious in tumors with higher glycolytic index <sup><a class=\"rlc-reference\" data-ref-info=\"McArthur GA, Puzanov I, Amaravadi R, et al: Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma. J Clin Oncol 30:1628-34, 2012.\" href=\"#_ENREF_158\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22454415\">158</a>,<a class=\"rlc-reference\" data-ref-info=\"Sondergaard JN, Nazarian R, Wang Q, et al: Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032. J Transl Med 8:39, 2010.\" href=\"#_ENREF_172\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/20406486\">172</a></sup>. As mentioned above, this metabolic trait could be useful as a predictive marker of response to BRAF inhibition. In addition, inhibition of BRAF(V600E) appears to induce a switch from glycolytic to OXPHOS metabolism, via induction of MITF, followed by MITF induction of PGC1\uf061 <a class=\"rlc-reference\" data-ref-info=\"Haq R, Shoag J, Andreu-Perez P, et al: Oncogenic BRAF Regulates Oxidative Metabolism via PGC1alpha and MITF. Cancer Cell 23:302-15, 2013.\" href=\"#_ENREF_162\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23477830\"><sup>162</sup></a>. A consequence of this shift is an apparent dependency of BRAF-inhibited cells upon OXPHOS, thus suggesting new BRAF-combination strategies for patients.</p>\n<p id=\"erb-5e880437-3022-4da2-a887-a1d3b7115a11\">The importance of OXPHOS in melanoma resistance to chemotherapy and targeted therapy with vemurafenib was highlighted in another study that aimed to explore the significance of a subpopulation of melanoma cells expressing H3K4 demethylase JARID1B. JARID1B melanoma cells cycle slowly, but can produce progeny of fast-dividing cells without having other hallmarks of stem cells <a class=\"rlc-reference\" data-ref-info=\"Roesch A, Fukunaga-Kalabis M, Schmidt EC, et al: A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell 141:583-94, 2010.\" href=\"#_ENREF_284\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/20478252\"><sup>284</sup></a>. Deeper analysis of these cells revealed that JARID1B positivity is associated with the post-treatment surviving fraction, and is marked by increased levels of OXPHOS which presumably contributes to their survival <a class=\"rlc-reference\" data-ref-info=\"Roesch A, Vultur A, Bogeski I, et al: Overcoming Intrinsic Multidrug Resistance in Melanoma by Blocking the Mitochondrial Respiratory Chain of Slow-Cycling JARID1B(high) Cells. Cancer Cell 23:811-25, 2013.\" href=\"#_ENREF_285\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23764003\"><sup>285</sup></a>. These resistant cells could be successfully targeted by inhibitors of OXPHOS such as phenformin, similar to findings in the study described above on MITF induction of PGC\uf061.</p>\n<p id=\"erb-f89548f4-aba3-48ca-8169-8625542bb4fa\">A most interesting study implicated enzyme PDH (pyruvate dehydrogenase) that links glycolysis to OXPHOS in the abrogation of mutant-BRAF-induced senescence (OIS). Oxygen consumption was increased in senescent cells modified to express mutant BRAF, which was mediated by activated PDH. Two key PDH-regulating enzymes were involved in the observed activation of PDH: inhibitory PDK1 was suppressed, while activating PDP2 was upregulated. Ectopic expression of PDK1 was able to overcome BRAF-induced senescence of melanocytes and promote robust tumor growth in vivo. Moreover, PDK1 depletion in melanoma tumors dramatically increased their sensitivity to vemurafenib <i>in vivo</i> by eliminating subpopulations of cells resistant to the drug <a class=\"rlc-reference\" data-ref-info=\"Kaplon J, Zheng L, Meissl K, et al: A key role for mitochondrial gatekeeper pyruvate dehydrogenase in oncogene-induced senescence. Nature, 2013.\" href=\"#_ENREF_286\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23685455\"><sup>286</sup></a>. These results established a direct role for metabolic axis in the development and drug resistance of melanomas.</p>\n<p id=\"erb-bc881a70-2dd3-457f-8d83-e2e8256a39d7\">The role of autophagy in tumor development and responses to various treatments remains controversial, most likely due to the fact that autophagy can contribute either to death or survival of cancer cells depending on the nature of the death signal and cellular context. Deprivation of amino acids is considered to be of potential benefit in melanoma treatment due to specific metabolic preferences/dependency of melanoma tumors, but induction of \"starvation-induced\" autophagy could be detrimental.</p>\n<p id=\"erb-3f5d0737-9b6f-40ea-8122-11a937664de1\"><b>Arginine deprivation. </b>Melanoma tumors, along with hepatocellular cancer (HCC) and prostate cancer, frequently show deficiency of the enzyme argininosuccinate synthetase (ASS) <a class=\"rlc-reference\" data-ref-info=\"Dillon BJ, Prieto VG, Curley SA, et al: Incidence and distribution of argininosuccinate synthetase deficiency in human cancers: a method for identifying cancers sensitive to arginine deprivation. Cancer 100:826-33, 2004.\" href=\"#_ENREF_287\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/14770441\"><sup>287</sup></a>, cannot synthesize arginine from citrulline, and depend on exogenous arginine for survival. Arginine degradation using arginine deiminase (ADI) leads to growth inhibition and eventually cell death, while normal cells that express ASS can survive (reviewed by Yoon<a class=\"rlc-reference\" data-ref-info=\"Yoon JK, Frankel AE, Feun LG, et al: Arginine deprivation therapy for malignant melanoma. Clin Pharmacol 5:11-9, 2013.\" href=\"#_ENREF_288\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23293541\"><sup>288</sup></a>). Pegylated ADI (ADI-PEG20) has shown antitumor activity in\u00a0melanoma <a class=\"rlc-reference\" data-ref-info=\"Ott PA, Carvajal RD, Pandit-Taskar N, et al: Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma. Invest New Drugs 31:425-34, 2013.\" href=\"#_ENREF_289\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22864522\"><sup>289</sup></a>. Another arginine- degrading enzyme, arginase, in a recombinant-pegylated and cobalt-substituted form, Co-ArgI-PEG, is being developed for clinical trials. It is already clear that treatment with ADI-PEG20 induces resistance in patients by at least two identified mechanisms: induction of protective autophagy and re-expression of ASS and activation of the MAPK pathway (reviewed by Yoon et al. <a class=\"rlc-reference\" data-ref-info=\"Yoon JK, Frankel AE, Feun LG, et al: Arginine deprivation therapy for malignant melanoma. Clin Pharmacol 5:11-9, 2013.\" href=\"#_ENREF_288\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23293541\"><sup>288</sup></a>). If arginine-deprivation therapy with arginine-degrading enzymes is to become a valid therapeutic option, concurrent therapies targeting autophagy or the MAPK pathway should be considered.</p>\n<p id=\"erb-4794f5f7-0758-4076-8216-71aca2855ef4\"><b>Leucine deprivation.</b> Leucine deprivation was also shown to induce apoptotic death in melanoma cells; moreover, the dependence of melanoma cells on leucine was functionally linked to the activated RAS-MAPK pathway, in particular BRAFV600E mutation. The latter rendered the mTOR pathway resistant to leucine deprivation, but inhibition of autophagy was able to restore sensitivity of these cells to leucine deprivation. Dietary leucine deprivation combined with an inhibitor of autophagy suppressed melanoma xenograft growth <i>in vivo</i> <a class=\"rlc-reference\" data-ref-info=\"Sheen JH, Zoncu R, Kim D, et al: Defective regulation of autophagy upon leucine deprivation reveals a targetable liability of human melanoma cells in vitro and in vivo. Cancer Cell 19:613-28, 2011.\" href=\"#_ENREF_290\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/21575862\"><sup>290</sup></a>.</p>\n<p id=\"erb-891c8456-a442-4f89-a13b-f79243413169\"><b>Autophagy </b>is a potential target in melanoma.<b> </b>However, drug-induced autophagy could be either suicidal or protective, which is reflected in the ongoing clinical studies. Metformin was shown to induce suicidal autophagy in melanoma cells <i>in vitro</i> and <i>in vivo</i> <a class=\"rlc-reference\" data-ref-info=\"Tomic T, Botton T, Cerezo M, et al: Metformin inhibits melanoma development through autophagy and apoptosis mechanisms. Cell Death Dis 2:e199, 2011.\" href=\"#_ENREF_291\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/21881601\"><sup>291</sup></a>. Metformin,<b> </b>an inhibitor of mitochondrial complex I, activates AMPK as a result of decreased AMP/ATP ratio, and inhibits mTOR. Long known for its antihyperglycemic properties, it is being explored for antineoplastic activities. A trial of metformin with vemurafenib is ongoing (<a href=\"http://clinicaltrials.gov/ct2/results?term=NCT01638676\">NCT01638676</a>). On the other hand, the old antimalarial drug hydroxychloroquine, an inhibitor of autophagy, is also trialed with vemurafenib (<a href=\"http://clinicaltrials.gov/ct2/show/NCT01897116\">NCT01897116</a>).</p>\n<p id=\"erb-f9d47759-2999-4d78-935e-e46e59cbf50c\">Because autophagy is known to be involved in both innate and adaptive immunity, there is an interest in exploring manipulation of autophagy for immunotherapy. Autophagy was reported to enhance antigen presentation by dendritic cells, therefore potentiating T-cell activation, and could be enhanced by nanoparticle-based antigen presentation <a class=\"rlc-reference\" data-ref-info=\"Li H, Li Y, Jiao J, et al: Alpha-alumina nanoparticles induce efficient autophagy-dependent cross-presentation and potent antitumour response. Nat Nanotechnol 6:645-50, 2011.\" href=\"#_ENREF_292\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/21926980\"><sup>292</sup></a>; autophagosome preparations enriched for tumor antigens were used to pulse dendritic cells for successful vaccination of tumor-bearing mice <a class=\"rlc-reference\" data-ref-info=\"Li Y, Wang LX, Pang P, et al: Tumor-derived autophagosome vaccine: mechanism of cross-presentation and therapeutic efficacy. Clin Cancer Res 17:7047-57, 2011.\" href=\"#_ENREF_293\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22068657\"><sup>293</sup></a>. On the other hand, inhibition of autophagy was shown to promote antitumor responses to systemic IL-2 immunotherapy <sup><a class=\"rlc-reference\" data-ref-info=\"Liang X, De Vera ME, Buchser WJ, et al: Inhibiting systemic autophagy during interleukin 2 immunotherapy promotes long-term tumor regression. Cancer Res 72:2791-801, 2012.\" href=\"#_ENREF_294\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22472122\">294</a>,<a class=\"rlc-reference\" data-ref-info=\"Lotze MT, Buchser WJ, Liang X: Blocking the interleukin 2 (IL2)-induced systemic autophagic syndrome promotes profound antitumor effects and limits toxicity. Autophagy 8:1264-6, 2012.\" href=\"#_ENREF_295\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22660171\">295</a></sup>. Apparently, the specific roles of autophagy in different immune responses would have to be explored individually.</p>\n<h1 id=\"erh-956508a6-47cf-4328-9937-6f384f3787be\">New Prognostic Markers</h1>\n<p id=\"erb-80d4f2bb-ff03-4118-aa2d-7fde5e33686b\"><b>Circulating melanoma cells</b></p>\n<p id=\"erb-b4b9e3a2-f78c-44fd-8289-fa9e123c7f0d\">Detection of circulating tumor cells (CTCs) in melanoma was explored for at least last 20 years. CTCs have been shown to serve as seeds for metastatic lesions, and therefore their presence could be interpreted as a prognostic marker. In addition, monitoring of CTC levels could serve as a marker of disease progression and treatment success or failure (reviewed by Ireland et al. and Tanaka et al.<sup><a class=\"rlc-reference\" data-ref-info=\"Ireland A, Millward M, Pearce R, et al: Genetic factors in metastatic progression of cutaneous melanoma: the future role of circulating melanoma cells in prognosis and management. Clin Exp Metastasis 28:327-36, 2011.\" href=\"#_ENREF_296\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/21311956\">296</a>,<a class=\"rlc-reference\" data-ref-info=\"Tanaka R, Koyanagi K, Narita N, et al: Prognostic molecular biomarkers for cutaneous malignant melanoma. J Surg Oncol 104:438-46, 2011.\" href=\"#_ENREF_297\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/21557225\">297</a></sup>). Molecular profiling of CTC could become a \u201cliquid biopsy\u201d, and could reflect genetic heterogeneity, both intratumoral or between multiple metastatic tumors.</p>\n<p id=\"erb-bed9f8de-beee-4365-bf99-f1947df31ea2\">The earlier attempts were directed mostly toward developing a multimarker RT-PCR to detect and monitor the presence of CTCs in the bloodstream. The first detection of melanoma CTCs was based on RT-PCR of tyrosinase <a class=\"rlc-reference\" data-ref-info=\"Smith B, Selby P, Southgate J, et al: Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction. Lancet 338:1227-9, 1991.\" href=\"#_ENREF_298\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/1719320\"><sup>298</sup></a>. Numerous studies have employed RT-PCR of a variety of melanoma markers to analyze peripheral blood preparations and examine prognostic significance of these assays. For example, a serial analysis of two melanoma-associated markers (tyrosinase and MART-1) was shown to be an independent predictor of disease recurrence for stage IV melanoma patients after surgery and adjuvant therapy <a class=\"rlc-reference\" data-ref-info=\"Mocellin S, Del Fiore P, Guarnieri L, et al: Molecular detection of circulating tumor cells is an independent prognostic factor in patients with high-risk cutaneous melanoma. Int J Cancer 111:741-5, 2004.\" href=\"#_ENREF_299\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/15252844\"><sup>299</sup></a>. A study that performed serial analysis of CTCs using a five-marker RT-PCR (MART-1, GalNAc-T, PAX-3, MITF and MAGE-A3) concluded that it could be useful for prognostic purposes <a class=\"rlc-reference\" data-ref-info=\"Koyanagi K, O'Day SJ, Boasberg P, et al: Serial monitoring of circulating tumor cells predicts outcome of induction biochemotherapy plus maintenance biotherapy for metastatic melanoma. Clin Cancer Res 16:2402-8, 2010.\" href=\"#_ENREF_300\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/20371696\"><sup>300</sup></a>. CTC assessment with three markers\u2014MART-1, MAGE-A3, and PAX3\u2014provided prognostic discrimination before and during adjuvant treatment for resected stage IV melanoma patients <a class=\"rlc-reference\" data-ref-info=\"Hoshimoto S, Faries MB, Morton DL, et al: Assessment of prognostic circulating tumor cells in a phase III trial of adjuvant immunotherapy after complete resection of stage IV melanoma. Ann Surg 255:357-62, 2012.\" href=\"#_ENREF_301\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22202581\"><sup>301</sup></a>. Similarly, a stage III clinical trial found that positivity for at least two out of three CTC biomarkers (MART-1, GalNAc-T and MAGE-A3) examined was significantly associated with decreased recurrence-free survival in patients with stage II melanoma and metastases to sentinel lymph nodes <a class=\"rlc-reference\" data-ref-info=\"Hoshimoto S, Shingai T, Morton DL, et al: Association between circulating tumor cells and prognosis in patients with stage III melanoma with sentinel lymph node metastasis in a phase III international multicenter trial. J Clin Oncol 30:3819-26, 2012.\" href=\"#_ENREF_302\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23008288\"><sup>302</sup></a>. These CTC markers were deemed to be useful in selecting patients for aggressive adjuvant treatments. A different set of CTC markers (MLANA, ABCB5, TGFbeta2, PAX3d and MCAM) was examined, and two of them (MLANA and ABCB5) were also found to be useful in predicting disease status <a class=\"rlc-reference\" data-ref-info=\"Reid AL, Millward M, Pearce R, et al: Markers of circulating tumour cells in the peripheral blood of patients with melanoma correlate with disease recurrence and progression. Br J Dermatol 168:85-92, 2013.\" href=\"#_ENREF_303\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23013138\"><sup>303</sup></a>. At the same time, analysis of cytokine- receptor expression in CTCs had no predictive significance for treatment outcomes <a class=\"rlc-reference\" data-ref-info=\"Fusi A, Liu Z, Kummerlen V, et al: Expression of chemokine receptors on circulating tumor cells in patients with solid tumors. J Transl Med 10:52, 2012.\" href=\"#_ENREF_304\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22433180\"><sup>304</sup></a>, possibly due to the choice markers. Overall, the many studies performed indicate that a validated set of CTC biomarkers as well as standardized methodology is necessary to make RT-PCR analysis of CTCs a useful tool in assessment of melanoma prognosis. For now, RT-PCR of peripheral blood is not considered to be highly promising.</p>\n<p id=\"erb-4ac26528-5080-430c-8c11-d5b01154e407\">A different approach involves physical separation of CTCs prior to their analyses. This methodology is somewhat limited by its most often used approach, which relies on expression of certain surface proteins on CTCs for their identification and separation. CellSearch Veridex technology, widely used for the detection of CTCs in blood, was designed for breast, prostate, colorectal, and lung cancer, which express EpCAM markers. Continuing expression of these proteins on CTCs could not be counted upon when de-differentiation (such as epithelial to mesenchyme transition in epithelial cancers) occurs during tumor progression. Nevertheless, use of the CellSearch platform was reported to detect CTCs in 40% of patients with advanced melanoma, and the number of CTCs was prognostic itself for overall survival and reflective of treatment outcomes <a class=\"rlc-reference\" data-ref-info=\"Khoja L, Lorigan P, Zhou C, et al: Biomarker Utility of Circulating Tumor Cells in Metastatic Cutaneous Melanoma. J Invest Dermatol, 2012.\" href=\"#_ENREF_305\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23223143\"><sup>305</sup></a>. The CellSearch Veridex platform was recently adapted for melanoma markers, and was reported to be successful in detection and quantification of CTCs in cerebrospinal fluid in two melanoma patients with leptomeningial metastases <a class=\"rlc-reference\" data-ref-info=\"Le Rhun E, Tu Q, De Carvalho Bittencourt M, et al: Detection and quantification of CSF malignant cells by the CellSearch technology in patients with melanoma leptomeningeal metastasis. Med Oncol 30:538, 2013.\" href=\"#_ENREF_306\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23504338\"><sup>306</sup></a></p>\n<p id=\"erb-de755a6a-9d18-48f1-8810-defa60f12afc\">New techniques are being developed, such as isolation by size of epithelial tumor cells (ISET), which was able to detect CTCs in 29% of patients with primary invasive melanoma and in 62.5% of metastatic melanoma patients, with an excellent correlation for detection of CTCs by RT-PCR of tyrosinase <a class=\"rlc-reference\" data-ref-info=\"De Giorgi V, Pinzani P, Salvianti F, et al: Application of a filtration- and isolation-by-size technique for the detection of circulating tumor cells in cutaneous melanoma. J Invest Dermatol 130:2440-7, 2010.\" href=\"#_ENREF_307\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/20535130\"><sup>307</sup></a>. Results obtained with ISET should, however, be considered carefully, because circulating melanocytes were detected in the blood of a patient with untypical melanocytic lesion <a class=\"rlc-reference\" data-ref-info=\"De Giorgi V, Pinzani P, Salvianti F, et al: Circulating benign nevus cells detected by ISET technique: warning for melanoma molecular diagnosis. Arch Dermatol 146:1120-4, 2010.\" href=\"#_ENREF_308\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/20956643\"><sup>308</sup></a>. A new technique named photoacoustic blood cancer testing was successfully applied to melanoma CTCs in mice and spiked human blood and could be used to capture CTCs <sup><a class=\"rlc-reference\" data-ref-info=\"Galanzha EI, Shashkov EV, Spring PM, et al: In vivo, noninvasive, label-free detection and eradication of circulating metastatic melanoma cells using two-color photoacoustic flow cytometry with a diode laser. Cancer Res 69:7926-34, 2009.\" href=\"#_ENREF_309\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/19826056\">309</a>,<a class=\"rlc-reference\" data-ref-info=\"O'Brien CM, Rood KD, Bhattacharyya K, et al: Capture of circulating tumor cells using photoacoustic flowmetry and two phase flow. J Biomed Opt 17:061221, 2012.\" href=\"#_ENREF_310\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22734751\">310</a></sup>. A recent report described a method to detect and isolate single circulating melanoma cells that integrates a polymer-nanofiber-embedded nanovelcro cell-affinity assay with a laser microdissection (LMD) technique. This method not only separates melanoma CTCs from peripheral blood, but also allows sequencing of individual cells for specific mutations <a class=\"rlc-reference\" data-ref-info=\"Hou S, Zhao L, Shen Q, et al: Polymer nanofiber-embedded microchips for detection, isolation, and molecular analysis of single circulating melanoma cells. Angew Chem Int Ed Engl 52:3379-83, 2013.\" href=\"#_ENREF_311\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23436302\"><sup>311</sup></a>.</p>\n<p id=\"erb-496068ba-a62c-4dc6-9bd3-cbc8b25be804\">The inertial focusing\u2013enhanced microfluidic CTC capture platform, termed \"CTC-iChip\" is capable of rapid sorting of rare CTCs from whole blood. The iChip technology is capable of isolating CTCs using strategies that involve recognition of extracellular epitopes, but could be used independently of tumor-specific membrane-protein recognition <a class=\"rlc-reference\" data-ref-info=\"Ozkumur E, Shah AM, Ciciliano JC, et al: Inertial focusing for tumor antigen-dependent and -independent sorting of rare circulating tumor cells. Sci Transl Med 5:179ra47, 2013.\" href=\"#_ENREF_312\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23552373\"><sup>312</sup></a>. The methodology was successfully tested in epithelial cancer and melanoma, and enables RNA profiling of single cells. Isolation of CTC using the ScreenCell filtration technique with quantitative analysis of CTC telomeres by TeloView was described recently <a class=\"rlc-reference\" data-ref-info=\"Adebayo Awe J, Xu MC, Wechsler J, et al: Three-Dimensional Telomeric Analysis of Isolated Circulating Tumor Cells (CTCs) Defines CTC Subpopulations. Transl Oncol 6:51-65, 2013.\" href=\"#_ENREF_313\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23418617\"><sup>313</sup></a>.</p>\n<p id=\"erb-6d11fbb6-dd5a-469d-bcd3-ae960234da18\">Molecular profiling of CTC might provide a very valuable representation of a tumor(s) genotype because CTCs presumably reflect tumor heterogeneity better than a single tumor biopsy. Indeed, several studies have discovered discordant mutations in CTCs versus biopsies. Inconsistencies of BRAF and KIT mutations between tumor biopsies and CTCs were described <sup><a class=\"rlc-reference\" data-ref-info=\"Fusi A, Berdel R, Havemann S, et al: Enhanced detection of BRAF-mutants by pre-PCR cleavage of wild-type sequences revealed circulating melanoma cells heterogeneity. Eur J Cancer 47:1971-6, 2011.\" href=\"#_ENREF_314\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/21570823\">314</a>,<a class=\"rlc-reference\" data-ref-info=\"Sakaizawa K, Goto Y, Kiniwa Y, et al: Mutation analysis of BRAF and KIT in circulating melanoma cells at the single cell level. Br J Cancer 106:939-46, 2012.\" href=\"#_ENREF_315\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22281663\">315</a></sup>. Presumably, CTCs also represent tumor cells with higher metastatic potential, and thus could be more relevant to the molecular profiling of aggressive tumor variants or metastases.</p>\n<p id=\"erb-2206afcf-8a8a-440f-81f7-0098dc2e7978\">Several clinical trials are ongoing that incorporate CTC detection and analyses prior to and after treatments to investigate the prognostic value of CTCs. The CellSearch Veridex technique will be evaluated in terms of its predictive and prognostic ability (<a href=\"http://clinicaltrials.gov/ct2/results?term=NCT01573494&amp;Search=Search\">NCT01573494</a>). CellSearch and Epispot (another platform based on immunomagnetic separation) are compared in <a href=\"http://clinicaltrials.gov/ct2/show/NCT01558349\">NCT01558349</a>. Trial <a href=\"http://clinicaltrials.gov/show/NCT01528774\">NCT01528774</a> addresses the possibility of long-term culture of melanoma CTCs isolated using TrueCells technology. A future trial <a href=\"http://www.clinicaltrials.gov/ct2/show/NCT01776905\">NCT01776905</a> will evaluate use of photoacoustic flow cytometry for <i>in vivo</i>, real-time detection of CTCs. Treatment with ipilimumab and stereotactic ablative radiation therapy (<a href=\"http://clinicaltrials.gov/show/NCT01565837\">NCT01565837</a>) or with Sargamostim/GM-CSF will include analysis of CTCs as predictive/prognostic markers (<a href=\"http://clinicaltrials.gov/ct2/show/NCT01489423\">NCT01489423</a>). Multiple parameters including CTCs are evaluated in an ongoing trial of imatininb (<a href=\"http://clinicaltrials.gov/show/NCT00470470\">NCT00470470</a>).</p>\n<p id=\"erb-6f085264-f9c6-4f9a-b1d4-4c508e96dd1f\">Recent studies have addressed the utility of yet another method of \u201cliquid biopsy\u201d, i.e., analysis of circulating tumor DNA (ctDNA) by NGS techniques rather than RT-PCR of defined biomarkers. A side-by-side comparison was performed on the analysis for a serum biomarker versus analysis of CTCs versus analysis of ctDNA by targeted- or whole-genomic sequence in breast cancer patients. This study reported the superiority of ctDNA analysis, as having a greater dynamic range, a greater correlation with changes in tumor burden, and better measure of treatment response <a class=\"rlc-reference\" data-ref-info=\"Dawson SJ, Tsui DW, Murtaza M, et al: Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med 368:1199-209, 2013.\" href=\"#_ENREF_316\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23484797\"><sup>316</sup></a>. The next publication from the same group reported monitoring of ctDNA by exomic sequencing in breast cancer patients prior to and during treatments <a class=\"rlc-reference\" data-ref-info=\"Murtaza M, Dawson SJ, Tsui DW, et al: Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature, 2013.\" href=\"#_ENREF_317\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23563269\"><sup>317</sup></a>. Serial analysis of ctDNA had successfully detected a number of prognostic genomic alterations that were either increased or appeared <i>de novo</i> as a consequence of treatments. It remains to be seen if detection of ctDNA will be a useful prognostic companion or even a substitute for tumor biopsies.</p>\n<p id=\"erb-0c2fc190-4628-4b95-be92-845e47352fa7\"><b>Prognostic test for uveal melanoma</b></p>\n<p id=\"erb-b8c9e674-e95d-4fd5-bfa2-6851948b51c2\">Uveal melanoma is a distinct type of melanoma with a clinical course and molecular landscape of its own. Even though patients rarely present with metastatic disease and are routinely subjected to surgery with curative intent, almost half have a high-risk disease that requires careful monitoring and/or adjuvant therapy after tumor resection. It has been difficult to stratify patients into high versus low risk of metastatic disease based on clinicopathological findings only.</p>\n<p id=\"erb-1e802947-777d-4460-99ce-b6ed29135c37\">DecisionDx-UM gene expression profile test was developed as a stand-alone platform, which requires no other information for prognostic accuracy. The test is PCR-based and measures the expression of 12 selected genes from primary uveal melanoma samples obtained by fine needle biopsy. The test allows patients to be stratified into risk categories such that high-risk patients can be offered intensive metastatic surveillance and adjuvant therapy while low-risk patients can be spared unnecessary chemotherapy and frequent monitoring <a class=\"rlc-reference\" data-ref-info=\"Harbour JW, Chen R: The DecisionDx-UM Gene Expression Profile Test Provides Risk Stratification and Individualized Patient Care in Uveal Melanoma. PLoS Curr 5, 2013.\" href=\"#_ENREF_318\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23591547\"><sup>318</sup></a>.</p>\n<p id=\"erb-80c936fe-5fde-494d-99fc-714433ddb4e5\"><b>Exosomes</b></p>\n<p id=\"erb-da65341e-cc5c-4f3c-a483-3ce0f6951478\">Exosomes are small membrane vesicles with an endosome origin that are released by cells into the extracellular environment. They could fuse with other cells, thereby transferring the RNAs and proteins they carry. Tumor-derived exosomes are emerging mediators of tumorigenesis; there is a growing interest in exploring treatment options targeting exosomes. Exosomes are thought to participate in the formation of a pre-metastatic niche, i.e., a specific microenvironment that is reprogrammed to support survival and growth of metastatic cells. There has been significant interest in exploring the role of exosomes as prognostic markers (reviewed by Ohno <a class=\"rlc-reference\" data-ref-info=\"Ohno S, Ishikawa A, Kuroda M: Roles of exosomes and microvesicles in disease pathogenesis. Adv Drug Deliv Rev 65:398-401, 2013.\" href=\"#_ENREF_319\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22981801\"><sup>319</sup></a>). A recent exciting study analyzed exosomes from highly metastatic melanomas. It found that these \"metastatic\" exosomes increased the invasive behavior of primary tumors by permanently \"educating\" bone marrow progenitors through the receptor tyrosine kinase MET. Melanoma-derived exosomes also induced vascular leakiness at premetastatic sites and reprogrammed bone marrow progenitors toward a pro-vasculogenic phenotype. Reducing MET expression in exosomes diminished the prometastatic behavior of bone marrow cells. Notably, MET expression was elevated in circulating bone marrow progenitors from individuals with metastatic melanoma. The study identified an exosome-specific melanoma signature with prognostic and therapeutic potential comprised of TYRP2, VLA-4, HSP70 (HSP90) isoform, and the MET oncoprotein <a class=\"rlc-reference\" data-ref-info=\"Peinado H, Aleckovic M, Lavotshkin S, et al: Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med 18:883-91, 2012.\" href=\"#_ENREF_320\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22635005\"><sup>320</sup></a>.</p>\n<h1 id=\"erh-97bb2e49-2845-4170-a3f7-f62698a70d7e\">Concluding Remarks</h1>\n<p id=\"erb-cb458123-a2bf-4659-9946-77dc75648377\">It is very likely, considering the most recent findings, that the majority of driver mutations in melanoma have been identified. The study most quoted in this paper <a class=\"rlc-reference\" data-ref-info=\"Hodis E, Watson IR, Kryukov GV, et al: A landscape of driver mutations in melanoma. Cell 150:251-63, 2012.\" href=\"#_ENREF_31\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22817889\"><sup>31</sup></a> reported that, outside of the most frequent mutations in BRAF and NRAS, driver mutations were identified in 83% of remaining BRAF and NRAS wild-type tumors. These results will be confirmed in much larger cohorts of melanoma tumors; some changes (identification of new rare-driver or helper mutations) could be anticipated. However, while many genetic alterations in melanoma have been identified, the issue of tumor heterogeneity, within different tumors in the same patient, or even within individual tumor, could be expected to be a big problem both in melanoma biology and clinical approaches.</p>\n<p id=\"erb-f1b3b2b2-1962-48b6-9516-54342ef24974\">However, the accumulated knowledge is already sufficient to concentrate on the biological significance of genetic aberrations identified in melanoma and to evaluate their suitability as targets. Combination therapies are obviously the way of the future and might include two or more targeted therapies in combination with immunotherapies. One can also envision combinations that include novel therapies that target basic processes (e.g., metabolism and autophagy) that are sufficiently deranged in melanoma compared to normal cells.</p>\n<p id=\"erb-a4064fad-042b-4ed3-97a5-5b49408d96dc\">The ubiquitous problem of resistance to targeted therapies could only be addressed by dedicated profiling of both inherent and acquired molecular features associated with resistance. This is a valid approach to either forestalling or overcoming resistance to targeted inhibitors, which is the biggest obstacle to development of meaningful precision treatment approaches in melanoma and other cancers.</p>\n<h1 id=\"erh-c60edfd5-81b9-4717-9196-7a8d28b6fa28\" lang=\"da-DK\">References</h1>\n<p id=\"erb-73646092-f2ac-4dc3-910c-12f1eff08f57\"><a name=\"_ENREF_1\"></a> 1. Berger MF, Hodis E, Heffernan TP, et al: Melanoma genome sequencing reveals frequent PREX2 mutations. Nature 485:502-6, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22622578\">http://www.ncbi.nlm.nih.gov/pubmed/22622578</a></p>\n<p id=\"erb-4efe4637-1e4a-40b5-96c6-6c58b70c757f\"><a name=\"_ENREF_2\"></a> 2. Furney SJ, Pedersen M, Gentien D, et al: SF3B1 mutations are associated with alternative splicing in uveal melanoma. Cancer Discov, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23861464\">http://www.ncbi.nlm.nih.gov/pubmed/23861464</a></p>\n<p id=\"erb-0ee5630d-5381-4372-9457-14f1d484faf5\"><a name=\"_ENREF_3\"></a> 3. Mar VJ, Wong SQ, Li J, et al: BRAF/NRAS wild-type melanomas have a high mutation load correlating with histological and molecular signatures of UV damage. Clin Cancer Res, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23833303\">http://www.ncbi.nlm.nih.gov/pubmed/23833303</a></p>\n<p id=\"erb-f368c064-0f6a-458a-bca5-19da9d781e8e\"><a name=\"_ENREF_4\"></a> 4. Furney SJ, Turajlic S, Stamp G, et al: Genome sequencing of mucosal melanomas reveals that they are driven by distinct mechanisms from cutaneous melanoma. J Pathol 230:261-9, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23620124\">http://www.ncbi.nlm.nih.gov/pubmed/23620124</a></p>\n<p id=\"erb-d65ed2aa-0a0e-4e4b-b79e-2ede1fd95596\"><a name=\"_ENREF_5\"></a> 5. Griewank KG, Westekemper H, Murali R, et al: Conjunctival Melanomas Harbor BRAF and NRAS Mutations and Copy Number Changes Similar to Cutaneous and Mucosal Melanomas. Clin Cancer Res 19:3143-3152, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23633454\">http://www.ncbi.nlm.nih.gov/pubmed/23633454</a></p>\n<p id=\"erb-8dcccb66-880c-44c6-9948-a560bc0035af\"><a name=\"_ENREF_6\"></a> 6. Pollock PM, Harper UL, Hansen KS, et al: High frequency of BRAF mutations in nevi. Nat Genet 33:19-20, 2003. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/12447372\">http://www.ncbi.nlm.nih.gov/pubmed/12447372</a></p>\n<p id=\"erb-74c90f21-654d-4f20-93c1-25710f53e232\"><a name=\"_ENREF_7\"></a> 7. Michaloglou C, Vredeveld LC, Soengas MS, et al: BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 436:720-4, 2005. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/16079850\">http://www.ncbi.nlm.nih.gov/pubmed/16079850</a></p>\n<p id=\"erb-038e7927-04c7-4e58-9c27-4155f9c3a2e1\"><a name=\"_ENREF_8\"></a> 8. Flaherty KT, Hodi FS, Fisher DE: From genes to drugs: targeted strategies for melanoma. Nat Rev Cancer 12:349-61, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22475929\">http://www.ncbi.nlm.nih.gov/pubmed/22475929</a></p>\n<p id=\"erb-9b09687c-a7e1-4f0f-890a-173c74a7d8b6\"><a name=\"_ENREF_9\"></a> 9. Flaherty KT, Puzanov I, Kim KB, et al: Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363:809-19, 2010. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/20818844\">http://www.ncbi.nlm.nih.gov/pubmed/20818844</a></p>\n<p id=\"erb-a4574180-ccf3-4e31-b506-ac50c2cd775b\"><a name=\"_ENREF_10\"></a> 10. Jordan EJ, Kelly CM: Vemurafenib for the treatment of melanoma. Expert Opin Pharmacother 13:2533-43, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23094782\">http://www.ncbi.nlm.nih.gov/pubmed/23094782</a></p>\n<p id=\"erb-23ad11c9-2641-4281-81d5-ab7f6186151a\"><a name=\"_ENREF_11\"></a> 11. Alloo A, Garibyan L, LeBoeuf N, et al: Photodynamic therapy for multiple eruptive keratoacanthomas associated with vemurafenib treatment for metastatic melanoma. Arch Dermatol 148:363-6, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22431777\">http://www.ncbi.nlm.nih.gov/pubmed/22431777</a></p>\n<p id=\"erb-73c6bfd9-8cd3-43e6-8edc-0f3ee6eed610\"><a name=\"_ENREF_12\"></a> 12. Callahan MK, Rampal R, Harding JJ, et al: Progression of RAS-mutant leukemia during RAF inhibitor treatment. N Engl J Med 367:2316-21, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23134356\">http://www.ncbi.nlm.nih.gov/pubmed/23134356</a></p>\n<p id=\"erb-efdc0a24-1250-4590-ba2d-298181a239d9\"><a name=\"_ENREF_13\"></a> 13. Gibney GT, Messina JL, Fedorenko IV, et al: Paradoxical oncogenesis-the long-term effects of BRAF inhibition in melanoma. Nat Rev Clin Oncol, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23712190\">http://www.ncbi.nlm.nih.gov/pubmed/23712190</a></p>\n<p id=\"erb-3b4ef4df-7fec-4390-b2de-1cdae26f3125\"><a name=\"_ENREF_14\"></a> 14. Poulikakos PI, Zhang C, Bollag G, et al: RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 464:427-30, 2010. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/20179705\">http://www.ncbi.nlm.nih.gov/pubmed/20179705</a></p>\n<p id=\"erb-9e1b6d68-24ef-44f1-b30b-a75545e7fdcd\"><a name=\"_ENREF_15\"></a> 15. Dalle S, Poulalhon N, Debarbieux S, et al: Second primary melanomas under vemurafenib. Br J Dermatol, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23066856\">http://www.ncbi.nlm.nih.gov/pubmed/23066856</a></p>\n<p id=\"erb-430d351e-8e60-4295-917f-c357f4345149\"><a name=\"_ENREF_16\"></a> 16. Zimmer L, Hillen U, Livingstone E, et al: Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition. J Clin Oncol 30:2375-83, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22614973\">http://www.ncbi.nlm.nih.gov/pubmed/22614973</a></p>\n<p id=\"erb-3c74447f-1421-44da-a1e4-78a9d8f1d150\"><a name=\"_ENREF_17\"></a> 17. Holderfield M, Merritt H, Chan J, et al: RAF Inhibitors Activate the MAPK Pathway by Relieving Inhibitory Autophosphorylation. Cancer Cell 23:594-602, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23680146\">http://www.ncbi.nlm.nih.gov/pubmed/23680146</a></p>\n<p id=\"erb-3c24d781-9f07-406d-a8c0-e23bd84308ef\"><a name=\"_ENREF_18\"></a> 18. Ascierto PA, Minor D, Ribas A, et al: Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic Melanoma. J Clin Oncol, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23918947\">http://www.ncbi.nlm.nih.gov/pubmed/23918947</a></p>\n<p id=\"erb-78cd1359-40cc-451f-aa4d-1a99e6c3fe37\"><a name=\"_ENREF_19\"></a> 19. Le K, Blomain E, Rodeck U, et al: Selective RAF inhibitor impairs ERK1/2 phosphorylation and growth in mutant NRAS, vemurafenib-resistant melanoma cells. Pigment Cell Melanoma Res, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23490205\">http://www.ncbi.nlm.nih.gov/pubmed/23490205</a></p>\n<p id=\"erb-b7d170c5-26de-47e8-bab5-42a2c2328968\"><a name=\"_ENREF_20\"></a> 20. Das Thakur M, Salangsang F, Landman AS, et al: Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23302800\">http://www.ncbi.nlm.nih.gov/pubmed/23302800</a></p>\n<p id=\"erb-10db8e22-e42e-46c4-8ad4-99d795928f96\"><a name=\"_ENREF_21\"></a> 21. Falchook GS, Lewis KD, Infante JR, et al: Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol 13:782-9, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22805292\">http://www.ncbi.nlm.nih.gov/pubmed/22805292</a></p>\n<p id=\"erb-eb7496c4-0c77-414b-8abe-34d9c3344585\"><a name=\"_ENREF_22\"></a> 22. Flaherty KT, Robert C, Hersey P, et al: Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 367:107-14, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22663011\">http://www.ncbi.nlm.nih.gov/pubmed/22663011</a></p>\n<p id=\"erb-3f441d65-68dc-43e3-a591-f34caf2cb5fd\"><a name=\"_ENREF_23\"></a> 23. Robert C, Dummer R, Gutzmer R, et al: Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study. Lancet Oncol 14:733-40, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23735514\">http://www.ncbi.nlm.nih.gov/pubmed/23735514</a></p>\n<p id=\"erb-4722f853-cf86-4f82-aa2b-68383ea8e20e\"><a name=\"_ENREF_24\"></a> 24. Kim KB, Kefford R, Pavlick AC, et al: Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol 31:482-9, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23248257\">http://www.ncbi.nlm.nih.gov/pubmed/23248257</a></p>\n<p id=\"erb-34e2d298-5986-461f-97bc-0f0976fe98ee\"><a name=\"_ENREF_25\"></a> 25. Flaherty KT, Infante JR, Daud A, et al: Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 367:1694-703, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23020132\">http://www.ncbi.nlm.nih.gov/pubmed/23020132</a></p>\n<p id=\"erb-fd5644b7-f6de-40d4-847e-3fb4739726e7\"><a name=\"_ENREF_26\"></a> 26. Morris EJ, Jha S, Restaino CR, et al: Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors. Cancer Discov 3:742-50, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23614898\">http://www.ncbi.nlm.nih.gov/pubmed/23614898</a></p>\n<p id=\"erb-5d02526c-8128-4788-b626-5227940b24d9\"><a name=\"_ENREF_27\"></a> 27. Davies H, Bignell GR, Cox C, et al: Mutations of the BRAF gene in human cancer. Nature 417:949-54, 2002. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/12068308\">http://www.ncbi.nlm.nih.gov/pubmed/12068308</a></p>\n<p id=\"erb-79600a8d-8512-46ea-aa23-27a4724dc3b7\"><a name=\"_ENREF_28\"></a> 28. Wan PT, Garnett MJ, Roe SM, et al: Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116:855-67, 2004. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/15035987\">http://www.ncbi.nlm.nih.gov/pubmed/15035987</a></p>\n<p id=\"erb-0e974191-c9a7-4ecf-978b-b5cca36b386c\"><a name=\"_ENREF_29\"></a> 29. Smalley KS, Xiao M, Villanueva J, et al: CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations. Oncogene 28:85-94, 2009. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/18794803\">http://www.ncbi.nlm.nih.gov/pubmed/18794803</a></p>\n<p id=\"erb-7da91038-5f0d-4696-9fe4-403616258bc2\"><a name=\"_ENREF_30\"></a> 30. Dahlman KB, Xia J, Hutchinson K, et al: BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors. Cancer Discov 2:791-7, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22798288\">http://www.ncbi.nlm.nih.gov/pubmed/22798288</a></p>\n<p id=\"erb-65502735-af42-41df-87ba-4a3bbfd58111\"><a name=\"_ENREF_31\"></a> 31. Hodis E, Watson IR, Kryukov GV, et al: A landscape of driver mutations in melanoma. Cell 150:251-63, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22817889\">http://www.ncbi.nlm.nih.gov/pubmed/22817889</a></p>\n<p id=\"erb-7c59bfb9-bf3d-4fd0-b4ca-a6862ccab26b\"><a name=\"_ENREF_32\"></a> 32. Ascierto PA, Schadendorf D, Berking C, et al: MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23414587\">http://www.ncbi.nlm.nih.gov/pubmed/23414587</a></p>\n<p id=\"erb-5e991bf0-1150-4cc7-8320-575a2b31dd20\"><a name=\"_ENREF_33\"></a> 33. Hatzivassiliou G, Haling JR, Chen H, et al: Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers. Nature, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23934108\">http://www.ncbi.nlm.nih.gov/pubmed/23934108</a></p>\n<p id=\"erb-c1e4b4bb-0d93-46bc-b353-0f261c7a3fb6\"><a name=\"_ENREF_34\"></a> 34. Roberts PJ, Usary JE, Darr DB, et al: Combined PI3K/mTOR and MEK inhibition provides broad antitumor activity in faithful murine cancer models. Clin Cancer Res 18:5290-303, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22872574\">http://www.ncbi.nlm.nih.gov/pubmed/22872574</a></p>\n<p id=\"erb-d16dd82d-7f24-41bb-acca-ac2ab502659d\"><a name=\"_ENREF_35\"></a> 35. Posch C, Moslehi H, Feeney L, et al: Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo. Proc Natl Acad Sci U S A, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23431193\">http://www.ncbi.nlm.nih.gov/pubmed/23431193</a></p>\n<p id=\"erb-31866a57-9297-4248-8ba5-7ee81f7edca8\"><a name=\"_ENREF_36\"></a> 36. Kwong LN, Costello JC, Liu H, et al: Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma. Nat Med 18:1503-10, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22983396\">http://www.ncbi.nlm.nih.gov/pubmed/22983396</a></p>\n<p id=\"erb-d89cca62-202d-46f5-890c-c3e82015e3a7\"><a name=\"_ENREF_37\"></a> 37. Barretina J, Caponigro G, Stransky N, et al: The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483:603-7, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22460905\">http://www.ncbi.nlm.nih.gov/pubmed/22460905</a></p>\n<p id=\"erb-ae1293ce-5982-4c29-90b2-ac7691c6dc03\"><a name=\"_ENREF_38\"></a> 38. Held MA, Langdon CG, Platt JT, et al: Genotype-selective combination therapies for melanoma identified by high-throughput drug screening. Cancer Discov 3:52-67, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23239741\">http://www.ncbi.nlm.nih.gov/pubmed/23239741</a></p>\n<p id=\"erb-0666972a-5743-4da4-9e04-c81fab0e3ada\"><a name=\"_ENREF_39\"></a> 39. Van Raamsdonk CD, Bezrookove V, Green G, et al: Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature 457:599-602, 2009. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/19078957\">http://www.ncbi.nlm.nih.gov/pubmed/19078957</a></p>\n<p id=\"erb-319e21ae-2ea0-44be-9f30-e469d83155b8\"><a name=\"_ENREF_40\"></a> 40. Van Raamsdonk CD, Griewank KG, Crosby MB, et al: Mutations in GNA11 in uveal melanoma. N Engl J Med 363:2191-9, 2010. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/21083380\">http://www.ncbi.nlm.nih.gov/pubmed/21083380</a></p>\n<p id=\"erb-0d2f20b9-a85e-4aa0-a51a-2c81cea74bb6\"><a name=\"_ENREF_41\"></a> 41. Daniels AB, Lee JE, MacConaill LE, et al: High throughput mass spectrometry-based mutation profiling of primary uveal melanoma. Invest Ophthalmol Vis Sci 53:6991-6, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22977135\">http://www.ncbi.nlm.nih.gov/pubmed/22977135</a></p>\n<p id=\"erb-61345bdb-25b2-4899-a3d7-36f6f4b5a292\"><a name=\"_ENREF_42\"></a> 42. Ho AL, Musi E, Ambrosini G, et al: Impact of combined mTOR and MEK inhibition in uveal melanoma is driven by tumor genotype. PLoS One 7:e40439, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22808163\">http://www.ncbi.nlm.nih.gov/pubmed/22808163</a></p>\n<p id=\"erb-0cc1a925-7daa-41c6-b139-f1fa3533c769\"><a name=\"_ENREF_43\"></a> 43. Khalili JS, Yu X, Wang J, et al: Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner. Clin Cancer Res 18:4345-55, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22733540\">http://www.ncbi.nlm.nih.gov/pubmed/22733540</a></p>\n<p id=\"erb-93017992-4d55-4f58-a50d-a7c04c7f9fa4\"><a name=\"_ENREF_44\"></a> 44. Wu X, Li J, Zhu M, et al: Protein kinase C inhibitor AEB071 targets ocular melanoma harboring GNAQ mutations via effects on the PKC/Erk1/2 and PKC/NF-kappaB pathways. Mol Cancer Ther 11:1905-14, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22653968\">http://www.ncbi.nlm.nih.gov/pubmed/22653968</a></p>\n<p id=\"erb-60583a8a-31b7-43a8-920d-80ef90e9f11b\"><a name=\"_ENREF_45\"></a> 45. Wu X, Zhu M, Fletcher JA, et al: The protein kinase C inhibitor enzastaurin exhibits antitumor activity against uveal melanoma. PLoS One 7:e29622, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22253748\">http://www.ncbi.nlm.nih.gov/pubmed/22253748</a></p>\n<p id=\"erb-048f5b64-f3d1-40c9-804a-2607603d711e\"><a name=\"_ENREF_46\"></a> 46. Vaque JP, Dorsam RT, Feng X, et al: A Genome-wide RNAi Screen Reveals a Trio-Regulated Rho GTPase Circuitry Transducing Mitogenic Signals Initiated by G Protein-Coupled Receptors. Mol Cell, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23177739\">http://www.ncbi.nlm.nih.gov/pubmed/23177739</a></p>\n<p id=\"erb-cd79a28c-cb82-4e07-8df8-3174de2c9c81\"><a name=\"_ENREF_47\"></a> 47. Garraway LA, Widlund HR, Rubin MA, et al: Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 436:117-22, 2005. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/16001072\">http://www.ncbi.nlm.nih.gov/pubmed/16001072</a></p>\n<p id=\"erb-b9d3b322-da68-4a7d-a1f5-1d2749f6dc60\"><a name=\"_ENREF_48\"></a> 48. Yokoyama S, Woods SL, Boyle GM, et al: A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma. Nature 480:99-103, 2011. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22080950\">http://www.ncbi.nlm.nih.gov/pubmed/22080950</a></p>\n<p id=\"erb-5a764182-3164-407e-a902-58c159316eb2\"><a name=\"_ENREF_49\"></a> 49. Du J, Widlund HR, Horstmann MA, et al: Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF. Cancer Cell 6:565-76, 2004. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/15607961\">http://www.ncbi.nlm.nih.gov/pubmed/15607961</a></p>\n<p id=\"erb-21ed2af7-679a-4b06-8023-dabdfc6d7041\"><a name=\"_ENREF_50\"></a> 50. Zhu S, Wurdak H, Wang Y, et al: A genomic screen identifies TYRO3 as a MITF regulator in melanoma. Proc Natl Acad Sci U S A 106:17025-30, 2009. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/19805117\">http://www.ncbi.nlm.nih.gov/pubmed/19805117</a></p>\n<p id=\"erb-fd84ecb9-2074-45e4-893d-ab24f8992dd9\"><a name=\"_ENREF_51\"></a> 51. Zhao X, Fiske B, Kawakami A, et al: Regulation of MITF stability by the USP13 deubiquitinase. Nat Commun 2:414, 2011. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/21811243\">http://www.ncbi.nlm.nih.gov/pubmed/21811243</a></p>\n<p id=\"erb-f1599830-287e-428f-a258-0778e655ac26\"><a name=\"_ENREF_52\"></a> 52. Busca R, Berra E, Gaggioli C, et al: Hypoxia-inducible factor 1{alpha} is a new target of microphthalmia-associated transcription factor (MITF) in melanoma cells. J Cell Biol 170:49-59, 2005. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/15983061\">http://www.ncbi.nlm.nih.gov/pubmed/15983061</a></p>\n<p id=\"erb-e6a6cfe9-f2a4-4d8d-8436-8dc25fd47083\"><a name=\"_ENREF_53\"></a> 53. Feige E, Yokoyama S, Levy C, et al: Hypoxia-induced transcriptional repression of the melanoma-associated oncogene MITF. Proc Natl Acad Sci U S A 108:E924-33, 2011. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/21949374\">http://www.ncbi.nlm.nih.gov/pubmed/21949374</a></p>\n<p id=\"erb-ddacf685-43f3-48af-9d51-ddf4e9ddfcdb\"><a name=\"_ENREF_54\"></a> 54. Hanna SC, Krishnan B, Bailey ST, et al: HIF1alpha and HIF2alpha independently activate SRC to promote melanoma metastases. J Clin Invest 123:2078-93, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23563312\">http://www.ncbi.nlm.nih.gov/pubmed/23563312</a></p>\n<p id=\"erb-998c0128-d28e-4813-baea-e690d9e8219d\"><a name=\"_ENREF_55\"></a> 55. Shah M, Bhoumik A, Goel V, et al: A role for ATF2 in regulating MITF and melanoma development. PLoS Genet 6:e1001258, 2010. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/21203491\">http://www.ncbi.nlm.nih.gov/pubmed/21203491</a></p>\n<p id=\"erb-518c4294-ffce-415b-8f06-adc12bf320cd\"><a name=\"_ENREF_56\"></a> 56. Shakhova O, Zingg D, Schaefer SM, et al: Sox10 promotes the formation and maintenance of giant congenital naevi and melanoma. Nat Cell Biol 14:882-90, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22772081\">http://www.ncbi.nlm.nih.gov/pubmed/22772081</a></p>\n<p id=\"erb-e4dafdf8-1356-42b5-bbed-1562b630fbbb\"><a name=\"_ENREF_57\"></a> 57. Puri N, Ahmed S, Janamanchi V, et al: c-Met is a potentially new therapeutic target for treatment of human melanoma. Clin Cancer Res 13:2246-53, 2007. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/17404109\">http://www.ncbi.nlm.nih.gov/pubmed/17404109</a></p>\n<p id=\"erb-91b71680-1154-4091-9811-a1ad26515c4e\"><a name=\"_ENREF_58\"></a> 58. Mascarenhas JB, Littlejohn EL, Wolsky RJ, et al: PAX3 and SOX10 activate MET receptor expression in melanoma. Pigment Cell Melanoma Res 23:225-37, 2010. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/20067553\">http://www.ncbi.nlm.nih.gov/pubmed/20067553</a></p>\n<p id=\"erb-0ef07ee6-9630-4a95-906a-e2538df8fb53\"><a name=\"_ENREF_59\"></a> 59. Vazquez F, Lim JH, Chim H, et al: PGC1alpha Expression Defines a Subset of Human Melanoma Tumors with Increased Mitochondrial Capacity and Resistance to Oxidative Stress. Cancer Cell, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23416000\">http://www.ncbi.nlm.nih.gov/pubmed/23416000</a></p>\n<p id=\"erb-2b47fc23-88e4-4ebd-b7a5-8bb24c601adf\"><a name=\"_ENREF_60\"></a> 60. Shoag J, Haq R, Zhang M, et al: PGC-1 Coactivators Regulate MITF and the Tanning Response. Mol Cell, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23201126\">http://www.ncbi.nlm.nih.gov/pubmed/23201126</a></p>\n<p id=\"erb-2bdd949c-67a1-4d55-8ce0-4d7562892fb2\"><a name=\"_ENREF_61\"></a> 61. Haq R, Yokoyama S, Hawryluk EB, et al: BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition. Proc Natl Acad Sci U S A 110:4321-6, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23447565\">http://www.ncbi.nlm.nih.gov/pubmed/23447565</a></p>\n<p id=\"erb-febbcb7d-a424-44e9-b3f5-05bad6595e46\"><a name=\"_ENREF_62\"></a> 62. Saez-Ayala M, Montenegro MF, Sanchez-Del-Campo L, et al: Directed Phenotype Switching as an Effective Antimelanoma Strategy. Cancer Cell, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23792190\">http://www.ncbi.nlm.nih.gov/pubmed/23792190</a></p>\n<p id=\"erb-078dbbe8-ce44-4cd3-ba89-6518e611ec78\"><a name=\"_ENREF_63\"></a> 63. Pogenberg V, Ogmundsdottir MH, Bergsteinsdottir K, et al: Restricted leucine zipper dimerization and specificity of DNA recognition of the melanocyte master regulator MITF. Genes Dev 26:2647-58, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23207919\">http://www.ncbi.nlm.nih.gov/pubmed/23207919</a></p>\n<p id=\"erb-9f929e08-a8f5-4b55-8e95-5166d0b75441\"><a name=\"_ENREF_64\"></a> 64. Yokoyama S, Feige E, Poling LL, et al: Pharmacologic suppression of MITF expression via HDAC inhibitors in the melanocyte lineage. Pigment Cell Melanoma Res 21:457-63, 2008. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/18627530\">http://www.ncbi.nlm.nih.gov/pubmed/18627530</a></p>\n<p id=\"erb-18f014e1-6a3c-44fc-9739-5ec3f4eab556\"><a name=\"_ENREF_65\"></a> 65. Varsano T, Lau E, Feng Y, et al: Inhibition of Melanoma Growth by Small Molecules That Promote the Mitochondrial Localization of ATF2. Clin Cancer Res 19:2710-22, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23589174\">http://www.ncbi.nlm.nih.gov/pubmed/23589174</a></p>\n<p id=\"erb-eef0da20-5e6f-4a50-ba0b-f8ac667f45ec\"><a name=\"_ENREF_66\"></a> 66. Curtin JA, Busam K, Pinkel D, et al: Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 24:4340-6, 2006. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/16908931\">http://www.ncbi.nlm.nih.gov/pubmed/16908931</a></p>\n<p id=\"erb-85169388-fd88-4009-aa2e-d3544d77d2dc\"><a name=\"_ENREF_67\"></a> 67. Woodman SE, Davies MA: Targeting KIT in melanoma: a paradigm of molecular medicine and targeted therapeutics. Biochem Pharmacol 80:568-74, 2010. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/20457136\">http://www.ncbi.nlm.nih.gov/pubmed/20457136</a></p>\n<p id=\"erb-ba2b5134-c57d-49c1-b1c1-c32d459d958c\"><a name=\"_ENREF_68\"></a> 68. Kim KB, Eton O, Davis DW, et al: Phase II trial of imatinib mesylate in patients with metastatic melanoma. Br J Cancer 99:734-40, 2008. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/18728664\">http://www.ncbi.nlm.nih.gov/pubmed/18728664</a></p>\n<p id=\"erb-0f1fc750-a935-47ca-91da-27d9457ea0dc\"><a name=\"_ENREF_69\"></a> 69. Penel N, Delcambre C, Durando X, et al: O-Mel-Inib: a Cancero-pole Nord-Ouest multicenter phase II trial of high-dose imatinib mesylate in metastatic uveal melanoma. Invest New Drugs 26:561-5, 2008. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/18551246\">http://www.ncbi.nlm.nih.gov/pubmed/18551246</a></p>\n<p id=\"erb-28d72d9b-e623-4625-a7ba-76f0e80cc95f\"><a name=\"_ENREF_70\"></a> 70. Wyman K, Atkins MB, Prieto V, et al: Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy. Cancer 106:2005-11, 2006. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/16565971\">http://www.ncbi.nlm.nih.gov/pubmed/16565971</a></p>\n<p id=\"erb-1fe66e75-cd57-41f4-8cb1-e1cec536c9d7\"><a name=\"_ENREF_71\"></a> 71. Kluger HM, Dudek AZ, McCann C, et al: A phase 2 trial of dasatinib in advanced melanoma. Cancer 117:2202-8, 2011. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/21523734\">http://www.ncbi.nlm.nih.gov/pubmed/21523734</a></p>\n<p id=\"erb-4bf2cfec-8372-4cdb-aee2-ecaae6cd9d79\"><a name=\"_ENREF_72\"></a> 72. Lutzky J, Bauer J, Bastian BC: Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation. Pigment Cell Melanoma Res 21:492-3, 2008. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/18510589\">http://www.ncbi.nlm.nih.gov/pubmed/18510589</a></p>\n<p id=\"erb-0c1ebd14-bdc2-4149-bffc-65edcb8e9b1c\"><a name=\"_ENREF_73\"></a> 73. Hodi FS, Friedlander P, Corless CL, et al: Major response to imatinib mesylate in KIT-mutated melanoma. J Clin Oncol 26:2046-51, 2008. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/18421059\">http://www.ncbi.nlm.nih.gov/pubmed/18421059</a></p>\n<p id=\"erb-a1fcd05d-57ce-4276-a740-bea7080bcdc9\"><a name=\"_ENREF_74\"></a> 74. Woodman SE, Trent JC, Stemke-Hale K, et al: Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates. Mol Cancer Ther 8:2079-85, 2009. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/19671763\">http://www.ncbi.nlm.nih.gov/pubmed/19671763</a></p>\n<p id=\"erb-1f4a61b3-0341-41b6-adcb-1202b2bf9125\"><a name=\"_ENREF_75\"></a> 75. Hofmann UB, Kauczok-Vetter CS, Houben R, et al: Overexpression of the KIT/SCF in uveal melanoma does not translate into clinical efficacy of imatinib mesylate. Clin Cancer Res 15:324-9, 2009. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/19118061\">http://www.ncbi.nlm.nih.gov/pubmed/19118061</a></p>\n<p id=\"erb-64dae639-4b49-4ae9-9281-a80bf490ba71\"><a name=\"_ENREF_76\"></a> 76. Mahipal A, Tijani L, Chan K, et al: A pilot study of sunitinib malate in patients with metastatic uveal melanoma. Melanoma Res 22:440-6, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23114504\">http://www.ncbi.nlm.nih.gov/pubmed/23114504</a></p>\n<p id=\"erb-24d50dfd-4cc2-4696-bccb-3f99ba961d51\"><a name=\"_ENREF_77\"></a> 77. Guo J, Si L, Kong Y, et al: Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol 29:2904-9, 2011. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/21690468\">http://www.ncbi.nlm.nih.gov/pubmed/21690468</a></p>\n<p id=\"erb-1c633e18-c66a-44b1-9355-7c7b14172678\"><a name=\"_ENREF_78\"></a> 78. Carvajal RD, Antonescu CR, Wolchok JD, et al: KIT as a therapeutic target in metastatic melanoma. JAMA 305:2327-34, 2011. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/21642685\">http://www.ncbi.nlm.nih.gov/pubmed/21642685</a></p>\n<p id=\"erb-990480f3-f5f5-455b-8b95-652b0df6698c\"><a name=\"_ENREF_79\"></a> 79. Minor DR, Kashani-Sabet M, Garrido M, et al: Sunitinib therapy for melanoma patients with KIT mutations. Clin Cancer Res 18:1457-63, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22261812\">http://www.ncbi.nlm.nih.gov/pubmed/22261812</a></p>\n<p id=\"erb-717932c4-e448-4bb1-9f10-a9fba9fe79b2\"><a name=\"_ENREF_80\"></a> 80. Cho JH, Kim KM, Kwon M, et al: Nilotinib in patients with metastatic melanoma harboring KIT gene aberration. Invest New Drugs 30:2008-14, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22068222\">http://www.ncbi.nlm.nih.gov/pubmed/22068222</a></p>\n<p id=\"erb-3df519ba-b4b0-48b5-a54e-42ca908e7986\"><a name=\"_ENREF_81\"></a> 81. Hodi FS, Corless CL, Giobbie-Hurder A, et al: Imatinib for Melanomas Harboring Mutationally Activated or Amplified KIT Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin. J Clin Oncol, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23775962\">http://www.ncbi.nlm.nih.gov/pubmed/23775962</a></p>\n<p id=\"erb-5f8c212c-f227-41e0-8359-63d90686a775\"><a name=\"_ENREF_82\"></a> 82. Carvajal RD: Another Option in Our KIT of Effective Therapies for Advanced Melanoma. J Clin Oncol, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23940226\">http://www.ncbi.nlm.nih.gov/pubmed/23940226</a></p>\n<p id=\"erb-2041a9de-d0ed-4ef2-a679-62aede4196f2\"><a name=\"_ENREF_83\"></a> 83. Johnson MR, Look AT, DeClue JE, et al: Inactivation of the NF1 gene in human melanoma and neuroblastoma cell lines without impaired regulation of GTP.Ras. Proc Natl Acad Sci U S A 90:5539-43, 1993. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/8516298\">http://www.ncbi.nlm.nih.gov/pubmed/8516298</a></p>\n<p id=\"erb-bb05c2be-a9be-4201-9e42-d19c4c27d55f\"><a name=\"_ENREF_84\"></a> 84. Gutzmer R, Herbst RA, Mommert S, et al: Allelic loss at the neurofibromatosis type 1 (NF1) gene locus is frequent in desmoplastic neurotropic melanoma. Hum Genet 107:357-61, 2000. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/11129335\">http://www.ncbi.nlm.nih.gov/pubmed/11129335</a></p>\n<p id=\"erb-36bdd25f-5fb0-4865-a595-3f798aa4578e\"><a name=\"_ENREF_85\"></a> 85. Maertens O, Johnson B, Hollstein P, et al: Elucidating distinct roles for NF1 in melanomagenesis. Cancer Discov, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23171796\">http://www.ncbi.nlm.nih.gov/pubmed/23171796</a></p>\n<p id=\"erb-08f22c73-2105-47b7-8e07-08fe34ef8788\"><a name=\"_ENREF_86\"></a> 86. Whittaker SR, Theurillat JP, Van Allen E, et al: A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. Cancer Discov, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23288408\">http://www.ncbi.nlm.nih.gov/pubmed/23288408</a></p>\n<p id=\"erb-7a4c487c-b59a-418f-8ff5-0be53b2e37c8\"><a name=\"_ENREF_87\"></a> 87. Horn S, Figl A, Rachakonda PS, et al: TERT Promoter Mutations in Familial and Sporadic Melanoma. Science, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23348503\">http://www.ncbi.nlm.nih.gov/pubmed/23348503</a></p>\n<p id=\"erb-4964f7e5-060b-4700-aac2-0c320326632d\"><a name=\"_ENREF_88\"></a> 88. Huang FW, Hodis E, Xu MJ, et al: Highly Recurrent TERT Promoter Mutations in Human Melanoma. Science, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23348506\">http://www.ncbi.nlm.nih.gov/pubmed/23348506</a></p>\n<p id=\"erb-209e5cc7-8f1e-456d-9e13-c408e7fbdeed\"><a name=\"_ENREF_89\"></a> 89. Dankort D, Curley DP, Cartlidge RA, et al: Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet 41:544-52, 2009. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/19282848\">http://www.ncbi.nlm.nih.gov/pubmed/19282848</a></p>\n<p id=\"erb-08e50dcf-778b-405e-8adb-5e811d8d78f9\"><a name=\"_ENREF_90\"></a> 90. Vredeveld LC, Possik PA, Smit MA, et al: Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis. Genes Dev 26:1055-69, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22549727\">http://www.ncbi.nlm.nih.gov/pubmed/22549727</a></p>\n<p id=\"erb-9cacb264-2e85-4698-83de-0c4d3eaafba8\"><a name=\"_ENREF_91\"></a> 91. Prickett TD, Agrawal NS, Wei X, et al: Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4. Nat Genet 41:1127-32, 2009. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/19718025\">http://www.ncbi.nlm.nih.gov/pubmed/19718025</a></p>\n<p id=\"erb-b6a0797d-ae97-4fb4-8bad-91f5007778dd\"><a name=\"_ENREF_92\"></a> 92. Dutton-Regester K, Irwin D, Hunt P, et al: A high-throughput panel for identifying clinically relevant mutation profiles in melanoma. Mol Cancer Ther 11:888-97, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22383533\">http://www.ncbi.nlm.nih.gov/pubmed/22383533</a></p>\n<p id=\"erb-c02b590f-22ef-472a-ace7-19f7c95e3b99\"><a name=\"_ENREF_93\"></a> 93. Zhou QM, Li W, Guan YX, et al: The absence of the ERBB4 hotspot mutations in melanomas in patients from southern China. Chin J Cancer 32:410-4, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23237222\">http://www.ncbi.nlm.nih.gov/pubmed/23237222</a></p>\n<p id=\"erb-de3221fe-9767-480e-9cad-16bf490dc7df\"><a name=\"_ENREF_94\"></a> 94. Moore SR, Persons DL, Sosman JA, et al: Detection of copy number alterations in metastatic melanoma by a DNA fluorescence in situ hybridization probe panel and array comparative genomic hybridization: a southwest oncology group study (S9431). Clin Cancer Res 14:2927-35, 2008. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/18483359\">http://www.ncbi.nlm.nih.gov/pubmed/18483359</a></p>\n<p id=\"erb-efd4a6b3-d096-4136-974d-2427f84e6ef1\"><a name=\"_ENREF_95\"></a> 95. Kenessey I, Keszthelyi M, Kramer Z, et al: Inhibition of c-Met with the specific small molecule tyrosine kinase inhibitor SU11274 decreases growth and metastasis formation of experimental human melanoma. Curr Cancer Drug Targets 10:332-42, 2010. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/20370683\">http://www.ncbi.nlm.nih.gov/pubmed/20370683</a></p>\n<p id=\"erb-82b6655c-201a-416a-bc14-b492a08b5f62\"><a name=\"_ENREF_96\"></a> 96. Schlegel J, Sambade MJ, Sather S, et al: MERTK receptor tyrosine kinase is a therapeutic target in melanoma. J Clin Invest, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23585477\">http://www.ncbi.nlm.nih.gov/pubmed/23585477</a></p>\n<p id=\"erb-3bf26777-dcf1-43cb-9528-030dbb204912\"><a name=\"_ENREF_97\"></a> 97. Tworkoski KA, Platt JT, Bacchiocchi A, et al: MERTK controls melanoma cell migration and survival and differentially regulates cell behavior relative to AXL. Pigment Cell Melanoma Res, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23617806\">http://www.ncbi.nlm.nih.gov/pubmed/23617806</a></p>\n<p id=\"erb-e7b7d16a-7502-48a6-9190-774fd47da373\"><a name=\"_ENREF_98\"></a> 98. Stahl JM, Sharma A, Cheung M, et al: Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res 64:7002-10, 2004. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/15466193\">http://www.ncbi.nlm.nih.gov/pubmed/15466193</a></p>\n<p id=\"erb-d783ea6b-4303-471e-89cb-9850e677cc01\"><a name=\"_ENREF_99\"></a> 99. Davies MA, Stemke-Hale K, Tellez C, et al: A novel AKT3 mutation in melanoma tumours and cell lines. Br J Cancer 99:1265-8, 2008. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/18813315\">http://www.ncbi.nlm.nih.gov/pubmed/18813315</a></p>\n<p id=\"erb-b273c0ec-ca04-4588-b325-28399a97d03d\"><a name=\"_ENREF_100\"></a> 100. Cheung M, Sharma A, Madhunapantula SV, et al: Akt3 and mutant V600E B-Raf cooperate to promote early melanoma development. Cancer Res 68:3429-39, 2008. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/18451171\">http://www.ncbi.nlm.nih.gov/pubmed/18451171</a></p>\n<p id=\"erb-96c96f29-dd2b-4b8d-8759-5599ff12a630\"><a name=\"_ENREF_101\"></a> 101. Tsao H, Zhang X, Benoit E, et al: Identification of PTEN/MMAC1 alterations in uncultured melanomas and melanoma cell lines. Oncogene 16:3397-402, 1998. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/9692547\">http://www.ncbi.nlm.nih.gov/pubmed/9692547</a></p>\n<p id=\"erb-3f769a1d-c6a7-4ebe-a32a-a149218bbff2\"><a name=\"_ENREF_102\"></a> 102. Karreth FA, Tay Y, Perna D, et al: In vivo identification of tumor- suppressive PTEN ceRNAs in an oncogenic BRAF-induced mouse model of melanoma. Cell 147:382-95, 2011. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22000016\">http://www.ncbi.nlm.nih.gov/pubmed/22000016</a></p>\n<p id=\"erb-98ed74d5-2668-48f2-bca7-e9c78c0c0eb4\"><a name=\"_ENREF_103\"></a> 103. Nathanson KL, Martin AM, Wubbenhorst B, et al: Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor Dabrafenib (GSK2118436). Clin Cancer Res, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23833299\">http://www.ncbi.nlm.nih.gov/pubmed/23833299</a></p>\n<p id=\"erb-e435e36e-77e1-43d2-9ddc-9becfbb4afc1\"><a name=\"_ENREF_104\"></a> 104. Cao J, Wan L, Hacker E, et al: MC1R Is a Potent Regulator of PTEN after UV Exposure in Melanocytes. Mol Cell 51:409-22, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23973372\">http://www.ncbi.nlm.nih.gov/pubmed/23973372</a></p>\n<p id=\"erb-2cd5fd0a-8400-43c8-af62-3570ba9ee5aa\"><a name=\"_ENREF_105\"></a> 105. Shull AY, Latham-Schwark A, Ramasamy P, et al: Novel somatic mutations to PI3K pathway genes in metastatic melanoma. PLoS One 7:e43369, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22912864\">http://www.ncbi.nlm.nih.gov/pubmed/22912864</a></p>\n<p id=\"erb-a0fe05da-2991-47d5-91da-ed6bcb0a44f5\"><a name=\"_ENREF_106\"></a> 106. Nikolaev SI, Rimoldi D, Iseli C, et al: Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma. Nat Genet 44:133-9, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22197931\">http://www.ncbi.nlm.nih.gov/pubmed/22197931</a></p>\n<p id=\"erb-f333dbf8-2d9a-4d67-892b-3ade7351335f\"><a name=\"_ENREF_107\"></a> 107. Jameson KL, Mazur PK, Zehnder AM, et al: IQGAP1 scaffold-kinase interaction blockade selectively targets RAS-MAP kinase-driven tumors. Nat Med, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23603816\">http://www.ncbi.nlm.nih.gov/pubmed/23603816</a></p>\n<p id=\"erb-f831f066-f355-44c5-ba94-4f4efe7786cc\"><a name=\"_ENREF_108\"></a> 108. Li A, Ma Y, Jin M, et al: Activated mutant NRas(Q61K) drives aberrant melanocyte signaling, survival, and invasiveness via a Rac1-dependent mechanism. J Invest Dermatol 132:2610-21, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22718121\">http://www.ncbi.nlm.nih.gov/pubmed/22718121</a></p>\n<p id=\"erb-ba330211-ed4d-423b-b043-53c5a4760388\"><a name=\"_ENREF_109\"></a> 109. Krauthammer M, Kong Y, Ha BH, et al: Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat Genet 44:1006-14, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22842228\">http://www.ncbi.nlm.nih.gov/pubmed/22842228</a></p>\n<p id=\"erb-c9f5391e-b1c1-45e9-ba83-8eb326b69859\"><a name=\"_ENREF_110\"></a> 110. Stark MS, Woods SL, Gartside MG, et al: Frequent somatic mutations in MAP3K5 and MAP3K9 in metastatic melanoma identified by exome sequencing. Nat Genet 44:165-9, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22197930\">http://www.ncbi.nlm.nih.gov/pubmed/22197930</a></p>\n<p id=\"erb-e0c0d1e5-7039-4a91-a73d-f391392900ae\"><a name=\"_ENREF_111\"></a> 111. Muthusamy V, Hobbs C, Nogueira C, et al: Amplification of CDK4 and MDM2 in malignant melanoma. Genes Chromosomes Cancer 45:447-54, 2006. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/16419059\">http://www.ncbi.nlm.nih.gov/pubmed/16419059</a></p>\n<p id=\"erb-cf2be9fd-a56b-4430-b964-97c7a1f2c457\"><a name=\"_ENREF_112\"></a> 112. Zuo L, Weger J, Yang Q, et al: Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nat Genet 12:97-9, 1996. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/8528263\">http://www.ncbi.nlm.nih.gov/pubmed/8528263</a></p>\n<p id=\"erb-4a224c2b-95bc-44bc-a33a-f8c90528e9f7\"><a name=\"_ENREF_113\"></a> 113. Dickson MA, Shah MA, Rathkopf D, et al: A phase I clinical trial of FOLFIRI in combination with the pan-cyclin-dependent kinase (CDK) inhibitor flavopiridol. Cancer Chemother Pharmacol 66:1113-21, 2010. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/20953860\">http://www.ncbi.nlm.nih.gov/pubmed/20953860</a></p>\n<p id=\"erb-f3254999-c743-455a-a028-fe6279eb673f\"><a name=\"_ENREF_114\"></a> 114. Hussussian CJ, Struewing JP, Goldstein AM, et al: Germline p16 mutations in familial melanoma. Nat Genet 8:15-21, 1994. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/7987387\">http://www.ncbi.nlm.nih.gov/pubmed/7987387</a></p>\n<p id=\"erb-2b779965-8d7d-4737-9a04-d1dfa80f8888\"><a name=\"_ENREF_115\"></a> 115. Polsky D, Bastian BC, Hazan C, et al: HDM2 protein overexpression, but not gene amplification, is related to tumorigenesis of cutaneous melanoma. Cancer Res 61:7642-6, 2001. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/11606406\">http://www.ncbi.nlm.nih.gov/pubmed/11606406</a></p>\n<p id=\"erb-bb5a53f1-1a60-4c3e-8bc8-a656186e1112\"><a name=\"_ENREF_116\"></a> 116. Gembarska A, Luciani F, Fedele C, et al: MDM4 is a key therapeutic target in cutaneous melanoma. Nat Med, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22820643\">http://www.ncbi.nlm.nih.gov/pubmed/22820643</a></p>\n<p id=\"erb-ae4bdf92-46e7-47f6-b788-766d3cc3d130\"><a name=\"_ENREF_117\"></a> 117. Matin RN, Chikh A, Law Pak Chong S, et al: p63 is an alternative p53 repressor in melanoma that confers chemoresistance and a poor prognosis. J Exp Med, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23420876\">http://www.ncbi.nlm.nih.gov/pubmed/23420876</a></p>\n<p id=\"erb-9a319d87-655d-4703-a3c6-421d80d04328\"><a name=\"_ENREF_118\"></a> 118. Bergamaschi D, Samuels Y, Sullivan A, et al: iASPP preferentially binds p53 proline-rich region and modulates apoptotic function of codon 72-polymorphic p53. Nat Genet 38:1133-41, 2006. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/16964264\">http://www.ncbi.nlm.nih.gov/pubmed/16964264</a></p>\n<p id=\"erb-1dacea00-6fc1-4d24-a3f8-0f07d4cbf492\"><a name=\"_ENREF_119\"></a> 119. Kamb A, Gruis NA, Weaver-Feldhaus J, et al: A cell cycle regulator potentially involved in genesis of many tumor types. Science 264:436-40, 1994. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/8153634\">http://www.ncbi.nlm.nih.gov/pubmed/8153634</a></p>\n<p id=\"erb-d6666cec-b963-4670-883f-0193e941d244\"><a name=\"_ENREF_120\"></a> 120. Kamb A, Shattuck-Eidens D, Eeles R, et al: Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nat Genet 8:23-6, 1994. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/7987388\">http://www.ncbi.nlm.nih.gov/pubmed/7987388</a></p>\n<p id=\"erb-bba42596-edef-4151-8b40-aee9ee2116d6\"><a name=\"_ENREF_121\"></a> 121. Ohta M, Berd D, Shimizu M, et al: Deletion mapping of chromosome region 9p21-p22 surrounding the CDKN2 locus in melanoma. Int J Cancer 65:762-7, 1996. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/8631588\">http://www.ncbi.nlm.nih.gov/pubmed/8631588</a></p>\n<p id=\"erb-c1be19c2-63e8-40e1-bfef-a0a72e1e13af\"><a name=\"_ENREF_122\"></a> 122. Dar AA, Majid S, Rittsteuer C, et al: The role of miR-18b in MDM2-p53 pathway signaling and melanoma progression. J Natl Cancer Inst 105:433-42, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23365201\">http://www.ncbi.nlm.nih.gov/pubmed/23365201</a></p>\n<p id=\"erb-f1cceebc-a833-4d4d-98d1-bcb30c858f17\"><a name=\"_ENREF_123\"></a> 123. Ray-Coquard I, Blay JY, Italiano A, et al: Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study. Lancet Oncol 13:1133-40, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23084521\">http://www.ncbi.nlm.nih.gov/pubmed/23084521</a></p>\n<p id=\"erb-241288f5-3d97-4e0b-9dcc-0eb3a4a0db5d\"><a name=\"_ENREF_124\"></a> 124. Ji Z, Kumar R, Taylor M, et al: Vemurafenib Synergizes with Nutlin-3 to Deplete Survivin and Suppress Melanoma Viability and Tumor Growth. Clin Cancer Res, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23812671\">http://www.ncbi.nlm.nih.gov/pubmed/23812671</a></p>\n<p id=\"erb-7c48bacc-0899-487b-8d71-414e0c7641e7\"><a name=\"_ENREF_125\"></a> 125. Brown CJ, Quah ST, Jong J, et al: Stapled peptides with improved potency and specificity that activate p53. ACS Chem Biol 8:506-12, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23214419\">http://www.ncbi.nlm.nih.gov/pubmed/23214419</a></p>\n<p id=\"erb-2a457cc2-a2df-46bf-8682-1d071e00c61c\"><a name=\"_ENREF_126\"></a> 126. Chang YS, Graves B, Guerlavais V, et al: Stapled alpha-helical peptide drug development: A potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy. Proc Natl Acad Sci U S A, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23946421\">http://www.ncbi.nlm.nih.gov/pubmed/23946421</a></p>\n<p id=\"erb-903f38fc-0256-456d-9ede-6fc66da1a9e1\"><a name=\"_ENREF_127\"></a> 127. Lu M, Breyssens H, Salter V, et al: Restoring p53 Function in Human Melanoma Cells by Inhibiting MDM2 and Cyclin B1/CDK1-Phosphorylated Nuclear iASPP. Cancer Cell, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23623661\">http://www.ncbi.nlm.nih.gov/pubmed/23623661</a></p>\n<p id=\"erb-5d64fbcc-3e54-4869-8c46-797db4585ce5\"><a name=\"_ENREF_128\"></a> 128. Ohanna M, Giuliano S, Bonet C, et al: Senescent cells develop a PARP-1 and nuclear factor-{kappa}B-associated secretome (PNAS). Genes Dev 25:1245-61, 2011. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/21646373\">http://www.ncbi.nlm.nih.gov/pubmed/21646373</a></p>\n<p id=\"erb-5e2f119f-007e-4bc6-9900-eb363986a8a7\"><a name=\"_ENREF_129\"></a> 129. Gartner JJ, Parker SC, Prickett TD, et al: Whole-genome sequencing identifies a recurrent functional synonymous mutation in melanoma. Proc Natl Acad Sci U S A 110:13481-6, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23901115\">http://www.ncbi.nlm.nih.gov/pubmed/23901115</a></p>\n<p id=\"erb-0ee34898-282c-4185-81b5-f21907109398\"><a name=\"_ENREF_130\"></a> 130. Anvekar RA, Asciolla JJ, Lopez-Rivera E, et al: Sensitization to the mitochondrial pathway of apoptosis augments melanoma tumor cell responses to conventional chemotherapeutic regimens. Cell Death Dis 3:e420, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23152056\">http://www.ncbi.nlm.nih.gov/pubmed/23152056</a></p>\n<p id=\"erb-8e30d039-44af-477e-af05-dccbf72cb953\"><a name=\"_ENREF_131\"></a> 131. Reifenberger J, Knobbe CB, Wolter M, et al: Molecular genetic analysis of malignant melanomas for aberrations of the WNT signaling pathway genes CTNNB1, APC, ICAT and BTRC. Int J Cancer 100:549-56, 2002. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/12124804\">http://www.ncbi.nlm.nih.gov/pubmed/12124804</a></p>\n<p id=\"erb-474e44be-c5e7-4e2b-936f-7efcaaab3e7c\"><a name=\"_ENREF_132\"></a> 132. Delmas V, Beermann F, Martinozzi S, et al: Beta-catenin induces immortalization of melanocytes by suppressing p16INK4a expression and cooperates with N-Ras in melanoma development. Genes Dev 21:2923-35, 2007. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/18006687\">http://www.ncbi.nlm.nih.gov/pubmed/18006687</a></p>\n<p id=\"erb-57a696d5-75ff-4427-8ba1-d49005bdb495\"><a name=\"_ENREF_133\"></a> 133. Grossmann AH, Yoo JH, Clancy J, et al: The Small GTPase ARF6 Stimulates beta-Catenin Transcriptional Activity During WNT5A-Mediated Melanoma Invasion and Metastasis. Sci Signal 6:ra14, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23462101\">http://www.ncbi.nlm.nih.gov/pubmed/23462101</a></p>\n<p id=\"erb-6f8c6f16-daa9-4dd7-91c4-017bd571bd5c\"><a name=\"_ENREF_134\"></a> 134. Damsky WE, Curley DP, Santhanakrishnan M, et al: beta-catenin signaling controls metastasis in Braf-activated Pten-deficient melanomas. Cancer Cell 20:741-54, 2011. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22172720\">http://www.ncbi.nlm.nih.gov/pubmed/22172720</a></p>\n<p id=\"erb-27fe5f21-398d-40ec-8333-75081cdcba70\"><a name=\"_ENREF_135\"></a> 135. Biechele TL, Kulikauskas RM, Toroni RA, et al: Wnt/beta-catenin signaling and AXIN1 regulate apoptosis triggered by inhibition of the mutant kinase BRAFV600E in human melanoma. Sci Signal 5:ra3, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22234612\">http://www.ncbi.nlm.nih.gov/pubmed/22234612</a></p>\n<p id=\"erb-fd055581-8a50-42f8-8d20-81409e98da46\"><a name=\"_ENREF_136\"></a> 136. Conrad WH, Swift RD, Biechele TL, et al: Regulating the response to targeted MEK inhibition in melanoma: enhancing apoptosis in NRAS- and BRAF-mutant melanoma cells with Wnt/beta-catenin activation. Cell Cycle 11:3724-30, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22895053\">http://www.ncbi.nlm.nih.gov/pubmed/22895053</a></p>\n<p id=\"erb-7566355c-3856-4cdd-9805-29e73c12fb0a\"><a name=\"_ENREF_137\"></a> 137. Jane-Valbuena J, Widlund HR, Perner S, et al: An oncogenic role for ETV1 in melanoma. Cancer Res 70:2075-84, 2010. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/20160028\">http://www.ncbi.nlm.nih.gov/pubmed/20160028</a></p>\n<p id=\"erb-4c1e01c8-bb5c-46cf-98ff-0366c7b8ff86\"><a name=\"_ENREF_138\"></a> 138. Kim M, Gans JD, Nogueira C, et al: Comparative oncogenomics identifies NEDD9 as a melanoma metastasis gene. Cell 125:1269-81, 2006. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/16814714\">http://www.ncbi.nlm.nih.gov/pubmed/16814714</a></p>\n<p id=\"erb-ed75fac2-6101-4abc-a240-92128c5e067c\"><a name=\"_ENREF_139\"></a> 139. Harbour JW, Onken MD, Roberson ED, et al: Frequent mutation of BAP1 in metastasizing uveal melanomas. Science 330:1410-3, 2010. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/21051595\">http://www.ncbi.nlm.nih.gov/pubmed/21051595</a></p>\n<p id=\"erb-5782fbad-9afa-484e-a304-6b5c31d52b9e\"><a name=\"_ENREF_140\"></a> 140. Wiesner T, Obenauf AC, Murali R, et al: Germline mutations in BAP1 predispose to melanocytic tumors. Nat Genet 43:1018-21, 2011. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/21874003\">http://www.ncbi.nlm.nih.gov/pubmed/21874003</a></p>\n<p id=\"erb-f99ab359-77ce-4ed2-bd99-ace13c1512fd\"><a name=\"_ENREF_141\"></a> 141. Njauw CN, Kim I, Piris A, et al: Germline BAP1 inactivation is preferentially associated with metastatic ocular melanoma and cutaneous-ocular melanoma families. PLoS One 7:e35295, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22545102\">http://www.ncbi.nlm.nih.gov/pubmed/22545102</a></p>\n<p id=\"erb-6d4df9e9-dfd2-4e07-a7ca-bfecf2853945\"><a name=\"_ENREF_142\"></a> 142. Landreville S, Agapova OA, Matatall KA, et al: Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma. Clin Cancer Res 18:408-16, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22038994\">http://www.ncbi.nlm.nih.gov/pubmed/22038994</a></p>\n<p id=\"erb-16990d1b-cc10-4160-b35d-aea65c3a9a84\"><a name=\"_ENREF_143\"></a> 143. Harbour JW, Roberson ED, Anbunathan H, et al: Recurrent mutations at codon 625 of the splicing factor SF3B1 in uveal melanoma. Nat Genet 45:133-5, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23313955\">http://www.ncbi.nlm.nih.gov/pubmed/23313955</a></p>\n<p id=\"erb-068e0264-cf27-4590-b65d-a6390a740966\"><a name=\"_ENREF_144\"></a> 144. Martin M, Masshofer L, Temming P, et al: Exome sequencing identifies recurrent somatic mutations in EIF1AX and SF3B1 in uveal melanoma with disomy 3. Nat Genet, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23793026\">http://www.ncbi.nlm.nih.gov/pubmed/23793026</a></p>\n<p id=\"erb-b51251c0-5bb5-437a-a25b-83eaa11b94bd\"><a name=\"_ENREF_145\"></a> 145. Ghai R, Mobli M, Norwood SJ, et al: Phox homology band 4.1/ezrin/radixin/moesin-like proteins function as molecular scaffolds that interact with cargo receptors and Ras GTPases. Proc Natl Acad Sci U S A 108:7763-8, 2011. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/21512128\">http://www.ncbi.nlm.nih.gov/pubmed/21512128</a></p>\n<p id=\"erb-f1fb8ee8-728c-48b4-af5c-b74bb5f8b09a\"><a name=\"_ENREF_146\"></a> 146. Forbes SA, Bindal N, Bamford S, et al: COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res 39:D945-50, 2011. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/20952405\">http://www.ncbi.nlm.nih.gov/pubmed/20952405</a></p>\n<p id=\"erb-08bccc0f-d9b0-4c9e-b50b-b890ff0a75eb\"><a name=\"_ENREF_147\"></a> 147. Liu W, Monahan KB, Pfefferle AD, et al: LKB1/STK11 inactivation leads to expansion of a prometastatic tumor subpopulation in melanoma. Cancer Cell 21:751-64, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22698401\">http://www.ncbi.nlm.nih.gov/pubmed/22698401</a></p>\n<p id=\"erb-a6aec49f-6715-44e6-a291-c2019a6ef960\"><a name=\"_ENREF_148\"></a> 148. Wei X, Walia V, Lin JC, et al: Exome sequencing identifies GRIN2A as frequently mutated in melanoma. Nat Genet 43:442-6, 2011. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/21499247\">http://www.ncbi.nlm.nih.gov/pubmed/21499247</a></p>\n<p id=\"erb-8607d3b8-cb6e-4be0-af90-21fa1070f032\"><a name=\"_ENREF_149\"></a> 149. Prickett TD, Wei X, Cardenas-Navia I, et al: Exon capture analysis of G protein-coupled receptors identifies activating mutations in GRM3 in melanoma. Nat Genet 43:1119-26, 2011. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/21946352\">http://www.ncbi.nlm.nih.gov/pubmed/21946352</a></p>\n<p id=\"erb-6c511563-fb71-4d4c-aa32-63313ceafcb3\"><a name=\"_ENREF_150\"></a> 150. Namkoong J, Shin SS, Lee HJ, et al: Metabotropic glutamate receptor 1 and glutamate signaling in human melanoma. Cancer Res 67:2298-305, 2007. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/17332361\">http://www.ncbi.nlm.nih.gov/pubmed/17332361</a></p>\n<p id=\"erb-fc0a2aa1-21a6-4c1d-b81b-b551bbc64249\"><a name=\"_ENREF_151\"></a> 151. Locasale JW, Grassian AR, Melman T, et al: Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. Nat Genet 43:869-74, 2011. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/21804546\">http://www.ncbi.nlm.nih.gov/pubmed/21804546</a></p>\n<p id=\"erb-b854395a-8e57-4075-8294-def4f1d2b92b\"><a name=\"_ENREF_152\"></a> 152. Magnussen GI, Holm R, Emilsen E, et al: High expression of Wee1 is associated with poor disease-free survival in malignant melanoma: potential for targeted therapy. PLoS One 7:e38254, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22719872\">http://www.ncbi.nlm.nih.gov/pubmed/22719872</a></p>\n<p id=\"erb-3bbc93fd-aa78-4b74-9ccd-1fdf70faab2a\"><a name=\"_ENREF_153\"></a> 153. Namiki T, Tanemura A, Valencia JC, et al: AMP kinase-related kinase NUAK2 affects tumor growth, migration, and clinical outcome of human melanoma. Proc Natl Acad Sci U S A 108:6597-602, 2011. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/21460252\">http://www.ncbi.nlm.nih.gov/pubmed/21460252</a></p>\n<p id=\"erb-0dc6fbcc-5309-4003-9e2f-cc5607a59e2c\"><a name=\"_ENREF_154\"></a> 154. van den Hurk K, Niessen HE, Veeck J, et al: Genetics and epigenetics of cutaneous malignant melanoma: A concert out of tune. Biochim Biophys Acta 1826:89-102, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22503822\">http://www.ncbi.nlm.nih.gov/pubmed/22503822</a></p>\n<p id=\"erb-27c6f35b-1ea0-4e6d-82d0-875a04560315\"><a name=\"_ENREF_155\"></a> 155. Smalley KS, Haass NK, Brafford PA, et al: Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Mol Cancer Ther 5:1136-44, 2006. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/16731745\">http://www.ncbi.nlm.nih.gov/pubmed/16731745</a></p>\n<p id=\"erb-8f74b63b-581f-4984-bc7e-e881a2dae2aa\"><a name=\"_ENREF_156\"></a> 156. Paraiso KH, Xiang Y, Rebecca VW, et al: PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res 71:2750-60, 2011. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/21317224\">http://www.ncbi.nlm.nih.gov/pubmed/21317224</a></p>\n<p id=\"erb-3a2305de-6ecf-4e24-8385-90fda923976d\"><a name=\"_ENREF_157\"></a> 157. Smalley KS, Lioni M, Dalla Palma M, et al: Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas. Mol Cancer Ther 7:2876-83, 2008. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/18790768\">http://www.ncbi.nlm.nih.gov/pubmed/18790768</a></p>\n<p id=\"erb-5efa0e2f-d575-43d8-9732-5341386df617\"><a name=\"_ENREF_158\"></a> 158. McArthur GA, Puzanov I, Amaravadi R, et al: Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma. J Clin Oncol 30:1628-34, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22454415\">http://www.ncbi.nlm.nih.gov/pubmed/22454415</a></p>\n<p id=\"erb-b04b1359-7944-4021-8cb2-c2487c12bf09\"><a name=\"_ENREF_159\"></a> 159. Vergani E, Vallacchi V, Frigerio S, et al: Identification of MET and SRC activation in melanoma cell lines showing primary resistance to PLX4032. Neoplasia 13:1132-42, 2011. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22241959\">http://www.ncbi.nlm.nih.gov/pubmed/22241959</a></p>\n<p id=\"erb-8b0a6870-6477-47e6-b5cb-1e693de432d5\"><a name=\"_ENREF_160\"></a> 160. Straussman R, Morikawa T, Shee K, et al: Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 487:500-4, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22763439\">http://www.ncbi.nlm.nih.gov/pubmed/22763439</a></p>\n<p id=\"erb-fb3bf95b-b30f-41db-98d7-215a42ff4dbb\"><a name=\"_ENREF_161\"></a> 161. Wroblewski D, Mijatov B, Mohana-Kumaran N, et al: The BH3-mimetic ABT-737 sensitizes human melanoma cells to apoptosis induced by selective BRAF inhibitors but does not reverse acquired resistance. Carcinogenesis, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23087082\">http://www.ncbi.nlm.nih.gov/pubmed/23087082</a></p>\n<p id=\"erb-8a955a05-7c47-4338-93aa-2af6eb3bf7c5\"><a name=\"_ENREF_162\"></a> 162. Haq R, Shoag J, Andreu-Perez P, et al: Oncogenic BRAF Regulates Oxidative Metabolism via PGC1alpha and MITF. Cancer Cell 23:302-15, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23477830\">http://www.ncbi.nlm.nih.gov/pubmed/23477830</a></p>\n<p id=\"erb-ed78e7d7-4ae1-43e4-a604-e81ad735c1f4\"><a name=\"_ENREF_163\"></a> 163. Basile KJ, Abel EV, Aplin AE: Adaptive upregulation of FOXD3 and resistance to PLX4032/4720-induced cell death in mutant B-RAF melanoma cells. Oncogene 31:2471-9, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/21996740\">http://www.ncbi.nlm.nih.gov/pubmed/21996740</a></p>\n<p id=\"erb-24c7acce-07a8-4e24-b210-dc9036cbbf7d\"><a name=\"_ENREF_164\"></a> 164. Abel EV, Basile KJ, Kugel CH, 3rd, et al: Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3. J Clin Invest, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23543055\">http://www.ncbi.nlm.nih.gov/pubmed/23543055</a></p>\n<p id=\"erb-c74ee03a-2b26-4506-b124-fed63bd2a591\"><a name=\"_ENREF_165\"></a> 165. Paraiso KH, Haarberg HE, Wood E, et al: The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms. Clin Cancer Res 18:2502-14, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22351686\">http://www.ncbi.nlm.nih.gov/pubmed/22351686</a></p>\n<p id=\"erb-483602dc-fc6b-4a55-bde0-54245b427323\"><a name=\"_ENREF_166\"></a> 166. Deng W, Gopal YN, Scott A, et al: Role and therapeutic potential of PI3K-mTOR signaling in de novo resistance to BRAF inhibition. Pigment Cell Melanoma Res 25:248-58, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22171948\">http://www.ncbi.nlm.nih.gov/pubmed/22171948</a></p>\n<p id=\"erb-da796d99-575b-4d34-afe4-85834b3d48e4\"><a name=\"_ENREF_167\"></a> 167. Corcoran RB, Rothenberg SM, Hata AN, et al: TORC1 Suppression Predicts Responsiveness to RAF and MEK Inhibition in BRAF-Mutant Melanoma. Sci Transl Med 5:196ra98, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23903755\">http://www.ncbi.nlm.nih.gov/pubmed/23903755</a></p>\n<p id=\"erb-598ea424-d26e-4018-80fc-e821adfe8593\"><a name=\"_ENREF_168\"></a> 168. Smith MP, Ferguson J, Arozarena I, et al: Effect of SMURF2 Targeting on Susceptibility to MEK Inhibitors in Melanoma. J Natl Cancer Inst 105:33-46, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23250956\">http://www.ncbi.nlm.nih.gov/pubmed/23250956</a></p>\n<p id=\"erb-dc8ceab9-21db-4ada-b07a-dbbd8761664f\"><a name=\"_ENREF_169\"></a> 169. Byron SA, Loch DC, Wellens CL, et al: Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status. Mol Cancer 11:75, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23039341\">http://www.ncbi.nlm.nih.gov/pubmed/23039341</a></p>\n<p id=\"erb-af7eafe8-57db-45f3-b655-f3f52f258d6f\"><a name=\"_ENREF_170\"></a> 170. Shimizu T, Tolcher AW, Papadopoulos KP, et al: The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer. Clin Cancer Res 18:2316-25, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22261800\">http://www.ncbi.nlm.nih.gov/pubmed/22261800</a></p>\n<p id=\"erb-1eea30bb-6431-4910-9c8c-5d8373f4b819\"><a name=\"_ENREF_171\"></a> 171. Zmajkovicova K, Jesenberger V, Catalanotti F, et al: MEK1 Is Required for PTEN Membrane Recruitment, AKT Regulation, and the Maintenance of Peripheral Tolerance. Mol Cell 50:43-55, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23453810\">http://www.ncbi.nlm.nih.gov/pubmed/23453810</a></p>\n<p id=\"erb-57b288d9-394a-4094-848e-3038fc9fa75f\"><a name=\"_ENREF_172\"></a> 172. Sondergaard JN, Nazarian R, Wang Q, et al: Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032. J Transl Med 8:39, 2010. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/20406486\">http://www.ncbi.nlm.nih.gov/pubmed/20406486</a></p>\n<p id=\"erb-75d90816-6828-410b-92f6-bcf7b6061d23\"><a name=\"_ENREF_173\"></a> 173. Wilson TR, Fridlyand J, Yan Y, et al: Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 487:505-9, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22763448\">http://www.ncbi.nlm.nih.gov/pubmed/22763448</a></p>\n<p id=\"erb-50bae73a-e5f7-45ac-8221-c4bd4a676378\"><a name=\"_ENREF_174\"></a> 174. Catalanotti F, Solit DB: Will Hsp90 inhibitors prove effective in BRAF-mutant melanomas? Clin Cancer Res 18:2420-2, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22442059\">http://www.ncbi.nlm.nih.gov/pubmed/22442059</a></p>\n<p id=\"erb-4eda61d4-d9fd-446b-8ff0-e98f084c58d1\"><a name=\"_ENREF_175\"></a> 175. Haarberg HE, Paraiso KH, Wood E, et al: Inhibition of Wee1, AKT and CDK4 underlies the efficacy of the HSP90 inhibitor XL888 in an in vivo model of NRAS mutant melanoma. Mol Cancer Ther, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23538902\">http://www.ncbi.nlm.nih.gov/pubmed/23538902</a></p>\n<p id=\"erb-7918ab7e-2df2-4f1a-8fb4-0820e8318f74\"><a name=\"_ENREF_176\"></a> 176. Poulikakos PI, Persaud Y, Janakiraman M, et al: RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 480:387-90, 2011. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22113612\">http://www.ncbi.nlm.nih.gov/pubmed/22113612</a></p>\n<p id=\"erb-27f0b360-3509-4c84-a4c2-3fe8c42782e3\"><a name=\"_ENREF_177\"></a> 177. Romano E, Pradervand S, Paillusson A, et al: Identification of Multiple Mechanisms of Resistance to Vemurafenib in a Patient with BRAFV600E-Mutated Cutaneous Melanoma Successfully Rechallenged after Progression. Clin Cancer Res, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23948972\">http://www.ncbi.nlm.nih.gov/pubmed/23948972</a></p>\n<p id=\"erb-6957e100-0207-4cf5-bc75-42f2f359d7b4\"><a name=\"_ENREF_178\"></a> 178. Shi H, Moriceau G, Kong X, et al: Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat Commun 3:724, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22395615\">http://www.ncbi.nlm.nih.gov/pubmed/22395615</a></p>\n<p id=\"erb-a375cea9-460d-449c-b034-3398cf186b54\"><a name=\"_ENREF_179\"></a> 179. Girotti MR, Pedersen M, Sanchez-Laorden B, et al: Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma. Cancer Discov, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23242808\">http://www.ncbi.nlm.nih.gov/pubmed/23242808</a></p>\n<p id=\"erb-95f77362-d2f2-46fb-b787-5e4e694693cc\"><a name=\"_ENREF_180\"></a> 180. Yadav V, Zhang X, Liu J, et al: Reactivation of mitogen-activated protein kinase (MAPK) pathway by FGF receptor 3 (FGFR3)/Ras mediates resistance to vemurafenib in human B-RAF V600E mutant melanoma. J Biol Chem 287:28087-98, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22730329\">http://www.ncbi.nlm.nih.gov/pubmed/22730329</a></p>\n<p id=\"erb-847a97d0-19f3-4081-8612-254256aa904d\"><a name=\"_ENREF_181\"></a> 181. Villanueva J, Vultur A, Lee JT, et al: Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 18:683-95, 2010. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/21156289\">http://www.ncbi.nlm.nih.gov/pubmed/21156289</a></p>\n<p id=\"erb-f16fcba2-183f-4b97-a55a-995b677db2ea\"><a name=\"_ENREF_182\"></a> 182. Fattore L, Marra E, Pisanu ME, et al: Activation of an early feedback survival loop involving phospho-ErbB3 is a general response of melanoma cells to RAF/MEK inhibition and is abrogated by anti-ErbB3 antibodies. J Transl Med 11:180, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23890105\">http://www.ncbi.nlm.nih.gov/pubmed/23890105</a></p>\n<p id=\"erb-4bc74b28-6f42-4e0e-a224-9ded4b551ac3\"><a name=\"_ENREF_183\"></a> 183. Nazarian R, Shi H, Wang Q, et al: Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468:973-7, 2010. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/21107323\">http://www.ncbi.nlm.nih.gov/pubmed/21107323</a></p>\n<p id=\"erb-fa554ebb-e85a-44dd-9d03-d5c553de712b\"><a name=\"_ENREF_184\"></a> 184. Johannessen CM, Boehm JS, Kim SY, et al: COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 468:968-72, 2010. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/21107320\">http://www.ncbi.nlm.nih.gov/pubmed/21107320</a></p>\n<p id=\"erb-d32254c1-0775-4f56-9ba1-b394a693bca8\"><a name=\"_ENREF_185\"></a> 185. Wagle N, Emery C, Berger MF, et al: Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol 29:3085-96, 2011. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/21383288\">http://www.ncbi.nlm.nih.gov/pubmed/21383288</a></p>\n<p id=\"erb-a06be7bc-f7be-4af3-98c7-59e0c0a45d2f\"><a name=\"_ENREF_186\"></a> 186. Trunzer K, Pavlick AC, Schuchter L, et al: Pharmacodynamic Effects and Mechanisms of Resistance to Vemurafenib in Patients With Metastatic Melanoma. J Clin Oncol, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23569304\">http://www.ncbi.nlm.nih.gov/pubmed/23569304</a></p>\n<p id=\"erb-83016b6e-d11a-41ee-b67b-9ff86d19245e\"><a name=\"_ENREF_187\"></a> 187. Emery CM, Vijayendran KG, Zipser MC, et al: MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci U S A 106:20411-6, 2009. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/19915144\">http://www.ncbi.nlm.nih.gov/pubmed/19915144</a></p>\n<p id=\"erb-6f880c6c-506f-4e58-9af1-6c041cd4820f\"><a name=\"_ENREF_188\"></a> 188. Shao Y, Aplin AE: Akt3-mediated resistance to apoptosis in B-RAF-targeted melanoma cells. Cancer Res 70:6670-81, 2010. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/20647317\">http://www.ncbi.nlm.nih.gov/pubmed/20647317</a></p>\n<p id=\"erb-109b755b-d32d-4080-b5fd-fff5238095f7\"><a name=\"_ENREF_189\"></a> 189. Jiang CC, Lai F, Thorne RF, et al: MEK-independent survival of B-RAFV600E melanoma cells selected for resistance to apoptosis induced by the RAF inhibitor PLX4720. Clin Cancer Res 17:721-30, 2011. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/21088259\">http://www.ncbi.nlm.nih.gov/pubmed/21088259</a></p>\n<p id=\"erb-a392aa18-3e23-425e-8f99-8c9a403ce070\"><a name=\"_ENREF_190\"></a> 190. Klein RM, Higgins PJ: A switch in RND3-RHOA signaling is critical for melanoma cell invasion following mutant-BRAF inhibition. Mol Cancer 10:114, 2011. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/21917148\">http://www.ncbi.nlm.nih.gov/pubmed/21917148</a></p>\n<p id=\"erb-021a617e-27bb-4813-bb30-bed376bef1ec\"><a name=\"_ENREF_191\"></a> 191. Reuveni H, Flashner-Abramson E, Steiner L, et al: Therapeutic destruction of insulin receptor substrates for cancer treatment. Cancer Res 73:4383-94, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23651636\">http://www.ncbi.nlm.nih.gov/pubmed/23651636</a></p>\n<p id=\"erb-7e042c80-eacf-4879-857e-c5cbf2759948\"><a name=\"_ENREF_192\"></a> 192. Villanueva J, Infante JR, Krepler C, et al: Concurrent MEK2 Mutation and BRAF Amplification Confer Resistance to BRAF and MEK Inhibitors in Melanoma. Cell Rep, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/24055054\">http://www.ncbi.nlm.nih.gov/pubmed/24055054</a></p>\n<p id=\"erb-508af8b0-2e40-4d4c-8156-68ac7d8e1250\"><a name=\"_ENREF_193\"></a> 193. Sullivan RJ, Flaherty KT: Resistance to BRAF-targeted therapy in melanoma. Eur J Cancer, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23290787\">http://www.ncbi.nlm.nih.gov/pubmed/23290787</a></p>\n<p id=\"erb-83225385-3195-4adc-bd58-a806efa784eb\"><a name=\"_ENREF_194\"></a> 194. Morris EJ, Jha S, Restino CR, et al: Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. Cancer Discov, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23614898\">http://www.ncbi.nlm.nih.gov/pubmed/23614898</a></p>\n<p id=\"erb-ff6e88cc-b08a-4181-9b27-a4c64ca1ca17\"><a name=\"_ENREF_195\"></a> 195. Duncan JS, Whittle MC, Nakamura K, et al: Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. Cell 149:307-21, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22500798\">http://www.ncbi.nlm.nih.gov/pubmed/22500798</a></p>\n<p id=\"erb-201df5b1-9fbe-4fee-812d-0ed5a51f7fa6\"><a name=\"_ENREF_196\"></a> 196. Gopal YN, Deng W, Woodman SE, et al: Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells. Cancer Res 70:8736-47, 2010. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/20959481\">http://www.ncbi.nlm.nih.gov/pubmed/20959481</a></p>\n<p id=\"erb-1165f917-dfb9-47df-8353-95bcdb794e02\"><a name=\"_ENREF_197\"></a> 197. Roller DG, Axelrod M, Capaldo BJ, et al: Synthetic lethal screening with small-molecule inhibitors provides a pathway to rational combination therapies for melanoma. Mol Cancer Ther 11:2505-15, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22962324\">http://www.ncbi.nlm.nih.gov/pubmed/22962324</a></p>\n<p id=\"erb-c788b2f9-b20a-4d60-bd40-4c11c1a1c0e2\"><a name=\"_ENREF_198\"></a> 198. Kawakami Y, Eliyahu S, Delgado CH, et al: Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci U S A 91:3515-9, 1994. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/8170938\">http://www.ncbi.nlm.nih.gov/pubmed/8170938</a></p>\n<p id=\"erb-c79e0e5a-6873-4132-837f-e7f72467fca6\"><a name=\"_ENREF_199\"></a> 199. Slingluff CL, Jr., Petroni GR, Yamshchikov GV, et al: Immunologic and clinical outcomes of vaccination with a multiepitope melanoma peptide vaccine plus low-dose interleukin-2 administered either concurrently or on a delayed schedule. J Clin Oncol 22:4474-85, 2004. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/15542798\">http://www.ncbi.nlm.nih.gov/pubmed/15542798</a></p>\n<p id=\"erb-b6982816-5499-4df8-bd6e-2518927cfa6c\"><a name=\"_ENREF_200\"></a> 200. Rosenberg SA, Yang JC, Restifo NP: Cancer immunotherapy: moving beyond current vaccines. Nat Med 10:909-15, 2004. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/15340416\">http://www.ncbi.nlm.nih.gov/pubmed/15340416</a></p>\n<p id=\"erb-1e7ef0bd-7a6d-45eb-9e71-12e6d7d03f2f\"><a name=\"_ENREF_201\"></a> 201. Spranger S, Spaapen RM, Zha Y, et al: Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells. Sci Transl Med 5:200ra116, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23986400\">http://www.ncbi.nlm.nih.gov/pubmed/23986400</a></p>\n<p id=\"erb-d85bd2e4-0067-46b5-9de9-dd494780a735\"><a name=\"_ENREF_202\"></a> 202. van Elsas A, Hurwitz AA, Allison JP: Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med 190:355-66, 1999. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/10430624\">http://www.ncbi.nlm.nih.gov/pubmed/10430624</a></p>\n<p id=\"erb-156093c5-7858-4faa-83ec-064f30254bba\"><a name=\"_ENREF_203\"></a> 203. Atkins MB, Lotze MT, Dutcher JP, et al: High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 17:2105-16, 1999. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/10561265\">http://www.ncbi.nlm.nih.gov/pubmed/10561265</a></p>\n<p id=\"erb-2dad7f69-4dec-43ce-814a-9d47611e4a6a\"><a name=\"_ENREF_204\"></a> 204. Hodi FS, O'Day SJ, McDermott DF, et al: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711-23, 2010. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/20525992\">http://www.ncbi.nlm.nih.gov/pubmed/20525992</a></p>\n<p id=\"erb-12f60fea-9f8a-46ed-8dda-5ea278d63bce\"><a name=\"_ENREF_205\"></a> 205. Robbins PF, Lu YC, El-Gamil M, et al: Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med 19:747-52, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23644516\">http://www.ncbi.nlm.nih.gov/pubmed/23644516</a></p>\n<p id=\"erb-49de2a6d-1d4a-4e5e-bc14-9266bf34df25\"><a name=\"_ENREF_206\"></a> 206. Ascierto PA, Kalos M, Schaer DA, et al: Biomarkers for Immunostimulatory Monoclonal Antibodies in Combination Strategies for Melanoma and Other Tumor Types. Clin Cancer Res 19:1009-1020, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23460532\">http://www.ncbi.nlm.nih.gov/pubmed/23460532</a></p>\n<p id=\"erb-1de2387d-3f6a-43c0-a082-cf94cce8b012\"><a name=\"_ENREF_207\"></a> 207. Peggs KS, Quezada SA, Chambers CA, et al: Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med 206:1717-25, 2009. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/19581407\">http://www.ncbi.nlm.nih.gov/pubmed/19581407</a></p>\n<p id=\"erb-87a62682-2cf3-4ede-92a1-9c8f312139dc\"><a name=\"_ENREF_208\"></a> 208. Contardi E, Palmisano GL, Tazzari PL, et al: CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction. Int J Cancer 117:538-50, 2005. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/15912538\">http://www.ncbi.nlm.nih.gov/pubmed/15912538</a></p>\n<p id=\"erb-7ea9ef92-9eab-428c-8859-7b49185c67f1\"><a name=\"_ENREF_209\"></a> 209. Shah KV, Chien AJ, Yee C, et al: CTLA-4 is a direct target of Wnt/beta-catenin signaling and is expressed in human melanoma tumors. J Invest Dermatol 128:2870-9, 2008. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/18563180\">http://www.ncbi.nlm.nih.gov/pubmed/18563180</a></p>\n<p id=\"erb-9daa6cfe-ce0e-4c0b-9516-243fe3f8d5ab\"><a name=\"_ENREF_210\"></a> 210. Sapoznik S, Hammer O, Ortenberg R, et al: Novel anti-melanoma immunotherapies: disarming tumor escape mechanisms. Clin Dev Immunol 2012:818214, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22778766\">http://www.ncbi.nlm.nih.gov/pubmed/22778766</a></p>\n<p id=\"erb-640c0067-2cb2-4cb5-a7db-25a399f748f8\"><a name=\"_ENREF_211\"></a> 211. Hamid O, Schmidt H, Nissan A, et al: A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. J Transl Med 9:204, 2011. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22123319\">http://www.ncbi.nlm.nih.gov/pubmed/22123319</a></p>\n<p id=\"erb-8532a23c-d441-403e-91ec-c450840ed39a\"><a name=\"_ENREF_212\"></a> 212. Holmgaard RB, Zamarin D, Munn DH, et al: Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. J Exp Med, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23752227\">http://www.ncbi.nlm.nih.gov/pubmed/23752227</a></p>\n<p id=\"erb-3b58d6d5-508a-4fce-98c0-ccc01eb76058\"><a name=\"_ENREF_213\"></a> 213. Iwai Y, Ishida M, Tanaka Y, et al: Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A 99:12293-7, 2002. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/12218188\">http://www.ncbi.nlm.nih.gov/pubmed/12218188</a></p>\n<p id=\"erb-f1c2b71c-569c-406b-b0ac-67f038fddd69\"><a name=\"_ENREF_214\"></a> 214. Freeman GJ, Long AJ, Iwai Y, et al: Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 192:1027-34, 2000. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/11015443\">http://www.ncbi.nlm.nih.gov/pubmed/11015443</a></p>\n<p id=\"erb-b7830649-bee1-4651-996d-806adb21e99d\"><a name=\"_ENREF_215\"></a> 215. Ahmadzadeh M, Johnson LA, Heemskerk B, et al: Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 114:1537-44, 2009. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/19423728\">http://www.ncbi.nlm.nih.gov/pubmed/19423728</a></p>\n<p id=\"erb-db829523-64d6-4f0e-8449-6b5c812e02b6\"><a name=\"_ENREF_216\"></a> 216. Topalian SL, Hodi FS, Brahmer JR, et al: Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443-54, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22658127\">http://www.ncbi.nlm.nih.gov/pubmed/22658127</a></p>\n<p id=\"erb-cd1279cd-b21b-4266-b715-9ce25e21c83a\"><a name=\"_ENREF_217\"></a> 217. Lipson EJ, Sharfman WH, Drake CG, et al: Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody. Clin Cancer Res 19:462-8, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23169436\">http://www.ncbi.nlm.nih.gov/pubmed/23169436</a></p>\n<p id=\"erb-1751fdb8-aa02-4a32-af21-3b9b33cadd82\"><a name=\"_ENREF_218\"></a> 218. Hamid O, Robert C, Daud A, et al: Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma. N Engl J Med, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23724846\">http://www.ncbi.nlm.nih.gov/pubmed/23724846</a></p>\n<p id=\"erb-29d0c219-e4b5-4584-97f1-ff89bd890e3d\"><a name=\"_ENREF_219\"></a> 219. Brahmer JR, Tykodi SS, Chow LQ, et al: Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366:2455-65, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22658128\">http://www.ncbi.nlm.nih.gov/pubmed/22658128</a></p>\n<p id=\"erb-bddaca63-1854-4c64-9c89-e3c56bd02953\"><a name=\"_ENREF_220\"></a> 220. Curran MA, Montalvo W, Yagita H, et al: PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A 107:4275-80, 2010. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/20160101\">http://www.ncbi.nlm.nih.gov/pubmed/20160101</a></p>\n<p id=\"erb-838e5445-3df4-4c5b-b10c-2337d359c254\"><a name=\"_ENREF_221\"></a> 221. Wolchok JD, Kluger H, Callahan MK, et al: Nivolumab plus Ipilimumab in Advanced Melanoma. N Engl J Med, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23724867\">http://www.ncbi.nlm.nih.gov/pubmed/23724867</a></p>\n<p id=\"erb-7155ca63-e7ae-4210-96d8-e35c680f0f52\"><a name=\"_ENREF_222\"></a> 222. Chacon JA, Wu RC, Sukhumalchandra P, et al: Co-Stimulation through 4-1BB/CD137 Improves the Expansion and Function of CD8(+) Melanoma Tumor-Infiltrating Lymphocytes for Adoptive T-Cell Therapy. PLoS One 8:e60031, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23560068\">http://www.ncbi.nlm.nih.gov/pubmed/23560068</a></p>\n<p id=\"erb-6e8999a4-ce11-4ff5-9887-d63d1edda935\"><a name=\"_ENREF_223\"></a> 223. Vonderheide RH, Flaherty KT, Khalil M, et al: Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clin Oncol 25:876-83, 2007. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/17327609\">http://www.ncbi.nlm.nih.gov/pubmed/17327609</a></p>\n<p id=\"erb-aa738bac-b47d-49af-becd-7909883d14ea\"><a name=\"_ENREF_224\"></a> 224. Schwartzentruber DJ, Lawson DH, Richards JM, et al: gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med 364:2119-27, 2011. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/21631324\">http://www.ncbi.nlm.nih.gov/pubmed/21631324</a></p>\n<p id=\"erb-1b4a2fe2-f297-4530-8018-da419c916090\"><a name=\"_ENREF_225\"></a> 225. Prieto PA, Yang JC, Sherry RM, et al: CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin Cancer Res 18:2039-47, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22271879\">http://www.ncbi.nlm.nih.gov/pubmed/22271879</a></p>\n<p id=\"erb-06fe3599-2bdd-434a-a013-60798dea5e3b\"><a name=\"_ENREF_226\"></a> 226. Petrella TM, Tozer R, Belanger K, et al: Interleukin-21 has activity in patients with metastatic melanoma: a phase II study. J Clin Oncol 30:3396-401, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22915661\">http://www.ncbi.nlm.nih.gov/pubmed/22915661</a></p>\n<p id=\"erb-b9899058-3c2f-4836-94c6-4fa2bb69c1c4\"><a name=\"_ENREF_227\"></a> 227. Galluzzi L, Vacchelli E, Eggermont A, et al: Trial Watch: Adoptive cell transfer immunotherapy. Oncoimmunology 1:306-315, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22737606\">http://www.ncbi.nlm.nih.gov/pubmed/22737606</a></p>\n<p id=\"erb-0a3b28d1-ddd7-47d0-bbbb-988ce2cdecd2\"><a name=\"_ENREF_228\"></a> 228. Itzhaki O, Levy D, Zikich D, et al: Adoptive T-cell transfer in melanoma. Immunotherapy 5:79-90, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23256800\">http://www.ncbi.nlm.nih.gov/pubmed/23256800</a></p>\n<p id=\"erb-2b3d215a-f0e0-4302-b9a6-025ce01fed3c\"><a name=\"_ENREF_229\"></a> 229. Rosenberg SA, Yang JC, Sherry RM, et al: Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 17:4550-7, 2011. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/21498393\">http://www.ncbi.nlm.nih.gov/pubmed/21498393</a></p>\n<p id=\"erb-6c3056b9-ed2e-4a1b-acb8-8bc06955f7ab\"><a name=\"_ENREF_230\"></a> 230. Purwar R, Schlapbach C, Xiao S, et al: Robust tumor immunity to melanoma mediated by interleukin-9-producing T cells. Nat Med, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22772464\">http://www.ncbi.nlm.nih.gov/pubmed/22772464</a></p>\n<p id=\"erb-b84b4adc-7228-4a88-9784-46c005c36970\"><a name=\"_ENREF_231\"></a> 231. Ellebaek E, Iversen TZ, Junker N, et al: Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients. J Transl Med 10:169, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22909342\">http://www.ncbi.nlm.nih.gov/pubmed/22909342</a></p>\n<p id=\"erb-7f480719-47a5-4a67-ae1f-6f25b3448177\"><a name=\"_ENREF_232\"></a> 232. Hirschhorn-Cymerman D, Budhu S, Kitano S, et al: Induction of tumoricidal function in CD4+ T cells is associated with concomitant memory and terminally differentiated phenotype. J Exp Med 209:2113-26, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23008334\">http://www.ncbi.nlm.nih.gov/pubmed/23008334</a></p>\n<p id=\"erb-22012e34-8f30-46dc-b524-1ff0f5872a46\"><a name=\"_ENREF_233\"></a> 233. Wang A, Chandran S, Shah SA, et al: The stoichiometric production of IL-2 and IFN-gamma mRNA defines memory T cells that can self-renew after adoptive transfer in humans. Sci Transl Med 4:149ra120, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22932225\">http://www.ncbi.nlm.nih.gov/pubmed/22932225</a></p>\n<p id=\"erb-e182d41a-eaa7-448f-9c13-e305400441aa\"><a name=\"_ENREF_234\"></a> 234. Landsberg J, Kohlmeyer J, Renn M, et al: Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation. Nature 490:412-6, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23051752\">http://www.ncbi.nlm.nih.gov/pubmed/23051752</a></p>\n<p id=\"erb-cefcce02-77bd-42f3-8850-ab4757b73dfd\"><a name=\"_ENREF_235\"></a> 235. Kodumudi KN, Weber A, Sarnaik AA, et al: Blockade of myeloid-derived suppressor cells after induction of lymphopenia improves adoptive T cell therapy in a murine model of melanoma. J Immunol 189:5147-54, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23100512\">http://www.ncbi.nlm.nih.gov/pubmed/23100512</a></p>\n<p id=\"erb-9d69739a-4b4f-4549-aa0f-020b2f81b954\"><a name=\"_ENREF_236\"></a> 236. Lu YC, Yao X, Li YF, et al: Mutated PPP1R3B Is Recognized by T Cells Used To Treat a Melanoma Patient Who Experienced a Durable Complete Tumor Regression. J Immunol 190:6034-42, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23690473\">http://www.ncbi.nlm.nih.gov/pubmed/23690473</a></p>\n<p id=\"erb-7fa39f51-06dd-4e4e-909b-3a3202f741fd\"><a name=\"_ENREF_237\"></a> 237. Radvanyi LG, Bernatchez C, Zhang M, et al: Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. Clin Cancer Res 18:6758-70, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23032743\">http://www.ncbi.nlm.nih.gov/pubmed/23032743</a></p>\n<p id=\"erb-067d11f9-810e-40ff-9c5a-fc1e3352b6c7\"><a name=\"_ENREF_238\"></a> 238. Dudley ME, Gross CA, Somerville RP, et al: Randomized Selection Design Trial Evaluating CD8+-Enriched Versus Unselected Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy for Patients With Melanoma. J Clin Oncol 31:2152-9, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23650429\">http://www.ncbi.nlm.nih.gov/pubmed/23650429</a></p>\n<p id=\"erb-318b5ca1-fd36-444a-810b-f65700ec0093\"><a name=\"_ENREF_239\"></a> 239. Butler MO, Friedlander P, Milstein MI, et al: Establishment of antitumor memory in humans using in vitro-educated CD8+ T cells. Sci Transl Med 3:80ra34, 2011. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/21525398\">http://www.ncbi.nlm.nih.gov/pubmed/21525398</a></p>\n<p id=\"erb-c0a45c4c-7a4a-4e5a-9af6-922f5c9f9b0f\"><a name=\"_ENREF_240\"></a> 240. Kershaw MH, Westwood JA, Darcy PK: Gene-engineered T cells for cancer therapy. Nat Rev Cancer 13:525-41, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23880905\">http://www.ncbi.nlm.nih.gov/pubmed/23880905</a></p>\n<p id=\"erb-2dd069bd-c75c-48c5-a563-ea7524d2bd5f\"><a name=\"_ENREF_241\"></a> 241. Stauss HJ, Morris EC: Immunotherapy with gene-modified T cells: limiting side effects provides new challenges. Gene Ther, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23804078\">http://www.ncbi.nlm.nih.gov/pubmed/23804078</a></p>\n<p id=\"erb-e7f508e6-c9fc-4c2e-8d2c-d4303827bd6e\"><a name=\"_ENREF_242\"></a> 242. Robbins PF, Morgan RA, Feldman SA, et al: Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol 29:917-24, 2011. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/21282551\">http://www.ncbi.nlm.nih.gov/pubmed/21282551</a></p>\n<p id=\"erb-630307e6-44d2-42dc-a2c6-8cc64b6231ad\"><a name=\"_ENREF_243\"></a> 243. Hunder NN, Wallen H, Cao J, et al: Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med 358:2698-703, 2008. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/18565862\">http://www.ncbi.nlm.nih.gov/pubmed/18565862</a></p>\n<p id=\"erb-ba02d7ec-635f-4770-826f-1e1a7890cda9\"><a name=\"_ENREF_244\"></a> 244. Braumuller H, Wieder T, Brenner E, et al: T-helper-1-cell cytokines drive cancer into senescence. Nature, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23376950\">http://www.ncbi.nlm.nih.gov/pubmed/23376950</a></p>\n<p id=\"erb-b939b558-b8a2-491a-a0b1-6467fac08794\"><a name=\"_ENREF_245\"></a> 245. Palucka K, Banchereau J: Cancer immunotherapy via dendritic cells. Nat Rev Cancer 12:265-77, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22437871\">http://www.ncbi.nlm.nih.gov/pubmed/22437871</a></p>\n<p id=\"erb-606f4b9b-5e66-4cc1-bbbe-8a5dd3556151\"><a name=\"_ENREF_246\"></a> 246. Nestle FO, Alijagic S, Gilliet M, et al: Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 4:328-32, 1998. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/9500607\">http://www.ncbi.nlm.nih.gov/pubmed/9500607</a></p>\n<p id=\"erb-dff5daf3-71d3-44f9-94e5-984a7a9a80d1\"><a name=\"_ENREF_247\"></a> 247. Thurner B, Haendle I, Roder C, et al: Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 190:1669-78, 1999. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/10587357\">http://www.ncbi.nlm.nih.gov/pubmed/10587357</a></p>\n<p id=\"erb-f92dac1f-6d3f-419d-ae54-43b6dae62d7d\"><a name=\"_ENREF_248\"></a> 248. Mackensen A, Herbst B, Chen JL, et al: Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34(+) hematopoietic progenitor cells. Int J Cancer 86:385-92, 2000. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/10760827\">http://www.ncbi.nlm.nih.gov/pubmed/10760827</a></p>\n<p id=\"erb-1a27532c-9b89-46c6-907c-b7c746b55fd4\"><a name=\"_ENREF_249\"></a> 249. Romano E, Rossi M, Ratzinger G, et al: Peptide-loaded Langerhans cells, despite increased IL15 secretion and T-cell activation in vitro, elicit antitumor T-cell responses comparable to peptide-loaded monocyte-derived dendritic cells in vivo. Clin Cancer Res 17:1984-97, 2011. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/21355077\">http://www.ncbi.nlm.nih.gov/pubmed/21355077</a></p>\n<p id=\"erb-ea041668-8069-4df6-9841-62386b9163f5\"><a name=\"_ENREF_250\"></a> 250. Verdijk P, Aarntzen EH, Lesterhuis WJ, et al: Limited amounts of dendritic cells migrate into the T-cell area of lymph nodes but have high immune activating potential in melanoma patients. Clin Cancer Res 15:2531-40, 2009. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/19318472\">http://www.ncbi.nlm.nih.gov/pubmed/19318472</a></p>\n<p id=\"erb-3353e706-0d95-4cb7-9d13-10ff94940518\"><a name=\"_ENREF_251\"></a> 251. Lesterhuis WJ, de Vries IJ, Schreibelt G, et al: Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients. Clin Cancer Res 17:5725-35, 2011. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/21771874\">http://www.ncbi.nlm.nih.gov/pubmed/21771874</a></p>\n<p id=\"erb-930b1eaa-6665-4f35-9391-84adb5f122f2\"><a name=\"_ENREF_252\"></a> 252. Mitchell DA, Nair SK: RNA-transfected dendritic cells in cancer immunotherapy. J Clin Invest 106:1065-9, 2000. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/11067858\">http://www.ncbi.nlm.nih.gov/pubmed/11067858</a></p>\n<p id=\"erb-6e2386a9-a0ad-4b8f-9c88-fb66655f21d7\"><a name=\"_ENREF_253\"></a> 253. Aarntzen EH, Schreibelt G, Bol K, et al: Vaccination with mRNA-electroporated dendritic cells induces robust tumor antigen-specific CD4+ and CD8+ T cells responses in stage III and IV melanoma patients. Clin Cancer Res 18:5460-70, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22896657\">http://www.ncbi.nlm.nih.gov/pubmed/22896657</a></p>\n<p id=\"erb-18630e88-47d5-4312-b554-d5389d1181c9\"><a name=\"_ENREF_254\"></a> 254. Dannull J, Haley NR, Archer G, et al: Melanoma immunotherapy using mature DCs expressing the constitutive proteasome. J Clin Invest 123:3135-45, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23934126\">http://www.ncbi.nlm.nih.gov/pubmed/23934126</a></p>\n<p id=\"erb-d386cac8-124a-415e-bdfd-164bdf75d45b\"><a name=\"_ENREF_255\"></a> 255. Carreno BM, Becker-Hapak M, Huang A, et al: IL-12p70-producing patient DC vaccine elicits Tc1-polarized immunity. J Clin Invest, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23867552\">http://www.ncbi.nlm.nih.gov/pubmed/23867552</a></p>\n<p id=\"erb-4dc0dbf6-4ac1-451a-8394-09ee7313b76c\"><a name=\"_ENREF_256\"></a> 256. Ribas A, Comin-Anduix B, Chmielowski B, et al: Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma. Clin Cancer Res 15:6267-76, 2009. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/19789309\">http://www.ncbi.nlm.nih.gov/pubmed/19789309</a></p>\n<p id=\"erb-ec66febc-56a2-4ec7-997d-c26efa921583\"><a name=\"_ENREF_257\"></a> 257. Rosenberg SA, Lotze MT, Yang JC, et al: Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst 85:622-32, 1993. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/8468720\">http://www.ncbi.nlm.nih.gov/pubmed/8468720</a></p>\n<p id=\"erb-1f6d231a-b344-42ba-a15f-060a738dfb38\"><a name=\"_ENREF_258\"></a> 258. Parkhurst MR, Riley JP, Dudley ME, et al: Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression. Clin Cancer Res 17:6287-97, 2011. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/21844012\">http://www.ncbi.nlm.nih.gov/pubmed/21844012</a></p>\n<p id=\"erb-85809f2d-66ae-4c30-9ee3-437e10ff99a0\"><a name=\"_ENREF_259\"></a> 259. Besser MJ, Shoham T, Harari-Steinberg O, et al: Development of allogeneic NK cell adoptive transfer therapy in metastatic melanoma patients: in vitro preclinical optimization studies. PLoS One 8:e57922, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23483943\">http://www.ncbi.nlm.nih.gov/pubmed/23483943</a></p>\n<p id=\"erb-123cdc9d-d164-4d1b-9d9d-83c103f3178d\"><a name=\"_ENREF_260\"></a> 260. Gammaitoni L, Giraudo L, Leuci V, et al: Effective Activity of Cytokine Induced Killer Cells against Autologous Metastatic Melanoma including Cells with Stemness Features. Clin Cancer Res, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23794732\">http://www.ncbi.nlm.nih.gov/pubmed/23794732</a></p>\n<p id=\"erb-4329de9e-47d9-47a2-89d6-9b8b786a0351\"><a name=\"_ENREF_261\"></a> 261. Sumimoto H, Imabayashi F, Iwata T, et al: The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells. J Exp Med 203:1651-6, 2006. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/16801397\">http://www.ncbi.nlm.nih.gov/pubmed/16801397</a></p>\n<p id=\"erb-dff60bf4-053b-4757-8c06-3adb8be69f88\"><a name=\"_ENREF_262\"></a> 262. Kono M, Dunn IS, Durda PJ, et al: Role of the mitogen-activated protein kinase signaling pathway in the regulation of human melanocytic antigen expression. Mol Cancer Res 4:779-92, 2006. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/17050671\">http://www.ncbi.nlm.nih.gov/pubmed/17050671</a></p>\n<p id=\"erb-5755b1ff-ed19-4849-b5ff-e0bd71d65c43\"><a name=\"_ENREF_263\"></a> 263. Khalili JS, Liu S, Rodriguez-Cruz TG, et al: Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma. Clin Cancer Res 18:5329-40, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22850568\">http://www.ncbi.nlm.nih.gov/pubmed/22850568</a></p>\n<p id=\"erb-65c43fd3-6d4c-4a15-b1d8-d64258ddb9bb\"><a name=\"_ENREF_264\"></a> 264. Knight DA, Ngiow SF, Li M, et al: Host immunity contributes to the anti-melanoma activity of BRAF inhibitors. J Clin Invest 123:1371-81, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23454771\">http://www.ncbi.nlm.nih.gov/pubmed/23454771</a></p>\n<p id=\"erb-ffda7d30-286e-4beb-8ca4-24e1c8ba026e\"><a name=\"_ENREF_265\"></a> 265. Boni A, Cogdill AP, Dang P, et al: Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res 70:5213-9, 2010. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/20551059\">http://www.ncbi.nlm.nih.gov/pubmed/20551059</a></p>\n<p id=\"erb-db5de006-69d5-41ee-b5a2-c67235098ca6\"><a name=\"_ENREF_266\"></a> 266. Wilmott JS, Long GV, Howle JR, et al: Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin Cancer Res 18:1386-94, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22156613\">http://www.ncbi.nlm.nih.gov/pubmed/22156613</a></p>\n<p id=\"erb-a5ef7f5b-5f1b-4ec5-9def-eab637b30d33\"><a name=\"_ENREF_267\"></a> 267. Hong DS, Vence L, Falchook G, et al: BRAF(V600) inhibitor GSK2118436 targeted inhibition of mutant BRAF in cancer patients does not impair overall immune competency. Clin Cancer Res 18:2326-35, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22355009\">http://www.ncbi.nlm.nih.gov/pubmed/22355009</a></p>\n<p id=\"erb-d3b52ffc-d126-4c85-be79-076d60f320d0\"><a name=\"_ENREF_268\"></a> 268. Hooijkaas A, Gadiot J, Morrow M, et al: Selective BRAF inhibition decreases tumor-resident lymphocyte frequencies in a mouse model of human melanoma. Oncoimmunology 1:609-617, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22934253\">http://www.ncbi.nlm.nih.gov/pubmed/22934253</a></p>\n<p id=\"erb-f19061da-0ebb-4b30-a8cc-d6fef976e2f9\"><a name=\"_ENREF_269\"></a> 269. Frederick DT, Piris A, Cogdill AP, et al: BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma. Clin Cancer Res, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23307859\">http://www.ncbi.nlm.nih.gov/pubmed/23307859</a></p>\n<p id=\"erb-a7f989c2-a776-4ff3-b0ea-549e1fa284d3\"><a name=\"_ENREF_270\"></a> 270. Koya RC, Mok S, Otte N, et al: BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy. Cancer Res 72:3928-37, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22693252\">http://www.ncbi.nlm.nih.gov/pubmed/22693252</a></p>\n<p id=\"erb-d4015ccd-2de4-4bde-b8f9-edf79baa687a\"><a name=\"_ENREF_271\"></a> 271. Liu C, Peng W, Xu C, et al: BRAF Inhibition Increases Tumor Infiltration by T cells and Enhances the Antitumor Activity of Adoptive Immunotherapy in Mice. Clin Cancer Res 19:393-403, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23204132\">http://www.ncbi.nlm.nih.gov/pubmed/23204132</a></p>\n<p id=\"erb-195bb76d-7372-44c9-9968-045422cb2462\"><a name=\"_ENREF_272\"></a> 272. Ott PA, Henry T, Baranda SJ, et al: Inhibition of both BRAF and MEK in BRAF(V600E) mutant melanoma restores compromised dendritic cell (DC) function while having differential direct effects on DC properties. Cancer Immunol Immunother, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23306863\">http://www.ncbi.nlm.nih.gov/pubmed/23306863</a></p>\n<p id=\"erb-42de41bd-d2a5-4c1d-98ec-088b2ba96936\"><a name=\"_ENREF_273\"></a> 273. Donia M, Fagone P, Nicoletti F, et al: BRAF inhibition improves tumor recognition by the immune system: Potential implications for combinatorial therapies against melanoma involving adoptive T-cell transfer. Oncoimmunology 1:1476-1483, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23264894\">http://www.ncbi.nlm.nih.gov/pubmed/23264894</a></p>\n<p id=\"erb-074ea502-286b-4a72-b867-132aee20ff5a\"><a name=\"_ENREF_274\"></a> 274. Ribas A, Hodi FS, Callahan M, et al: Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med 368:1365-6, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23550685\">http://www.ncbi.nlm.nih.gov/pubmed/23550685</a></p>\n<p id=\"erb-36a2a5ae-9b3f-414f-b05a-dce0b2493563\"><a name=\"_ENREF_275\"></a> 275. Joseph RW, Sullivan RJ, Harrell R, et al: Correlation of NRAS mutations with clinical response to high-dose IL-2 in patients with advanced melanoma. J Immunother 35:66-72, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22130161\">http://www.ncbi.nlm.nih.gov/pubmed/22130161</a></p>\n<p id=\"erb-687dbd10-f1e5-4e8b-a89d-60beb963e6b7\"><a name=\"_ENREF_276\"></a> 276. Yaguchi T, Goto Y, Kido K, et al: Immune suppression and resistance mediated by constitutive activation of Wnt/beta-catenin signaling in human melanoma cells. J Immunol 189:2110-7, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22815287\">http://www.ncbi.nlm.nih.gov/pubmed/22815287</a></p>\n<p id=\"erb-95c47ca0-a68b-47be-9628-eec75dd5dbc1\"><a name=\"_ENREF_277\"></a> 277. Gilbert AE, Karagiannis P, Dodev T, et al: Monitoring the systemic human memory B cell compartment of melanoma patients for anti-tumor IgG antibodies. PLoS One 6:e19330, 2011. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/21559411\">http://www.ncbi.nlm.nih.gov/pubmed/21559411</a></p>\n<p id=\"erb-c224ed7f-d2f1-4a9d-bdcf-d23502a936fe\"><a name=\"_ENREF_278\"></a> 278. Carpenter EL, Mick R, Rech AJ, et al: Collapse of the CD27+ B-cell compartment associated with systemic plasmacytosis in patients with advanced melanoma and other cancers. Clin Cancer Res 15:4277-87, 2009. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/19549767\">http://www.ncbi.nlm.nih.gov/pubmed/19549767</a></p>\n<p id=\"erb-5a7b3085-b4a0-4903-aa20-797b1e9a6779\"><a name=\"_ENREF_279\"></a> 279. Karagiannis P, Gilbert AE, Josephs DH, et al: IgG4 subclass antibodies impair antitumor immunity in melanoma. J Clin Invest, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23454746\">http://www.ncbi.nlm.nih.gov/pubmed/23454746</a></p>\n<p id=\"erb-678004c2-c698-44c6-8398-6eab9e798999\"><a name=\"_ENREF_280\"></a> 280. Jochems C, Schlom J: Tumor-infiltrating immune cells and prognosis: the potential link between conventional cancer therapy and immunity. Exp Biol Med (Maywood) 236:567-79, 2011. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/21486861\">http://www.ncbi.nlm.nih.gov/pubmed/21486861</a></p>\n<p id=\"erb-3e0dd15e-3e20-4b7a-bb3b-be4e15a7b87a\"><a name=\"_ENREF_281\"></a> 281. Messina JL, Fenstermacher DA, Eschrich S, et al: 12-Chemokine gene signature identifies lymph node-like structures in melanoma: potential for patient selection for immunotherapy? Sci Rep 2:765, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23097687\">http://www.ncbi.nlm.nih.gov/pubmed/23097687</a></p>\n<p id=\"erb-ad5d0f8f-1fdb-404e-bf34-a3394d3995f3\"><a name=\"_ENREF_282\"></a> 282. Sonveaux P, Vegran F, Schroeder T, et al: Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J Clin Invest 118:3930-42, 2008. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/19033663\">http://www.ncbi.nlm.nih.gov/pubmed/19033663</a></p>\n<p id=\"erb-567a41a4-d187-48ab-97c0-ee028f42e770\"><a name=\"_ENREF_283\"></a> 283. O'Day SJ, Eggermont AM, Chiarion-Sileni V, et al: Final Results of Phase III SYMMETRY Study: Randomized, Double-Blind Trial of Elesclomol Plus Paclitaxel Versus Paclitaxel Alone As Treatment for Chemotherapy-Naive Patients With Advanced Melanoma. J Clin Oncol, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23401447\">http://www.ncbi.nlm.nih.gov/pubmed/23401447</a></p>\n<p id=\"erb-69d77047-618f-46ec-ab0f-a349e78a5c4b\"><a name=\"_ENREF_284\"></a> 284. Roesch A, Fukunaga-Kalabis M, Schmidt EC, et al: A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell 141:583-94, 2010. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/20478252\">http://www.ncbi.nlm.nih.gov/pubmed/20478252</a></p>\n<p id=\"erb-37c56535-b2ca-4940-bacb-ab95ecb841ef\"><a name=\"_ENREF_285\"></a> 285. Roesch A, Vultur A, Bogeski I, et al: Overcoming Intrinsic Multidrug Resistance in Melanoma by Blocking the Mitochondrial Respiratory Chain of Slow-Cycling JARID1B(high) Cells. Cancer Cell 23:811-25, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23764003\">http://www.ncbi.nlm.nih.gov/pubmed/23764003</a></p>\n<p id=\"erb-923d232e-c0da-4c5e-a800-30a55f5e24a4\"><a name=\"_ENREF_286\"></a> 286. Kaplon J, Zheng L, Meissl K, et al: A key role for mitochondrial gatekeeper pyruvate dehydrogenase in oncogene-induced senescence. Nature, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23685455\">http://www.ncbi.nlm.nih.gov/pubmed/23685455</a></p>\n<p id=\"erb-9643b46c-8360-4f03-bb06-f45904ef643c\"><a name=\"_ENREF_287\"></a> 287. Dillon BJ, Prieto VG, Curley SA, et al: Incidence and distribution of argininosuccinate synthetase deficiency in human cancers: a method for identifying cancers sensitive to arginine deprivation. Cancer 100:826-33, 2004. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/14770441\">http://www.ncbi.nlm.nih.gov/pubmed/14770441</a></p>\n<p id=\"erb-7847b3a5-fed7-49c7-8a92-79c8500f57b6\"><a name=\"_ENREF_288\"></a> 288. Yoon JK, Frankel AE, Feun LG, et al: Arginine deprivation therapy for malignant melanoma. Clin Pharmacol 5:11-9, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23293541\">http://www.ncbi.nlm.nih.gov/pubmed/23293541</a></p>\n<p id=\"erb-7a8b2a3c-76e7-4127-a2e3-622c9ccd3fa0\"><a name=\"_ENREF_289\"></a> 289. Ott PA, Carvajal RD, Pandit-Taskar N, et al: Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma. Invest New Drugs 31:425-34, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22864522\">http://www.ncbi.nlm.nih.gov/pubmed/22864522</a></p>\n<p id=\"erb-6fd0d2a2-eda1-43ef-804d-efd6ff5b32f4\"><a name=\"_ENREF_290\"></a> 290. Sheen JH, Zoncu R, Kim D, et al: Defective regulation of autophagy upon leucine deprivation reveals a targetable liability of human melanoma cells in vitro and in vivo. Cancer Cell 19:613-28, 2011. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/21575862\">http://www.ncbi.nlm.nih.gov/pubmed/21575862</a></p>\n<p id=\"erb-92698907-429f-4f1c-bb61-9b804e8ee9e6\"><a name=\"_ENREF_291\"></a> 291. Tomic T, Botton T, Cerezo M, et al: Metformin inhibits melanoma development through autophagy and apoptosis mechanisms. Cell Death Dis 2:e199, 2011. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/21881601\">http://www.ncbi.nlm.nih.gov/pubmed/21881601</a></p>\n<p id=\"erb-a8fa7629-0782-4cfe-9b75-045f3455f04a\"><a name=\"_ENREF_292\"></a> 292. Li H, Li Y, Jiao J, et al: Alpha-alumina nanoparticles induce efficient autophagy-dependent cross-presentation and potent antitumour response. Nat Nanotechnol 6:645-50, 2011. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/21926980\">http://www.ncbi.nlm.nih.gov/pubmed/21926980</a></p>\n<p id=\"erb-32b942a5-02e0-4643-95cd-c0803a468f71\"><a name=\"_ENREF_293\"></a> 293. Li Y, Wang LX, Pang P, et al: Tumor-derived autophagosome vaccine: mechanism of cross-presentation and therapeutic efficacy. Clin Cancer Res 17:7047-57, 2011. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22068657\">http://www.ncbi.nlm.nih.gov/pubmed/22068657</a></p>\n<p id=\"erb-ec92a317-ef61-4ab5-ae08-5e9f024b5561\"><a name=\"_ENREF_294\"></a> 294. Liang X, De Vera ME, Buchser WJ, et al: Inhibiting systemic autophagy during interleukin 2 immunotherapy promotes long-term tumor regression. Cancer Res 72:2791-801, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22472122\">http://www.ncbi.nlm.nih.gov/pubmed/22472122</a></p>\n<p id=\"erb-5602e782-0638-42f5-a98f-496b7fff0864\"><a name=\"_ENREF_295\"></a> 295. Lotze MT, Buchser WJ, Liang X: Blocking the interleukin 2 (IL2)-induced systemic autophagic syndrome promotes profound antitumor effects and limits toxicity. Autophagy 8:1264-6, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22660171\">http://www.ncbi.nlm.nih.gov/pubmed/22660171</a></p>\n<p id=\"erb-e63d88e5-d885-4b57-bc89-2ad453e8add8\"><a name=\"_ENREF_296\"></a> 296. Ireland A, Millward M, Pearce R, et al: Genetic factors in metastatic progression of cutaneous melanoma: the future role of circulating melanoma cells in prognosis and management. Clin Exp Metastasis 28:327-36, 2011. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/21311956\">http://www.ncbi.nlm.nih.gov/pubmed/21311956</a></p>\n<p id=\"erb-e760ebaf-0a61-4d3a-8b56-09a27928ea38\"><a name=\"_ENREF_297\"></a> 297. Tanaka R, Koyanagi K, Narita N, et al: Prognostic molecular biomarkers for cutaneous malignant melanoma. J Surg Oncol 104:438-46, 2011. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/21557225\">http://www.ncbi.nlm.nih.gov/pubmed/21557225</a></p>\n<p id=\"erb-12c7e762-f24b-48a8-8fcd-c6c89daba911\"><a name=\"_ENREF_298\"></a> 298. Smith B, Selby P, Southgate J, et al: Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction. Lancet 338:1227-9, 1991. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/1719320\">http://www.ncbi.nlm.nih.gov/pubmed/1719320</a></p>\n<p id=\"erb-6cd717ab-abec-4d75-9aa5-f3ac7a83c8e1\"><a name=\"_ENREF_299\"></a> 299. Mocellin S, Del Fiore P, Guarnieri L, et al: Molecular detection of circulating tumor cells is an independent prognostic factor in patients with high-risk cutaneous melanoma. Int J Cancer 111:741-5, 2004. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/15252844\">http://www.ncbi.nlm.nih.gov/pubmed/15252844</a></p>\n<p id=\"erb-49f644c3-1c90-4f16-9178-4e0569697a8f\"><a name=\"_ENREF_300\"></a> 300. Koyanagi K, O'Day SJ, Boasberg P, et al: Serial monitoring of circulating tumor cells predicts outcome of induction biochemotherapy plus maintenance biotherapy for metastatic melanoma. Clin Cancer Res 16:2402-8, 2010. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/20371696\">http://www.ncbi.nlm.nih.gov/pubmed/20371696</a></p>\n<p id=\"erb-f1a06011-bac2-4334-8a7b-7711377ef823\"><a name=\"_ENREF_301\"></a> 301. Hoshimoto S, Faries MB, Morton DL, et al: Assessment of prognostic circulating tumor cells in a phase III trial of adjuvant immunotherapy after complete resection of stage IV melanoma. Ann Surg 255:357-62, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22202581\">http://www.ncbi.nlm.nih.gov/pubmed/22202581</a></p>\n<p id=\"erb-55ba7bdc-bde2-4c36-9f98-d7de53a95acc\"><a name=\"_ENREF_302\"></a> 302. Hoshimoto S, Shingai T, Morton DL, et al: Association between circulating tumor cells and prognosis in patients with stage III melanoma with sentinel lymph node metastasis in a phase III international multicenter trial. J Clin Oncol 30:3819-26, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23008288\">http://www.ncbi.nlm.nih.gov/pubmed/23008288</a></p>\n<p id=\"erb-467c29e6-34f3-477e-af05-9f01389b8485\"><a name=\"_ENREF_303\"></a> 303. Reid AL, Millward M, Pearce R, et al: Markers of circulating tumour cells in the peripheral blood of patients with melanoma correlate with disease recurrence and progression. Br J Dermatol 168:85-92, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23013138\">http://www.ncbi.nlm.nih.gov/pubmed/23013138</a></p>\n<p id=\"erb-76874611-a15d-4f57-82c7-564306d1230f\"><a name=\"_ENREF_304\"></a> 304. Fusi A, Liu Z, Kummerlen V, et al: Expression of chemokine receptors on circulating tumor cells in patients with solid tumors. J Transl Med 10:52, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22433180\">http://www.ncbi.nlm.nih.gov/pubmed/22433180</a></p>\n<p id=\"erb-86e71e09-a10a-4462-a32a-8096d876ed3e\"><a name=\"_ENREF_305\"></a> 305. Khoja L, Lorigan P, Zhou C, et al: Biomarker Utility of Circulating Tumor Cells in Metastatic Cutaneous Melanoma. J Invest Dermatol, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23223143\">http://www.ncbi.nlm.nih.gov/pubmed/23223143</a></p>\n<p id=\"erb-23ede70c-15a0-4eeb-8966-df15cf1cbeb1\"><a name=\"_ENREF_306\"></a> 306. Le Rhun E, Tu Q, De Carvalho Bittencourt M, et al: Detection and quantification of CSF malignant cells by the CellSearch technology in patients with melanoma leptomeningeal metastasis. Med Oncol 30:538, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23504338\">http://www.ncbi.nlm.nih.gov/pubmed/23504338</a></p>\n<p id=\"erb-edad9c6f-a1e0-4a19-ad3a-87ed381527d0\"><a name=\"_ENREF_307\"></a> 307. De Giorgi V, Pinzani P, Salvianti F, et al: Application of a filtration- and isolation-by-size technique for the detection of circulating tumor cells in cutaneous melanoma. J Invest Dermatol 130:2440-7, 2010. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/20535130\">http://www.ncbi.nlm.nih.gov/pubmed/20535130</a></p>\n<p id=\"erb-d68e66a7-8cb6-49a9-8b5f-24bf67419adc\"><a name=\"_ENREF_308\"></a> 308. De Giorgi V, Pinzani P, Salvianti F, et al: Circulating benign nevus cells detected by ISET technique: warning for melanoma molecular diagnosis. Arch Dermatol 146:1120-4, 2010. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/20956643\">http://www.ncbi.nlm.nih.gov/pubmed/20956643</a></p>\n<p id=\"erb-0f3203db-6426-4ea9-af66-ec72bd9685d6\"><a name=\"_ENREF_309\"></a> 309. Galanzha EI, Shashkov EV, Spring PM, et al: In vivo, noninvasive, label-free detection and eradication of circulating metastatic melanoma cells using two-color photoacoustic flow cytometry with a diode laser. Cancer Res 69:7926-34, 2009. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/19826056\">http://www.ncbi.nlm.nih.gov/pubmed/19826056</a></p>\n<p id=\"erb-fe3e5b7c-6607-4b3b-b5cf-0843094bb408\"><a name=\"_ENREF_310\"></a> 310. O'Brien CM, Rood KD, Bhattacharyya K, et al: Capture of circulating tumor cells using photoacoustic flowmetry and two phase flow. J Biomed Opt 17:061221, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22734751\">http://www.ncbi.nlm.nih.gov/pubmed/22734751</a></p>\n<p id=\"erb-5bfe48b3-6dd0-40fb-9061-419ac0d4fe4b\"><a name=\"_ENREF_311\"></a> 311. Hou S, Zhao L, Shen Q, et al: Polymer nanofiber-embedded microchips for detection, isolation, and molecular analysis of single circulating melanoma cells. Angew Chem Int Ed Engl 52:3379-83, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23436302\">http://www.ncbi.nlm.nih.gov/pubmed/23436302</a></p>\n<p id=\"erb-b6664c95-121b-4cc6-8d60-dfa0df96b52b\"><a name=\"_ENREF_312\"></a> 312. Ozkumur E, Shah AM, Ciciliano JC, et al: Inertial focusing for tumor antigen-dependent and -independent sorting of rare circulating tumor cells. Sci Transl Med 5:179ra47, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23552373\">http://www.ncbi.nlm.nih.gov/pubmed/23552373</a></p>\n<p id=\"erb-4c61c16e-49bb-4c32-b1a3-f665d3af3694\"><a name=\"_ENREF_313\"></a> 313. Adebayo Awe J, Xu MC, Wechsler J, et al: Three-Dimensional Telomeric Analysis of Isolated Circulating Tumor Cells (CTCs) Defines CTC Subpopulations. Transl Oncol 6:51-65, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23418617\">http://www.ncbi.nlm.nih.gov/pubmed/23418617</a></p>\n<p id=\"erb-48f0224a-e7a4-48a0-8554-188102d6fcb3\"><a name=\"_ENREF_314\"></a> 314. Fusi A, Berdel R, Havemann S, et al: Enhanced detection of BRAF-mutants by pre-PCR cleavage of wild-type sequences revealed circulating melanoma cells heterogeneity. Eur J Cancer 47:1971-6, 2011. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/21570823\">http://www.ncbi.nlm.nih.gov/pubmed/21570823</a></p>\n<p id=\"erb-1bb46d58-078b-48c9-95b0-a261d81c87af\"><a name=\"_ENREF_315\"></a> 315. Sakaizawa K, Goto Y, Kiniwa Y, et al: Mutation analysis of BRAF and KIT in circulating melanoma cells at the single cell level. Br J Cancer 106:939-46, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22281663\">http://www.ncbi.nlm.nih.gov/pubmed/22281663</a></p>\n<p id=\"erb-08299af8-a24b-4f20-87d3-c98f48c82c13\"><a name=\"_ENREF_316\"></a> 316. Dawson SJ, Tsui DW, Murtaza M, et al: Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med 368:1199-209, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23484797\">http://www.ncbi.nlm.nih.gov/pubmed/23484797</a></p>\n<p id=\"erb-bba2420a-a207-4532-b6a1-2aef7c6aa709\"><a name=\"_ENREF_317\"></a> 317. Murtaza M, Dawson SJ, Tsui DW, et al: Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23563269\">http://www.ncbi.nlm.nih.gov/pubmed/23563269</a></p>\n<p id=\"erb-55b6195d-650d-4ad4-b81a-eaf308076c11\"><a name=\"_ENREF_318\"></a> 318. Harbour JW, Chen R: The DecisionDx-UM Gene Expression Profile Test Provides Risk Stratification and Individualized Patient Care in Uveal Melanoma. PLoS Curr 5, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23591547\">http://www.ncbi.nlm.nih.gov/pubmed/23591547</a></p>\n<p id=\"erb-e9ba2891-279a-4183-b6a6-3b1a353df9a9\"><a name=\"_ENREF_319\"></a> 319. Ohno S, Ishikawa A, Kuroda M: Roles of exosomes and microvesicles in disease pathogenesis. Adv Drug Deliv Rev 65:398-401, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22981801\">http://www.ncbi.nlm.nih.gov/pubmed/22981801</a></p>\n<p id=\"erb-60ccf06f-ad35-4c38-b5f3-25416312b10b\"><a name=\"_ENREF_320\"></a> 320. Peinado H, Aleckovic M, Lavotshkin S, et al: Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med 18:883-91, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22635005\">http://www.ncbi.nlm.nih.gov/pubmed/22635005</a></p>\n", 
        "publication_link": "http://www.example.com/", 
        "revision_date": "2013-09-04T04:39:34Z", 
        "publication_date": "2013-08-05T19:30:20Z", 
        "title": "Pathways and Therapeutic Targets of Melanoma"
    }
},
{
    "pk": 2, 
    "model": "er.evidencereview", 
    "fields": {
        "content": "<h1>second er test</h1>\r\n<div>this here is another test</div>\r\n", 
        "publication_link": "http://www.example.com/", 
        "revision_date": "2013-08-05T22:44:04Z", 
        "publication_date": "2013-08-05T22:44:02Z", 
        "title": "test number 2"
    }
},
{
    "pk": 3, 
    "model": "er.evidencereview", 
    "fields": {
        "content": "<h1 id=\"erh-d7a3a627-f300-439d-a4c2-2dba622ca151\">INTRODUCTION</h1>\n<p id=\"erb-5d8c5ee9-730e-4196-a05a-6410357f4e11\">The revolutionary discovery of a striking, if temporary, effect that targeted inhibition of BRAF has on the clinical course of metastatic melanoma has spiked a new wave of research into molecular targets. In addition, it has raised a number of new questions: what are the mechanisms of both inherent and acquired resistance to BRAF inhibitors and the possible ways to overcome this resistance; how is the activating effect of BRAF inhibition on the MAPK pathway in cells with nonmutated BRAF avoided; how should melanoma tumors that have no activating mutations in BRAF, such as tumors with mutated NRAS or NF1, or tumors that are wild type for both BRAF and NRAS, be targeted; which targeted or nontargeted drug combinations should be pursued as determined by the molecular profile of each and every tumor; what is the future of combination targeted therapy and immunotherapy; and many more.</p>\n<p id=\"erb-b8608426-6d28-4fe8-aad9-7771a5364d67\">The mutational landscape of melanoma was examined in several large studies employing NGS (next-generation sequencing) and large-scale expression analyses of tumors. The mutation rate of melanoma, on average, exceeds those reported for other aggressive tumors, probably due to the involvement of ultraviolet (UV) radiation in the genesis of superficial cutaneous melanomas. Indeed, the rate of transversions characteristic of UV-induced lesions is much higher in melanoma than the rates of other nucleotide substitutions. The high rate of mutations in melanoma makes it particularly difficult to distinguish between causative (\"driver\") mutations and bystander (\"passenger\") mutations.</p>\n<p id=\"erb-93120161-84be-419f-9bc0-9d90b08c4efc\">In one recent study <a class=\"rlc-reference\" data-ref-info=\"Berger MF, Hodis E, Heffernan TP, et al: Melanoma genome sequencing reveals frequent PREX2 mutations. Nature 485:502-6, 2012.\" href=\"#_ENREF_1\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22622578\"><sup>1</sup></a>, a wide range of point-mutation rates was observed: they were lowest in melanomas in which primaries arose on non-UV-exposed hairless skin of the extremities (3 and 14 mutations per megabase [Mb] of genome); intermediate in those originating from hair-bearing skin of the trunk (5-55 mutations/Mb); and highest in a patient with a documented history of chronic sun exposure (111 mutations/Mb). Uveal melanomas, tumors with generally poor prognosis, nevertheless have a fairly low mutation rate <a class=\"rlc-reference\" data-ref-info=\"Furney SJ, Pedersen M, Gentien D, et al: SF3B1 mutations are associated with alternative splicing in uveal melanoma. Cancer Discov, 2013.\" href=\"#_ENREF_2\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23861464\"><sup>2</sup></a>. Interestingly, melanomas that are wild type for both BRAF and NRAS have almost five times higher mutational loads than tumors where one of these oncogenes is mutated <a class=\"rlc-reference\" data-ref-info=\"Mar VJ, Wong SQ, Li J, et al: BRAF/NRAS wild-type melanomas have a high mutation load correlating with histological and molecular signatures of UV damage. Clin Cancer Res, 2013.\" href=\"#_ENREF_3\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23833303\"><sup>3</sup></a>.</p>\n<p id=\"erb-6932eba6-0670-41c7-ba37-f0015e23cb3f\">The different types of melanoma appear to have distinct sets of relevant somatogenic alterations (Tables 1 and 2). Some of the difference could be attributed to the lack of UV involvement in pathogenesis of acral and mucosal melanomas. Uveal melanoma was recognized as distinct tumor for a long time, and it is reflected in predominance of driver mutations in G protein subunits rather then BRAF or NRAS mutations. Mutational analyses of mucosal melanoma concluded that this subtype shares with cutaneous melanoma relatively few mutations in specific genes, suggesting different mechanisms of carcinogenesis <a class=\"rlc-reference\" data-ref-info=\"Furney SJ, Turajlic S, Stamp G, et al: Genome sequencing of mucosal melanomas reveals that they are driven by distinct mechanisms from cutaneous melanoma. J Pathol 230:261-9, 2013.\" href=\"#_ENREF_4\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23620124\"><sup>4</sup></a>. The rare conjuctival melanoma apparently has a mutational landscape similar to cutaneous melanoma <a class=\"rlc-reference\" data-ref-info=\"Griewank KG, Westekemper H, Murali R, et al: Conjunctival Melanomas Harbor BRAF and NRAS Mutations and Copy Number Changes Similar to Cutaneous and Mucosal Melanomas. Clin Cancer Res 19:3143-3152, 2013.\" href=\"#_ENREF_5\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23633454\"><sup>5</sup></a>, pending confirmation from an analysis of a larger number of tumors.</p>\n<p id=\"erb-00a28a48-20a6-43d0-a52b-4c277df6a9c7\">This paper describes genetic alterations that are known to occur in melanoma and information about their role in melanomagenesis, as well as their suitability as targets for therapeutic intervention. The latest information on molecular events underlying inherent or acquired resistance to targeted therapies is also included, along with immunotherapeutic approaches and prognostic methodologies.</p>\n<p id=\"erb-09064d79-b381-4456-9575-37bc083389eb\">Multiple cellular pathways have been implicated in melanomagenesis, ranging from signal transduction to developmental and transcriptional pathways and cell cycle deregulation (Table 1). The search for driver mutations in melanoma continues, with the previously identified subtypes involving BRAF, NRAS, KIT, GNAQ, and GNA11 expanded recently to include NF1 and telomerase (Table 2). Together, these driver mutations are very likely to define the vast majority of molecular subtypes in melanoma and, eventually, the identified mutations in drivers will guide targeted therapy choices. However, for a number of reasons, such as oncogene-induced senescence (discussed below), driver mutations result in a frank tumorigenic phenotype only in the presence of \"supporting mutations\" that are also listed in Table 2 and described below. It is likely that these supporting mutations have to be targeted along with driver mutations to achieve durable responses. Finally, immunotherapies continue to play an important role in melanoma treatment strategies and are also described here.</p>\n\n<h3>Table 1. Pathways Involved In Melanomagenesis</h3>\n\n<table border=\"1\" cellpadding=\"7\" cellspacing=\"0\" id=\"erb-87dc1858-b815-4ba2-acc9-2b25f873ee99\" width=\"643\">\n<colgroup>\n<col width=\"191\"></col>\n<col width=\"154\"></col>\n<col width=\"256\"></col>\n</colgroup>\n<tbody>\n<tr valign=\"TOP\">\n<td height=\"23\" width=\"191\">\n<p><b>PATHWAY*</b></p>\n</td>\n<td width=\"154\">\n<p><b>COMPONENTS MUTATED/ACTIVATED</b></p>\n</td>\n<td width=\"256\">\n<p><b>TYPE OF ALTERATION</b></p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td rowspan=\"5\" width=\"191\">\n<p>\u00a0</p>\n<p>\u00a0</p>\n<p>Receptor tyrosine kinases</p>\n<p>\u00a0</p>\n</td>\n<td width=\"154\">\n<p>KIT</p>\n</td>\n<td width=\"256\">\n<p>Mutation/amplification</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"154\">\n<p>EGFR</p>\n</td>\n<td width=\"256\">\n<p>Activation</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"154\">\n<p>MET</p>\n</td>\n<td width=\"256\">\n<p>Activation; high level of ligand in stroma</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"154\">\n<p>ERBB4</p>\n</td>\n<td width=\"256\">\n<p>Mutation</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"154\">\n<p>FGFR</p>\n</td>\n<td width=\"256\">\n<p>Activation; high levels of ligands</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"191\">\n<p>Integrin adaptors/ECM signaling</p>\n</td>\n<td width=\"154\">\n<p>NEDD9/HEF</p>\n</td>\n<td width=\"256\">\n<p>Amplification</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td rowspan=\"3\" width=\"191\">\n<p>\u00a0</p>\n<p>RAS/RAF/MEK/ERK</p>\n</td>\n<td width=\"154\">\n<p>NRAS</p>\n</td>\n<td width=\"256\">\n<p>Mutation</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"154\">\n<p>BRAF</p>\n</td>\n<td width=\"256\">\n<p>Mutation</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"154\">\n<p>MEK1</p>\n</td>\n<td width=\"256\">\n<p>Mutation</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td rowspan=\"4\" width=\"191\">\n<p>\u00a0</p>\n<p>RAS/PI3K/PTEN/AKT/mTOR</p>\n</td>\n<td width=\"154\">\n<p>PIK3CA</p>\n</td>\n<td width=\"256\">\n<p>Mutation</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"154\">\n<p>PTEN</p>\n</td>\n<td width=\"256\">\n<p>Mutation</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"154\">\n<p>AKT1, AKT2</p>\n</td>\n<td width=\"256\">\n<p>Rare mutation</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"154\">\n<p>AKT3</p>\n</td>\n<td width=\"256\">\n<p>Amplification</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"191\">\n<p>NF1 (PI3K + MAPK pathways)</p>\n</td>\n<td width=\"154\">\n<p>NF1</p>\n</td>\n<td width=\"256\">\n<p>Mutation</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td rowspan=\"3\" width=\"191\">\n<p>\u00a0</p>\n<p>RHO/RAC/other MAPKs</p>\n</td>\n<td width=\"154\">\n<p>RAC</p>\n</td>\n<td width=\"256\">\n<p>Mutation</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"154\">\n<p>MAP3K5 &amp; MAP3K9</p>\n</td>\n<td width=\"256\">\n<p>Mutation</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"154\">\n<p>PREX</p>\n</td>\n<td width=\"256\">\n<p>Mutation</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td rowspan=\"2\" width=\"191\">\n<p>Glutamate receptors</p>\n</td>\n<td width=\"154\">\n<p>GRIN2A</p>\n</td>\n<td width=\"256\">\n<p>Mutation</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"154\">\n<p>GRM3</p>\n</td>\n<td width=\"256\">\n<p>Mutation</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td rowspan=\"2\" width=\"191\">\n<p>G proteins other than RAS, effectors of MAPK</p>\n</td>\n<td width=\"154\">\n<p>GNAQ</p>\n</td>\n<td width=\"256\">\n<p>Mutation</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"154\">\n<p>GNA11</p>\n</td>\n<td width=\"256\">\n<p>Mutation</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"191\">\n<p>Apoptosis</p>\n</td>\n<td width=\"154\">\n<p>BCL2A1</p>\n</td>\n<td width=\"256\">\n<p>Amplification</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"191\">\n<p>WNT/\uf062-catenin</p>\n</td>\n<td width=\"154\">\n<p>CTNNB1</p>\n</td>\n<td width=\"256\">\n<p>Mutation</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td rowspan=\"2\" width=\"191\">\n<p>CDK</p>\n</td>\n<td width=\"154\">\n<p>CDK4</p>\n</td>\n<td width=\"256\">\n<p>Mutation/amplification</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"154\">\n<p>CCND1</p>\n</td>\n<td width=\"256\">\n<p>Amplification</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td rowspan=\"2\" width=\"191\">\n<p>P53</p>\n</td>\n<td width=\"154\">\n<p>P14ARF (CDKN2A)</p>\n</td>\n<td width=\"256\">\n<p>Mutation/deletion</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"154\">\n<p>MDM4</p>\n</td>\n<td width=\"256\">\n<p>Amplification</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"191\">\n<p>RB1</p>\n</td>\n<td width=\"154\">\n<p>P116INK4A (CDKN2A)</p>\n</td>\n<td width=\"256\">\n<p>Mutation/deletion</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"191\">\n<p>MITF transcriptional program</p>\n</td>\n<td width=\"154\">\n<p>MITF</p>\n</td>\n<td width=\"256\">\n<p>Mutation/amplification</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"191\">\n<p>MYC transcriptional program</p>\n</td>\n<td width=\"154\">\n<p>MYC</p>\n</td>\n<td width=\"256\">\n<p>Amplification/overexpression</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"191\">\n<p>ETV1 transcriptional program</p>\n</td>\n<td width=\"154\">\n<p>ETV1</p>\n</td>\n<td width=\"256\">\n<p>Amplification</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"191\">\n<p>TERT</p>\n</td>\n<td width=\"154\">\n<p>Promoter region of catalytic subunit</p>\n</td>\n<td width=\"256\">\n<p>Mutation</p>\n</td>\n</tr>\n<tr>\n<td colspan=\"3\" valign=\"TOP\" width=\"629\">\n<p>* <i>The order of pathways in this Table has no relationship to their significance in melanoma; it is simply from the cell periphery to the nucleus.</i></p>\n<p>\u00a0</p>\n</td>\n</tr>\n</tbody>\n</table>\n\n<h1 id=\"erh-2d16e0e7-a1a2-49ac-9448-14d3713ceb70\">MOLECULAR SUBTYPES</h1>\n<p id=\"erb-0a6c4b32-9845-4c1c-8cdf-5c069212ae31\">Table 1 summarizes the molecular pathways involved in melanomagenesis, and Table 2 lists the known driver and additional mutations/alterations.</p>\n\n\n\n<h3>Table\u00a02. Genes Known To Be Altered in Melanoma</h3>\n\n<table border=\"1\" cellpadding=\"7\" cellspacing=\"0\" id=\"erb-20be40f0-a1de-4767-88e7-973c6a6dd7ab\" width=\"696\">\n<colgroup>\n<col width=\"106\"></col>\n<col width=\"120\"></col>\n<col width=\"104\"></col>\n<col width=\"98\"></col>\n<col width=\"84\"></col>\n<col width=\"100\"></col>\n</colgroup>\n<tbody>\n<tr valign=\"TOP\">\n<td height=\"15\" width=\"106\">\n<p><b>PRIMARY SUBTYPES</b></p>\n</td>\n<td width=\"120\">\n<p><b>PATHWAY </b></p>\n</td>\n<td width=\"104\">\n<p><b>ABERRATION</b></p>\n</td>\n<td width=\"98\">\n<p><b>FOUND IN TUMORS WITH\u2026</b></p>\n</td>\n<td width=\"84\">\n<p><b>FREQUENCY</b></p>\n</td>\n<td width=\"100\">\n<p><b>POSSIBLE THERAPIES</b></p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"106\">\n<p><b>BRAF</b></p>\n</td>\n<td width=\"120\">\n<p>MAPK</p>\n</td>\n<td width=\"104\">\n<p>Point mutation</p>\n</td>\n<td width=\"98\">\n<p>NRAS wild type</p>\n</td>\n<td width=\"84\">\n<p>50-60%</p>\n</td>\n<td width=\"100\">\n<p>BRAFi + MEKi</p>\n<p>BRAFi + EGFRi + AKTi</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"106\">\n<p><b>NRAS</b></p>\n</td>\n<td width=\"120\">\n<p>MAPK, PI3K, RALGDS</p>\n</td>\n<td width=\"104\">\n<p>\u00a0</p>\n</td>\n<td width=\"98\">\n<p>BRAF wild type</p>\n</td>\n<td width=\"84\">\n<p>20-25%</p>\n</td>\n<td width=\"100\">\n<p>HMGCRi + CDKi</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td height=\"20\" width=\"106\">\n<p><b>KIT</b></p>\n</td>\n<td width=\"120\">\n<p>MAPK, PI3K</p>\n</td>\n<td width=\"104\">\n<p>Point mutation, amplification</p>\n</td>\n<td width=\"98\">\n<p>NRAS BRAF wild type mostly</p>\n</td>\n<td width=\"84\">\n<p>1% overall; 10% in in mucosal; 10% in acral</p>\n</td>\n<td width=\"100\">\n<p>Sunitinib, nilotinib, imatinib</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"106\">\n<p><b>GNAQ/GNA11</b></p>\n</td>\n<td width=\"120\">\n<p>G\u03b1(q) family of G protein \u03b1 subunits; MAPK activators</p>\n</td>\n<td width=\"104\">\n<p>Point mutation</p>\n</td>\n<td width=\"98\">\n<p>NRAS BRAF wild type</p>\n</td>\n<td width=\"84\">\n<p>1%; 40-50% each in uveal</p>\n</td>\n<td width=\"100\">\n<p>MEKi + PI3Ki, enzastaurin</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"106\">\n<p><b>MITF*</b></p>\n</td>\n<td width=\"120\">\n<p>Transcription, lineage, cell cycle</p>\n</td>\n<td width=\"104\">\n<p>Amplification</p>\n</td>\n<td width=\"98\">\n<p>ALL???</p>\n</td>\n<td width=\"84\">\n<p>20%</p>\n</td>\n<td width=\"100\">\n<p>HDACi</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td height=\"24\" width=\"106\">\n<p><b>NF1*</b></p>\n</td>\n<td width=\"120\">\n<p>MAPK, PI3K negative regulator of RAS</p>\n</td>\n<td width=\"104\">\n<p>Mutations, loss of expression</p>\n</td>\n<td width=\"98\">\n<p>BRAF, NRAS wild type, but also in mutated</p>\n</td>\n<td width=\"84\">\n<p>4% overall; 25% of BRAF, NRAS wild type</p>\n</td>\n<td width=\"100\">\n<p>MEKi + mTORi or PI3Ki</p>\n<p>\u00a0</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"106\">\n<p>TERT*</p>\n</td>\n<td width=\"120\">\n<p>Telomerase</p>\n</td>\n<td width=\"104\">\n<p>Mutations in the promoter of catalytic subunit</p>\n</td>\n<td width=\"98\">\n<p>ND</p>\n</td>\n<td width=\"84\">\n<p>70-80% overall;</p>\n<p>33% primary; 85% metastatic</p>\n</td>\n<td width=\"100\">\n<p>TERT inhibitors in preclinical</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"106\">\n<p>ERBB4</p>\n</td>\n<td width=\"120\">\n<p>PI3K, MAPK</p>\n</td>\n<td width=\"104\">\n<p>Point mutation</p>\n</td>\n<td width=\"98\">\n<p>All types</p>\n</td>\n<td width=\"84\">\n<p>15-20%</p>\n</td>\n<td width=\"100\">\n<p>Lapatinib (ERBBi) + PI3Ki</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"106\">\n<p>MET</p>\n</td>\n<td width=\"120\">\n<p>PI3K, MAPK</p>\n</td>\n<td width=\"104\">\n<p>Activation by stromal HGF</p>\n</td>\n<td width=\"98\">\n<p>All types</p>\n</td>\n<td width=\"84\">\n<p>ND</p>\n</td>\n<td width=\"100\">\n<p>Cabozantinib?</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"106\">\n<p>AKT3</p>\n</td>\n<td width=\"120\">\n<p>PI3K</p>\n</td>\n<td width=\"104\">\n<p>Amplification</p>\n</td>\n<td width=\"98\">\n<p>All types</p>\n</td>\n<td width=\"84\">\n<p>25%</p>\n</td>\n<td width=\"100\">\n<p>AKTi, PI3Ki, mTORi</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"106\">\n<p>PTEN</p>\n</td>\n<td width=\"120\">\n<p>PI3K</p>\n</td>\n<td width=\"104\">\n<p>Point mutation or deletions</p>\n</td>\n<td width=\"98\">\n<p>BRAF mutated; BRAF and NRAS wild type</p>\n</td>\n<td width=\"84\">\n<p>40-60%</p>\n</td>\n<td width=\"100\">\n<p>PI3Ki</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"106\">\n<p>MAGI</p>\n</td>\n<td width=\"120\">\n<p>PI3K; stabilizes PTEN</p>\n</td>\n<td width=\"104\">\n<p>--</p>\n</td>\n<td width=\"98\">\n<p>All types</p>\n</td>\n<td width=\"84\">\n<p>--</p>\n</td>\n<td width=\"100\">\n<p>PI3Ki</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"106\">\n<p>TACC</p>\n</td>\n<td width=\"120\">\n<p>Possibly stimulates PI3K AURKA signaling</p>\n</td>\n<td width=\"104\">\n<p>--</p>\n</td>\n<td width=\"98\">\n<p>BRAF and NRAS mutated</p>\n</td>\n<td width=\"84\">\n<p>5%</p>\n</td>\n<td width=\"100\">\n<p>PI3Ki, AURKAi</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"106\">\n<p>PREX2</p>\n</td>\n<td width=\"120\">\n<p>RHO/RAC/MAPK; Rac exchange factor</p>\n</td>\n<td width=\"104\">\n<p>Point mutations</p>\n</td>\n<td width=\"98\">\n<p>BRAF or NRAS mutated</p>\n</td>\n<td width=\"84\">\n<p>14%</p>\n</td>\n<td width=\"100\">\n<p>--</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"106\">\n<p>RAC1</p>\n</td>\n<td width=\"120\">\n<p>RHO/RAC/MAPK; Regulator of cell adhesion, invasion, migration</p>\n</td>\n<td width=\"104\">\n<p>Point mutations</p>\n</td>\n<td width=\"98\">\n<p>BRAF or NRAS mutated</p>\n</td>\n<td width=\"84\">\n<p>9% of sun exposed</p>\n</td>\n<td width=\"100\">\n<p>--</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"106\">\n<p>MAP2K1, MAP2K2</p>\n</td>\n<td width=\"120\">\n<p>MAPK (MEK1/2)</p>\n</td>\n<td width=\"104\">\n<p>Mutations</p>\n</td>\n<td width=\"98\">\n<p>BRAF mutated; BRAF, NRAF wild type</p>\n</td>\n<td width=\"84\">\n<p>5%</p>\n</td>\n<td width=\"100\">\n<p>ERKi</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"106\">\n<p>MAP3K5, MAP3K9</p>\n</td>\n<td width=\"120\">\n<p>RHO/RAC/MAPK</p>\n</td>\n<td width=\"104\">\n<p>Mutations, loss of heterozygocity</p>\n</td>\n<td width=\"98\">\n<p>All types</p>\n</td>\n<td width=\"84\">\n<p>85% and 67%</p>\n</td>\n<td width=\"100\">\n<p>MEKi, ERKi</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"106\">\n<p>\u00a0</p>\n</td>\n<td width=\"120\">\n<p>\u00a0</p>\n</td>\n<td width=\"104\">\n<p>\u00a0</p>\n</td>\n<td width=\"98\">\n<p>\u00a0</p>\n</td>\n<td width=\"84\">\n<p>\u00a0</p>\n</td>\n<td width=\"100\">\n<p>\u00a0</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"106\">\n<p>MYC</p>\n</td>\n<td width=\"120\">\n<p>Transcription</p>\n</td>\n<td width=\"104\">\n<p>Amplification</p>\n</td>\n<td width=\"98\">\n<p>All types</p>\n</td>\n<td width=\"84\">\n<p>20-40%</p>\n</td>\n<td width=\"100\">\n<p>mTORi?<i> </i></p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"106\">\n<p>ETV1</p>\n</td>\n<td width=\"120\">\n<p>Transcription</p>\n</td>\n<td width=\"104\">\n<p>Amplification</p>\n</td>\n<td width=\"98\">\n<p>All types</p>\n</td>\n<td width=\"84\">\n<p>15%</p>\n</td>\n<td width=\"100\">\n<p>--</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"106\">\n<p>TP53</p>\n</td>\n<td width=\"120\">\n<p>Cell cycle, apoptosis</p>\n</td>\n<td width=\"104\">\n<p>Point mutation</p>\n</td>\n<td width=\"98\">\n<p>All types</p>\n</td>\n<td width=\"84\">\n<p>10-20%</p>\n</td>\n<td width=\"100\">\n<p>--</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"106\">\n<p>MDM4</p>\n</td>\n<td width=\"120\">\n<p>Negative regulator of p53</p>\n</td>\n<td width=\"104\">\n<p>Overexpression</p>\n</td>\n<td width=\"98\">\n<p>All types</p>\n</td>\n<td width=\"84\">\n<p>65%</p>\n</td>\n<td width=\"100\">\n<p>--</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"106\">\n<p>CDKN2A</p>\n<p>(P16INK4a, p14ARF)*</p>\n</td>\n<td width=\"120\">\n<p>Negative regulator of TP53 and RB</p>\n</td>\n<td width=\"104\">\n<p>Point mutation, deletion</p>\n</td>\n<td width=\"98\">\n<p>BRAF and NRAS mutated, KIT amplified</p>\n</td>\n<td width=\"84\">\n<p>30-40%</p>\n</td>\n<td width=\"100\">\n<p>--</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"106\">\n<p>BCL2, BCL2A1</p>\n</td>\n<td width=\"120\">\n<p>Suppression of apoptosis</p>\n</td>\n<td width=\"104\">\n<p>Elevated expression,</p>\n<p>amplification (BCL2A1)</p>\n</td>\n<td width=\"98\">\n<p>All types</p>\n</td>\n<td width=\"84\">\n<p>ND</p>\n<p>30% (BCL2A1)</p>\n</td>\n<td width=\"100\">\n<p>BH3 mimetics?</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"106\">\n<p>CCND1</p>\n</td>\n<td width=\"120\">\n<p>Cell cycle, G1/S cyclin</p>\n</td>\n<td width=\"104\">\n<p>Amplifications</p>\n</td>\n<td width=\"98\">\n<p>More frequent in BRAF, NRAS wild type</p>\n</td>\n<td width=\"84\">\n<p>11%</p>\n</td>\n<td width=\"100\">\n<p>CDKi?</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"106\">\n<p>CDK4*</p>\n</td>\n<td width=\"120\">\n<p>Cell cycle, G1/S cyclin-dependent kinase</p>\n</td>\n<td width=\"104\">\n<p>Amplifications</p>\n</td>\n<td width=\"98\">\n<p>More frequent in BRAF, NRAS wild type</p>\n</td>\n<td width=\"84\">\n<p>3%</p>\n</td>\n<td width=\"100\">\n<p>Flavopiridol, selective CDKi</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"106\">\n<p>PPP6C</p>\n</td>\n<td width=\"120\">\n<p>Catalytic unit of phosphatase, negative regulator of CCND1, Aurora</p>\n</td>\n<td width=\"104\">\n<p>Point mutations</p>\n</td>\n<td width=\"98\">\n<p>BRAF and NRAS mutated</p>\n</td>\n<td width=\"84\">\n<p>12% sun exposed</p>\n</td>\n<td width=\"100\">\n<p>AURKAi?</p>\n<p>CDKi?</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"106\">\n<p>STK19</p>\n</td>\n<td width=\"120\">\n<p>Kinase; unknown function</p>\n</td>\n<td width=\"104\">\n<p>Point mutations</p>\n</td>\n<td width=\"98\">\n<p>BRAF and NRAS mutated</p>\n</td>\n<td width=\"84\">\n<p>5%</p>\n</td>\n<td width=\"100\">\n<p>--</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"106\">\n<p>SNX3</p>\n</td>\n<td width=\"120\">\n<p>Endosome protein sorting</p>\n</td>\n<td width=\"104\">\n<p>Point mutations</p>\n</td>\n<td width=\"98\">\n<p>BRAF mutated; BRAF,NRAS wild type</p>\n</td>\n<td width=\"84\">\n<p>7%</p>\n</td>\n<td width=\"100\">\n<p>--</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"106\">\n<p>GRIN2A</p>\n</td>\n<td width=\"120\">\n<p>Ionotropic glutamate-gated ion channel, NMDA binding</p>\n</td>\n<td width=\"104\">\n<p>--</p>\n</td>\n<td width=\"98\">\n<p>--</p>\n</td>\n<td width=\"84\">\n<p>25%</p>\n</td>\n<td width=\"100\">\n<p>--</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"106\">\n<p>GRM3</p>\n</td>\n<td width=\"120\">\n<p>Possibly accessory MAPK signaling</p>\n</td>\n<td width=\"104\">\n<p>Point mutations</p>\n</td>\n<td width=\"98\">\n<p>ND</p>\n</td>\n<td width=\"84\">\n<p>--</p>\n</td>\n<td width=\"100\">\n<p>--</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"106\">\n<p>TRRAP</p>\n</td>\n<td width=\"120\">\n<p>Part of histone acetyltransferase complex</p>\n</td>\n<td width=\"104\">\n<p>Point mutations</p>\n</td>\n<td width=\"98\">\n<p>ND</p>\n</td>\n<td width=\"84\">\n<p>--</p>\n</td>\n<td width=\"100\">\n<p>--</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"106\">\n<p>ARID2</p>\n</td>\n<td width=\"120\">\n<p>SWI/SNF Chromatin remodeling, SWI/SNF complex</p>\n</td>\n<td width=\"104\">\n<p>Inactivating mutations</p>\n</td>\n<td width=\"98\">\n<p>BRAF, NRAS mutated</p>\n</td>\n<td width=\"84\">\n<p>7-9%</p>\n</td>\n<td width=\"100\">\n<p>--</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"106\">\n<p>BAP1</p>\n</td>\n<td width=\"120\">\n<p>BRCA1 DNA repair</p>\n</td>\n<td width=\"104\">\n<p>Inactivating mutations</p>\n</td>\n<td width=\"98\">\n<p>BRAF, NRAS wild type\u2014uveal</p>\n</td>\n<td width=\"84\">\n<p>1% overall, 84% uveal</p>\n</td>\n<td width=\"100\">\n<p>--</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"106\">\n<p>NEDD9</p>\n</td>\n<td width=\"120\">\n<p>Integrin adaptor, promotes EMT and migration; metastasis</p>\n</td>\n<td width=\"104\">\n<p>Amplification</p>\n</td>\n<td width=\"98\">\n<p>Probably all</p>\n</td>\n<td width=\"84\">\n<p>50-60%</p>\n</td>\n<td width=\"100\">\n<p>--</p>\n</td>\n</tr>\n<tr>\n<td colspan=\"6\" height=\"116\" valign=\"TOP\" width=\"682\">\n<p><i><b>Bold font</b></i><i> of gene names indicates that these mutations are considered to be driver mutations based on presence in familial melanoma and/or high frequency of mutations is sporadic, even though experimental evidence of their precise role in melanomagenesi is not always available.</i></p>\n<p><i>* germline mutations in high-risk melanoma families; MC1R mutation is not listed. </i></p>\n<p><i>Not listed: rare mutations in HRAS, RAF1 and other oncogenes.</i></p>\n<p><i>Many of the data on the mutation frequency are based on relatively small sample tumor sizes and should be considered with caution.</i></p>\n<p>\u00a0</p>\n</td>\n</tr>\n</tbody>\n</table>\n\n<p id=\"erb-3a917676-18b9-4a45-b9b9-40422fdcacde\"><b>BRAF</b></p>\n<p id=\"erb-e1a55794-e3c6-4b3e-897b-6fc90acde642\">BRAF mutations (V600E in 70% to 80% of all BRAF mutations in all cancers) occur early in melanomagenesis and are found in a high percentage of melanocytic nevi. Other mutations at the V600 position leading to alternate amino acid substitutions (V600K, V600D, V600R) account for another 5% to 15% of all BRAF mutations. Mutations in BRAF alone do not induce melanoma, and the high frequency of BRAF mutations in benign nevi supports this conclusion <a class=\"rlc-reference\" data-ref-info=\"Pollock PM, Harper UL, Hansen KS, et al: High frequency of BRAF mutations in nevi. Nat Genet 33:19-20, 2003.\" href=\"#_ENREF_6\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/12447372\"><sup>6</sup></a>. Moreover, expression of the BRAF mutations in preclinical models is associated with the phenomenon known as oncogene-induced senescence (OIS) <a class=\"rlc-reference\" data-ref-info=\"Michaloglou C, Vredeveld LC, Soengas MS, et al: BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 436:720-4, 2005.\" href=\"#_ENREF_7\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/16079850\"><sup>7</sup></a>, which results in a cell-cycle arrest in BRAFV600E-expressing cells. Additional genetic events in BRAF-mutant cells, such as deletion of CDKN2A or PTEN, are necessary to elicit a fully cancerous phenotype (reviewed by Flaherty, 2012 <a class=\"rlc-reference\" data-ref-info=\"Flaherty KT, Hodi FS, Fisher DE: From genes to drugs: targeted strategies for melanoma. Nat Rev Cancer 12:349-61, 2012.\" href=\"#_ENREF_8\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22475929\"><sup>8</sup></a>).</p>\n<p id=\"erb-c48a741c-5cdb-4b39-9460-b9cd14a83421\">Overall, about 50% of melanomas of all clinical types have mutations in BRAF. BRAF mutations are more frequent in melanomas that develop in intermittently sun-exposed skin and less so in acral and mucosal melanomas. BRAF mutations are not found in uveal melanomas. Mutations in BRAF and NRAS (~20% of melanomas of the same origin/location as BRAF-mutated melanomas) are almost always mutually exclusive. The V600E mutation in BRAF confers to this kinase the ability to activate MEK (the only known downstream target of BRAF) independent of RAS.</p>\n<p id=\"erb-3df6fc53-3ec1-43bd-81c1-82e40a4d318e\">The reported results of trials with selective oral BRAF inhibitors showed efficacy in melanoma patients with BRAFV600E mutations <a class=\"rlc-reference\" data-ref-info=\"Flaherty KT, Puzanov I, Kim KB, et al: Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363:809-19, 2010.\" href=\"#_ENREF_9\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/20818844\"><sup>9</sup></a>. In addition, inhibition of MEK (the only known phosphorylation substrate of BRAF) is considered to be a valid therapeutic intervention for both BRAF- and NRAS-mutated melanoma. However, the success of BRAF inhibitors has not come without problems:</p>\n<ul>\n<li>\n<p>A significant minority of patients with mutant BRAF show no response to BRAF inhibition <a class=\"rlc-reference\" data-ref-info=\"Jordan EJ, Kelly CM: Vemurafenib for the treatment of melanoma. Expert Opin Pharmacother 13:2533-43, 2012.\" href=\"#_ENREF_10\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23094782\"><sup>10</sup></a>. Preclinical results suggest that this group has a variety of additional genomic somatic alterations that confer the resistance phenotype (discussed below).</p>\n</li>\n<li>\n<p>Most patients initially responding to BRAF inhibitors develop resistance to those inhibitors within a relatively short period of time (&lt;1 year).</p>\n</li>\n<li>\n<p>About 20% of BRAF inhibitor-treated patients developed cutaneous squamous cell carcinomas <a class=\"rlc-reference\" data-ref-info=\"Jordan EJ, Kelly CM: Vemurafenib for the treatment of melanoma. Expert Opin Pharmacother 13:2533-43, 2012.\" href=\"#_ENREF_10\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23094782\"><sup>10</sup></a>. Photodynamic therapy (PTD) was reported to be effective in treatment of these usually numerous tumors <a class=\"rlc-reference\" data-ref-info=\"Alloo A, Garibyan L, LeBoeuf N, et al: Photodynamic therapy for multiple eruptive keratoacanthomas associated with vemurafenib treatment for metastatic melanoma. Arch Dermatol 148:363-6, 2012.\" href=\"#_ENREF_11\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22431777\"><sup>11</sup></a>. Accelerated development of RAS-mutant leukemia in a patient treated with vemurafenib was also described <a class=\"rlc-reference\" data-ref-info=\"Callahan MK, Rampal R, Harding JJ, et al: Progression of RAS-mutant leukemia during RAF inhibitor treatment. N Engl J Med 367:2316-21, 2012.\" href=\"#_ENREF_12\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23134356\"><sup>12</sup></a>, raising concern about the development of squamous cell carcinoma (SCC) and other malignancies as a consequence of BRAF inhibition <a class=\"rlc-reference\" data-ref-info=\"Gibney GT, Messina JL, Fedorenko IV, et al: Paradoxical oncogenesis-the long-term effects of BRAF inhibition in melanoma. Nat Rev Clin Oncol, 2013.\" href=\"#_ENREF_13\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23712190\"><sup>13</sup></a>.</p>\n</li>\n<li>\n<p>Paradoxical effects of BRAFV600 inhibitors in activating wild-type BRAF and/or CRAF. The mechanism of this is thought to be due to conformational changes in wild-type BRAF protein induced by binding of the inhibitors promoting the formation of heterodimers with other RAF isoforms, leading to MEK activation <a class=\"rlc-reference\" data-ref-info=\"Poulikakos PI, Zhang C, Bollag G, et al: RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 464:427-30, 2010.\" href=\"#_ENREF_14\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/20179705\"><sup>14</sup></a>. This effect might trigger growth of new malignant melanoma tumors that have wild-type BRAF, but high expression of RAS-GTP, Akt, and cyclin D1 <sup><a class=\"rlc-reference\" data-ref-info=\"Dalle S, Poulalhon N, Debarbieux S, et al: Second primary melanomas under vemurafenib. Br J Dermatol, 2012.\" href=\"#_ENREF_15\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23066856\">15</a>,<a class=\"rlc-reference\" data-ref-info=\"Zimmer L, Hillen U, Livingstone E, et al: Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition. J Clin Oncol 30:2375-83, 2012.\" href=\"#_ENREF_16\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22614973\">16</a></sup>. A recent study provided a possible mechanism of activation of wild-type BRAF by inhibitors through a relief of inhibitory autophosphorylation <a class=\"rlc-reference\" data-ref-info=\"Holderfield M, Merritt H, Chan J, et al: RAF Inhibitors Activate the MAPK Pathway by Relieving Inhibitory Autophosphorylation. Cancer Cell 23:594-602, 2013.\" href=\"#_ENREF_17\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23680146\"><sup>17</sup></a>.</p>\n</li>\n</ul>\n\n<p id=\"erb-399b74ba-6689-42b6-bac7-068784f156bf\"><u>Treatment approaches</u></p>\n<p id=\"erb-7425b0ee-7e11-4782-ad34-65dfee876f06\">The U.S. Food and Drug Administration (FDA) approved the mutant BRAF inhibitor <a href=\"http://www.cancer.gov/drugdictionary?CdrID=528954\">vemurafenib</a>/Zelboraf in 2011. Another inhibitor, <a href=\"http://www.cancer.gov/drugdictionary?CdrID=641977\">dabrafenib</a>/Tafinlar, was approved in May 2013. Dabrafenib showed clinical responses in 59% of patients with V600E/K mutation, including 7% complete responders <a class=\"rlc-reference\" data-ref-info=\"Ascierto PA, Minor D, Ribas A, et al: Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic Melanoma. J Clin Oncol, 2013.\" href=\"#_ENREF_18\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23918947\"><sup>18</sup></a>. A newer inhibitor, <a href=\"http://www.cancer.gov/drugdictionary?CdrID=712549\">LGX818</a>, is in early stages of testing (Supplemental Table 1). New inhibitors are in development to eliminate the side effects associated with the paradoxical activation by vemurafenib of the ERK1/2 pathway in wild-type BRAF cells. PLX7904, a new \u201cparadox-breaking\u201d BRAF inhibitor, appears to inhibit ERK1/2 in BRAF-mutant cells without activating BRAF in BRAF wild-type cells <a class=\"rlc-reference\" data-ref-info=\"Le K, Blomain E, Rodeck U, et al: Selective RAF inhibitor impairs ERK1/2 phosphorylation and growth in mutant NRAS, vemurafenib-resistant melanoma cells. Pigment Cell Melanoma Res, 2013.\" href=\"#_ENREF_19\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23490205\"><sup>19</sup></a>. Dosing schedules with BRAF inhibitors were explored in a genetically engineered mouse model (GEMM), where intermittent inhibition of BRAF by vemurafenib works better than continuous treatment <a class=\"rlc-reference\" data-ref-info=\"Das Thakur M, Salangsang F, Landman AS, et al: Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature, 2013.\" href=\"#_ENREF_20\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23302800\"><sup>20</sup></a>. Intermittent dosing of vemurafenib has not yet been tested in clinical trials.</p>\n<p id=\"erb-b9336ea1-12b3-44f3-941d-9e8d4f9fc368\">Inhibition of MEK has been explored in clinical trials for melanoma patients with mutant BRAF <sup><a class=\"rlc-reference\" data-ref-info=\"Falchook GS, Lewis KD, Infante JR, et al: Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol 13:782-9, 2012.\" href=\"#_ENREF_21\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22805292\">21</a>,<a class=\"rlc-reference\" data-ref-info=\"Flaherty KT, Robert C, Hersey P, et al: Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 367:107-14, 2012.\" href=\"#_ENREF_22\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22663011\">22</a></sup>. A phase III randomized trial comparing MEK inhibitor trametinib to chemotherapy showed a marked improvement in both progression free and overall survival (PFS and OS) in the trametinib arm <a class=\"rlc-reference\" data-ref-info=\"Flaherty KT, Robert C, Hersey P, et al: Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 367:107-14, 2012.\" href=\"#_ENREF_22\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22663011\"><sup>22</sup></a>. Combination of <a href=\"http://www.cancer.gov/drugdictionary?CdrID=532294\">selumetinib</a>/AZD6244 with alkylating agent dacarbazine improved PFS in a randomized clinical trial <a class=\"rlc-reference\" data-ref-info=\"Robert C, Dummer R, Gutzmer R, et al: Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study. Lancet Oncol 14:733-40, 2013.\" href=\"#_ENREF_23\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23735514\"><sup>23</sup></a>. MEK inhibitor <a href=\"http://www.cancer.gov/drugdictionary?CdrID=599034\">trametinib</a> showed some clinical responses in BRAF-mutant patients that had undergone previous immune- or chemotherapy, but had no effect in patients who were previously treated with vemurafenib <a class=\"rlc-reference\" data-ref-info=\"Kim KB, Kefford R, Pavlick AC, et al: Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol 31:482-9, 2013.\" href=\"#_ENREF_24\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23248257\"><sup>24</sup></a>. This strongly indicates that mechanisms involved in development of resistance to mutant BRAF confer resistance to MEK inhibition as well. FDA approved trametinib/Mekinist for melanoma in May 2013.</p>\n<p id=\"erb-20466fe4-b2c4-4bda-bf8b-0e4ae60c8115\">Most importantly, it is increasingly clear that combination treatments, such as BRAF and MEK inhibition investigated in a recently reported clinical study <a class=\"rlc-reference\" data-ref-info=\"Flaherty KT, Infante JR, Daud A, et al: Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 367:1694-703, 2012.\" href=\"#_ENREF_25\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23020132\"><sup>25</sup></a>, have potential for a robust and lasting clinical response in the treatment of BRAF-mutant melanoma. Combination dabrafenib+trametinib trial responses were not only more numerous compared to dabrafenib alone, but also more durable. This combination is now being considered for approval by the FDA. BRAF inhibitors are explored in a number of clinical trials in combination with inhibitors of MEK, including four phase III trials (<a href=\"http://www.clinicaltrials.gov/ct2/show/NCT01689519\">NCT01689519</a>, <u><a href=\"http://clinicaltrials.gov/ct2/results?term=NCT01597908&amp;Search=Search\">NCT01597908</a>, <a href=\"http://clinicaltrials.gov/ct2/results?term=NCT01682083&amp;Search=Search\">NCT01682083</a>, <a href=\"http://clinicaltrials.gov/ct2/results?term=NCT01682083&amp;Search=Search\">NCT01682083</a>), </u> the first of which involves a new MEK inhibitor GDC-0973 or cobimetinib<u>. </u>Other early-phase combination trials with approved BRAF inhibitors explore addition of inhibitors of PI3K, AKT, CDK, HSP90, RTKs and other targets, as well as immunotherapy (<a href=\"http://www.cancercommons.org/researchers-clinicians/melanoma/melanoma-stats-page/#tabs3\">Supplemental Table 2</a>).</p>\n<p id=\"erb-00e4aeed-05c7-4c1f-b6e2-319e554e2ce1\">Targeting ERK1/2, the kinases at the lower end of the MAPK cascade, is an emerging therapeutic strategy, with several candidate drugs in preclinical development. ERK inhibitors have an important advantage of being potentially active in the setting of acquired resistance to inhibitors of BRAF or MEK <a class=\"rlc-reference\" data-ref-info=\"Morris EJ, Jha S, Restaino CR, et al: Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors. Cancer Discov 3:742-50, 2013.\" href=\"#_ENREF_26\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23614898\"><sup>26</sup></a>.</p>\n\n<p id=\"erb-2397f2b4-48cb-4573-b9f9-8332aee247fc\"><b>BRAF mutations other than V600:</b></p>\n<p id=\"erb-db0b0ad8-d261-4566-9777-6aa64cd53f28\">A number of BRAF mutants other than V600 were identified in human cancers <a class=\"rlc-reference\" data-ref-info=\"Davies H, Bignell GR, Cox C, et al: Mutations of the BRAF gene in human cancer. Nature 417:949-54, 2002.\" href=\"#_ENREF_27\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/12068308\"><sup>27</sup></a>. Some of these have a relatively low kinase activity compared to BRAFV600E <a class=\"rlc-reference\" data-ref-info=\"Wan PT, Garnett MJ, Roe SM, et al: Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116:855-67, 2004.\" href=\"#_ENREF_28\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/15035987\"><sup>28</sup></a>. Three mutants with low activity\u2014G469E, G466A, and N581S\u2014were shown to still activate ERK via a mechanism involving their ability to strongly activate CRAF<a class=\"rlc-reference\" data-ref-info=\"Wan PT, Garnett MJ, Roe SM, et al: Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116:855-67, 2004.\" href=\"#_ENREF_28\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/15035987\"><sup>28</sup></a>. The low-activity BRAF mutations G469E/D594G that signal through CRAF were later identified in a panel of melanoma cell lines <a class=\"rlc-reference\" data-ref-info=\"Smalley KS, Xiao M, Villanueva J, et al: CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations. Oncogene 28:85-94, 2009.\" href=\"#_ENREF_29\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/18794803\"><sup>29</sup></a>. Analysis of BRAF exon 15 in 49 tumors negative for BRAFV600 mutations, as well as other known driver mutations in KIT, NRAS, GNAQ, and GNA11, showed that two (4%) harbored L597 mutations and another two involved BRAF D594 and K601 mutations <a class=\"rlc-reference\" data-ref-info=\"Smalley KS, Xiao M, Villanueva J, et al: CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations. Oncogene 28:85-94, 2009.\" href=\"#_ENREF_29\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/18794803\"><sup>29</sup></a>.</p>\n<p id=\"erb-b97a3395-aa48-48a7-95e1-e1114e0ca301\">Melanomas with BRAF mutations other than V600 have not been specifically targeted in clinical trials. Kinase inhibitor <a href=\"http://www.cancer.gov/drugdictionary?CdrID=299013\">sorafenib</a> is a better inhibitor of CRAF than mutant BRAF; sorafenib induced apoptosis <i>in vitro</i> and in a xenograft model <i>in vivo</i> in tumors with G469E/D594G <a class=\"rlc-reference\" data-ref-info=\"Smalley KS, Xiao M, Villanueva J, et al: CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations. Oncogene 28:85-94, 2009.\" href=\"#_ENREF_29\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/18794803\"><sup>29</sup></a>. A patient with BRAF(L597S)-mutant metastatic melanoma responded significantly to treatment with the MEK inhibitor <a href=\"http://www.cancer.gov/drugdictionary?CdrID=651550\">TAK-733</a> <a class=\"rlc-reference\" data-ref-info=\"Dahlman KB, Xia J, Hutchinson K, et al: BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors. Cancer Discov 2:791-7, 2012.\" href=\"#_ENREF_30\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22798288\"><sup>30</sup></a>. Another patient with this mutation responded to trametinib in the phase I clinical trials mentioned above <a class=\"rlc-reference\" data-ref-info=\"Falchook GS, Lewis KD, Infante JR, et al: Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol 13:782-9, 2012.\" href=\"#_ENREF_21\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22805292\"><sup>21</sup></a>.</p>\n\n<p id=\"erb-29e0c1a8-d990-408d-a9c5-9a0e2b31624f\"><b>NRAS</b></p>\n<p id=\"erb-121014bf-56a1-442d-819e-b88d758f4a78\">Approximately 20% of melanomas have mutations in the GTPase NRAS. NRAS and BRAF mutations are almost always mutually exclusive. Therapeutic approaches targeting mutant NRAS directly have not been successful. Combination treatments targeting the downstream effectors of NRAS remain a viable option.</p>\n\n<p id=\"erb-c83f0610-fc64-4d20-8c1a-4d621e037ad6\"><u>Potential treatment approaches</u></p>\n<p id=\"erb-2f5b6058-6774-4e28-992d-e7a3ec729b13\">The pathways downstream of NRAS that could be targeted simultaneously in NRAS-mutant melanoma include, but are not limited to, MEK, PI3K/mTOR, and cell-cycle-related targets. PTEN abnormalities are rarely found in NRAS-mutant tumors <a class=\"rlc-reference\" data-ref-info=\"Hodis E, Watson IR, Kryukov GV, et al: A landscape of driver mutations in melanoma. Cell 150:251-63, 2012.\" href=\"#_ENREF_31\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22817889\"><sup>31</sup></a>. Monotherapy with the MEK inhibitor MEK162 showed limited partial responses (20%) in NRAS-mutant patients and represents the most active single-agent targeted therapy evaluated to date <a class=\"rlc-reference\" data-ref-info=\"Ascierto PA, Schadendorf D, Berking C, et al: MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol, 2013.\" href=\"#_ENREF_32\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23414587\"><sup>32</sup></a>. A recent study identified the basis of different activity of MEK inhibitors in BRAF versus KRAS mutant cancers. Unlike trametinib-like inhibitors that inhibit phosphorylated MEK and are effective in the setting of BRAFV600 mutants, the new class of inhibitors, like <a href=\"http://www.cancer.gov/drugdictionary?CdrID=673612\">GDC-0623</a>, inhibit feedback activation of MEK by RAF, and are therefore more efficacious in the setting of mutant KRAS <a class=\"rlc-reference\" data-ref-info=\"Hatzivassiliou G, Haling JR, Chen H, et al: Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers. Nature, 2013.\" href=\"#_ENREF_33\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23934108\"><sup>33</sup></a>. It is likely that GDC-0623, which is currently in a phase I clinical trial, might be efficacious in melanomas with mutant NRAS.</p>\n<p id=\"erb-1d94764c-cc8e-46a1-9141-20b6d76bca68\">Preclinical studies indicate several potential points of intervention:</p>\n<ul>\n<li>\n<p>NRAS-driven melanoma in genetically engineered mice responded only to the combination of MEK and PI3K/mTOR dual inhibitors out of 16 treatment combinations tested <a class=\"rlc-reference\" data-ref-info=\"Roberts PJ, Usary JE, Darr DB, et al: Combined PI3K/mTOR and MEK inhibition provides broad antitumor activity in faithful murine cancer models. Clin Cancer Res 18:5290-303, 2012.\" href=\"#_ENREF_34\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22872574\"><sup>34</sup></a>. Combined targeting of MEK and PI3K was superior to MEK and mTOR inhibition in NRAS-mutant melanoma cell lines and xenografts <a class=\"rlc-reference\" data-ref-info=\"Posch C, Moslehi H, Feeney L, et al: Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo. Proc Natl Acad Sci U S A, 2013.\" href=\"#_ENREF_35\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23431193\"><sup>35</sup></a>. A number of clinical trials examining this combination are ongoing (Supplemental Table 2).</p>\n</li>\n<li>\n<p>In an inducible model of NRAS-mutant melanoma, genetic ablation of NRAS triggered cell-cycle arrest and apoptosis, while pharmacological inhibition of MEK activated apoptosis, but not cell-cycle arrest. CDK4 was implicated as a key driver of these differences and combined pharmacological inhibition of MEK and CDK4 in vivo led to substantial synergy in therapeutic efficacy in a mouse model <a class=\"rlc-reference\" data-ref-info=\"Kwong LN, Costello JC, Liu H, et al: Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma. Nat Med 18:1503-10, 2012.\" href=\"#_ENREF_36\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22983396\"><sup>36</sup></a>. The phase I/II trial <a href=\"http://clinicaltrials.gov/show/NCT01781572\">NCT01781572</a> with MEK inhibitor MEK162 and CDK inhibitor <a href=\"http://www.cancer.gov/drugdictionary?CdrID=689330\">LEE011</a> for NRAS-mutant melanoma is ongoing.</p>\n</li>\n<li>\n<p>Sensitivity of NRAS-mutant cell lines to MEK inhibitors was shown to be associated with expression of AHR (aryl hydrocarbon receptor) <i>in vitro</i> <a class=\"rlc-reference\" data-ref-info=\"Barretina J, Caponigro G, Stransky N, et al: The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483:603-7, 2012.\" href=\"#_ENREF_37\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22460905\"><sup>37</sup></a>.</p>\n</li>\n<li>\n<p>A study of combinatorial drug interactions <i>in vitro</i> pinpointed the combination of simvastatin with a CDK inhibitor as the only fairly effective cytotoxic treatment for NRAS-mutated melanoma cell lines <a class=\"rlc-reference\" data-ref-info=\"Held MA, Langdon CG, Platt JT, et al: Genotype-selective combination therapies for melanoma identified by high-throughput drug screening. Cancer Discov 3:52-67, 2013.\" href=\"#_ENREF_38\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23239741\"><sup>38</sup></a>.</p>\n</li>\n</ul>\n<p id=\"erb-7b5ee0ed-beab-42a7-8107-a48cabf5db8f\">The combinations of inhibitors to\u00a0target NRAS-activated signaling through MEK and PI3K, MEK and AKT, MEK and PI3K/mTOR, as well as MEK and VEGF-receptor inhibition, are now in early phase clinical trials. Only a few trials specifically target melanomas with NRAS mutations, but a number of trials use combinations of agents or single agents that could have therapeutic benefits in this subgroup of melanoma. Single agents in phase I or early phase II trials include inhibitors of CDK (<a href=\"http://www.cancer.gov/drugdictionary?cdrid=454586\">PD0332991</a>, <a href=\"http://www.cancer.gov/drugdictionary?CdrID=612855\">dinaciclib</a> , <a href=\"http://www.cancer.gov/drugdictionary?CdrID=706364\">LY2835219</a>, <a href=\"http://www.cancer.gov/drugdictionary?CdrID=684718\">BAY1000394</a>, <a href=\"http://www.cancer.gov/drugdictionary?CdrID=689330\">LEE011</a>), the Notch pathway (<a href=\"http://www.cancer.gov/drugdictionary?CdrID=662240\">RO4929097</a>), and Aurora kinase A (<a href=\"http://www.cancer.gov/drugdictionary?CdrID=561286\">MLN8237/alisertib</a>, <a href=\"http://www.cancer.gov/drugdictionary?CdrID=670668\">GSK1070916A</a>) (<a href=\"http://www.cancercommons.org/researchers-clinicians/melanoma/melanoma-stats-page/#tabs3\">Supplemental Table 2</a>).</p>\n\n<p id=\"erb-b071a755-298f-4257-a9f9-fcab63525f79\"><b>GNAQ and GNA11</b></p>\n<p id=\"erb-6dc97bcb-38cc-4190-880b-813767ccf9ce\">Activating mutations in GNAQ and GNA11, encoding members of the G\u03b1(q) family of G protein \u03b1 subunits, are driver oncogenes in uveal melanoma <sup><a class=\"rlc-reference\" data-ref-info=\"Van Raamsdonk CD, Bezrookove V, Green G, et al: Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature 457:599-602, 2009.\" href=\"#_ENREF_39\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/19078957\">39</a>,<a class=\"rlc-reference\" data-ref-info=\"Van Raamsdonk CD, Griewank KG, Crosby MB, et al: Mutations in GNA11 in uveal melanoma. N Engl J Med 363:2191-9, 2010.\" href=\"#_ENREF_40\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/21083380\">40</a></sup>. Mutations in GNAQ and GNA11 are mutually exclusive and are present in the vast majority of uveal melanomas <a class=\"rlc-reference\" data-ref-info=\"Daniels AB, Lee JE, MacConaill LE, et al: High throughput mass spectrometry-based mutation profiling of primary uveal melanoma. Invest Ophthalmol Vis Sci 53:6991-6, 2012.\" href=\"#_ENREF_41\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22977135\"><sup>41</sup></a>. GNA11 has a stronger association with metastatic uveal melanoma than GNAQ. Mutations in these GTP-binding proteins activate the MAPK pathway.</p>\n\n<p id=\"erb-fc13c7db-5dbf-416b-bbf6-8b50f985234c\"><u>Potential treatment approaches</u></p>\n<p id=\"erb-3f45a8cb-c2c6-407e-89ee-618c96ac11d7\">A randomized phase II clinical trial compared the MEK inhibitor <a href=\"http://www.cancer.gov/drugdictionary?CdrID=532294\">selumetinib</a> (AZD6244) with temozolomide (<a href=\"http://clinicaltrials.gov/ct2/show/NCT01143402\">NCT01143402</a>) with results showing superiority of selumetinib in terms of PFS and overall response rate (ORR), but not OS (J Clin Oncol 31, 2013 (suppl; abstr CRA9003). GNAQ mutation promotes resistance <i>in vitro</i> to selumetinib, but the combination of selumetinib with the ATP-competitive mTOR inhibitor <a href=\"http://www.cancer.gov/drugdictionary?CdrID=612860\">AZD8055</a> might be more promising <a class=\"rlc-reference\" data-ref-info=\"Ho AL, Musi E, Ambrosini G, et al: Impact of combined mTOR and MEK inhibition in uveal melanoma is driven by tumor genotype. PLoS One 7:e40439, 2012.\" href=\"#_ENREF_42\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22808163\"><sup>42</sup></a>. A trial of the MTOR inhibitor <a href=\"http://www.cancer.gov/drugdictionary\">everolimus</a> and the somatostatin-receptor-activating peptide <a href=\"http://www.cancer.gov/drugdictionary?CdrID=540440\">pasireotide</a>/SOM232 is recruiting patients (<a href=\"http://clinicaltrials.gov/show/NCT01252251\">NCT01252251</a>).</p>\n<p id=\"erb-36843aa5-922c-45aa-a04b-78ca7a0eca9a\">Inhibition of both PI3K and MAPK, but neither of them singly, might also work in uveal melanoma as seen from <i>in vitro</i> experiments <a class=\"rlc-reference\" data-ref-info=\"Khalili JS, Yu X, Wang J, et al: Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner. Clin Cancer Res 18:4345-55, 2012.\" href=\"#_ENREF_43\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22733540\"><sup>43</sup></a>. No trials involving this combination are ongoing.</p>\n<p id=\"erb-77521ba1-23f5-48e5-b4f9-cbdf0205ea7f\"><a href=\"http://www.cancer.gov/drugdictionary?CdrID=269069\">Enzastaurin</a> and <a href=\"http://www.cancer.gov/drugdictionary?CdrID=708113\">AEB071</a>, PKC inhibitors, have shown some activity against uveal melanoma cell lines <i>in vitro</i> <sup><a class=\"rlc-reference\" data-ref-info=\"Wu X, Li J, Zhu M, et al: Protein kinase C inhibitor AEB071 targets ocular melanoma harboring GNAQ mutations via effects on the PKC/Erk1/2 and PKC/NF-kappaB pathways. Mol Cancer Ther 11:1905-14, 2012.\" href=\"#_ENREF_44\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22653968\">44</a>,<a class=\"rlc-reference\" data-ref-info=\"Wu X, Zhu M, Fletcher JA, et al: The protein kinase C inhibitor enzastaurin exhibits antitumor activity against uveal melanoma. PLoS One 7:e29622, 2012.\" href=\"#_ENREF_45\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22253748\">45</a></sup>. PKC is involved in signal transduction from GNAQ to MEK. AEB071 is tested in a phase I clinical study <a href=\"http://clinicaltrials.gov/ct2/show/NCT01430416\">NCT01430416</a> as a single agent, and will be examined in combination with trametinib in <a href=\"http://clinicaltrials.gov/ct2/show/NCT01801358\">NCT01801358</a>.</p>\n<p id=\"erb-bc0149e9-addd-4f3c-820f-ed69b2d7d6b4\">Recently, it was shown that the guanine nucleotide exchange factor Trio is involved in mitogenic signaling through GNAQ and GNA11. Trio is essential for activating Rho- and Rac-regulated signaling pathways acting on JNK and p38, thereby transducing proliferative signals from G\u03b1(q) to the nucleus independently of phospholipase C-\u03b2 <a class=\"rlc-reference\" data-ref-info=\"Vaque JP, Dorsam RT, Feng X, et al: A Genome-wide RNAi Screen Reveals a Trio-Regulated Rho GTPase Circuitry Transducing Mitogenic Signals Initiated by G Protein-Coupled Receptors. Mol Cell, 2012.\" href=\"#_ENREF_46\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23177739\"><sup>46</sup></a>. These findings might open new avenues for treatment of uveal melanoma.</p>\n\n<p id=\"erb-bc5644e0-ee25-42fe-8ec3-babba6273873\"><b>MITF</b></p>\n<p id=\"erb-fa44da54-6f72-405c-8c16-ee1ef6408231\">Microphthalmia-associated transcription factor\u00a0MITF is a lineage survival oncogene, amplified in 20% of melanoma cases <a class=\"rlc-reference\" data-ref-info=\"Garraway LA, Widlund HR, Rubin MA, et al: Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 436:117-22, 2005.\" href=\"#_ENREF_47\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/16001072\"><sup>47</sup></a>; amplification of MITF is associated with a reduced 5-year survival. MITF is mutated in some familial melanomas <a class=\"rlc-reference\" data-ref-info=\"Yokoyama S, Woods SL, Boyle GM, et al: A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma. Nature 480:99-103, 2011.\" href=\"#_ENREF_48\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22080950\"><sup>48</sup></a>. The variant MITF(E318K) co-segregates with affected individuals in familial melanoma and is likely to be a gain-of-function (GOF) mutation. It abolishes a SUMO-ilation site on MITF that reportedly acts to inhibit transcriptional activity of MITF. Transcriptional targets of MITF have been identified and, besides a large number of lineage-specific transcripts, include genes related to regulation of cell cycle, among them CDK2 <a class=\"rlc-reference\" data-ref-info=\"Du J, Widlund HR, Horstmann MA, et al: Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF. Cancer Cell 6:565-76, 2004.\" href=\"#_ENREF_49\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/15607961\"><sup>49</sup></a>. Considering that MITF itself is currently not a druggable target, inhibition of CDK2 is a plausible aim in melanoma with MITF aberrations.</p>\n<p id=\"erb-6d81f45f-3bff-497a-b563-d2ab588338a3\">Other candidate targets in the MITF program include receptor tyrosine kinase TYRO3, which regulates expression of MITF in a SOX-10-dependent manner <a class=\"rlc-reference\" data-ref-info=\"Zhu S, Wurdak H, Wang Y, et al: A genomic screen identifies TYRO3 as a MITF regulator in melanoma. Proc Natl Acad Sci U S A 106:17025-30, 2009.\" href=\"#_ENREF_50\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/19805117\"><sup>50</sup></a>. Ubiquitin-specific protease 13 (USP13) was shown to be responsible for MITF deubiquitination and stabilization. USP13 is essential for melanoma growth <i>in vitro</i> and <i>in vivo</i> and might be another target in MITF-mutated melanoma <a class=\"rlc-reference\" data-ref-info=\"Zhao X, Fiske B, Kawakami A, et al: Regulation of MITF stability by the USP13 deubiquitinase. Nat Commun 2:414, 2011.\" href=\"#_ENREF_51\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/21811243\"><sup>51</sup></a>.</p>\n<p id=\"erb-79dbc95a-ad74-4dbb-afff-c6ef6388d5e0\">Hypoxia-inducible factor HIF1\uf061 was also reported to be a transcriptional target of MITF<a class=\"rlc-reference\" data-ref-info=\"Busca R, Berra E, Gaggioli C, et al: Hypoxia-inducible factor 1{alpha} is a new target of microphthalmia-associated transcription factor (MITF) in melanoma cells. J Cell Biol 170:49-59, 2005.\" href=\"#_ENREF_52\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/15983061\"><sup>52</sup></a>, and its expression is apparently stimulated by MITF with the well-known consequences of stimulating tumor survival, angiogenesis, and metastases. Paradoxically, expression of MITF itself is reduced under hypoxic conditions in normal melanocytes and melanoma via direct binding of transcription repressor DEC1, which is activated by HIF1\uf061 <a class=\"rlc-reference\" data-ref-info=\"Feige E, Yokoyama S, Levy C, et al: Hypoxia-induced transcriptional repression of the melanoma-associated oncogene MITF. Proc Natl Acad Sci U S A 108:E924-33, 2011.\" href=\"#_ENREF_53\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/21949374\"><sup>53</sup></a>. This suggests a negative feedback loop. A recent study implicated HIF1 factors in promoting melanoma invasion and metastases without affecting proliferation of the primary tumors <a class=\"rlc-reference\" data-ref-info=\"Hanna SC, Krishnan B, Bailey ST, et al: HIF1alpha and HIF2alpha independently activate SRC to promote melanoma metastases. J Clin Invest 123:2078-93, 2013.\" href=\"#_ENREF_54\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23563312\"><sup>54</sup></a>.</p>\n<p id=\"erb-66ff1602-c394-4575-9eae-8363fe1184de\">MITF is regulated by the transcription factor ATF2. Primary melanoma specimens that exhibit a high nuclear ATF2:MITF ratio were found to be associated with metastatic disease and poor prognosis <a class=\"rlc-reference\" data-ref-info=\"Shah M, Bhoumik A, Goel V, et al: A role for ATF2 in regulating MITF and melanoma development. PLoS Genet 6:e1001258, 2010.\" href=\"#_ENREF_55\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/21203491\"><sup>55</sup></a>. ATF2 control of melanoma development is mediated, in part, through its negative regulation of SOX10 and consequently, of MITF transcription. In human patients, virtually all congenital nevi and melanomas are SOX10 positive. SOX10 silencing in human melanoma cells suppresses neural crest stem cell properties, counteracts proliferation and cell survival, and completely abolishes <i>in vivo</i> tumor formation <a class=\"rlc-reference\" data-ref-info=\"Shakhova O, Zingg D, Schaefer SM, et al: Sox10 promotes the formation and maintenance of giant congenital naevi and melanoma. Nat Cell Biol 14:882-90, 2012.\" href=\"#_ENREF_56\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22772081\"><sup>56</sup></a>.</p>\n<p id=\"erb-d200f60f-071b-4017-aac2-19426ad77f8e\">SOX10, PAX3, and MITF participate in regulation of MET (HGF receptor), which is expressed at high levels in human melanoma <a class=\"rlc-reference\" data-ref-info=\"Puri N, Ahmed S, Janamanchi V, et al: c-Met is a potentially new therapeutic target for treatment of human melanoma. Clin Cancer Res 13:2246-53, 2007.\" href=\"#_ENREF_57\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/17404109\"><sup>57</sup></a>. MITF and PAX3 bind directly to the MET promoter; coexpression of these three proteins is found in melanoma biopsies <a class=\"rlc-reference\" data-ref-info=\"Mascarenhas JB, Littlejohn EL, Wolsky RJ, et al: PAX3 and SOX10 activate MET receptor expression in melanoma. Pigment Cell Melanoma Res 23:225-37, 2010.\" href=\"#_ENREF_58\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/20067553\"><sup>58</sup></a>.</p>\n<p id=\"erb-d1ee5b38-1cf4-4c2b-8f1a-82fcffe388aa\">PPAR-\u03b3 coactivators PGC-1\u03b1 and PGC-1\u03b2 are critical components of the melanogenic system governed by MITF. Melanomas with high expression of PGC-1\u03b1 exhibit increased expression of mitochondrial respiration complexes and increased oxidative phosphorylation <a class=\"rlc-reference\" data-ref-info=\"Vazquez F, Lim JH, Chim H, et al: PGC1alpha Expression Defines a Subset of Human Melanoma Tumors with Increased Mitochondrial Capacity and Resistance to Oxidative Stress. Cancer Cell, 2013.\" href=\"#_ENREF_59\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23416000\"><sup>59</sup></a>. The high MITF-high PGC-1\u03b1 expressing cells have an increased capacity to withstand oxidative stress, and, unlike PGC-1\u03b1 low cells, respond poorly to ROS-inducing agents such as PEITC or piperlongumine <a class=\"rlc-reference\" data-ref-info=\"Vazquez F, Lim JH, Chim H, et al: PGC1alpha Expression Defines a Subset of Human Melanoma Tumors with Increased Mitochondrial Capacity and Resistance to Oxidative Stress. Cancer Cell, 2013.\" href=\"#_ENREF_59\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23416000\"><sup>59</sup></a>. In addition, polymorphism studies reveal expression quantitative trait loci (eQTLs) in the PGC-1\u03b2 gene that correlate with protection from\u00a0melanoma\u00a0in humans <a class=\"rlc-reference\" data-ref-info=\"Shoag J, Haq R, Zhang M, et al: PGC-1 Coactivators Regulate MITF and the Tanning Response. Mol Cell, 2012.\" href=\"#_ENREF_60\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23201126\"><sup>60</sup></a>.</p>\n<p id=\"erb-e068becb-3c96-410d-a893-0d6bb568e710\">BCL2A1, a lineage-specific anti-apoptotic protein in the BCL2 family, is amplified and overexpressed in MITF-high melanomas, and confers resistance to BRAF inhibitor <a class=\"rlc-reference\" data-ref-info=\"Haq R, Yokoyama S, Hawryluk EB, et al: BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition. Proc Natl Acad Sci U S A 110:4321-6, 2013.\" href=\"#_ENREF_61\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23447565\"><sup>61</sup></a>. Suppression of BCL2A1 might have clinical benefit in this group of melanomas <a class=\"rlc-reference\" data-ref-info=\"Haq R, Yokoyama S, Hawryluk EB, et al: BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition. Proc Natl Acad Sci U S A 110:4321-6, 2013.\" href=\"#_ENREF_61\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23447565\"><sup>61</sup></a>.</p>\n<p id=\"erb-fe156a72-fc5c-4c7b-9d06-1eafd96aa9c7\">A recent paper proposed targeting of tyrosinase (MITF transcriptional target) by first inducing expression of MITF in melanoma cells using the well-known anti-folate drug methotrexate. The second step is to target the now high-MITF expressing cells with a designed pro-drug that is converted to a cytotoxic anti-folate drug by the MITF-induced tyrosinase <a class=\"rlc-reference\" data-ref-info=\"Saez-Ayala M, Montenegro MF, Sanchez-Del-Campo L, et al: Directed Phenotype Switching as an Effective Antimelanoma Strategy. Cancer Cell, 2013.\" href=\"#_ENREF_62\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23792190\"><sup>62</sup></a>. The death of thus targeted cells should then ensue as a consequence of dTTP depletion. There are many questions regarding the rationale and execution of this strategy, including how methotrexate induces MITF expression, how to reconcile the known oncogenic role of MITF in melanoma to further increase its expression, and how targeting DHFR<u>\u001f</u>\u2014a long explored target in cancer\u2014could overcome the acquired resistance long associated with methotrexate. The loss of tyrosinase expression in advanced amelanotic tumors would need to be considered as well.</p>\n<p id=\"erb-3382b250-c2fe-44b0-b3c7-bf0bf1d77968\">The crystal structure of MITF was resolved recently, paving the way for the future targeting of MITF in melanoma and other cancers <a class=\"rlc-reference\" data-ref-info=\"Pogenberg V, Ogmundsdottir MH, Bergsteinsdottir K, et al: Restricted leucine zipper dimerization and specificity of DNA recognition of the melanocyte master regulator MITF. Genes Dev 26:2647-58, 2012.\" href=\"#_ENREF_63\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23207919\"><sup>63</sup></a>.</p>\n\n<p id=\"erb-4c4936ae-46df-414a-ae19-014199f13b9a\"><u>Potential treatment approaches</u></p>\n<p id=\"erb-eb5ce7b7-720d-4dd4-9089-154cc95d4eb8\">These findings on MITF-mediated pathways remain in the domain of preclinical research, although targeting MET receptor is feasible because MET inhibitors (<a href=\"http://www.cancer.gov/drugdictionary?CdrID=461103\">cabozantinib</a> <i>et al.</i>) are in clinical trials for cancers other than melanoma.<u> </u>For now, <a href=\"http://www.cancer.gov/drugdictionary?CdrID=530790\">panobinostat</a>/ LBH589 (HDAC inhibitor) is in early clinical testing in melanoma (<a href=\"http://clinicaltrials.gov/ct2/show/NCT01065467\">NCT01065467</a>), and also involves examining the effect of panobinostat on MITF expression. The rationale behind investigating HAD inhibitors is supported by a study demonstrating efficacy of the HDAC inhibitor in suppressing MITF expression <i>in vitro</i> and <i>in vivo</i> <a class=\"rlc-reference\" data-ref-info=\"Yokoyama S, Feige E, Poling LL, et al: Pharmacologic suppression of MITF expression via HDAC inhibitors in the melanocyte lineage. Pigment Cell Melanoma Res 21:457-63, 2008.\" href=\"#_ENREF_64\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/18627530\"><sup>64</sup></a>.</p>\n<p id=\"erb-c00cea11-aeb5-4d3f-980d-3ddb71ceb33e\">A new study opened a possibility of targeting the nuclear translocation of ATF2 by inhibiting PKC\u03b5, which phosphorylates ATF2 and induces its transport to the nucleus. The two compounds found to promote cytoplasmic localization of ATF2 were identified in an image-based screen <a class=\"rlc-reference\" data-ref-info=\"Varsano T, Lau E, Feng Y, et al: Inhibition of Melanoma Growth by Small Molecules That Promote the Mitochondrial Localization of ATF2. Clin Cancer Res 19:2710-22, 2013.\" href=\"#_ENREF_65\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23589174\"><sup>65</sup></a>.</p>\n\n<p id=\"erb-269058c9-f44a-44d0-bea2-5a64411df53d\"><b>KIT </b></p>\n<p id=\"erb-35caa90b-a71f-46b3-a6f4-500b0c83963c\">KIT is a receptor tyrosine kinase activated by binding of the cytokine stem cell factor (SCF); mutations and amplification of KIT are found in particular subsets of melanoma. KIT mutations activate signal-transduction pathways (MAPK and PI3K) that ultimately lead to cell proliferation. Mutations in KIT are found in mucosal, acral, and chronically sun-exposed skin melanomas <a class=\"rlc-reference\" data-ref-info=\"Curtin JA, Busam K, Pinkel D, et al: Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 24:4340-6, 2006.\" href=\"#_ENREF_66\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/16908931\"><sup>66</sup></a>. KIT mutations are rare in melanoma, but the availability of selective inhibitors for KIT has prompted interest in targeting this oncogene. These inhibitors\u2014imatinib, sunitinib, nilotinib, and dasatanib\u2014were developed for different cancers (chronic myeloid leukemia, gastrointestinal stromal tumors) and different kinases, but they showed activity against KIT. Approximately 70% of KIT mutations identified in melanoma are found in exon 11, most commonly L576P, and in the kinase domain in exon 13, most often K642E <a class=\"rlc-reference\" data-ref-info=\"Woodman SE, Davies MA: Targeting KIT in melanoma: a paradigm of molecular medicine and targeted therapeutics. Biochem Pharmacol 80:568-74, 2010.\" href=\"#_ENREF_67\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/20457136\"><sup>67</sup></a>. The majority of mutations of KIT found in melanoma also occur in other cancers that are responsive to KIT inhibitors.</p>\n\n<p id=\"erb-fac81726-d7fd-4e34-981f-5935c8c8d4ac\"><u>Treatment approaches </u></p>\n<p id=\"erb-6d60f451-15c1-4e1e-8571-a5beac0ec930\">Targeting KIT with <a href=\"http://www.cancer.gov/drugdictionary?CdrID=37862\">imatinib</a> has demonstrated remarkable efficacy in patients with gastrointestinal stromal tumors (GIST), but initial trials in\u00a0melanoma\u00a0were unsuccessful, clearly due to the absence of selection of patients with aberrations in KIT <a class=\"rlc-reference\" data-ref-info=\"Kim KB, Eton O, Davis DW, et al: Phase II trial of imatinib mesylate in patients with metastatic melanoma. Br J Cancer 99:734-40, 2008.\" href=\"#_ENREF_68\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/18728664\"><sup>68-70</sup></a>. Dasatinib was tested as a single agent in unselected melanoma patients and also showed poor response and high toxicity <a class=\"rlc-reference\" data-ref-info=\"Kluger HM, Dudek AZ, McCann C, et al: A phase 2 trial of dasatinib in advanced melanoma. Cancer 117:2202-8, 2011.\" href=\"#_ENREF_71\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/21523734\"><sup>71</sup></a>. Nevertheless, case reports continued to surface that demonstrated the efficacy of imatinib in melanoma patients with specific KIT genetic aberrations, such as mutation K642E <a class=\"rlc-reference\" data-ref-info=\"Lutzky J, Bauer J, Bastian BC: Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation. Pigment Cell Melanoma Res 21:492-3, 2008.\" href=\"#_ENREF_72\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/18510589\"><sup>72</sup></a> and a small duplication <a class=\"rlc-reference\" data-ref-info=\"Hodi FS, Friedlander P, Corless CL, et al: Major response to imatinib mesylate in KIT-mutated melanoma. J Clin Oncol 26:2046-51, 2008.\" href=\"#_ENREF_73\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/18421059\"><sup>73</sup></a>. Two patients whose melanomas harbored L576P responded to dasatinib <a class=\"rlc-reference\" data-ref-info=\"Woodman SE, Trent JC, Stemke-Hale K, et al: Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates. Mol Cancer Ther 8:2079-85, 2009.\" href=\"#_ENREF_74\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/19671763\"><sup>74</sup></a>. Even when alterations in KIT are present in tumors, not all are predictive of responses to kinase inhibitors. Overexpression of KIT in melanoma was found not to confer sensitivity to imatinib <a class=\"rlc-reference\" data-ref-info=\"Hofmann UB, Kauczok-Vetter CS, Houben R, et al: Overexpression of the KIT/SCF in uveal melanoma does not translate into clinical efficacy of imatinib mesylate. Clin Cancer Res 15:324-9, 2009.\" href=\"#_ENREF_75\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/19118061\"><sup>75</sup></a>. <a href=\"http://www.cancer.gov/drugdictionary?CdrID=299061\">Sunitinib malate</a> was tested in another trial; again, no correlation was observed between the degree of KIT expression and longer PFS or OS <a class=\"rlc-reference\" data-ref-info=\"Mahipal A, Tijani L, Chan K, et al: A pilot study of sunitinib malate in patients with metastatic uveal melanoma. Melanoma Res 22:440-6, 2012.\" href=\"#_ENREF_76\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23114504\"><sup>76</sup></a>.</p>\n<p id=\"erb-c4c7d8c3-be99-4dae-a327-4b837d66fda4\">Recently, trials of imatinib and <a href=\"http://www.cancer.gov/drugdictionary?CdrID=435988\">nilotinib</a> have shown promising results in trials where patients were selected for KIT mutations. Phase II trials of imatinib in melanoma produced only modest responses to treatment, but 9 of the 10 partial responses (PRs) were observed in patients with mutations in exons 11 or 13 <a class=\"rlc-reference\" data-ref-info=\"Guo J, Si L, Kong Y, et al: Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol 29:2904-9, 2011.\" href=\"#_ENREF_77\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/21690468\"><sup>77</sup></a>. Another phase II trial of imatinib in 28 patients with alterations in KIT produced durable responses in 16% of patients, predominantly in those with KIT mutations versus those with amplifications <a class=\"rlc-reference\" data-ref-info=\"Carvajal RD, Antonescu CR, Wolchok JD, et al: KIT as a therapeutic target in metastatic melanoma. JAMA 305:2327-34, 2011.\" href=\"#_ENREF_78\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/21642685\"><sup>78</sup></a>. Sunitinib induced responses in 3 out of 4 patients with KIT mutations in exons 11 and 13, but only in one out of six patients with KIT amplification <a class=\"rlc-reference\" data-ref-info=\"Minor DR, Kashani-Sabet M, Garrido M, et al: Sunitinib therapy for melanoma patients with KIT mutations. Clin Cancer Res 18:1457-63, 2012.\" href=\"#_ENREF_79\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22261812\"><sup>79</sup></a>. Preliminary results of a trial with <a href=\"http://www.cancer.gov/drugdictionary?CdrID=435988\">nilotinib</a> were published when it showed durable responses in patients with KIT mutations <a class=\"rlc-reference\" data-ref-info=\"Cho JH, Kim KM, Kwon M, et al: Nilotinib in patients with metastatic melanoma harboring KIT gene aberration. Invest New Drugs 30:2008-14, 2012.\" href=\"#_ENREF_80\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22068222\"><sup>80</sup></a>. A recent phase II trial of imatinib in selected patient population with mucosal, acral, or chronically sun-damaged melanoma concluded with an overall disease-control rate of 50%, but the responses were observed in 77% of patients with mutated KIT and only in 18% of those with amplified KIT. The best ORR was, respectively, 54% versus 0% <a class=\"rlc-reference\" data-ref-info=\"Hodi FS, Corless CL, Giobbie-Hurder A, et al: Imatinib for Melanomas Harboring Mutationally Activated or Amplified KIT Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin. J Clin Oncol, 2013.\" href=\"#_ENREF_81\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23775962\"><sup>81</sup></a>. Preexisting NRAS mutations conferred intrinsic resistance to imatinib <a class=\"rlc-reference\" data-ref-info=\"Hodi FS, Corless CL, Giobbie-Hurder A, et al: Imatinib for Melanomas Harboring Mutationally Activated or Amplified KIT Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin. J Clin Oncol, 2013.\" href=\"#_ENREF_81\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23775962\"><sup>81</sup></a> and to sunitinib (<a class=\"rlc-reference\" data-ref-info=\"Corcoran RB, Rothenberg SM, Hata AN, et al: TORC1 Suppression Predicts Responsiveness to RAF and MEK Inhibition in BRAF-Mutant Melanoma. Sci Transl Med 5:196ra98, 2013.\" href=\"#_ENREF_175\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23903755\">Minor et al., 2012</a>) in patients with KIT mutation. It is becoming clear that inhibitors of KIT should be used in selected patient populations whose tumors have KIT mutations in exon 11 and 13 but not where KIT is not mutated but amplified <a class=\"rlc-reference\" data-ref-info=\"Carvajal RD: Another Option in Our KIT of Effective Therapies for Advanced Melanoma. J Clin Oncol, 2013.\" href=\"#_ENREF_82\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23940226\"><sup>82</sup></a>.</p>\n<p id=\"erb-5d888505-81c6-4afe-b6b5-9af82513d338\">At least 10 ongoing trials test the activity of the aforementioned inhibitors in KIT-mutated melanoma as single agents (Supplemental Table 2). Planned and ongoing trials include combinations of KIT inhibitors with other targeted drugs and immunotherapy. Trial <a href=\"http://clinicaltrials.gov/ct2/show/NCT01738139\">NCT01738139</a> recruits patients for the combination of imatinib with ipilimumab (an immunomodulatory antibody to CTLA4) in patients with various tumors that have somatic alterations of KIT.</p>\n\n<p id=\"erb-23bd3084-f8ff-496e-b878-ca29a1aa4d22\"><b>NF1/neurofibromin</b></p>\n<p id=\"erb-a62cb7f2-6fc9-43ed-93ec-07f4a1109c50\">NF1 is a tumor suppressor regulating signaling from RAS; germline mutations in NF1 deregulate both PI3K and MAPK pathways and result in familial neurofibromatosis. Some neurofibromatosis patients with inactivation of NF1 develop melanomas. Moreover, NF1 expression is low in 47% of uveal melanomas <a class=\"rlc-reference\" data-ref-info=\"Johnson MR, Look AT, DeClue JE, et al: Inactivation of the NF1 gene in human melanoma and neuroblastoma cell lines without impaired regulation of GTP.Ras. Proc Natl Acad Sci U S A 90:5539-43, 1993.\" href=\"#_ENREF_83\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/8516298\"><sup>83</sup></a> and allelic losses are seen in other types of melanoma <a class=\"rlc-reference\" data-ref-info=\"Gutzmer R, Herbst RA, Mommert S, et al: Allelic loss at the neurofibromatosis type 1 (NF1) gene locus is frequent in desmoplastic neurotropic melanoma. Hum Genet 107:357-61, 2000.\" href=\"#_ENREF_84\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/11129335\"><sup>84</sup></a>. Mutations in NF1 are enriched in melanoma that have wild-type BRAF and NRAS (25% of those had NF1 mutations as reported in Hodis, 2012 <a class=\"rlc-reference\" data-ref-info=\"Hodis E, Watson IR, Kryukov GV, et al: A landscape of driver mutations in melanoma. Cell 150:251-63, 2012.\" href=\"#_ENREF_31\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22817889\"><sup>31</sup></a>, albeit a relatively small number of patients was analyzed), suggesting that they could be considered as driver mutations in this subset that was, until now, not amenable to targeted therapy approaches. In addition, NF1 mutations or suppression occur in human melanomas that harbor concurrent BRAF mutations <sup><a class=\"rlc-reference\" data-ref-info=\"Hodis E, Watson IR, Kryukov GV, et al: A landscape of driver mutations in melanoma. Cell 150:251-63, 2012.\" href=\"#_ENREF_31\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22817889\">31</a>,<a class=\"rlc-reference\" data-ref-info=\"Maertens O, Johnson B, Hollstein P, et al: Elucidating distinct roles for NF1 in melanomagenesis. Cancer Discov, 2012.\" href=\"#_ENREF_85\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23171796\">85</a></sup>. Mutations in the NF1 cooperate with BRAF mutations in a mouse model of melanomagenesis by suppressing BRAF-induced senescence (OIS), promoting melanocyte hyperproliferation and enhancing melanoma development. Knockdown of NF1 <i>in vitro</i> promotes activation of both KRAS and CRAF.</p>\n\n<p id=\"erb-dabb2ab5-bcce-42c7-85da-e087454a0b2f\"><u>Potential treatment approaches</u></p>\n<p id=\"erb-80c0e207-df8d-42f2-a61d-0d07057891be\">In recent studies NF1 could be successfully targeted in mouse models with a combination of MEK and PI3K/mTOR inhibitors <a class=\"rlc-reference\" data-ref-info=\"Maertens O, Johnson B, Hollstein P, et al: Elucidating distinct roles for NF1 in melanomagenesis. Cancer Discov, 2012.\" href=\"#_ENREF_85\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23171796\"><sup>85</sup></a>; a combination of irreversible RAF inhibition and MEK inhibition was also effective <i>in vivo</i> <a class=\"rlc-reference\" data-ref-info=\"Whittaker SR, Theurillat JP, Van Allen E, et al: A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. Cancer Discov, 2013.\" href=\"#_ENREF_86\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23288408\"><sup>86</sup></a>.</p>\n\n<p id=\"erb-64bfebf8-8d06-430c-b7b4-76c21e94ae48\"><b>Telomerase</b></p>\n<p id=\"erb-d918898f-46b6-4018-9b07-bb343c62d6af\">Two very recent studies\u2014one based on analysis of genomic alterations in a melanoma-prone family, the other based on analysis of the genomic sequence data from melanoma tumors\u2014have revealed new, frequent, and unexpected mutations in the regulatory regions of the catalytic subunit of telomerase <sup><a class=\"rlc-reference\" data-ref-info=\"Horn S, Figl A, Rachakonda PS, et al: TERT Promoter Mutations in Familial and Sporadic Melanoma. Science, 2013.\" href=\"#_ENREF_87\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23348503\">87</a>,<a class=\"rlc-reference\" data-ref-info=\"Huang FW, Hodis E, Xu MJ, et al: Highly Recurrent TERT Promoter Mutations in Human Melanoma. Science, 2013.\" href=\"#_ENREF_88\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23348506\">88</a></sup>. Mutations were found in 33% primary and 85% metastatic tumors in the first study versus 71% of all tumors in the second study. Mutations create a new binding motif for TCF/ETS transcription factors and result in an increased transcription from TERT promoter. Mutations in the promoter region of TERT are considered to be driver mutations because of their association with familial melanoma and high frequency in sporadic melanoma. TERT promoter mutations are not limited to melanoma, and were found in 16% of tumor cell lines from diverse cancers <a class=\"rlc-reference\" data-ref-info=\"Huang FW, Hodis E, Xu MJ, et al: Highly Recurrent TERT Promoter Mutations in Human Melanoma. Science, 2013.\" href=\"#_ENREF_88\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23348506\"><sup>88</sup></a>.</p>\n\n<p id=\"erb-8565322e-83f4-469e-9e5b-8c9beec72a04\"><u>Potential treatment options</u></p>\n<p id=\"erb-214e509d-5190-4711-9e1b-a5f89bfed56b\">Telomerase inhibitor <a href=\"http://www.cancer.gov/drugdictionary?CdrID=447136\">imetelstat sodium</a>/GRN163L (antisense oligonucleotide) is trialed in breast cancer and a telomerase vaccine GV1001 in nonsmall cell lung cancer (NSCLC).</p>\n\n<p id=\"erb-b3135c8b-ba9d-4ab4-a8da-b72e3725b98a\"><b>Receptor tyrosine kinases and PI3K pathway</b></p>\n\n<p id=\"erb-51b3b5bb-659d-429a-b61b-5f6d0af80514\">Activation of the PI3K pathway serves to overcome OIS that is associated with mutant BRAF. PTEN aberrations are often associated with the presence of BRAFV600E, and cooperate with mutant BRAF in a GEMM <a class=\"rlc-reference\" data-ref-info=\"Dankort D, Curley DP, Cartlidge RA, et al: Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet 41:544-52, 2009.\" href=\"#_ENREF_89\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/19282848\"><sup>89</sup></a>, most likely by overcoming OIS associated with mutant BRAF. In support of this notion, while BRAF mutations are present in both nevi and melanoma sections of contiguous nevi-melanoma biopsies, activation of PI3K (through loss of PTEN expression or activation of AKT3) was detected in the melanoma portions only <a class=\"rlc-reference\" data-ref-info=\"Vredeveld LC, Possik PA, Smit MA, et al: Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis. Genes Dev 26:1055-69, 2012.\" href=\"#_ENREF_90\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22549727\"><sup>90</sup></a>. This indicates that the AKT3/PI3K pathway is activated during progression to malignant melanoma, most likely as a means of overcoming OIS. PI3K pathway activation serves as a rate-limiting event and dual inhibition of PI3K/mutant BRAF eliminated cells resistant to BRAF inhibition <i>in vitro</i> <a class=\"rlc-reference\" data-ref-info=\"Vredeveld LC, Possik PA, Smit MA, et al: Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis. Genes Dev 26:1055-69, 2012.\" href=\"#_ENREF_90\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22549727\"><sup>90</sup></a>. Several mutations in different components of the PI3K pathway, from receptor tyrosine kinases (RTK) to PTEN and to AKT3, have been described.</p>\n\n<p id=\"erb-e5bf7d7e-2eae-49e5-ae7f-62d8e74831de\"><b>ERBB4.</b> Mutations in this tyrosine kinase receptor are<b> </b>found in 19% of melanomas, based on the results of targeted sequencing of the tyrosine kinase family in seven melanoma tumors <a class=\"rlc-reference\" data-ref-info=\"Prickett TD, Agrawal NS, Wei X, et al: Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4. Nat Genet 41:1127-32, 2009.\" href=\"#_ENREF_91\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/19718025\"><sup>91</sup></a>. The pattern of mutations, however, did not exhibit recurrent hot spots. Subsequent studies have reported either much lower incidence (2% of 271 tumors) of ERBB4 mutations in melanoma <a class=\"rlc-reference\" data-ref-info=\"Dutton-Regester K, Irwin D, Hunt P, et al: A high-throughput panel for identifying clinically relevant mutation profiles in melanoma. Mol Cancer Ther 11:888-97, 2012.\" href=\"#_ENREF_92\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22383533\"><sup>92</sup></a>, or lack of any in sampling of 117 tumors <a class=\"rlc-reference\" data-ref-info=\"Zhou QM, Li W, Guan YX, et al: The absence of the ERBB4 hotspot mutations in melanomas in patients from southern China. Chin J Cancer 32:410-4, 2013.\" href=\"#_ENREF_93\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23237222\"><sup>93</sup></a>. Nevertheless, <a href=\"http://www.cancer.gov/drugdictionary?CdrID=269659\">lapatinib</a>, a reversible inhibitor of EGFR, ERBB2, and other kinases is currently in a clinical trial for advanced melanoma with ERBB4 mutations (<a href=\"http://clinicaltrials.gov/ct2/results?term=NCT01264081&amp;Search=Search\">NCT01264081</a>).</p>\n\n<p id=\"erb-1d59162e-e6d2-4100-923c-35b9f540082b\"><b>MET.</b> Mutations in MET have not been described in melanoma, but there is strong evidence that this RTK is involved in melanoma growth and metastases (see below: WNT pathway and HGF expression in stroma). Copy number gains involving MET locus in melanomas were documented <a class=\"rlc-reference\" data-ref-info=\"Moore SR, Persons DL, Sosman JA, et al: Detection of copy number alterations in metastatic melanoma by a DNA fluorescence in situ hybridization probe panel and array comparative genomic hybridization: a southwest oncology group study (S9431). Clin Cancer Res 14:2927-35, 2008.\" href=\"#_ENREF_94\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/18483359\"><sup>94</sup></a>. SU11274, an inhibitor of MET, has shown significant activity in a xenograft model <a class=\"rlc-reference\" data-ref-info=\"Kenessey I, Keszthelyi M, Kramer Z, et al: Inhibition of c-Met with the specific small molecule tyrosine kinase inhibitor SU11274 decreases growth and metastasis formation of experimental human melanoma. Curr Cancer Drug Targets 10:332-42, 2010.\" href=\"#_ENREF_95\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/20370683\"><sup>95</sup></a>. <a href=\"http://www.cancer.gov/drugdictionary?CdrID=461103\">Cabozantinib</a>, an inhibitor of MET and other RTKs is in clinical trials for a variety of cancers with deregulated RTK signaling. In melanoma, cabozantinib will be trialed in combination with vemurafenib (<a href=\"http://clinicaltrials.gov/ct2/show/NCT01835184\">NCT01835184</a>).</p>\n\n<p id=\"erb-08eaa597-e259-4710-9d85-47ef31c3bc8e\"><b>MERTK.</b> MER, a receptor tyrosine kinase (RTK) sharing a family relationship with TYRO3 and AXL, was found to be expressed at increasing levels during progression from nevi to metastatic melanoma. Stimulation of MER with its ligand GAS6 leads to activation of MAPK, PI3K, and JAK/STAT pathways. Inhibition of MERTK with a synthetic compound UNC1062 inhibits invasion and induces apoptosis in melanoma cells in vitro <a class=\"rlc-reference\" data-ref-info=\"Schlegel J, Sambade MJ, Sather S, et al: MERTK receptor tyrosine kinase is a therapeutic target in melanoma. J Clin Invest, 2013.\" href=\"#_ENREF_96\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23585477\"><sup>96</sup></a>. MERTK and AXL are expressed alternatively in melanoma <a class=\"rlc-reference\" data-ref-info=\"Tworkoski KA, Platt JT, Bacchiocchi A, et al: MERTK controls melanoma cell migration and survival and differentially regulates cell behavior relative to AXL. Pigment Cell Melanoma Res, 2013.\" href=\"#_ENREF_97\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23617806\"><sup>97</sup></a>. MERTK-expressing melanoma cells are more proliferative than AXL-expressing cells, though the latter are more invasive <a class=\"rlc-reference\" data-ref-info=\"Tworkoski KA, Platt JT, Bacchiocchi A, et al: MERTK controls melanoma cell migration and survival and differentially regulates cell behavior relative to AXL. Pigment Cell Melanoma Res, 2013.\" href=\"#_ENREF_97\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23617806\"><sup>97</sup></a>.</p>\n\n<p id=\"erb-8c304abb-66c4-43f8-af41-77b34555ed15\"><b>AKT.</b> Deregulated Akt3 activity was shown to promote development of malignant melanoma; amplifications of Akt3 were detected in melanoma <a class=\"rlc-reference\" data-ref-info=\"Stahl JM, Sharma A, Cheung M, et al: Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res 64:7002-10, 2004.\" href=\"#_ENREF_98\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/15466193\"><sup>98</sup></a>. Alterations of AKT1 and AKT2 are rare, but genetic gain of Akt3 is seen in 25% of melanoma tumors. A screen of 137 melanomas and 65 cell lines identified an activating mutation E17A in AKT1 (one patient) and AKT3 (one patient and two cell lines), all with concurrent BRAF mutations <a class=\"rlc-reference\" data-ref-info=\"Davies MA, Stemke-Hale K, Tellez C, et al: A novel AKT3 mutation in melanoma tumours and cell lines. Br J Cancer 99:1265-8, 2008.\" href=\"#_ENREF_99\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/18813315\"><sup>99</sup></a>. High activity of AKT3 was shown to promote progression of BRAFV600E-positive nevi to melanoma <a class=\"rlc-reference\" data-ref-info=\"Cheung M, Sharma A, Madhunapantula SV, et al: Akt3 and mutant V600E B-Raf cooperate to promote early melanoma development. Cancer Res 68:3429-39, 2008.\" href=\"#_ENREF_100\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/18451171\"><sup>100</sup></a>. A trial combining <a href=\"http://www.cancer.gov/drugdictionary?CdrID=596332\">MK2206</a> (Akt inhibitor) in combination with <a href=\"http://www.cancer.gov/drugdictionary?CdrID=532294\">AZD6244</a> (the MEK inhibitor selumetinib) is in progress (<a href=\"http://clinicaltrials.gov/ct2/results?term=NCT01519427\">NCT01519427</a>).</p>\n\n<p id=\"erb-876e5da3-e4c2-48b5-a5a5-d04ee7334bd9\"><b>PTEN</b> is a well-known tumor suppressor affected in approximately 25%-30% of melanoma, most commonly via allelic loss and focal deletions <sup><a class=\"rlc-reference\" data-ref-info=\"Hodis E, Watson IR, Kryukov GV, et al: A landscape of driver mutations in melanoma. Cell 150:251-63, 2012.\" href=\"#_ENREF_31\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22817889\">31</a>,<a class=\"rlc-reference\" data-ref-info=\"Tsao H, Zhang X, Benoit E, et al: Identification of PTEN/MMAC1 alterations in uncultured melanomas and melanoma cell lines. Oncogene 16:3397-402, 1998.\" href=\"#_ENREF_101\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/9692547\">101</a></sup>. PTEN is also deregulated in melanoma via loss of ZEB2, a competitive endogenous RNA (ceRNA) <a class=\"rlc-reference\" data-ref-info=\"Karreth FA, Tay Y, Perna D, et al: In vivo identification of tumor- suppressive PTEN ceRNAs in an oncogenic BRAF-induced mouse model of melanoma. Cell 147:382-95, 2011.\" href=\"#_ENREF_102\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22000016\"><sup>102</sup></a>. In addition, disruptions of MAGI2, a protein that associates with and stabilizes PTEN, occur in melanoma <a class=\"rlc-reference\" data-ref-info=\"Berger MF, Hodis E, Heffernan TP, et al: Melanoma genome sequencing reveals frequent PREX2 mutations. Nature 485:502-6, 2012.\" href=\"#_ENREF_1\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22622578\"><sup>1</sup></a>. PTEN aberrations are often associated with the presence of BRAFV600E, and cooperate with mutant BRAF in a GEMM <a class=\"rlc-reference\" data-ref-info=\"Dankort D, Curley DP, Cartlidge RA, et al: Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet 41:544-52, 2009.\" href=\"#_ENREF_89\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/19282848\"><sup>89</sup></a>, most likely providing an OIS inhibitory function by activating the PI3K pathway. In this model, growth of melanoma could be inhibited by combined treatment with PD325901 (MEK inhibitor) and rapamycin (mTOR inhibitor). PTEN-inactivating aberrations are not associated with NRAS mutations, perhaps because the latter lead to activation of PI3K in the absence of this pathway's mutations. PTEN mutations and copy losses are associated with lower PFS in response to inhibition of mutant BRAF in patients <a class=\"rlc-reference\" data-ref-info=\"Nathanson KL, Martin AM, Wubbenhorst B, et al: Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor Dabrafenib (GSK2118436). Clin Cancer Res, 2013.\" href=\"#_ENREF_103\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23833299\"><sup>103</sup></a>. PTEN (or rather lack of PTEN) was shown to play a key role in the predisposition to melanoma in individuals carrying certain variants of melanocortin-1 receptor (MC1R). The mechanisms through which MC1R variants associated with red hair and fair skin predispose to melanoma were not understood until recently, when it was shown that wild-type but not variant MC1R protein associates with PTEN and protects it from degradation after UVB exposure. Disrupted MC1R-PTEN association was shown to be responsible for the oncogenic transformation promoted by MC1R variants in presence of BRAFV600E <a class=\"rlc-reference\" data-ref-info=\"Cao J, Wan L, Hacker E, et al: MC1R Is a Potent Regulator of PTEN after UV Exposure in Melanocytes. Mol Cell 51:409-22, 2013.\" href=\"#_ENREF_104\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23973372\"><sup>104</sup></a>.</p>\n\n<p id=\"erb-b4305d72-d949-49c3-aa12-ca309784a040\"><b>Other PI3K pathway mutations.</b> Mutations in other PI3K pathways genes MTOR, IRS4, PIK3R1, PIK3R4, and PIK3R5 were detected in 17% of BRAFV600 and in 9% of NRAS-mutant tumors <a class=\"rlc-reference\" data-ref-info=\"Shull AY, Latham-Schwark A, Ramasamy P, et al: Novel somatic mutations to PI3K pathway genes in metastatic melanoma. PLoS One 7:e43369, 2012.\" href=\"#_ENREF_105\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22912864\"><sup>105</sup></a>, even though their functional significance remains to be determined.</p>\n\n<p id=\"erb-e02542bd-6224-4af7-aa44-576365aacc14\"><b>MAPK pathway downstream of BRAF</b></p>\n\n<p id=\"erb-371bf51e-cb65-46dc-80b9-39c7d1cea2f4\"><b>MEK1 and MEK2</b>. Sequencing of seven melanoma cell lines and donor-matched germline cells found MAP2K1 and MAP2K2 (MEK1 and MEK2, respectively) mutations, resulting in constitutive ERK phosphorylation and higher resistance to MEK inhibitors. Screening of a larger cohort of melanoma tumors revealed the presence of recurring somatic MAP2K1 and MAP2K2 mutations at an overall frequency of 8% <a class=\"rlc-reference\" data-ref-info=\"Nikolaev SI, Rimoldi D, Iseli C, et al: Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma. Nat Genet 44:133-9, 2012.\" href=\"#_ENREF_106\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22197931\"><sup>106</sup></a>.</p>\n\n<p id=\"erb-683add4f-68a6-41a9-91b9-8075773b5c36\"><b>IQGAP1: a scaffold protein in MAPK pathway as a possible target.</b> There are new data indicating that it might be possible to target the MAPK pathway without direct inhibition of enzymatic activity of kinases in this pathway. It is well known that kinases usually depend on scaffold proteins that assemble signaling complexes. One of these scaffold proteins, IQGAP1 is essential for activity of ERK1/2, and disruption of IQGAP interaction with ERK using a small peptide inhibited RAS- or BRAF-driven tumorigenesis and even overcame resistance to vemurafenib <a class=\"rlc-reference\" data-ref-info=\"Jameson KL, Mazur PK, Zehnder AM, et al: IQGAP1 scaffold-kinase interaction blockade selectively targets RAS-MAP kinase-driven tumors. Nat Med, 2013.\" href=\"#_ENREF_107\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23603816\"><sup>107</sup></a>.</p>\n\n<p id=\"erb-71d8cf7d-f2f7-4413-860a-2c3866a40fdf\"><b>RAC pathway.</b> RAC1 is a<b> </b>Rho GTPase, a GTP exchange protein known to affect the cell cytoskeleton and motility. Its role in conveying oncogenic signaling from mutant NRAS in melanoma was described (Li et al. <a class=\"rlc-reference\" data-ref-info=\"Li A, Ma Y, Jin M, et al: Activated mutant NRas(Q61K) drives aberrant melanocyte signaling, survival, and invasiveness via a Rac1-dependent mechanism. J Invest Dermatol 132:2610-21, 2012.\" href=\"#_ENREF_108\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22718121\"><sup>108</sup></a> and references therein). Recently P29S mutations in the conserved switch domain were described in melanoma, in 5% of tumors in the experimental set <sup><a class=\"rlc-reference\" data-ref-info=\"Hodis E, Watson IR, Kryukov GV, et al: A landscape of driver mutations in melanoma. Cell 150:251-63, 2012.\" href=\"#_ENREF_31\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22817889\">31</a>,<a class=\"rlc-reference\" data-ref-info=\"Krauthammer M, Kong Y, Ha BH, et al: Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat Genet 44:1006-14, 2012.\" href=\"#_ENREF_109\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22842228\">109</a></sup>, and their functional role <i>in vitro</i> was confirmed. Mutations were also found in other Rho family members\uf0beRAC2 (P29L), RHOT1 (P30L), and in CDC42 (G12D) \uf0bemaking RAC pathway a target of frequent hotspot mutation.</p>\n\n<p id=\"erb-604101ba-d8c5-4ce9-9840-5662891f871e\"><b>MAP3K5 and MAP3K9</b>. These MAP3 kinases are directly downstream of Rac and Rho signaling activated by various stress signals. Mutations and the loss of heterozygosity of MAP3K5 and MAP3K9 in 85% and 67% of melanoma samples, respectively, suggest inactivation of these kinases. Indeed, mutants MAP3K5 I780F and MAP3K9 W333* variants had reduced kinase activity <i>in vitro</i>. Overexpression of these mutants reduced the phosphorylation of downstream MAP kinases, while siRNA-mediated depletion of MAP3K9 in melanoma cells led to increased cell viability after temozolomide treatment, suggesting that decreased MAP3K activity acts as a pro-survival adaptation <a class=\"rlc-reference\" data-ref-info=\"Stark MS, Woods SL, Gartside MG, et al: Frequent somatic mutations in MAP3K5 and MAP3K9 in metastatic melanoma identified by exome sequencing. Nat Genet 44:165-9, 2012.\" href=\"#_ENREF_110\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22197930\"><sup>110</sup></a>.</p>\n\n<p id=\"erb-a754be66-ac40-4feb-8ba9-6d8a5517064e\"><b>PREX2.</b> Mutations of<b> </b>phosphatidylinositol-3,4,5-trisphosphate-dependent Rac exchange factor 2 were found in 14% of a cohort of 107 tumors <a class=\"rlc-reference\" data-ref-info=\"Berger MF, Hodis E, Heffernan TP, et al: Melanoma genome sequencing reveals frequent PREX2 mutations. Nature 485:502-6, 2012.\" href=\"#_ENREF_1\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22622578\"><sup>1</sup></a>. Functional studies <i>in vitro</i> have confirmed a role for PREX2 in melanomagenesis. Presence of mutations in three functional components of RAC pathways (Rho family proteins, MAP3K5 and MAP3K9, PREX2) strongly indicates involvement of RAC pathway in pathogenesis of melanoma.</p>\n\n<p id=\"erb-9b1363b2-f1d2-47b8-96ff-ba3e54708e39\"><b>Cell cycle and apoptosis related genes</b></p>\n\n<p id=\"erb-74e7db2b-93af-4cf3-b5e2-aab32f4dc2bc\"><b>CDK4</b>, a cell cycle G1/S kinase, and<b> </b>Cyclin D1 (CCND1)<b> </b>were shown to be amplified in melanoma <a class=\"rlc-reference\" data-ref-info=\"Muthusamy V, Hobbs C, Nogueira C, et al: Amplification of CDK4 and MDM2 in malignant melanoma. Genes Chromosomes Cancer 45:447-54, 2006.\" href=\"#_ENREF_111\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/16419059\"><sup>111</sup></a>. CDK4 mutations are associated with familial melanoma <a class=\"rlc-reference\" data-ref-info=\"Zuo L, Weger J, Yang Q, et al: Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nat Genet 12:97-9, 1996.\" href=\"#_ENREF_112\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/8528263\"><sup>112</sup></a>. In a clinical study of FOLFIRI (chemotherapeutic agent) with the nonselective CDK inhibitor flavopirodol in solid tumors, one melanoma patient had a complete response <a class=\"rlc-reference\" data-ref-info=\"Dickson MA, Shah MA, Rathkopf D, et al: A phase I clinical trial of FOLFIRI in combination with the pan-cyclin-dependent kinase (CDK) inhibitor flavopiridol. Cancer Chemother Pharmacol 66:1113-21, 2010.\" href=\"#_ENREF_113\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/20953860\"><sup>113</sup></a>. Targeted CDK inhibitors<u> </u>are in clinical development (<a href=\"http://www.cancer.gov/drugdictionary?cdrid=454586\">PD0332991</a>, <a href=\"http://www.cancer.gov/drugdictionary?CdrID=612855\">dinaciclib</a>, <a href=\"http://www.cancer.gov/drugdictionary?CdrID=706364\">LY2835219</a>, <a href=\"http://www.cancer.gov/drugdictionary?CdrID=684718\">BAY1000394</a>, <a href=\"http://www.cancer.gov/drugdictionary?CdrID=689330\">LEE011</a>), and at least four of them are currently tested in trials for melanoma and other tumors (Supplemental Tables 1 and 2).</p>\n\n<p id=\"erb-751ee530-7b90-4920-b25b-d9ee2821b534\"><b>TP53 pathway.</b> TP53 mutations are found in 19% of melanoma tumors <a class=\"rlc-reference\" data-ref-info=\"Hodis E, Watson IR, Kryukov GV, et al: A landscape of driver mutations in melanoma. Cell 150:251-63, 2012.\" href=\"#_ENREF_31\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22817889\"><sup>31</sup></a>, a frequency relatively low compared to other cancers, raising the possibility that melanomas uses alternative ways to overcome p53-mediated tumor suppression. Indeed, several alterations in genes affecting p53 activity have been discovered in melanoma. Among them are the long known mutations in p14ARF<a class=\"rlc-reference\" data-ref-info=\"Hussussian CJ, Struewing JP, Goldstein AM, et al: Germline p16 mutations in familial melanoma. Nat Genet 8:15-21, 1994.\" href=\"#_ENREF_114\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/7987387\"><sup>114</sup></a>, overexpression of MDM2 <a class=\"rlc-reference\" data-ref-info=\"Polsky D, Bastian BC, Hazan C, et al: HDM2 protein overexpression, but not gene amplification, is related to tumorigenesis of cutaneous melanoma. Cancer Res 61:7642-6, 2001.\" href=\"#_ENREF_115\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/11606406\"><sup>115</sup></a>, amplification of MDM4 in melanoma<a class=\"rlc-reference\" data-ref-info=\"Gembarska A, Luciani F, Fedele C, et al: MDM4 is a key therapeutic target in cutaneous melanoma. Nat Med, 2012.\" href=\"#_ENREF_116\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22820643\"><sup>116</sup></a>, elevated expression and the anti-apoptotic role of p53-related protein p63 <a class=\"rlc-reference\" data-ref-info=\"Matin RN, Chikh A, Law Pak Chong S, et al: p63 is an alternative p53 repressor in melanoma that confers chemoresistance and a poor prognosis. J Exp Med, 2013.\" href=\"#_ENREF_117\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23420876\"><sup>117</sup></a>, and increased expression of iASPP <a class=\"rlc-reference\" data-ref-info=\"Bergamaschi D, Samuels Y, Sullivan A, et al: iASPP preferentially binds p53 proline-rich region and modulates apoptotic function of codon 72-polymorphic p53. Nat Genet 38:1133-41, 2006.\" href=\"#_ENREF_118\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/16964264\"><sup>118</sup></a> \uf0beall of which act to inhibit the function of p53. This means that the rare \"p53 mutant subtype\" could now be expanded to a \"p53 pathway aberrations\" subtype.</p>\n\n<p id=\"erb-184b5a64-ad6f-4fac-b4e0-c38f3ebaa9d4\"><b>CDKN2A</b> locus is frequently deleted in melanoma of all primary subtypes <a class=\"rlc-reference\" data-ref-info=\"Kamb A, Gruis NA, Weaver-Feldhaus J, et al: A cell cycle regulator potentially involved in genesis of many tumor types. Science 264:436-40, 1994.\" href=\"#_ENREF_119\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/8153634\"><sup>119-121</sup></a>. Two tumor suppressors are encoded within this locus: p14ARF, which activates p53 through inhibition of its major negative regulator MDM2; and p16INK4a, a cyclin-dependent kinase inhibitor that activates retinoblastoma (RB) through negative regulation of CDK4. Loss of CDKN2A was reported to occur in 16% to 41% of sporadic melanoma and with a high frequency in familial melanoma <a class=\"rlc-reference\" data-ref-info=\"Hussussian CJ, Struewing JP, Goldstein AM, et al: Germline p16 mutations in familial melanoma. Nat Genet 8:15-21, 1994.\" href=\"#_ENREF_114\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/7987387\"><sup>114</sup></a>.</p>\n\n<p id=\"erb-4ab77836-6c0d-480b-80d9-3ae4de6ba683\"><b>MDM2. </b>This protein binds to p53 and promotes its degradation and inactivation. MDM2 is considered to be the major negative regulator of p53. Recently, it has been reported that in a fraction of melanoma tumors MDM2 expression is upregulated owing to the silencing of a microRNA, miR-18b, that targets Mdm2 mRNA <a class=\"rlc-reference\" data-ref-info=\"Dar AA, Majid S, Rittsteuer C, et al: The role of miR-18b in MDM2-p53 pathway signaling and melanoma progression. J Natl Cancer Inst 105:433-42, 2013.\" href=\"#_ENREF_122\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23365201\"><sup>122</sup></a>. The authors suggest that targeted overexpression of miR-18b could be considered as a novel strategy for activation of the p53 pathway in melanoma.</p>\n\n<p id=\"erb-75d836a9-55d3-4c0c-adfe-5ada2bf31839\"><b>MDM4</b>. In a recent study it was shown that MDM4, a negative regulator of p53, is upregulated in about 65% of melanomas, and that melanocyte-specific Mdm4 overexpression enhanced tumorigenesis in a mouse model of\u00a0melanoma\u00a0induced by\u00a0Nras <a class=\"rlc-reference\" data-ref-info=\"Gembarska A, Luciani F, Fedele C, et al: MDM4 is a key therapeutic target in cutaneous melanoma. Nat Med, 2012.\" href=\"#_ENREF_116\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22820643\"><sup>116</sup></a>. Inhibition of the MDM4-p53 interaction restored p53 function in\u00a0melanoma\u00a0cells, resulting in increased sensitivity to cytotoxic chemotherapy and to inhibitors of the BRAFV600E mutation. MDM4 could be a key determinant of impaired p53 function in human\u00a0melanoma\u00a0and a promising target for anti-melanoma combination therapy <a class=\"rlc-reference\" data-ref-info=\"Gembarska A, Luciani F, Fedele C, et al: MDM4 is a key therapeutic target in cutaneous melanoma. Nat Med, 2012.\" href=\"#_ENREF_116\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22820643\"><sup>116</sup></a>.</p>\n\n<p id=\"erb-1a9fc978-8a90-462d-8056-04ff437c7377\"><u>Potential treatment</u> of melanoma harboring inactivated wild-type p53 would involve inhibition of CDK4, and MDM2-p53 and MDM4-p53 interactions. The MDM2-p53 interaction has attracted serious efforts to develop specific inhibitors, of which Nutlin analogues are the more advanced. The new generations of Nutlin-based drugs are in clinical studies for various solid tumors. Encouraging results were reported for one of them, <a href=\"http://www.asco.org/ASCOv2/Meetings/Abstracts?&amp;vmview=abst_detail_view&amp;confID=102&amp;abstractID=80576\">RG7112</a>, in early clinical testing for liposarcoma and other tumors <a class=\"rlc-reference\" data-ref-info=\"Ray-Coquard I, Blay JY, Italiano A, et al: Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study. Lancet Oncol 13:1133-40, 2012.\" href=\"#_ENREF_123\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23084521\"><sup>123</sup></a>. Nutlin3, an early prototype inhibitor of p53-MDM2 interaction, was shown to synergize with vemurafenib in inducing cell death in melanoma cell lines and inhibiting tumor growth <i>in vivo </i><a class=\"rlc-reference\" data-ref-info=\"Ji Z, Kumar R, Taylor M, et al: Vemurafenib Synergizes with Nutlin-3 to Deplete Survivin and Suppress Melanoma Viability and Tumor Growth. Clin Cancer Res, 2013.\" href=\"#_ENREF_124\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23812671\"><sup>124</sup></a>. An alternative approach under development is based on the use of stapled peptides against MDM2/MDM4, which exhibit high potency and selectivity <a class=\"rlc-reference\" data-ref-info=\"Brown CJ, Quah ST, Jong J, et al: Stapled peptides with improved potency and specificity that activate p53. ACS Chem Biol 8:506-12, 2013.\" href=\"#_ENREF_125\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23214419\"><sup>125</sup></a>. A potent inhibitor of MDM2 and MDMX interactions, ATSP-7041, reactivated TP53 function and inhibited tumor growth in vitro and in vivo <a class=\"rlc-reference\" data-ref-info=\"Chang YS, Graves B, Guerlavais V, et al: Stapled alpha-helical peptide drug development: A potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy. Proc Natl Acad Sci U S A, 2013.\" href=\"#_ENREF_126\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23946421\"><sup>126</sup></a>.</p>\n\n<p id=\"erb-04d08faf-652e-464d-9c57-563a959ea03c\"><b>P63</b>,<b> </b>a protein related to p53, has been reported to have an anti-apoptotic role in melanoma, which is mediated through its interaction with p53. P63 is expressed at high levels in melanoma cell lines and clinical samples and prevents translocation of p53 to the nucleus <a class=\"rlc-reference\" data-ref-info=\"Matin RN, Chikh A, Law Pak Chong S, et al: p63 is an alternative p53 repressor in melanoma that confers chemoresistance and a poor prognosis. J Exp Med, 2013.\" href=\"#_ENREF_117\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23420876\"><sup>117</sup></a>. This study further expands the role of the aberrations of the p53 pathway in melanomagenesis.</p>\n\n<p id=\"erb-dcb3847d-1d64-442f-ba2e-b1eeb10d64f0\"><b>iASPP</b> is a conserved ankyrin repeat protein that shuttles between nuclear and cytoplasmic compartments, and nuclear iASPP is found in proliferating cells. The nuclear iASPP was shown to inhibit the pro-apoptotic function of p53 <a class=\"rlc-reference\" data-ref-info=\"Bergamaschi D, Samuels Y, Sullivan A, et al: iASPP preferentially binds p53 proline-rich region and modulates apoptotic function of codon 72-polymorphic p53. Nat Genet 38:1133-41, 2006.\" href=\"#_ENREF_118\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/16964264\"><sup>118</sup></a>. High levels of nuclear iASPP were observed in metastatic melanoma versus primary melanoma <a class=\"rlc-reference\" data-ref-info=\"Lu M, Breyssens H, Salter V, et al: Restoring p53 Function in Human Melanoma Cells by Inhibiting MDM2 and Cyclin B1/CDK1-Phosphorylated Nuclear iASPP. Cancer Cell, 2013.\" href=\"#_ENREF_127\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23623661\"><sup>127</sup></a>. The researchers found that iASPP is phosphorylated by cyclin B/CDK1, which promotes its nuclear localization and binding to p53, inhibiting its pro-apoptotic function. Prevention of iASPP phosphorylation by CDK1 inhibitor or knock-down of iASPP induced apoptotic death in melanoma cell lines, which is further enhanced by Nutlin3 (inhibitor of p53-MDM2 interaction and degradation of p53). Furthermore, inhibition of BRAF with vemurafenib, or MEK with UO126, potentiated effects of Nutlin3 and cyclin B /CDK1 inhibition, inducing apoptosis of melanoma <i>in vitro</i> and <i>in vivo</i> <a class=\"rlc-reference\" data-ref-info=\"Lu M, Breyssens H, Salter V, et al: Restoring p53 Function in Human Melanoma Cells by Inhibiting MDM2 and Cyclin B1/CDK1-Phosphorylated Nuclear iASPP. Cancer Cell, 2013.\" href=\"#_ENREF_127\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23623661\"><sup>127</sup></a>. These findings indicate an alternative strategy for combining therapies that target MAPK pathway and cyclin B/CDK1 in wild-type p53 melanoma.</p>\n\n<p id=\"erb-b128e6f7-3b24-46a3-bc26-f9592246d5b7\">\u00a0<b>NFkB</b>. As in many, many other tumors, the NFkB pathway is activated in melanoma, but systemic inhibition of NFkB might have catastrophic general adverse effects and toxicity. A new faucet of NFkB activation was described recently in drug-treated melanoma cells that might acquire a senescent secretory phenotype; the latter results in a pro-inflammatory and pro-metastatic phenotype characterized by production of CCL-2. Activated NFkB and PARP-1 contribute to this phenomenon and could be involved in the therapeutic failure <a class=\"rlc-reference\" data-ref-info=\"Ohanna M, Giuliano S, Bonet C, et al: Senescent cells develop a PARP-1 and nuclear factor-{kappa}B-associated secretome (PNAS). Genes Dev 25:1245-61, 2011.\" href=\"#_ENREF_128\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/21646373\"><sup>128</sup></a>.</p>\n\n<p id=\"erb-7b7ac0de-feb5-4901-b658-9f1e45c9cfb4\"><b>BCL2.</b> There is abundant literature that documents elevated BCL2 expression in melanoma and its contribution to melanoma and melanocyte cell survival. A member of this family, BCL2A1, was shown to be amplified in 30% of melanoma and contribute to resistance to BRAF inhibition <a class=\"rlc-reference\" data-ref-info=\"Haq R, Yokoyama S, Hawryluk EB, et al: BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition. Proc Natl Acad Sci U S A 110:4321-6, 2013.\" href=\"#_ENREF_61\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23447565\"><sup>61</sup></a> (see section \u201cIntrinsic Resistance to BRAF and MEK Inhibitors\u201d). Another member of BCL2 family, BCL2L12 is mutated in 4% of melanomas, but mutation is synonymous. mRNA from this mutated BCL2L12 is stable due to failure of targeting by specific miRNA and leads to higher levels of protein. BCL2L12 binds and inhibits tumor suppressor TP53 <a class=\"rlc-reference\" data-ref-info=\"Gartner JJ, Parker SC, Prickett TD, et al: Whole-genome sequencing identifies a recurrent functional synonymous mutation in melanoma. Proc Natl Acad Sci U S A 110:13481-6, 2013.\" href=\"#_ENREF_129\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23901115\"><sup>129</sup></a>.</p>\n<p id=\"erb-6abaa658-b1c8-4dd5-a4a3-64b5496e0b06\">Attempts to target BCL2 with antisense RNA in melanoma patients have not been successful. <a href=\"http://www.cancer.gov/drugdictionary?CdrID=504100\">Obatoclax</a>, a drug inhibiting interaction of BCL2 with pro-apoptotic proteins Bax and Bak, is in clinical trials for other malignancies. BH3 mimetics to inhibit function of anti-apoptotic proteins, such as BCL2 and BCL-xL, are still subjects of significant interest. One of them, ABT-737, resensitized both melanoma cell lines <i>in vitro</i> and tumors in the <i>in vivo</i> model to common chemotherapeutics (including the only FDA-approved chemotherapeutic for melanoma, dacarbazine), leading to marked BIM (Bcl-2-interacting mediator of cell death)<b> </b>-mediated apoptosis. ABT-737 may be a beneficial adjuvant therapy to improve melanoma response rates when conventional chemotherapy is the only option <a class=\"rlc-reference\" data-ref-info=\"Anvekar RA, Asciolla JJ, Lopez-Rivera E, et al: Sensitization to the mitochondrial pathway of apoptosis augments melanoma tumor cell responses to conventional chemotherapeutic regimens. Cell Death Dis 3:e420, 2012.\" href=\"#_ENREF_130\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23152056\"><sup>130</sup></a>.</p>\n\n<p id=\"erb-3a28c78b-2ff2-48ca-a3a3-4a42d95334a7\"><b>\u03b2-catenin and WNT pathway</b></p>\n<p id=\"erb-bef78459-3499-4f10-b4ec-155eebc33c46\">A number of reports have heavily implicated WNT signaling in melanoma progression and metastases. \u03b2-catenin fortifies the cadherin-based adhesion at the plasma membrane, but, when detached from cadherins, activates transcription of target genes, frequently with oncogenic consequences. Rare mutations in \uf062-catenin and in other members of the WNT signaling family were identified in malignant melanoma 10 years ago <a class=\"rlc-reference\" data-ref-info=\"Reifenberger J, Knobbe CB, Wolter M, et al: Molecular genetic analysis of malignant melanomas for aberrations of the WNT signaling pathway genes CTNNB1, APC, ICAT and BTRC. Int J Cancer 100:549-56, 2002.\" href=\"#_ENREF_131\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/12124804\"><sup>131</sup></a>. \uf062-catenin suppresses expression of p16INK and cooperates with NRAS in transformation to a frank melanoma <a class=\"rlc-reference\" data-ref-info=\"Delmas V, Beermann F, Martinozzi S, et al: Beta-catenin induces immortalization of melanocytes by suppressing p16INK4a expression and cooperates with N-Ras in melanoma development. Genes Dev 21:2923-35, 2007.\" href=\"#_ENREF_132\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/18006687\"><sup>132</sup></a>. WNT5a, in particular, by binding to the Frizzled4- LRP6 complex, activates ARF6 (guanosine triphosphatase adenosine diphosphate ribosylation factor 6), leading to displacement of \uf062-catenin from N-cadherin in melanoma. This stimulates signaling from \uf062-catenin and increases invasiveness <a class=\"rlc-reference\" data-ref-info=\"Grossmann AH, Yoo JH, Clancy J, et al: The Small GTPase ARF6 Stimulates beta-Catenin Transcriptional Activity During WNT5A-Mediated Melanoma Invasion and Metastasis. Sci Signal 6:ra14, 2013.\" href=\"#_ENREF_133\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23462101\"><sup>133</sup></a>.</p>\n<p id=\"erb-9d1a653f-b7a6-44b0-b2b9-1daa5d1ebe62\">In a mouse melanoma model based on PTEN loss and BRAFV600E mutation, \uf062-catenin was shown to be a central mediator of metastases as well as a regulator of both MAPK and PI3K pathways. Recent findings established WNT signaling as a metastasis regulator in\u00a0melanoma <a class=\"rlc-reference\" data-ref-info=\"Damsky WE, Curley DP, Santhanakrishnan M, et al: beta-catenin signaling controls metastasis in Braf-activated Pten-deficient melanomas. Cancer Cell 20:741-54, 2011.\" href=\"#_ENREF_134\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22172720\"><sup>134</sup></a>. Mutant BRAF signaling is thought to inhibit WNT/\uf062-catenin signaling. Endogenous \uf062-catenin was apparently required for the efficacy of PLX4720 <i>in vitro</i>; activation of WNT/\uf062-catenin signaling was found to enhance the anticancer activity of PLX4720 <i>in vitro</i> and <i>in vivo</i> <a class=\"rlc-reference\" data-ref-info=\"Biechele TL, Kulikauskas RM, Toroni RA, et al: Wnt/beta-catenin signaling and AXIN1 regulate apoptosis triggered by inhibition of the mutant kinase BRAFV600E in human melanoma. Sci Signal 5:ra3, 2012.\" href=\"#_ENREF_135\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22234612\"><sup>135</sup></a>.</p>\n<p id=\"erb-7e32bea0-95b2-4026-b2ee-caf1ca56f49f\">Negative regulation of WNT/\uf062-catenin signaling by MAPK pathway was confirmed in an additional study <a class=\"rlc-reference\" data-ref-info=\"Conrad WH, Swift RD, Biechele TL, et al: Regulating the response to targeted MEK inhibition in melanoma: enhancing apoptosis in NRAS- and BRAF-mutant melanoma cells with Wnt/beta-catenin activation. Cell Cycle 11:3724-30, 2012.\" href=\"#_ENREF_136\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22895053\"><sup>136</sup></a>. Treatment of BRAF-mutant and NRAS-mutant\u00a0melanoma\u00a0lines with WNT3A and the MEK inhibitor AZD6244 induces apoptosis. The susceptibility of BRAF- and NRAS-mutant lines to apoptosis correlated with negative regulation of\u00a0Wnt/\u03b2-catenin signaling by ERK/MAPK signaling and dynamic decreases in abundance of the downstream scaffolding protein, AXIN1 <a class=\"rlc-reference\" data-ref-info=\"Conrad WH, Swift RD, Biechele TL, et al: Regulating the response to targeted MEK inhibition in melanoma: enhancing apoptosis in NRAS- and BRAF-mutant melanoma cells with Wnt/beta-catenin activation. Cell Cycle 11:3724-30, 2012.\" href=\"#_ENREF_136\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22895053\"><sup>136</sup></a>. WNT inhibitors such as <a href=\"http://www.cancer.gov/drugdictionary?CdrID=696436\">PRI-724</a> (inhibitor of interaction between \uf062-catenin and CBP) and <a href=\"http://www.cancer.gov/drugdictionary?CdrID=734935\">OMP-54F28</a> (a fusion protein antagonistic to Fzd8) are starting to enter clinical testing in tumors other than melanoma.</p>\n\n<p id=\"erb-0d62c939-3275-42fc-be13-db95168d7475\"><b>Transcriptional factors in melanoma</b></p>\n\n<p id=\"erb-59949133-759b-4917-83e4-481738ae7264\"><b>MYC.</b> This universal oncogene and transcriptional master regulator is overexpressed or present at increased copy numbers in<b> </b>41% or more of melanoma tumors <a class=\"rlc-reference\" data-ref-info=\"Moore SR, Persons DL, Sosman JA, et al: Detection of copy number alterations in metastatic melanoma by a DNA fluorescence in situ hybridization probe panel and array comparative genomic hybridization: a southwest oncology group study (S9431). Clin Cancer Res 14:2927-35, 2008.\" href=\"#_ENREF_94\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/18483359\"><sup>94</sup></a>. It is currently considered not to be druggable.</p>\n\n<p id=\"erb-a98f4070-d8e8-47ce-bf9a-3d7ca9232b17\"><b>ETV1.</b> This transcription factor from the ETS family was implicated as an oncogene in melanoma and copy-gain numbers were found in 40% of cases examined, with amplification of ETV1 in 13% to18% of cases <a class=\"rlc-reference\" data-ref-info=\"Jane-Valbuena J, Widlund HR, Perner S, et al: An oncogenic role for ETV1 in melanoma. Cancer Res 70:2075-84, 2010.\" href=\"#_ENREF_137\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/20160028\"><sup>137</sup></a>.</p>\n\n<p id=\"erb-f5e5d271-9c84-4cca-8cf9-9c3a824e4884\"><b>Other significant genetic abnormalities in melanoma</b></p>\n\n<p id=\"erb-cccbb060-00e5-465a-b418-5c4b22b0a599\"><b>NEDD9</b>, an integrin adaptor protein related to P130CAS, and a member of a family implicated in pathogenesis of a variety of cancers, was identified as a bona fide melanoma metastasis gene in melanoma. NEDD9 enhanced invasion <i>in vitro</i> and metastasis <i>in vivo</i> of both normal and transformed melanocytes, and was frequently overexpressed in metastatic melanoma relative to primary melanoma <a class=\"rlc-reference\" data-ref-info=\"Kim M, Gans JD, Nogueira C, et al: Comparative oncogenomics identifies NEDD9 as a melanoma metastasis gene. Cell 125:1269-81, 2006.\" href=\"#_ENREF_138\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/16814714\"><sup>138</sup></a>. Fifty-seven percent of melanomas were found to have amplification of NEDD9 <a class=\"rlc-reference\" data-ref-info=\"Moore SR, Persons DL, Sosman JA, et al: Detection of copy number alterations in metastatic melanoma by a DNA fluorescence in situ hybridization probe panel and array comparative genomic hybridization: a southwest oncology group study (S9431). Clin Cancer Res 14:2927-35, 2008.\" href=\"#_ENREF_94\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/18483359\"><sup>94</sup></a>.</p>\n\n<p id=\"erb-f68d3494-d9c4-42f1-bbff-801cf7711e80\"><b>PPP6C</b> is a serine-threonine phosphatase, mutated in 12% of sun-exposed melanomas exclusively with BRAF or NRAS mutations <sup><a class=\"rlc-reference\" data-ref-info=\"Hodis E, Watson IR, Kryukov GV, et al: A landscape of driver mutations in melanoma. Cell 150:251-63, 2012.\" href=\"#_ENREF_31\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22817889\">31</a>,<a class=\"rlc-reference\" data-ref-info=\"Krauthammer M, Kong Y, Ha BH, et al: Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat Genet 44:1006-14, 2012.\" href=\"#_ENREF_109\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22842228\">109</a></sup>. PPP6C is the catalytic unit of a phosphatase complex that negatively regulates activity of the mitotic Aurora kinase, a known oncogene. Most mutations map in the conserved domain that is involved in interaction with the regulatory subunit of the complex.</p>\n\n<p id=\"erb-dccdf626-9e84-4fc6-8e56-36b52c4fa50e\"><b>TACC1</b> (transforming acidic coiled-coil containing protein 1) is mutated in 5% of an experimental set of 121. TACC1 is known to stimulate the PI3K and Ras pathways and interact with Aurora kinase, which is notable considering that PPP6C mutations (above) also inactivate Aurora kinase <a class=\"rlc-reference\" data-ref-info=\"Hodis E, Watson IR, Kryukov GV, et al: A landscape of driver mutations in melanoma. Cell 150:251-63, 2012.\" href=\"#_ENREF_31\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22817889\"><sup>31</sup></a>. At least 16 Aurora kinase inhibitors are in clinical studies, of which two (<a href=\"http://www.cancer.gov/drugdictionary?CdrID=561286\">MLN8237/alisertib</a>, <a href=\"http://www.cancer.gov/drugdictionary?CdrID=670668\">GSK1070916A</a>) are investigated in melanoma (Supplemental Tables 1 and 2).</p>\n\n<p id=\"erb-2b1d96c6-4f28-4c7a-b068-dcacb95264bc\"><b>BAP1</b> (BRCA1-associated protein-1/ubiquitin carboxy-terminal hydrolase) is involved in metastatic progression of ocular and cutaneous melanoma. BAP1 is a known tumor-suppressor gene. BAP1 mutations are frequently found in uveal melanoma <a class=\"rlc-reference\" data-ref-info=\"Harbour JW, Onken MD, Roberson ED, et al: Frequent mutation of BAP1 in metastasizing uveal melanomas. Science 330:1410-3, 2010.\" href=\"#_ENREF_139\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/21051595\"><sup>139</sup></a>. Germline BAP1 mutations have recently been associated with an increased risk of several cancers, including atypical melanocytic tumors <a class=\"rlc-reference\" data-ref-info=\"Wiesner T, Obenauf AC, Murali R, et al: Germline mutations in BAP1 predispose to melanocytic tumors. Nat Genet 43:1018-21, 2011.\" href=\"#_ENREF_140\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/21874003\"><sup>140</sup></a> and uveal melanoma <a class=\"rlc-reference\" data-ref-info=\"Njauw CN, Kim I, Piris A, et al: Germline BAP1 inactivation is preferentially associated with metastatic ocular melanoma and cutaneous-ocular melanoma families. PLoS One 7:e35295, 2012.\" href=\"#_ENREF_141\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22545102\"><sup>141</sup></a>. Uveal melanoma might be sensitive to <a href=\"http://www.cancer.gov/drugdictionary\">HDAC inhibitors</a> <a class=\"rlc-reference\" data-ref-info=\"Landreville S, Agapova OA, Matatall KA, et al: Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma. Clin Cancer Res 18:408-16, 2012.\" href=\"#_ENREF_142\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22038994\"><sup>142</sup></a>, and a clinical trial of HDAC inhibitor vorinostat/SAHA in uveal melanoma is ongoing (phase II <a href=\"http://clinicaltrials.gov/ct2/show/NCT01587352\">NCT01587352</a>).</p>\n\n<p id=\"erb-d899b0ce-39c6-4100-9b5e-fe5b7c8747b6\"><b>SF3B1.</b> Codon 625 of the SF3B1 gene, encoding splicing factor 3B subunit 1, is consistently mutated in low-grade uveal melanomas with good prognosis <a class=\"rlc-reference\" data-ref-info=\"Harbour JW, Roberson ED, Anbunathan H, et al: Recurrent mutations at codon 625 of the splicing factor SF3B1 in uveal melanoma. Nat Genet 45:133-5, 2013.\" href=\"#_ENREF_143\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23313955\"><sup>143</sup></a>. Mutations of SF3B1 are associated with disomy 3 <a class=\"rlc-reference\" data-ref-info=\"Martin M, Masshofer L, Temming P, et al: Exome sequencing identifies recurrent somatic mutations in EIF1AX and SF3B1 in uveal melanoma with disomy 3. Nat Genet, 2013.\" href=\"#_ENREF_144\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23793026\"><sup>144</sup></a>, are mutually exclusive with BAP1 mutations and lead to aberrant splicing of transcripts of a number of genes <a class=\"rlc-reference\" data-ref-info=\"Furney SJ, Pedersen M, Gentien D, et al: SF3B1 mutations are associated with alternative splicing in uveal melanoma. Cancer Discov, 2013.\" href=\"#_ENREF_2\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23861464\"><sup>2</sup></a>.</p>\n\n<p id=\"erb-7730175a-087b-4e4d-9427-4621ff3d06e8\"><b>SNX31</b> was identified as one of the 11 new genes mutated in melanoma <a class=\"rlc-reference\" data-ref-info=\"Hodis E, Watson IR, Kryukov GV, et al: A landscape of driver mutations in melanoma. Cell 150:251-63, 2012.\" href=\"#_ENREF_31\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22817889\"><sup>31</sup></a>. It encodes a poorly characterized sorting nexin 31 protein. It could be a Ras effector protein that selectively binds GTP-loaded H-RAS <a class=\"rlc-reference\" data-ref-info=\"Ghai R, Mobli M, Norwood SJ, et al: Phox homology band 4.1/ezrin/radixin/moesin-like proteins function as molecular scaffolds that interact with cargo receptors and Ras GTPases. Proc Natl Acad Sci U S A 108:7763-8, 2011.\" href=\"#_ENREF_145\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/21512128\"><sup>145</sup></a>.</p>\n\n<p id=\"erb-4c60223f-2e2c-46db-96cb-f444a2963dad\"><b>STK19.</b> A 5% mutation rate of this kinase gene with unknown functions is seen in melanoma <a class=\"rlc-reference\" data-ref-info=\"Hodis E, Watson IR, Kryukov GV, et al: A landscape of driver mutations in melanoma. Cell 150:251-63, 2012.\" href=\"#_ENREF_31\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22817889\"><sup>31</sup></a>.</p>\n\n<p id=\"erb-6091a9ff-ec54-4c29-b36b-691dcc955534\"><b>LKB1/STK11</b>. LKB1 might be a central kinase that integrates energy metabolism and tumor growth, in part through activation of the family of AMPK kinases. Germline mutations in LKB1 (STK11) are associated with the Peutz-Jeghers syndrome (PJS), which includes aberrant mucocutaneous pigmentation, and somatic LKB1 mutations, which occur in 10% of cutaneous melanoma <a class=\"rlc-reference\" data-ref-info=\"Forbes SA, Bindal N, Bamford S, et al: COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res 39:D945-50, 2011.\" href=\"#_ENREF_146\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/20952405\"><sup>146</sup></a>. Somatic inactivation of LKB1 with K-Ras activation in murine melanocytes led to highly metastatic melanoma with 100% penetrance. Downstream events of LKB1 inactivation, in addition to AMPK-related effects, included increased phosphorylation of the SRC family kinase YES, increased expression of WNT target genes, and expansion of a CD24(+) cell population in melanoma with increased metastatic behavior <i>in vitro</i> and <i>in vivo </i><a class=\"rlc-reference\" data-ref-info=\"Liu W, Monahan KB, Pfefferle AD, et al: LKB1/STK11 inactivation leads to expansion of a prometastatic tumor subpopulation in melanoma. Cancer Cell 21:751-64, 2012.\" href=\"#_ENREF_147\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22698401\"><sup>147</sup></a>. <a href=\"http://www.cancer.gov/drugdictionary?CdrID=315885\">Dasatinib</a>, an SRC inhibitor, was shown previously to exhibit a higher activity towards YES rather than SRC, and could be a promising treatment for LKB1-mutated melanoma <a class=\"rlc-reference\" data-ref-info=\"Liu W, Monahan KB, Pfefferle AD, et al: LKB1/STK11 inactivation leads to expansion of a prometastatic tumor subpopulation in melanoma. Cancer Cell 21:751-64, 2012.\" href=\"#_ENREF_147\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22698401\"><sup>147</sup></a>. <a href=\"http://www.cancer.gov/drugdictionary?CdrID=593641\">Metformin</a>, an indirect activator of AMPK, the downstream target of LKB1, is currently in a clinical trial in combination with vemurafenib (NCT01638676).</p>\n\n<p id=\"erb-6f8ecbe3-6e3a-4a3d-b61a-6c9831593d9b\"><b>ARID2 </b>is a component of the SWI/SNF chromatin-remodeling complex. Loss-of-function mutations were found in 7% of melanomas. Targeted search identified mutations in other members of the ARID family (ARID1B, ARID1A, SMARCA4), altogether amounting to 13% of the experimental set <a class=\"rlc-reference\" data-ref-info=\"Hodis E, Watson IR, Kryukov GV, et al: A landscape of driver mutations in melanoma. Cell 150:251-63, 2012.\" href=\"#_ENREF_31\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22817889\"><sup>31</sup></a>.</p>\n\n<p id=\"erb-d984eeef-30c5-4b42-974c-4163f37c4e25\"><b>TRRAP2</b>. Identified mutations occur in 4% of the melanoma set examined. TRRAP functions as part of a multiprotein coactivator complex possessing histone acetyltranferase activity that is central to the transcriptional activity of p53, c-Myc, and E2F1 <a class=\"rlc-reference\" data-ref-info=\"Wei X, Walia V, Lin JC, et al: Exome sequencing identifies GRIN2A as frequently mutated in melanoma. Nat Genet 43:442-6, 2011.\" href=\"#_ENREF_148\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/21499247\"><sup>148</sup></a>.</p>\n\n<p id=\"erb-9705e888-0545-4652-9951-f456e3c050b5\"><b>GRIN2A </b>encodes the glutamate N-methyl-D-aspartic acid (NMDA) receptor subunit \u03b5-1 that is part of the class of ionotropic glutamate receptors and bears the agonist binding site for glutamate. GRIN2A was found to be mutated in 25% of melanomas <a class=\"rlc-reference\" data-ref-info=\"Wei X, Walia V, Lin JC, et al: Exome sequencing identifies GRIN2A as frequently mutated in melanoma. Nat Genet 43:442-6, 2011.\" href=\"#_ENREF_148\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/21499247\"><sup>148</sup></a>; this was confirmed in another study <a class=\"rlc-reference\" data-ref-info=\"Stark MS, Woods SL, Gartside MG, et al: Frequent somatic mutations in MAP3K5 and MAP3K9 in metastatic melanoma identified by exome sequencing. Nat Genet 44:165-9, 2012.\" href=\"#_ENREF_110\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22197930\"><sup>110</sup></a>. Many mutations are missense or nonsense; therefore, it is unlikely to behave as a canonical oncogene.</p>\n\n<p id=\"erb-fee765e5-fd53-4cd5-9706-c81a82f8be9c\"><b>GRM3 </b>is a metabotropic glutamate receptor, a G-protein-coupled receptor (GPCR) that activates phospholipase C upon ligand binding. It was found to be mutated in melanoma through exome-capture analysis of GPCR genes <a class=\"rlc-reference\" data-ref-info=\"Prickett TD, Wei X, Cardenas-Navia I, et al: Exon capture analysis of G protein-coupled receptors identifies activating mutations in GRM3 in melanoma. Nat Genet 43:1119-26, 2011.\" href=\"#_ENREF_149\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/21946352\"><sup>149</sup></a>. Mutated GRM3 was shown to contribute to the proliferation and invasiveness of melanoma cells <i>in vitro</i> and induce an increased phosphorylation of MEK. AZD-6244, an inhibitor of MEK, was able to reduce cell proliferation by inducing apoptosis <i>in vitro</i>. There is some interest in using available inhibitors of glutamate release for treatment of melanoma, since one of them, <a href=\"http://www.cancer.gov/drugdictionary?CdrID=594943\">riluzole</a>, was shown to inhibit growth of melanoma cells <i>in vitro</i> and <i>in vivo</i> <a class=\"rlc-reference\" data-ref-info=\"Namkoong J, Shin SS, Lee HJ, et al: Metabotropic glutamate receptor 1 and glutamate signaling in human melanoma. Cancer Res 67:2298-305, 2007.\" href=\"#_ENREF_150\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/17332361\"><sup>150</sup></a>. Even though riluzole was shown to inhibit growth of cell lines expressing GRM1, a clinical trial is ongoing to explore the antitumor activity of riluzole in melanoma without prior analysis of GRM3 status.</p>\n\n<p id=\"erb-bf4fd364-2e02-445d-aef8-3e5b9433a5e9\"><b>Phosphoglycerate dehydrogenase PHGDH</b> serves to divert glycolytic carbon into serine and glycine metabolism in some cancer cells to supply the increased biosynthetic needs of transformed phenotype <a class=\"rlc-reference\" data-ref-info=\"Locasale JW, Grassian AR, Melman T, et al: Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. Nat Genet 43:869-74, 2011.\" href=\"#_ENREF_151\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/21804546\"><sup>151</sup></a>. The same study found that PHGDH is recurrently amplified in a genomic region of a focal copy number gain most commonly found in melanoma. PHGDH catalyzes the first step in the biosynthesis of serine and subsequent generation of nucleotides. Melanoma cell lines with amplified PHGDH had increased flux through the serine pathway. This pathway, as well as proliferation of cells with high PHGDH, was sensitive to short hairpin RNA (shRNA)-mediated knockdown of PHGDH <a class=\"rlc-reference\" data-ref-info=\"Locasale JW, Grassian AR, Melman T, et al: Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. Nat Genet 43:869-74, 2011.\" href=\"#_ENREF_151\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/21804546\"><sup>151</sup></a>.</p>\n\n<p id=\"erb-2036a01f-c735-4eff-bbaa-0b0690b09bd1\"><b>WEE1.</b> Cell cycle regulatory kinase Wee1 is upregulated in melanoma and is associated with poor prognosis <a class=\"rlc-reference\" data-ref-info=\"Magnussen GI, Holm R, Emilsen E, et al: High expression of Wee1 is associated with poor disease-free survival in malignant melanoma: potential for targeted therapy. PLoS One 7:e38254, 2012.\" href=\"#_ENREF_152\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22719872\"><sup>152</sup></a>. Selective inhibitor of Wee1 <a href=\"http://www.cancer.gov/drugdictionary?CdrID=594147\">MK-1775</a> showed somewhat promising results as a single agent in previously treated patients with metastatic melanoma, but additional trials are not being conducted at this time.</p>\n\n<p id=\"erb-0844e75b-d145-4f51-b848-6130e2b993d8\"><b>NUAK2</b> (AMPK-related kinase). High levels of expression of NUAK2 were found in patients with acral melanoma and are associated with increased risk of relapse <a class=\"rlc-reference\" data-ref-info=\"Namiki T, Tanemura A, Valencia JC, et al: AMP kinase-related kinase NUAK2 affects tumor growth, migration, and clinical outcome of human melanoma. Proc Natl Acad Sci U S A 108:6597-602, 2011.\" href=\"#_ENREF_153\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/21460252\"><sup>153</sup></a>. NUAK2 knockdown suppresses melanoma cell growth <i>in vitro</i> and tumorigenicity <i>in vivo</i> and has been proposed as a new oncogene in acral melanoma.</p>\n\n<p id=\"erb-516bacf3-768c-44c3-ac30-2b5225dadcb6\"><b>Various noncoding RNAs and other epigenetic alterations</b></p>\n<p id=\"erb-e9ca8b0b-a19e-428e-b029-463a68e8d219\">A number of reports found significant roles for miRNA, ncRNA, or ceRNA in pathogenesis of melanoma; for example, ZEB2, a ceRNA for PTEN, upregulates expression of this tumor suppressor in melanoma. Abrogated ZEB2 cooperates with BRAFV600E to promote melanomagenesis <a class=\"rlc-reference\" data-ref-info=\"Karreth FA, Tay Y, Perna D, et al: In vivo identification of tumor- suppressive PTEN ceRNAs in an oncogenic BRAF-induced mouse model of melanoma. Cell 147:382-95, 2011.\" href=\"#_ENREF_102\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22000016\"><sup>102</sup></a>. ADAR1, a protein of the family known as adenosine deaminase acting on RNA, is substantially downregulated during metastatic progression of melanoma. ADAR1 was found to regulate expression of numerous miRNAs, as well as of the key miRNA processing protein DICER. Two miRNAS were implicated in silencing of ADAR1 itself (http://www.jci.org/articles/view/62980). These findings reaffirm the significant contribution of epigenetic miRNA regulation to melanoma pathogenesis.</p>\n<p id=\"erb-267c20fa-fbd4-4303-aa6b-c08647d8e364\">Strategies to inhibit or increase expression of ncRNAs in clinical setting are only beginning to emerge. A growing interest in epigenetic alterations such as chromatin remodeling, DNA methylation, and histone modification regarding their role in melanomagenesis, might lead to the identification of novel therapeutic targets (reviewed by van den Hurk, 2012 <a class=\"rlc-reference\" data-ref-info=\"van den Hurk K, Niessen HE, Veeck J, et al: Genetics and epigenetics of cutaneous malignant melanoma: A concert out of tune. Biochim Biophys Acta 1826:89-102, 2012.\" href=\"#_ENREF_154\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22503822\"><sup>154</sup></a>).</p>\n\n<h1 id=\"erh-00582ad2-5f80-4391-9ebc-6ba1b87ae4d3\">INTRINSIC RESISTANCE TO BRAF AND MEK INHIBITORS (Table 3)</h1>\n<p id=\"erb-0daf11b8-3030-421b-94c0-184f14f0bc81\">Resistance to BRAF inhibitors could be intrinsic (as in lack of response to selective BRAF inhibitors in patients with BRAF-mutated tumors) or acquired (development of resistance after treatment with BRAF or MEK inhibitors). Both are of the utmost concern. The current understanding of the origins of intrinsic resistance, as well as possible approaches to overcoming it, are addressedhere (seeTable 3).</p>\n<p id=\"erb-22979e65-4687-4672-bbf9-2afbb3e31900\">It is well established that BRAF mutations play a role in melanomagenesis; however, without additional genetic alterations, tumor development is restricted by OIS. As described in the earlier section, and in Table 1, additional genetic alterations are present in BRAF-mutant tumors, some of which serve to overcome OIS, and could play a role in inherent resistance to mutant BRAF and MEK inhibitors. These two groups overlap, as could be expected. The necessity of targeting multiple signaling pathways to overcome drug resistance of aggressive melanoma was demonstrated <i>in vitro</i> <a class=\"rlc-reference\" data-ref-info=\"Smalley KS, Haass NK, Brafford PA, et al: Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Mol Cancer Ther 5:1136-44, 2006.\" href=\"#_ENREF_155\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/16731745\"><sup>155</sup></a>. Genomic analyses and the informed choice of combinatorial approaches analyzed in preclinical models are critical in selecting the right combination of targeted therapies in a personalized approach to melanoma treatment. In general, in addition to the MAPK pathway that is deregulated in most melanomas, the other targets might include any of the ones listed in Table 1. Experimental evidence indicating involvement of several pathways/genes in inherent resistance to BRAF inhibition is cited below in Table 3.</p>\n<h3>Table 3. Intrinsic Resistance to BRAF and MEK Inhibitors</h3>\n<table border=\"1\" cellpadding=\"7\" cellspacing=\"0\" id=\"erb-f0991301-5283-4c8b-8344-7ae28f545e0f\" width=\"672\">\n<colgroup>\n<col width=\"208\"></col>\n<col width=\"172\"></col>\n<col width=\"106\"></col>\n<col width=\"130\"></col>\n</colgroup>\n<tbody>\n<tr valign=\"TOP\">\n<td width=\"208\">\n<p><b>MOLECULAR CHANGE</b></p>\n</td>\n<td width=\"172\">\n<p><b>CONFIRMED IN PATIENT BIOPSIES?</b></p>\n</td>\n<td width=\"106\">\n<p><b>DRUGS TO ADD TO OVERCOME RESISTANCE</b></p>\n</td>\n<td width=\"130\">\n<p><b>REFERENCE</b></p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"208\">\n<p><b>Resistance to Vemurafenib </b></p>\n</td>\n<td width=\"172\">\n<p>\u00a0</p>\n</td>\n<td width=\"106\">\n<p>\u00a0</p>\n</td>\n<td width=\"130\">\n<p>\u00a0</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"208\">\n<p>Loss of PTEN and consequent loss of BIM expression</p>\n</td>\n<td width=\"172\">\n<p><i>Yes</i></p>\n</td>\n<td width=\"106\">\n<p>PI3Ki + MEKi</p>\n</td>\n<td width=\"130\">\n<p><a class=\"rlc-reference\" data-ref-info=\"Paraiso KH, Xiang Y, Rebecca VW, et al: PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res 71:2750-60, 2011.\" href=\"#_ENREF_156\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/21317224\"><sup>156</sup></a>,<a class=\"rlc-reference\" data-ref-info=\"Vredeveld LC, Possik PA, Smit MA, et al: Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis. Genes Dev 26:1055-69, 2012.\" href=\"#_ENREF_90\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22549727\"><sup>90</sup></a>, <a class=\"rlc-reference\" data-ref-info=\"Nathanson KL, Martin AM, Wubbenhorst B, et al: Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor Dabrafenib (GSK2118436). Clin Cancer Res, 2013.\" href=\"#_ENREF_103\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23833299\"><sup>103</sup></a></p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"208\">\n<p>NF1 mutation or loss of expression</p>\n</td>\n<td width=\"172\">\n<p>Yes</p>\n</td>\n<td width=\"106\">\n<p>MEKi/mTORi</p>\n</td>\n<td width=\"130\">\n<p><a class=\"rlc-reference\" data-ref-info=\"Maertens O, Johnson B, Hollstein P, et al: Elucidating distinct roles for NF1 in melanomagenesis. Cancer Discov, 2012.\" href=\"#_ENREF_85\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23171796\"><sup>85</sup></a>, <a class=\"rlc-reference\" data-ref-info=\"Whittaker SR, Theurillat JP, Van Allen E, et al: A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. Cancer Discov, 2013.\" href=\"#_ENREF_86\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23288408\"><sup>86</sup></a></p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"208\">\n<p>Activation of CDK pathway</p>\n</td>\n<td width=\"172\">\n<p>No, <i>in vitro</i> only</p>\n</td>\n<td width=\"106\">\n<p>CDKi</p>\n</td>\n<td width=\"130\">\n<p><a class=\"rlc-reference\" data-ref-info=\"Smalley KS, Lioni M, Dalla Palma M, et al: Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas. Mol Cancer Ther 7:2876-83, 2008.\" href=\"#_ENREF_157\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/18790768\"><sup>157</sup></a>, <a class=\"rlc-reference\" data-ref-info=\"Nathanson KL, Martin AM, Wubbenhorst B, et al: Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor Dabrafenib (GSK2118436). Clin Cancer Res, 2013.\" href=\"#_ENREF_103\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23833299\"><sup>103</sup></a></p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"208\">\n<p>Metabolic signature</p>\n</td>\n<td width=\"172\">\n<p>Yes, high FDG uptake is associated with response to BRAFi</p>\n</td>\n<td width=\"106\">\n<p>\u00a0</p>\n</td>\n<td width=\"130\">\n<p><a class=\"rlc-reference\" data-ref-info=\"McArthur GA, Puzanov I, Amaravadi R, et al: Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma. J Clin Oncol 30:1628-34, 2012.\" href=\"#_ENREF_158\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22454415\"><sup>158</sup></a></p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"208\">\n<p>MET and SRC signaling</p>\n</td>\n<td width=\"172\">\n<p>\u00a0</p>\n</td>\n<td width=\"106\">\n<p>METi?</p>\n</td>\n<td width=\"130\">\n<p><a class=\"rlc-reference\" data-ref-info=\"Vergani E, Vallacchi V, Frigerio S, et al: Identification of MET and SRC activation in melanoma cell lines showing primary resistance to PLX4032. Neoplasia 13:1132-42, 2011.\" href=\"#_ENREF_159\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22241959\"><sup>159</sup></a></p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"208\">\n<p>Production of HGF by stroma</p>\n</td>\n<td width=\"172\">\n<p>Observed in patients' tumors; functionally confirmed <i>in vitro</i></p>\n</td>\n<td width=\"106\">\n<p>METi?</p>\n</td>\n<td width=\"130\">\n<p><a class=\"rlc-reference\" data-ref-info=\"Straussman R, Morikawa T, Shee K, et al: Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 487:500-4, 2012.\" href=\"#_ENREF_160\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22763439\"><sup>160</sup></a></p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"208\">\n<p>Expression of antiapoptotic proteins, BCL2 and BCL2A1</p>\n</td>\n<td width=\"172\">\n<p>Observed in tumors</p>\n</td>\n<td width=\"106\">\n<p>BH3 mimetics</p>\n</td>\n<td width=\"130\">\n<p><a class=\"rlc-reference\" data-ref-info=\"Wroblewski D, Mijatov B, Mohana-Kumaran N, et al: The BH3-mimetic ABT-737 sensitizes human melanoma cells to apoptosis induced by selective BRAF inhibitors but does not reverse acquired resistance. Carcinogenesis, 2012.\" href=\"#_ENREF_161\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23087082\"><sup>161</sup></a> <a class=\"rlc-reference\" data-ref-info=\"Haq R, Yokoyama S, Hawryluk EB, et al: BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition. Proc Natl Acad Sci U S A 110:4321-6, 2013.\" href=\"#_ENREF_61\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23447565\"><sup>61</sup></a></p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"208\">\n<p>Elevated expression of MITF and PGC1a</p>\n</td>\n<td width=\"172\">\n<p>Yes</p>\n</td>\n<td width=\"106\">\n<p>OXPHOSi</p>\n</td>\n<td width=\"130\">\n<p><a class=\"rlc-reference\" data-ref-info=\"Haq R, Shoag J, Andreu-Perez P, et al: Oncogenic BRAF Regulates Oxidative Metabolism via PGC1alpha and MITF. Cancer Cell 23:302-15, 2013.\" href=\"#_ENREF_162\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23477830\"><sup>162</sup></a></p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"208\">\n<p>Elevated expression of FOXD3 and ERBB3</p>\n</td>\n<td width=\"172\">\n<p>No</p>\n</td>\n<td width=\"106\">\n<p>ERBB2/3i</p>\n</td>\n<td width=\"130\">\n<p><a class=\"rlc-reference\" data-ref-info=\"Basile KJ, Abel EV, Aplin AE: Adaptive upregulation of FOXD3 and resistance to PLX4032/4720-induced cell death in mutant B-RAF melanoma cells. Oncogene 31:2471-9, 2012.\" href=\"#_ENREF_163\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/21996740\"><sup>163</sup></a>, <a class=\"rlc-reference\" data-ref-info=\"Abel EV, Basile KJ, Kugel CH, 3rd, et al: Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3. J Clin Invest, 2013.\" href=\"#_ENREF_164\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23543055\"><sup>164</sup></a></p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"208\">\n<p>Expression of Hsp90</p>\n</td>\n<td width=\"172\">\n<p>In vitro</p>\n</td>\n<td width=\"106\">\n<p>XL888, Hsp90i</p>\n</td>\n<td width=\"130\">\n<p><a class=\"rlc-reference\" data-ref-info=\"Paraiso KH, Haarberg HE, Wood E, et al: The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms. Clin Cancer Res 18:2502-14, 2012.\" href=\"#_ENREF_165\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22351686\"><sup>165</sup></a></p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"208\">\n<p>Persistent activity of mTORC1</p>\n</td>\n<td width=\"172\">\n<p>Yes</p>\n</td>\n<td width=\"106\">\n<p>mTORi</p>\n</td>\n<td width=\"130\">\n<p>\u00a0</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"208\">\n<p><b>Resistance to MEK Inhibitors </b></p>\n</td>\n<td width=\"172\">\n<p>\u00a0</p>\n</td>\n<td width=\"106\">\n<p>\u00a0</p>\n</td>\n<td width=\"130\">\n<p>\u00a0</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"208\">\n<p>Signaling through TGF-\uf062/SMURF2/PAX3 and MITF</p>\n</td>\n<td width=\"172\">\n<p>No</p>\n<p>\u00a0</p>\n</td>\n<td width=\"106\">\n<p>\u00a0</p>\n</td>\n<td width=\"130\">\n<p><a class=\"rlc-reference\" data-ref-info=\"Smith MP, Ferguson J, Arozarena I, et al: Effect of SMURF2 Targeting on Susceptibility to MEK Inhibitors in Melanoma. J Natl Cancer Inst 105:33-46, 2013.\" href=\"#_ENREF_166\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23250956\"><sup>166</sup></a></p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"208\">\n<p>Downregulation of PTEN, activation of PI3K</p>\n</td>\n<td width=\"172\">\n<p>No</p>\n</td>\n<td width=\"106\">\n<p>PI3Ki + MEKi</p>\n</td>\n<td width=\"130\">\n<p><a class=\"rlc-reference\" data-ref-info=\"Byron SA, Loch DC, Wellens CL, et al: Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status. Mol Cancer 11:75, 2012.\" href=\"#_ENREF_167\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23039341\"><sup>167</sup></a></p>\n</td>\n</tr>\n</tbody>\n</table>\n\n<p id=\"erb-6d03411d-257f-4ca7-8119-29e2f1eb3ce4\"><b>PI3K/AKT</b>. Mutations of the PI3K pathway are frequent in the BRAF-mutant setting. These have been shown to overcome BRAFV600E-induced OIS and contribute to inherent resistance to BRAF inhibitors <a class=\"rlc-reference\" data-ref-info=\"Vredeveld LC, Possik PA, Smit MA, et al: Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis. Genes Dev 26:1055-69, 2012.\" href=\"#_ENREF_90\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22549727\"><sup>90</sup></a>. In particular, loss of PTEN and consequent loss of expression of the pro-apoptotic BIM that is distantly regulated by PTEN were implicated in inherent resistance to BRAF inhibitor <i>in vitro</i> <a class=\"rlc-reference\" data-ref-info=\"Paraiso KH, Xiang Y, Rebecca VW, et al: PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res 71:2750-60, 2011.\" href=\"#_ENREF_156\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/21317224\"><sup>156</sup></a> and to dabrafenib in patients <a class=\"rlc-reference\" data-ref-info=\"Nathanson KL, Martin AM, Wubbenhorst B, et al: Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor Dabrafenib (GSK2118436). Clin Cancer Res, 2013.\" href=\"#_ENREF_103\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23833299\"><sup>103</sup></a>. PTEN-negative or AKT3-overexpressing melanomas do not undergo apoptosis in response to BRAF inhibition and do not upregulate pro-apoptotic protein BIM. PLX4720 was found to stimulate AKT signaling in the PTEN\u2013, but not the PTEN+, cell lines. A clinical trial with inhibitors of both MAPK and PI3K showed promise in patients with various solid tumors <a class=\"rlc-reference\" data-ref-info=\"Shimizu T, Tolcher AW, Papadopoulos KP, et al: The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer. Clin Cancer Res 18:2316-25, 2012.\" href=\"#_ENREF_168\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22261800\"><sup>168</sup></a>.</p>\n<p id=\"erb-a9ed6bb6-2891-43f0-975b-b534638f69e9\">Recent study demonstrated an essential role for ERK-phosphorylated MEK1 (pT292) in membrane recruitment of PTEN and consequent negative regulation of AKT <a class=\"rlc-reference\" data-ref-info=\"Zmajkovicova K, Jesenberger V, Catalanotti F, et al: MEK1 Is Required for PTEN Membrane Recruitment, AKT Regulation, and the Maintenance of Peripheral Tolerance. Mol Cell 50:43-55, 2013.\" href=\"#_ENREF_169\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23453810\"><sup>169</sup></a>. Inhibition of BRAFV600-MEK1-ERK therefore might lead to the inhibition of the restraining role that this pathway has on activity of PI3K/AKT pathway via PTEN.</p>\n\n<p id=\"erb-480bfbed-083b-40a8-a04b-cd7f7a7d0b2d\"><b>CDK4 pathway</b>. Increased cyclin D expression mediates inherent resistance to mutant BRAF inhibition <a class=\"rlc-reference\" data-ref-info=\"Smalley KS, Lioni M, Dalla Palma M, et al: Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas. Mol Cancer Ther 7:2876-83, 2008.\" href=\"#_ENREF_157\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/18790768\"><sup>157</sup></a>, and copy number changes in CDKN2A, CCND1 correlated with the shortened duration of PFS in patients treated with dabrafenib <a class=\"rlc-reference\" data-ref-info=\"Nathanson KL, Martin AM, Wubbenhorst B, et al: Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor Dabrafenib (GSK2118436). Clin Cancer Res, 2013.\" href=\"#_ENREF_103\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23833299\"><sup>103</sup></a>.</p>\n\n<p id=\"erb-4efdcbd1-893e-42ee-b9ce-e3f9a3db28f2\"><b>NF1 mutations</b>. In a mouse model, NF1 ablation decreases the sensitivity of NF1 wild-type melanoma cell lines to BRAF inhibitors, and NF1 is lost in tumors from patients following treatment with these agents. Nf1/BRAF-mutant tumors are resistant to BRAF inhibitors, but are sensitive to combined MEK/mTOR inhibition <a class=\"rlc-reference\" data-ref-info=\"Maertens O, Johnson B, Hollstein P, et al: Elucidating distinct roles for NF1 in melanomagenesis. Cancer Discov, 2012.\" href=\"#_ENREF_85\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23171796\"><sup>85</sup></a>. In another study, NF1 mutations were documented in BRAF-mutant tumor cells that were intrinsically resistant to BRAF inhibition, and in melanoma tumors from patients exhibiting resistance\u00a0to vemurafenib, thus demonstrating the clinical significance for NF1-driven\u00a0resistance\u00a0to RAF/MEK-targeted therapies <a class=\"rlc-reference\" data-ref-info=\"Whittaker SR, Theurillat JP, Van Allen E, et al: A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. Cancer Discov, 2013.\" href=\"#_ENREF_86\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23288408\"><sup>86</sup></a>.</p>\n\n<p id=\"erb-0f9186a5-fd83-411e-96c9-0dbeab42c260\"><b>MET and SRC.</b> The activation of MET and SRC signaling was detected in two patient-derived melanoma cell lines with BRAFV600E that were resistant to BRAF inhibitor PLX4032. MET or SRC, respectively, were targeted with siRNA or drugs in combination with PLX4032. This was effective in inhibiting cell growth and reducing cell invasion and migration, indicating a functional role for MET and SRC signaling in primary resistance to PLX4032 <a class=\"rlc-reference\" data-ref-info=\"Vergani E, Vallacchi V, Frigerio S, et al: Identification of MET and SRC activation in melanoma cell lines showing primary resistance to PLX4032. Neoplasia 13:1132-42, 2011.\" href=\"#_ENREF_159\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22241959\"><sup>159</sup></a>.</p>\n\n<p id=\"erb-1a67c68f-2991-4a35-8c50-431643c26334\"><b>Metabolic signature of melanoma sensitive to mutant BRAF inhibition. </b>An interesting study could not find correlation between sensitivity to PLX4032 and genetic profiles in a panel of BRAF-mutant cell lines. However, the sensitive cell lines had a more profound inhibition of FDG uptake upon exposure to PLX4032 than resistant cell lines. This indicates that melanomas with a higher dependence on glycolysis might be more sensitive to mutant BRAF inhibition. This also indicates that FDG-PET could be useful in assessing sensitivity to BRAF inhibitors <a class=\"rlc-reference\" data-ref-info=\"Sondergaard JN, Nazarian R, Wang Q, et al: Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032. J Transl Med 8:39, 2010.\" href=\"#_ENREF_170\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/20406486\"><sup>170</sup></a>. Indeed, a clinical study that incorporated FDG-PET monitoring of responses to vemurafenib strongly indicated that there is a positive correlation between responses to therapy (PFS) and reduction in the uptake of FDG <a class=\"rlc-reference\" data-ref-info=\"McArthur GA, Puzanov I, Amaravadi R, et al: Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma. J Clin Oncol 30:1628-34, 2012.\" href=\"#_ENREF_158\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22454415\"><sup>158</sup></a>.</p>\n\n<p id=\"erb-d685adff-1f82-4829-a80c-e2130e39266c\"><b>MITF-PGC1</b>a<b> axis in resistance to BRAF inhibition</b>. Inhibition of BRAFV600 and, to a lesser extent of MEK, were found to induce expression of genes involved in citric acid cycle and oxidative phosphorylation (OXPHOS) in melanoma. Search for factors regulating OXPHOS revealed that PGC1a is upregulated in resistant melanoma lines <a class=\"rlc-reference\" data-ref-info=\"Haq R, Shoag J, Andreu-Perez P, et al: Oncogenic BRAF Regulates Oxidative Metabolism via PGC1alpha and MITF. Cancer Cell 23:302-15, 2013.\" href=\"#_ENREF_162\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23477830\"><sup>162</sup></a>. PGC1a, in turn, was found to be a direct transcriptional target of MITF <sup><a class=\"rlc-reference\" data-ref-info=\"Vazquez F, Lim JH, Chim H, et al: PGC1alpha Expression Defines a Subset of Human Melanoma Tumors with Increased Mitochondrial Capacity and Resistance to Oxidative Stress. Cancer Cell, 2013.\" href=\"#_ENREF_59\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23416000\">59</a>,<a class=\"rlc-reference\" data-ref-info=\"Haq R, Shoag J, Andreu-Perez P, et al: Oncogenic BRAF Regulates Oxidative Metabolism via PGC1alpha and MITF. Cancer Cell 23:302-15, 2013.\" href=\"#_ENREF_162\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23477830\">162</a></sup>. MITF expression and, as a consequence, PGC1a levels are upregulated in melanoma lines and in tumors of patients treated with Vemurafenib. Inhibition of BRAF leads to inhibition of glycolytic pathway for ATP production, but MITF-expressing melanomas can undergo a bioenergetics adaptation via MITF-PGC1a-OXPHOS upregulation <a class=\"rlc-reference\" data-ref-info=\"Haq R, Shoag J, Andreu-Perez P, et al: Oncogenic BRAF Regulates Oxidative Metabolism via PGC1alpha and MITF. Cancer Cell 23:302-15, 2013.\" href=\"#_ENREF_162\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23477830\"><sup>162</sup></a>. The authors suggest targeting OXPHOS in this group of patients prior to use of MAPK inhibitors because lines selected to resistance to Vemurafenib have elevated levels of PGC1a.</p>\n\n<p id=\"erb-a8efd55a-a57a-46e8-92e5-60140fa66035\"><b>Tumor stroma influence.</b> An important study demonstrated production of HGF by stromal cells in patients with melanoma, which resulted in activation of the HGF receptor MET, reactivation of the MAPK and PI3K pathways, and resistance to BRAF <a class=\"rlc-reference\" data-ref-info=\"Straussman R, Morikawa T, Shee K, et al: Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 487:500-4, 2012.\" href=\"#_ENREF_160\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22763439\"><sup>160</sup></a>. Addition of growth factors was shown to rescue various tumor cells lines from killing by kinase inhibitors including vemurafenib in melanoma <a class=\"rlc-reference\" data-ref-info=\"Wilson TR, Fridlyand J, Yan Y, et al: Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 487:505-9, 2012.\" href=\"#_ENREF_171\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22763448\"><sup>171</sup></a>. High production of HGF was observed in the stroma samples from patients who had a poor response to the inhibition of mutant BRAF. In a cellular model, co-treatment with BRAF and HGF or MET inhibitors reversed drug resistance\u00a0<a class=\"rlc-reference\" data-ref-info=\"Straussman R, Morikawa T, Shee K, et al: Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 487:500-4, 2012.\" href=\"#_ENREF_160\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22763439\"><sup>160</sup></a>.</p>\n\n<p id=\"erb-dfc1bcc6-50ca-4436-bbec-f216d3421a4d\"><b>BCL-2.</b> Inhibition of anti-apoptotic protein Bcl-2 might have a potential role in the future studies aimed to prevent the development of resistance to BRAF inhibition. The BH3 mimetic ABT-737 (inhibiting both Bcl2 and Bcl-xL) sensitizes human melanoma cells to apoptosis induced by selective BRAF inhibitors, but does not reverse acquired resistance <i>in vitro</i> <a class=\"rlc-reference\" data-ref-info=\"Wroblewski D, Mijatov B, Mohana-Kumaran N, et al: The BH3-mimetic ABT-737 sensitizes human melanoma cells to apoptosis induced by selective BRAF inhibitors but does not reverse acquired resistance. Carcinogenesis, 2012.\" href=\"#_ENREF_161\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23087082\"><sup>161</sup></a>.</p>\n\n<p id=\"erb-bed584b2-2932-4a09-b232-b77d0d0ff7d4\"><b>BCL2A1</b>. Amplification of one family member, BCL2A1 in 30% of melanoma was shown to contribute to resistance to BRAF inhibition <a class=\"rlc-reference\" data-ref-info=\"Haq R, Yokoyama S, Hawryluk EB, et al: BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition. Proc Natl Acad Sci U S A 110:4321-6, 2013.\" href=\"#_ENREF_61\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23447565\"><sup>61</sup></a>. BCL2A1 expression is apparently restricted to melanocytic lineage as it is indirectly controlled by MITF, and because of this its expression is limited to high-MITF-expressing melanomas. Obatoclax, inhibitor of the BCL family, helps to overcome the resistance of cell lines with amplified BCL2A1 to BRAF inhibition.</p>\n\n<p id=\"erb-a32022be-5bde-4420-bf29-803e6a954674\"><b>FOXD3-ERBB3</b>. Transcription factor FOXD3 was shown to be upregulated when mutant BRAF is inhibited in melanoma cell lines PGC1a <a class=\"rlc-reference\" data-ref-info=\"Basile KJ, Abel EV, Aplin AE: Adaptive upregulation of FOXD3 and resistance to PLX4032/4720-induced cell death in mutant B-RAF melanoma cells. Oncogene 31:2471-9, 2012.\" href=\"#_ENREF_163\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/21996740\"><sup>163</sup></a>. Subsequent work revealed that FOXD3 directly activates expression of ERBB3 that contributes to resistance to vemurafenib via activation of PI3K pathway, with involvement of ERBB2. The latter finding indicates a possibility of targeting ERBB2 alongside BRAF to overcome resistance <a class=\"rlc-reference\" data-ref-info=\"Abel EV, Basile KJ, Kugel CH, 3rd, et al: Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3. J Clin Invest, 2013.\" href=\"#_ENREF_164\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23543055\"><sup>164</sup></a>.</p>\n\n<p id=\"erb-4d8c0d95-9173-48f6-b354-37de41c4c207\">Chaperone Hsp90 is required for the stability of several of the oncoproteins that mediate RAF inhibitor resistance. Inhibitors of Hsp90 may be effective in patients with intrinsic or acquired resistance to BRAF inhibition <a class=\"rlc-reference\" data-ref-info=\"Catalanotti F, Solit DB: Will Hsp90 inhibitors prove effective in BRAF-mutant melanomas? Clin Cancer Res 18:2420-2, 2012.\" href=\"#_ENREF_172\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22442059\"><sup>172</sup></a>. In lab studies, treatment of melanoma cells with XL888, the inhibitor of Hsp90, induced apoptosis more effectively than dual MEK/PI3K inhibition in several different models of resistance <a class=\"rlc-reference\" data-ref-info=\"Paraiso KH, Haarberg HE, Wood E, et al: The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms. Clin Cancer Res 18:2502-14, 2012.\" href=\"#_ENREF_165\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22351686\"><sup>165</sup></a>. Multiple proteins, including PDGFR\u03b2, COT, IGFR1, CRAF, ARAF, S6, cyclin D1, and AKT, were degraded as a result of inhibition of Hsp90, which led to the nuclear accumulation of FOXO3a, an increase in BIM expression, and the downregulation of Mcl-1. XL888 was effective against NRAS mutant melanoma cells in vitro and in xenografts, most likely by decreasing protein levels of AKT, CDK4 and WEE1 <a class=\"rlc-reference\" data-ref-info=\"Haarberg HE, Paraiso KH, Wood E, et al: Inhibition of Wee1, AKT and CDK4 underlies the efficacy of the HSP90 inhibitor XL888 in an in vivo model of NRAS mutant melanoma. Mol Cancer Ther, 2013.\" href=\"#_ENREF_173\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23538902\"><sup>173</sup></a>. <a href=\"http://www.cancer.gov/drugdictionary?CdrID=629922\">XL888</a> is now in clinical studies in combination with vemurafenib (NCT01657591). Another non-geldanamycin Hsp90 inhibitor, <a href=\"http://www.cancer.gov/drugdictionary?CdrID=598379\">STA-9090</a> (ganetispib), is also in clinical trials.</p>\n<h1 id=\"erh-2eed4c3d-22cb-419d-ac8e-c75ebaeb0535\"><br/>\r\n\u00a0</h1>\n<p id=\"erb-9ddf1ab9-8186-4fad-9d24-046913f5e31f\">mTORC1 activity. Activity of mTORC1 after treatment of melanoma cells <i>in vitro</i> was found to be a faithful predictor of the response <a class=\"rlc-reference\" data-ref-info=\"Deng W, Gopal YN, Scott A, et al: Role and therapeutic potential of PI3K-mTOR signaling in de novo resistance to BRAF inhibition. Pigment Cell Melanoma Res 25:248-58, 2012.\" href=\"#_ENREF_174\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22171948\"><sup>174</sup></a>. Suppression of mTORC1 as seen from inhibited phosphorylation of the surrogate marker ribosomal s6 protein was highly predictive of death response to BRAF and MEK inhibitors. In patients, suppression of phospho-S6 was significantly associated with improved PFS <a class=\"rlc-reference\" data-ref-info=\"Corcoran RB, Rothenberg SM, Hata AN, et al: TORC1 Suppression Predicts Responsiveness to RAF and MEK Inhibition in BRAF-Mutant Melanoma. Sci Transl Med 5:196ra98, 2013.\" href=\"#_ENREF_175\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23903755\"><sup>175</sup></a>. Quantitation of p-S6 could serve as a biomarker to guide treatment of BRAF mutant melanoma. It also raises the possibility that simultaneous inhibition of mutant BRAF and PI3K or mTORC1 might be of clinical value. Several early-phase clinical trials examining MEK inhibitors with PI3K/mTOR inhibitors are recruiting patients.</p>\n<h1 id=\"erh-c775d5d0-3579-4100-a424-d25d587609bf\"><br/>\r\n\u00a0</h1>\n<p id=\"erb-d4b2bf52-2af4-40e9-966a-17476becbab9\"><b>Intrinsic resistance to MEK inhibitors</b></p>\n\n<p id=\"erb-51b83742-04b4-4c3d-86fc-affc210eae9b\"><b>Signaling through TGF-\u03b2/SMURF2/PAX3 and MITF. </b> In an <i>in vitro</i> study, cells sensitive to MEK inhibition demonstrated increased transforming growth\u00a0factor\u00a0\u03b2 (TGF-\u03b2) signaling. Melanoma\u00a0cells resistant to the cytotoxic effects of MEK inhibitors counteracted TGF-\u03b2 signaling through overexpression of the E3 ubiquitin ligase SMURF2, which resulted in increased expression of the\u00a0transcription\u00a0factors PAX3 and\u00a0MITF. High\u00a0MITF\u00a0expression protected\u00a0melanoma\u00a0cells against MEK inhibitor cytotoxicity. The study also found increased SMURF2 expression in advanced stages of melanoma <a class=\"rlc-reference\" data-ref-info=\"Smith MP, Ferguson J, Arozarena I, et al: Effect of SMURF2 Targeting on Susceptibility to MEK Inhibitors in Melanoma. J Natl Cancer Inst 105:33-46, 2013.\" href=\"#_ENREF_166\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23250956\"><sup>166</sup></a>.</p>\n<p id=\"erb-e4ca6651-0277-4010-82c8-45305fc4c66c\">Activation of the <b>PI3K</b> pathway<b> </b>was seen as a factor in resistance of a panel of melanoma cell lines to novel MEK inhibitor E6201. The sensitivity of cell lines to MEK inhibition correlated with wild-type PTEN and mutant BRAF <a class=\"rlc-reference\" data-ref-info=\"Byron SA, Loch DC, Wellens CL, et al: Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status. Mol Cancer 11:75, 2012.\" href=\"#_ENREF_167\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23039341\"><sup>167</sup></a>.</p>\n\n<h1 id=\"erh-68694966-6f5e-413b-a797-00bdc8787221\">ACQUIRED RESISTANCE TO BRAF AND MEK INHIBITORS (Table 4)</h1>\n<h3>Table 4. Acquired Resistance to BRAF and MEK Inhibitors</h3>\n<table border=\"1\" cellpadding=\"7\" cellspacing=\"0\" id=\"erb-d00f18de-2707-4a7b-acac-d161399fdd74\" width=\"618\">\n<colgroup>\n<col width=\"196\"></col>\n<col width=\"154\"></col>\n<col width=\"112\"></col>\n<col width=\"100\"></col>\n</colgroup>\n<tbody>\n<tr valign=\"TOP\">\n<td width=\"196\">\n<p><b>MOLECULAR CHANGE</b></p>\n</td>\n<td width=\"154\">\n<p><b>CONFIRMED IN PATIENT BIOPSIES?</b></p>\n</td>\n<td width=\"112\">\n<p align=\"CENTER\"><b>DRUGS TO ADD TO OVERCOME RESISTANCE</b></p>\n</td>\n<td width=\"100\">\n<p align=\"CENTER\"><b>REFERENCE</b></p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"196\">\n<p><b>Resistance to vemurafenib</b></p>\n</td>\n<td width=\"154\">\n<p>\u00a0</p>\n</td>\n<td width=\"112\">\n<p align=\"CENTER\">\u00a0</p>\n</td>\n<td width=\"100\">\n<p align=\"CENTER\">\u00a0</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"196\">\n<p>Expression of splicing variant of BRAF lacking exons 4-8</p>\n</td>\n<td width=\"154\">\n<p>Yes, in 6/19 relapsed patients</p>\n</td>\n<td width=\"112\">\n<p align=\"CENTER\">\u00a0</p>\n</td>\n<td width=\"100\">\n<p align=\"CENTER\"><a class=\"rlc-reference\" data-ref-info=\"Poulikakos PI, Persaud Y, Janakiraman M, et al: RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 480:387-90, 2011.\" href=\"#_ENREF_176\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22113612\"><sup>176</sup></a></p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"196\">\n<p>Amplification of BRAF</p>\n</td>\n<td width=\"154\">\n<p>Yes, in 4/20 relapsed patients</p>\n</td>\n<td width=\"112\">\n<p align=\"CENTER\">\u00a0</p>\n</td>\n<td width=\"100\">\n<p align=\"CENTER\"><a class=\"rlc-reference\" data-ref-info=\"Shi H, Moriceau G, Kong X, et al: Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat Commun 3:724, 2012.\" href=\"#_ENREF_177\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22395615\"><sup>177</sup></a></p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"196\">\n<p>Activation of EGFR/SFK/STAT3</p>\n</td>\n<td width=\"154\">\n<p>Yes</p>\n</td>\n<td width=\"112\">\n<p align=\"CENTER\">EGFRi, SRKi</p>\n</td>\n<td width=\"100\">\n<p align=\"CENTER\"><a class=\"rlc-reference\" data-ref-info=\"Girotti MR, Pedersen M, Sanchez-Laorden B, et al: Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma. Cancer Discov, 2012.\" href=\"#_ENREF_178\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23242808\"><sup>178</sup></a></p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"196\">\n<p>Activation of FGFR3-RAS pathway</p>\n</td>\n<td width=\"154\">\n<p><i>In vitro</i> only</p>\n</td>\n<td width=\"112\">\n<p align=\"CENTER\">FGFRi</p>\n</td>\n<td width=\"100\">\n<p align=\"CENTER\"><a class=\"rlc-reference\" data-ref-info=\"Yadav V, Zhang X, Liu J, et al: Reactivation of mitogen-activated protein kinase (MAPK) pathway by FGF receptor 3 (FGFR3)/Ras mediates resistance to vemurafenib in human B-RAF V600E mutant melanoma. J Biol Chem 287:28087-98, 2012.\" href=\"#_ENREF_179\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22730329\"><sup>179</sup></a></p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"196\">\n<p>Activation of IGFR1-PIK3 pathway</p>\n</td>\n<td width=\"154\">\n<p>Yes</p>\n</td>\n<td width=\"112\">\n<p align=\"CENTER\">IGFRi</p>\n</td>\n<td width=\"100\">\n<p align=\"CENTER\"><a class=\"rlc-reference\" data-ref-info=\"Villanueva J, Vultur A, Lee JT, et al: Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 18:683-95, 2010.\" href=\"#_ENREF_180\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/21156289\"><sup>180</sup></a></p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"196\">\n<p>Activation of PDGFR\uf062- NRAS</p>\n</td>\n<td width=\"154\">\n<p>Yes</p>\n</td>\n<td width=\"112\">\n<p align=\"CENTER\">RTKi</p>\n</td>\n<td width=\"100\">\n<p align=\"CENTER\"><a class=\"rlc-reference\" data-ref-info=\"Nazarian R, Shi H, Wang Q, et al: Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468:973-7, 2010.\" href=\"#_ENREF_181\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/21107323\"><sup>181</sup></a></p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"196\">\n<p>Loss or mutations in NF1</p>\n</td>\n<td width=\"154\">\n<p>Yes</p>\n</td>\n<td width=\"112\">\n<p align=\"CENTER\">MEKi + PI3Ki + RAFi</p>\n</td>\n<td width=\"100\">\n<p align=\"CENTER\"><sup><a class=\"rlc-reference\" data-ref-info=\"Maertens O, Johnson B, Hollstein P, et al: Elucidating distinct roles for NF1 in melanomagenesis. Cancer Discov, 2012.\" href=\"#_ENREF_85\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23171796\">85</a>,<a class=\"rlc-reference\" data-ref-info=\"Whittaker SR, Theurillat JP, Van Allen E, et al: A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. Cancer Discov, 2013.\" href=\"#_ENREF_86\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23288408\">86</a></sup></p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"196\">\n<p>Mutation of NRAS</p>\n</td>\n<td width=\"154\">\n<p>Yes</p>\n</td>\n<td width=\"112\">\n<p align=\"CENTER\">MEKi?</p>\n</td>\n<td width=\"100\">\n<p align=\"CENTER\"><a class=\"rlc-reference\" data-ref-info=\"Nazarian R, Shi H, Wang Q, et al: Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468:973-7, 2010.\" href=\"#_ENREF_181\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/21107323\"><sup>181</sup></a></p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"196\">\n<p>Activation of MAP3K8/COT, ERK activating kinase independent of MEK</p>\n</td>\n<td width=\"154\">\n<p>Yes</p>\n</td>\n<td width=\"112\">\n<p align=\"CENTER\">\u00a0</p>\n</td>\n<td width=\"100\">\n<p align=\"CENTER\"><a class=\"rlc-reference\" data-ref-info=\"Johannessen CM, Boehm JS, Kim SY, et al: COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 468:968-72, 2010.\" href=\"#_ENREF_182\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/21107320\"><sup>182</sup></a></p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"196\">\n<p>MEK mutations</p>\n</td>\n<td width=\"154\">\n<p>Yes</p>\n</td>\n<td width=\"112\">\n<p align=\"CENTER\">\u00a0</p>\n</td>\n<td width=\"100\">\n<p align=\"CENTER\"><a class=\"rlc-reference\" data-ref-info=\"Wagle N, Emery C, Berger MF, et al: Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol 29:3085-96, 2011.\" href=\"#_ENREF_183\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/21383288\"><sup>183</sup></a> <a class=\"rlc-reference\" data-ref-info=\"Trunzer K, Pavlick AC, Schuchter L, et al: Pharmacodynamic Effects and Mechanisms of Resistance to Vemurafenib in Patients With Metastatic Melanoma. J Clin Oncol, 2013.\" href=\"#_ENREF_184\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23569304\"><sup>184</sup></a></p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"196\">\n<p>AKT3</p>\n</td>\n<td width=\"154\">\n<p><i>In vitro</i> only</p>\n</td>\n<td width=\"112\">\n<p align=\"CENTER\">AKTi</p>\n</td>\n<td width=\"100\">\n<p align=\"CENTER\"><a class=\"rlc-reference\" data-ref-info=\"Shao Y, Aplin AE: Akt3-mediated resistance to apoptosis in B-RAF-targeted melanoma cells. Cancer Res 70:6670-81, 2010.\" href=\"#_ENREF_185\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/20647317\"><sup>185</sup></a></p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"196\">\n<p>Activation of ERK independently of MEK through PI3K</p>\n</td>\n<td width=\"154\">\n<p><i>In vitro</i> only</p>\n</td>\n<td width=\"112\">\n<p align=\"CENTER\">\u00a0</p>\n</td>\n<td width=\"100\">\n<p align=\"CENTER\"><a class=\"rlc-reference\" data-ref-info=\"Jiang CC, Lai F, Thorne RF, et al: MEK-independent survival of B-RAFV600E melanoma cells selected for resistance to apoptosis induced by the RAF inhibitor PLX4720. Clin Cancer Res 17:721-30, 2011.\" href=\"#_ENREF_186\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/21088259\"><sup>186</sup></a></p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"196\">\n<p>Loss of expression of RND3</p>\n</td>\n<td width=\"154\">\n<p><i>In vitro</i> only</p>\n</td>\n<td width=\"112\">\n<p align=\"CENTER\">\u00a0</p>\n</td>\n<td width=\"100\">\n<p align=\"CENTER\"><a class=\"rlc-reference\" data-ref-info=\"Klein RM, Higgins PJ: A switch in RND3-RHOA signaling is critical for melanoma cell invasion following mutant-BRAF inhibition. Mol Cancer 10:114, 2011.\" href=\"#_ENREF_187\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/21917148\"><sup>187</sup></a></p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"196\">\n<p>High levels of insulin receptor substrate 1 (IRS1)</p>\n</td>\n<td width=\"154\">\n<p><i>In vitro:</i> established and patient-derived cell lines</p>\n</td>\n<td width=\"112\">\n<p align=\"CENTER\">New IRS inhibitors in preclinical</p>\n</td>\n<td width=\"100\">\n<p align=\"CENTER\"><a class=\"rlc-reference\" data-ref-info=\"Reuveni H, Flashner-Abramson E, Steiner L, et al: Therapeutic destruction of insulin receptor substrates for cancer treatment. Cancer Res 73:4383-94, 2013.\" href=\"#_ENREF_188\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23651636\"><sup>188</sup></a></p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"196\">\n<p><b>Resistance to MEK Inhibitors</b></p>\n</td>\n<td width=\"154\">\n<p>\u00a0</p>\n</td>\n<td width=\"112\">\n<p align=\"CENTER\">\u00a0</p>\n</td>\n<td width=\"100\">\n<p align=\"CENTER\">\u00a0</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"196\">\n<p>Mutations in MEK</p>\n</td>\n<td width=\"154\">\n<p><i>In vitro</i> only</p>\n<p>\u00a0</p>\n</td>\n<td width=\"112\">\n<p align=\"CENTER\">BRAFi + MEKi</p>\n<p align=\"CENTER\">\u00a0</p>\n</td>\n<td width=\"100\">\n<p align=\"CENTER\"><a class=\"rlc-reference\" data-ref-info=\"Emery CM, Vijayendran KG, Zipser MC, et al: MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci U S A 106:20411-6, 2009.\" href=\"#_ENREF_189\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/19915144\"><sup>189</sup></a></p>\n<p align=\"CENTER\">\u00a0</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"196\">\n<p>Activation of PI3K/AKT</p>\n</td>\n<td width=\"154\">\n<p><i>In vitro</i> only</p>\n</td>\n<td width=\"112\">\n<p align=\"CENTER\">IGFRi, AKTi, mTORi</p>\n</td>\n<td width=\"100\">\n<p align=\"CENTER\"><a class=\"rlc-reference\" data-ref-info=\"Gopal YN, Deng W, Woodman SE, et al: Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells. Cancer Res 70:8736-47, 2010.\" href=\"#_ENREF_190\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/20959481\"><sup>190</sup></a></p>\n</td>\n</tr>\n</tbody>\n</table>\n\n<p id=\"erb-0e8a9541-2efb-4e26-9cb5-76e09d672686\">Mechanistic studies have provided insights into the development of resistance through two major mechanisms: new mutations in the RAF-MAPK pathway itself and changes in other oncogenic pathways that relieve melanoma cells from reliance on BRAF signaling <a class=\"rlc-reference\" data-ref-info=\"Sullivan RJ, Flaherty KT: Resistance to BRAF-targeted therapy in melanoma. Eur J Cancer, 2013.\" href=\"#_ENREF_191\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23290787\"><sup>191</sup></a>.</p>\n<p id=\"erb-9441dbfe-a01d-4cc1-8d75-f9bab670da93\">The identification of mechanisms of acquired resistance to BRAF inhibitors usually involves selection of surviving cells/clones from BRAF-mutant cell lines <i>in vitro</i> after treatment with a BRAF inhibitor and identification of newly acquired mutations or other somatic changes. Biopsies from relapsed patients are then analyzed for the presence of these <i>in vitro</i>\u2013identified changes. Alternatively, biopsies are subjected to massive sequencing for the identification of newly acquired mutations/aberrations. A clinical study that examined mechanisms of developing resistance to vemurafenib concluded that it resulted mainly from reactivation of MAPK signaling <a class=\"rlc-reference\" data-ref-info=\"Trunzer K, Pavlick AC, Schuchter L, et al: Pharmacodynamic Effects and Mechanisms of Resistance to Vemurafenib in Patients With Metastatic Melanoma. J Clin Oncol, 2013.\" href=\"#_ENREF_184\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23569304\"><sup>184</sup></a>. Based on findings described below, it appears that many of the confirmed mechanisms of resistance are indeed in this category, though activation of pathways \u201cparallel\u201d to BRAF-MAPK has been documented (Table 4).</p>\n\n<p id=\"erb-abb54a78-c9e9-41ec-892f-5e1798731b87\"><b>New aberrations in BRAF.</b> Unlike the experiences with other molecularly targeted therapies of oncogenic kinases, treatment with BRAFV600E inhibitors did not lead to the emergence of gatekeeper mutations in BRAF itself. However, amplification of mutant BRAF was detected in 4 of 20 patients who developed resistance to vemurafenib <a class=\"rlc-reference\" data-ref-info=\"Shi H, Moriceau G, Kong X, et al: Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat Commun 3:724, 2012.\" href=\"#_ENREF_177\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22395615\"><sup>177</sup></a>.</p>\n<p id=\"erb-a1e2dfc5-7384-4536-b0b3-f22b2e141e8c\">Analysis of a subset of cells resistant to vemurafenib (PLX4032) <i>in vitro</i> detected the 61-kDa variant form of BRAFV600E, p61BRAFV600E, which lacks exons 4 to 8, a region that encompasses the RAS-binding domain. p61BRAFV600E shows enhanced dimerization in cells with low levels of RAS activation, as compared to full-length BRAFV600E that acts as a monomer. The p61BRAFV600E splicing variants lacking the RAS-binding domain were identified in the tumors of 6 of 19 patients with acquired resistance to vemurafenib. These data determined a novel mechanism of acquired resistance in patients: expression of splicing isoforms of BRAFV600E that dimerize in a RAS-independent manner <a class=\"rlc-reference\" data-ref-info=\"Poulikakos PI, Persaud Y, Janakiraman M, et al: RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 480:387-90, 2011.\" href=\"#_ENREF_176\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22113612\"><sup>176</sup></a>.</p>\n\n<p id=\"erb-f67698ed-9e4d-4f29-9049-59c96a5a4560\"><b>Activation of signaling through RTKs</b></p>\n\n<p id=\"erb-c893a804-d3be-468c-8405-0d0bcd40efd2\"><b>EGFR/SFK/STAT3.</b> BRAF inhibitor-mediated activation of EGFR/SRC family kinase/STAT3 signaling was shown to mediate resistance in BRAF-mutant\u00a0melanoma cell lines and was demonstrated in\u00a0patient biopsies. <i>In vitro</i> treatments with an EGFR inhibitor in combination with a BRAF inhibitor, or monotherapy with dasatinib, appeared to overcome this resistance and could deliver therapeutic efficacy in drug-resistant BRAF-mutant melanoma\u00a0patients <a class=\"rlc-reference\" data-ref-info=\"Girotti MR, Pedersen M, Sanchez-Laorden B, et al: Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma. Cancer Discov, 2012.\" href=\"#_ENREF_178\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23242808\"><sup>178</sup></a>.</p>\n<p id=\"erb-dce5b4ee-72af-47d5-847b-a8cca7a3eab0\">Upregulation of FGFR3 signaling in selected vemurafenib-resistant cells was described <i>in vitro</i>. Signaling through FGFR3 activated the MAPK pathway through RAS, but these cells were still sensitive to inhibition of MEK or pan-RAF inhibition <a class=\"rlc-reference\" data-ref-info=\"Yadav V, Zhang X, Liu J, et al: Reactivation of mitogen-activated protein kinase (MAPK) pathway by FGF receptor 3 (FGFR3)/Ras mediates resistance to vemurafenib in human B-RAF V600E mutant melanoma. J Biol Chem 287:28087-98, 2012.\" href=\"#_ENREF_179\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22730329\"><sup>179</sup></a>.</p>\n\n<p id=\"erb-1ddabde5-d303-48bc-bf8c-acbc0d55cfef\"><b>IGF-1R/PI3K pathway. </b> Mutations in the IGF-1R/PI3K pathway were identified as another way for developing resistance to the BRAF inhibitor SB590885. IGF-1R/PI3K signaling was enhanced in resistant melanomas; combined treatment with IGF-1R/PI3K and MEK inhibitors induced death of BRAF inhibitor-resistant cells. Increased IGF-1R and pAKT levels in a post-relapse human tumor sample were consistent with the proposed role for IGF-1R/PI3K-dependent resistance to BRAF inhibitors <a class=\"rlc-reference\" data-ref-info=\"Villanueva J, Vultur A, Lee JT, et al: Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 18:683-95, 2010.\" href=\"#_ENREF_180\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/21156289\"><sup>180</sup></a>.</p>\n<p id=\"erb-7636ea7b-d758-44ad-8ef7-ee2b190db34d\">Activation of PDGFR\uf062 signaling was shown to occur during selection for BRAF inhibitor resistance <i>in vitro</i>. The clones with PDGFR\uf062 activation were also resistant to MEK inhibition implying that activation of PDGFR bypasses the tumor dependence on RAF signaling entirely <a class=\"rlc-reference\" data-ref-info=\"Nazarian R, Shi H, Wang Q, et al: Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468:973-7, 2010.\" href=\"#_ENREF_181\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/21107323\"><sup>181</sup></a>. These findings were validated in resistant tumors <a class=\"rlc-reference\" data-ref-info=\"Nazarian R, Shi H, Wang Q, et al: Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468:973-7, 2010.\" href=\"#_ENREF_181\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/21107323\"><sup>181</sup></a>.</p>\n\n<p id=\"erb-150d6579-913c-4aaa-aed8-0458e7b86c3b\"><b>NF1</b> expression is lost in tumors from patients following treatment with BRAF and MEK inhibitors <a class=\"rlc-reference\" data-ref-info=\"Maertens O, Johnson B, Hollstein P, et al: Elucidating distinct roles for NF1 in melanomagenesis. Cancer Discov, 2012.\" href=\"#_ENREF_85\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23171796\"><sup>85</sup></a>. NF1 mutations were observed in melanoma tumors obtained from patients exhibiting resistance\u00a0to vemurafenib, as already mentioned. However, cells lacking\u00a0NF1\u00a0retained sensitivity to the irreversible RAF inhibitor AZ628 and an ERK inhibitor <a class=\"rlc-reference\" data-ref-info=\"Whittaker SR, Theurillat JP, Van Allen E, et al: A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. Cancer Discov, 2013.\" href=\"#_ENREF_86\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23288408\"><sup>86</sup></a>.</p>\n\n<p id=\"erb-76ca6900-403d-4eca-87ac-87da7e76bb72\"><b>NRAS.</b> Secondary mutations in NRAS<b> </b>were shown to confer resistance to PLX4032 <i>in vitro</i> <a class=\"rlc-reference\" data-ref-info=\"Nazarian R, Shi H, Wang Q, et al: Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468:973-7, 2010.\" href=\"#_ENREF_181\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/21107323\"><sup>181</sup></a>. These acquired changes were mutually exclusive with PDGFR\uf062 activation observed in the same study. In contrast to PDGFR-activated resistant cells, NRAS-mutated cells were sensitive to MEK inhibitors. Mutations of NRAS were also found in 4 out of 19 patients that developed resistance to PLX4032 <a class=\"rlc-reference\" data-ref-info=\"Nazarian R, Shi H, Wang Q, et al: Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468:973-7, 2010.\" href=\"#_ENREF_181\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/21107323\"><sup>181</sup></a>, and in additional patients in a clinical trial exploring mechanism of acquired resistance to Vemurafenib <a class=\"rlc-reference\" data-ref-info=\"Trunzer K, Pavlick AC, Schuchter L, et al: Pharmacodynamic Effects and Mechanisms of Resistance to Vemurafenib in Patients With Metastatic Melanoma. J Clin Oncol, 2013.\" href=\"#_ENREF_184\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23569304\"><sup>184</sup></a>. New mutant BRAF inhibitors, such as PLX7904 have been explored <i>in vitro</i>. PLX7904 inhibits ERK1/2 activation in cells with mutant BRAF, but not in cells with wild type BRAF <a class=\"rlc-reference\" data-ref-info=\"Le K, Blomain E, Rodeck U, et al: Selective RAF inhibitor impairs ERK1/2 phosphorylation and growth in mutant NRAS, vemurafenib-resistant melanoma cells. Pigment Cell Melanoma Res, 2013.\" href=\"#_ENREF_19\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23490205\"><sup>19</sup></a>. Promisingly, PLX 7904 inhibited ERK1/2 phosphorylation in mutant BRAF melanoma cells with acquired resistance to vemurafenib/PLX4720 that is mediated by a secondary mutation in NRAS.</p>\n\n<p id=\"erb-88a72099-c9a9-464c-9354-d66c3d6f25ac\"><b>AKT3.</b> Activation of AKT3 in response to BRAF inhibitor PLX4720 or BRAF siRNA was implicated in the resistance of primary three-dimensional cultures of melanoma cells to BRAFV600E inhibitors <a class=\"rlc-reference\" data-ref-info=\"Shao Y, Aplin AE: Akt3-mediated resistance to apoptosis in B-RAF-targeted melanoma cells. Cancer Res 70:6670-81, 2010.\" href=\"#_ENREF_185\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/20647317\"><sup>185</sup></a>.</p>\n\n<p id=\"erb-7dd48b81-2326-422a-b3e8-c2cf7438c232\"><b>ERK</b> activation, independent of classical RAF/MEK/ERK pathways, was shown to occur in resistant lines with mutant BRAF. PI3K<b> </b>pathway activation could be responsible for ERK activity. Inhibition of either PIK3CA or ERK slowed the growth of these lines selected <i>in vitro</i> for resistance to PLX4720 <a class=\"rlc-reference\" data-ref-info=\"Jiang CC, Lai F, Thorne RF, et al: MEK-independent survival of B-RAFV600E melanoma cells selected for resistance to apoptosis induced by the RAF inhibitor PLX4720. Clin Cancer Res 17:721-30, 2011.\" href=\"#_ENREF_186\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/21088259\"><sup>186</sup></a>. Targeting ERK activation is a promising strategy to overcome resistance to BRAF and MEK inhibitors. A new ERK inhibitor, SCH772984, is active in nanomolar concentrations <i>in vitro</i> and inhibited tumor growth <i>in vivo</i>. More importantly, SCH772984 was able to overcome resistance to BRAF or MEK inhibition in cells and tumors that became resistant by acquiring mutations in NRAS or MEK1, respectively. SCH772984 was able to suppress growth of melanoma cells engineered to contain amplified BRAFV600E and even growth of melanoma lines selected for double resistance to BRAF and MEK inhibition <a class=\"rlc-reference\" data-ref-info=\"Morris EJ, Jha S, Restino CR, et al: Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. Cancer Discov, 2013.\" href=\"#_ENREF_192\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23614898\"><sup>192</sup></a>.</p>\n\n<p id=\"erb-5426b262-0f42-4daa-80a6-4f3924f8b86e\"><b>MAP3K8/COT.</b> In a massive functional kinome screening study, a kinase known as MAP3K8/COT was implicated in both inherent and acquired resistance to BRAFV600E inhibitors. COT is a MAPK independent of RAF and is expressed highly in inherently resistant melanoma or in cells from patients with acquired resistance. Its expression drives resistance to BRAF inhibitors <i>in vitro</i> and occurs in relapsing patient tumors <a class=\"rlc-reference\" data-ref-info=\"Johannessen CM, Boehm JS, Kim SY, et al: COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 468:968-72, 2010.\" href=\"#_ENREF_182\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/21107320\"><sup>182</sup></a>. COT-mediated resistance to a RAF inhibitor cannot be overcome by a MEK inhibitor, suggesting that activation of ERK in these tumors occurs outside of the classical RAF-MAPK-ERK pathway. COT might be a direct ERK phosphorylating kinase.</p>\n\n<p id=\"erb-16c3a6a2-5671-4c79-8aae-f49bb05ecb6e\"><b>MEK1</b> mutation C121S was identified in a patient treated with vemurafenib <a class=\"rlc-reference\" data-ref-info=\"Wagle N, Emery C, Berger MF, et al: Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol 29:3085-96, 2011.\" href=\"#_ENREF_183\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/21383288\"><sup>183</sup></a>. This mutation was shown to increase kinase activity of MEK1 and confer resistance to both BRAF and MEK inhibition. Two new mutations of MEK, E203K and Q56P were found in tumors that developed resistance to Vemurafenib and <a class=\"rlc-reference\" data-ref-info=\"Trunzer K, Pavlick AC, Schuchter L, et al: Pharmacodynamic Effects and Mechanisms of Resistance to Vemurafenib in Patients With Metastatic Melanoma. J Clin Oncol, 2013.\" href=\"#_ENREF_184\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23569304\"><sup>184</sup></a>.</p>\n\n<p id=\"erb-7bc3bad9-21e3-43db-9189-1e1b29fd1968\"><b>RND3.</b> An <i>in vitro</i> study with a single BRAF-mutant melanoma line showed that BRAF-inhibitor treatments were associated with reduced expression of RND3, an antagonist of RHOA activation, and elevated RHOA-dependent signaling. Restoration of RND3 expression or RHOA knockdown attenuated the migratory ability of residual cells without affecting overall cell survival <a class=\"rlc-reference\" data-ref-info=\"Klein RM, Higgins PJ: A switch in RND3-RHOA signaling is critical for melanoma cell invasion following mutant-BRAF inhibition. Mol Cancer 10:114, 2011.\" href=\"#_ENREF_187\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/21917148\"><sup>187</sup></a>.</p>\n\n<p id=\"erb-bebc3fe7-62fc-4a0d-b74b-79e82552d6e4\"><b>IRS1.</b> Insulin receptor substrates 1 and 2 (IRS1/2) mediate oncogenic signaling from IGF-1R and are upregulated in melanoma cell lines resistant to BRAF inhibitors or derived from patients that developed resistance to Vemurafenib treatment. A new class of drugs that promote phosphorylation and degradation of IRS1/2 were also able to overcome acquired resistance to vemurafenib <i>in vitro</i> <a class=\"rlc-reference\" data-ref-info=\"Reuveni H, Flashner-Abramson E, Steiner L, et al: Therapeutic destruction of insulin receptor substrates for cancer treatment. Cancer Res 73:4383-94, 2013.\" href=\"#_ENREF_188\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23651636\"><sup>188</sup></a>.</p>\n\n<p id=\"erb-a1c1b91a-3895-44b7-b4e4-022b501c58ea\"><b>Factors that mediate acquired resistance to MEK inhibitors (Table 4)</b></p>\n<p id=\"erb-a253ed4e-43e2-4f85-999f-5c09cc5484c1\">Similar to the adaptation of BRAF-mutant melanoma cells to BRAF inhibition, resistance to MEK inhibitors could involve multiple pathways. In a study of triple-negative breast cancer treated with a MEK inhibitor, it was found that inhibition of MEK, similar to inhibition of BRAFV600E in melanoma, induces a reprogramming of RTK activation <a class=\"rlc-reference\" data-ref-info=\"Duncan JS, Whittle MC, Nakamura K, et al: Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. Cell 149:307-21, 2012.\" href=\"#_ENREF_193\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22500798\"><sup>193</sup></a>. It is possible that activation of RTK when MEK is acutely inhibited is also involved in responses of melanoma to MEK inhibition, though this has not been shown yet.</p>\n\n<p id=\"erb-ccab339e-f6e0-48a3-9156-9057d0d9bee8\"><b>Mutations in MEK1 and MEK2. </b><i>De novo</i> mutations in MEK1 were strongly implicated in resistance to MEK inhibitor selumetinib/AZD6244, both in treated cell lines and in a metastatic tumor from a relapsed patient <a class=\"rlc-reference\" data-ref-info=\"Emery CM, Vijayendran KG, Zipser MC, et al: MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci U S A 106:20411-6, 2009.\" href=\"#_ENREF_189\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/19915144\"><sup>189</sup></a>. Mutations in selected lines resulted in constitutive ERK phosphorylation and higher resistance to MEK inhibitors, but also conferred cross-resistance to mutant BRAF inhibitor PLX4023. Variant MEK1(P124L) was identified in a resistant metastatic focus that emerged in a melanoma patient treated with selumetinib.</p>\n\n<p id=\"erb-efa9faa1-6a03-4ada-bae1-80ea29aa0962\"><b>PI3K-AKT pathway</b>. A study <i>in vitro</i> has identified basal and treatment-induced activation of the PI3K-AKT pathway as a critical regulator of selumetinib sensitivity in BRAF-mutant cutaneous melanoma cells. Sensitive, but not resistant lines showed upregulation of PTEN expression by selumetinib. Combination of a MEK inhibitor with inhibitors of Akt, mTOR, or IGF1R was able to overcome resistance to MEK inhibitors <a class=\"rlc-reference\" data-ref-info=\"Gopal YN, Deng W, Woodman SE, et al: Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells. Cancer Res 70:8736-47, 2010.\" href=\"#_ENREF_190\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/20959481\"><sup>190</sup></a>.</p>\n\n<h1 id=\"erh-5dd71168-f58a-4e7d-a99f-65f8ba5abc3c\">COMBINATORIAL THERAPIES</h1>\n<p id=\"erb-aa3e6a94-0074-45a4-b769-19db4135261d\">Inherent resistance, partial and low durability responses, and acquired resistance are major problems in the clinical development of targeted therapies. Recent results of clinical studies combining two targeted therapies have confirmed the long held belief that combinatorial approaches have significant advantages over monotherapy <sup><a class=\"rlc-reference\" data-ref-info=\"Flaherty KT, Infante JR, Daud A, et al: Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 367:1694-703, 2012.\" href=\"#_ENREF_25\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23020132\">25</a>,<a class=\"rlc-reference\" data-ref-info=\"Shimizu T, Tolcher AW, Papadopoulos KP, et al: The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer. Clin Cancer Res 18:2316-25, 2012.\" href=\"#_ENREF_168\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22261800\">168</a></sup>.</p>\n<p id=\"erb-e0753f36-ab76-4b6f-9366-5dafc7f923f1\">Two recent publications examined possible synergistic interactions between targeted therapies. The first study <a class=\"rlc-reference\" data-ref-info=\"Roller DG, Axelrod M, Capaldo BJ, et al: Synthetic lethal screening with small-molecule inhibitors provides a pathway to rational combination therapies for melanoma. Mol Cancer Ther 11:2505-15, 2012.\" href=\"#_ENREF_194\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22962324\"><sup>194</sup></a> looked at synthetic lethal pairwise interactions of a library of 300 compounds in a panel of nine established melanoma cell lines. This study did not find synergistic interactions that were genotype-specific (BRAF, NRAS-mutant or wild-type cell lines were screened). A synergistic interaction was found for just one combination, which was not genotype-related: sorafenib and the nonsteroidal anti-inflammatory drug (NSAID) diclofenac. Drug substitution experiments confirmed that the synergy is due to the combined effects on MAPK and cyclooxygenase (COX). The use of established cell lines in this study was a limiting factor.</p>\n<p id=\"erb-b28aa7b0-91c4-4755-b189-7dacc4c8b732\">The second study\u00a0<a class=\"rlc-reference\" data-ref-info=\"Held MA, Langdon CG, Platt JT, et al: Genotype-selective combination therapies for melanoma identified by high-throughput drug screening. Cancer Discov 3:52-67, 2013.\" href=\"#_ENREF_38\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23239741\"><sup>38</sup></a> examined drug interactions between 150 small molecule inhibitors in a panel of 28 early passage cell lines from melanomas with mutations either in BRAF, NRAS, or neither. The authors first selected inhibitors that showed some activity in at least one group of cell lines, and proceeded to analyze the antiproliferative effects of all drugs pairwise (over 7,000 combinations). The single drug screen produced several drugs with activity in BRAF-mutant melanoma, some of them known (vemurafenib and MEK inhibitors), but also non-BRAF-targeted kinase inhibitors of SRC/ABL (bosutinib), FGFR (dovitinib), and EGFR (gefitinib). There were almost no drugs effective against NRAS-mutant lines, except 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) inhibitor simvastatin, which indirectly blocked prenylation and membrane localization of RAS. Drug combination analysis showed that the most effective combination for BRAF-mutant lines was that of vemurafenib, EGFR, and AKT inhibitors, which was cytotoxic even in lines with primary resistance to vemurafenib or in lines selected for resistance to vemurafenib. NRAS-mutant lines were most sensitive to combination of the HMGCR inhibitor simvastatin and a nonspecific CDK inhibitor flavopiridol, which was in line with the previous studies highlighting the role of CDK activation in pathogenesis of NRAS driven melanoma <a class=\"rlc-reference\" data-ref-info=\"Kwong LN, Costello JC, Liu H, et al: Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma. Nat Med 18:1503-10, 2012.\" href=\"#_ENREF_36\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22983396\"><sup>36</sup></a>. Simvastatin was able to displace NRAS from the plasma membrane, thus exhibiting an inhibitory effect on its activity. These findings could be important in guiding the future preclinical and clinical studies.</p>\n\n<h1 id=\"erh-b87d6198-db29-485a-be6c-a9351795c717\">IMMUNOTHERAPY</h1>\n<p id=\"erb-a758942c-9d2b-4df9-8c32-16d826f268bd\">Malignant melanoma is a tumor extensively investigated as target for immunotherapy for reasons including its high immunogenic potential and the availability of tumor infiltrating lymphocytes reactive against melanoma antigens <a class=\"rlc-reference\" data-ref-info=\"Kawakami Y, Eliyahu S, Delgado CH, et al: Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci U S A 91:3515-9, 1994.\" href=\"#_ENREF_195\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/8170938\"><sup>195</sup></a>. Earliest approaches had employed active immunization against the constantly growing repertoire of melanoma regression antigens <a class=\"rlc-reference\" data-ref-info=\"Slingluff CL, Jr., Petroni GR, Yamshchikov GV, et al: Immunologic and clinical outcomes of vaccination with a multiepitope melanoma peptide vaccine plus low-dose interleukin-2 administered either concurrently or on a delayed schedule. J Clin Oncol 22:4474-85, 2004.\" href=\"#_ENREF_196\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/15542798\"><sup>196</sup></a>, but enthusiasm subsided because of the very modest objective responses to immunization, mostly obtained for low volume disease <a class=\"rlc-reference\" data-ref-info=\"Rosenberg SA, Yang JC, Restifo NP: Cancer immunotherapy: moving beyond current vaccines. Nat Med 10:909-15, 2004.\" href=\"#_ENREF_197\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/15340416\"><sup>197</sup></a>. The puzzling question of why hasn\u2019t successful immunization, generating tumor-cognate lymphocytes, been yielding measurable tumor responses led to the recognition of the inhibitory role of immune check point modulators expressed on melanoma cells or on activated lymphocytes <sup><a class=\"rlc-reference\" data-ref-info=\"Spranger S, Spaapen RM, Zha Y, et al: Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells. Sci Transl Med 5:200ra116, 2013.\" href=\"#_ENREF_198\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23986400\">198</a>,<a class=\"rlc-reference\" data-ref-info=\"van Elsas A, Hurwitz AA, Allison JP: Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med 190:355-66, 1999.\" href=\"#_ENREF_199\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/10430624\">199</a></sup>. Understanding the role of costimulation opened a new era in the clinic and an intense search for additional targets for immunotherapies with improved efficacy: toxicity ratio.</p>\n<p id=\"erb-fd24a296-0a53-4f1f-b6a1-69fd143a6041\">Interleukin-2 was the earliest immunotherapy for metastatic melanoma approved by the FDA in 1998, followed by interferon-\u03b12b as an adjuvant therapy and ipilimumab (anti-CTLA-4 antibody) as therapy for advanced disease were approved by the U.S. Food and Drug Administration (FDA) for melanoma in March 2011. While the response rates to IL-2 and ipilimumab given as a single agent are in the range of 10-20% <sup><a class=\"rlc-reference\" data-ref-info=\"Atkins MB, Lotze MT, Dutcher JP, et al: High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 17:2105-16, 1999.\" href=\"#_ENREF_200\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/10561265\">200</a>,<a class=\"rlc-reference\" data-ref-info=\"Hodi FS, O'Day SJ, McDermott DF, et al: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711-23, 2010.\" href=\"#_ENREF_201\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/20525992\">201</a></sup>, when induced, responses to IL-2 and ipilimumab are typically long lasting and sometimes complete. In recent years, investigational agents have included adoptive T cell transfer, blocking antibodies against inhibitory immune molecules, stimulatory antibodies for immune cells, and immunization with distinct cancer cell antigens. Recently, interest in the role of mutated antigens being more immunogenic and therefore triggering a more robust immune response, has risen <a class=\"rlc-reference\" data-ref-info=\"Robbins PF, Lu YC, El-Gamil M, et al: Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med 19:747-52, 2013.\" href=\"#_ENREF_202\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23644516\"><sup>202</sup></a>. Identification and validation of biomarkers predictive of responses to immunotherapy is a rapidly developing field is identification and validation of biomarkers predictive of responses to immunotherapy (reviewed in <a class=\"rlc-reference\" data-ref-info=\"Ascierto PA, Kalos M, Schaer DA, et al: Biomarkers for Immunostimulatory Monoclonal Antibodies in Combination Strategies for Melanoma and Other Tumor Types. Clin Cancer Res 19:1009-1020, 2013.\" href=\"#_ENREF_203\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23460532\"><sup>203</sup></a>). These might include a variety of tumor and tumor microenvironment specific alterations, the immune parameters of the individual patient. The mutational load of a tumor could be also a predictive factor, as it is plausible that highly mutated tumors are more immunogenic, therefore triggering a more robust immune response.</p>\n<p id=\"erb-e52f34a1-118e-43c8-8629-7427e6333c2e\">In light of the complexity of the immune response, it is very likely that combining immunotherapies will be necessary to induce better clinical responses, but even at this point it is clear that there is a life-prolonging effect of immunotherapy on many patients and a potential for cure.</p>\n\n<p id=\"erb-96e3cc17-58dc-4e9a-a1ec-cae39f73ac08\"><b>Immunomodulatory antibodies</b></p>\n<p id=\"erb-ea630335-358d-4a01-ac62-8bc3574af8a8\">The use of immune checkpoint inhibitors (antibodies that block proteins inhibiting immune response) has gained particular interest after approval of ipilimumab/anti-CTLA4 antibody for treatment of melanoma in 2011, and more so after the recent reports on the clinical efficacy of antibodies blocking PD-1. Table 5 shows some of the clinical trials with the immune system targeting antibodies, which are described below.</p>\n\n\n<h3>Table 5. Antibody-based immunotherapy of melanoma</h3>\n<table border=\"1\" cellpadding=\"7\" cellspacing=\"0\" id=\"erb-04f9c5c6-780c-45ca-bc93-beb24a211ae1\" width=\"655\">\n<colgroup>\n<col width=\"71\"></col>\n<col width=\"190\"></col>\n<col width=\"104\"></col>\n<col width=\"234\"></col>\n</colgroup>\n<tbody>\n<tr valign=\"TOP\">\n<td width=\"71\">\n<p><b>Target</b></p>\n</td>\n<td width=\"190\">\n<p><b>Desired effects</b></p>\n</td>\n<td width=\"104\">\n<p><b>Antibodies </b></p>\n</td>\n<td width=\"234\">\n<p><b>Trials</b></p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"71\">\n<p>CTLA-4</p>\n</td>\n<td width=\"190\">\n<p>Relieve the immune checkpoint</p>\n</td>\n<td width=\"104\">\n<p>Ipilimumab/Yervoy</p>\n</td>\n<td width=\"234\">\n<p>Approved</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"71\">\n<p>PD-1</p>\n</td>\n<td width=\"190\">\n<p>Relieve the immune checkpoint</p>\n</td>\n<td width=\"104\">\n<p>MDX-1106, CT-011, MK-3475</p>\n</td>\n<td width=\"234\">\n<p><a href=\"http://clinicaltrials.gov/ct2/results?term=NCT01024231&amp;Search=Search\">NCT01024231</a>, <a href=\"http://clinicaltrials.gov/ct2/results?term=NCT01176461&amp;Search=Search\">NCT01176461</a>, <a href=\"http://clinicaltrials.gov/ct2/results?term=NCT01721746&amp;Search=Search\">NCT01721746</a>, <a href=\"http://clinicaltrials.gov/ct2/results?term=NCT01621490&amp;Search=Search\">NCT01621490</a>, <a href=\"http://clinicaltrials.gov/ct2/results?term=NCT01721772&amp;Search=Search\">NCT01721772</a>, <a href=\"http://clinicaltrials.gov/ct2/results?term=NCT01783938&amp;Search=Search\">NCT01783938</a>, <a href=\"http://clinicaltrials.gov/ct2/results?term=NCT01714739&amp;Search=Search\">NCT01714739</a>, <a href=\"http://clinicaltrials.gov/ct2/results?term=NCT01435369&amp;Search=Search\">NCT01435369</a>, <a href=\"http://clinicaltrials.gov/ct2/results?term=NCT01295827&amp;Search=Search\">NCT01295827</a>,</p>\n<p><a href=\"http://clinicaltrials.gov/ct2/results?term=NCT01704287&amp;Search=Search\">NCT01704287</a></p>\n<p lang=\"da-DK\">\u00a0</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"71\">\n<p>PD-L1/B7-H1</p>\n</td>\n<td width=\"190\">\n<p>Relieve the immune checkpoint</p>\n</td>\n<td width=\"104\">\n<p>MDX-1105-01, MPDL3280A, MEDI4736</p>\n</td>\n<td width=\"234\">\n<p><a href=\"http://clinicaltrials.gov/ct2/results?term=NCT00729664&amp;Search=Search\">NCT00729664</a>, <a href=\"http://www.clinicaltrials.gov/ct2/show/NCT01633970\">NCT01633970</a>, <a href=\"http://clinicaltrials.gov/show/NCT01375842\">NCT01375842</a></p>\n<p><a href=\"http://clinicaltrials.gov/ct2/results?term=NCT01693562&amp;Search=Search\">NCT01693562</a></p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"71\">\n<p>4-1BB/CD137</p>\n</td>\n<td width=\"190\">\n<p>Stimulate T cells</p>\n</td>\n<td width=\"104\">\n<p>BMS-663513</p>\n</td>\n<td width=\"234\">\n<p><a href=\"http://clinicaltrials.gov/ct2/results?term=NCT01471210&amp;Search=Search\">NCT01471210</a></p>\n<p lang=\"da-DK\">\u00a0</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"71\">\n<p>CD40</p>\n</td>\n<td width=\"190\">\n<p>Stimulate T cells</p>\n</td>\n<td width=\"104\">\n<p>CP870,893</p>\n</td>\n<td width=\"234\">\n<p><a href=\"http://clinicaltrials.gov/ct2/results?term=NCT01103635&amp;Search=Search\">NCT01103635</a></p>\n<p lang=\"da-DK\">\u00a0</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"71\">\n<p>GITR</p>\n</td>\n<td width=\"190\">\n<p>Inhibit T regs</p>\n</td>\n<td width=\"104\">\n<p>TRX518</p>\n</td>\n<td width=\"234\">\n<p><a href=\"http://clinicaltrials.gov/ct2/results?term=NCT01239134&amp;Search=Search\">NCT01239134</a></p>\n<p lang=\"da-DK\">\u00a0</p>\n</td>\n</tr>\n<tr valign=\"TOP\">\n<td width=\"71\">\n<p>OX40/CD134</p>\n</td>\n<td width=\"190\">\n<p>Stimulate T cells</p>\n</td>\n<td width=\"104\">\n<p>Anti-OX40</p>\n</td>\n<td width=\"234\">\n<p><a href=\"http://clinicaltrials.gov/ct2/results?term=NCT01689870&amp;Search=Search\">NCT01689870</a></p>\n<p lang=\"da-DK\">\u00a0</p>\n</td>\n</tr>\n</tbody>\n</table>\n\n<p id=\"erb-7cf15538-6a55-4fd2-9155-58d380433d92\"><b>CTLA4 </b>is an inhibitory molecule expressed on T cells that is involved in the negative regulation of the T cell interaction with antigen presenting dendritic cells (APCs). CTLA4 inhibits binding of CD28 on T cells to B7 proteins on APCs, thus weakening the costimulation of effector T cells. In addition, CTLA4 is expressed on regulatory T-cells (Treg), and the immune effects of anti-CTLA4 may be a combination of enhancing effector T-cell function while blocking Treg <a class=\"rlc-reference\" data-ref-info=\"Peggs KS, Quezada SA, Chambers CA, et al: Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med 206:1717-25, 2009.\" href=\"#_ENREF_204\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/19581407\"><sup>204</sup></a>. CTLA4 is also expressed on tumor cell lines <a class=\"rlc-reference\" data-ref-info=\"Contardi E, Palmisano GL, Tazzari PL, et al: CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction. Int J Cancer 117:538-50, 2005.\" href=\"#_ENREF_205\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/15912538\"><sup>205</sup></a> and in human melanoma <a class=\"rlc-reference\" data-ref-info=\"Shah KV, Chien AJ, Yee C, et al: CTLA-4 is a direct target of Wnt/beta-catenin signaling and is expressed in human melanoma tumors. J Invest Dermatol 128:2870-9, 2008.\" href=\"#_ENREF_206\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/18563180\"><sup>206</sup></a>; blockade of CTLA4 <i>in vitro</i> induces apoptosis of melanoma cells, indicating that CTLA4 might have non-immune functions. Available results from clinical trials indicate that the response rates to CTLA4 blockade with human monoclonal antibodies <a href=\"http://www.cancer.gov/drugdictionary?CdrID=38447\">ipilimumab</a> and t<a href=\"http://www.cancer.gov/drugdictionary?CdrID=448620\">remelimumab</a> are, at most, at 18%, but overall survival is superior to what is seen with cytotoxic therapies. Significant immune toxicities were reported in a number of trials, and, interestingly, strong association of immune-related toxicities and\u00a0responses\u00a0were observed (reviewed in <sup><a class=\"rlc-reference\" data-ref-info=\"Flaherty KT, Hodi FS, Fisher DE: From genes to drugs: targeted strategies for melanoma. Nat Rev Cancer 12:349-61, 2012.\" href=\"#_ENREF_8\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22475929\">8</a>,<a class=\"rlc-reference\" data-ref-info=\"Sapoznik S, Hammer O, Ortenberg R, et al: Novel anti-melanoma immunotherapies: disarming tumor escape mechanisms. Clin Dev Immunol 2012:818214, 2012.\" href=\"#_ENREF_207\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22778766\">207</a></sup>).</p>\n<p id=\"erb-d23db0cb-3226-4b97-b910-8d1a12e51627\">Potential markers that could predict response to ipilimumab are of obvious importance. Clinical trial <a href=\"http://clinicaltrials.gov/ct2/show/NCT00261365\">NCT00261365</a> incorporated investigation of a number of parameters in tumor biopsies pre- and post-treatment with ipilimumab. Significant associations were detected between clinical activity and high-baseline expression of FoxP3 and indoleamine 2,3-dioxygenase (IDO), and the increase in tumor-infiltrating lymphocytes (TILs) <a class=\"rlc-reference\" data-ref-info=\"Hamid O, Schmidt H, Nissan A, et al: A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. J Transl Med 9:204, 2011.\" href=\"#_ENREF_208\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22123319\"><sup>208</sup></a>. The immunosuppressive role of IDO in the context of immunotherapies was later shown in the B16 murine melanoma model <a class=\"rlc-reference\" data-ref-info=\"Holmgaard RB, Zamarin D, Munn DH, et al: Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. J Exp Med, 2013.\" href=\"#_ENREF_209\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23752227\"><sup>209</sup></a>.</p>\n<p id=\"erb-78f71103-d62b-441c-8e23-97fbe6645504\">Trials of ipilimumab and <a href=\"http://www.cancer.gov/drugdictionary?CdrID=42211\">gp100</a> peptide vaccine, each as a single agent or in combination, showed limited responses, but the responses were long lasting. Early phase combination trials with ipilimumab include the following second agents: <a href=\"http://www.cancer.gov/drugdictionary\">bevacizumab</a>, high doze <a href=\"http://www.cancer.gov/drugdictionary?CdrID=462279\">interferon </a><a href=\"http://www.cancer.gov/drugdictionary?CdrID=462279\">\uf061-2b</a>, <a href=\"http://www.cancer.gov/drugdictionary?CdrID=39756\">IL-2</a>, <a href=\"http://www.cancer.gov/drugdictionary?CdrID=40566\">GM-CSF</a>, <a href=\"http://www.cancer.gov/drugdictionary?CdrID=539733\">anti-PD-1 antibody</a> (see below), antibody to NK receptor KIR BMS-986015 (in patients with melanoma or other tumors), immunostimulatory cytokine IL-21 and even an oncolytic herpes simplex 1 virus (<a href=\"http://en.wikipedia.org/wiki/Talimogene_laherparepvec\">talimogene laherparepvec</a>/T-VEC) designed to replicate selectively in tumor cells and to express GM-CSF (the virus preparation is injectable directly into tumors), as well as a variety of chemotherapeutic agents and surgical/radiotherapy interventions (Supplementary Table 2).. Reported results from trial <a href=\"http://clinicaltrials.gov/ct2/results?term=NCT01134614\">NCT01134614</a> combining ipilimumab with GM-CSF showed an increased OS in the combination arm (ASCO abstract # CRA9007, 2013).</p>\n\n<p id=\"erb-70d59e3e-5012-422e-8127-21fc252d13f9\"><b>PD-1</b>, like CTLA-4, is an inhibitory receptor; however, its expression is not limited to T cells and is found in B cells and some myeloid cells. PD-1 ligands, PD-L1 and PD-L2, have different expression patterns, with PD-L1 found on multiple normal and cancerous cells including melanoma tumors, where it provides, once bound by PD-1, peripheral tolerance to \"self\" antigens <a class=\"rlc-reference\" data-ref-info=\"Iwai Y, Ishida M, Tanaka Y, et al: Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A 99:12293-7, 2002.\" href=\"#_ENREF_210\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/12218188\"><sup>210</sup></a>. PD-L2 is expressed on APC cells, providing tolerance to orally administered antigens. Interactions between PD-1 and its ligands attenuate immune responses <a class=\"rlc-reference\" data-ref-info=\"Freeman GJ, Long AJ, Iwai Y, et al: Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 192:1027-34, 2000.\" href=\"#_ENREF_211\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/11015443\"><sup>211</sup></a>, and, in the context of cancer, serve to protect tumor cells from cytotoxic T cells. At the same time, PD-1 is expressed on CD8+ T cells in patients with metastatic melanoma, particularly within the tumor microenvironment where they encounter chronic antigen exposure <a class=\"rlc-reference\" data-ref-info=\"Ahmadzadeh M, Johnson LA, Heemskerk B, et al: Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 114:1537-44, 2009.\" href=\"#_ENREF_212\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/19423728\"><sup>212</sup></a>, which suggests that the immune response to melanoma is inhibited under these circumstances.</p>\n<p id=\"erb-4a06e36c-7185-489b-afaf-d0a999d0010f\">Humanized antibodies to PD-1 and PD-L1 have been developed and tested in clinical trials for several cancers including melanoma. Anti-PD1 antibody <a href=\"http://www.cancer.gov/drugdictionary?CdrID=539733\">nivolumab</a> was well tolerated, and the maximum tolerated dose has not been reached <a class=\"rlc-reference\" data-ref-info=\"Topalian SL, Hodi FS, Brahmer JR, et al: Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443-54, 2012.\" href=\"#_ENREF_213\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22658127\"><sup>213</sup></a>. This study also found a strong correlation between pretreatment tumor expression of PD-L1 and responses, with a 36% responses rate in patients whose tumors expressed PD-L1, and 0% in PD-L1 \u2013 negative group. However, a larger study of PD-L1 expression as a biomarker of response in solid tumors including melanoma reported that the correlation is not as solid as reported, because some patients with PD-L1 negative tumors had clinical responses to nivolumab (<a href=\"http://meetinglibrary.asco.org/content/113904-132\">http://meetinglibrary.asco.org/content/113904-132</a>). This may be because PD-L1 expression in the tumor is dynamic and is upregulated by factors such as the production of gamma interferon by infiltrating T-cells. The better safety profile of PD-1 antibody versus CTLA-4 antibody is most likely due to the fact that the latter targets a peripheral interaction between T cells and tumor or APCs. Inhibition of PD-1 probably inhibits peripheral interactions as well, through PD-L2 on APCs, but it could be expected to act more locally at tumor sites by preventing inhibition of tumor-infiltrating PD-1 expressing T cells through interaction with PD-L1 on tumor cells.</p>\n\n<p id=\"erb-8846be74-cc96-493f-83f2-dbe66706b037\"><b>Clinical trials targeting PD-1/ PD-L1 interaction</b></p>\n<p id=\"erb-7c6fa2a9-7c21-4116-af77-89f27892c25c\">Results from an early-phase clinical trial with anti-PD1 antibody BMS-936558 (<a href=\"http://www.cancer.gov/drugdictionary?CdrID=539733\">MDX-1106</a>, ONO-4538, Nivolumab) showed durable responses in 28% of patients with melanoma <a class=\"rlc-reference\" data-ref-info=\"Lipson EJ, Sharfman WH, Drake CG, et al: Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody. Clin Cancer Res 19:462-8, 2013.\" href=\"#_ENREF_214\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23169436\"><sup>214</sup></a>. Currently there are at least eight trials ongoing with MDX-1106 for melanoma.</p>\n<p id=\"erb-55f4401a-2a0a-46b5-89a7-b7fc95efcfea\">Two other anti-PD-1 antibodies (<a href=\"http://www.cancer.gov/drugdictionary?CdrID=573227\">CT-011</a>: CureTech Ltd. and MK-3475/Lambrolizumab: Merck) are also in clinical trials. Results of a clinical trial of Lambrolizumab in advanced melanoma produced very promising results. Of 135 patients treated, 38% had durable responses as evaluated by RECIST. Remarkably, patients that have received ipilimumab prior to enrolling in this trial had a similar response rate. Importantly, Lambrolizumab showed a favorable safety profile <a class=\"rlc-reference\" data-ref-info=\"Hamid O, Robert C, Daud A, et al: Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma. N Engl J Med, 2013.\" href=\"#_ENREF_215\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23724846\"><sup>215</sup></a>.</p>\n<p id=\"erb-8cc84489-beb2-4ca3-9759-d552d89a2afa\">An anti-PD-L1antibody (<a href=\"http://www.cancer.gov/drugdictionary?CdrID=702758\">MPDL3280A</a>/BMS-936559/MDX-1105 is being tested as well. Preliminary results with anti-PD-L1 antibody showed significant tumor shrinkage in 21 percent of 140 patients who had a variety of cancers; 9 of 52 melanoma patients had objective and durable <a class=\"rlc-reference\" data-ref-info=\"Brahmer JR, Tykodi SS, Chow LQ, et al: Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366:2455-65, 2012.\" href=\"#_ENREF_216\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22658128\"><sup>216</sup></a>.</p>\n<p id=\"erb-d8b07762-1657-49df-9113-a1184d6b618e\">An important paper has shown that combining blockade of both immune checkpoints (PD-1 and CTLA4) is highly synergistic in rejection of melanoma tumors in an animal model through strong stimulation of effector T cells and IFN-g production <a class=\"rlc-reference\" data-ref-info=\"Curran MA, Montalvo W, Yagita H, et al: PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A 107:4275-80, 2010.\" href=\"#_ENREF_217\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/20160101\"><sup>217</sup></a>. Anti-PD-1/nivolumab/MK-3475 and anti-CTLA-4/Yervoy antibodies are being combined in clinical trials with the hope of synergistic effects (NCT01024231). This combination treatment, when administered concurrently to 52 patients at a variety of dose levels, produced an objective response rate of 40% with 5 complete responses. The degree of observed tumor shrinkage was more than 80% for most of responding patients. In several patients in the study, tumors disappeared completely, as could be determined by imaging. Grade 3 or 4 adverse events related to therapy occurred in 53% of patients, but were generally reversible <a class=\"rlc-reference\" data-ref-info=\"Wolchok JD, Kluger H, Callahan MK, et al: Nivolumab plus Ipilimumab in Advanced Melanoma. N Engl J Med, 2013.\" href=\"#_ENREF_218\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23724867\"><sup>218</sup></a>. A randomized phase III trial <a href=\"http://clinicaltrials.gov/ct2/results?term=NCT01844505&amp;Search=Search\">NCT01844505</a> for ipilimumab <u>+</u> nivolumab with the endpoint of OS is recruiting melanoma patients. Phase II trial <a href=\"http://clinicaltrials.gov/ct2/results?term=NCT01783938\">NCT01783938</a> will explore sequential administration of nivolumab and ipilimumab.</p>\n<p id=\"erb-fc7ddb10-12bf-4dbd-ab65-e414160fb6cc\">In general, a concept is emerging that different immune checkpoints might have non-overlapping functions in immune escape, and therefore targeting more than one inhibitory molecule might be a general strategy for future approaches to immunotherapies. In addition to CTLA and PD-1/PD-L1, other proteins (LAG-3 and TIM-3) act as checkpoints. In addition, several proteins listed below are known to positively modulate T cells function. There are dozens of molecules now known to upregulate or downregulate immune responses and future trials evaluating agonists and antagonists of these molecules in combination may be promising.</p>\n\n<p id=\"erb-f66006b5-3c45-4431-ab39-e887832db156\"><b>4-1BB.</b> Also known as CD137, 4-1BB is a member of the TNF receptor superfamily, and is an activation-induced costimulatory molecule. Binding of 4-1BB by its ligand or antibody induces powerful CD8+ T-cell activation, IFN-\u03b3 production, and cytolytic activity. An agonistic antibody, <a href=\"http://www.cancer.gov/drugdictionary?CdrID=489120\">BMS-663513</a> (Bristol-Myers Squibb) was in clinical trials for melanoma and other tumors. Safety concerns caused suspension of the trial after several patients developed liver problems, including high-grade hepatitis. However, the antibody has a promise in expanding the repertoire of functional CD8+ effector cells during T cell expansion for autologous cell transfer (ACT). A recent study showed that addition of BMS-663513 to the expansion cultures of T cells isolated from metastases strongly increased the frequency and yield of CD8+ cells as well as their cytotoxic activity in vitro <a class=\"rlc-reference\" data-ref-info=\"Chacon JA, Wu RC, Sukhumalchandra P, et al: Co-Stimulation through 4-1BB/CD137 Improves the Expansion and Function of CD8(+) Melanoma Tumor-Infiltrating Lymphocytes for Adoptive T-Cell Therapy. PLoS One 8:e60031, 2013.\" href=\"#_ENREF_219\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23560068\"><sup>219</sup></a>.</p>\n\n<p id=\"erb-1de009a7-9b69-4ae1-bfe4-c2c2b8168da0\"><b>GITR</b> is a costimulatory receptor expressed after T cell activation that enhances T cell function and survival. GITR also negatively affects regulatory T cells (Tregs), a specialized T-cell lineage that downregulates cellular immunity. A trial with anti-GITR antibody TRX-518 is ongoing (<a href=\"http://clinicaltrials.gov/ct2/show/NCT01239134\">NCT01239134</a>).</p>\n\n<p id=\"erb-8e578e12-4d2f-472d-bd77-11d0b32fad43\"><b>OX40</b> is not involved in effector T cell activation, but rather, promotes T cell survival and expansion. In a clinical study, based at the Portland Providence Medical Center in Oregon, patients received three infusions of the agonistic mouse anti-OX40 antibody within a week. The xenogeneic nature of the antibody precluded further treatments. Nine of 27 patients experienced minor tumor shrinkage, although none met RECIST (response evaluation criteria in solid tumors) criteria for objective responses.</p>\n\n<p id=\"erb-41663f80-35d7-4c15-adc7-53d2dd7cf3ed\"><b>CD40.</b> Unlike the costimulatory targets above, CD40 is expressed on APCs, while its ligand is expressed on T cells. Binding of the two acts as a powerful enhancer of APCs\u2019 ability to present antigens and activate T cells against foreign targets <a class=\"rlc-reference\" data-ref-info=\"Vonderheide RH, Flaherty KT, Khalil M, et al: Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clin Oncol 25:876-83, 2007.\" href=\"#_ENREF_220\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/17327609\"><sup>220</sup></a>. A number of cancer patients with diverse solid tumors have received infusions of agonistic antibody <a href=\"http://www.cancer.gov/drugdictionary?CdrID=588974\">CP870,893</a>, often in combination with conventional chemotherapy, making it difficult to evaluate the antibody contribution. In those given antibody alone some objective responses were observed, particularly in a few patients with melanoma. A surprising finding was that treatments did not increase numbers of TILs in the tumors. In a mouse model, antibody treatments induced an influx of macrophages into tumors, presumably with enhanced cytotoxic activities. A phase I trial <a href=\"http://clinicaltrials.gov/ct2/show/NCT01103635\">NCT01103635</a> combining CP870,893 with <a href=\"http://www.cancer.gov/drugdictionary?CdrID=448620\">tremelimumab</a> in melanoma and other tumors is ongoing. A dose escalation trial of CP870,893 is ongoing where antibody is combined with Oncovir poly IC:LC and NY-ESO-1/gp100 <a href=\"http://clinicaltrials.gov/ct2/show/NCT01008527\">NCT01008527</a>.</p>\n\n<p id=\"erb-48a17b78-2aed-42ff-aa9d-452fed5cf024\"><b>CEACAM1</b> is a potential new target for the development of targeting antibodies. CEACAM1 is a carcinoembryonic, antigen-related adhesion molecule 1 from the IG superfamily whose expression is absent from normal melanocytes, but often found in melanomas, particularly those that are metastatic. CEACAM1 was shown to protect melanoma cells from T cells <i>in vitro</i>, and, moreover, its expression was found on T cells and NK cells from melanoma patients, presumably enabling a homotypic inhibitory interaction. A mouse antibody to CEACAM has no apparent effect on CEACAM1-expressing melanoma cells <i>in vitro</i>, but renders them susceptible to elimination by T cells <i>in vitro</i> and in an <i>in vivo</i> xenograft model. These findings provide a strong rationale for developing CEACAM1-based therapeutics for the treatment of metastatic melanoma <a class=\"rlc-reference\" data-ref-info=\"Sapoznik S, Hammer O, Ortenberg R, et al: Novel anti-melanoma immunotherapies: disarming tumor escape mechanisms. Clin Dev Immunol 2012:818214, 2012.\" href=\"#_ENREF_207\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22778766\"><sup>207</sup></a>.</p>\n\n<p id=\"erb-dbae3c7e-5cd2-46d1-b212-68ec487e2174\"><b>Cytokines</b></p>\n<p id=\"erb-cbe72a9e-83aa-47b4-8d9a-501b04aeae45\">Interleukin-2 (IL-2), a protein produced primarily by CD4+ T-cells that activates and induces proliferation of Natural Killer Cells, CD8+ and CD4+ T-cells, is FDA approved for the treatment of metastatic melanoma. This is due to the long, durable responses lasting over 10 years in a subset of patients. However, objective clinical responses to IL-2 alone are under 15% in most series, and the treatment is related to significant adverse reactions including pulmonary edema, hypotension, fever and chills. In a randomized clinical trial for metastatic melanoma patients, IL-2 combined with a gp100 peptide vaccine doubled the clinical responses compared to those patients receiving IL-2 alone. The vaccine + IL-2 group also had increased progression free survival (PFS), but only a trend towards improved overall survival <a class=\"rlc-reference\" data-ref-info=\"Schwartzentruber DJ, Lawson DH, Richards JM, et al: gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med 364:2119-27, 2011.\" href=\"#_ENREF_221\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/21631324\"><sup>221</sup></a>. Currently, a trial with IL-2 in combination with a MAGE vaccine containing an improved adjuvant is ongoing. One interesting small trial combined high-dose IL-2 with ipilimumab in 36 patients with metastatic melanoma <a class=\"rlc-reference\" data-ref-info=\"Prieto PA, Yang JC, Sherry RM, et al: CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin Cancer Res 18:2039-47, 2012.\" href=\"#_ENREF_222\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22271879\"><sup>222</sup></a>. The overall response rate of 25% was most notable because 6 of the 9 responders achieved CRs (CR rate 17%) and all were sustained beyond six years. This suggests that combining stimulatory cytokines with checkpoint blockade is a strategy worth further investigation.</p>\n<p id=\"erb-9100208a-9a38-4c62-be89-57c23bffd79d\">Interferon alpha is FDA approved for the treatment of stage III melanoma in the adjuvant setting. Interferon has been shown to increase relapse free survival (RFS) but in most studies, not overall survival. Recently a weekly pegylated formulation was also FDA approved for the same indication. Data suggests that patients with ulcerated primaries and microscopic compared to palpable nodal disease are subsets that may benefit most from interferon. Toxicities of interferon include immune hepatitis, fever, chills, and fatigue, and the recommended regimen includes one month of high dose i.v. therapy followed by 11 months of s.c. injections.</p>\n<p id=\"erb-1d5c8e89-333d-428f-8b0f-df5ab06c837a\">Cytokines under investigation for the treatment of metastatic melanoma include IL-21, which produced an ORR of 22.5% <a class=\"rlc-reference\" data-ref-info=\"Petrella TM, Tozer R, Belanger K, et al: Interleukin-21 has activity in patients with metastatic melanoma: a phase II study. J Clin Oncol 30:3396-401, 2012.\" href=\"#_ENREF_223\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22915661\"><sup>223</sup></a>, and is tested both alone and in phase I trials in combination with anti-CTLA4 (NCT01489059) and anti-PD1 antibody (<a href=\"http://clinicaltrials.gov/ct2/show/NCT01629758\">NCT01629758</a>).</p>\n\n<p id=\"erb-a402bdae-7644-44a4-ba96-a9cf1bf3bd3c\"><b>Adoptive cell transfer</b></p>\n<p id=\"erb-6f2d5101-031a-4a8c-b2ee-eb4747f7e104\">Adoptive cell transfer (ACT) involves the selection of autologous lymphocytes with antitumor activity, their expansion/activation <i>ex vivo</i>, and their reinfusion into the patient, often in the context of lymphodepleting regimens to minimize endogenous immunosuppression (reviewed in Galluzzi, et al, 2007; Itzhaki, et al, 2013 <sup><a class=\"rlc-reference\" data-ref-info=\"Galluzzi L, Vacchelli E, Eggermont A, et al: Trial Watch: Adoptive cell transfer immunotherapy. Oncoimmunology 1:306-315, 2012.\" href=\"#_ENREF_224\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22737606\">224</a>,<a class=\"rlc-reference\" data-ref-info=\"Itzhaki O, Levy D, Zikich D, et al: Adoptive T-cell transfer in melanoma. Immunotherapy 5:79-90, 2013.\" href=\"#_ENREF_225\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23256800\">225</a></sup>.. T cell adoptive therapy for metastatic melanoma has been quite successful in achieving objective regressions in about 50% of patients <a class=\"rlc-reference\" data-ref-info=\"Rosenberg SA, Yang JC, Sherry RM, et al: Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 17:4550-7, 2011.\" href=\"#_ENREF_226\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/21498393\"><sup>226</sup></a> and produced durable complete regressions. Despite the clear therapeutic efficacy in some melanoma patients with ACT, there are a number of challenges for this approach to become widely accepted and FDA approved, including the complex methodology required to manufacture large numbers of T-cells, which has restricted this therapy to a limited number of patients in a handful of centers. Increased utilization of this approach will require a simplification and improvement of the methods for T-cell expansion and a modification of the treatment regimen associated with decreased toxicity such as the use of lower doses of IL-2. Importantly, while it is clear that patients failing anti-CTLA4 can respond to ACT, future studies will determine whether the same is true for patients who fail anti-PD1 therapy.</p>\n<p id=\"erb-78f845c6-9d25-4c95-a1cb-62b38e432cd6\">Different aspects of ACT are being examined, among them the role of cytokines such as IL-15 and T cell-produced IL-9 in T cell-based therapy <a class=\"rlc-reference\" data-ref-info=\"Purwar R, Schlapbach C, Xiao S, et al: Robust tumor immunity to melanoma mediated by interleukin-9-producing T cells. Nat Med, 2012.\" href=\"#_ENREF_227\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22772464\"><sup>227</sup></a>; concomitant low-dose IL-2 in patients treated with ACT <a class=\"rlc-reference\" data-ref-info=\"Ellebaek E, Iversen TZ, Junker N, et al: Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients. J Transl Med 10:169, 2012.\" href=\"#_ENREF_228\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22909342\"><sup>228</sup></a>; facilitation of the long-term engraftment of T cells by using the memory T cell population <sup><a class=\"rlc-reference\" data-ref-info=\"Hirschhorn-Cymerman D, Budhu S, Kitano S, et al: Induction of tumoricidal function in CD4+ T cells is associated with concomitant memory and terminally differentiated phenotype. J Exp Med 209:2113-26, 2012.\" href=\"#_ENREF_229\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23008334\">229</a>,<a class=\"rlc-reference\" data-ref-info=\"Wang A, Chandran S, Shah SA, et al: The stoichiometric production of IL-2 and IFN-gamma mRNA defines memory T cells that can self-renew after adoptive transfer in humans. Sci Transl Med 4:149ra120, 2012.\" href=\"#_ENREF_230\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22932225\">230</a></sup>; the basis for the relapses frequently observed after ACT immunotherapy, such as inflammation-induced reversible loss of melanocytic antigens mediated by TNF-a <a class=\"rlc-reference\" data-ref-info=\"Landsberg J, Kohlmeyer J, Renn M, et al: Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation. Nature 490:412-6, 2012.\" href=\"#_ENREF_231\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23051752\"><sup>231</sup></a>; the immunosuppressive role of Tregs and myeloid-derived suppressor cells (MDSC) <a class=\"rlc-reference\" data-ref-info=\"Kodumudi KN, Weber A, Sarnaik AA, et al: Blockade of myeloid-derived suppressor cells after induction of lymphopenia improves adoptive T cell therapy in a murine model of melanoma. J Immunol 189:5147-54, 2012.\" href=\"#_ENREF_232\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23100512\"><sup>232</sup></a>, and the nature of the relevant tumor rejection antigens being targeted.</p>\n<p id=\"erb-cd6d1ec9-09a3-4b02-aa49-1f073999767d\">Analysis of the repertoire of the T cells in the successful ACT treatments of three melanoma patients through exomic sequencing of tumors established a correlation between the ability of infused T cells to recognize specific mutated proteins present in tumors. Candidate mutated epitopes were identified using major histocompatibility complex-binding algorithm for recognition by TILs <a class=\"rlc-reference\" data-ref-info=\"Robbins PF, Lu YC, El-Gamil M, et al: Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med 19:747-52, 2013.\" href=\"#_ENREF_202\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23644516\"><sup>202</sup></a>. In one patient successfully treated by ACT in a previous trial, the specific T cells recognizing a mutated epitope persisted in peripheral blood for over 5 years <a class=\"rlc-reference\" data-ref-info=\"Lu YC, Yao X, Li YF, et al: Mutated PPP1R3B Is Recognized by T Cells Used To Treat a Melanoma Patient Who Experienced a Durable Complete Tumor Regression. J Immunol 190:6034-42, 2013.\" href=\"#_ENREF_233\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23690473\"><sup>233</sup></a>.</p>\n<p id=\"erb-996e6e08-1191-481a-87c4-be6a7d81ce41\">A recent phase II clinical trial reported objective clinical responses in almost half of the 31 patients enrolled, with two complete remissions and a significant increase in PFS <a class=\"rlc-reference\" data-ref-info=\"Radvanyi LG, Bernatchez C, Zhang M, et al: Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. Clin Cancer Res 18:6758-70, 2012.\" href=\"#_ENREF_234\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23032743\"><sup>234</sup></a>. The study also analyzed characteristics of infused T cells associated with significant responses, and found significant correlations with: higher number of TIL infused, a higher proportion of CD8(+) T cells in the infusion product, a more differentiated effector phenotype of the CD8(+) population, and, unexpectedly, a higher frequency of CD8(+) T cells co-expressing the negative costimulation molecule \"B- and T-lymphocyte attenuator\" (BTLA). A phase I/II trial is investigating the use autologous TILs enriched for CD8 and engineered to secrete IL-12, which will be infused after patients undergo myeloablative regimen of chemotherapy (<a href=\"http://clinicaltrials.gov/ct2/results?term=NCT+01236573\">NCT</a><a href=\"http://clinicaltrials.gov/ct2/results?term=NCT+01236573\"> 01236573</a>). On the other hand, a randomized trial suggested that use of unselected young autologous T cells is preferable to enrichment for CD8+ cells because the latter are more laborious to prepare and did not offer a therapeutic advantage <a class=\"rlc-reference\" data-ref-info=\"Dudley ME, Gross CA, Somerville RP, et al: Randomized Selection Design Trial Evaluating CD8+-Enriched Versus Unselected Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy for Patients With Melanoma. J Clin Oncol 31:2152-9, 2013.\" href=\"#_ENREF_235\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23650429\"><sup>235</sup></a>.</p>\n<p id=\"erb-07c02334-42fb-4a5d-bfc7-d5b1a869403d\">Failure of the infused CD8 cells to persist in the patients could be a major cause for the limited efficacy of TIL approaches to treatment. In a number of trials this was addressed by administration of IL2 after infusion, or lymphodepletion prior to infusion. To increase the persistence of infused T cells in patients, an approach was tested to stimulate CD8+ cells <i>in vitro</i> with MART-1 presenting APCs in the presence of IL2 and IL15. These CTLs displayed a memory phenotype, both central and effector, trafficked successfully to the tumor sites, and produced a complete response in one of nine patients, as well as several partial responses and disease stabilization <a class=\"rlc-reference\" data-ref-info=\"Butler MO, Friedlander P, Milstein MI, et al: Establishment of antitumor memory in humans using in vitro-educated CD8+ T cells. Sci Transl Med 3:80ra34, 2011.\" href=\"#_ENREF_236\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/21525398\"><sup>236</sup></a>.</p>\n<p id=\"erb-3ce94586-8175-4be6-8047-3582bbc3e9fb\">Another approach to ACT therapy is to create tumor-reactive T-cell populations from PBL by retrovirally transducing them with chimeric antigen receptors (CAR) to tumor-associated antigens or natural T-cell receptors against antigens presented in the context of MHC. CAR-modified T cells do not depend on MHC mediated antigen presentation, which is frequently dysfunctional in tumors. The steps and considerations in producing T cells with CARs and their advantages as well as pitfalls were recently reviewed <a class=\"rlc-reference\" data-ref-info=\"Kershaw MH, Westwood JA, Darcy PK: Gene-engineered T cells for cancer therapy. Nat Rev Cancer 13:525-41, 2013.\" href=\"#_ENREF_237\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23880905\"><sup>237</sup></a>. In melanoma, T cells redirected to recognize MART-1 have produced significant clinical responses (reviewed in <a class=\"rlc-reference\" data-ref-info=\"Stauss HJ, Morris EC: Immunotherapy with gene-modified T cells: limiting side effects provides new challenges. Gene Ther, 2013.\" href=\"#_ENREF_238\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23804078\"><sup>238</sup></a>). A tumor-testis antigen on melanoma and other tumors, NY-ESO-1, has been effectively targeted with an MHC-restricted T-cell receptor in another trial<a class=\"rlc-reference\" data-ref-info=\"Robbins PF, Morgan RA, Feldman SA, et al: Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol 29:917-24, 2011.\" href=\"#_ENREF_239\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/21282551\"><sup>239</sup></a>.</p>\n<p id=\"erb-870adeb1-9175-4507-8935-eb170f5d5336\">Some remarkable responses were observed in individual patients treated with CD4+T cells. For example, autologous transfer of expanded CD4+ T cells recognizing melanoma antigen NY-ESO-1 produced a complete and durable response in one patient trial <a class=\"rlc-reference\" data-ref-info=\"Hunder NN, Wallen H, Cao J, et al: Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med 358:2698-703, 2008.\" href=\"#_ENREF_240\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/18565862\"><sup>240</sup></a>. Recent findings indicate that CD4+ T cells could also contribute to the success of ACT by inducing tumor senescence through production of high levels of IFN-\uf067 and TNF <a class=\"rlc-reference\" data-ref-info=\"Braumuller H, Wieder T, Brenner E, et al: T-helper-1-cell cytokines drive cancer into senescence. Nature, 2013.\" href=\"#_ENREF_241\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23376950\"><sup>241</sup></a>.</p>\n\n<p id=\"erb-47d28fe4-66d6-4337-9d14-dc9eedac828a\"><b>Dendritic cell based immunotherapy.</b></p>\n<p id=\"erb-e0968d32-d3f4-4577-9aac-4ea533545d8a\">Dendritic cells (DC) are the most potent antigen presenting cells in the immune system, and clinical efforts to use DC to induce potent anti-melanoma immune responses have been ongoing for at least a decade <a class=\"rlc-reference\" data-ref-info=\"Palucka K, Banchereau J: Cancer immunotherapy via dendritic cells. Nat Rev Cancer 12:265-77, 2012.\" href=\"#_ENREF_242\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22437871\"><sup>242</sup></a>. However, as with most immunotherapies, the responses to DC-mediated vaccination have been unpredictable and variable.</p>\n<p id=\"erb-261d57bb-15ca-4be0-a9fe-dc3318abd854\">Stimulation of anti-melanoma responses by DC involves a number of steps that need better scientific understanding and clinical exploration. To arm DC with the antigens needed to be presented to immune effector cells, DC are usually \u201cloaded\u201d with antigens expressed in tumors by incubation with the tumor antigens and an adjuvant <i>ex vivo</i>. This process induces maturation of DC, which involves processing the antigens via proteasomal degradation and presenting them to T-cells on a variety of MHC family molecules. As so-called \u2018professional antigen presenting cells\u2019, DCs can present antigen to and efficiently co-stimulate both CD4+ cells and CD8+ cells. The T helper cells could stimulate B cell based humoral responses, and killer T cells could have direct cytotoxic activity against antigen presenting tumor cells. DCs can also react to as well as stimulate the components of the innate immune system such as natural killer (NK) cells and phagocytes. Yet other DC interactions can also induce regulatory T-cells that dampen immune responses. Finally, DCs are also influenced by a large variety of soluble factors, many of which are abundant in the tumor microenvironment.</p>\n<p id=\"erb-6c27c6fe-7fa7-4d4d-ba43-6ed01e5587cb\">A number of variables remain to be fully explored in DC vaccination: the source of DC, the optimal methods for maturation <i>ex vivo</i>, the route of introduction into patients, the ways to overcome the tumor-generated immunosuppressory activities and more.</p>\n<p id=\"erb-fdabc686-20a4-4d03-8a7d-75a98dd0dc08\">Clinical trials have explored DC generated by different methods and injected by different routes in patients with metastatic melanoma (only a few are mentioned here). DC can be isolated from peripheral blood and from Langerhans cells \u2013 a subset of DC present in skin, or other sources (see below). For example, an early clinical trial that concluded in 1998 produced promising results. Patients were vaccinated with monocyte-derived DC pulsed with tumor lysate or a mix of tumor-related peptides, and stimulated with GM-CSF and IL-4. Five of 16 patients had objective responses <a class=\"rlc-reference\" data-ref-info=\"Nestle FO, Alijagic S, Gilliet M, et al: Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 4:328-32, 1998.\" href=\"#_ENREF_243\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/9500607\"><sup>243</sup></a>. Monocyte-derived DC were pulsed with a single tumor peptide from Mage-3A1 and a recall antigen in another study. Evaluation of immune responses showed that 8 of 11 patients had an expansion of Mage-3A1 recognizing CD8+ T cells, and 6 patients showed regression of some metastases but no formal PRs or CRs were achieved <a class=\"rlc-reference\" data-ref-info=\"Thurner B, Haendle I, Roder C, et al: Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 190:1669-78, 1999.\" href=\"#_ENREF_244\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/10587357\"><sup>244</sup></a>. It was noted that some non-regressing tumors lacked Mage-3A1 expression and specific T cells.</p>\n<p id=\"erb-c3e6746e-55e1-4958-8a30-e64cfe4c7eec\">In a different approach, immature DC were generated from CD34+ hematopoietic progenitor cells through stimulation with a pre-defined cytokine cocktail, and matured <i>in vitro</i> by pulsing with a pool of peptides derived from known melanoma antigens <a class=\"rlc-reference\" data-ref-info=\"Mackensen A, Herbst B, Chen JL, et al: Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34(+) hematopoietic progenitor cells. Int J Cancer 86:385-92, 2000.\" href=\"#_ENREF_245\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/10760827\"><sup>245</sup></a>. This study reported durable immune responses and perhaps one objective clinical response.</p>\n<p id=\"erb-ee49394f-7883-457e-b9c6-a7bb3d343bbe\">Langerhans cells were directly compared to monocyte-derived DC in a clinical trial, and were found to be similar in terms of eliciting immune responses, but different in terms of the need for cytokine stimulation <a class=\"rlc-reference\" data-ref-info=\"Romano E, Rossi M, Ratzinger G, et al: Peptide-loaded Langerhans cells, despite increased IL15 secretion and T-cell activation in vitro, elicit antitumor T-cell responses comparable to peptide-loaded monocyte-derived dendritic cells in vivo. Clin Cancer Res 17:1984-97, 2011.\" href=\"#_ENREF_246\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/21355077\"><sup>246</sup></a>. The role of the route of injection was explored in a study that injected monocyte-derived stimulated DC either intranodally or intradermally. The latter produced very low percentages of cells surviving and migrating to lymph nodes <a class=\"rlc-reference\" data-ref-info=\"Verdijk P, Aarntzen EH, Lesterhuis WJ, et al: Limited amounts of dendritic cells migrate into the T-cell area of lymph nodes but have high immune activating potential in melanoma patients. Clin Cancer Res 15:2531-40, 2009.\" href=\"#_ENREF_247\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/19318472\"><sup>247</sup></a>, but the induced immune responses (stimulation of tumor-specific T cells) were superior in the patients receiving intradermal inoculation <a class=\"rlc-reference\" data-ref-info=\"Lesterhuis WJ, de Vries IJ, Schreibelt G, et al: Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients. Clin Cancer Res 17:5725-35, 2011.\" href=\"#_ENREF_248\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/21771874\"><sup>248</sup></a>.</p>\n<p id=\"erb-55c25f82-cebb-450b-8da4-1bd8a046d49b\">Stimulation of DC could be performed not only by exposing them to tumor antigens, but also by transfection of mRNA coding for the antigens <a class=\"rlc-reference\" data-ref-info=\"Mitchell DA, Nair SK: RNA-transfected dendritic cells in cancer immunotherapy. J Clin Invest 106:1065-9, 2000.\" href=\"#_ENREF_249\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/11067858\"><sup>249</sup></a>. The latter might have an advantage of longer exposure and correct processing of the antigens. Indeed, it was shown to produce strong immune responses after intranodal injection, inducing a broad repertoire of IFN\u03b3 producing TAA-specific CD8(+) and CD4(+) T-cell <a class=\"rlc-reference\" data-ref-info=\"Aarntzen EH, Schreibelt G, Bol K, et al: Vaccination with mRNA-electroporated dendritic cells induces robust tumor antigen-specific CD4+ and CD8+ T cells responses in stage III and IV melanoma patients. Clin Cancer Res 18:5460-70, 2012.\" href=\"#_ENREF_250\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22896657\"><sup>250</sup></a>. Stage III melanoma patients in this study also had significant immune responses.</p>\n<p id=\"erb-f75915ac-0d96-4ce8-bfd4-86753b98c1ea\">A recent study reported a further significant improvement on DC maturation ex vivo. Mature DC (used for vaccination) express a specific type of proteasomes, the immunoproteasomes (iPs) that are responsible for antigen processing in immune cells. However, tumor cells express constitutive proteasomes (cPs) that contain three different subunits. It was hypothesized that generating T-cells against epitopes from one type of proteasome (iPs) might not result in recognition of epitopes generated by target cell proteasomes (cPs), preventing optimal recognition and immune attack of tumor cells. Therefore, the patient derived DC were transfected not only with the RNA for tumor antigens, but also with shRNA which enforced the default use of only cPs in the DCs. Patients vaccinated with cPs-expressing DC had lower levels of circulating melanoma cells and enhanced melanoma-directed T cell lytic activity, which was of a longer duration compared to patients in control arms of the study. Of the five patients vaccinated with cPs-expressing DC, one had a complete response, and one had a partial response <a class=\"rlc-reference\" data-ref-info=\"Dannull J, Haley NR, Archer G, et al: Melanoma immunotherapy using mature DCs expressing the constitutive proteasome. J Clin Invest 123:3135-45, 2013.\" href=\"#_ENREF_251\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23934126\"><sup>251</sup></a>.</p>\n<p id=\"erb-e91b91f8-085f-4b2d-b0ab-cb8621864673\">Another important component of successful vaccination with DC is their ability to stimulate CD8+ T cells which requires production of IL12-p70 by DC, which, in turn, depends on stimulation of DC by two signals: CD40 or TLR and INF-\uf067. A recent small clinical trial used DC from PBMC of melanoma patients pulsed with gp100 peptides. In addition, maturation <i>in vitro</i> included stimulation of DC from PBMC with both CD40L and INF-\uf067. The study of seven patients showed a straightforward correlation between the clinical responses and levels of IL12 produced by their DC. The one patient with complete remission had the highest levels of IL12. Moreover, the study has identified the deficiency in non-responding patients as the inability to produce IL12 without additional stimulation with TLR agonist. Addition of poly I:C to the maturation protocol has rescued production of IL12 by these DC in vitro and improved the clinical outcomes <a class=\"rlc-reference\" data-ref-info=\"Carreno BM, Becker-Hapak M, Huang A, et al: IL-12p70-producing patient DC vaccine elicits Tc1-polarized immunity. J Clin Invest, 2013.\" href=\"#_ENREF_252\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23867552\"><sup>252</sup></a>.</p>\n<p id=\"erb-c794669b-91f2-4aa6-b2e8-12d965313ab4\">Although combination immunotherapies involving dendritic cells and immunomodulatory antibodies may hold promise <a class=\"rlc-reference\" data-ref-info=\"Ribas A, Comin-Anduix B, Chmielowski B, et al: Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma. Clin Cancer Res 15:6267-76, 2009.\" href=\"#_ENREF_253\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/19789309\"><sup>253</sup></a>. overall clinical results with DC vaccines remain sporadic, anecdotal and inconsistent. Clinical investigators continue to struggle with an overwhelming number of variables, reflecting the complicated biology and role of this immune cell.</p>\n\n<p id=\"erb-dc09d798-f98a-4deb-bc62-acce7d8bb105\"><b>Adoptive transfer of natural killer cells</b>. Natural killer (NK) cells are an essential part of the innate immune system and have been considered in immunotherapies of melanoma. NK cells in principle are able to recognize and destroy virally infected or malignant cells without a need for antecedent antigenic stimulation. However, their activity, as with other immune effector cells, also depends on balance of stimulatory or inhibitory factors. NK cells themselves are regulated by inhibitory receptors, one of which, KIR (killer-cell immunoglobulin-like receptors), is being targeted in a clinical trial with the antagonistic antibody BMS-986015 that is designed to block the inhibition by KIR of tumor cell cytolysis.</p>\n<p id=\"erb-8ea3c3ac-584c-4b19-9178-602adb8c9356\">NK cells can be obtained from peripheral blood mononuclear cells (PBMC) where they comprise 5-15 % of the lymphocyte population, expanded and activated <i>in vitro</i> and adoptively transferred. In fact lymphokine activated killer cells (LAK cells) given in large numbers 20 years ago were largely IL-2 activated NK cells <a class=\"rlc-reference\" data-ref-info=\"Rosenberg SA, Lotze MT, Yang JC, et al: Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst 85:622-32, 1993.\" href=\"#_ENREF_254\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/8468720\"><sup>254</sup></a>. These prior trials, as well as a more recent trial combining autologous NK transfer with preparative lymphodepletion, have not demonstrated benefit attributable to the NK cells <a class=\"rlc-reference\" data-ref-info=\"Parkhurst MR, Riley JP, Dudley ME, et al: Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression. Clin Cancer Res 17:6287-97, 2011.\" href=\"#_ENREF_255\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/21844012\"><sup>255</sup></a>. New strategies might include combination of NK transfer with immunomodulatory antibodies or even transfer of activated allogeneic NK cells <a class=\"rlc-reference\" data-ref-info=\"Besser MJ, Shoham T, Harari-Steinberg O, et al: Development of allogeneic NK cell adoptive transfer therapy in metastatic melanoma patients: in vitro preclinical optimization studies. PLoS One 8:e57922, 2013.\" href=\"#_ENREF_256\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23483943\"><sup>256</sup></a>. The cytokine induced killer cells (CIK) which can also be isolated from PBMC were recently characterized as a variant NK subtype that have a cytotoxic activity against autologous melanoma cells <a class=\"rlc-reference\" data-ref-info=\"Gammaitoni L, Giraudo L, Leuci V, et al: Effective Activity of Cytokine Induced Killer Cells against Autologous Metastatic Melanoma including Cells with Stemness Features. Clin Cancer Res, 2013.\" href=\"#_ENREF_257\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23794732\"><sup>257</sup></a>.</p>\n\n<p id=\"erb-6fac8227-628c-4f09-9592-5b7c879ee2c8\"><b>Influence of targeted therapies on the responses to immune therapy</b></p>\n\n<p id=\"erb-a64d1b60-8c9d-4ad9-bbd0-5c49a469659e\"><b>BRAF/MAPK signaling and TIL</b>. Activated BRAF/MAPK signaling was shown to be essential in the development of immune evasion in melanoma <a class=\"rlc-reference\" data-ref-info=\"Sumimoto H, Imabayashi F, Iwata T, et al: The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells. J Exp Med 203:1651-6, 2006.\" href=\"#_ENREF_258\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/16801397\"><sup>258</sup></a>. Prior to clinical development of BRAF and MEK inhibitors, it was shown that inhibition of the MAPK pathway leads to increased expression of melanocytic antigen expression, including MART-1, gp100, and tyrosinase; whereas enforced expression of mutant RAF downregulated expression of these antigens <a class=\"rlc-reference\" data-ref-info=\"Kono M, Dunn IS, Durda PJ, et al: Role of the mitogen-activated protein kinase signaling pathway in the regulation of human melanocytic antigen expression. Mol Cancer Res 4:779-92, 2006.\" href=\"#_ENREF_259\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/17050671\"><sup>259</sup></a>. Mutant BRAF induces expression of IL1\uf061 in stroma, also leading to immune suppression <a class=\"rlc-reference\" data-ref-info=\"Khalili JS, Liu S, Rodriguez-Cruz TG, et al: Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma. Clin Cancer Res 18:5329-40, 2012.\" href=\"#_ENREF_260\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22850568\"><sup>260</sup></a>. In a mouse model, BRAFV600E induced expression of CCL2, an immunosuppressive chemokine, while PLX4720 treatment downregulated tumor CCL2 gene expression and increased numbers of CD8 TILs <a class=\"rlc-reference\" data-ref-info=\"Knight DA, Ngiow SF, Li M, et al: Host immunity contributes to the anti-melanoma activity of BRAF inhibitors. J Clin Invest 123:1371-81, 2013.\" href=\"#_ENREF_261\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23454771\"><sup>261</sup></a>.</p>\n<p id=\"erb-9b462c3c-9e4f-41a7-836d-9058c2016b11\">There were concerns that treatment with BRAF/MEK inhibitors might have a direct inhibitory effect on T cell function and it was indeed shown later that treatment with MEK inhibitors, but not BRAFV600E inhibitors, impairs T lymphocyte function <a class=\"rlc-reference\" data-ref-info=\"Boni A, Cogdill AP, Dang P, et al: Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res 70:5213-9, 2010.\" href=\"#_ENREF_262\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/20551059\"><sup>262</sup></a>.</p>\n<p id=\"erb-102029f3-d441-411a-88f9-6fd9af1dc2d0\">A number of subsequent reports have confirmed that inhibition of mutant BRAF could potentiate immune responses in melanoma, suggesting that blockade of immune checkpoints in combination of BRAF inhibitors could have clinical value. Treatment with BRAF inhibitors vemurafenib and dabrafenib resulted in markedly increased numbers of TIL (tumor infiltrating lymphocytes) in tumor biopsies obtained pre- and post-treatment in 15 patients <a class=\"rlc-reference\" data-ref-info=\"Wilmott JS, Long GV, Howle JR, et al: Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin Cancer Res 18:1386-94, 2012.\" href=\"#_ENREF_263\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22156613\"><sup>263</sup></a>. Another study found that dabrafenib has no detectable negative impact on existing systemic immunity or the <i>de novo</i> generation of tumor-specific T cells in patients <a class=\"rlc-reference\" data-ref-info=\"Hong DS, Vence L, Falchook G, et al: BRAF(V600) inhibitor GSK2118436 targeted inhibition of mutant BRAF in cancer patients does not impair overall immune competency. Clin Cancer Res 18:2326-35, 2012.\" href=\"#_ENREF_264\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22355009\"><sup>264</sup></a>.</p>\n<p id=\"erb-55174a26-d379-479c-bae6-21cce144a83c\">A single report claimed that selective BRAF inhibition decreases tumor-resident lymphocyte frequencies in a genetically engineered mouse (GEM) melanoma model; moreover, treatment with ipilimumab did not restore the numbers of TIL <a class=\"rlc-reference\" data-ref-info=\"Hooijkaas A, Gadiot J, Morrow M, et al: Selective BRAF inhibition decreases tumor-resident lymphocyte frequencies in a mouse model of human melanoma. Oncoimmunology 1:609-617, 2012.\" href=\"#_ENREF_265\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22934253\"><sup>265</sup></a>. Although GEM models are clearly helpful in studies of targeted therapies, their utility in the evaluation of immunotherapies is not clear. This is because it is likely that melanoma is immunogenic due to the large number of missense mutations inducing antigens that are recognized as \u201cforeign\u201d by the immune system, and many of the GEM models have very few mutations.</p>\n<p id=\"erb-62f9015a-a0e4-4c3a-8dc2-dea4a0569085\">The latest reported analysis of biopsies taken before and after treatment with BRAF or BRAF+MEK inhibitors showed the following: enhancement of melanoma antigen expression, increase in CD8+ TILs, and decrease in immunosuppressive cytokines IL6 and IL8. Interestingly, inhibitory PD-1 was increased on T cells and its immunosuppressive ligand PDL1 was also increased with BRAF inhibition. This supports the hypothesis that targeting inhibitory immune interactions may be critical in augmenting responses to BRAF-targeted therapy in patients with melanoma <a class=\"rlc-reference\" data-ref-info=\"Frederick DT, Piris A, Cogdill AP, et al: BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma. Clin Cancer Res, 2013.\" href=\"#_ENREF_266\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23307859\"><sup>266</sup></a>.</p>\n\n<p id=\"erb-bbafead9-b3f3-4128-bf91-28ad59084bb0\"><b>Adoptive cell transfer therapy and targeted therapies</b>. Adoptive cell transfer therapy could also be of more benefit when combined with vemurafenib, as a mouse model suggests <a class=\"rlc-reference\" data-ref-info=\"Koya RC, Mok S, Otte N, et al: BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy. Cancer Res 72:3928-37, 2012.\" href=\"#_ENREF_267\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22693252\"><sup>267</sup></a>. In a recent study, vemurafenib increased MAPK signaling, <i>in vivo</i> cytotoxic activity, and intratumoral cytokine secretion by adoptively transferred cells (T cells genetically engineered to recognize tumor-expressing antigens). Another study reported that administration of PLX4720 significantly increased tumor infiltration of adoptively transferred T cells <i>in vivo</i> and enhanced their antitumor activity in a mouse model. Apparently, PLX4720 negatively affected expression of VEGF by tumor cells. Importantly, analysis of human melanoma biopsies before and during BRAF inhibitor treatment also showed downregulation of VEGF consistent with the preclinical murine model <a class=\"rlc-reference\" data-ref-info=\"Liu C, Peng W, Xu C, et al: BRAF Inhibition Increases Tumor Infiltration by T cells and Enhances the Antitumor Activity of Adoptive Immunotherapy in Mice. Clin Cancer Res 19:393-403, 2013.\" href=\"#_ENREF_268\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23204132\"><sup>268</sup></a>.</p>\n<p id=\"erb-3ee6e4e3-9a54-481c-89c4-8ada2014bbf9\">An <i>in vitro</i> study analyzed effects of BRAF and MEK inhibition on function of dendritic cells (DC) <i>in vitro</i> and found that BRAF-mutant melanomas suppress immune function of dendritic cells. Inhibition of BRAF, but not MEK could reverse suppression of DC function. As has been reported for the effects of MEK inhibition on T cells <a class=\"rlc-reference\" data-ref-info=\"Boni A, Cogdill AP, Dang P, et al: Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res 70:5213-9, 2010.\" href=\"#_ENREF_262\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/20551059\"><sup>262</sup></a>, inhibition of MEK did negatively affect DC function and viability. Vemurafenib, but not MEK inhibitors, was therefore suggested as a preferable candidate for combination immunotherapy approaches in BRAF-mutant melanoma. <a class=\"rlc-reference\" data-ref-info=\"Ott PA, Henry T, Baranda SJ, et al: Inhibition of both BRAF and MEK in BRAF(V600E) mutant melanoma restores compromised dendritic cell (DC) function while having differential direct effects on DC properties. Cancer Immunol Immunother, 2013.\" href=\"#_ENREF_269\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23306863\"><sup>269</sup></a>.</p>\n<p id=\"erb-485d6fb7-0d54-4c50-8a19-061bc16711f3\">Another <i>in vitro</i> study examined how vemurafenib affects the ability of the tumor-infiltrating lymphocytes to recognize autologous BRAF(V600) mutant melanoma cell lines <i>in vitro</i> <a class=\"rlc-reference\" data-ref-info=\"Donia M, Fagone P, Nicoletti F, et al: BRAF inhibition improves tumor recognition by the immune system: Potential implications for combinatorial therapies against melanoma involving adoptive T-cell transfer. Oncoimmunology 1:1476-1483, 2012.\" href=\"#_ENREF_270\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23264894\"><sup>270</sup></a>. The results showed a significant increase in recognition of the inhibitor-treated melanoma cells that was attributed to increased expression of MHC class I-associated proteins and heat-shock proteins.</p>\n<p id=\"erb-6cc9ee7f-5118-429a-9d99-f55f9df65262\">These studies in general provide a strong rationale for combination therapies involving BRAF inhibition with immunotherapies involving either antibodies to immunosuppressive molecules or adoptive cell transfer. Several trials are ongoing, but one has been closed for toxicity. The phase I trial (<a href=\"http://clinicaltrials.gov/ct2/results?term=NCT01400451&amp;Search=Search\">NCT01400451</a>) of concurrent vemurafenib and ipilimumab was closed in March 2013, due to dose-limiting liver toxicities <a class=\"rlc-reference\" data-ref-info=\"Ribas A, Hodi FS, Callahan M, et al: Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med 368:1365-6, 2013.\" href=\"#_ENREF_271\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23550685\"><sup>271</sup></a>. This highlights the need for careful evaluation of combination strategies, in particular because the drugs in this trial were approved, and had little overlap in terms of side effects. Other trials will evaluate combinations of vemurafenib and anti-PD-L1 antibody MPDL3280A (<a href=\"http://clinicaltrials.gov/ct2/results?term=NCT01656642&amp;Search=Search\">NCT01656642</a>), vemurafenib and HD-IL2 (<a href=\"http://clinicaltrials.gov/show/NCT01683188\">NCT01683188</a>), vemurafenib and adoptive cell transfer (<a href=\"http://clinicaltrials.gov/show/NCT01585415\">NCT01585415</a>), and HD-IL2 + adoptive cell transfer + vemurafenib (<a href=\"http://clinicaltrials.gov/show/NCT01659151\">NCT01659151</a>) and more. Whether to give targeted therapy or immunotherapy first to patients with BRAF mutant melanoma remains an important clinical question. Patients with rapidly progressing disease may need to start with BRAF inhibitors since this treatment works quickly. On the other hand, if the disease is not rapidly progressing, beginning with immunotherapy makes sense due to the durability of response in some patients.</p>\n<p id=\"erb-30467588-553e-4afc-bfa9-f3f9307478d4\">Mutant BRAF and/or its inhibition are not expected to influence outcomes of all immune therapies. For example, a recent trial showed that treatment with IL21 produced an overall response rate of 22.5% in melanoma and responses were not related to the status of BRAF <a class=\"rlc-reference\" data-ref-info=\"Petrella TM, Tozer R, Belanger K, et al: Interleukin-21 has activity in patients with metastatic melanoma: a phase II study. J Clin Oncol 30:3396-401, 2012.\" href=\"#_ENREF_223\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22915661\"><sup>223</sup></a>. Treatment with high-dose IL-2 was more effective in patients in patients with NRAS mutations versus BRAF mutations or WT/WT tumors <a class=\"rlc-reference\" data-ref-info=\"Joseph RW, Sullivan RJ, Harrell R, et al: Correlation of NRAS mutations with clinical response to high-dose IL-2 in patients with advanced melanoma. J Immunother 35:66-72, 2012.\" href=\"#_ENREF_272\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22130161\"><sup>272</sup></a>.</p>\n<p id=\"erb-0a3e3212-f531-4db1-a10f-81cf2399d6a1\">Other melanoma-related pathways might also play a role in responses to immune therapy. Wnt/\uf062-catenin signaling might be involved in immunosuppression in melanoma, as high levels of nuclear \uf062-catenin in melanoma cells impaired maturation of DC at least in part through increased production of IL-10 and inhibited IFN-\uf067 production by melanoma-specific CTLs <a class=\"rlc-reference\" data-ref-info=\"Yaguchi T, Goto Y, Kido K, et al: Immune suppression and resistance mediated by constitutive activation of Wnt/beta-catenin signaling in human melanoma cells. J Immunol 189:2110-7, 2012.\" href=\"#_ENREF_273\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22815287\"><sup>273</sup></a>. It is entirely possible and even likely that other oncogenic pathways in melanoma also mediate immune suppression in melanoma.</p>\n\n<p id=\"erb-1c838028-2862-4a72-8225-c1a7137dda3e\"><b>Tumor microenvironment and immune responses</b></p>\n\n<p id=\"erb-2e19f43e-bf5c-4874-b74b-cb29831192cb\"><b>The role of B cells in the immune responses in melanoma.</b> An extensive study measured humoral B cell responses in melanoma patients, and concluded that on average melanoma patients have highly increased antibody responses against melanoma cells compared to healthy volunteers. Interestingly, the B cell mediated immune responses were significantly diminished in patients with metastatic melanoma versus primary disease <a class=\"rlc-reference\" data-ref-info=\"Gilbert AE, Karagiannis P, Dodev T, et al: Monitoring the systemic human memory B cell compartment of melanoma patients for anti-tumor IgG antibodies. PLoS One 6:e19330, 2011.\" href=\"#_ENREF_274\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/21559411\"><sup>274</sup></a>. The impaired B cell functionality with loss of CD27+ (memory) cells was previously reported in metastatic melanoma <a class=\"rlc-reference\" data-ref-info=\"Carpenter EL, Mick R, Rech AJ, et al: Collapse of the CD27+ B-cell compartment associated with systemic plasmacytosis in patients with advanced melanoma and other cancers. Clin Cancer Res 15:4277-87, 2009.\" href=\"#_ENREF_275\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/19549767\"><sup>275</sup></a>.</p>\n<p id=\"erb-68f0804d-b30f-4b7e-b4cf-a8f902864f86\">Intratumoral IgG producing B cells have been reported in melanoma, but their functional significance was largely unknown. A study published in March of 2013 found a skewing of B cell repertoire in melanoma tumors, with highly increased numbers of IgG4 producing B cells relative to normal ratios. High IgG4/IgGtotal ratios are considered a limiting response by the immune system to contain immune activation. In melanoma production of B cells secreting inhibitory IgG4 is stimulated by the tumor secreted IL-10 and IL-4. The tumor-specific IgG4 even inhibited IgG1-dependent tumor cell killing through engagement of the Fc\u03b3RI effector mechanisms. Moreover, high circulating levels of IgG4 in serum of patients were associated with poor prognosis <a class=\"rlc-reference\" data-ref-info=\"Karagiannis P, Gilbert AE, Josephs DH, et al: IgG4 subclass antibodies impair antitumor immunity in melanoma. J Clin Invest, 2013.\" href=\"#_ENREF_276\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23454746\"><sup>276</sup></a>.</p>\n\n<p id=\"erb-62ef3ac9-43b4-45ef-9871-a5a4c5021932\"><b>Immune cell infiltrates in melanoma</b>. The presence of lymph node-like structures in solid tumors has been recognized relatively recently, and is considered to have a prognostic value, in particular as related to immune therapy <a class=\"rlc-reference\" data-ref-info=\"Jochems C, Schlom J: Tumor-infiltrating immune cells and prognosis: the potential link between conventional cancer therapy and immunity. Exp Biol Med (Maywood) 236:567-79, 2011.\" href=\"#_ENREF_277\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/21486861\"><sup>277</sup></a>. It was suggested that the presence of these lymphoid structures could be due to locally tumor-produced chemokines, and might be useful in selection of patients for whom immunotherapies might work best. Moreover, a particular 12 chemokine signature produced by tumors, was identified by expression profiling, and was shown to be predictive of the formation of these lymph node-like structures. The hope is that this expression signature might be used for selection of patients for whom long-lasting responses to immunotherapy are possible <a class=\"rlc-reference\" data-ref-info=\"Messina JL, Fenstermacher DA, Eschrich S, et al: 12-Chemokine gene signature identifies lymph node-like structures in melanoma: potential for patient selection for immunotherapy? Sci Rep 2:765, 2012.\" href=\"#_ENREF_278\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23097687\"><sup>278</sup></a>. However, the subset of melanoma tumors characterized by the presence of T cell infiltrates show activation of three immunosuppressive markers: indoleamine-2,3-dioxygenase (IDO), PD-L1, and FoxP3(+) regulatory T cells (Tregs). Moreover, expression of these actually was shown to be secondary to the infiltration of CD8+ T cells, implying that the immune system rather than the tumor initiates the creation of immunosuppressive environment <a class=\"rlc-reference\" data-ref-info=\"Spranger S, Spaapen RM, Zha Y, et al: Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells. Sci Transl Med 5:200ra116, 2013.\" href=\"#_ENREF_198\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23986400\"><sup>198</sup></a>. Nevertheless, these findings still support the notion that tumors with CD8+ T cell infiltrates could benefit from treatments with immune modulatory antibodies.</p>\n\n\n<h1 id=\"erh-125b182c-3834-45f0-86c1-f58065a0a247\">METABOLISM AND AUTOPHAGY AS TARGETS IN MELANOMA THERAPY</h1>\n\n<p id=\"erb-948b0457-74f0-4f7a-8c75-1ed5e1922b9c\">There have been few attempts to target melanoma metabolism with the exception of several known metabolic preferences listed below. However, recent discoveries, such as high levels of OXPHOS (oxidative phosphorylation) in highly aggressive melanoma mediated by elevated expression of PGC-1a <a class=\"rlc-reference\" data-ref-info=\"Vazquez F, Lim JH, Chim H, et al: PGC1alpha Expression Defines a Subset of Human Melanoma Tumors with Increased Mitochondrial Capacity and Resistance to Oxidative Stress. Cancer Cell, 2013.\" href=\"#_ENREF_59\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23416000\"><sup>59</sup></a> might prompt more interest in targeting melanoma metabolism. For many years, serum lactate dehydrogenase (LDH) levels were used as a predictive factor to identify melanoma patients with worsened prognosis, and they presumably are indicative of the high glycolytic character of tumors, though the energy requirements of melanoma might be fulfilled through a more complex relationship between glycolysis and OXPHOS <a class=\"rlc-reference\" data-ref-info=\"Sonveaux P, Vegran F, Schroeder T, et al: Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J Clin Invest 118:3930-42, 2008.\" href=\"#_ENREF_279\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/19033663\"><sup>279</sup></a>. An OXPHOS inhibitor elesclomol in combination with paclitaxel was clinically tested in a randomized trial in unselected patients. The study was terminated due to increased death in patients with high LDH receiving paclitaxel alone <a class=\"rlc-reference\" data-ref-info=\"O'Day SJ, Eggermont AM, Chiarion-Sileni V, et al: Final Results of Phase III SYMMETRY Study: Randomized, Double-Blind Trial of Elesclomol Plus Paclitaxel Versus Paclitaxel Alone As Treatment for Chemotherapy-Naive Patients With Advanced Melanoma. J Clin Oncol, 2013.\" href=\"#_ENREF_280\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23401447\"><sup>280</sup></a>. However, the study revealed a statistically significant increase in PFS in patients with normal serum levels of LDH receiving elesclomol, that is, a group of patients with tumors that rely on OXPHOS.</p>\n<p id=\"erb-8b9a1f6c-1d88-47fd-92df-9ada17ee9691\">Regarding the possible effects of metabolic preferences of melanoma tumors on the efficacy of targeted therapy, it is of interest that mutant BRAF inhibition might be more efficacious in tumors with higher glycolytic index <sup><a class=\"rlc-reference\" data-ref-info=\"McArthur GA, Puzanov I, Amaravadi R, et al: Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma. J Clin Oncol 30:1628-34, 2012.\" href=\"#_ENREF_158\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22454415\">158</a>,<a class=\"rlc-reference\" data-ref-info=\"Sondergaard JN, Nazarian R, Wang Q, et al: Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032. J Transl Med 8:39, 2010.\" href=\"#_ENREF_170\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/20406486\">170</a></sup>. As mentioned above, this metabolic trait could be useful as a predictive marker of response to BRAF inhibition. In addition, inhibition of BRAF(V600E) appears to induce a switch from glycolytic to OXPHOS metabolism, via induction of MITF, followed by MITF's induction of PGC1\uf061 <a class=\"rlc-reference\" data-ref-info=\"Haq R, Shoag J, Andreu-Perez P, et al: Oncogenic BRAF Regulates Oxidative Metabolism via PGC1alpha and MITF. Cancer Cell 23:302-15, 2013.\" href=\"#_ENREF_162\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23477830\"><sup>162</sup></a>. A consequence of this shift is an apparent dependency of BRAF-inhibited cells upon OXPHOS, thus suggesting new BRAF-combination strategies for patients.</p>\n<p id=\"erb-3721baee-b091-4dfa-b417-1b6c2fb49a11\">The importance of OXPHOS in melanoma resistance to chemotherapy and targeted therapy with Vemurafenib was highlighted in another study that aimed to explore the significance of a subpopulation of melanoma cells expressing H3K4 demethylase JARID1B. JARID1B melanoma cells cycle slowly, but can produce progeny of fast-dividing cells without having other hallmarks of stem cells <a class=\"rlc-reference\" data-ref-info=\"Roesch A, Fukunaga-Kalabis M, Schmidt EC, et al: A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell 141:583-94, 2010.\" href=\"#_ENREF_281\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/20478252\"><sup>281</sup></a>. Deeper analysis of these cells revealed that JARID1B positivity is associated with the post-treatment surviving fraction, and is marked by increased levels of OXPHOS which presumably contributes to their survival <a class=\"rlc-reference\" data-ref-info=\"Roesch A, Vultur A, Bogeski I, et al: Overcoming Intrinsic Multidrug Resistance in Melanoma by Blocking the Mitochondrial Respiratory Chain of Slow-Cycling JARID1B(high) Cells. Cancer Cell 23:811-25, 2013.\" href=\"#_ENREF_282\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23764003\"><sup>282</sup></a>. These resistant cells could be successfully targeted by inhibitors of OXPHOS such as phenformin, similar to findings in the study described above on MITF induction of PGC\uf061.</p>\n<p id=\"erb-1622a362-4cab-4e12-9c58-19b44bb30c0c\">A most interesting study implicated enzyme PDH (pyruvate dehydrogenase) that links glycolysis to OXPHOS in the abrogation of mutant BRAF induced senescence (OIS). Oxygen consumption was increased in senescent cells modified to express mutant BRAF, which was mediated by activated PDH. Two key PDH regulating enzymes were involved in the observed activation of PDH: inhibitory PDK1 was suppressed, while activating PDP2 was upregulated. Ectopic expression of PDK1 was able to overcome BRAF induced senescence of melanocytes and promote robust tumor growth in vivo. Moreover, PDK1 depletion in melanoma tumors dramatically increased their sensitivity to vemurafenib in vivo by eliminating subpopulation of cells resistance to the drug <a class=\"rlc-reference\" data-ref-info=\"Kaplon J, Zheng L, Meissl K, et al: A key role for mitochondrial gatekeeper pyruvate dehydrogenase in oncogene-induced senescence. Nature, 2013.\" href=\"#_ENREF_283\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23685455\"><sup>283</sup></a>. These results established a direct role for metabolic axis in the development and drug resistance of melanomas.</p>\n<p id=\"erb-d9261a35-ce24-474f-a0d2-10680bfa5ede\">The role of autophagy in tumor development and responses to various treatments remains controversial, most likely due to the fact that autophagy can contribute either to death or survival of cancer cells depending on the nature of the death signal and cellular context. Deprivation of amino acids is considered to be of potential benefit in melanoma treatment due to specific metabolic preferences/dependency of melanoma tumors, but induction of \"starvation-induced\" autophagy could be detrimental.</p>\n\n<p id=\"erb-ffcfcb97-0ea8-46ba-bd88-76fccd621301\"><b>Arginine deprivation. </b>Melanoma tumors, along with hepatocellular cancer (HCC) and prostate cancer, frequently show deficiency of the enzyme argininosuccinate synthetase (ASS) <a class=\"rlc-reference\" data-ref-info=\"Dillon BJ, Prieto VG, Curley SA, et al: Incidence and distribution of argininosuccinate synthetase deficiency in human cancers: a method for identifying cancers sensitive to arginine deprivation. Cancer 100:826-33, 2004.\" href=\"#_ENREF_284\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/14770441\"><sup>284</sup></a>, cannot synthesize arginine from citrulline, and depend on exogenous arginine for survival. Arginine degradation using arginine deiminase (ADI) leads to growth inhibition and eventually cell death, while normal cells that express ASS can survive (reviewed in <a class=\"rlc-reference\" data-ref-info=\"Yoon JK, Frankel AE, Feun LG, et al: Arginine deprivation therapy for malignant melanoma. Clin Pharmacol 5:11-9, 2013.\" href=\"#_ENREF_285\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23293541\"><sup>285</sup></a>). Pegylated ADI (ADI-PEG20) has shown antitumor activity in\u00a0melanoma [183]. Another arginine degrading enzyme, arginase, in a recombinant pegylated and cobalt-substituted form, Co-ArgI-PEG, is being developed for clinical trials. It is already clear that treatment with ADI-PEG20 induces resistance in patients by at least two identified mechanisms: induction of protective autophagy and re-expression of ASS and activation of the MAPK pathway (reviewed in Yoon, et al, 2013 <a class=\"rlc-reference\" data-ref-info=\"Yoon JK, Frankel AE, Feun LG, et al: Arginine deprivation therapy for malignant melanoma. Clin Pharmacol 5:11-9, 2013.\" href=\"#_ENREF_285\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23293541\"><sup>285</sup></a>). If arginine deprivation therapy with arginine-degrading enzymes is to become a valid therapeutic option, concurrent therapies targeting autophagy or the MAPK pathway should be considered.</p>\n\n<p id=\"erb-11e90b5c-c63d-49a2-a687-8532023d90ad\"><b>Leucine deprivation.</b> Leucine deprivation was also shown to induce apoptotic death in melanoma cells; moreover, the dependence of melanoma cells on leucine was functionally linked to the activated RAS-MAPK pathway, in particular BRAFV600E mutation. The latter rendered the mTOR pathway resistant to leucine deprivation, but inhibition of autophagy was able to restore sensitivity of these cells to leucine deprivation. Dietary leucine deprivation combined with an inhibitor of autophagy suppressed melanoma xenograft growth <i>in vivo</i> <a class=\"rlc-reference\" data-ref-info=\"Sheen JH, Zoncu R, Kim D, et al: Defective regulation of autophagy upon leucine deprivation reveals a targetable liability of human melanoma cells in vitro and in vivo. Cancer Cell 19:613-28, 2011.\" href=\"#_ENREF_286\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/21575862\"><sup>286</sup></a>.</p>\n\n<p id=\"erb-fb1ed472-f289-43f9-99e3-103d680905fb\"><b>Autophagy </b>is a potential target in melanoma.<b> </b>However, drug-induced autophagy could be either suicidal or protective, which is reflected in the ongoing clinical studies. Metformin was shown to induce suicidal autophagy in melanoma cells <i>in vitro</i> and <i>in vivo</i> <a class=\"rlc-reference\" data-ref-info=\"Tomic T, Botton T, Cerezo M, et al: Metformin inhibits melanoma development through autophagy and apoptosis mechanisms. Cell Death Dis 2:e199, 2011.\" href=\"#_ENREF_287\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/21881601\"><sup>287</sup></a>. Metformin,<b> </b>an inhibitor of mitochondrial complex I, activates AMPK as a result of decreased AMP/ATP ratio, and inhibits mTOR. Long known for its antihyperglycemic properties, it is being explored for antineoplastic activities. A trial of metformin with vemurafenib is ongoing (<a href=\"http://clinicaltrials.gov/ct2/results?term=NCT01638676\">NCT01638676</a>). On the other hand, the old antimalarial drug hydroxychloroquine, an inhibitor of autophagy, is also trialed with vemurafenib (<a href=\"http://clinicaltrials.gov/ct2/show/NCT01897116\">NCT01897116</a>).</p>\n\n<p id=\"erb-f6d941c5-24f2-4589-bffb-5abbf42ef615\">Because autophagy is known to be involved in both innate and adaptive immunity, there is an interest in exploring manipulation of autophagy for immunotherapy. Autophagy was reported to enhance antigen presentation by dendritic cells, therefore potentiating T cell activation, and could be enhanced by nanoparticle-based antigen presentation <a class=\"rlc-reference\" data-ref-info=\"Li H, Li Y, Jiao J, et al: Alpha-alumina nanoparticles induce efficient autophagy-dependent cross-presentation and potent antitumour response. Nat Nanotechnol 6:645-50, 2011.\" href=\"#_ENREF_288\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/21926980\"><sup>288</sup></a>; autophagosome preparations enriched for tumor antigens were used to pulse dendritic cells for successful vaccination of tumor-bearing mice <a class=\"rlc-reference\" data-ref-info=\"Li Y, Wang LX, Pang P, et al: Tumor-derived autophagosome vaccine: mechanism of cross-presentation and therapeutic efficacy. Clin Cancer Res 17:7047-57, 2011.\" href=\"#_ENREF_289\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22068657\"><sup>289</sup></a>. On the other hand, inhibition of autophagy was shown to promote antitumor responses to systemic IL-2 immunotherapy <sup><a class=\"rlc-reference\" data-ref-info=\"Liang X, De Vera ME, Buchser WJ, et al: Inhibiting systemic autophagy during interleukin 2 immunotherapy promotes long-term tumor regression. Cancer Res 72:2791-801, 2012.\" href=\"#_ENREF_290\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22472122\">290</a>,<a class=\"rlc-reference\" data-ref-info=\"Lotze MT, Buchser WJ, Liang X: Blocking the interleukin 2 (IL2)-induced systemic autophagic syndrome promotes profound antitumor effects and limits toxicity. Autophagy 8:1264-6, 2012.\" href=\"#_ENREF_291\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22660171\">291</a></sup>. Apparently, the specific roles of autophagy in different immune responses would have to be explored individually.</p>\n\n<h1 id=\"erh-406b93a9-9d6c-47e9-b0bf-3ce042f2f20f\">NEW PROGNOSTIC MARKERS</h1>\n<p id=\"erb-b1d46d9b-81fe-45d1-8dd7-8fdf5f46c5a9\"><b>Circulating Melanoma Cells</b></p>\n<p id=\"erb-e337d070-f1b0-48b6-8878-cb6339d0925c\">Detection of circulating tumor cells (CTC) in melanoma was explored for at least last twenty years. CTC have been shown to serve as seeds for metastatic lesions, and therefore their presence could be interpreted as a prognostic marker. In addition, monitoring of CTC levels could serve as a marker of disease progression and treatment success or failure (reviewed in<sup><a class=\"rlc-reference\" data-ref-info=\"Ireland A, Millward M, Pearce R, et al: Genetic factors in metastatic progression of cutaneous melanoma: the future role of circulating melanoma cells in prognosis and management. Clin Exp Metastasis 28:327-36, 2011.\" href=\"#_ENREF_292\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/21311956\">292</a>,<a class=\"rlc-reference\" data-ref-info=\"Tanaka R, Koyanagi K, Narita N, et al: Prognostic molecular biomarkers for cutaneous malignant melanoma. J Surg Oncol 104:438-46, 2011.\" href=\"#_ENREF_293\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/21557225\">293</a></sup>). Molecular profiling of CTC could become a \u201cliquid biopsy\u201d, and could reflect genetic heterogeneity, both intratumoral or between multiple metastatic tumors.</p>\n<p id=\"erb-8ad4859d-2975-4e8a-b477-2acc6602287e\">The earlier attempts were directed mostly towards developing a multimarker RT-PCR to detect and monitor the presence of circulating tumor cells (CTC) in the bloodstream. The first detection of melanoma CTC was based on RT-PCR of tyrosinase <a class=\"rlc-reference\" data-ref-info=\"Smith B, Selby P, Southgate J, et al: Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction. Lancet 338:1227-9, 1991.\" href=\"#_ENREF_294\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/1719320\"><sup>294</sup></a>. Numerous studies have employed RT-PCR of a variety of melanoma markers to analyze peripheral blood preparations and examine prognostic significance of these assays. For example, a serial analysis of two melanoma-associated markers (tyrosinase and MART-1) was shown to be an independent predictor of disease recurrence for stage IV melanoma patients after surgery and adjuvant therapy <a class=\"rlc-reference\" data-ref-info=\"Mocellin S, Del Fiore P, Guarnieri L, et al: Molecular detection of circulating tumor cells is an independent prognostic factor in patients with high-risk cutaneous melanoma. Int J Cancer 111:741-5, 2004.\" href=\"#_ENREF_295\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/15252844\"><sup>295</sup></a>. A study that performed serial analysis of CTC using a five-marker RT-PCR (MART-1, GalNAc-T, PAX-3, MITF and MAGE-A3) concluded that it could be useful for prognostic purposes <a class=\"rlc-reference\" data-ref-info=\"Koyanagi K, O'Day SJ, Boasberg P, et al: Serial monitoring of circulating tumor cells predicts outcome of induction biochemotherapy plus maintenance biotherapy for metastatic melanoma. Clin Cancer Res 16:2402-8, 2010.\" href=\"#_ENREF_296\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/20371696\"><sup>296</sup></a>. CTC assessment with three markers - MART-1, MAGE-A3, and PAX3 - provided prognostic discrimination before and during adjuvant treatment for resected stage IV melanoma patients <a class=\"rlc-reference\" data-ref-info=\"Hoshimoto S, Faries MB, Morton DL, et al: Assessment of prognostic circulating tumor cells in a phase III trial of adjuvant immunotherapy after complete resection of stage IV melanoma. Ann Surg 255:357-62, 2012.\" href=\"#_ENREF_297\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22202581\"><sup>297</sup></a>. Similarly, a stage III clinical trial found that positivity for at least two out of three CTC biomarkers (MART-1, GalNAc-T and MAGE-A3) examined was significantly associated with decreased recurrence-free survival in patients with stage II melanoma and metastases to sentinel lymph nodes <a class=\"rlc-reference\" data-ref-info=\"Hoshimoto S, Shingai T, Morton DL, et al: Association between circulating tumor cells and prognosis in patients with stage III melanoma with sentinel lymph node metastasis in a phase III international multicenter trial. J Clin Oncol 30:3819-26, 2012.\" href=\"#_ENREF_298\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23008288\"><sup>298</sup></a>. These CTC markers were deemed to be useful in selecting patients for aggressive adjuvant treatments. A different set of CTC markers (MLANA, ABCB5, TGFbeta2, PAX3d and MCAM) was examined, and two of them (MLANA and ABCB5) were also found to be useful in predicting disease status <a class=\"rlc-reference\" data-ref-info=\"Reid AL, Millward M, Pearce R, et al: Markers of circulating tumour cells in the peripheral blood of patients with melanoma correlate with disease recurrence and progression. Br J Dermatol 168:85-92, 2013.\" href=\"#_ENREF_299\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23013138\"><sup>299</sup></a>. At the same time, analysis of cytokine receptors expression in CTC had no predictive significance for treatment outcomes <a class=\"rlc-reference\" data-ref-info=\"Fusi A, Liu Z, Kummerlen V, et al: Expression of chemokine receptors on circulating tumor cells in patients with solid tumors. J Transl Med 10:52, 2012.\" href=\"#_ENREF_300\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22433180\"><sup>300</sup></a>, possibly due to the choice markers. Overall, the many studies performed indicate that a validated set of CTC biomarkers as well as standardized methodology is necessary to make RT-PCR analysis of CTC a useful tool in assessment of melanoma prognosis. For now, RT-PCR of peripheral blood is not considered to be highly promising.</p>\n<p id=\"erb-6860dca3-566b-43ad-a332-733cab69f137\">A different approach involves physical separation of CTC prior to their analyses. This methodology is somewhat limited by its most often used approach, which relies on expression of certain surface proteins on circulating tumor cells for their identification and separation. CellSearch Veridex technology, widely used for the detection of circulating tumor cells (CTC) in blood was designed for breast, prostate, colorectal, and lung cancer, which express EpCAM markers. Continuing expression of these proteins on CTC could not be counted upon when de-differentiation (such as epithelial to mesenchyme transition in epithelial cancers) occurs during tumor progression. Nevertheless, use of CellSearch platform was reported to detect CTC in 40% of patients with advanced melanoma, and the numbers of CTC were prognostic in themselves for overall survival and reflect treatments\u2019 outcomes <a class=\"rlc-reference\" data-ref-info=\"Khoja L, Lorigan P, Zhou C, et al: Biomarker Utility of Circulating Tumor Cells in Metastatic Cutaneous Melanoma. J Invest Dermatol, 2012.\" href=\"#_ENREF_301\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23223143\"><sup>301</sup></a>. The CellSearch Veridex platform was recently adapted for melanoma markers, and was reported to be successful in detection and quantification of CTC in cerebrospinal fluid in two melanoma patients with leptomeningial metastases <a class=\"rlc-reference\" data-ref-info=\"Le Rhun E, Tu Q, De Carvalho Bittencourt M, et al: Detection and quantification of CSF malignant cells by the CellSearch technology in patients with melanoma leptomeningeal metastasis. Med Oncol 30:538, 2013.\" href=\"#_ENREF_302\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23504338\"><sup>302</sup></a></p>\n<p id=\"erb-98f969d9-63dc-40d9-9745-300db5693301\">New techniques are being developed, such as isolation by size of epithelial tumor cells (ISET), which was able to detect CTC in 29% of patients with primary invasive melanoma and in 62.5% of metastatic melanoma patients, with an excellent correlation for detection of CTC by RT-PCR of tyrosinase <a class=\"rlc-reference\" data-ref-info=\"De Giorgi V, Pinzani P, Salvianti F, et al: Application of a filtration- and isolation-by-size technique for the detection of circulating tumor cells in cutaneous melanoma. J Invest Dermatol 130:2440-7, 2010.\" href=\"#_ENREF_303\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/20535130\"><sup>303</sup></a>. Results obtained with ISET should be, however, considered carefully, because circulating melanocytes were detected in blood of a patient with a untypical melanocytic lesion <a class=\"rlc-reference\" data-ref-info=\"De Giorgi V, Pinzani P, Salvianti F, et al: Circulating benign nevus cells detected by ISET technique: warning for melanoma molecular diagnosis. Arch Dermatol 146:1120-4, 2010.\" href=\"#_ENREF_304\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/20956643\"><sup>304</sup></a>. A new technique named photoacoustic blood cancer testing was successfully applied to melanoma CTC in mice and spiked human blood and could be used to capture CTC <sup><a class=\"rlc-reference\" data-ref-info=\"Galanzha EI, Shashkov EV, Spring PM, et al: In vivo, noninvasive, label-free detection and eradication of circulating metastatic melanoma cells using two-color photoacoustic flow cytometry with a diode laser. Cancer Res 69:7926-34, 2009.\" href=\"#_ENREF_305\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/19826056\">305</a>,<a class=\"rlc-reference\" data-ref-info=\"O'Brien CM, Rood KD, Bhattacharyya K, et al: Capture of circulating tumor cells using photoacoustic flowmetry and two phase flow. J Biomed Opt 17:061221, 2012.\" href=\"#_ENREF_306\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22734751\">306</a></sup>. A recent report described a method to detect and isolate single circulating melanoma cells that integrates a polymer-nanofiber-embedded nanovelcro cell-affinity assay with a laser microdissection (LMD) technique. This method not only separates melanoma CTC from peripheral blood, but also allows sequencing of individual cells for specific mutations <a class=\"rlc-reference\" data-ref-info=\"Hou S, Zhao L, Shen Q, et al: Polymer nanofiber-embedded microchips for detection, isolation, and molecular analysis of single circulating melanoma cells. Angew Chem Int Ed Engl 52:3379-83, 2013.\" href=\"#_ENREF_307\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23436302\"><sup>307</sup></a>.</p>\n<p id=\"erb-4ab02aab-05d6-4bf3-bd31-b87acba8c853\">The inertial focusing-enhanced microfluidic CTC capture platform, termed \"CTC-iChip\" is capable of rapid sorting of rare CTCs from whole blood. The iChip technology is capable of isolating CTCs using strategies that involve recognition of extracellular epitopes, but could be used independently of tumor-specific membrane protein recognition <a class=\"rlc-reference\" data-ref-info=\"Ozkumur E, Shah AM, Ciciliano JC, et al: Inertial focusing for tumor antigen-dependent and -independent sorting of rare circulating tumor cells. Sci Transl Med 5:179ra47, 2013.\" href=\"#_ENREF_308\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23552373\"><sup>308</sup></a>. The methodology was successfully tested in epithelial cancer and melanoma, and enables RNA profiling of single cells. Isolation of CTC using the ScreenCell filtration technique with quantitative analysis of CTC telomeres by TeloView was described recently <a class=\"rlc-reference\" data-ref-info=\"Adebayo Awe J, Xu MC, Wechsler J, et al: Three-Dimensional Telomeric Analysis of Isolated Circulating Tumor Cells (CTCs) Defines CTC Subpopulations. Transl Oncol 6:51-65, 2013.\" href=\"#_ENREF_309\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23418617\"><sup>309</sup></a>.</p>\n<p id=\"erb-338be80b-e2df-4b68-942e-1a461ce2d3a7\">Molecular profiling of CTC might provide a very valuable representation of a tumor(s) genotype because CTC presumably reflect tumor heterogeneity better than a single tumor biopsy. Indeed, several studies have discovered discordant mutations in CTC versus biopsies. Inconsistencies of BRAF and KIT mutations between tumor biopsies and CTC were described <sup><a class=\"rlc-reference\" data-ref-info=\"Fusi A, Berdel R, Havemann S, et al: Enhanced detection of BRAF-mutants by pre-PCR cleavage of wild-type sequences revealed circulating melanoma cells heterogeneity. Eur J Cancer 47:1971-6, 2011.\" href=\"#_ENREF_310\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/21570823\">310</a>,<a class=\"rlc-reference\" data-ref-info=\"Sakaizawa K, Goto Y, Kiniwa Y, et al: Mutation analysis of BRAF and KIT in circulating melanoma cells at the single cell level. Br J Cancer 106:939-46, 2012.\" href=\"#_ENREF_311\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22281663\">311</a></sup>. Presumably, CTCs also represent tumor cells with higher metastatic potential, and thus could be more relevant to the molecular profiling of aggressive tumor variants or metastases.</p>\n<p id=\"erb-725bd76f-20d9-4015-a5fa-f513e15e7c7b\">Several clinical trials are ongoing that incorporate CTC detection and analyses prior to and after treatments to investigate the prognostic value of CTC. The CellSearch Veridex technique will be evaluated in terms of its predictive and prognostic ability (<a href=\"http://clinicaltrials.gov/ct2/results?term=NCT01573494&amp;Search=Search\">NCT01573494</a>). CellSearch and Epispot (another platform based on immunomagnetic separation) are compared in <a href=\"http://clinicaltrials.gov/ct2/show/NCT01558349\">NCT01558349</a>. Trial <a href=\"http://clinicaltrials.gov/show/NCT01528774\">NCT01528774</a> addresses the possibility of long term culture of melanoma CTCs isolated using TrueCells technology. A future trial <a href=\"http://www.clinicaltrials.gov/ct2/show/NCT01776905\">NCT01776905</a> will evaluate use of photoacoustic flow cytometry for in vivo, real time detection of CTC. Treatment with ipilimumab and stereotactic ablative radiation therapy (<a href=\"http://clinicaltrials.gov/show/NCT01565837\">NCT01565837</a>) or with Sargamostim/GM-CSF will include analysis of CTC as a predictive/prognostic markers (<a href=\"http://clinicaltrials.gov/ct2/show/NCT01489423\">NCT01489423</a>). Multiple parameters including CTC are evaluated in an ongoing trial of Imatininb (<a href=\"http://clinicaltrials.gov/show/NCT00470470\">NCT00470470</a>).</p>\n<p id=\"erb-28b958d7-c6fe-49d4-a11f-87c177e5cd3e\">Recent studies have addressed the utility of yet another method of \u201cliquid biopsy\u201d, i.e. analysis of circulating tumor DNA (ctDNA) by NGS techniques rather than RT-PCR of defined biomarkers. A side-by-side comparison was performed of the analyses for a serum biomarker versus analysis of CTC versus analysis of ctDNA by targeted or whole genomic sequence in breast cancer patients. This study reported the superiority of ctDNA analysis, as having a greater dynamic range, a greater correlation with changes in tumor burden, and better measure of treatment response <a class=\"rlc-reference\" data-ref-info=\"Dawson SJ, Tsui DW, Murtaza M, et al: Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med 368:1199-209, 2013.\" href=\"#_ENREF_312\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23484797\"><sup>312</sup></a>. The next publication from the same group reported monitoring of ctDNA by exomic sequencing in breast cancer patients prior to and during treatments <a class=\"rlc-reference\" data-ref-info=\"Murtaza M, Dawson SJ, Tsui DW, et al: Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature, 2013.\" href=\"#_ENREF_313\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23563269\"><sup>313</sup></a>. Serial analysis of ctDNA had successfully detected a number of prognostic genomic alterations that were either increased or appeared de novo as a consequence of treatments. It remains to be seen if detection of ctDNA will be a useful prognostic companion or even a substitute for tumor biopsies.</p>\n\n<p id=\"erb-bc22a9bf-2e57-44b5-a6ad-529ebc19d3af\"><b>Prognostic test for uveal melanoma</b></p>\n<p id=\"erb-e85fb44c-872c-43d0-a8c0-5376e8fcd8c3\">Uveal melanoma is a distinct type of melanoma with a clinical course and molecular landscape of its own. Even though patients rarely present with metastatic disease and are routinely subjected to surgery with curative intent, almost half have a high-risk disease that requires careful monitoring and/or adjuvant therapy after tumor resection. It has been difficult to stratify patients into high- versus low risk of metastatic disease based on clinicopathological findings only.</p>\n<p id=\"erb-bdadd597-a6d1-432f-b739-1fd6550b3c63\">DecisionDx-UM gene expression profile test was developed as a stand-alone platform, which requires no other information for prognostic accuracy. The test is PCR-based and measures the expression of 12 selected genes from primary uveal melanoma samples obtained by fine needle biopsy. The test allows patients to be stratified into risk categories such that high-risk patients can be offered intensive metastatic surveillance and adjuvant therapy while low-risk patients can be spared unnecessary chemotherapy and frequent monitoring <a class=\"rlc-reference\" data-ref-info=\"Harbour JW, Chen R: The DecisionDx-UM Gene Expression Profile Test Provides Risk Stratification and Individualized Patient Care in Uveal Melanoma. PLoS Curr 5, 2013.\" href=\"#_ENREF_314\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/23591547\"><sup>314</sup></a>.</p>\n\n<p id=\"erb-8434eba1-1772-41bc-b9d8-8689045c92fc\"><b>Exosomes.</b></p>\n<p id=\"erb-9bd2368b-8833-4e59-b64c-6119477fb502\">Exosomes are small membrane vesicles with an endosome origin that are released by cells into the extracellular environment. They could fuse with other cells thereby transferring the RNAs and proteins they carry. Tumor-derived exosomes are emerging mediators of tumorigenesis; there is a growing interest in exploring treatment options targeting exosomes. Exosomes are thought to participate in the formation of pre-metastatic niche, i.e. specific microenvironment that is re-programmed to support survival and growth of metastatic cells. There has been significant interest in exploring the role of exosomes as prognostic markers (reviewed in <a class=\"rlc-reference\" data-ref-info=\"Ohno S, Ishikawa A, Kuroda M: Roles of exosomes and microvesicles in disease pathogenesis. Adv Drug Deliv Rev 65:398-401, 2013.\" href=\"#_ENREF_315\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22981801\"><sup>315</sup></a>). A recent exciting study analyzed exosomes from highly metastatic melanomas. It found that these \"metastatic\" exosomes increased the invasive behavior of primary tumors by permanently \"educating\" bone marrow progenitors through the receptor tyrosine kinase MET. Melanoma-derived exosomes also induced vascular leakiness at premetastatic sites and reprogrammed bone marrow progenitors toward a pro-vasculogenic phenotype. Reducing MET expression in exosomes diminished the prometastatic behavior of bone marrow cells. Notably, MET expression was elevated in circulating bone marrow progenitors from individuals with metastatic melanoma. The study identified an exosome-specific melanoma signature with prognostic and therapeutic potential comprised of TYRP2, VLA-4, HSP70 (HSP90) isoform, and the MET oncoprotein <a class=\"rlc-reference\" data-ref-info=\"Peinado H, Aleckovic M, Lavotshkin S, et al: Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med 18:883-91, 2012.\" href=\"#_ENREF_316\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22635005\"><sup>316</sup></a>.</p>\n\n<h1 id=\"erh-bea4a42a-fd00-4aa3-b71e-331bb7aca6fe\">CONCLUDING REMARKS</h1>\n<p id=\"erb-231ecf21-327a-4502-a575-a1fd13621403\">It is very likely, considering the most recent findings, that the majority of driver mutations in melanoma have been identified. The study most quoted in this paper <a class=\"rlc-reference\" data-ref-info=\"Hodis E, Watson IR, Kryukov GV, et al: A landscape of driver mutations in melanoma. Cell 150:251-63, 2012.\" href=\"#_ENREF_31\" url=\"http://www.ncbi.nlm.nih.gov/pubmed/22817889\"><sup>31</sup></a> reported that, outside of the most frequent mutations in BRAF and NRAS, driver mutations were identified in 83% of remaining BRAF and NRAS wild-type tumors. These results will be confirmed in much larger cohorts of melanoma tumors; some changes (identification of new rare driver or helper mutations) could be anticipated. However, while many genetic alterations in melanoma have been identified, the issue of tumor heterogeneity, within different tumors in the same patient, or even within individual tumor, could be expected to be a big problem both in melanoma biology and clinical approaches.</p>\n<p id=\"erb-1d08c934-d472-4d0c-9dc0-09dcb784e9cd\">However, the accumulated knowledge is already sufficient to concentrate on the biological significance of genetic aberrations identified in melanoma and to evaluate their suitability as targets. Combination therapies are obviously the way of the future and might include two or more targeted therapies in combination with immunotherapies. One can also envision combinations that include novel therapies that target basic processes (<i>e.g.</i>, metabolism, autophagy) that are sufficiently deranged in melanoma compared to normal cells.</p>\n<p id=\"erb-50f66d75-4c53-48d9-95c0-37e4640f42ac\">The ubiquitous problem of resistance to targeted therapies could only be addressed by dedicated profiling of both inherent and acquired molecular features associated with resistance. This is a valid approach to either forestalling or overcoming resistance to targeted inhibitors, which is the biggest obstacle to development of meaningful precision treatment approaches in melanoma and other cancers.</p>\n\n\n<h1 id=\"erh-63096cf1-4daf-4b19-916c-09012502806d\">REFERENCES</h1>\n<p id=\"erb-0c0464c7-5906-41e1-bc4f-c923be3cf503\"><a name=\"_ENREF_1\"></a> 1. Berger MF, Hodis E, Heffernan TP, et al: Melanoma genome sequencing reveals frequent PREX2 mutations. Nature 485:502-6, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22622578\">http://www.ncbi.nlm.nih.gov/pubmed/22622578</a></p>\n<p id=\"erb-3397dbd1-ccba-4140-adf1-ee718395a0d0\"><a name=\"_ENREF_2\"></a> 2. Furney SJ, Pedersen M, Gentien D, et al: SF3B1 mutations are associated with alternative splicing in uveal melanoma. Cancer Discov, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23861464\">http://www.ncbi.nlm.nih.gov/pubmed/23861464</a></p>\n<p id=\"erb-690cd9f1-022c-4aea-826e-70f494cc1ba6\"><a name=\"_ENREF_3\"></a> 3. Mar VJ, Wong SQ, Li J, et al: BRAF/NRAS wild-type melanomas have a high mutation load correlating with histological and molecular signatures of UV damage. Clin Cancer Res, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23833303\">http://www.ncbi.nlm.nih.gov/pubmed/23833303</a></p>\n<p id=\"erb-eb6efe72-0aa2-4194-8df1-e230f5e12f95\"><a name=\"_ENREF_4\"></a> 4. Furney SJ, Turajlic S, Stamp G, et al: Genome sequencing of mucosal melanomas reveals that they are driven by distinct mechanisms from cutaneous melanoma. J Pathol 230:261-9, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23620124\">http://www.ncbi.nlm.nih.gov/pubmed/23620124</a></p>\n<p id=\"erb-7ea96a42-fb58-4667-9eaa-f9f941483038\"><a name=\"_ENREF_5\"></a> 5. Griewank KG, Westekemper H, Murali R, et al: Conjunctival Melanomas Harbor BRAF and NRAS Mutations and Copy Number Changes Similar to Cutaneous and Mucosal Melanomas. Clin Cancer Res 19:3143-3152, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23633454\">http://www.ncbi.nlm.nih.gov/pubmed/23633454</a></p>\n<p id=\"erb-d28469d3-be11-47e0-9e6c-aabad8c6ff72\"><a name=\"_ENREF_6\"></a> 6. Pollock PM, Harper UL, Hansen KS, et al: High frequency of BRAF mutations in nevi. Nat Genet 33:19-20, 2003. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/12447372\">http://www.ncbi.nlm.nih.gov/pubmed/12447372</a></p>\n<p id=\"erb-d53d77fe-0f9d-4d53-936b-92e2bf7821e4\"><a name=\"_ENREF_7\"></a> 7. Michaloglou C, Vredeveld LC, Soengas MS, et al: BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 436:720-4, 2005. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/16079850\">http://www.ncbi.nlm.nih.gov/pubmed/16079850</a></p>\n<p id=\"erb-e143f4d8-17e9-4fe5-9979-079f4b3a28c7\"><a name=\"_ENREF_8\"></a> 8. Flaherty KT, Hodi FS, Fisher DE: From genes to drugs: targeted strategies for melanoma. Nat Rev Cancer 12:349-61, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22475929\">http://www.ncbi.nlm.nih.gov/pubmed/22475929</a></p>\n<p id=\"erb-82561da6-db18-41f9-a4e7-0e355bee64e4\"><a name=\"_ENREF_9\"></a> 9. Flaherty KT, Puzanov I, Kim KB, et al: Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363:809-19, 2010. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/20818844\">http://www.ncbi.nlm.nih.gov/pubmed/20818844</a></p>\n<p id=\"erb-0537eb74-e575-43b5-8557-8f06f7ecab9b\"><a name=\"_ENREF_10\"></a> 10. Jordan EJ, Kelly CM: Vemurafenib for the treatment of melanoma. Expert Opin Pharmacother 13:2533-43, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23094782\">http://www.ncbi.nlm.nih.gov/pubmed/23094782</a></p>\n<p id=\"erb-1d655272-6716-4f96-bf01-0ddee49b6a52\"><a name=\"_ENREF_11\"></a> 11. Alloo A, Garibyan L, LeBoeuf N, et al: Photodynamic therapy for multiple eruptive keratoacanthomas associated with vemurafenib treatment for metastatic melanoma. Arch Dermatol 148:363-6, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22431777\">http://www.ncbi.nlm.nih.gov/pubmed/22431777</a></p>\n<p id=\"erb-b7999240-5d75-4a4d-a8ab-0568e4d42801\"><a name=\"_ENREF_12\"></a> 12. Callahan MK, Rampal R, Harding JJ, et al: Progression of RAS-mutant leukemia during RAF inhibitor treatment. N Engl J Med 367:2316-21, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23134356\">http://www.ncbi.nlm.nih.gov/pubmed/23134356</a></p>\n<p id=\"erb-c49246af-c6b9-45c4-ab15-2b8447b3dfb8\"><a name=\"_ENREF_13\"></a> 13. Gibney GT, Messina JL, Fedorenko IV, et al: Paradoxical oncogenesis-the long-term effects of BRAF inhibition in melanoma. Nat Rev Clin Oncol, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23712190\">http://www.ncbi.nlm.nih.gov/pubmed/23712190</a></p>\n<p id=\"erb-d18ee6d1-6445-4c8e-a047-37535dbd61a0\"><a name=\"_ENREF_14\"></a> 14. Poulikakos PI, Zhang C, Bollag G, et al: RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 464:427-30, 2010. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/20179705\">http://www.ncbi.nlm.nih.gov/pubmed/20179705</a></p>\n<p id=\"erb-e0cfb3b3-a7a6-4199-8cca-4c2d980d090d\"><a name=\"_ENREF_15\"></a> 15. Dalle S, Poulalhon N, Debarbieux S, et al: Second primary melanomas under vemurafenib. Br J Dermatol, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23066856\">http://www.ncbi.nlm.nih.gov/pubmed/23066856</a></p>\n<p id=\"erb-658aebc8-a41f-4f9e-80e9-06f40588ca07\"><a name=\"_ENREF_16\"></a> 16. Zimmer L, Hillen U, Livingstone E, et al: Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition. J Clin Oncol 30:2375-83, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22614973\">http://www.ncbi.nlm.nih.gov/pubmed/22614973</a></p>\n<p id=\"erb-3c819248-7371-4f91-ac8c-1a683fe1b62a\"><a name=\"_ENREF_17\"></a> 17. Holderfield M, Merritt H, Chan J, et al: RAF Inhibitors Activate the MAPK Pathway by Relieving Inhibitory Autophosphorylation. Cancer Cell 23:594-602, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23680146\">http://www.ncbi.nlm.nih.gov/pubmed/23680146</a></p>\n<p id=\"erb-b79af6ac-70ee-4103-ad79-3f579bbd24ae\"><a name=\"_ENREF_18\"></a> 18. Ascierto PA, Minor D, Ribas A, et al: Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic Melanoma. J Clin Oncol, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23918947\">http://www.ncbi.nlm.nih.gov/pubmed/23918947</a></p>\n<p id=\"erb-40655d9a-1ff0-4987-9d3a-44fda7098362\"><a name=\"_ENREF_19\"></a> 19. Le K, Blomain E, Rodeck U, et al: Selective RAF inhibitor impairs ERK1/2 phosphorylation and growth in mutant NRAS, vemurafenib-resistant melanoma cells. Pigment Cell Melanoma Res, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23490205\">http://www.ncbi.nlm.nih.gov/pubmed/23490205</a></p>\n<p id=\"erb-17409a75-e526-4595-a4b5-6adeea0ab05c\"><a name=\"_ENREF_20\"></a> 20. Das Thakur M, Salangsang F, Landman AS, et al: Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23302800\">http://www.ncbi.nlm.nih.gov/pubmed/23302800</a></p>\n<p id=\"erb-094b3409-8d96-4d9c-bfe5-2f13344c711f\"><a name=\"_ENREF_21\"></a> 21. Falchook GS, Lewis KD, Infante JR, et al: Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol 13:782-9, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22805292\">http://www.ncbi.nlm.nih.gov/pubmed/22805292</a></p>\n<p id=\"erb-b1a0a665-7535-44b7-a483-6e8306d1ebcf\"><a name=\"_ENREF_22\"></a> 22. Flaherty KT, Robert C, Hersey P, et al: Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 367:107-14, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22663011\">http://www.ncbi.nlm.nih.gov/pubmed/22663011</a></p>\n<p id=\"erb-823e96d6-1d53-45d6-b19e-34763fd6b185\"><a name=\"_ENREF_23\"></a> 23. Robert C, Dummer R, Gutzmer R, et al: Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study. Lancet Oncol 14:733-40, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23735514\">http://www.ncbi.nlm.nih.gov/pubmed/23735514</a></p>\n<p id=\"erb-33add46d-08a4-4037-b0ff-7f1a88873c67\"><a name=\"_ENREF_24\"></a> 24. Kim KB, Kefford R, Pavlick AC, et al: Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol 31:482-9, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23248257\">http://www.ncbi.nlm.nih.gov/pubmed/23248257</a></p>\n<p id=\"erb-4e0b2272-7dbd-4a1c-a07a-053b32fbe5ea\"><a name=\"_ENREF_25\"></a> 25. Flaherty KT, Infante JR, Daud A, et al: Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 367:1694-703, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23020132\">http://www.ncbi.nlm.nih.gov/pubmed/23020132</a></p>\n<p id=\"erb-ee403280-1e59-48f7-84d0-a614107dc129\"><a name=\"_ENREF_26\"></a> 26. Morris EJ, Jha S, Restaino CR, et al: Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors. Cancer Discov 3:742-50, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23614898\">http://www.ncbi.nlm.nih.gov/pubmed/23614898</a></p>\n<p id=\"erb-36d8a0e6-bd3f-4fc1-b43f-fe3e42e172da\"><a name=\"_ENREF_27\"></a> 27. Davies H, Bignell GR, Cox C, et al: Mutations of the BRAF gene in human cancer. Nature 417:949-54, 2002. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/12068308\">http://www.ncbi.nlm.nih.gov/pubmed/12068308</a></p>\n<p id=\"erb-e94e3464-a728-4c9c-b7fe-2b74bcfde816\"><a name=\"_ENREF_28\"></a> 28. Wan PT, Garnett MJ, Roe SM, et al: Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116:855-67, 2004. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/15035987\">http://www.ncbi.nlm.nih.gov/pubmed/15035987</a></p>\n<p id=\"erb-0559b273-f486-485a-a032-f249f82d3d0f\"><a name=\"_ENREF_29\"></a> 29. Smalley KS, Xiao M, Villanueva J, et al: CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations. Oncogene 28:85-94, 2009. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/18794803\">http://www.ncbi.nlm.nih.gov/pubmed/18794803</a></p>\n<p id=\"erb-7f409e16-5927-4a45-b228-6f93d478c608\"><a name=\"_ENREF_30\"></a> 30. Dahlman KB, Xia J, Hutchinson K, et al: BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors. Cancer Discov 2:791-7, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22798288\">http://www.ncbi.nlm.nih.gov/pubmed/22798288</a></p>\n<p id=\"erb-5daf18f6-8271-4a4d-8d9d-a77b27338eb8\"><a name=\"_ENREF_31\"></a> 31. Hodis E, Watson IR, Kryukov GV, et al: A landscape of driver mutations in melanoma. Cell 150:251-63, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22817889\">http://www.ncbi.nlm.nih.gov/pubmed/22817889</a></p>\n<p id=\"erb-71089432-f265-49c4-85be-af05f22cc6fc\"><a name=\"_ENREF_32\"></a> 32. Ascierto PA, Schadendorf D, Berking C, et al: MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23414587\">http://www.ncbi.nlm.nih.gov/pubmed/23414587</a></p>\n<p id=\"erb-df2eb93c-bf61-4239-a405-9d65d3939915\"><a name=\"_ENREF_33\"></a> 33. Hatzivassiliou G, Haling JR, Chen H, et al: Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers. Nature, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23934108\">http://www.ncbi.nlm.nih.gov/pubmed/23934108</a></p>\n<p id=\"erb-38cc2a9a-958c-4f46-9a91-2500d2303782\"><a name=\"_ENREF_34\"></a> 34. Roberts PJ, Usary JE, Darr DB, et al: Combined PI3K/mTOR and MEK inhibition provides broad antitumor activity in faithful murine cancer models. Clin Cancer Res 18:5290-303, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22872574\">http://www.ncbi.nlm.nih.gov/pubmed/22872574</a></p>\n<p id=\"erb-81dd1e5e-1595-48c5-915a-7c4e0c80b3ec\"><a name=\"_ENREF_35\"></a> 35. Posch C, Moslehi H, Feeney L, et al: Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo. Proc Natl Acad Sci U S A, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23431193\">http://www.ncbi.nlm.nih.gov/pubmed/23431193</a></p>\n<p id=\"erb-c79e7532-04d5-4ab7-be20-ee0aabcd1803\"><a name=\"_ENREF_36\"></a> 36. Kwong LN, Costello JC, Liu H, et al: Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma. Nat Med 18:1503-10, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22983396\">http://www.ncbi.nlm.nih.gov/pubmed/22983396</a></p>\n<p id=\"erb-322e5285-4bf9-4d47-b24f-d1891d582a29\"><a name=\"_ENREF_37\"></a> 37. Barretina J, Caponigro G, Stransky N, et al: The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483:603-7, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22460905\">http://www.ncbi.nlm.nih.gov/pubmed/22460905</a></p>\n<p id=\"erb-7ff008ca-7500-4c49-bf6d-ef4b83eb89ea\"><a name=\"_ENREF_38\"></a> 38. Held MA, Langdon CG, Platt JT, et al: Genotype-selective combination therapies for melanoma identified by high-throughput drug screening. Cancer Discov 3:52-67, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23239741\">http://www.ncbi.nlm.nih.gov/pubmed/23239741</a></p>\n<p id=\"erb-95bbc57d-77a7-4c33-b4da-df89a9f7b678\"><a name=\"_ENREF_39\"></a> 39. Van Raamsdonk CD, Bezrookove V, Green G, et al: Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature 457:599-602, 2009. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/19078957\">http://www.ncbi.nlm.nih.gov/pubmed/19078957</a></p>\n<p id=\"erb-eabe3ef1-921e-4a8d-ad32-e60c9bed4e75\"><a name=\"_ENREF_40\"></a> 40. Van Raamsdonk CD, Griewank KG, Crosby MB, et al: Mutations in GNA11 in uveal melanoma. N Engl J Med 363:2191-9, 2010. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/21083380\">http://www.ncbi.nlm.nih.gov/pubmed/21083380</a></p>\n<p id=\"erb-13799afb-20ee-4c65-8941-5d2d11628b05\"><a name=\"_ENREF_41\"></a> 41. Daniels AB, Lee JE, MacConaill LE, et al: High throughput mass spectrometry-based mutation profiling of primary uveal melanoma. Invest Ophthalmol Vis Sci 53:6991-6, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22977135\">http://www.ncbi.nlm.nih.gov/pubmed/22977135</a></p>\n<p id=\"erb-684e2fbf-4eb8-4d8c-aad3-5b85db2dc58b\"><a name=\"_ENREF_42\"></a> 42. Ho AL, Musi E, Ambrosini G, et al: Impact of combined mTOR and MEK inhibition in uveal melanoma is driven by tumor genotype. PLoS One 7:e40439, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22808163\">http://www.ncbi.nlm.nih.gov/pubmed/22808163</a></p>\n<p id=\"erb-6228190e-b0ba-4551-b697-60bf219d1a36\"><a name=\"_ENREF_43\"></a> 43. Khalili JS, Yu X, Wang J, et al: Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner. Clin Cancer Res 18:4345-55, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22733540\">http://www.ncbi.nlm.nih.gov/pubmed/22733540</a></p>\n<p id=\"erb-f79262c5-9757-491c-a30a-06f100b8a86d\"><a name=\"_ENREF_44\"></a> 44. Wu X, Li J, Zhu M, et al: Protein kinase C inhibitor AEB071 targets ocular melanoma harboring GNAQ mutations via effects on the PKC/Erk1/2 and PKC/NF-kappaB pathways. Mol Cancer Ther 11:1905-14, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22653968\">http://www.ncbi.nlm.nih.gov/pubmed/22653968</a></p>\n<p id=\"erb-8727dc7c-6027-4f80-ad9e-5f02615508c3\"><a name=\"_ENREF_45\"></a> 45. Wu X, Zhu M, Fletcher JA, et al: The protein kinase C inhibitor enzastaurin exhibits antitumor activity against uveal melanoma. PLoS One 7:e29622, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22253748\">http://www.ncbi.nlm.nih.gov/pubmed/22253748</a></p>\n<p id=\"erb-beacb5a8-a535-43b7-a5e4-7b41a814aa3d\"><a name=\"_ENREF_46\"></a> 46. Vaque JP, Dorsam RT, Feng X, et al: A Genome-wide RNAi Screen Reveals a Trio-Regulated Rho GTPase Circuitry Transducing Mitogenic Signals Initiated by G Protein-Coupled Receptors. Mol Cell, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23177739\">http://www.ncbi.nlm.nih.gov/pubmed/23177739</a></p>\n<p id=\"erb-46cfcb38-0e15-4368-9b61-1379bd2cc3e2\"><a name=\"_ENREF_47\"></a> 47. Garraway LA, Widlund HR, Rubin MA, et al: Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 436:117-22, 2005. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/16001072\">http://www.ncbi.nlm.nih.gov/pubmed/16001072</a></p>\n<p id=\"erb-c793c6e3-fd34-4f7a-97df-f69d783385ed\"><a name=\"_ENREF_48\"></a> 48. Yokoyama S, Woods SL, Boyle GM, et al: A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma. Nature 480:99-103, 2011. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22080950\">http://www.ncbi.nlm.nih.gov/pubmed/22080950</a></p>\n<p id=\"erb-3d67adfa-dbc6-4ab2-a973-616477bd4534\"><a name=\"_ENREF_49\"></a> 49. Du J, Widlund HR, Horstmann MA, et al: Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF. Cancer Cell 6:565-76, 2004. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/15607961\">http://www.ncbi.nlm.nih.gov/pubmed/15607961</a></p>\n<p id=\"erb-a484d862-735e-4f0c-99db-1451000357fe\"><a name=\"_ENREF_50\"></a> 50. Zhu S, Wurdak H, Wang Y, et al: A genomic screen identifies TYRO3 as a MITF regulator in melanoma. Proc Natl Acad Sci U S A 106:17025-30, 2009. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/19805117\">http://www.ncbi.nlm.nih.gov/pubmed/19805117</a></p>\n<p id=\"erb-3fac64d3-e0bc-4ebb-bc7f-5209e9ae9683\"><a name=\"_ENREF_51\"></a> 51. Zhao X, Fiske B, Kawakami A, et al: Regulation of MITF stability by the USP13 deubiquitinase. Nat Commun 2:414, 2011. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/21811243\">http://www.ncbi.nlm.nih.gov/pubmed/21811243</a></p>\n<p id=\"erb-4f28c914-13c0-4a3f-b75f-290b4bd46de7\"><a name=\"_ENREF_52\"></a> 52. Busca R, Berra E, Gaggioli C, et al: Hypoxia-inducible factor 1{alpha} is a new target of microphthalmia-associated transcription factor (MITF) in melanoma cells. J Cell Biol 170:49-59, 2005. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/15983061\">http://www.ncbi.nlm.nih.gov/pubmed/15983061</a></p>\n<p id=\"erb-06d4d889-4a6a-4b1d-a3ce-5f4f6e9667d1\"><a name=\"_ENREF_53\"></a> 53. Feige E, Yokoyama S, Levy C, et al: Hypoxia-induced transcriptional repression of the melanoma-associated oncogene MITF. Proc Natl Acad Sci U S A 108:E924-33, 2011. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/21949374\">http://www.ncbi.nlm.nih.gov/pubmed/21949374</a></p>\n<p id=\"erb-798fb3cd-b568-40a1-a33b-cfc50b1d6786\"><a name=\"_ENREF_54\"></a> 54. Hanna SC, Krishnan B, Bailey ST, et al: HIF1alpha and HIF2alpha independently activate SRC to promote melanoma metastases. J Clin Invest 123:2078-93, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23563312\">http://www.ncbi.nlm.nih.gov/pubmed/23563312</a></p>\n<p id=\"erb-cce52907-6e99-46d0-a997-db4ffec2cf0a\"><a name=\"_ENREF_55\"></a> 55. Shah M, Bhoumik A, Goel V, et al: A role for ATF2 in regulating MITF and melanoma development. PLoS Genet 6:e1001258, 2010. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/21203491\">http://www.ncbi.nlm.nih.gov/pubmed/21203491</a></p>\n<p id=\"erb-5329ae0e-42ea-441d-ae58-f65acc6a6213\"><a name=\"_ENREF_56\"></a> 56. Shakhova O, Zingg D, Schaefer SM, et al: Sox10 promotes the formation and maintenance of giant congenital naevi and melanoma. Nat Cell Biol 14:882-90, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22772081\">http://www.ncbi.nlm.nih.gov/pubmed/22772081</a></p>\n<p id=\"erb-7d352cb4-373f-405f-ae3f-681b2059682e\"><a name=\"_ENREF_57\"></a> 57. Puri N, Ahmed S, Janamanchi V, et al: c-Met is a potentially new therapeutic target for treatment of human melanoma. Clin Cancer Res 13:2246-53, 2007. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/17404109\">http://www.ncbi.nlm.nih.gov/pubmed/17404109</a></p>\n<p id=\"erb-c818bc6e-f510-439b-b8b5-2dcbb98cbc0a\"><a name=\"_ENREF_58\"></a> 58. Mascarenhas JB, Littlejohn EL, Wolsky RJ, et al: PAX3 and SOX10 activate MET receptor expression in melanoma. Pigment Cell Melanoma Res 23:225-37, 2010. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/20067553\">http://www.ncbi.nlm.nih.gov/pubmed/20067553</a></p>\n<p id=\"erb-f78377d1-17dd-4bfb-a9bf-6ecab6aa75ed\"><a name=\"_ENREF_59\"></a> 59. Vazquez F, Lim JH, Chim H, et al: PGC1alpha Expression Defines a Subset of Human Melanoma Tumors with Increased Mitochondrial Capacity and Resistance to Oxidative Stress. Cancer Cell, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23416000\">http://www.ncbi.nlm.nih.gov/pubmed/23416000</a></p>\n<p id=\"erb-f88b54d7-e431-4c7c-9852-dd1d3dad33b2\"><a name=\"_ENREF_60\"></a> 60. Shoag J, Haq R, Zhang M, et al: PGC-1 Coactivators Regulate MITF and the Tanning Response. Mol Cell, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23201126\">http://www.ncbi.nlm.nih.gov/pubmed/23201126</a></p>\n<p id=\"erb-d0f02028-57a0-4a22-876d-81526ee0820d\"><a name=\"_ENREF_61\"></a> 61. Haq R, Yokoyama S, Hawryluk EB, et al: BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition. Proc Natl Acad Sci U S A 110:4321-6, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23447565\">http://www.ncbi.nlm.nih.gov/pubmed/23447565</a></p>\n<p id=\"erb-45ac4c66-72a6-4705-8a80-01ab892c7780\"><a name=\"_ENREF_62\"></a> 62. Saez-Ayala M, Montenegro MF, Sanchez-Del-Campo L, et al: Directed Phenotype Switching as an Effective Antimelanoma Strategy. Cancer Cell, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23792190\">http://www.ncbi.nlm.nih.gov/pubmed/23792190</a></p>\n<p id=\"erb-b14cf080-0e71-4466-9008-01156a3a3d5c\"><a name=\"_ENREF_63\"></a> 63. Pogenberg V, Ogmundsdottir MH, Bergsteinsdottir K, et al: Restricted leucine zipper dimerization and specificity of DNA recognition of the melanocyte master regulator MITF. Genes Dev 26:2647-58, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23207919\">http://www.ncbi.nlm.nih.gov/pubmed/23207919</a></p>\n<p id=\"erb-cbacfaad-1bf2-427f-987a-77ef6c8acd72\"><a name=\"_ENREF_64\"></a> 64. Yokoyama S, Feige E, Poling LL, et al: Pharmacologic suppression of MITF expression via HDAC inhibitors in the melanocyte lineage. Pigment Cell Melanoma Res 21:457-63, 2008. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/18627530\">http://www.ncbi.nlm.nih.gov/pubmed/18627530</a></p>\n<p id=\"erb-56a5feb1-4ac7-44de-afc0-631f62cf935f\"><a name=\"_ENREF_65\"></a> 65. Varsano T, Lau E, Feng Y, et al: Inhibition of Melanoma Growth by Small Molecules That Promote the Mitochondrial Localization of ATF2. Clin Cancer Res 19:2710-22, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23589174\">http://www.ncbi.nlm.nih.gov/pubmed/23589174</a></p>\n<p id=\"erb-ccc54ef2-a6d8-407c-8b4f-8bf09803d6c3\"><a name=\"_ENREF_66\"></a> 66. Curtin JA, Busam K, Pinkel D, et al: Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 24:4340-6, 2006. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/16908931\">http://www.ncbi.nlm.nih.gov/pubmed/16908931</a></p>\n<p id=\"erb-a5205fe9-ead8-4827-aeec-ca94eafa430b\"><a name=\"_ENREF_67\"></a> 67. Woodman SE, Davies MA: Targeting KIT in melanoma: a paradigm of molecular medicine and targeted therapeutics. Biochem Pharmacol 80:568-74, 2010. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/20457136\">http://www.ncbi.nlm.nih.gov/pubmed/20457136</a></p>\n<p id=\"erb-c052a5f3-99c5-41d2-8cce-ca7f76c1c70e\"><a name=\"_ENREF_68\"></a> 68. Kim KB, Eton O, Davis DW, et al: Phase II trial of imatinib mesylate in patients with metastatic melanoma. Br J Cancer 99:734-40, 2008. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/18728664\">http://www.ncbi.nlm.nih.gov/pubmed/18728664</a></p>\n<p id=\"erb-fbd87c44-02a0-42b6-b7d5-fa41c36e27b9\"><a name=\"_ENREF_69\"></a> 69. Penel N, Delcambre C, Durando X, et al: O-Mel-Inib: a Cancero-pole Nord-Ouest multicenter phase II trial of high-dose imatinib mesylate in metastatic uveal melanoma. Invest New Drugs 26:561-5, 2008. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/18551246\">http://www.ncbi.nlm.nih.gov/pubmed/18551246</a></p>\n<p id=\"erb-01ceb05d-c9c6-489d-a7f6-58fcf1bcc137\"><a name=\"_ENREF_70\"></a> 70. Wyman K, Atkins MB, Prieto V, et al: Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy. Cancer 106:2005-11, 2006. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/16565971\">http://www.ncbi.nlm.nih.gov/pubmed/16565971</a></p>\n<p id=\"erb-330b697d-97d9-4f20-816f-c6b16cc432d5\"><a name=\"_ENREF_71\"></a> 71. Kluger HM, Dudek AZ, McCann C, et al: A phase 2 trial of dasatinib in advanced melanoma. Cancer 117:2202-8, 2011. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/21523734\">http://www.ncbi.nlm.nih.gov/pubmed/21523734</a></p>\n<p id=\"erb-cb04c50b-a7f7-4a3a-8cfa-37a82f181282\"><a name=\"_ENREF_72\"></a> 72. Lutzky J, Bauer J, Bastian BC: Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation. Pigment Cell Melanoma Res 21:492-3, 2008. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/18510589\">http://www.ncbi.nlm.nih.gov/pubmed/18510589</a></p>\n<p id=\"erb-40a18874-d676-4586-85b3-bcebf2e00678\"><a name=\"_ENREF_73\"></a> 73. Hodi FS, Friedlander P, Corless CL, et al: Major response to imatinib mesylate in KIT-mutated melanoma. J Clin Oncol 26:2046-51, 2008. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/18421059\">http://www.ncbi.nlm.nih.gov/pubmed/18421059</a></p>\n<p id=\"erb-458eb2a1-a739-4a28-8654-d325b51de36e\"><a name=\"_ENREF_74\"></a> 74. Woodman SE, Trent JC, Stemke-Hale K, et al: Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates. Mol Cancer Ther 8:2079-85, 2009. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/19671763\">http://www.ncbi.nlm.nih.gov/pubmed/19671763</a></p>\n<p id=\"erb-8470c3e7-5d90-4854-a31d-fe587b403677\"><a name=\"_ENREF_75\"></a> 75. Hofmann UB, Kauczok-Vetter CS, Houben R, et al: Overexpression of the KIT/SCF in uveal melanoma does not translate into clinical efficacy of imatinib mesylate. Clin Cancer Res 15:324-9, 2009. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/19118061\">http://www.ncbi.nlm.nih.gov/pubmed/19118061</a></p>\n<p id=\"erb-3d1aa943-86b5-4c42-93f0-96de598da65c\"><a name=\"_ENREF_76\"></a> 76. Mahipal A, Tijani L, Chan K, et al: A pilot study of sunitinib malate in patients with metastatic uveal melanoma. Melanoma Res 22:440-6, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23114504\">http://www.ncbi.nlm.nih.gov/pubmed/23114504</a></p>\n<p id=\"erb-9b1e555c-c0cc-4f82-8026-fda37fc0fd6c\"><a name=\"_ENREF_77\"></a> 77. Guo J, Si L, Kong Y, et al: Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol 29:2904-9, 2011. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/21690468\">http://www.ncbi.nlm.nih.gov/pubmed/21690468</a></p>\n<p id=\"erb-b55e56b4-f6da-44dd-9a37-b5fc770a54da\"><a name=\"_ENREF_78\"></a> 78. Carvajal RD, Antonescu CR, Wolchok JD, et al: KIT as a therapeutic target in metastatic melanoma. JAMA 305:2327-34, 2011. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/21642685\">http://www.ncbi.nlm.nih.gov/pubmed/21642685</a></p>\n<p id=\"erb-dead9bf9-1ee4-46bb-9c1d-4ba942684e4e\"><a name=\"_ENREF_79\"></a> 79. Minor DR, Kashani-Sabet M, Garrido M, et al: Sunitinib therapy for melanoma patients with KIT mutations. Clin Cancer Res 18:1457-63, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22261812\">http://www.ncbi.nlm.nih.gov/pubmed/22261812</a></p>\n<p id=\"erb-72ff5825-52a2-4090-bff1-02cae53da1a0\"><a name=\"_ENREF_80\"></a> 80. Cho JH, Kim KM, Kwon M, et al: Nilotinib in patients with metastatic melanoma harboring KIT gene aberration. Invest New Drugs 30:2008-14, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22068222\">http://www.ncbi.nlm.nih.gov/pubmed/22068222</a></p>\n<p id=\"erb-b0c2c0e4-7da8-4ccd-a4d2-4f8dac0974c2\"><a name=\"_ENREF_81\"></a> 81. Hodi FS, Corless CL, Giobbie-Hurder A, et al: Imatinib for Melanomas Harboring Mutationally Activated or Amplified KIT Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin. J Clin Oncol, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23775962\">http://www.ncbi.nlm.nih.gov/pubmed/23775962</a></p>\n<p id=\"erb-4ae67e3f-9b65-4761-8943-9c6d4dbb21d6\"><a name=\"_ENREF_82\"></a> 82. Carvajal RD: Another Option in Our KIT of Effective Therapies for Advanced Melanoma. J Clin Oncol, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23940226\">http://www.ncbi.nlm.nih.gov/pubmed/23940226</a></p>\n<p id=\"erb-1ba1d05c-03ed-4424-ab08-042f49d010a9\"><a name=\"_ENREF_83\"></a> 83. Johnson MR, Look AT, DeClue JE, et al: Inactivation of the NF1 gene in human melanoma and neuroblastoma cell lines without impaired regulation of GTP.Ras. Proc Natl Acad Sci U S A 90:5539-43, 1993. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/8516298\">http://www.ncbi.nlm.nih.gov/pubmed/8516298</a></p>\n<p id=\"erb-42570308-7646-4fc2-9f22-0036a4660065\"><a name=\"_ENREF_84\"></a> 84. Gutzmer R, Herbst RA, Mommert S, et al: Allelic loss at the neurofibromatosis type 1 (NF1) gene locus is frequent in desmoplastic neurotropic melanoma. Hum Genet 107:357-61, 2000. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/11129335\">http://www.ncbi.nlm.nih.gov/pubmed/11129335</a></p>\n<p id=\"erb-28186159-5c01-4aeb-a494-d0b3fe11cf32\"><a name=\"_ENREF_85\"></a> 85. Maertens O, Johnson B, Hollstein P, et al: Elucidating distinct roles for NF1 in melanomagenesis. Cancer Discov, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23171796\">http://www.ncbi.nlm.nih.gov/pubmed/23171796</a></p>\n<p id=\"erb-be0aa840-ef45-4cce-9ef0-12fc6407454f\"><a name=\"_ENREF_86\"></a> 86. Whittaker SR, Theurillat JP, Van Allen E, et al: A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. Cancer Discov, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23288408\">http://www.ncbi.nlm.nih.gov/pubmed/23288408</a></p>\n<p id=\"erb-e6019359-8f9f-48be-a128-6b2ae39299c3\"><a name=\"_ENREF_87\"></a> 87. Horn S, Figl A, Rachakonda PS, et al: TERT Promoter Mutations in Familial and Sporadic Melanoma. Science, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23348503\">http://www.ncbi.nlm.nih.gov/pubmed/23348503</a></p>\n<p id=\"erb-a9e65c8d-521b-4291-8d1a-81e331002676\"><a name=\"_ENREF_88\"></a> 88. Huang FW, Hodis E, Xu MJ, et al: Highly Recurrent TERT Promoter Mutations in Human Melanoma. Science, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23348506\">http://www.ncbi.nlm.nih.gov/pubmed/23348506</a></p>\n<p id=\"erb-eb2257b3-def8-4263-b79c-7dd7f6dd98fe\"><a name=\"_ENREF_89\"></a> 89. Dankort D, Curley DP, Cartlidge RA, et al: Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet 41:544-52, 2009. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/19282848\">http://www.ncbi.nlm.nih.gov/pubmed/19282848</a></p>\n<p id=\"erb-9ba0be4c-20ab-443d-a358-fbd18a426c65\"><a name=\"_ENREF_90\"></a> 90. Vredeveld LC, Possik PA, Smit MA, et al: Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis. Genes Dev 26:1055-69, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22549727\">http://www.ncbi.nlm.nih.gov/pubmed/22549727</a></p>\n<p id=\"erb-757e3f22-4ba2-4826-8ac9-cbffceb7d306\"><a name=\"_ENREF_91\"></a> 91. Prickett TD, Agrawal NS, Wei X, et al: Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4. Nat Genet 41:1127-32, 2009. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/19718025\">http://www.ncbi.nlm.nih.gov/pubmed/19718025</a></p>\n<p id=\"erb-fdd9f8fa-0306-4f6a-8869-e7061fa97754\"><a name=\"_ENREF_92\"></a> 92. Dutton-Regester K, Irwin D, Hunt P, et al: A high-throughput panel for identifying clinically relevant mutation profiles in melanoma. Mol Cancer Ther 11:888-97, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22383533\">http://www.ncbi.nlm.nih.gov/pubmed/22383533</a></p>\n<p id=\"erb-25355f54-aa71-402e-912f-6328a828fabe\"><a name=\"_ENREF_93\"></a> 93. Zhou QM, Li W, Guan YX, et al: The absence of the ERBB4 hotspot mutations in melanomas in patients from southern China. Chin J Cancer 32:410-4, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23237222\">http://www.ncbi.nlm.nih.gov/pubmed/23237222</a></p>\n<p id=\"erb-e8243e2c-d745-437f-9e36-6162e38e3580\"><a name=\"_ENREF_94\"></a> 94. Moore SR, Persons DL, Sosman JA, et al: Detection of copy number alterations in metastatic melanoma by a DNA fluorescence in situ hybridization probe panel and array comparative genomic hybridization: a southwest oncology group study (S9431). Clin Cancer Res 14:2927-35, 2008. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/18483359\">http://www.ncbi.nlm.nih.gov/pubmed/18483359</a></p>\n<p id=\"erb-f856f624-be31-44f2-b703-6c2e97f50668\"><a name=\"_ENREF_95\"></a> 95. Kenessey I, Keszthelyi M, Kramer Z, et al: Inhibition of c-Met with the specific small molecule tyrosine kinase inhibitor SU11274 decreases growth and metastasis formation of experimental human melanoma. Curr Cancer Drug Targets 10:332-42, 2010. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/20370683\">http://www.ncbi.nlm.nih.gov/pubmed/20370683</a></p>\n<p id=\"erb-fdabed53-6a6e-49b1-935a-bb899beb6718\"><a name=\"_ENREF_96\"></a> 96. Schlegel J, Sambade MJ, Sather S, et al: MERTK receptor tyrosine kinase is a therapeutic target in melanoma. J Clin Invest, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23585477\">http://www.ncbi.nlm.nih.gov/pubmed/23585477</a></p>\n<p id=\"erb-f15e274f-6e14-46d5-b09e-962b15e9e8fb\"><a name=\"_ENREF_97\"></a> 97. Tworkoski KA, Platt JT, Bacchiocchi A, et al: MERTK controls melanoma cell migration and survival and differentially regulates cell behavior relative to AXL. Pigment Cell Melanoma Res, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23617806\">http://www.ncbi.nlm.nih.gov/pubmed/23617806</a></p>\n<p id=\"erb-443a3a9f-fe99-434e-9a7c-562409c569e6\"><a name=\"_ENREF_98\"></a> 98. Stahl JM, Sharma A, Cheung M, et al: Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res 64:7002-10, 2004. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/15466193\">http://www.ncbi.nlm.nih.gov/pubmed/15466193</a></p>\n<p id=\"erb-d7a17c29-0710-4f68-9a24-c130fc0d1f00\"><a name=\"_ENREF_99\"></a> 99. Davies MA, Stemke-Hale K, Tellez C, et al: A novel AKT3 mutation in melanoma tumours and cell lines. Br J Cancer 99:1265-8, 2008. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/18813315\">http://www.ncbi.nlm.nih.gov/pubmed/18813315</a></p>\n<p id=\"erb-1b310e83-428a-433b-a28a-8e6f80061230\"><a name=\"_ENREF_100\"></a> 100. Cheung M, Sharma A, Madhunapantula SV, et al: Akt3 and mutant V600E B-Raf cooperate to promote early melanoma development. Cancer Res 68:3429-39, 2008. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/18451171\">http://www.ncbi.nlm.nih.gov/pubmed/18451171</a></p>\n<p id=\"erb-63fc9e02-4b7a-4499-9989-a4b2cab4bf8a\"><a name=\"_ENREF_101\"></a> 101. Tsao H, Zhang X, Benoit E, et al: Identification of PTEN/MMAC1 alterations in uncultured melanomas and melanoma cell lines. Oncogene 16:3397-402, 1998. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/9692547\">http://www.ncbi.nlm.nih.gov/pubmed/9692547</a></p>\n<p id=\"erb-b3c3513e-4a13-4f48-bb07-abc385f21159\"><a name=\"_ENREF_102\"></a> 102. Karreth FA, Tay Y, Perna D, et al: In vivo identification of tumor- suppressive PTEN ceRNAs in an oncogenic BRAF-induced mouse model of melanoma. Cell 147:382-95, 2011. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22000016\">http://www.ncbi.nlm.nih.gov/pubmed/22000016</a></p>\n<p id=\"erb-9a1830a0-2f55-4a3a-8dd8-a9e6ad80718a\"><a name=\"_ENREF_103\"></a> 103. Nathanson KL, Martin AM, Wubbenhorst B, et al: Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor Dabrafenib (GSK2118436). Clin Cancer Res, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23833299\">http://www.ncbi.nlm.nih.gov/pubmed/23833299</a></p>\n<p id=\"erb-3265ac7d-1344-4429-8c35-137a9f499fca\"><a name=\"_ENREF_104\"></a> 104. Cao J, Wan L, Hacker E, et al: MC1R Is a Potent Regulator of PTEN after UV Exposure in Melanocytes. Mol Cell 51:409-22, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23973372\">http://www.ncbi.nlm.nih.gov/pubmed/23973372</a></p>\n<p id=\"erb-b6c485dd-84df-4a1f-9f71-f7c243779d2c\"><a name=\"_ENREF_105\"></a> 105. Shull AY, Latham-Schwark A, Ramasamy P, et al: Novel somatic mutations to PI3K pathway genes in metastatic melanoma. PLoS One 7:e43369, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22912864\">http://www.ncbi.nlm.nih.gov/pubmed/22912864</a></p>\n<p id=\"erb-4e874d09-ab1c-471b-ad8a-db2a6a31c516\"><a name=\"_ENREF_106\"></a> 106. Nikolaev SI, Rimoldi D, Iseli C, et al: Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma. Nat Genet 44:133-9, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22197931\">http://www.ncbi.nlm.nih.gov/pubmed/22197931</a></p>\n<p id=\"erb-ce653721-1f44-408b-bec8-0fa870086116\"><a name=\"_ENREF_107\"></a> 107. Jameson KL, Mazur PK, Zehnder AM, et al: IQGAP1 scaffold-kinase interaction blockade selectively targets RAS-MAP kinase-driven tumors. Nat Med, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23603816\">http://www.ncbi.nlm.nih.gov/pubmed/23603816</a></p>\n<p id=\"erb-b781241d-752e-42e9-a46e-3d6c0534ea18\"><a name=\"_ENREF_108\"></a> 108. Li A, Ma Y, Jin M, et al: Activated mutant NRas(Q61K) drives aberrant melanocyte signaling, survival, and invasiveness via a Rac1-dependent mechanism. J Invest Dermatol 132:2610-21, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22718121\">http://www.ncbi.nlm.nih.gov/pubmed/22718121</a></p>\n<p id=\"erb-9f4d11ae-e5f3-4809-8b32-d93d0610f89e\"><a name=\"_ENREF_109\"></a> 109. Krauthammer M, Kong Y, Ha BH, et al: Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat Genet 44:1006-14, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22842228\">http://www.ncbi.nlm.nih.gov/pubmed/22842228</a></p>\n<p id=\"erb-42bb8ace-969a-41b5-b743-0e2aa4f71a28\"><a name=\"_ENREF_110\"></a> 110. Stark MS, Woods SL, Gartside MG, et al: Frequent somatic mutations in MAP3K5 and MAP3K9 in metastatic melanoma identified by exome sequencing. Nat Genet 44:165-9, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22197930\">http://www.ncbi.nlm.nih.gov/pubmed/22197930</a></p>\n<p id=\"erb-0545a36b-40b9-4358-b79d-58ecf0282f62\"><a name=\"_ENREF_111\"></a> 111. Muthusamy V, Hobbs C, Nogueira C, et al: Amplification of CDK4 and MDM2 in malignant melanoma. Genes Chromosomes Cancer 45:447-54, 2006. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/16419059\">http://www.ncbi.nlm.nih.gov/pubmed/16419059</a></p>\n<p id=\"erb-1eaaea0b-ad13-4de3-81ba-6d740f3cef33\"><a name=\"_ENREF_112\"></a> 112. Zuo L, Weger J, Yang Q, et al: Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nat Genet 12:97-9, 1996. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/8528263\">http://www.ncbi.nlm.nih.gov/pubmed/8528263</a></p>\n<p id=\"erb-6037a01b-54d6-4b3c-bf64-24e94655c837\"><a name=\"_ENREF_113\"></a> 113. Dickson MA, Shah MA, Rathkopf D, et al: A phase I clinical trial of FOLFIRI in combination with the pan-cyclin-dependent kinase (CDK) inhibitor flavopiridol. Cancer Chemother Pharmacol 66:1113-21, 2010. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/20953860\">http://www.ncbi.nlm.nih.gov/pubmed/20953860</a></p>\n<p id=\"erb-5db31747-1e9f-4052-a867-435687fe1355\"><a name=\"_ENREF_114\"></a> 114. Hussussian CJ, Struewing JP, Goldstein AM, et al: Germline p16 mutations in familial melanoma. Nat Genet 8:15-21, 1994. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/7987387\">http://www.ncbi.nlm.nih.gov/pubmed/7987387</a></p>\n<p id=\"erb-6cc8bcd7-eb9d-4a03-add6-613476485f16\"><a name=\"_ENREF_115\"></a> 115. Polsky D, Bastian BC, Hazan C, et al: HDM2 protein overexpression, but not gene amplification, is related to tumorigenesis of cutaneous melanoma. Cancer Res 61:7642-6, 2001. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/11606406\">http://www.ncbi.nlm.nih.gov/pubmed/11606406</a></p>\n<p id=\"erb-fb64cd91-c031-4648-8eb3-4b2ad3c0ac5d\"><a name=\"_ENREF_116\"></a> 116. Gembarska A, Luciani F, Fedele C, et al: MDM4 is a key therapeutic target in cutaneous melanoma. Nat Med, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22820643\">http://www.ncbi.nlm.nih.gov/pubmed/22820643</a></p>\n<p id=\"erb-6798bc29-bc4a-4ebf-868c-62db49ac57d5\"><a name=\"_ENREF_117\"></a> 117. Matin RN, Chikh A, Law Pak Chong S, et al: p63 is an alternative p53 repressor in melanoma that confers chemoresistance and a poor prognosis. J Exp Med, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23420876\">http://www.ncbi.nlm.nih.gov/pubmed/23420876</a></p>\n<p id=\"erb-c701cbf7-942f-4102-82a2-fccd3b7095f3\"><a name=\"_ENREF_118\"></a> 118. Bergamaschi D, Samuels Y, Sullivan A, et al: iASPP preferentially binds p53 proline-rich region and modulates apoptotic function of codon 72-polymorphic p53. Nat Genet 38:1133-41, 2006. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/16964264\">http://www.ncbi.nlm.nih.gov/pubmed/16964264</a></p>\n<p id=\"erb-729d275e-cbfe-4e38-a6d5-25116eb169ce\"><a name=\"_ENREF_119\"></a> 119. Kamb A, Gruis NA, Weaver-Feldhaus J, et al: A cell cycle regulator potentially involved in genesis of many tumor types. Science 264:436-40, 1994. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/8153634\">http://www.ncbi.nlm.nih.gov/pubmed/8153634</a></p>\n<p id=\"erb-f9a2d2ec-c07b-41ef-ae80-6b88f0674915\"><a name=\"_ENREF_120\"></a> 120. Kamb A, Shattuck-Eidens D, Eeles R, et al: Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nat Genet 8:23-6, 1994. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/7987388\">http://www.ncbi.nlm.nih.gov/pubmed/7987388</a></p>\n<p id=\"erb-e1e5fc0d-f602-452c-9f90-3888247f4da8\"><a name=\"_ENREF_121\"></a> 121. Ohta M, Berd D, Shimizu M, et al: Deletion mapping of chromosome region 9p21-p22 surrounding the CDKN2 locus in melanoma. Int J Cancer 65:762-7, 1996. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/8631588\">http://www.ncbi.nlm.nih.gov/pubmed/8631588</a></p>\n<p id=\"erb-2cd9ec5c-643e-4d4c-afe6-2e5cb9de2966\"><a name=\"_ENREF_122\"></a> 122. Dar AA, Majid S, Rittsteuer C, et al: The role of miR-18b in MDM2-p53 pathway signaling and melanoma progression. J Natl Cancer Inst 105:433-42, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23365201\">http://www.ncbi.nlm.nih.gov/pubmed/23365201</a></p>\n<p id=\"erb-58da4727-c47d-4f42-b6d2-f6aee659d0ed\"><a name=\"_ENREF_123\"></a> 123. Ray-Coquard I, Blay JY, Italiano A, et al: Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study. Lancet Oncol 13:1133-40, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23084521\">http://www.ncbi.nlm.nih.gov/pubmed/23084521</a></p>\n<p id=\"erb-db3ea2b0-1764-457f-b8b6-1e1643a0d046\"><a name=\"_ENREF_124\"></a> 124. Ji Z, Kumar R, Taylor M, et al: Vemurafenib Synergizes with Nutlin-3 to Deplete Survivin and Suppress Melanoma Viability and Tumor Growth. Clin Cancer Res, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23812671\">http://www.ncbi.nlm.nih.gov/pubmed/23812671</a></p>\n<p id=\"erb-9b4fc9f8-3018-4748-84db-770b5d523025\"><a name=\"_ENREF_125\"></a> 125. Brown CJ, Quah ST, Jong J, et al: Stapled peptides with improved potency and specificity that activate p53. ACS Chem Biol 8:506-12, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23214419\">http://www.ncbi.nlm.nih.gov/pubmed/23214419</a></p>\n<p id=\"erb-7ed5125b-7ab3-4815-9f00-1c2feb4b2719\"><a name=\"_ENREF_126\"></a> 126. Chang YS, Graves B, Guerlavais V, et al: Stapled alpha-helical peptide drug development: A potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy. Proc Natl Acad Sci U S A, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23946421\">http://www.ncbi.nlm.nih.gov/pubmed/23946421</a></p>\n<p id=\"erb-a243cf67-f6c9-4238-bd50-378f568def37\"><a name=\"_ENREF_127\"></a> 127. Lu M, Breyssens H, Salter V, et al: Restoring p53 Function in Human Melanoma Cells by Inhibiting MDM2 and Cyclin B1/CDK1-Phosphorylated Nuclear iASPP. Cancer Cell, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23623661\">http://www.ncbi.nlm.nih.gov/pubmed/23623661</a></p>\n<p id=\"erb-30acf820-5933-457d-89b6-df8d32d8bdba\"><a name=\"_ENREF_128\"></a> 128. Ohanna M, Giuliano S, Bonet C, et al: Senescent cells develop a PARP-1 and nuclear factor-{kappa}B-associated secretome (PNAS). Genes Dev 25:1245-61, 2011. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/21646373\">http://www.ncbi.nlm.nih.gov/pubmed/21646373</a></p>\n<p id=\"erb-a7a66fad-478d-4ab4-8dd9-43b3842f5363\"><a name=\"_ENREF_129\"></a> 129. Gartner JJ, Parker SC, Prickett TD, et al: Whole-genome sequencing identifies a recurrent functional synonymous mutation in melanoma. Proc Natl Acad Sci U S A 110:13481-6, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23901115\">http://www.ncbi.nlm.nih.gov/pubmed/23901115</a></p>\n<p id=\"erb-f1131527-1cb8-4bc4-84e7-e28351882763\"><a name=\"_ENREF_130\"></a> 130. Anvekar RA, Asciolla JJ, Lopez-Rivera E, et al: Sensitization to the mitochondrial pathway of apoptosis augments melanoma tumor cell responses to conventional chemotherapeutic regimens. Cell Death Dis 3:e420, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23152056\">http://www.ncbi.nlm.nih.gov/pubmed/23152056</a></p>\n<p id=\"erb-64a3d3f1-4103-4142-be24-d94ff0e4fa25\"><a name=\"_ENREF_131\"></a> 131. Reifenberger J, Knobbe CB, Wolter M, et al: Molecular genetic analysis of malignant melanomas for aberrations of the WNT signaling pathway genes CTNNB1, APC, ICAT and BTRC. Int J Cancer 100:549-56, 2002. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/12124804\">http://www.ncbi.nlm.nih.gov/pubmed/12124804</a></p>\n<p id=\"erb-38467678-352d-429f-ac21-9fa2740497fe\"><a name=\"_ENREF_132\"></a> 132. Delmas V, Beermann F, Martinozzi S, et al: Beta-catenin induces immortalization of melanocytes by suppressing p16INK4a expression and cooperates with N-Ras in melanoma development. Genes Dev 21:2923-35, 2007. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/18006687\">http://www.ncbi.nlm.nih.gov/pubmed/18006687</a></p>\n<p id=\"erb-f84d21b2-d1d5-4f12-8e65-81e9824c1289\"><a name=\"_ENREF_133\"></a> 133. Grossmann AH, Yoo JH, Clancy J, et al: The Small GTPase ARF6 Stimulates beta-Catenin Transcriptional Activity During WNT5A-Mediated Melanoma Invasion and Metastasis. Sci Signal 6:ra14, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23462101\">http://www.ncbi.nlm.nih.gov/pubmed/23462101</a></p>\n<p id=\"erb-f6945e3e-f856-4c07-96af-d10be452eb53\"><a name=\"_ENREF_134\"></a> 134. Damsky WE, Curley DP, Santhanakrishnan M, et al: beta-catenin signaling controls metastasis in Braf-activated Pten-deficient melanomas. Cancer Cell 20:741-54, 2011. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22172720\">http://www.ncbi.nlm.nih.gov/pubmed/22172720</a></p>\n<p id=\"erb-8f0bf7bd-954e-49b3-8697-940911e3379e\"><a name=\"_ENREF_135\"></a> 135. Biechele TL, Kulikauskas RM, Toroni RA, et al: Wnt/beta-catenin signaling and AXIN1 regulate apoptosis triggered by inhibition of the mutant kinase BRAFV600E in human melanoma. Sci Signal 5:ra3, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22234612\">http://www.ncbi.nlm.nih.gov/pubmed/22234612</a></p>\n<p id=\"erb-1cbd608e-30a4-436d-bea4-30df26955c8e\"><a name=\"_ENREF_136\"></a> 136. Conrad WH, Swift RD, Biechele TL, et al: Regulating the response to targeted MEK inhibition in melanoma: enhancing apoptosis in NRAS- and BRAF-mutant melanoma cells with Wnt/beta-catenin activation. Cell Cycle 11:3724-30, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22895053\">http://www.ncbi.nlm.nih.gov/pubmed/22895053</a></p>\n<p id=\"erb-68006ae4-cb09-4c7f-98f3-e834c3578891\"><a name=\"_ENREF_137\"></a> 137. Jane-Valbuena J, Widlund HR, Perner S, et al: An oncogenic role for ETV1 in melanoma. Cancer Res 70:2075-84, 2010. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/20160028\">http://www.ncbi.nlm.nih.gov/pubmed/20160028</a></p>\n<p id=\"erb-458d2793-871d-4baa-a1c4-392adf274222\"><a name=\"_ENREF_138\"></a> 138. Kim M, Gans JD, Nogueira C, et al: Comparative oncogenomics identifies NEDD9 as a melanoma metastasis gene. Cell 125:1269-81, 2006. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/16814714\">http://www.ncbi.nlm.nih.gov/pubmed/16814714</a></p>\n<p id=\"erb-18ba2e27-45b2-4045-a319-5c601b3463cf\"><a name=\"_ENREF_139\"></a> 139. Harbour JW, Onken MD, Roberson ED, et al: Frequent mutation of BAP1 in metastasizing uveal melanomas. Science 330:1410-3, 2010. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/21051595\">http://www.ncbi.nlm.nih.gov/pubmed/21051595</a></p>\n<p id=\"erb-c7b50b10-cc81-4445-8e86-1567d5dc0823\"><a name=\"_ENREF_140\"></a> 140. Wiesner T, Obenauf AC, Murali R, et al: Germline mutations in BAP1 predispose to melanocytic tumors. Nat Genet 43:1018-21, 2011. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/21874003\">http://www.ncbi.nlm.nih.gov/pubmed/21874003</a></p>\n<p id=\"erb-2193cffb-7d85-423e-8ca1-e71bfbf7ef5a\"><a name=\"_ENREF_141\"></a> 141. Njauw CN, Kim I, Piris A, et al: Germline BAP1 inactivation is preferentially associated with metastatic ocular melanoma and cutaneous-ocular melanoma families. PLoS One 7:e35295, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22545102\">http://www.ncbi.nlm.nih.gov/pubmed/22545102</a></p>\n<p id=\"erb-01bb2a8c-ede9-442c-a384-f1ac9c51e15e\"><a name=\"_ENREF_142\"></a> 142. Landreville S, Agapova OA, Matatall KA, et al: Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma. Clin Cancer Res 18:408-16, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22038994\">http://www.ncbi.nlm.nih.gov/pubmed/22038994</a></p>\n<p id=\"erb-e935a328-c43b-42db-bb3b-2735036ec818\"><a name=\"_ENREF_143\"></a> 143. Harbour JW, Roberson ED, Anbunathan H, et al: Recurrent mutations at codon 625 of the splicing factor SF3B1 in uveal melanoma. Nat Genet 45:133-5, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23313955\">http://www.ncbi.nlm.nih.gov/pubmed/23313955</a></p>\n<p id=\"erb-516ff404-fe9d-4d35-b0cf-d18e62c4e8b6\"><a name=\"_ENREF_144\"></a> 144. Martin M, Masshofer L, Temming P, et al: Exome sequencing identifies recurrent somatic mutations in EIF1AX and SF3B1 in uveal melanoma with disomy 3. Nat Genet, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23793026\">http://www.ncbi.nlm.nih.gov/pubmed/23793026</a></p>\n<p id=\"erb-0aa772f6-9f9c-4b17-bc4c-5adc970c5dc3\"><a name=\"_ENREF_145\"></a> 145. Ghai R, Mobli M, Norwood SJ, et al: Phox homology band 4.1/ezrin/radixin/moesin-like proteins function as molecular scaffolds that interact with cargo receptors and Ras GTPases. Proc Natl Acad Sci U S A 108:7763-8, 2011. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/21512128\">http://www.ncbi.nlm.nih.gov/pubmed/21512128</a></p>\n<p id=\"erb-477694ac-2da4-4b8b-9db4-a340931c8dce\"><a name=\"_ENREF_146\"></a> 146. Forbes SA, Bindal N, Bamford S, et al: COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res 39:D945-50, 2011. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/20952405\">http://www.ncbi.nlm.nih.gov/pubmed/20952405</a></p>\n<p id=\"erb-251c58fd-068b-4b7d-9040-b0a9c2e01055\"><a name=\"_ENREF_147\"></a> 147. Liu W, Monahan KB, Pfefferle AD, et al: LKB1/STK11 inactivation leads to expansion of a prometastatic tumor subpopulation in melanoma. Cancer Cell 21:751-64, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22698401\">http://www.ncbi.nlm.nih.gov/pubmed/22698401</a></p>\n<p id=\"erb-b2425248-3a94-40b4-8ef2-db160d54b2ef\"><a name=\"_ENREF_148\"></a> 148. Wei X, Walia V, Lin JC, et al: Exome sequencing identifies GRIN2A as frequently mutated in melanoma. Nat Genet 43:442-6, 2011. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/21499247\">http://www.ncbi.nlm.nih.gov/pubmed/21499247</a></p>\n<p id=\"erb-db90f2a1-e6a7-4f47-9ebd-1734ef272640\"><a name=\"_ENREF_149\"></a> 149. Prickett TD, Wei X, Cardenas-Navia I, et al: Exon capture analysis of G protein-coupled receptors identifies activating mutations in GRM3 in melanoma. Nat Genet 43:1119-26, 2011. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/21946352\">http://www.ncbi.nlm.nih.gov/pubmed/21946352</a></p>\n<p id=\"erb-3987ecb6-5469-4a52-b8a0-913864950b27\"><a name=\"_ENREF_150\"></a> 150. Namkoong J, Shin SS, Lee HJ, et al: Metabotropic glutamate receptor 1 and glutamate signaling in human melanoma. Cancer Res 67:2298-305, 2007. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/17332361\">http://www.ncbi.nlm.nih.gov/pubmed/17332361</a></p>\n<p id=\"erb-b4b9005d-6cb6-4496-9607-53bc5c910ad8\"><a name=\"_ENREF_151\"></a> 151. Locasale JW, Grassian AR, Melman T, et al: Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. Nat Genet 43:869-74, 2011. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/21804546\">http://www.ncbi.nlm.nih.gov/pubmed/21804546</a></p>\n<p id=\"erb-fbc14473-e26a-4bce-a91a-a5eae892c75a\"><a name=\"_ENREF_152\"></a> 152. Magnussen GI, Holm R, Emilsen E, et al: High expression of Wee1 is associated with poor disease-free survival in malignant melanoma: potential for targeted therapy. PLoS One 7:e38254, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22719872\">http://www.ncbi.nlm.nih.gov/pubmed/22719872</a></p>\n<p id=\"erb-dba0a92a-52ee-4ec2-b223-fee9164687ec\"><a name=\"_ENREF_153\"></a> 153. Namiki T, Tanemura A, Valencia JC, et al: AMP kinase-related kinase NUAK2 affects tumor growth, migration, and clinical outcome of human melanoma. Proc Natl Acad Sci U S A 108:6597-602, 2011. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/21460252\">http://www.ncbi.nlm.nih.gov/pubmed/21460252</a></p>\n<p id=\"erb-485511c3-8101-495e-9417-6ec82759c776\"><a name=\"_ENREF_154\"></a> 154. van den Hurk K, Niessen HE, Veeck J, et al: Genetics and epigenetics of cutaneous malignant melanoma: A concert out of tune. Biochim Biophys Acta 1826:89-102, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22503822\">http://www.ncbi.nlm.nih.gov/pubmed/22503822</a></p>\n<p id=\"erb-5a4aad7d-1b71-45ba-a221-292777013726\"><a name=\"_ENREF_155\"></a> 155. Smalley KS, Haass NK, Brafford PA, et al: Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Mol Cancer Ther 5:1136-44, 2006. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/16731745\">http://www.ncbi.nlm.nih.gov/pubmed/16731745</a></p>\n<p id=\"erb-83e96752-cdc6-482f-87d3-2264a55bb366\"><a name=\"_ENREF_156\"></a> 156. Paraiso KH, Xiang Y, Rebecca VW, et al: PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res 71:2750-60, 2011. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/21317224\">http://www.ncbi.nlm.nih.gov/pubmed/21317224</a></p>\n<p id=\"erb-cde300b6-03a7-46c0-9d4e-89b2c59c187f\"><a name=\"_ENREF_157\"></a> 157. Smalley KS, Lioni M, Dalla Palma M, et al: Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas. Mol Cancer Ther 7:2876-83, 2008. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/18790768\">http://www.ncbi.nlm.nih.gov/pubmed/18790768</a></p>\n<p id=\"erb-d7a3361d-fd33-45b3-9584-a9a6893d427f\"><a name=\"_ENREF_158\"></a> 158. McArthur GA, Puzanov I, Amaravadi R, et al: Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma. J Clin Oncol 30:1628-34, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22454415\">http://www.ncbi.nlm.nih.gov/pubmed/22454415</a></p>\n<p id=\"erb-834a9e14-c8e6-42e3-85c6-eca78f55ee56\"><a name=\"_ENREF_159\"></a> 159. Vergani E, Vallacchi V, Frigerio S, et al: Identification of MET and SRC activation in melanoma cell lines showing primary resistance to PLX4032. Neoplasia 13:1132-42, 2011. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22241959\">http://www.ncbi.nlm.nih.gov/pubmed/22241959</a></p>\n<p id=\"erb-5eef0083-624a-47e9-aff0-c457f50e762c\"><a name=\"_ENREF_160\"></a> 160. Straussman R, Morikawa T, Shee K, et al: Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 487:500-4, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22763439\">http://www.ncbi.nlm.nih.gov/pubmed/22763439</a></p>\n<p id=\"erb-0847f466-207f-4a41-8898-c7acb8bf302a\"><a name=\"_ENREF_161\"></a> 161. Wroblewski D, Mijatov B, Mohana-Kumaran N, et al: The BH3-mimetic ABT-737 sensitizes human melanoma cells to apoptosis induced by selective BRAF inhibitors but does not reverse acquired resistance. Carcinogenesis, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23087082\">http://www.ncbi.nlm.nih.gov/pubmed/23087082</a></p>\n<p id=\"erb-31602756-e765-443a-a10d-344026a56e7d\"><a name=\"_ENREF_162\"></a> 162. Haq R, Shoag J, Andreu-Perez P, et al: Oncogenic BRAF Regulates Oxidative Metabolism via PGC1alpha and MITF. Cancer Cell 23:302-15, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23477830\">http://www.ncbi.nlm.nih.gov/pubmed/23477830</a></p>\n<p id=\"erb-8f72a52c-5e4c-4144-b5c3-24d7ec60e431\"><a name=\"_ENREF_163\"></a> 163. Basile KJ, Abel EV, Aplin AE: Adaptive upregulation of FOXD3 and resistance to PLX4032/4720-induced cell death in mutant B-RAF melanoma cells. Oncogene 31:2471-9, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/21996740\">http://www.ncbi.nlm.nih.gov/pubmed/21996740</a></p>\n<p id=\"erb-0b8a47c2-02cd-4bf3-a58c-7986166b73bb\"><a name=\"_ENREF_164\"></a> 164. Abel EV, Basile KJ, Kugel CH, 3rd, et al: Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3. J Clin Invest, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23543055\">http://www.ncbi.nlm.nih.gov/pubmed/23543055</a></p>\n<p id=\"erb-c7a916d4-2716-47a3-ac35-42cf086122aa\"><a name=\"_ENREF_165\"></a> 165. Paraiso KH, Haarberg HE, Wood E, et al: The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms. Clin Cancer Res 18:2502-14, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22351686\">http://www.ncbi.nlm.nih.gov/pubmed/22351686</a></p>\n<p id=\"erb-79b32147-60e2-4735-9cce-e50f706651cf\"><a name=\"_ENREF_166\"></a> 166. Smith MP, Ferguson J, Arozarena I, et al: Effect of SMURF2 Targeting on Susceptibility to MEK Inhibitors in Melanoma. J Natl Cancer Inst 105:33-46, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23250956\">http://www.ncbi.nlm.nih.gov/pubmed/23250956</a></p>\n<p id=\"erb-73b1a6f6-9485-4c21-b0c3-555e7eb4cdaf\"><a name=\"_ENREF_167\"></a> 167. Byron SA, Loch DC, Wellens CL, et al: Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status. Mol Cancer 11:75, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23039341\">http://www.ncbi.nlm.nih.gov/pubmed/23039341</a></p>\n<p id=\"erb-c4c1a572-1162-461f-9cbc-ba54128d5132\"><a name=\"_ENREF_168\"></a> 168. Shimizu T, Tolcher AW, Papadopoulos KP, et al: The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer. Clin Cancer Res 18:2316-25, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22261800\">http://www.ncbi.nlm.nih.gov/pubmed/22261800</a></p>\n<p id=\"erb-9c035e5a-8971-4411-96c1-85765bf1baf4\"><a name=\"_ENREF_169\"></a> 169. Zmajkovicova K, Jesenberger V, Catalanotti F, et al: MEK1 Is Required for PTEN Membrane Recruitment, AKT Regulation, and the Maintenance of Peripheral Tolerance. Mol Cell 50:43-55, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23453810\">http://www.ncbi.nlm.nih.gov/pubmed/23453810</a></p>\n<p id=\"erb-3e4ccf6f-f030-4eaa-92a9-93e633f43fa7\"><a name=\"_ENREF_170\"></a> 170. Sondergaard JN, Nazarian R, Wang Q, et al: Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032. J Transl Med 8:39, 2010. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/20406486\">http://www.ncbi.nlm.nih.gov/pubmed/20406486</a></p>\n<p id=\"erb-54b7a631-c3dc-426a-b9ef-0817b3d64bd1\"><a name=\"_ENREF_171\"></a> 171. Wilson TR, Fridlyand J, Yan Y, et al: Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 487:505-9, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22763448\">http://www.ncbi.nlm.nih.gov/pubmed/22763448</a></p>\n<p id=\"erb-936a912e-44e0-41f7-8fc3-03a4b6532052\"><a name=\"_ENREF_172\"></a> 172. Catalanotti F, Solit DB: Will Hsp90 inhibitors prove effective in BRAF-mutant melanomas? Clin Cancer Res 18:2420-2, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22442059\">http://www.ncbi.nlm.nih.gov/pubmed/22442059</a></p>\n<p id=\"erb-30e09452-5ada-46b7-adae-c1a0f7e13f23\"><a name=\"_ENREF_173\"></a> 173. Haarberg HE, Paraiso KH, Wood E, et al: Inhibition of Wee1, AKT and CDK4 underlies the efficacy of the HSP90 inhibitor XL888 in an in vivo model of NRAS mutant melanoma. Mol Cancer Ther, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23538902\">http://www.ncbi.nlm.nih.gov/pubmed/23538902</a></p>\n<p id=\"erb-daeeac5d-72e5-4cb1-86b2-0bf9b0c2403f\"><a name=\"_ENREF_174\"></a> 174. Deng W, Gopal YN, Scott A, et al: Role and therapeutic potential of PI3K-mTOR signaling in de novo resistance to BRAF inhibition. Pigment Cell Melanoma Res 25:248-58, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22171948\">http://www.ncbi.nlm.nih.gov/pubmed/22171948</a></p>\n<p id=\"erb-ab2941d4-2eed-459d-a831-746adb1cba56\"><a name=\"_ENREF_175\"></a> 175. Corcoran RB, Rothenberg SM, Hata AN, et al: TORC1 Suppression Predicts Responsiveness to RAF and MEK Inhibition in BRAF-Mutant Melanoma. Sci Transl Med 5:196ra98, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23903755\">http://www.ncbi.nlm.nih.gov/pubmed/23903755</a></p>\n<p id=\"erb-e6128661-f90e-4989-b975-1ee7e1648013\"><a name=\"_ENREF_176\"></a> 176. Poulikakos PI, Persaud Y, Janakiraman M, et al: RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 480:387-90, 2011. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22113612\">http://www.ncbi.nlm.nih.gov/pubmed/22113612</a></p>\n<p id=\"erb-525cd221-5f9e-4b91-b25f-9b43fb9d8576\"><a name=\"_ENREF_177\"></a> 177. Shi H, Moriceau G, Kong X, et al: Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat Commun 3:724, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22395615\">http://www.ncbi.nlm.nih.gov/pubmed/22395615</a></p>\n<p id=\"erb-20268d79-52de-4f13-bf7b-73b8127c8809\"><a name=\"_ENREF_178\"></a> 178. Girotti MR, Pedersen M, Sanchez-Laorden B, et al: Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma. Cancer Discov, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23242808\">http://www.ncbi.nlm.nih.gov/pubmed/23242808</a></p>\n<p id=\"erb-e1b08d18-53f1-44c1-b6c7-5fe552618a57\"><a name=\"_ENREF_179\"></a> 179. Yadav V, Zhang X, Liu J, et al: Reactivation of mitogen-activated protein kinase (MAPK) pathway by FGF receptor 3 (FGFR3)/Ras mediates resistance to vemurafenib in human B-RAF V600E mutant melanoma. J Biol Chem 287:28087-98, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22730329\">http://www.ncbi.nlm.nih.gov/pubmed/22730329</a></p>\n<p id=\"erb-120d25bc-8fab-4be5-b6a2-72a5948ee4cb\"><a name=\"_ENREF_180\"></a> 180. Villanueva J, Vultur A, Lee JT, et al: Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 18:683-95, 2010. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/21156289\">http://www.ncbi.nlm.nih.gov/pubmed/21156289</a></p>\n<p id=\"erb-5a389de5-d23a-463e-bf4e-cafca62e28db\"><a name=\"_ENREF_181\"></a> 181. Nazarian R, Shi H, Wang Q, et al: Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468:973-7, 2010. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/21107323\">http://www.ncbi.nlm.nih.gov/pubmed/21107323</a></p>\n<p id=\"erb-146bafb5-ee16-43d1-915d-c5a84204226d\"><a name=\"_ENREF_182\"></a> 182. Johannessen CM, Boehm JS, Kim SY, et al: COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 468:968-72, 2010. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/21107320\">http://www.ncbi.nlm.nih.gov/pubmed/21107320</a></p>\n<p id=\"erb-d1d1e8b0-85bf-427f-bbc0-336bc4547355\"><a name=\"_ENREF_183\"></a> 183. Wagle N, Emery C, Berger MF, et al: Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol 29:3085-96, 2011. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/21383288\">http://www.ncbi.nlm.nih.gov/pubmed/21383288</a></p>\n<p id=\"erb-216698bc-0b5b-4a68-bcc8-41ba3ff676fa\"><a name=\"_ENREF_184\"></a> 184. Trunzer K, Pavlick AC, Schuchter L, et al: Pharmacodynamic Effects and Mechanisms of Resistance to Vemurafenib in Patients With Metastatic Melanoma. J Clin Oncol, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23569304\">http://www.ncbi.nlm.nih.gov/pubmed/23569304</a></p>\n<p id=\"erb-ee6c94d3-2846-491e-a3d0-bdea66f1391e\"><a name=\"_ENREF_185\"></a> 185. Shao Y, Aplin AE: Akt3-mediated resistance to apoptosis in B-RAF-targeted melanoma cells. Cancer Res 70:6670-81, 2010. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/20647317\">http://www.ncbi.nlm.nih.gov/pubmed/20647317</a></p>\n<p id=\"erb-19bc8e5f-0de2-45fc-99f6-b94da0ad6dc5\"><a name=\"_ENREF_186\"></a> 186. Jiang CC, Lai F, Thorne RF, et al: MEK-independent survival of B-RAFV600E melanoma cells selected for resistance to apoptosis induced by the RAF inhibitor PLX4720. Clin Cancer Res 17:721-30, 2011. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/21088259\">http://www.ncbi.nlm.nih.gov/pubmed/21088259</a></p>\n<p id=\"erb-4abf1320-5772-4515-a240-f79d9b310385\"><a name=\"_ENREF_187\"></a> 187. Klein RM, Higgins PJ: A switch in RND3-RHOA signaling is critical for melanoma cell invasion following mutant-BRAF inhibition. Mol Cancer 10:114, 2011. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/21917148\">http://www.ncbi.nlm.nih.gov/pubmed/21917148</a></p>\n<p id=\"erb-61663dc8-13e9-48d0-8895-274b88421f3f\"><a name=\"_ENREF_188\"></a> 188. Reuveni H, Flashner-Abramson E, Steiner L, et al: Therapeutic destruction of insulin receptor substrates for cancer treatment. Cancer Res 73:4383-94, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23651636\">http://www.ncbi.nlm.nih.gov/pubmed/23651636</a></p>\n<p id=\"erb-51c564f9-5275-4f76-9cd2-59d578c03e85\"><a name=\"_ENREF_189\"></a> 189. Emery CM, Vijayendran KG, Zipser MC, et al: MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci U S A 106:20411-6, 2009. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/19915144\">http://www.ncbi.nlm.nih.gov/pubmed/19915144</a></p>\n<p id=\"erb-5dcd4587-6155-4f80-b668-f9a62a3f7bf8\"><a name=\"_ENREF_190\"></a> 190. Gopal YN, Deng W, Woodman SE, et al: Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells. Cancer Res 70:8736-47, 2010. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/20959481\">http://www.ncbi.nlm.nih.gov/pubmed/20959481</a></p>\n<p id=\"erb-b3522226-2ae9-4eab-b9dc-6ae4305eb96f\"><a name=\"_ENREF_191\"></a> 191. Sullivan RJ, Flaherty KT: Resistance to BRAF-targeted therapy in melanoma. Eur J Cancer, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23290787\">http://www.ncbi.nlm.nih.gov/pubmed/23290787</a></p>\n<p id=\"erb-4b5ea91d-c16a-468f-b530-9bcff532ecf3\"><a name=\"_ENREF_192\"></a> 192. Morris EJ, Jha S, Restino CR, et al: Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. Cancer Discov, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23614898\">http://www.ncbi.nlm.nih.gov/pubmed/23614898</a></p>\n<p id=\"erb-d4dbb7f4-9fea-4d50-8d81-22f7c44d2ed3\"><a name=\"_ENREF_193\"></a> 193. Duncan JS, Whittle MC, Nakamura K, et al: Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. Cell 149:307-21, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22500798\">http://www.ncbi.nlm.nih.gov/pubmed/22500798</a></p>\n<p id=\"erb-cbf9af8c-389f-42b9-a6fa-e8dcfd7d1caf\"><a name=\"_ENREF_194\"></a> 194. Roller DG, Axelrod M, Capaldo BJ, et al: Synthetic lethal screening with small-molecule inhibitors provides a pathway to rational combination therapies for melanoma. Mol Cancer Ther 11:2505-15, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22962324\">http://www.ncbi.nlm.nih.gov/pubmed/22962324</a></p>\n<p id=\"erb-42633339-9aca-4a3e-bae2-55e7d264369e\"><a name=\"_ENREF_195\"></a> 195. Kawakami Y, Eliyahu S, Delgado CH, et al: Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci U S A 91:3515-9, 1994. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/8170938\">http://www.ncbi.nlm.nih.gov/pubmed/8170938</a></p>\n<p id=\"erb-7cab8cfc-9d3b-4819-b20d-7b6d48da6084\"><a name=\"_ENREF_196\"></a> 196. Slingluff CL, Jr., Petroni GR, Yamshchikov GV, et al: Immunologic and clinical outcomes of vaccination with a multiepitope melanoma peptide vaccine plus low-dose interleukin-2 administered either concurrently or on a delayed schedule. J Clin Oncol 22:4474-85, 2004. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/15542798\">http://www.ncbi.nlm.nih.gov/pubmed/15542798</a></p>\n<p id=\"erb-23b9518a-0682-4736-a9f5-a724aef25e92\"><a name=\"_ENREF_197\"></a> 197. Rosenberg SA, Yang JC, Restifo NP: Cancer immunotherapy: moving beyond current vaccines. Nat Med 10:909-15, 2004. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/15340416\">http://www.ncbi.nlm.nih.gov/pubmed/15340416</a></p>\n<p id=\"erb-eafb7835-6d15-4f77-8dad-88163f271b9d\"><a name=\"_ENREF_198\"></a> 198. Spranger S, Spaapen RM, Zha Y, et al: Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells. Sci Transl Med 5:200ra116, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23986400\">http://www.ncbi.nlm.nih.gov/pubmed/23986400</a></p>\n<p id=\"erb-2ee5d480-a424-43c4-8fbc-1837bcb23bc0\"><a name=\"_ENREF_199\"></a> 199. van Elsas A, Hurwitz AA, Allison JP: Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med 190:355-66, 1999. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/10430624\">http://www.ncbi.nlm.nih.gov/pubmed/10430624</a></p>\n<p id=\"erb-a0c96f00-b081-467d-a858-f6d80ed534c0\"><a name=\"_ENREF_200\"></a> 200. Atkins MB, Lotze MT, Dutcher JP, et al: High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 17:2105-16, 1999. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/10561265\">http://www.ncbi.nlm.nih.gov/pubmed/10561265</a></p>\n<p id=\"erb-0c68e99d-c787-4228-b534-be6a4d6a54f4\"><a name=\"_ENREF_201\"></a> 201. Hodi FS, O'Day SJ, McDermott DF, et al: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711-23, 2010. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/20525992\">http://www.ncbi.nlm.nih.gov/pubmed/20525992</a></p>\n<p id=\"erb-786d30d1-a1ad-4b92-9f2a-edecb80762fa\"><a name=\"_ENREF_202\"></a> 202. Robbins PF, Lu YC, El-Gamil M, et al: Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med 19:747-52, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23644516\">http://www.ncbi.nlm.nih.gov/pubmed/23644516</a></p>\n<p id=\"erb-3ce5096f-1602-4f9d-9b5e-eca701d5e34f\"><a name=\"_ENREF_203\"></a> 203. Ascierto PA, Kalos M, Schaer DA, et al: Biomarkers for Immunostimulatory Monoclonal Antibodies in Combination Strategies for Melanoma and Other Tumor Types. Clin Cancer Res 19:1009-1020, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23460532\">http://www.ncbi.nlm.nih.gov/pubmed/23460532</a></p>\n<p id=\"erb-26b7a019-6574-4297-bf99-8b0b0ce89200\"><a name=\"_ENREF_204\"></a> 204. Peggs KS, Quezada SA, Chambers CA, et al: Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med 206:1717-25, 2009. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/19581407\">http://www.ncbi.nlm.nih.gov/pubmed/19581407</a></p>\n<p id=\"erb-7cdb652b-c634-481a-938c-3be6d723d00b\"><a name=\"_ENREF_205\"></a> 205. Contardi E, Palmisano GL, Tazzari PL, et al: CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction. Int J Cancer 117:538-50, 2005. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/15912538\">http://www.ncbi.nlm.nih.gov/pubmed/15912538</a></p>\n<p id=\"erb-793fa487-9d6f-4b62-aa8f-88dd8fb8aa43\"><a name=\"_ENREF_206\"></a> 206. Shah KV, Chien AJ, Yee C, et al: CTLA-4 is a direct target of Wnt/beta-catenin signaling and is expressed in human melanoma tumors. J Invest Dermatol 128:2870-9, 2008. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/18563180\">http://www.ncbi.nlm.nih.gov/pubmed/18563180</a></p>\n<p id=\"erb-18576e39-9390-4b4b-91a4-2a183e2be907\"><a name=\"_ENREF_207\"></a> 207. Sapoznik S, Hammer O, Ortenberg R, et al: Novel anti-melanoma immunotherapies: disarming tumor escape mechanisms. Clin Dev Immunol 2012:818214, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22778766\">http://www.ncbi.nlm.nih.gov/pubmed/22778766</a></p>\n<p id=\"erb-f6be598e-8a12-43cf-aeb6-b79360187377\"><a name=\"_ENREF_208\"></a> 208. Hamid O, Schmidt H, Nissan A, et al: A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. J Transl Med 9:204, 2011. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22123319\">http://www.ncbi.nlm.nih.gov/pubmed/22123319</a></p>\n<p id=\"erb-9c2b7b63-ea90-4cb6-8944-618dd969afe8\"><a name=\"_ENREF_209\"></a> 209. Holmgaard RB, Zamarin D, Munn DH, et al: Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. J Exp Med, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23752227\">http://www.ncbi.nlm.nih.gov/pubmed/23752227</a></p>\n<p id=\"erb-308694d1-68b8-4cdb-ad92-c4fee6a8b20d\"><a name=\"_ENREF_210\"></a> 210. Iwai Y, Ishida M, Tanaka Y, et al: Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A 99:12293-7, 2002. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/12218188\">http://www.ncbi.nlm.nih.gov/pubmed/12218188</a></p>\n<p id=\"erb-bc51f51a-7fd0-4a7b-964c-281664712c39\"><a name=\"_ENREF_211\"></a> 211. Freeman GJ, Long AJ, Iwai Y, et al: Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 192:1027-34, 2000. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/11015443\">http://www.ncbi.nlm.nih.gov/pubmed/11015443</a></p>\n<p id=\"erb-395739a7-1362-4480-b9e4-506acce4cd44\"><a name=\"_ENREF_212\"></a> 212. Ahmadzadeh M, Johnson LA, Heemskerk B, et al: Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 114:1537-44, 2009. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/19423728\">http://www.ncbi.nlm.nih.gov/pubmed/19423728</a></p>\n<p id=\"erb-8f70326a-7529-4006-b62d-bdcfaed76499\"><a name=\"_ENREF_213\"></a> 213. Topalian SL, Hodi FS, Brahmer JR, et al: Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443-54, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22658127\">http://www.ncbi.nlm.nih.gov/pubmed/22658127</a></p>\n<p id=\"erb-69c3fb22-7aad-40c6-90c9-8eac312baf7c\"><a name=\"_ENREF_214\"></a> 214. Lipson EJ, Sharfman WH, Drake CG, et al: Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody. Clin Cancer Res 19:462-8, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23169436\">http://www.ncbi.nlm.nih.gov/pubmed/23169436</a></p>\n<p id=\"erb-5b381507-55c2-4cee-9b87-ff61fbdbc36e\"><a name=\"_ENREF_215\"></a> 215. Hamid O, Robert C, Daud A, et al: Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma. N Engl J Med, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23724846\">http://www.ncbi.nlm.nih.gov/pubmed/23724846</a></p>\n<p id=\"erb-a81522d1-29f0-4241-a233-665092814b02\"><a name=\"_ENREF_216\"></a> 216. Brahmer JR, Tykodi SS, Chow LQ, et al: Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366:2455-65, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22658128\">http://www.ncbi.nlm.nih.gov/pubmed/22658128</a></p>\n<p id=\"erb-05a04233-ec02-4b8d-b280-05c6e2ae6ab2\"><a name=\"_ENREF_217\"></a> 217. Curran MA, Montalvo W, Yagita H, et al: PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A 107:4275-80, 2010. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/20160101\">http://www.ncbi.nlm.nih.gov/pubmed/20160101</a></p>\n<p id=\"erb-1fc38e37-a15d-4379-8671-2ff462c94ca4\"><a name=\"_ENREF_218\"></a> 218. Wolchok JD, Kluger H, Callahan MK, et al: Nivolumab plus Ipilimumab in Advanced Melanoma. N Engl J Med, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23724867\">http://www.ncbi.nlm.nih.gov/pubmed/23724867</a></p>\n<p id=\"erb-1dcb261a-d6ae-4ba0-9658-a2c5a04b61d7\"><a name=\"_ENREF_219\"></a> 219. Chacon JA, Wu RC, Sukhumalchandra P, et al: Co-Stimulation through 4-1BB/CD137 Improves the Expansion and Function of CD8(+) Melanoma Tumor-Infiltrating Lymphocytes for Adoptive T-Cell Therapy. PLoS One 8:e60031, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23560068\">http://www.ncbi.nlm.nih.gov/pubmed/23560068</a></p>\n<p id=\"erb-86f9e5a4-90c3-4e05-a7d0-31107dc0a67a\"><a name=\"_ENREF_220\"></a> 220. Vonderheide RH, Flaherty KT, Khalil M, et al: Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clin Oncol 25:876-83, 2007. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/17327609\">http://www.ncbi.nlm.nih.gov/pubmed/17327609</a></p>\n<p id=\"erb-ada060ed-33e4-45c0-86db-d3f408e5f037\"><a name=\"_ENREF_221\"></a> 221. Schwartzentruber DJ, Lawson DH, Richards JM, et al: gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med 364:2119-27, 2011. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/21631324\">http://www.ncbi.nlm.nih.gov/pubmed/21631324</a></p>\n<p id=\"erb-fb3b2458-2702-44b1-9d91-ca4daad9f446\"><a name=\"_ENREF_222\"></a> 222. Prieto PA, Yang JC, Sherry RM, et al: CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin Cancer Res 18:2039-47, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22271879\">http://www.ncbi.nlm.nih.gov/pubmed/22271879</a></p>\n<p id=\"erb-8634977f-c091-468e-b977-9d6a743ec966\"><a name=\"_ENREF_223\"></a> 223. Petrella TM, Tozer R, Belanger K, et al: Interleukin-21 has activity in patients with metastatic melanoma: a phase II study. J Clin Oncol 30:3396-401, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22915661\">http://www.ncbi.nlm.nih.gov/pubmed/22915661</a></p>\n<p id=\"erb-60003344-626a-4f53-a42b-8af53028a14b\"><a name=\"_ENREF_224\"></a> 224. Galluzzi L, Vacchelli E, Eggermont A, et al: Trial Watch: Adoptive cell transfer immunotherapy. Oncoimmunology 1:306-315, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22737606\">http://www.ncbi.nlm.nih.gov/pubmed/22737606</a></p>\n<p id=\"erb-3a3e9b99-cb7a-49a6-9187-e8b154e27037\"><a name=\"_ENREF_225\"></a> 225. Itzhaki O, Levy D, Zikich D, et al: Adoptive T-cell transfer in melanoma. Immunotherapy 5:79-90, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23256800\">http://www.ncbi.nlm.nih.gov/pubmed/23256800</a></p>\n<p id=\"erb-6db15a52-67e3-492c-a4a4-1d680fa8f92f\"><a name=\"_ENREF_226\"></a> 226. Rosenberg SA, Yang JC, Sherry RM, et al: Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 17:4550-7, 2011. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/21498393\">http://www.ncbi.nlm.nih.gov/pubmed/21498393</a></p>\n<p id=\"erb-af00a660-b4b2-4ac7-b8b0-d620a6a82340\"><a name=\"_ENREF_227\"></a> 227. Purwar R, Schlapbach C, Xiao S, et al: Robust tumor immunity to melanoma mediated by interleukin-9-producing T cells. Nat Med, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22772464\">http://www.ncbi.nlm.nih.gov/pubmed/22772464</a></p>\n<p id=\"erb-50be168c-8c12-4d33-80bf-6ae7e8e3d0b0\"><a name=\"_ENREF_228\"></a> 228. Ellebaek E, Iversen TZ, Junker N, et al: Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients. J Transl Med 10:169, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22909342\">http://www.ncbi.nlm.nih.gov/pubmed/22909342</a></p>\n<p id=\"erb-990b39cd-ec7e-4865-8f0c-07aeeaef2f23\"><a name=\"_ENREF_229\"></a> 229. Hirschhorn-Cymerman D, Budhu S, Kitano S, et al: Induction of tumoricidal function in CD4+ T cells is associated with concomitant memory and terminally differentiated phenotype. J Exp Med 209:2113-26, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23008334\">http://www.ncbi.nlm.nih.gov/pubmed/23008334</a></p>\n<p id=\"erb-b585c4ef-5c35-459a-a3c1-8bd2de000e19\"><a name=\"_ENREF_230\"></a> 230. Wang A, Chandran S, Shah SA, et al: The stoichiometric production of IL-2 and IFN-gamma mRNA defines memory T cells that can self-renew after adoptive transfer in humans. Sci Transl Med 4:149ra120, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22932225\">http://www.ncbi.nlm.nih.gov/pubmed/22932225</a></p>\n<p id=\"erb-5db54a51-9d51-4893-8c1e-6d5bccc0e57b\"><a name=\"_ENREF_231\"></a> 231. Landsberg J, Kohlmeyer J, Renn M, et al: Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation. Nature 490:412-6, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23051752\">http://www.ncbi.nlm.nih.gov/pubmed/23051752</a></p>\n<p id=\"erb-ef91362d-4b25-4196-af69-322b93c22d29\"><a name=\"_ENREF_232\"></a> 232. Kodumudi KN, Weber A, Sarnaik AA, et al: Blockade of myeloid-derived suppressor cells after induction of lymphopenia improves adoptive T cell therapy in a murine model of melanoma. J Immunol 189:5147-54, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23100512\">http://www.ncbi.nlm.nih.gov/pubmed/23100512</a></p>\n<p id=\"erb-b22f95f5-80a6-41d5-a24c-671362beb14a\"><a name=\"_ENREF_233\"></a> 233. Lu YC, Yao X, Li YF, et al: Mutated PPP1R3B Is Recognized by T Cells Used To Treat a Melanoma Patient Who Experienced a Durable Complete Tumor Regression. J Immunol 190:6034-42, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23690473\">http://www.ncbi.nlm.nih.gov/pubmed/23690473</a></p>\n<p id=\"erb-5a6ef92e-f331-487a-b30d-f58e71a685cb\"><a name=\"_ENREF_234\"></a> 234. Radvanyi LG, Bernatchez C, Zhang M, et al: Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. Clin Cancer Res 18:6758-70, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23032743\">http://www.ncbi.nlm.nih.gov/pubmed/23032743</a></p>\n<p id=\"erb-c597e3f6-9180-4208-8150-d76715efefa2\"><a name=\"_ENREF_235\"></a> 235. Dudley ME, Gross CA, Somerville RP, et al: Randomized Selection Design Trial Evaluating CD8+-Enriched Versus Unselected Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy for Patients With Melanoma. J Clin Oncol 31:2152-9, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23650429\">http://www.ncbi.nlm.nih.gov/pubmed/23650429</a></p>\n<p id=\"erb-95dbfec0-ba2d-4b6b-9116-400903317bf9\"><a name=\"_ENREF_236\"></a> 236. Butler MO, Friedlander P, Milstein MI, et al: Establishment of antitumor memory in humans using in vitro-educated CD8+ T cells. Sci Transl Med 3:80ra34, 2011. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/21525398\">http://www.ncbi.nlm.nih.gov/pubmed/21525398</a></p>\n<p id=\"erb-b90c1fd2-37f4-4290-9251-b5a673a3f2b8\"><a name=\"_ENREF_237\"></a> 237. Kershaw MH, Westwood JA, Darcy PK: Gene-engineered T cells for cancer therapy. Nat Rev Cancer 13:525-41, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23880905\">http://www.ncbi.nlm.nih.gov/pubmed/23880905</a></p>\n<p id=\"erb-d61657d6-fc35-4309-a719-4fd27556aa86\"><a name=\"_ENREF_238\"></a> 238. Stauss HJ, Morris EC: Immunotherapy with gene-modified T cells: limiting side effects provides new challenges. Gene Ther, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23804078\">http://www.ncbi.nlm.nih.gov/pubmed/23804078</a></p>\n<p id=\"erb-98d081c3-3ab7-4bda-acca-55476a3dc766\"><a name=\"_ENREF_239\"></a> 239. Robbins PF, Morgan RA, Feldman SA, et al: Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol 29:917-24, 2011. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/21282551\">http://www.ncbi.nlm.nih.gov/pubmed/21282551</a></p>\n<p id=\"erb-d0a6dfa2-9e75-486d-a2d4-21181085457e\"><a name=\"_ENREF_240\"></a> 240. Hunder NN, Wallen H, Cao J, et al: Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med 358:2698-703, 2008. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/18565862\">http://www.ncbi.nlm.nih.gov/pubmed/18565862</a></p>\n<p id=\"erb-4ae1c66f-9678-473a-abe4-afc48de981ec\"><a name=\"_ENREF_241\"></a> 241. Braumuller H, Wieder T, Brenner E, et al: T-helper-1-cell cytokines drive cancer into senescence. Nature, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23376950\">http://www.ncbi.nlm.nih.gov/pubmed/23376950</a></p>\n<p id=\"erb-375d0845-051b-420c-a319-ec290ff8034f\"><a name=\"_ENREF_242\"></a> 242. Palucka K, Banchereau J: Cancer immunotherapy via dendritic cells. Nat Rev Cancer 12:265-77, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22437871\">http://www.ncbi.nlm.nih.gov/pubmed/22437871</a></p>\n<p id=\"erb-485dca96-e754-4e0b-86e7-382caba1f872\"><a name=\"_ENREF_243\"></a> 243. Nestle FO, Alijagic S, Gilliet M, et al: Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 4:328-32, 1998. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/9500607\">http://www.ncbi.nlm.nih.gov/pubmed/9500607</a></p>\n<p id=\"erb-1a266cc6-88ae-4d70-8a9e-0c00a6502ab2\"><a name=\"_ENREF_244\"></a> 244. Thurner B, Haendle I, Roder C, et al: Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 190:1669-78, 1999. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/10587357\">http://www.ncbi.nlm.nih.gov/pubmed/10587357</a></p>\n<p id=\"erb-521ae3a6-10a5-4614-bb85-72b96c3ec426\"><a name=\"_ENREF_245\"></a> 245. Mackensen A, Herbst B, Chen JL, et al: Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34(+) hematopoietic progenitor cells. Int J Cancer 86:385-92, 2000. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/10760827\">http://www.ncbi.nlm.nih.gov/pubmed/10760827</a></p>\n<p id=\"erb-abaf1312-f63c-48d7-891f-a8eea7767043\"><a name=\"_ENREF_246\"></a> 246. Romano E, Rossi M, Ratzinger G, et al: Peptide-loaded Langerhans cells, despite increased IL15 secretion and T-cell activation in vitro, elicit antitumor T-cell responses comparable to peptide-loaded monocyte-derived dendritic cells in vivo. Clin Cancer Res 17:1984-97, 2011. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/21355077\">http://www.ncbi.nlm.nih.gov/pubmed/21355077</a></p>\n<p id=\"erb-7c351349-58ec-4bcc-af24-5fc0aa9f6462\"><a name=\"_ENREF_247\"></a> 247. Verdijk P, Aarntzen EH, Lesterhuis WJ, et al: Limited amounts of dendritic cells migrate into the T-cell area of lymph nodes but have high immune activating potential in melanoma patients. Clin Cancer Res 15:2531-40, 2009. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/19318472\">http://www.ncbi.nlm.nih.gov/pubmed/19318472</a></p>\n<p id=\"erb-affc4a42-5f3f-4dec-8113-3bef1f144a42\"><a name=\"_ENREF_248\"></a> 248. Lesterhuis WJ, de Vries IJ, Schreibelt G, et al: Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients. Clin Cancer Res 17:5725-35, 2011. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/21771874\">http://www.ncbi.nlm.nih.gov/pubmed/21771874</a></p>\n<p id=\"erb-9b6e7fbf-b20f-48d8-aa47-6629d57a4602\"><a name=\"_ENREF_249\"></a> 249. Mitchell DA, Nair SK: RNA-transfected dendritic cells in cancer immunotherapy. J Clin Invest 106:1065-9, 2000. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/11067858\">http://www.ncbi.nlm.nih.gov/pubmed/11067858</a></p>\n<p id=\"erb-e6a74285-668d-47ce-8303-17b47798d7fd\"><a name=\"_ENREF_250\"></a> 250. Aarntzen EH, Schreibelt G, Bol K, et al: Vaccination with mRNA-electroporated dendritic cells induces robust tumor antigen-specific CD4+ and CD8+ T cells responses in stage III and IV melanoma patients. Clin Cancer Res 18:5460-70, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22896657\">http://www.ncbi.nlm.nih.gov/pubmed/22896657</a></p>\n<p id=\"erb-400d87d8-f89b-4937-8bca-ee73879b77b9\"><a name=\"_ENREF_251\"></a> 251. Dannull J, Haley NR, Archer G, et al: Melanoma immunotherapy using mature DCs expressing the constitutive proteasome. J Clin Invest 123:3135-45, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23934126\">http://www.ncbi.nlm.nih.gov/pubmed/23934126</a></p>\n<p id=\"erb-420a1c61-a747-4fee-82fc-2ef28b75a18c\"><a name=\"_ENREF_252\"></a> 252. Carreno BM, Becker-Hapak M, Huang A, et al: IL-12p70-producing patient DC vaccine elicits Tc1-polarized immunity. J Clin Invest, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23867552\">http://www.ncbi.nlm.nih.gov/pubmed/23867552</a></p>\n<p id=\"erb-bbbb25e6-4b97-469c-9a29-5753142a6b50\"><a name=\"_ENREF_253\"></a> 253. Ribas A, Comin-Anduix B, Chmielowski B, et al: Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma. Clin Cancer Res 15:6267-76, 2009. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/19789309\">http://www.ncbi.nlm.nih.gov/pubmed/19789309</a></p>\n<p id=\"erb-97678c1f-7669-4788-95ab-3ba6fa447195\"><a name=\"_ENREF_254\"></a> 254. Rosenberg SA, Lotze MT, Yang JC, et al: Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst 85:622-32, 1993. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/8468720\">http://www.ncbi.nlm.nih.gov/pubmed/8468720</a></p>\n<p id=\"erb-5ca51819-da9d-466d-b60e-b69995abd770\"><a name=\"_ENREF_255\"></a> 255. Parkhurst MR, Riley JP, Dudley ME, et al: Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression. Clin Cancer Res 17:6287-97, 2011. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/21844012\">http://www.ncbi.nlm.nih.gov/pubmed/21844012</a></p>\n<p id=\"erb-e6e28106-e7f2-4607-a8af-c28c0d0253c2\"><a name=\"_ENREF_256\"></a> 256. Besser MJ, Shoham T, Harari-Steinberg O, et al: Development of allogeneic NK cell adoptive transfer therapy in metastatic melanoma patients: in vitro preclinical optimization studies. PLoS One 8:e57922, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23483943\">http://www.ncbi.nlm.nih.gov/pubmed/23483943</a></p>\n<p id=\"erb-5e05c404-4841-4f32-aa5f-2282c27e9cf0\"><a name=\"_ENREF_257\"></a> 257. Gammaitoni L, Giraudo L, Leuci V, et al: Effective Activity of Cytokine Induced Killer Cells against Autologous Metastatic Melanoma including Cells with Stemness Features. Clin Cancer Res, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23794732\">http://www.ncbi.nlm.nih.gov/pubmed/23794732</a></p>\n<p id=\"erb-8806de99-b7c1-4807-a412-d8ea9dfc9cc4\"><a name=\"_ENREF_258\"></a> 258. Sumimoto H, Imabayashi F, Iwata T, et al: The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells. J Exp Med 203:1651-6, 2006. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/16801397\">http://www.ncbi.nlm.nih.gov/pubmed/16801397</a></p>\n<p id=\"erb-14448a4d-0ba0-4737-97ee-8c848cd48454\"><a name=\"_ENREF_259\"></a> 259. Kono M, Dunn IS, Durda PJ, et al: Role of the mitogen-activated protein kinase signaling pathway in the regulation of human melanocytic antigen expression. Mol Cancer Res 4:779-92, 2006. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/17050671\">http://www.ncbi.nlm.nih.gov/pubmed/17050671</a></p>\n<p id=\"erb-615d585f-be2d-4aca-94e6-ab11ad79d31d\"><a name=\"_ENREF_260\"></a> 260. Khalili JS, Liu S, Rodriguez-Cruz TG, et al: Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma. Clin Cancer Res 18:5329-40, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22850568\">http://www.ncbi.nlm.nih.gov/pubmed/22850568</a></p>\n<p id=\"erb-e4e30ea9-62ec-4945-a197-2cd104342026\"><a name=\"_ENREF_261\"></a> 261. Knight DA, Ngiow SF, Li M, et al: Host immunity contributes to the anti-melanoma activity of BRAF inhibitors. J Clin Invest 123:1371-81, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23454771\">http://www.ncbi.nlm.nih.gov/pubmed/23454771</a></p>\n<p id=\"erb-9fec53e1-51ad-44ca-b803-d4d8fa179141\"><a name=\"_ENREF_262\"></a> 262. Boni A, Cogdill AP, Dang P, et al: Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res 70:5213-9, 2010. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/20551059\">http://www.ncbi.nlm.nih.gov/pubmed/20551059</a></p>\n<p id=\"erb-cd48a73c-04fa-4066-8555-c0bdeffac62e\"><a name=\"_ENREF_263\"></a> 263. Wilmott JS, Long GV, Howle JR, et al: Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin Cancer Res 18:1386-94, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22156613\">http://www.ncbi.nlm.nih.gov/pubmed/22156613</a></p>\n<p id=\"erb-65f4d9ff-2384-4835-95aa-121e4e4699b0\"><a name=\"_ENREF_264\"></a> 264. Hong DS, Vence L, Falchook G, et al: BRAF(V600) inhibitor GSK2118436 targeted inhibition of mutant BRAF in cancer patients does not impair overall immune competency. Clin Cancer Res 18:2326-35, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22355009\">http://www.ncbi.nlm.nih.gov/pubmed/22355009</a></p>\n<p id=\"erb-83d38e19-c842-475c-ab6a-0293c45e2205\"><a name=\"_ENREF_265\"></a> 265. Hooijkaas A, Gadiot J, Morrow M, et al: Selective BRAF inhibition decreases tumor-resident lymphocyte frequencies in a mouse model of human melanoma. Oncoimmunology 1:609-617, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22934253\">http://www.ncbi.nlm.nih.gov/pubmed/22934253</a></p>\n<p id=\"erb-d754715b-441f-4f1c-9381-b158f500c321\"><a name=\"_ENREF_266\"></a> 266. Frederick DT, Piris A, Cogdill AP, et al: BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma. Clin Cancer Res, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23307859\">http://www.ncbi.nlm.nih.gov/pubmed/23307859</a></p>\n<p id=\"erb-de471d03-1467-4626-a83d-cda77aee0ca8\"><a name=\"_ENREF_267\"></a> 267. Koya RC, Mok S, Otte N, et al: BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy. Cancer Res 72:3928-37, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22693252\">http://www.ncbi.nlm.nih.gov/pubmed/22693252</a></p>\n<p id=\"erb-a7ef2912-04b5-4959-9325-5217f4bcc8cf\"><a name=\"_ENREF_268\"></a> 268. Liu C, Peng W, Xu C, et al: BRAF Inhibition Increases Tumor Infiltration by T cells and Enhances the Antitumor Activity of Adoptive Immunotherapy in Mice. Clin Cancer Res 19:393-403, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23204132\">http://www.ncbi.nlm.nih.gov/pubmed/23204132</a></p>\n<p id=\"erb-53a66a8f-e6bc-47e0-9fd4-a0172e74ca7c\"><a name=\"_ENREF_269\"></a> 269. Ott PA, Henry T, Baranda SJ, et al: Inhibition of both BRAF and MEK in BRAF(V600E) mutant melanoma restores compromised dendritic cell (DC) function while having differential direct effects on DC properties. Cancer Immunol Immunother, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23306863\">http://www.ncbi.nlm.nih.gov/pubmed/23306863</a></p>\n<p id=\"erb-834283ea-0b02-4ea0-82c4-2345e4caa37c\"><a name=\"_ENREF_270\"></a> 270. Donia M, Fagone P, Nicoletti F, et al: BRAF inhibition improves tumor recognition by the immune system: Potential implications for combinatorial therapies against melanoma involving adoptive T-cell transfer. Oncoimmunology 1:1476-1483, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23264894\">http://www.ncbi.nlm.nih.gov/pubmed/23264894</a></p>\n<p id=\"erb-5970b0f8-5edf-4ad9-8144-2f99467a6795\"><a name=\"_ENREF_271\"></a> 271. Ribas A, Hodi FS, Callahan M, et al: Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med 368:1365-6, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23550685\">http://www.ncbi.nlm.nih.gov/pubmed/23550685</a></p>\n<p id=\"erb-d34536a1-442f-414d-9ca9-dfcd910b5288\"><a name=\"_ENREF_272\"></a> 272. Joseph RW, Sullivan RJ, Harrell R, et al: Correlation of NRAS mutations with clinical response to high-dose IL-2 in patients with advanced melanoma. J Immunother 35:66-72, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22130161\">http://www.ncbi.nlm.nih.gov/pubmed/22130161</a></p>\n<p id=\"erb-dd9a2a4a-726a-48be-a1ac-03ed009f73ba\"><a name=\"_ENREF_273\"></a> 273. Yaguchi T, Goto Y, Kido K, et al: Immune suppression and resistance mediated by constitutive activation of Wnt/beta-catenin signaling in human melanoma cells. J Immunol 189:2110-7, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22815287\">http://www.ncbi.nlm.nih.gov/pubmed/22815287</a></p>\n<p id=\"erb-79b95c00-609c-4ec5-91cb-cdc62394c82c\"><a name=\"_ENREF_274\"></a> 274. Gilbert AE, Karagiannis P, Dodev T, et al: Monitoring the systemic human memory B cell compartment of melanoma patients for anti-tumor IgG antibodies. PLoS One 6:e19330, 2011. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/21559411\">http://www.ncbi.nlm.nih.gov/pubmed/21559411</a></p>\n<p id=\"erb-37ff9cb4-cb0f-466d-a92c-565e22c95311\"><a name=\"_ENREF_275\"></a> 275. Carpenter EL, Mick R, Rech AJ, et al: Collapse of the CD27+ B-cell compartment associated with systemic plasmacytosis in patients with advanced melanoma and other cancers. Clin Cancer Res 15:4277-87, 2009. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/19549767\">http://www.ncbi.nlm.nih.gov/pubmed/19549767</a></p>\n<p id=\"erb-638d4036-5620-445a-848f-e3772d4845d9\"><a name=\"_ENREF_276\"></a> 276. Karagiannis P, Gilbert AE, Josephs DH, et al: IgG4 subclass antibodies impair antitumor immunity in melanoma. J Clin Invest, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23454746\">http://www.ncbi.nlm.nih.gov/pubmed/23454746</a></p>\n<p id=\"erb-d4f8a087-a4a2-453a-8071-cbb33109ebf0\"><a name=\"_ENREF_277\"></a> 277. Jochems C, Schlom J: Tumor-infiltrating immune cells and prognosis: the potential link between conventional cancer therapy and immunity. Exp Biol Med (Maywood) 236:567-79, 2011. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/21486861\">http://www.ncbi.nlm.nih.gov/pubmed/21486861</a></p>\n<p id=\"erb-eca88b02-6fa2-40d1-a5bf-acb1224fbbbe\"><a name=\"_ENREF_278\"></a> 278. Messina JL, Fenstermacher DA, Eschrich S, et al: 12-Chemokine gene signature identifies lymph node-like structures in melanoma: potential for patient selection for immunotherapy? Sci Rep 2:765, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23097687\">http://www.ncbi.nlm.nih.gov/pubmed/23097687</a></p>\n<p id=\"erb-0d010c01-34eb-45e3-b040-5b97c6755184\"><a name=\"_ENREF_279\"></a> 279. Sonveaux P, Vegran F, Schroeder T, et al: Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J Clin Invest 118:3930-42, 2008. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/19033663\">http://www.ncbi.nlm.nih.gov/pubmed/19033663</a></p>\n<p id=\"erb-55b6bf78-3b21-4f4e-a82a-0b8e3aef2da1\"><a name=\"_ENREF_280\"></a> 280. O'Day SJ, Eggermont AM, Chiarion-Sileni V, et al: Final Results of Phase III SYMMETRY Study: Randomized, Double-Blind Trial of Elesclomol Plus Paclitaxel Versus Paclitaxel Alone As Treatment for Chemotherapy-Naive Patients With Advanced Melanoma. J Clin Oncol, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23401447\">http://www.ncbi.nlm.nih.gov/pubmed/23401447</a></p>\n<p id=\"erb-8d4253d8-5185-48bf-9e8a-5e75c89000c6\"><a name=\"_ENREF_281\"></a> 281. Roesch A, Fukunaga-Kalabis M, Schmidt EC, et al: A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell 141:583-94, 2010. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/20478252\">http://www.ncbi.nlm.nih.gov/pubmed/20478252</a></p>\n<p id=\"erb-7c0bbe05-f37f-4c49-9d0b-d9bdbc95fd35\"><a name=\"_ENREF_282\"></a> 282. Roesch A, Vultur A, Bogeski I, et al: Overcoming Intrinsic Multidrug Resistance in Melanoma by Blocking the Mitochondrial Respiratory Chain of Slow-Cycling JARID1B(high) Cells. Cancer Cell 23:811-25, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23764003\">http://www.ncbi.nlm.nih.gov/pubmed/23764003</a></p>\n<p id=\"erb-c5af78ac-eb0e-4a09-b411-67a893d7ff85\"><a name=\"_ENREF_283\"></a> 283. Kaplon J, Zheng L, Meissl K, et al: A key role for mitochondrial gatekeeper pyruvate dehydrogenase in oncogene-induced senescence. Nature, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23685455\">http://www.ncbi.nlm.nih.gov/pubmed/23685455</a></p>\n<p id=\"erb-0fad9505-d169-44d4-80f1-f168d9f8a12e\"><a name=\"_ENREF_284\"></a> 284. Dillon BJ, Prieto VG, Curley SA, et al: Incidence and distribution of argininosuccinate synthetase deficiency in human cancers: a method for identifying cancers sensitive to arginine deprivation. Cancer 100:826-33, 2004. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/14770441\">http://www.ncbi.nlm.nih.gov/pubmed/14770441</a></p>\n<p id=\"erb-dc76ae30-0fdc-4f94-9586-94bf9e3adac4\"><a name=\"_ENREF_285\"></a> 285. Yoon JK, Frankel AE, Feun LG, et al: Arginine deprivation therapy for malignant melanoma. Clin Pharmacol 5:11-9, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23293541\">http://www.ncbi.nlm.nih.gov/pubmed/23293541</a></p>\n<p id=\"erb-69fb32b6-e754-474d-ad5b-a83810d11ff2\"><a name=\"_ENREF_286\"></a> 286. Sheen JH, Zoncu R, Kim D, et al: Defective regulation of autophagy upon leucine deprivation reveals a targetable liability of human melanoma cells in vitro and in vivo. Cancer Cell 19:613-28, 2011. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/21575862\">http://www.ncbi.nlm.nih.gov/pubmed/21575862</a></p>\n<p id=\"erb-151440e9-2035-4af4-bbed-fd2d10f86b8b\"><a name=\"_ENREF_287\"></a> 287. Tomic T, Botton T, Cerezo M, et al: Metformin inhibits melanoma development through autophagy and apoptosis mechanisms. Cell Death Dis 2:e199, 2011. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/21881601\">http://www.ncbi.nlm.nih.gov/pubmed/21881601</a></p>\n<p id=\"erb-b00ae624-3b27-487b-8f92-092249591aa3\"><a name=\"_ENREF_288\"></a> 288. Li H, Li Y, Jiao J, et al: Alpha-alumina nanoparticles induce efficient autophagy-dependent cross-presentation and potent antitumour response. Nat Nanotechnol 6:645-50, 2011. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/21926980\">http://www.ncbi.nlm.nih.gov/pubmed/21926980</a></p>\n<p id=\"erb-f6e71b4f-a8a4-4a6c-9ee7-e772bc36a0de\"><a name=\"_ENREF_289\"></a> 289. Li Y, Wang LX, Pang P, et al: Tumor-derived autophagosome vaccine: mechanism of cross-presentation and therapeutic efficacy. Clin Cancer Res 17:7047-57, 2011. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22068657\">http://www.ncbi.nlm.nih.gov/pubmed/22068657</a></p>\n<p id=\"erb-b69da3b0-d636-4fa2-a354-1f57a1bc1ed1\"><a name=\"_ENREF_290\"></a> 290. Liang X, De Vera ME, Buchser WJ, et al: Inhibiting systemic autophagy during interleukin 2 immunotherapy promotes long-term tumor regression. Cancer Res 72:2791-801, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22472122\">http://www.ncbi.nlm.nih.gov/pubmed/22472122</a></p>\n<p id=\"erb-81a48223-3967-48ca-8aac-2d99a73a20e6\"><a name=\"_ENREF_291\"></a> 291. Lotze MT, Buchser WJ, Liang X: Blocking the interleukin 2 (IL2)-induced systemic autophagic syndrome promotes profound antitumor effects and limits toxicity. Autophagy 8:1264-6, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22660171\">http://www.ncbi.nlm.nih.gov/pubmed/22660171</a></p>\n<p id=\"erb-473c4a5f-57e8-4b2c-9825-019bf28fa8a3\"><a name=\"_ENREF_292\"></a> 292. Ireland A, Millward M, Pearce R, et al: Genetic factors in metastatic progression of cutaneous melanoma: the future role of circulating melanoma cells in prognosis and management. Clin Exp Metastasis 28:327-36, 2011. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/21311956\">http://www.ncbi.nlm.nih.gov/pubmed/21311956</a></p>\n<p id=\"erb-ebfc8c62-9690-4c1b-803a-bc54361d155c\"><a name=\"_ENREF_293\"></a> 293. Tanaka R, Koyanagi K, Narita N, et al: Prognostic molecular biomarkers for cutaneous malignant melanoma. J Surg Oncol 104:438-46, 2011. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/21557225\">http://www.ncbi.nlm.nih.gov/pubmed/21557225</a></p>\n<p id=\"erb-e37977d8-0cd2-4f4f-9993-9fd71fa76fb1\"><a name=\"_ENREF_294\"></a> 294. Smith B, Selby P, Southgate J, et al: Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction. Lancet 338:1227-9, 1991. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/1719320\">http://www.ncbi.nlm.nih.gov/pubmed/1719320</a></p>\n<p id=\"erb-86653e1d-6c50-4279-b911-658d7e6307e4\"><a name=\"_ENREF_295\"></a> 295. Mocellin S, Del Fiore P, Guarnieri L, et al: Molecular detection of circulating tumor cells is an independent prognostic factor in patients with high-risk cutaneous melanoma. Int J Cancer 111:741-5, 2004. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/15252844\">http://www.ncbi.nlm.nih.gov/pubmed/15252844</a></p>\n<p id=\"erb-7c576888-fdb8-4c62-b3f2-bdde4bf83403\"><a name=\"_ENREF_296\"></a> 296. Koyanagi K, O'Day SJ, Boasberg P, et al: Serial monitoring of circulating tumor cells predicts outcome of induction biochemotherapy plus maintenance biotherapy for metastatic melanoma. Clin Cancer Res 16:2402-8, 2010. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/20371696\">http://www.ncbi.nlm.nih.gov/pubmed/20371696</a></p>\n<p id=\"erb-e2268412-c963-42b6-8035-a352535af5a3\"><a name=\"_ENREF_297\"></a> 297. Hoshimoto S, Faries MB, Morton DL, et al: Assessment of prognostic circulating tumor cells in a phase III trial of adjuvant immunotherapy after complete resection of stage IV melanoma. Ann Surg 255:357-62, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22202581\">http://www.ncbi.nlm.nih.gov/pubmed/22202581</a></p>\n<p id=\"erb-58f29b04-078d-4b9d-b869-20181b7f10a9\"><a name=\"_ENREF_298\"></a> 298. Hoshimoto S, Shingai T, Morton DL, et al: Association between circulating tumor cells and prognosis in patients with stage III melanoma with sentinel lymph node metastasis in a phase III international multicenter trial. J Clin Oncol 30:3819-26, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23008288\">http://www.ncbi.nlm.nih.gov/pubmed/23008288</a></p>\n<p id=\"erb-1becedd0-cbfd-4198-99dc-de3d12308ab3\"><a name=\"_ENREF_299\"></a> 299. Reid AL, Millward M, Pearce R, et al: Markers of circulating tumour cells in the peripheral blood of patients with melanoma correlate with disease recurrence and progression. Br J Dermatol 168:85-92, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23013138\">http://www.ncbi.nlm.nih.gov/pubmed/23013138</a></p>\n<p id=\"erb-e71b38c3-2f25-49e0-bd29-be88495f10b6\"><a name=\"_ENREF_300\"></a> 300. Fusi A, Liu Z, Kummerlen V, et al: Expression of chemokine receptors on circulating tumor cells in patients with solid tumors. J Transl Med 10:52, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22433180\">http://www.ncbi.nlm.nih.gov/pubmed/22433180</a></p>\n<p id=\"erb-f63189e0-031e-4ffa-8095-fa2e0a891cb4\"><a name=\"_ENREF_301\"></a> 301. Khoja L, Lorigan P, Zhou C, et al: Biomarker Utility of Circulating Tumor Cells in Metastatic Cutaneous Melanoma. J Invest Dermatol, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23223143\">http://www.ncbi.nlm.nih.gov/pubmed/23223143</a></p>\n<p id=\"erb-35528e3a-38b8-4486-b1bd-859dc1a08f8f\"><a name=\"_ENREF_302\"></a> 302. Le Rhun E, Tu Q, De Carvalho Bittencourt M, et al: Detection and quantification of CSF malignant cells by the CellSearch technology in patients with melanoma leptomeningeal metastasis. Med Oncol 30:538, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23504338\">http://www.ncbi.nlm.nih.gov/pubmed/23504338</a></p>\n<p id=\"erb-2180434e-c695-4224-8247-592672ad9d2e\"><a name=\"_ENREF_303\"></a> 303. De Giorgi V, Pinzani P, Salvianti F, et al: Application of a filtration- and isolation-by-size technique for the detection of circulating tumor cells in cutaneous melanoma. J Invest Dermatol 130:2440-7, 2010. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/20535130\">http://www.ncbi.nlm.nih.gov/pubmed/20535130</a></p>\n<p id=\"erb-cb2cd1bb-4df2-487d-9efe-4defe6f7713a\"><a name=\"_ENREF_304\"></a> 304. De Giorgi V, Pinzani P, Salvianti F, et al: Circulating benign nevus cells detected by ISET technique: warning for melanoma molecular diagnosis. Arch Dermatol 146:1120-4, 2010. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/20956643\">http://www.ncbi.nlm.nih.gov/pubmed/20956643</a></p>\n<p id=\"erb-5e88fe9c-6721-4eb6-b4a2-239000de73e2\"><a name=\"_ENREF_305\"></a> 305. Galanzha EI, Shashkov EV, Spring PM, et al: In vivo, noninvasive, label-free detection and eradication of circulating metastatic melanoma cells using two-color photoacoustic flow cytometry with a diode laser. Cancer Res 69:7926-34, 2009. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/19826056\">http://www.ncbi.nlm.nih.gov/pubmed/19826056</a></p>\n<p id=\"erb-72a3b065-6831-4fdb-b632-274fde606356\"><a name=\"_ENREF_306\"></a> 306. O'Brien CM, Rood KD, Bhattacharyya K, et al: Capture of circulating tumor cells using photoacoustic flowmetry and two phase flow. J Biomed Opt 17:061221, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22734751\">http://www.ncbi.nlm.nih.gov/pubmed/22734751</a></p>\n<p id=\"erb-b0447128-64a4-4643-ba6d-e6d56edac620\"><a name=\"_ENREF_307\"></a> 307. Hou S, Zhao L, Shen Q, et al: Polymer nanofiber-embedded microchips for detection, isolation, and molecular analysis of single circulating melanoma cells. Angew Chem Int Ed Engl 52:3379-83, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23436302\">http://www.ncbi.nlm.nih.gov/pubmed/23436302</a></p>\n<p id=\"erb-9d42f9aa-a446-4ec0-a39e-361ddc14cc53\"><a name=\"_ENREF_308\"></a> 308. Ozkumur E, Shah AM, Ciciliano JC, et al: Inertial focusing for tumor antigen-dependent and -independent sorting of rare circulating tumor cells. Sci Transl Med 5:179ra47, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23552373\">http://www.ncbi.nlm.nih.gov/pubmed/23552373</a></p>\n<p id=\"erb-cadfea13-6bd8-4b7f-b13f-fe5e51d279c8\"><a name=\"_ENREF_309\"></a> 309. Adebayo Awe J, Xu MC, Wechsler J, et al: Three-Dimensional Telomeric Analysis of Isolated Circulating Tumor Cells (CTCs) Defines CTC Subpopulations. Transl Oncol 6:51-65, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23418617\">http://www.ncbi.nlm.nih.gov/pubmed/23418617</a></p>\n<p id=\"erb-7da7ed0b-9aab-4d2a-97eb-61e1b0715ff0\"><a name=\"_ENREF_310\"></a> 310. Fusi A, Berdel R, Havemann S, et al: Enhanced detection of BRAF-mutants by pre-PCR cleavage of wild-type sequences revealed circulating melanoma cells heterogeneity. Eur J Cancer 47:1971-6, 2011. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/21570823\">http://www.ncbi.nlm.nih.gov/pubmed/21570823</a></p>\n<p id=\"erb-ddc575b0-ea76-4778-a68d-0b686295e4e5\"><a name=\"_ENREF_311\"></a> 311. Sakaizawa K, Goto Y, Kiniwa Y, et al: Mutation analysis of BRAF and KIT in circulating melanoma cells at the single cell level. Br J Cancer 106:939-46, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22281663\">http://www.ncbi.nlm.nih.gov/pubmed/22281663</a></p>\n<p id=\"erb-f3ceef83-603f-46c0-9975-fca24e8d2537\"><a name=\"_ENREF_312\"></a> 312. Dawson SJ, Tsui DW, Murtaza M, et al: Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med 368:1199-209, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23484797\">http://www.ncbi.nlm.nih.gov/pubmed/23484797</a></p>\n<p id=\"erb-348094b1-f1b4-4a4d-abd2-b7fd9922d521\"><a name=\"_ENREF_313\"></a> 313. Murtaza M, Dawson SJ, Tsui DW, et al: Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23563269\">http://www.ncbi.nlm.nih.gov/pubmed/23563269</a></p>\n<p id=\"erb-76874cf4-0a07-45b6-836f-7fab0baab039\"><a name=\"_ENREF_314\"></a> 314. Harbour JW, Chen R: The DecisionDx-UM Gene Expression Profile Test Provides Risk Stratification and Individualized Patient Care in Uveal Melanoma. PLoS Curr 5, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23591547\">http://www.ncbi.nlm.nih.gov/pubmed/23591547</a></p>\n<p id=\"erb-92273fde-003b-49df-8aa7-1f963ee6c7dc\"><a name=\"_ENREF_315\"></a> 315. Ohno S, Ishikawa A, Kuroda M: Roles of exosomes and microvesicles in disease pathogenesis. Adv Drug Deliv Rev 65:398-401, 2013. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22981801\">http://www.ncbi.nlm.nih.gov/pubmed/22981801</a></p>\n<p id=\"erb-d3eb8d62-8311-4119-99b9-3cbc3f21dd65\"><a name=\"_ENREF_316\"></a> 316. Peinado H, Aleckovic M, Lavotshkin S, et al: Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med 18:883-91, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22635005\">http://www.ncbi.nlm.nih.gov/pubmed/22635005</a></p>\n\n\n", 
        "publication_link": "http://www.example.com/", 
        "revision_date": "2013-09-09T20:50:22Z", 
        "publication_date": "2013-08-13T22:49:50Z", 
        "title": "Old version: Pathways and Therapeutic Targets of Melanoma"
    }
},
{
    "pk": 3856, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "The revolutionary discovery of a striking, if temporary, effect that targeted inhibition of BRAF has", 
        "paper": 3, 
        "tag_id": "erb-5d8c5ee9-730e-4196-a05a-6410357f4e11"
    }
},
{
    "pk": 3857, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "The mutational landscape of melanoma was examined in several large studies employing NGS (next-gener", 
        "paper": 3, 
        "tag_id": "erb-b8608426-6d28-4fe8-aad9-7771a5364d67"
    }
},
{
    "pk": 3858, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "In one recent study 1, a wide range of point-mutation rates was observed: they were lowest in melano", 
        "paper": 3, 
        "tag_id": "erb-93120161-84be-419f-9bc0-9d90b08c4efc"
    }
},
{
    "pk": 3859, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "The different types of melanoma appear to have distinct sets of relevant somatogenic alterations (Ta", 
        "paper": 3, 
        "tag_id": "erb-6932eba6-0670-41c7-ba37-f0015e23cb3f"
    }
},
{
    "pk": 3860, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "This paper describes genetic alterations that are known to occur in melanoma and information about t", 
        "paper": 3, 
        "tag_id": "erb-00a28a48-20a6-43d0-a52b-4c277df6a9c7"
    }
},
{
    "pk": 3861, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Multiple cellular pathways have been implicated in melanomagenesis, ranging from signal transduction", 
        "paper": 3, 
        "tag_id": "erb-09064d79-b381-4456-9575-37bc083389eb"
    }
},
{
    "pk": 3862, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "\n\n\n\n\n\n\n\n\nPATHWAY*\n\n\nCOMPONENTS MUTATED/ACTIVATED\n\n\nTYPE OF ALTERATION\n\n\n\n\n\u00a0\n\u00a0\nReceptor tyrosine kina", 
        "paper": 3, 
        "tag_id": "erb-87dc1858-b815-4ba2-acc9-2b25f873ee99"
    }
},
{
    "pk": 3863, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Table 1 summarizes the molecular pathways involved in melanomagenesis, and Table 2 lists the known d", 
        "paper": 3, 
        "tag_id": "erb-0a6c4b32-9845-4c1c-8cdf-5c069212ae31"
    }
},
{
    "pk": 3864, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "\n\n\n\n\n\n\n\n\n\n\n\nPRIMARY SUBTYPES\n\n\nPATHWAY \n\n\nABERRATION\n\n\nFOUND IN TUMORS WITH\u2026\n\n\nFREQUENCY\n\n\nPOSSIBLE ", 
        "paper": 3, 
        "tag_id": "erb-20be40f0-a1de-4767-88e7-973c6a6dd7ab"
    }
},
{
    "pk": 3865, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "BRAF", 
        "paper": 3, 
        "tag_id": "erb-3a917676-18b9-4a45-b9b9-40422fdcacde"
    }
},
{
    "pk": 3866, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "BRAF mutations (V600E in 70% to 80% of all BRAF mutations in all cancers) occur early in melanomagen", 
        "paper": 3, 
        "tag_id": "erb-e1a55794-e3c6-4b3e-897b-6fc90acde642"
    }
},
{
    "pk": 3867, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Overall, about 50% of melanomas of all clinical types have mutations in BRAF. BRAF mutations are mor", 
        "paper": 3, 
        "tag_id": "erb-c48a741c-5cdb-4b39-9460-b9cd14a83421"
    }
},
{
    "pk": 3868, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "The reported results of trials with selective oral BRAF inhibitors showed efficacy in melanoma patie", 
        "paper": 3, 
        "tag_id": "erb-3df6fc53-3ec1-43bd-81c1-82e40a4d318e"
    }
},
{
    "pk": 3869, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Treatment approaches", 
        "paper": 3, 
        "tag_id": "erb-399b74ba-6689-42b6-bac7-068784f156bf"
    }
},
{
    "pk": 3870, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "The U.S. Food and Drug Administration (FDA) approved the mutant BRAF inhibitor vemurafenib/Zelboraf ", 
        "paper": 3, 
        "tag_id": "erb-7425b0ee-7e11-4782-ad34-65dfee876f06"
    }
},
{
    "pk": 3871, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Inhibition of MEK has been explored in clinical trials for melanoma patients with mutant BRAF 21,22.", 
        "paper": 3, 
        "tag_id": "erb-b9336ea1-12b3-44f3-941d-9e8d4f9fc368"
    }
},
{
    "pk": 3872, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Most importantly, it is increasingly clear that combination treatments, such as BRAF and MEK inhibit", 
        "paper": 3, 
        "tag_id": "erb-20466fe4-b2c4-4bda-bf8b-0e4ae60c8115"
    }
},
{
    "pk": 3873, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Targeting ERK1/2, the kinases at the lower end of the MAPK cascade, is an emerging therapeutic strat", 
        "paper": 3, 
        "tag_id": "erb-00e4aeed-05c7-4c1f-b6e2-319e554e2ce1"
    }
},
{
    "pk": 3874, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "BRAF mutations other than V600:", 
        "paper": 3, 
        "tag_id": "erb-2397f2b4-48cb-4573-b9f9-8332aee247fc"
    }
},
{
    "pk": 3875, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "A number of BRAF mutants other than V600 were identified in human cancers 27. Some of these have a r", 
        "paper": 3, 
        "tag_id": "erb-db0b0ad8-d261-4566-9777-6aa64cd53f28"
    }
},
{
    "pk": 3876, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Melanomas with BRAF mutations other than V600 have not been specifically targeted in clinical trials", 
        "paper": 3, 
        "tag_id": "erb-b97a3395-aa48-48a7-95e1-e1114e0ca301"
    }
},
{
    "pk": 3877, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "NRAS", 
        "paper": 3, 
        "tag_id": "erb-29e0c1a8-d990-408d-a9c5-9a0e2b31624f"
    }
},
{
    "pk": 3878, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Approximately 20% of melanomas have mutations in the GTPase NRAS. NRAS and BRAF mutations are almost", 
        "paper": 3, 
        "tag_id": "erb-121014bf-56a1-442d-819e-b88d758f4a78"
    }
},
{
    "pk": 3879, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Potential treatment approaches", 
        "paper": 3, 
        "tag_id": "erb-c83f0610-fc64-4d20-8c1a-4d621e037ad6"
    }
},
{
    "pk": 3880, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "The pathways downstream of NRAS that could be targeted simultaneously in NRAS-mutant melanoma includ", 
        "paper": 3, 
        "tag_id": "erb-2f5b6058-6774-4e28-992d-e7a3ec729b13"
    }
},
{
    "pk": 3881, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Preclinical studies indicate several potential points of intervention:", 
        "paper": 3, 
        "tag_id": "erb-1d94764c-cc8e-46a1-9141-20b6d76bca68"
    }
},
{
    "pk": 3882, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "The combinations of inhibitors to\u00a0target NRAS-activated signaling through MEK and PI3K, MEK and AKT,", 
        "paper": 3, 
        "tag_id": "erb-7b5ee0ed-beab-42a7-8107-a48cabf5db8f"
    }
},
{
    "pk": 3883, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "GNAQ and GNA11", 
        "paper": 3, 
        "tag_id": "erb-b071a755-298f-4257-a9f9-fcab63525f79"
    }
},
{
    "pk": 3884, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Activating mutations in GNAQ and GNA11, encoding members of the G\u03b1(q) family of G protein \u03b1 subunits", 
        "paper": 3, 
        "tag_id": "erb-6dc97bcb-38cc-4190-880b-813767ccf9ce"
    }
},
{
    "pk": 3885, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Potential treatment approaches", 
        "paper": 3, 
        "tag_id": "erb-fc13c7db-5dbf-416b-bbf6-8b50f985234c"
    }
},
{
    "pk": 3886, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "A randomized phase II clinical trial compared the MEK inhibitor selumetinib (AZD6244) with temozolom", 
        "paper": 3, 
        "tag_id": "erb-3f45a8cb-c2c6-407e-89ee-618c96ac11d7"
    }
},
{
    "pk": 3887, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Inhibition of both PI3K and MAPK, but neither of them singly, might also work in uveal melanoma as s", 
        "paper": 3, 
        "tag_id": "erb-36843aa5-922c-45aa-a04b-78ca7a0eca9a"
    }
},
{
    "pk": 3888, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Enzastaurin and AEB071, PKC inhibitors, have shown some activity against uveal melanoma cell lines i", 
        "paper": 3, 
        "tag_id": "erb-77521ba1-23f5-48e5-b4f9-cbdf0205ea7f"
    }
},
{
    "pk": 3889, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Recently, it was shown that the guanine nucleotide exchange factor Trio is involved in mitogenic sig", 
        "paper": 3, 
        "tag_id": "erb-bc0149e9-addd-4f3c-820f-ed69b2d7d6b4"
    }
},
{
    "pk": 3890, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "MITF", 
        "paper": 3, 
        "tag_id": "erb-bc5644e0-ee25-42fe-8ec3-babba6273873"
    }
},
{
    "pk": 3891, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Microphthalmia-associated transcription factor\u00a0MITF is a lineage survival oncogene, amplified in 20%", 
        "paper": 3, 
        "tag_id": "erb-fa44da54-6f72-405c-8c16-ee1ef6408231"
    }
},
{
    "pk": 3892, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Other candidate targets in the MITF program include receptor tyrosine kinase TYRO3, which regulates ", 
        "paper": 3, 
        "tag_id": "erb-6d81f45f-3bff-497a-b563-d2ab588338a3"
    }
},
{
    "pk": 3893, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Hypoxia-inducible factor HIF1\uf061 was also reported to be a transcriptional target of MITF52, and its e", 
        "paper": 3, 
        "tag_id": "erb-79dbc95a-ad74-4dbb-afff-c6ef6388d5e0"
    }
},
{
    "pk": 3894, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "MITF is regulated by the transcription factor ATF2. Primary melanoma specimens that exhibit a high n", 
        "paper": 3, 
        "tag_id": "erb-66ff1602-c394-4575-9eae-8363fe1184de"
    }
},
{
    "pk": 3895, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "SOX10, PAX3, and MITF participate in regulation of MET (HGF receptor), which is expressed at high le", 
        "paper": 3, 
        "tag_id": "erb-d200f60f-071b-4017-aac2-19426ad77f8e"
    }
},
{
    "pk": 3896, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "PPAR-\u03b3 coactivators PGC-1\u03b1 and PGC-1\u03b2 are critical components of the melanogenic system governed by ", 
        "paper": 3, 
        "tag_id": "erb-d1ee5b38-1cf4-4c2b-8f1a-82fcffe388aa"
    }
},
{
    "pk": 3897, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "BCL2A1, a lineage-specific anti-apoptotic protein in the BCL2 family, is amplified and overexpressed", 
        "paper": 3, 
        "tag_id": "erb-e068becb-3c96-410d-a893-0d6bb568e710"
    }
},
{
    "pk": 3898, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "A recent paper proposed targeting of tyrosinase (MITF transcriptional target) by first inducing expr", 
        "paper": 3, 
        "tag_id": "erb-fe156a72-fc5c-4c7b-9d06-1eafd96aa9c7"
    }
},
{
    "pk": 3899, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "The crystal structure of MITF was resolved recently, paving the way for the future targeting of MITF", 
        "paper": 3, 
        "tag_id": "erb-3382b250-c2fe-44b0-b3c7-bf0bf1d77968"
    }
},
{
    "pk": 3900, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Potential treatment approaches", 
        "paper": 3, 
        "tag_id": "erb-4c4936ae-46df-414a-ae19-014199f13b9a"
    }
},
{
    "pk": 3901, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "These findings on MITF-mediated pathways remain in the domain of preclinical research, although targ", 
        "paper": 3, 
        "tag_id": "erb-eb5ce7b7-720d-4dd4-9089-154cc95d4eb8"
    }
},
{
    "pk": 3902, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "A new study opened a possibility of targeting the nuclear translocation of ATF2 by inhibiting PKC\u03b5, ", 
        "paper": 3, 
        "tag_id": "erb-c00cea11-aeb5-4d3f-980d-3ddb71ceb33e"
    }
},
{
    "pk": 3903, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "KIT ", 
        "paper": 3, 
        "tag_id": "erb-269058c9-f44a-44d0-bea2-5a64411df53d"
    }
},
{
    "pk": 3904, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "KIT is a receptor tyrosine kinase activated by binding of the cytokine stem cell factor (SCF); mutat", 
        "paper": 3, 
        "tag_id": "erb-35caa90b-a71f-46b3-a6f4-500b0c83963c"
    }
},
{
    "pk": 3905, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Treatment approaches ", 
        "paper": 3, 
        "tag_id": "erb-fac81726-d7fd-4e34-981f-5935c8c8d4ac"
    }
},
{
    "pk": 3906, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Targeting KIT with imatinib has demonstrated remarkable efficacy in patients with gastrointestinal s", 
        "paper": 3, 
        "tag_id": "erb-6d60f451-15c1-4e1e-8571-a5beac0ec930"
    }
},
{
    "pk": 3907, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Recently, trials of imatinib and nilotinib have shown promising results in trials where patients wer", 
        "paper": 3, 
        "tag_id": "erb-c4c7d8c3-be99-4dae-a327-4b837d66fda4"
    }
},
{
    "pk": 3908, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "At least 10 ongoing trials test the activity of the aforementioned inhibitors in KIT-mutated melanom", 
        "paper": 3, 
        "tag_id": "erb-5d888505-81c6-4afe-b6b5-9af82513d338"
    }
},
{
    "pk": 3909, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "NF1/neurofibromin", 
        "paper": 3, 
        "tag_id": "erb-23bd3084-f8ff-496e-b878-ca29a1aa4d22"
    }
},
{
    "pk": 3910, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "NF1 is a tumor suppressor regulating signaling from RAS; germline mutations in NF1 deregulate both P", 
        "paper": 3, 
        "tag_id": "erb-a62cb7f2-6fc9-43ed-93ec-07f4a1109c50"
    }
},
{
    "pk": 3911, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Potential treatment approaches", 
        "paper": 3, 
        "tag_id": "erb-dabb2ab5-bcce-42c7-85da-e087454a0b2f"
    }
},
{
    "pk": 3912, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "In recent studies NF1 could be successfully targeted in mouse models with a combination of MEK and P", 
        "paper": 3, 
        "tag_id": "erb-80c0e207-df8d-42f2-a61d-0d07057891be"
    }
},
{
    "pk": 3913, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Telomerase", 
        "paper": 3, 
        "tag_id": "erb-64bfebf8-8d06-430c-b7b4-76c21e94ae48"
    }
},
{
    "pk": 3914, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Two very recent studies\u2014one based on analysis of genomic alterations in a melanoma-prone family, the", 
        "paper": 3, 
        "tag_id": "erb-d918898f-46b6-4018-9b07-bb343c62d6af"
    }
},
{
    "pk": 3915, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Potential treatment options", 
        "paper": 3, 
        "tag_id": "erb-8565322e-83f4-469e-9e5b-8c9beec72a04"
    }
},
{
    "pk": 3916, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Telomerase inhibitor imetelstat sodium/GRN163L (antisense oligonucleotide) is trialed in breast canc", 
        "paper": 3, 
        "tag_id": "erb-214e509d-5190-4711-9e1b-a5f89bfed56b"
    }
},
{
    "pk": 3917, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Receptor tyrosine kinases and PI3K pathway", 
        "paper": 3, 
        "tag_id": "erb-b3135c8b-ba9d-4ab4-a8da-b72e3725b98a"
    }
},
{
    "pk": 3918, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Activation of the PI3K pathway serves to overcome OIS that is associated with mutant BRAF. PTEN aber", 
        "paper": 3, 
        "tag_id": "erb-51b3b5bb-659d-429a-b61b-5f6d0af80514"
    }
},
{
    "pk": 3919, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "ERBB4. Mutations in this tyrosine kinase receptor are found in 19% of melanomas, based on the result", 
        "paper": 3, 
        "tag_id": "erb-e5bf7d7e-2eae-49e5-ae7f-62d8e74831de"
    }
},
{
    "pk": 3920, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "MET. Mutations in MET have not been described in melanoma, but there is strong evidence that this RT", 
        "paper": 3, 
        "tag_id": "erb-1d59162e-e6d2-4100-923c-35b9f540082b"
    }
},
{
    "pk": 3921, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "MERTK. MER, a receptor tyrosine kinase (RTK) sharing a family relationship with TYRO3 and AXL, was f", 
        "paper": 3, 
        "tag_id": "erb-08eaa597-e259-4710-9d85-47ef31c3bc8e"
    }
},
{
    "pk": 3922, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "AKT. Deregulated Akt3 activity was shown to promote development of malignant melanoma; amplification", 
        "paper": 3, 
        "tag_id": "erb-8c304abb-66c4-43f8-af41-77b34555ed15"
    }
},
{
    "pk": 3923, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "PTEN is a well-known tumor suppressor affected in approximately 25%-30% of melanoma, most commonly v", 
        "paper": 3, 
        "tag_id": "erb-876e5da3-e4c2-48b5-a5a5-d04ee7334bd9"
    }
},
{
    "pk": 3924, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Other PI3K pathway mutations. Mutations in other PI3K pathways genes MTOR, IRS4, PIK3R1, PIK3R4, and", 
        "paper": 3, 
        "tag_id": "erb-b4305d72-d949-49c3-aa12-ca309784a040"
    }
},
{
    "pk": 3925, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "MAPK pathway downstream of BRAF", 
        "paper": 3, 
        "tag_id": "erb-e02542bd-6224-4af7-aa44-576365aacc14"
    }
},
{
    "pk": 3926, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "MEK1 and MEK2. Sequencing of seven melanoma cell lines and donor-matched germline cells found MAP2K1", 
        "paper": 3, 
        "tag_id": "erb-371bf51e-cb65-46dc-80b9-39c7d1cea2f4"
    }
},
{
    "pk": 3927, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "IQGAP1: a scaffold protein in MAPK pathway as a possible target. There are new data indicating that ", 
        "paper": 3, 
        "tag_id": "erb-683add4f-68a6-41a9-91b9-8075773b5c36"
    }
},
{
    "pk": 3928, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "RAC pathway. RAC1 is a Rho GTPase, a GTP exchange protein known to affect the cell cytoskeleton and ", 
        "paper": 3, 
        "tag_id": "erb-71d8cf7d-f2f7-4413-860a-2c3866a40fdf"
    }
},
{
    "pk": 3929, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "MAP3K5 and MAP3K9. These MAP3 kinases are directly downstream of Rac and Rho signaling activated by ", 
        "paper": 3, 
        "tag_id": "erb-604101ba-d8c5-4ce9-9840-5662891f871e"
    }
},
{
    "pk": 3930, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "PREX2. Mutations of phosphatidylinositol-3,4,5-trisphosphate-dependent Rac exchange factor 2 were fo", 
        "paper": 3, 
        "tag_id": "erb-a754be66-ac40-4feb-8ba9-6d8a5517064e"
    }
},
{
    "pk": 3931, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Cell cycle and apoptosis related genes", 
        "paper": 3, 
        "tag_id": "erb-9b1363b2-f1d2-47b8-96ff-ba3e54708e39"
    }
},
{
    "pk": 3932, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "CDK4, a cell cycle G1/S kinase, and Cyclin D1 (CCND1) were shown to be amplified in melanoma 111. CD", 
        "paper": 3, 
        "tag_id": "erb-74e7db2b-93af-4cf3-b5e2-aab32f4dc2bc"
    }
},
{
    "pk": 3933, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "TP53 pathway. TP53 mutations are found in 19% of melanoma tumors 31, a frequency relatively low comp", 
        "paper": 3, 
        "tag_id": "erb-751ee530-7b90-4920-b25b-d9ee2821b534"
    }
},
{
    "pk": 3934, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "CDKN2A locus is frequently deleted in melanoma of all primary subtypes 119-121. Two tumor suppressor", 
        "paper": 3, 
        "tag_id": "erb-184b5a64-ad6f-4fac-b4e0-c38f3ebaa9d4"
    }
},
{
    "pk": 3935, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "MDM2. This protein binds to p53 and promotes its degradation and inactivation. MDM2 is considered to", 
        "paper": 3, 
        "tag_id": "erb-4ab77836-6c0d-480b-80d9-3ae4de6ba683"
    }
},
{
    "pk": 3936, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "MDM4. In a recent study it was shown that MDM4, a negative regulator of p53, is upregulated in about", 
        "paper": 3, 
        "tag_id": "erb-75d836a9-55d3-4c0c-adfe-5ada2bf31839"
    }
},
{
    "pk": 3937, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Potential treatment of melanoma harboring inactivated wild-type p53 would involve inhibition of CDK4", 
        "paper": 3, 
        "tag_id": "erb-1a9fc978-8a90-462d-8056-04ff437c7377"
    }
},
{
    "pk": 3938, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "P63, a protein related to p53, has been reported to have an anti-apoptotic role in melanoma, which i", 
        "paper": 3, 
        "tag_id": "erb-04d08faf-652e-464d-9c57-563a959ea03c"
    }
},
{
    "pk": 3939, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "iASPP is a conserved ankyrin repeat protein that shuttles between nuclear and cytoplasmic compartmen", 
        "paper": 3, 
        "tag_id": "erb-dcb3847d-1d64-442f-ba2e-b1eeb10d64f0"
    }
},
{
    "pk": 3940, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "\u00a0NFkB. As in many, many other tumors, the NFkB pathway is activated in melanoma, but systemic inhibi", 
        "paper": 3, 
        "tag_id": "erb-b128e6f7-3b24-46a3-bc26-f9592246d5b7"
    }
},
{
    "pk": 3941, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "BCL2. There is abundant literature that documents elevated BCL2 expression in melanoma and its contr", 
        "paper": 3, 
        "tag_id": "erb-7b7ac0de-feb5-4901-b658-9f1e45c9cfb4"
    }
},
{
    "pk": 3942, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Attempts to target BCL2 with antisense RNA in melanoma patients have not been successful. Obatoclax,", 
        "paper": 3, 
        "tag_id": "erb-6abaa658-b1c8-4dd5-a4a3-64b5496e0b06"
    }
},
{
    "pk": 3943, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "\u03b2-catenin and WNT pathway", 
        "paper": 3, 
        "tag_id": "erb-3a28c78b-2ff2-48ca-a3a3-4a42d95334a7"
    }
},
{
    "pk": 3944, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "A number of reports have heavily implicated WNT signaling in melanoma progression and metastases. \u03b2-", 
        "paper": 3, 
        "tag_id": "erb-bef78459-3499-4f10-b4ec-155eebc33c46"
    }
},
{
    "pk": 3945, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "In a mouse melanoma model based on PTEN loss and BRAFV600E mutation, \uf062-catenin was shown to be a cen", 
        "paper": 3, 
        "tag_id": "erb-9d1a653f-b7a6-44b0-b2b9-1daa5d1ebe62"
    }
},
{
    "pk": 3946, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Negative regulation of WNT/\uf062-catenin signaling by MAPK pathway was confirmed in an additional study ", 
        "paper": 3, 
        "tag_id": "erb-7e32bea0-95b2-4026-b2ee-caf1ca56f49f"
    }
},
{
    "pk": 3947, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Transcriptional factors in melanoma", 
        "paper": 3, 
        "tag_id": "erb-0d62c939-3275-42fc-be13-db95168d7475"
    }
},
{
    "pk": 3948, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "MYC. This universal oncogene and transcriptional master regulator is overexpressed or present at inc", 
        "paper": 3, 
        "tag_id": "erb-59949133-759b-4917-83e4-481738ae7264"
    }
},
{
    "pk": 3949, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "ETV1. This transcription factor from the ETS family was implicated as an oncogene in melanoma and co", 
        "paper": 3, 
        "tag_id": "erb-a98f4070-d8e8-47ce-bf9a-3d7ca9232b17"
    }
},
{
    "pk": 3950, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Other significant genetic abnormalities in melanoma", 
        "paper": 3, 
        "tag_id": "erb-f5e5d271-9c84-4cca-8cf9-9c3a824e4884"
    }
},
{
    "pk": 3951, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "NEDD9, an integrin adaptor protein related to P130CAS, and a member of a family implicated in pathog", 
        "paper": 3, 
        "tag_id": "erb-cccbb060-00e5-465a-b418-5c4b22b0a599"
    }
},
{
    "pk": 3952, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "PPP6C is a serine-threonine phosphatase, mutated in 12% of sun-exposed melanomas exclusively with BR", 
        "paper": 3, 
        "tag_id": "erb-f68d3494-d9c4-42f1-bbff-801cf7711e80"
    }
},
{
    "pk": 3953, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "TACC1 (transforming acidic coiled-coil containing protein 1) is mutated in 5% of an experimental set", 
        "paper": 3, 
        "tag_id": "erb-dccdf626-9e84-4fc6-8e56-36b52c4fa50e"
    }
},
{
    "pk": 3954, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "BAP1 (BRCA1-associated protein-1/ubiquitin carboxy-terminal hydrolase) is involved in metastatic pro", 
        "paper": 3, 
        "tag_id": "erb-2b1d96c6-4f28-4c7a-b068-dcacb95264bc"
    }
},
{
    "pk": 3955, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "SF3B1. Codon 625 of the SF3B1 gene, encoding splicing factor 3B subunit 1, is consistently mutated i", 
        "paper": 3, 
        "tag_id": "erb-d899b0ce-39c6-4100-9b5e-fe5b7c8747b6"
    }
},
{
    "pk": 3956, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "SNX31 was identified as one of the 11 new genes mutated in melanoma 31. It encodes a poorly characte", 
        "paper": 3, 
        "tag_id": "erb-7730175a-087b-4e4d-9427-4621ff3d06e8"
    }
},
{
    "pk": 3957, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "STK19. A 5% mutation rate of this kinase gene with unknown functions is seen in melanoma 31.", 
        "paper": 3, 
        "tag_id": "erb-4c60223f-2e2c-46db-96cb-f444a2963dad"
    }
},
{
    "pk": 3958, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "LKB1/STK11. LKB1 might be a central kinase that integrates energy metabolism and tumor growth, in pa", 
        "paper": 3, 
        "tag_id": "erb-6091a9ff-ec54-4c29-b36b-691dcc955534"
    }
},
{
    "pk": 3959, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "ARID2 is a component of the SWI/SNF chromatin-remodeling complex. Loss-of-function mutations were fo", 
        "paper": 3, 
        "tag_id": "erb-6f8ecbe3-6e3a-4a3d-b61a-6c9831593d9b"
    }
},
{
    "pk": 3960, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "TRRAP2. Identified mutations occur in 4% of the melanoma set examined. TRRAP functions as part of a ", 
        "paper": 3, 
        "tag_id": "erb-d984eeef-30c5-4b42-974c-4163f37c4e25"
    }
},
{
    "pk": 3961, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "GRIN2A encodes the glutamate N-methyl-D-aspartic acid (NMDA) receptor subunit \u03b5-1 that is part of th", 
        "paper": 3, 
        "tag_id": "erb-9705e888-0545-4652-9951-f456e3c050b5"
    }
},
{
    "pk": 3962, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "GRM3 is a metabotropic glutamate receptor, a G-protein-coupled receptor (GPCR) that activates phosph", 
        "paper": 3, 
        "tag_id": "erb-fee765e5-fd53-4cd5-9706-c81a82f8be9c"
    }
},
{
    "pk": 3963, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Phosphoglycerate dehydrogenase PHGDH serves to divert glycolytic carbon into serine and glycine meta", 
        "paper": 3, 
        "tag_id": "erb-bf4fd364-2e02-445d-aef8-3e5b9433a5e9"
    }
},
{
    "pk": 3964, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "WEE1. Cell cycle regulatory kinase Wee1 is upregulated in melanoma and is associated with poor progn", 
        "paper": 3, 
        "tag_id": "erb-2036a01f-c735-4eff-bbaa-0b0690b09bd1"
    }
},
{
    "pk": 3965, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "NUAK2 (AMPK-related kinase). High levels of expression of NUAK2 were found in patients with acral me", 
        "paper": 3, 
        "tag_id": "erb-0844e75b-d145-4f51-b848-6130e2b993d8"
    }
},
{
    "pk": 3966, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Various noncoding RNAs and other epigenetic alterations", 
        "paper": 3, 
        "tag_id": "erb-516bacf3-768c-44c3-ac30-2b5225dadcb6"
    }
},
{
    "pk": 3967, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "A number of reports found significant roles for miRNA, ncRNA, or ceRNA in pathogenesis of melanoma; ", 
        "paper": 3, 
        "tag_id": "erb-e9ca8b0b-a19e-428e-b029-463a68e8d219"
    }
},
{
    "pk": 3968, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Strategies to inhibit or increase expression of ncRNAs in clinical setting are only beginning to eme", 
        "paper": 3, 
        "tag_id": "erb-267c20fa-fbd4-4303-aa6b-c08647d8e364"
    }
},
{
    "pk": 3969, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Resistance to BRAF inhibitors could be intrinsic (as in lack of response to selective BRAF inhibitor", 
        "paper": 3, 
        "tag_id": "erb-0daf11b8-3030-421b-94c0-184f14f0bc81"
    }
},
{
    "pk": 3970, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "It is well established that BRAF mutations play a role in melanomagenesis; however, without addition", 
        "paper": 3, 
        "tag_id": "erb-22979e65-4687-4672-bbf9-2afbb3e31900"
    }
},
{
    "pk": 3971, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "\n\n\n\n\n\n\n\n\n\nMOLECULAR CHANGE\n\n\nCONFIRMED IN PATIENT BIOPSIES?\n\n\nDRUGS TO ADD TO OVERCOME RESISTANCE\n\n\n", 
        "paper": 3, 
        "tag_id": "erb-f0991301-5283-4c8b-8344-7ae28f545e0f"
    }
},
{
    "pk": 3972, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "PI3K/AKT. Mutations of the PI3K pathway are frequent in the BRAF-mutant setting. These have been sho", 
        "paper": 3, 
        "tag_id": "erb-6d03411d-257f-4ca7-8119-29e2f1eb3ce4"
    }
},
{
    "pk": 3973, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Recent study demonstrated an essential role for ERK-phosphorylated MEK1 (pT292) in membrane recruitm", 
        "paper": 3, 
        "tag_id": "erb-a9ed6bb6-2891-43f0-975b-b534638f69e9"
    }
},
{
    "pk": 3974, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "CDK4 pathway. Increased cyclin D expression mediates inherent resistance to mutant BRAF inhibition 1", 
        "paper": 3, 
        "tag_id": "erb-480bfbed-083b-40a8-a04b-cd7f7a7d0b2d"
    }
},
{
    "pk": 3975, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "NF1 mutations. In a mouse model, NF1 ablation decreases the sensitivity of NF1 wild-type melanoma ce", 
        "paper": 3, 
        "tag_id": "erb-4efdcbd1-893e-42ee-b9ce-e3f9a3db28f2"
    }
},
{
    "pk": 3976, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "MET and SRC. The activation of MET and SRC signaling was detected in two patient-derived melanoma ce", 
        "paper": 3, 
        "tag_id": "erb-0f9186a5-fd83-411e-96c9-0dbeab42c260"
    }
},
{
    "pk": 3977, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Metabolic signature of melanoma sensitive to mutant BRAF inhibition. An interesting study could not ", 
        "paper": 3, 
        "tag_id": "erb-1a67c68f-2991-4a35-8c50-431643c26334"
    }
},
{
    "pk": 3978, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "MITF-PGC1a axis in resistance to BRAF inhibition. Inhibition of BRAFV600 and, to a lesser extent of ", 
        "paper": 3, 
        "tag_id": "erb-d685adff-1f82-4829-a80c-e2130e39266c"
    }
},
{
    "pk": 3979, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Tumor stroma influence. An important study demonstrated production of HGF by stromal cells in patien", 
        "paper": 3, 
        "tag_id": "erb-a8efd55a-a57a-46e8-92e5-60140fa66035"
    }
},
{
    "pk": 3980, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "BCL-2. Inhibition of anti-apoptotic protein Bcl-2 might have a potential role in the future studies ", 
        "paper": 3, 
        "tag_id": "erb-dfc1bcc6-50ca-4436-bbec-f216d3421a4d"
    }
},
{
    "pk": 3981, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "BCL2A1. Amplification of one family member, BCL2A1 in 30% of melanoma was shown to contribute to res", 
        "paper": 3, 
        "tag_id": "erb-bed584b2-2932-4a09-b232-b77d0d0ff7d4"
    }
},
{
    "pk": 3982, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "FOXD3-ERBB3. Transcription factor FOXD3 was shown to be upregulated when mutant BRAF is inhibited in", 
        "paper": 3, 
        "tag_id": "erb-a32022be-5bde-4420-bf29-803e6a954674"
    }
},
{
    "pk": 3983, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Chaperone Hsp90 is required for the stability of several of the oncoproteins that mediate RAF inhibi", 
        "paper": 3, 
        "tag_id": "erb-4d8c0d95-9173-48f6-b354-37de41c4c207"
    }
},
{
    "pk": 3984, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "mTORC1 activity. Activity of mTORC1 after treatment of melanoma cells in vitro was found to be a fai", 
        "paper": 3, 
        "tag_id": "erb-9ddf1ab9-8186-4fad-9d24-046913f5e31f"
    }
},
{
    "pk": 3985, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Intrinsic resistance to MEK inhibitors", 
        "paper": 3, 
        "tag_id": "erb-d4b2bf52-2af4-40e9-966a-17476becbab9"
    }
},
{
    "pk": 3986, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Signaling through TGF-\u03b2/SMURF2/PAX3 and MITF.  In an in vitro study, cells sensitive to MEK inhibiti", 
        "paper": 3, 
        "tag_id": "erb-51b83742-04b4-4c3d-86fc-affc210eae9b"
    }
},
{
    "pk": 3987, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Activation of the PI3K pathway was seen as a factor in resistance of a panel of melanoma cell lines ", 
        "paper": 3, 
        "tag_id": "erb-e4ca6651-0277-4010-82c8-45305fc4c66c"
    }
},
{
    "pk": 3988, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "\n\n\n\n\n\n\n\n\n\nMOLECULAR CHANGE\n\n\nCONFIRMED IN PATIENT BIOPSIES?\n\n\nDRUGS TO ADD TO OVERCOME RESISTANCE\n\n\n", 
        "paper": 3, 
        "tag_id": "erb-d00f18de-2707-4a7b-acac-d161399fdd74"
    }
},
{
    "pk": 3989, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Mechanistic studies have provided insights into the development of resistance through two major mech", 
        "paper": 3, 
        "tag_id": "erb-0e8a9541-2efb-4e26-9cb5-76e09d672686"
    }
},
{
    "pk": 3990, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "The identification of mechanisms of acquired resistance to BRAF inhibitors usually involves selectio", 
        "paper": 3, 
        "tag_id": "erb-9441dbfe-a01d-4cc1-8d75-f9bab670da93"
    }
},
{
    "pk": 3991, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "New aberrations in BRAF. Unlike the experiences with other molecularly targeted therapies of oncogen", 
        "paper": 3, 
        "tag_id": "erb-abb54a78-c9e9-41ec-892f-5e1798731b87"
    }
},
{
    "pk": 3992, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Analysis of a subset of cells resistant to vemurafenib (PLX4032) in vitro detected the 61-kDa varian", 
        "paper": 3, 
        "tag_id": "erb-a1e2dfc5-7384-4536-b0b3-f22b2e141e8c"
    }
},
{
    "pk": 3993, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Activation of signaling through RTKs", 
        "paper": 3, 
        "tag_id": "erb-f67698ed-9e4d-4f29-9049-59c96a5a4560"
    }
},
{
    "pk": 3994, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "EGFR/SFK/STAT3. BRAF inhibitor-mediated activation of EGFR/SRC family kinase/STAT3 signaling was sho", 
        "paper": 3, 
        "tag_id": "erb-c893a804-d3be-468c-8405-0d0bcd40efd2"
    }
},
{
    "pk": 3995, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Upregulation of FGFR3 signaling in selected vemurafenib-resistant cells was described in vitro. Sign", 
        "paper": 3, 
        "tag_id": "erb-dce5b4ee-72af-47d5-847b-a8cca7a3eab0"
    }
},
{
    "pk": 3996, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "IGF-1R/PI3K pathway.  Mutations in the IGF-1R/PI3K pathway were identified as another way for develo", 
        "paper": 3, 
        "tag_id": "erb-1ddabde5-d303-48bc-bf8c-acbc0d55cfef"
    }
},
{
    "pk": 3997, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Activation of PDGFR\uf062 signaling was shown to occur during selection for BRAF inhibitor resistance in ", 
        "paper": 3, 
        "tag_id": "erb-7636ea7b-d758-44ad-8ef7-ee2b190db34d"
    }
},
{
    "pk": 3998, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "NF1 expression is lost in tumors from patients following treatment with BRAF and MEK inhibitors 85. ", 
        "paper": 3, 
        "tag_id": "erb-150d6579-913c-4aaa-aed8-0458e7b86c3b"
    }
},
{
    "pk": 3999, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "NRAS. Secondary mutations in NRAS were shown to confer resistance to PLX4032 in vitro 181. These acq", 
        "paper": 3, 
        "tag_id": "erb-76ca6900-403d-4eca-87ac-87da7e76bb72"
    }
},
{
    "pk": 4000, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "AKT3. Activation of AKT3 in response to BRAF inhibitor PLX4720 or BRAF siRNA was implicated in the r", 
        "paper": 3, 
        "tag_id": "erb-88a72099-c9a9-464c-9354-d66c3d6f25ac"
    }
},
{
    "pk": 4001, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "ERK activation, independent of classical RAF/MEK/ERK pathways, was shown to occur in resistant lines", 
        "paper": 3, 
        "tag_id": "erb-7dd48b81-2326-422a-b3e8-c2cf7438c232"
    }
},
{
    "pk": 4002, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "MAP3K8/COT. In a massive functional kinome screening study, a kinase known as MAP3K8/COT was implica", 
        "paper": 3, 
        "tag_id": "erb-5426b262-0f42-4daa-80a6-4f3924f8b86e"
    }
},
{
    "pk": 4003, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "MEK1 mutation C121S was identified in a patient treated with vemurafenib 183. This mutation was show", 
        "paper": 3, 
        "tag_id": "erb-16c3a6a2-5671-4c79-8aae-f49bb05ecb6e"
    }
},
{
    "pk": 4004, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "RND3. An in vitro study with a single BRAF-mutant melanoma line showed that BRAF-inhibitor treatment", 
        "paper": 3, 
        "tag_id": "erb-7bc3bad9-21e3-43db-9189-1e1b29fd1968"
    }
},
{
    "pk": 4005, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "IRS1. Insulin receptor substrates 1 and 2 (IRS1/2) mediate oncogenic signaling from IGF-1R and are u", 
        "paper": 3, 
        "tag_id": "erb-bebc3fe7-62fc-4a0d-b74b-79e82552d6e4"
    }
},
{
    "pk": 4006, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Factors that mediate acquired resistance to MEK inhibitors (Table 4)", 
        "paper": 3, 
        "tag_id": "erb-a1c1b91a-3895-44b7-b4e4-022b501c58ea"
    }
},
{
    "pk": 4007, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Similar to the adaptation of BRAF-mutant melanoma cells to BRAF inhibition, resistance to MEK inhibi", 
        "paper": 3, 
        "tag_id": "erb-a253ed4e-43e2-4f85-999f-5c09cc5484c1"
    }
},
{
    "pk": 4008, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Mutations in MEK1 and MEK2. De novo mutations in MEK1 were strongly implicated in resistance to MEK ", 
        "paper": 3, 
        "tag_id": "erb-ccab339e-f6e0-48a3-9156-9057d0d9bee8"
    }
},
{
    "pk": 4009, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "PI3K-AKT pathway. A study in vitro has identified basal and treatment-induced activation of the PI3K", 
        "paper": 3, 
        "tag_id": "erb-efa9faa1-6a03-4ada-bae1-80ea29aa0962"
    }
},
{
    "pk": 4010, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Inherent resistance, partial and low durability responses, and acquired resistance are major problem", 
        "paper": 3, 
        "tag_id": "erb-aa3e6a94-0074-45a4-b769-19db4135261d"
    }
},
{
    "pk": 4011, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Two recent publications examined possible synergistic interactions between targeted therapies. The f", 
        "paper": 3, 
        "tag_id": "erb-e0753f36-ab76-4b6f-9366-5dafc7f923f1"
    }
},
{
    "pk": 4012, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "The second study\u00a038 examined drug interactions between 150 small molecule inhibitors in a panel of 2", 
        "paper": 3, 
        "tag_id": "erb-b28aa7b0-91c4-4755-b189-7dacc4c8b732"
    }
},
{
    "pk": 4013, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Malignant melanoma is a tumor extensively investigated as target for immunotherapy for reasons inclu", 
        "paper": 3, 
        "tag_id": "erb-a758942c-9d2b-4df9-8c32-16d826f268bd"
    }
},
{
    "pk": 4014, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Interleukin-2 was the earliest immunotherapy for metastatic melanoma approved by the FDA in 1998, fo", 
        "paper": 3, 
        "tag_id": "erb-fd24a296-0a53-4f1f-b6a1-69fd143a6041"
    }
},
{
    "pk": 4015, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "In light of the complexity of the immune response, it is very likely that combining immunotherapies ", 
        "paper": 3, 
        "tag_id": "erb-e52f34a1-118e-43c8-8629-7427e6333c2e"
    }
},
{
    "pk": 4016, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Immunomodulatory antibodies", 
        "paper": 3, 
        "tag_id": "erb-96e3cc17-58dc-4e9a-a1ec-cae39f73ac08"
    }
},
{
    "pk": 4017, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "The use of immune checkpoint inhibitors (antibodies that block proteins inhibiting immune response) ", 
        "paper": 3, 
        "tag_id": "erb-ea630335-358d-4a01-ac62-8bc3574af8a8"
    }
},
{
    "pk": 4018, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "\n\n\n\n\n\n\n\n\n\nTarget\n\n\nDesired effects\n\n\nAntibodies \n\n\nTrials\n\n\n\n\nCTLA-4\n\n\nRelieve the immune checkpoint", 
        "paper": 3, 
        "tag_id": "erb-04f9c5c6-780c-45ca-bc93-beb24a211ae1"
    }
},
{
    "pk": 4019, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "CTLA4 is an inhibitory molecule expressed on T cells that is involved in the negative regulation of ", 
        "paper": 3, 
        "tag_id": "erb-7cf15538-6a55-4fd2-9155-58d380433d92"
    }
},
{
    "pk": 4020, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Potential markers that could predict response to ipilimumab are of obvious importance. Clinical tria", 
        "paper": 3, 
        "tag_id": "erb-d23db0cb-3226-4b97-b910-8d1a12e51627"
    }
},
{
    "pk": 4021, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Trials of ipilimumab and gp100 peptide vaccine, each as a single agent or in combination, showed lim", 
        "paper": 3, 
        "tag_id": "erb-78f71103-d62b-441c-8e23-97fbe6645504"
    }
},
{
    "pk": 4022, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "PD-1, like CTLA-4, is an inhibitory receptor; however, its expression is not limited to T cells and ", 
        "paper": 3, 
        "tag_id": "erb-70d59e3e-5012-422e-8127-21fc252d13f9"
    }
},
{
    "pk": 4023, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Humanized antibodies to PD-1 and PD-L1 have been developed and tested in clinical trials for several", 
        "paper": 3, 
        "tag_id": "erb-4a06e36c-7185-489b-afaf-d0a999d0010f"
    }
},
{
    "pk": 4024, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Clinical trials targeting PD-1/ PD-L1 interaction", 
        "paper": 3, 
        "tag_id": "erb-8846be74-cc96-493f-83f2-dbe66706b037"
    }
},
{
    "pk": 4025, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Results from an early-phase clinical trial with anti-PD1 antibody BMS-936558 (MDX-1106, ONO-4538, Ni", 
        "paper": 3, 
        "tag_id": "erb-7c6fa2a9-7c21-4116-af77-89f27892c25c"
    }
},
{
    "pk": 4026, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Two other anti-PD-1 antibodies (CT-011: CureTech Ltd. and MK-3475/Lambrolizumab: Merck) are also in ", 
        "paper": 3, 
        "tag_id": "erb-55f4401a-2a0a-46b5-89a7-b7fc95efcfea"
    }
},
{
    "pk": 4027, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "An anti-PD-L1antibody (MPDL3280A/BMS-936559/MDX-1105 is being tested as well. Preliminary results wi", 
        "paper": 3, 
        "tag_id": "erb-8cc84489-beb2-4ca3-9759-d552d89a2afa"
    }
},
{
    "pk": 4028, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "An important paper has shown that combining blockade of both immune checkpoints (PD-1 and CTLA4) is ", 
        "paper": 3, 
        "tag_id": "erb-d8b07762-1657-49df-9113-a1184d6b618e"
    }
},
{
    "pk": 4029, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "In general, a concept is emerging that different immune checkpoints might have non-overlapping funct", 
        "paper": 3, 
        "tag_id": "erb-fc7ddb10-12bf-4dbd-ab65-e414160fb6cc"
    }
},
{
    "pk": 4030, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "4-1BB. Also known as CD137, 4-1BB is a member of the TNF receptor superfamily, and is an activation-", 
        "paper": 3, 
        "tag_id": "erb-f66006b5-3c45-4431-ab39-e887832db156"
    }
},
{
    "pk": 4031, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "GITR is a costimulatory receptor expressed after T cell activation that enhances T cell function and", 
        "paper": 3, 
        "tag_id": "erb-1de009a7-9b69-4ae1-bfe4-c2c2b8168da0"
    }
},
{
    "pk": 4032, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "OX40 is not involved in effector T cell activation, but rather, promotes T cell survival and expansi", 
        "paper": 3, 
        "tag_id": "erb-8e578e12-4d2f-472d-bd77-11d0b32fad43"
    }
},
{
    "pk": 4033, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "CD40. Unlike the costimulatory targets above, CD40 is expressed on APCs, while its ligand is express", 
        "paper": 3, 
        "tag_id": "erb-41663f80-35d7-4c15-adc7-53d2dd7cf3ed"
    }
},
{
    "pk": 4034, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "CEACAM1 is a potential new target for the development of targeting antibodies. CEACAM1 is a carcinoe", 
        "paper": 3, 
        "tag_id": "erb-48a17b78-2aed-42ff-aa9d-452fed5cf024"
    }
},
{
    "pk": 4035, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Cytokines", 
        "paper": 3, 
        "tag_id": "erb-dbae3c7e-5cd2-46d1-b212-68ec487e2174"
    }
},
{
    "pk": 4036, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Interleukin-2 (IL-2), a protein produced primarily by CD4+ T-cells that activates and induces prolif", 
        "paper": 3, 
        "tag_id": "erb-cbe72a9e-83aa-47b4-8d9a-501b04aeae45"
    }
},
{
    "pk": 4037, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Interferon alpha is FDA approved for the treatment of stage III melanoma in the adjuvant setting. In", 
        "paper": 3, 
        "tag_id": "erb-9100208a-9a38-4c62-be89-57c23bffd79d"
    }
},
{
    "pk": 4038, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Cytokines under investigation for the treatment of metastatic melanoma include IL-21, which produced", 
        "paper": 3, 
        "tag_id": "erb-1d5c8e89-333d-428f-8b0f-df5ab06c837a"
    }
},
{
    "pk": 4039, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Adoptive cell transfer", 
        "paper": 3, 
        "tag_id": "erb-a402bdae-7644-44a4-ba96-a9cf1bf3bd3c"
    }
},
{
    "pk": 4040, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Adoptive cell transfer (ACT) involves the selection of autologous lymphocytes with antitumor activit", 
        "paper": 3, 
        "tag_id": "erb-6f2d5101-031a-4a8c-b2ee-eb4747f7e104"
    }
},
{
    "pk": 4041, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Different aspects of ACT are being examined, among them the role of cytokines such as IL-15 and T ce", 
        "paper": 3, 
        "tag_id": "erb-78f845c6-9d25-4c95-a1cb-62b38e432cd6"
    }
},
{
    "pk": 4042, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Analysis of the repertoire of the T cells in the successful ACT treatments of three melanoma patient", 
        "paper": 3, 
        "tag_id": "erb-cd6d1ec9-09a3-4b02-aa49-1f073999767d"
    }
},
{
    "pk": 4043, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "A recent phase II clinical trial reported objective clinical responses in almost half of the 31 pati", 
        "paper": 3, 
        "tag_id": "erb-996e6e08-1191-481a-87c4-be6a7d81ce41"
    }
},
{
    "pk": 4044, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Failure of the infused CD8 cells to persist in the patients could be a major cause for the limited e", 
        "paper": 3, 
        "tag_id": "erb-07c02334-42fb-4a5d-bfc7-d5b1a869403d"
    }
},
{
    "pk": 4045, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Another approach to ACT therapy is to create tumor-reactive T-cell populations from PBL by retrovira", 
        "paper": 3, 
        "tag_id": "erb-3ce94586-8175-4be6-8047-3582bbc3e9fb"
    }
},
{
    "pk": 4046, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Some remarkable responses were observed in individual patients treated with CD4+T cells. For example", 
        "paper": 3, 
        "tag_id": "erb-870adeb1-9175-4507-8935-eb170f5d5336"
    }
},
{
    "pk": 4047, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Dendritic cell based immunotherapy.", 
        "paper": 3, 
        "tag_id": "erb-47d28fe4-66d6-4337-9d14-dc9eedac828a"
    }
},
{
    "pk": 4048, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Dendritic cells (DC) are the most potent antigen presenting cells in the immune system, and clinical", 
        "paper": 3, 
        "tag_id": "erb-e0968d32-d3f4-4577-9aac-4ea533545d8a"
    }
},
{
    "pk": 4049, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Stimulation of anti-melanoma responses by DC involves a number of steps that need better scientific ", 
        "paper": 3, 
        "tag_id": "erb-261d57bb-15ca-4be0-a9fe-dc3318abd854"
    }
},
{
    "pk": 4050, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "A number of variables remain to be fully explored in DC vaccination: the source of DC, the optimal m", 
        "paper": 3, 
        "tag_id": "erb-6c27c6fe-7fa7-4d4d-ba43-6ed01e5587cb"
    }
},
{
    "pk": 4051, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Clinical trials have explored DC generated by different methods and injected by different routes in ", 
        "paper": 3, 
        "tag_id": "erb-fdabc686-20a4-4d03-8a7d-75a98dd0dc08"
    }
},
{
    "pk": 4052, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "In a different approach, immature DC were generated from CD34+ hematopoietic progenitor cells throug", 
        "paper": 3, 
        "tag_id": "erb-c3e6746e-55e1-4958-8a30-e64cfe4c7eec"
    }
},
{
    "pk": 4053, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Langerhans cells were directly compared to monocyte-derived DC in a clinical trial, and were found t", 
        "paper": 3, 
        "tag_id": "erb-ee49394f-7883-457e-b9c6-a7bb3d343bbe"
    }
},
{
    "pk": 4054, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Stimulation of DC could be performed not only by exposing them to tumor antigens, but also by transf", 
        "paper": 3, 
        "tag_id": "erb-55c25f82-cebb-450b-8da4-1bd8a046d49b"
    }
},
{
    "pk": 4055, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "A recent study reported a further significant improvement on DC maturation ex vivo. Mature DC (used ", 
        "paper": 3, 
        "tag_id": "erb-f75915ac-0d96-4ce8-bfd4-86753b98c1ea"
    }
},
{
    "pk": 4056, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Another important component of successful vaccination with DC is their ability to stimulate CD8+ T c", 
        "paper": 3, 
        "tag_id": "erb-e91b91f8-085f-4b2d-b0ab-cb8621864673"
    }
},
{
    "pk": 4057, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Although combination immunotherapies involving dendritic cells and immunomodulatory antibodies may h", 
        "paper": 3, 
        "tag_id": "erb-c794669b-91f2-4aa6-b2e8-12d965313ab4"
    }
},
{
    "pk": 4058, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Adoptive transfer of natural killer cells. Natural killer (NK) cells are an essential part of the in", 
        "paper": 3, 
        "tag_id": "erb-dc09d798-f98a-4deb-bc62-acce7d8bb105"
    }
},
{
    "pk": 4059, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "NK cells can be obtained from peripheral blood mononuclear cells (PBMC) where they comprise 5-15 % o", 
        "paper": 3, 
        "tag_id": "erb-8ea3c3ac-584c-4b19-9178-602adb8c9356"
    }
},
{
    "pk": 4060, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Influence of targeted therapies on the responses to immune therapy", 
        "paper": 3, 
        "tag_id": "erb-6fac8227-628c-4f09-9592-5b7c879ee2c8"
    }
},
{
    "pk": 4061, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "BRAF/MAPK signaling and TIL. Activated BRAF/MAPK signaling was shown to be essential in the developm", 
        "paper": 3, 
        "tag_id": "erb-a64d1b60-8c9d-4ad9-bbd0-5c49a469659e"
    }
},
{
    "pk": 4062, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "There were concerns that treatment with BRAF/MEK inhibitors might have a direct inhibitory effect on", 
        "paper": 3, 
        "tag_id": "erb-9b462c3c-9e4f-41a7-836d-9058c2016b11"
    }
},
{
    "pk": 4063, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "A number of subsequent reports have confirmed that inhibition of mutant BRAF could potentiate immune", 
        "paper": 3, 
        "tag_id": "erb-102029f3-d441-411a-88f9-6fd9af1dc2d0"
    }
},
{
    "pk": 4064, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "A single report claimed that selective BRAF inhibition decreases tumor-resident lymphocyte frequenci", 
        "paper": 3, 
        "tag_id": "erb-55174a26-d379-479c-bae6-21cce144a83c"
    }
},
{
    "pk": 4065, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "The latest reported analysis of biopsies taken before and after treatment with BRAF or BRAF+MEK inhi", 
        "paper": 3, 
        "tag_id": "erb-62f9015a-a0e4-4c3a-8dc2-dea4a0569085"
    }
},
{
    "pk": 4066, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Adoptive cell transfer therapy and targeted therapies. Adoptive cell transfer therapy could also be ", 
        "paper": 3, 
        "tag_id": "erb-bbafead9-b3f3-4128-bf91-28ad59084bb0"
    }
},
{
    "pk": 4067, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "An in vitro study analyzed effects of BRAF and MEK inhibition on function of dendritic cells (DC) in", 
        "paper": 3, 
        "tag_id": "erb-3ee6e4e3-9a54-481c-89c4-8ada2014bbf9"
    }
},
{
    "pk": 4068, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Another in vitro study examined how vemurafenib affects the ability of the tumor-infiltrating lympho", 
        "paper": 3, 
        "tag_id": "erb-485d6fb7-0d54-4c50-8a19-061bc16711f3"
    }
},
{
    "pk": 4069, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "These studies in general provide a strong rationale for combination therapies involving BRAF inhibit", 
        "paper": 3, 
        "tag_id": "erb-6cc9ee7f-5118-429a-9d99-f55f9df65262"
    }
},
{
    "pk": 4070, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Mutant BRAF and/or its inhibition are not expected to influence outcomes of all immune therapies. Fo", 
        "paper": 3, 
        "tag_id": "erb-30467588-553e-4afc-bfa9-f3f9307478d4"
    }
},
{
    "pk": 4071, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Other melanoma-related pathways might also play a role in responses to immune therapy. Wnt/\uf062-catenin", 
        "paper": 3, 
        "tag_id": "erb-0a3e3212-f531-4db1-a10f-81cf2399d6a1"
    }
},
{
    "pk": 4072, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Tumor microenvironment and immune responses", 
        "paper": 3, 
        "tag_id": "erb-1c838028-2862-4a72-8225-c1a7137dda3e"
    }
},
{
    "pk": 4073, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "The role of B cells in the immune responses in melanoma. An extensive study measured humoral B cell ", 
        "paper": 3, 
        "tag_id": "erb-2e19f43e-bf5c-4874-b74b-cb29831192cb"
    }
},
{
    "pk": 4074, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Intratumoral IgG producing B cells have been reported in melanoma, but their functional significance", 
        "paper": 3, 
        "tag_id": "erb-68f0804d-b30f-4b7e-b4cf-a8f902864f86"
    }
},
{
    "pk": 4075, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Immune cell infiltrates in melanoma. The presence of lymph node-like structures in solid tumors has ", 
        "paper": 3, 
        "tag_id": "erb-62ef3ac9-43b4-45ef-9871-a5a4c5021932"
    }
},
{
    "pk": 4076, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "There have been few attempts to target melanoma metabolism with the exception of several known metab", 
        "paper": 3, 
        "tag_id": "erb-948b0457-74f0-4f7a-8c75-1ed5e1922b9c"
    }
},
{
    "pk": 4077, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Regarding the possible effects of metabolic preferences of melanoma tumors on the efficacy of target", 
        "paper": 3, 
        "tag_id": "erb-8b9a1f6c-1d88-47fd-92df-9ada17ee9691"
    }
},
{
    "pk": 4078, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "The importance of OXPHOS in melanoma resistance to chemotherapy and targeted therapy with Vemurafeni", 
        "paper": 3, 
        "tag_id": "erb-3721baee-b091-4dfa-b417-1b6c2fb49a11"
    }
},
{
    "pk": 4079, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "A most interesting study implicated enzyme PDH (pyruvate dehydrogenase) that links glycolysis to OXP", 
        "paper": 3, 
        "tag_id": "erb-1622a362-4cab-4e12-9c58-19b44bb30c0c"
    }
},
{
    "pk": 4080, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "The role of autophagy in tumor development and responses to various treatments remains controversial", 
        "paper": 3, 
        "tag_id": "erb-d9261a35-ce24-474f-a0d2-10680bfa5ede"
    }
},
{
    "pk": 4081, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Arginine deprivation. Melanoma tumors, along with hepatocellular cancer (HCC) and prostate cancer, f", 
        "paper": 3, 
        "tag_id": "erb-ffcfcb97-0ea8-46ba-bd88-76fccd621301"
    }
},
{
    "pk": 4082, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Leucine deprivation. Leucine deprivation was also shown to induce apoptotic death in melanoma cells;", 
        "paper": 3, 
        "tag_id": "erb-11e90b5c-c63d-49a2-a687-8532023d90ad"
    }
},
{
    "pk": 4083, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Autophagy is a potential target in melanoma. However, drug-induced autophagy could be either suicida", 
        "paper": 3, 
        "tag_id": "erb-fb1ed472-f289-43f9-99e3-103d680905fb"
    }
},
{
    "pk": 4084, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Because autophagy is known to be involved in both innate and adaptive immunity, there is an interest", 
        "paper": 3, 
        "tag_id": "erb-f6d941c5-24f2-4589-bffb-5abbf42ef615"
    }
},
{
    "pk": 4085, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Circulating Melanoma Cells", 
        "paper": 3, 
        "tag_id": "erb-b1d46d9b-81fe-45d1-8dd7-8fdf5f46c5a9"
    }
},
{
    "pk": 4086, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Detection of circulating tumor cells (CTC) in melanoma was explored for at least last twenty years. ", 
        "paper": 3, 
        "tag_id": "erb-e337d070-f1b0-48b6-8878-cb6339d0925c"
    }
},
{
    "pk": 4087, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "The earlier attempts were directed mostly towards developing a multimarker RT-PCR to detect and moni", 
        "paper": 3, 
        "tag_id": "erb-8ad4859d-2975-4e8a-b477-2acc6602287e"
    }
},
{
    "pk": 4088, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "A different approach involves physical separation of CTC prior to their analyses. This methodology i", 
        "paper": 3, 
        "tag_id": "erb-6860dca3-566b-43ad-a332-733cab69f137"
    }
},
{
    "pk": 4089, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "New techniques are being developed, such as isolation by size of epithelial tumor cells (ISET), whic", 
        "paper": 3, 
        "tag_id": "erb-98f969d9-63dc-40d9-9745-300db5693301"
    }
},
{
    "pk": 4090, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "The inertial focusing-enhanced microfluidic CTC capture platform, termed \"CTC-iChip\" is capable of r", 
        "paper": 3, 
        "tag_id": "erb-4ab02aab-05d6-4bf3-bd31-b87acba8c853"
    }
},
{
    "pk": 4091, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Molecular profiling of CTC might provide a very valuable representation of a tumor(s) genotype becau", 
        "paper": 3, 
        "tag_id": "erb-338be80b-e2df-4b68-942e-1a461ce2d3a7"
    }
},
{
    "pk": 4092, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Several clinical trials are ongoing that incorporate CTC detection and analyses prior to and after t", 
        "paper": 3, 
        "tag_id": "erb-725bd76f-20d9-4015-a5fa-f513e15e7c7b"
    }
},
{
    "pk": 4093, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Recent studies have addressed the utility of yet another method of \u201cliquid biopsy\u201d, i.e. analysis of", 
        "paper": 3, 
        "tag_id": "erb-28b958d7-c6fe-49d4-a11f-87c177e5cd3e"
    }
},
{
    "pk": 4094, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Prognostic test for uveal melanoma", 
        "paper": 3, 
        "tag_id": "erb-bc22a9bf-2e57-44b5-a6ad-529ebc19d3af"
    }
},
{
    "pk": 4095, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Uveal melanoma is a distinct type of melanoma with a clinical course and molecular landscape of its ", 
        "paper": 3, 
        "tag_id": "erb-e85fb44c-872c-43d0-a8c0-5376e8fcd8c3"
    }
},
{
    "pk": 4096, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "DecisionDx-UM gene expression profile test was developed as a stand-alone platform, which requires n", 
        "paper": 3, 
        "tag_id": "erb-bdadd597-a6d1-432f-b739-1fd6550b3c63"
    }
},
{
    "pk": 4097, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Exosomes.", 
        "paper": 3, 
        "tag_id": "erb-8434eba1-1772-41bc-b9d8-8689045c92fc"
    }
},
{
    "pk": 4098, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Exosomes are small membrane vesicles with an endosome origin that are released by cells into the ext", 
        "paper": 3, 
        "tag_id": "erb-9bd2368b-8833-4e59-b64c-6119477fb502"
    }
},
{
    "pk": 4099, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "It is very likely, considering the most recent findings, that the majority of driver mutations in me", 
        "paper": 3, 
        "tag_id": "erb-231ecf21-327a-4502-a575-a1fd13621403"
    }
},
{
    "pk": 4100, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "However, the accumulated knowledge is already sufficient to concentrate on the biological significan", 
        "paper": 3, 
        "tag_id": "erb-1d08c934-d472-4d0c-9dc0-09dcb784e9cd"
    }
},
{
    "pk": 4101, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "The ubiquitous problem of resistance to targeted therapies could only be addressed by dedicated prof", 
        "paper": 3, 
        "tag_id": "erb-50f66d75-4c53-48d9-95c0-37e4640f42ac"
    }
},
{
    "pk": 4102, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 1. Berger MF, Hodis E, Heffernan TP, et al: Melanoma genome sequencing reveals frequent PREX2 mutat", 
        "paper": 3, 
        "tag_id": "erb-0c0464c7-5906-41e1-bc4f-c923be3cf503"
    }
},
{
    "pk": 4103, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 2. Furney SJ, Pedersen M, Gentien D, et al: SF3B1 mutations are associated with alternative splicin", 
        "paper": 3, 
        "tag_id": "erb-3397dbd1-ccba-4140-adf1-ee718395a0d0"
    }
},
{
    "pk": 4104, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 3. Mar VJ, Wong SQ, Li J, et al: BRAF/NRAS wild-type melanomas have a high mutation load correlatin", 
        "paper": 3, 
        "tag_id": "erb-690cd9f1-022c-4aea-826e-70f494cc1ba6"
    }
},
{
    "pk": 4105, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 4. Furney SJ, Turajlic S, Stamp G, et al: Genome sequencing of mucosal melanomas reveals that they ", 
        "paper": 3, 
        "tag_id": "erb-eb6efe72-0aa2-4194-8df1-e230f5e12f95"
    }
},
{
    "pk": 4106, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 5. Griewank KG, Westekemper H, Murali R, et al: Conjunctival Melanomas Harbor BRAF and NRAS Mutatio", 
        "paper": 3, 
        "tag_id": "erb-7ea96a42-fb58-4667-9eaa-f9f941483038"
    }
},
{
    "pk": 4107, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 6. Pollock PM, Harper UL, Hansen KS, et al: High frequency of BRAF mutations in nevi. Nat Genet 33:", 
        "paper": 3, 
        "tag_id": "erb-d28469d3-be11-47e0-9e6c-aabad8c6ff72"
    }
},
{
    "pk": 4108, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 7. Michaloglou C, Vredeveld LC, Soengas MS, et al: BRAFE600-associated senescence-like cell cycle a", 
        "paper": 3, 
        "tag_id": "erb-d53d77fe-0f9d-4d53-936b-92e2bf7821e4"
    }
},
{
    "pk": 4109, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 8. Flaherty KT, Hodi FS, Fisher DE: From genes to drugs: targeted strategies for melanoma. Nat Rev ", 
        "paper": 3, 
        "tag_id": "erb-e143f4d8-17e9-4fe5-9979-079f4b3a28c7"
    }
},
{
    "pk": 4110, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 9. Flaherty KT, Puzanov I, Kim KB, et al: Inhibition of mutated, activated BRAF in metastatic melan", 
        "paper": 3, 
        "tag_id": "erb-82561da6-db18-41f9-a4e7-0e355bee64e4"
    }
},
{
    "pk": 4111, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 10. Jordan EJ, Kelly CM: Vemurafenib for the treatment of melanoma. Expert Opin Pharmacother 13:253", 
        "paper": 3, 
        "tag_id": "erb-0537eb74-e575-43b5-8557-8f06f7ecab9b"
    }
},
{
    "pk": 4112, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 11. Alloo A, Garibyan L, LeBoeuf N, et al: Photodynamic therapy for multiple eruptive keratoacantho", 
        "paper": 3, 
        "tag_id": "erb-1d655272-6716-4f96-bf01-0ddee49b6a52"
    }
},
{
    "pk": 4113, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 12. Callahan MK, Rampal R, Harding JJ, et al: Progression of RAS-mutant leukemia during RAF inhibit", 
        "paper": 3, 
        "tag_id": "erb-b7999240-5d75-4a4d-a8ab-0568e4d42801"
    }
},
{
    "pk": 4114, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 13. Gibney GT, Messina JL, Fedorenko IV, et al: Paradoxical oncogenesis-the long-term effects of BR", 
        "paper": 3, 
        "tag_id": "erb-c49246af-c6b9-45c4-ab15-2b8447b3dfb8"
    }
},
{
    "pk": 4115, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 14. Poulikakos PI, Zhang C, Bollag G, et al: RAF inhibitors transactivate RAF dimers and ERK signal", 
        "paper": 3, 
        "tag_id": "erb-d18ee6d1-6445-4c8e-a047-37535dbd61a0"
    }
},
{
    "pk": 4116, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 15. Dalle S, Poulalhon N, Debarbieux S, et al: Second primary melanomas under vemurafenib. Br J Der", 
        "paper": 3, 
        "tag_id": "erb-e0cfb3b3-a7a6-4199-8cca-4c2d980d090d"
    }
},
{
    "pk": 4117, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 16. Zimmer L, Hillen U, Livingstone E, et al: Atypical melanocytic proliferations and new primary m", 
        "paper": 3, 
        "tag_id": "erb-658aebc8-a41f-4f9e-80e9-06f40588ca07"
    }
},
{
    "pk": 4118, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 17. Holderfield M, Merritt H, Chan J, et al: RAF Inhibitors Activate the MAPK Pathway by Relieving ", 
        "paper": 3, 
        "tag_id": "erb-3c819248-7371-4f91-ac8c-1a683fe1b62a"
    }
},
{
    "pk": 4119, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 18. Ascierto PA, Minor D, Ribas A, et al: Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib", 
        "paper": 3, 
        "tag_id": "erb-b79af6ac-70ee-4103-ad79-3f579bbd24ae"
    }
},
{
    "pk": 4120, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 19. Le K, Blomain E, Rodeck U, et al: Selective RAF inhibitor impairs ERK1/2 phosphorylation and gr", 
        "paper": 3, 
        "tag_id": "erb-40655d9a-1ff0-4987-9d3a-44fda7098362"
    }
},
{
    "pk": 4121, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 20. Das Thakur M, Salangsang F, Landman AS, et al: Modelling vemurafenib resistance in melanoma rev", 
        "paper": 3, 
        "tag_id": "erb-17409a75-e526-4595-a4b5-6adeea0ab05c"
    }
},
{
    "pk": 4122, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 21. Falchook GS, Lewis KD, Infante JR, et al: Activity of the oral MEK inhibitor trametinib in pati", 
        "paper": 3, 
        "tag_id": "erb-094b3409-8d96-4d9c-bfe5-2f13344c711f"
    }
},
{
    "pk": 4123, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 22. Flaherty KT, Robert C, Hersey P, et al: Improved survival with MEK inhibition in BRAF-mutated m", 
        "paper": 3, 
        "tag_id": "erb-b1a0a665-7535-44b7-a483-6e8306d1ebcf"
    }
},
{
    "pk": 4124, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 23. Robert C, Dummer R, Gutzmer R, et al: Selumetinib plus dacarbazine versus placebo plus dacarbaz", 
        "paper": 3, 
        "tag_id": "erb-823e96d6-1d53-45d6-b19e-34763fd6b185"
    }
},
{
    "pk": 4125, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 24. Kim KB, Kefford R, Pavlick AC, et al: Phase II study of the MEK1/MEK2 inhibitor Trametinib in p", 
        "paper": 3, 
        "tag_id": "erb-33add46d-08a4-4037-b0ff-7f1a88873c67"
    }
},
{
    "pk": 4126, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 25. Flaherty KT, Infante JR, Daud A, et al: Combined BRAF and MEK inhibition in melanoma with BRAF ", 
        "paper": 3, 
        "tag_id": "erb-4e0b2272-7dbd-4a1c-a07a-053b32fbe5ea"
    }
},
{
    "pk": 4127, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 26. Morris EJ, Jha S, Restaino CR, et al: Discovery of a Novel ERK Inhibitor with Activity in Model", 
        "paper": 3, 
        "tag_id": "erb-ee403280-1e59-48f7-84d0-a614107dc129"
    }
},
{
    "pk": 4128, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 27. Davies H, Bignell GR, Cox C, et al: Mutations of the BRAF gene in human cancer. Nature 417:949-", 
        "paper": 3, 
        "tag_id": "erb-36d8a0e6-bd3f-4fc1-b43f-fe3e42e172da"
    }
},
{
    "pk": 4129, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 28. Wan PT, Garnett MJ, Roe SM, et al: Mechanism of activation of the RAF-ERK signaling pathway by ", 
        "paper": 3, 
        "tag_id": "erb-e94e3464-a728-4c9c-b7fe-2b74bcfde816"
    }
},
{
    "pk": 4130, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 29. Smalley KS, Xiao M, Villanueva J, et al: CRAF inhibition induces apoptosis in melanoma cells wi", 
        "paper": 3, 
        "tag_id": "erb-0559b273-f486-485a-a032-f249f82d3d0f"
    }
},
{
    "pk": 4131, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 30. Dahlman KB, Xia J, Hutchinson K, et al: BRAF(L597) mutations in melanoma are associated with se", 
        "paper": 3, 
        "tag_id": "erb-7f409e16-5927-4a45-b228-6f93d478c608"
    }
},
{
    "pk": 4132, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 31. Hodis E, Watson IR, Kryukov GV, et al: A landscape of driver mutations in melanoma. Cell 150:25", 
        "paper": 3, 
        "tag_id": "erb-5daf18f6-8271-4a4d-8d9d-a77b27338eb8"
    }
},
{
    "pk": 4133, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 32. Ascierto PA, Schadendorf D, Berking C, et al: MEK162 for patients with advanced melanoma harbou", 
        "paper": 3, 
        "tag_id": "erb-71089432-f265-49c4-85be-af05f22cc6fc"
    }
},
{
    "pk": 4134, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 33. Hatzivassiliou G, Haling JR, Chen H, et al: Mechanism of MEK inhibition determines efficacy in ", 
        "paper": 3, 
        "tag_id": "erb-df2eb93c-bf61-4239-a405-9d65d3939915"
    }
},
{
    "pk": 4135, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 34. Roberts PJ, Usary JE, Darr DB, et al: Combined PI3K/mTOR and MEK inhibition provides broad anti", 
        "paper": 3, 
        "tag_id": "erb-38cc2a9a-958c-4f46-9a91-2500d2303782"
    }
},
{
    "pk": 4136, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 35. Posch C, Moslehi H, Feeney L, et al: Combined targeting of MEK and PI3K/mTOR effector pathways ", 
        "paper": 3, 
        "tag_id": "erb-81dd1e5e-1595-48c5-915a-7c4e0c80b3ec"
    }
},
{
    "pk": 4137, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 36. Kwong LN, Costello JC, Liu H, et al: Oncogenic NRAS signaling differentially regulates survival", 
        "paper": 3, 
        "tag_id": "erb-c79e7532-04d5-4ab7-be20-ee0aabcd1803"
    }
},
{
    "pk": 4138, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 37. Barretina J, Caponigro G, Stransky N, et al: The Cancer Cell Line Encyclopedia enables predicti", 
        "paper": 3, 
        "tag_id": "erb-322e5285-4bf9-4d47-b24f-d1891d582a29"
    }
},
{
    "pk": 4139, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 38. Held MA, Langdon CG, Platt JT, et al: Genotype-selective combination therapies for melanoma ide", 
        "paper": 3, 
        "tag_id": "erb-7ff008ca-7500-4c49-bf6d-ef4b83eb89ea"
    }
},
{
    "pk": 4140, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 39. Van Raamsdonk CD, Bezrookove V, Green G, et al: Frequent somatic mutations of GNAQ in uveal mel", 
        "paper": 3, 
        "tag_id": "erb-95bbc57d-77a7-4c33-b4da-df89a9f7b678"
    }
},
{
    "pk": 4141, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 40. Van Raamsdonk CD, Griewank KG, Crosby MB, et al: Mutations in GNA11 in uveal melanoma. N Engl J", 
        "paper": 3, 
        "tag_id": "erb-eabe3ef1-921e-4a8d-ad32-e60c9bed4e75"
    }
},
{
    "pk": 4142, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 41. Daniels AB, Lee JE, MacConaill LE, et al: High throughput mass spectrometry-based mutation prof", 
        "paper": 3, 
        "tag_id": "erb-13799afb-20ee-4c65-8941-5d2d11628b05"
    }
},
{
    "pk": 4143, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 42. Ho AL, Musi E, Ambrosini G, et al: Impact of combined mTOR and MEK inhibition in uveal melanoma", 
        "paper": 3, 
        "tag_id": "erb-684e2fbf-4eb8-4d8c-aad3-5b85db2dc58b"
    }
},
{
    "pk": 4144, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 43. Khalili JS, Yu X, Wang J, et al: Combination small molecule MEK and PI3K inhibition enhances uv", 
        "paper": 3, 
        "tag_id": "erb-6228190e-b0ba-4551-b697-60bf219d1a36"
    }
},
{
    "pk": 4145, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 44. Wu X, Li J, Zhu M, et al: Protein kinase C inhibitor AEB071 targets ocular melanoma harboring G", 
        "paper": 3, 
        "tag_id": "erb-f79262c5-9757-491c-a30a-06f100b8a86d"
    }
},
{
    "pk": 4146, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 45. Wu X, Zhu M, Fletcher JA, et al: The protein kinase C inhibitor enzastaurin exhibits antitumor ", 
        "paper": 3, 
        "tag_id": "erb-8727dc7c-6027-4f80-ad9e-5f02615508c3"
    }
},
{
    "pk": 4147, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 46. Vaque JP, Dorsam RT, Feng X, et al: A Genome-wide RNAi Screen Reveals a Trio-Regulated Rho GTPa", 
        "paper": 3, 
        "tag_id": "erb-beacb5a8-a535-43b7-a5e4-7b41a814aa3d"
    }
},
{
    "pk": 4148, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 47. Garraway LA, Widlund HR, Rubin MA, et al: Integrative genomic analyses identify MITF as a linea", 
        "paper": 3, 
        "tag_id": "erb-46cfcb38-0e15-4368-9b61-1379bd2cc3e2"
    }
},
{
    "pk": 4149, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 48. Yokoyama S, Woods SL, Boyle GM, et al: A novel recurrent mutation in MITF predisposes to famili", 
        "paper": 3, 
        "tag_id": "erb-c793c6e3-fd34-4f7a-97df-f69d783385ed"
    }
},
{
    "pk": 4150, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 49. Du J, Widlund HR, Horstmann MA, et al: Critical role of CDK2 for melanoma growth linked to its ", 
        "paper": 3, 
        "tag_id": "erb-3d67adfa-dbc6-4ab2-a973-616477bd4534"
    }
},
{
    "pk": 4151, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 50. Zhu S, Wurdak H, Wang Y, et al: A genomic screen identifies TYRO3 as a MITF regulator in melano", 
        "paper": 3, 
        "tag_id": "erb-a484d862-735e-4f0c-99db-1451000357fe"
    }
},
{
    "pk": 4152, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 51. Zhao X, Fiske B, Kawakami A, et al: Regulation of MITF stability by the USP13 deubiquitinase. N", 
        "paper": 3, 
        "tag_id": "erb-3fac64d3-e0bc-4ebb-bc7f-5209e9ae9683"
    }
},
{
    "pk": 4153, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 52. Busca R, Berra E, Gaggioli C, et al: Hypoxia-inducible factor 1{alpha} is a new target of micro", 
        "paper": 3, 
        "tag_id": "erb-4f28c914-13c0-4a3f-b75f-290b4bd46de7"
    }
},
{
    "pk": 4154, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 53. Feige E, Yokoyama S, Levy C, et al: Hypoxia-induced transcriptional repression of the melanoma-", 
        "paper": 3, 
        "tag_id": "erb-06d4d889-4a6a-4b1d-a3ce-5f4f6e9667d1"
    }
},
{
    "pk": 4155, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 54. Hanna SC, Krishnan B, Bailey ST, et al: HIF1alpha and HIF2alpha independently activate SRC to p", 
        "paper": 3, 
        "tag_id": "erb-798fb3cd-b568-40a1-a33b-cfc50b1d6786"
    }
},
{
    "pk": 4156, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 55. Shah M, Bhoumik A, Goel V, et al: A role for ATF2 in regulating MITF and melanoma development. ", 
        "paper": 3, 
        "tag_id": "erb-cce52907-6e99-46d0-a997-db4ffec2cf0a"
    }
},
{
    "pk": 4157, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 56. Shakhova O, Zingg D, Schaefer SM, et al: Sox10 promotes the formation and maintenance of giant ", 
        "paper": 3, 
        "tag_id": "erb-5329ae0e-42ea-441d-ae58-f65acc6a6213"
    }
},
{
    "pk": 4158, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 57. Puri N, Ahmed S, Janamanchi V, et al: c-Met is a potentially new therapeutic target for treatme", 
        "paper": 3, 
        "tag_id": "erb-7d352cb4-373f-405f-ae3f-681b2059682e"
    }
},
{
    "pk": 4159, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 58. Mascarenhas JB, Littlejohn EL, Wolsky RJ, et al: PAX3 and SOX10 activate MET receptor expressio", 
        "paper": 3, 
        "tag_id": "erb-c818bc6e-f510-439b-b8b5-2dcbb98cbc0a"
    }
},
{
    "pk": 4160, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 59. Vazquez F, Lim JH, Chim H, et al: PGC1alpha Expression Defines a Subset of Human Melanoma Tumor", 
        "paper": 3, 
        "tag_id": "erb-f78377d1-17dd-4bfb-a9bf-6ecab6aa75ed"
    }
},
{
    "pk": 4161, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 60. Shoag J, Haq R, Zhang M, et al: PGC-1 Coactivators Regulate MITF and the Tanning Response. Mol ", 
        "paper": 3, 
        "tag_id": "erb-f88b54d7-e431-4c7c-9852-dd1d3dad33b2"
    }
},
{
    "pk": 4162, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 61. Haq R, Yokoyama S, Hawryluk EB, et al: BCL2A1 is a lineage-specific antiapoptotic melanoma onco", 
        "paper": 3, 
        "tag_id": "erb-d0f02028-57a0-4a22-876d-81526ee0820d"
    }
},
{
    "pk": 4163, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 62. Saez-Ayala M, Montenegro MF, Sanchez-Del-Campo L, et al: Directed Phenotype Switching as an Eff", 
        "paper": 3, 
        "tag_id": "erb-45ac4c66-72a6-4705-8a80-01ab892c7780"
    }
},
{
    "pk": 4164, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 63. Pogenberg V, Ogmundsdottir MH, Bergsteinsdottir K, et al: Restricted leucine zipper dimerizatio", 
        "paper": 3, 
        "tag_id": "erb-b14cf080-0e71-4466-9008-01156a3a3d5c"
    }
},
{
    "pk": 4165, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 64. Yokoyama S, Feige E, Poling LL, et al: Pharmacologic suppression of MITF expression via HDAC in", 
        "paper": 3, 
        "tag_id": "erb-cbacfaad-1bf2-427f-987a-77ef6c8acd72"
    }
},
{
    "pk": 4166, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 65. Varsano T, Lau E, Feng Y, et al: Inhibition of Melanoma Growth by Small Molecules That Promote ", 
        "paper": 3, 
        "tag_id": "erb-56a5feb1-4ac7-44de-afc0-631f62cf935f"
    }
},
{
    "pk": 4167, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 66. Curtin JA, Busam K, Pinkel D, et al: Somatic activation of KIT in distinct subtypes of melanoma", 
        "paper": 3, 
        "tag_id": "erb-ccc54ef2-a6d8-407c-8b4f-8bf09803d6c3"
    }
},
{
    "pk": 4168, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 67. Woodman SE, Davies MA: Targeting KIT in melanoma: a paradigm of molecular medicine and targeted", 
        "paper": 3, 
        "tag_id": "erb-a5205fe9-ead8-4827-aeec-ca94eafa430b"
    }
},
{
    "pk": 4169, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 68. Kim KB, Eton O, Davis DW, et al: Phase II trial of imatinib mesylate in patients with metastati", 
        "paper": 3, 
        "tag_id": "erb-c052a5f3-99c5-41d2-8cce-ca7f76c1c70e"
    }
},
{
    "pk": 4170, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 69. Penel N, Delcambre C, Durando X, et al: O-Mel-Inib: a Cancero-pole Nord-Ouest multicenter phase", 
        "paper": 3, 
        "tag_id": "erb-fbd87c44-02a0-42b6-b7d5-fa41c36e27b9"
    }
},
{
    "pk": 4171, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 70. Wyman K, Atkins MB, Prieto V, et al: Multicenter Phase II trial of high-dose imatinib mesylate ", 
        "paper": 3, 
        "tag_id": "erb-01ceb05d-c9c6-489d-a7f6-58fcf1bcc137"
    }
},
{
    "pk": 4172, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 71. Kluger HM, Dudek AZ, McCann C, et al: A phase 2 trial of dasatinib in advanced melanoma. Cancer", 
        "paper": 3, 
        "tag_id": "erb-330b697d-97d9-4f20-816f-c6b16cc432d5"
    }
},
{
    "pk": 4173, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 72. Lutzky J, Bauer J, Bastian BC: Dose-dependent, complete response to imatinib of a metastatic mu", 
        "paper": 3, 
        "tag_id": "erb-cb04c50b-a7f7-4a3a-8cfa-37a82f181282"
    }
},
{
    "pk": 4174, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 73. Hodi FS, Friedlander P, Corless CL, et al: Major response to imatinib mesylate in KIT-mutated m", 
        "paper": 3, 
        "tag_id": "erb-40a18874-d676-4586-85b3-bcebf2e00678"
    }
},
{
    "pk": 4175, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 74. Woodman SE, Trent JC, Stemke-Hale K, et al: Activity of dasatinib against L576P KIT mutant mela", 
        "paper": 3, 
        "tag_id": "erb-458eb2a1-a739-4a28-8654-d325b51de36e"
    }
},
{
    "pk": 4176, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 75. Hofmann UB, Kauczok-Vetter CS, Houben R, et al: Overexpression of the KIT/SCF in uveal melanoma", 
        "paper": 3, 
        "tag_id": "erb-8470c3e7-5d90-4854-a31d-fe587b403677"
    }
},
{
    "pk": 4177, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 76. Mahipal A, Tijani L, Chan K, et al: A pilot study of sunitinib malate in patients with metastat", 
        "paper": 3, 
        "tag_id": "erb-3d1aa943-86b5-4c42-93f0-96de598da65c"
    }
},
{
    "pk": 4178, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 77. Guo J, Si L, Kong Y, et al: Phase II, open-label, single-arm trial of imatinib mesylate in pati", 
        "paper": 3, 
        "tag_id": "erb-9b1e555c-c0cc-4f82-8026-fda37fc0fd6c"
    }
},
{
    "pk": 4179, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 78. Carvajal RD, Antonescu CR, Wolchok JD, et al: KIT as a therapeutic target in metastatic melanom", 
        "paper": 3, 
        "tag_id": "erb-b55e56b4-f6da-44dd-9a37-b5fc770a54da"
    }
},
{
    "pk": 4180, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 79. Minor DR, Kashani-Sabet M, Garrido M, et al: Sunitinib therapy for melanoma patients with KIT m", 
        "paper": 3, 
        "tag_id": "erb-dead9bf9-1ee4-46bb-9c1d-4ba942684e4e"
    }
},
{
    "pk": 4181, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 80. Cho JH, Kim KM, Kwon M, et al: Nilotinib in patients with metastatic melanoma harboring KIT gen", 
        "paper": 3, 
        "tag_id": "erb-72ff5825-52a2-4090-bff1-02cae53da1a0"
    }
},
{
    "pk": 4182, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 81. Hodi FS, Corless CL, Giobbie-Hurder A, et al: Imatinib for Melanomas Harboring Mutationally Act", 
        "paper": 3, 
        "tag_id": "erb-b0c2c0e4-7da8-4ccd-a4d2-4f8dac0974c2"
    }
},
{
    "pk": 4183, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 82. Carvajal RD: Another Option in Our KIT of Effective Therapies for Advanced Melanoma. J Clin Onc", 
        "paper": 3, 
        "tag_id": "erb-4ae67e3f-9b65-4761-8943-9c6d4dbb21d6"
    }
},
{
    "pk": 4184, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 83. Johnson MR, Look AT, DeClue JE, et al: Inactivation of the NF1 gene in human melanoma and neuro", 
        "paper": 3, 
        "tag_id": "erb-1ba1d05c-03ed-4424-ab08-042f49d010a9"
    }
},
{
    "pk": 4185, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 84. Gutzmer R, Herbst RA, Mommert S, et al: Allelic loss at the neurofibromatosis type 1 (NF1) gene", 
        "paper": 3, 
        "tag_id": "erb-42570308-7646-4fc2-9f22-0036a4660065"
    }
},
{
    "pk": 4186, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 85. Maertens O, Johnson B, Hollstein P, et al: Elucidating distinct roles for NF1 in melanomagenesi", 
        "paper": 3, 
        "tag_id": "erb-28186159-5c01-4aeb-a494-d0b3fe11cf32"
    }
},
{
    "pk": 4187, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 86. Whittaker SR, Theurillat JP, Van Allen E, et al: A genome-scale RNA interference screen implica", 
        "paper": 3, 
        "tag_id": "erb-be0aa840-ef45-4cce-9ef0-12fc6407454f"
    }
},
{
    "pk": 4188, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 87. Horn S, Figl A, Rachakonda PS, et al: TERT Promoter Mutations in Familial and Sporadic Melanoma", 
        "paper": 3, 
        "tag_id": "erb-e6019359-8f9f-48be-a128-6b2ae39299c3"
    }
},
{
    "pk": 4189, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 88. Huang FW, Hodis E, Xu MJ, et al: Highly Recurrent TERT Promoter Mutations in Human Melanoma. Sc", 
        "paper": 3, 
        "tag_id": "erb-a9e65c8d-521b-4291-8d1a-81e331002676"
    }
},
{
    "pk": 4190, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 89. Dankort D, Curley DP, Cartlidge RA, et al: Braf(V600E) cooperates with Pten loss to induce meta", 
        "paper": 3, 
        "tag_id": "erb-eb2257b3-def8-4263-b79c-7dd7f6dd98fe"
    }
},
{
    "pk": 4191, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 90. Vredeveld LC, Possik PA, Smit MA, et al: Abrogation of BRAFV600E-induced senescence by PI3K pat", 
        "paper": 3, 
        "tag_id": "erb-9ba0be4c-20ab-443d-a358-fbd18a426c65"
    }
},
{
    "pk": 4192, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 91. Prickett TD, Agrawal NS, Wei X, et al: Analysis of the tyrosine kinome in melanoma reveals recu", 
        "paper": 3, 
        "tag_id": "erb-757e3f22-4ba2-4826-8ac9-cbffceb7d306"
    }
},
{
    "pk": 4193, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 92. Dutton-Regester K, Irwin D, Hunt P, et al: A high-throughput panel for identifying clinically r", 
        "paper": 3, 
        "tag_id": "erb-fdd9f8fa-0306-4f6a-8869-e7061fa97754"
    }
},
{
    "pk": 4194, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 93. Zhou QM, Li W, Guan YX, et al: The absence of the ERBB4 hotspot mutations in melanomas in patie", 
        "paper": 3, 
        "tag_id": "erb-25355f54-aa71-402e-912f-6328a828fabe"
    }
},
{
    "pk": 4195, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 94. Moore SR, Persons DL, Sosman JA, et al: Detection of copy number alterations in metastatic mela", 
        "paper": 3, 
        "tag_id": "erb-e8243e2c-d745-437f-9e36-6162e38e3580"
    }
},
{
    "pk": 4196, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 95. Kenessey I, Keszthelyi M, Kramer Z, et al: Inhibition of c-Met with the specific small molecule", 
        "paper": 3, 
        "tag_id": "erb-f856f624-be31-44f2-b703-6c2e97f50668"
    }
},
{
    "pk": 4197, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 96. Schlegel J, Sambade MJ, Sather S, et al: MERTK receptor tyrosine kinase is a therapeutic target", 
        "paper": 3, 
        "tag_id": "erb-fdabed53-6a6e-49b1-935a-bb899beb6718"
    }
},
{
    "pk": 4198, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 97. Tworkoski KA, Platt JT, Bacchiocchi A, et al: MERTK controls melanoma cell migration and surviv", 
        "paper": 3, 
        "tag_id": "erb-f15e274f-6e14-46d5-b09e-962b15e9e8fb"
    }
},
{
    "pk": 4199, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 98. Stahl JM, Sharma A, Cheung M, et al: Deregulated Akt3 activity promotes development of malignan", 
        "paper": 3, 
        "tag_id": "erb-443a3a9f-fe99-434e-9a7c-562409c569e6"
    }
},
{
    "pk": 4200, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 99. Davies MA, Stemke-Hale K, Tellez C, et al: A novel AKT3 mutation in melanoma tumours and cell l", 
        "paper": 3, 
        "tag_id": "erb-d7a17c29-0710-4f68-9a24-c130fc0d1f00"
    }
},
{
    "pk": 4201, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 100. Cheung M, Sharma A, Madhunapantula SV, et al: Akt3 and mutant V600E B-Raf cooperate to promote", 
        "paper": 3, 
        "tag_id": "erb-1b310e83-428a-433b-a28a-8e6f80061230"
    }
},
{
    "pk": 4202, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 101. Tsao H, Zhang X, Benoit E, et al: Identification of PTEN/MMAC1 alterations in uncultured melan", 
        "paper": 3, 
        "tag_id": "erb-63fc9e02-4b7a-4499-9989-a4b2cab4bf8a"
    }
},
{
    "pk": 4203, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 102. Karreth FA, Tay Y, Perna D, et al: In vivo identification of tumor- suppressive PTEN ceRNAs in", 
        "paper": 3, 
        "tag_id": "erb-b3c3513e-4a13-4f48-bb07-abc385f21159"
    }
},
{
    "pk": 4204, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 103. Nathanson KL, Martin AM, Wubbenhorst B, et al: Tumor genetic analyses of patients with metasta", 
        "paper": 3, 
        "tag_id": "erb-9a1830a0-2f55-4a3a-8dd8-a9e6ad80718a"
    }
},
{
    "pk": 4205, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 104. Cao J, Wan L, Hacker E, et al: MC1R Is a Potent Regulator of PTEN after UV Exposure in Melanoc", 
        "paper": 3, 
        "tag_id": "erb-3265ac7d-1344-4429-8c35-137a9f499fca"
    }
},
{
    "pk": 4206, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 105. Shull AY, Latham-Schwark A, Ramasamy P, et al: Novel somatic mutations to PI3K pathway genes i", 
        "paper": 3, 
        "tag_id": "erb-b6c485dd-84df-4a1f-9f71-f7c243779d2c"
    }
},
{
    "pk": 4207, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 106. Nikolaev SI, Rimoldi D, Iseli C, et al: Exome sequencing identifies recurrent somatic MAP2K1 a", 
        "paper": 3, 
        "tag_id": "erb-4e874d09-ab1c-471b-ad8a-db2a6a31c516"
    }
},
{
    "pk": 4208, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 107. Jameson KL, Mazur PK, Zehnder AM, et al: IQGAP1 scaffold-kinase interaction blockade selective", 
        "paper": 3, 
        "tag_id": "erb-ce653721-1f44-408b-bec8-0fa870086116"
    }
},
{
    "pk": 4209, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 108. Li A, Ma Y, Jin M, et al: Activated mutant NRas(Q61K) drives aberrant melanocyte signaling, su", 
        "paper": 3, 
        "tag_id": "erb-b781241d-752e-42e9-a46e-3d6c0534ea18"
    }
},
{
    "pk": 4210, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 109. Krauthammer M, Kong Y, Ha BH, et al: Exome sequencing identifies recurrent somatic RAC1 mutati", 
        "paper": 3, 
        "tag_id": "erb-9f4d11ae-e5f3-4809-8b32-d93d0610f89e"
    }
},
{
    "pk": 4211, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 110. Stark MS, Woods SL, Gartside MG, et al: Frequent somatic mutations in MAP3K5 and MAP3K9 in met", 
        "paper": 3, 
        "tag_id": "erb-42bb8ace-969a-41b5-b743-0e2aa4f71a28"
    }
},
{
    "pk": 4212, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 111. Muthusamy V, Hobbs C, Nogueira C, et al: Amplification of CDK4 and MDM2 in malignant melanoma.", 
        "paper": 3, 
        "tag_id": "erb-0545a36b-40b9-4358-b79d-58ecf0282f62"
    }
},
{
    "pk": 4213, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 112. Zuo L, Weger J, Yang Q, et al: Germline mutations in the p16INK4a binding domain of CDK4 in fa", 
        "paper": 3, 
        "tag_id": "erb-1eaaea0b-ad13-4de3-81ba-6d740f3cef33"
    }
},
{
    "pk": 4214, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 113. Dickson MA, Shah MA, Rathkopf D, et al: A phase I clinical trial of FOLFIRI in combination wit", 
        "paper": 3, 
        "tag_id": "erb-6037a01b-54d6-4b3c-bf64-24e94655c837"
    }
},
{
    "pk": 4215, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 114. Hussussian CJ, Struewing JP, Goldstein AM, et al: Germline p16 mutations in familial melanoma.", 
        "paper": 3, 
        "tag_id": "erb-5db31747-1e9f-4052-a867-435687fe1355"
    }
},
{
    "pk": 4216, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 115. Polsky D, Bastian BC, Hazan C, et al: HDM2 protein overexpression, but not gene amplification,", 
        "paper": 3, 
        "tag_id": "erb-6cc8bcd7-eb9d-4a03-add6-613476485f16"
    }
},
{
    "pk": 4217, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 116. Gembarska A, Luciani F, Fedele C, et al: MDM4 is a key therapeutic target in cutaneous melanom", 
        "paper": 3, 
        "tag_id": "erb-fb64cd91-c031-4648-8eb3-4b2ad3c0ac5d"
    }
},
{
    "pk": 4218, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 117. Matin RN, Chikh A, Law Pak Chong S, et al: p63 is an alternative p53 repressor in melanoma tha", 
        "paper": 3, 
        "tag_id": "erb-6798bc29-bc4a-4ebf-868c-62db49ac57d5"
    }
},
{
    "pk": 4219, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 118. Bergamaschi D, Samuels Y, Sullivan A, et al: iASPP preferentially binds p53 proline-rich regio", 
        "paper": 3, 
        "tag_id": "erb-c701cbf7-942f-4102-82a2-fccd3b7095f3"
    }
},
{
    "pk": 4220, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 119. Kamb A, Gruis NA, Weaver-Feldhaus J, et al: A cell cycle regulator potentially involved in gen", 
        "paper": 3, 
        "tag_id": "erb-729d275e-cbfe-4e38-a6d5-25116eb169ce"
    }
},
{
    "pk": 4221, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 120. Kamb A, Shattuck-Eidens D, Eeles R, et al: Analysis of the p16 gene (CDKN2) as a candidate for", 
        "paper": 3, 
        "tag_id": "erb-f9a2d2ec-c07b-41ef-ae80-6b88f0674915"
    }
},
{
    "pk": 4222, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 121. Ohta M, Berd D, Shimizu M, et al: Deletion mapping of chromosome region 9p21-p22 surrounding t", 
        "paper": 3, 
        "tag_id": "erb-e1e5fc0d-f602-452c-9f90-3888247f4da8"
    }
},
{
    "pk": 4223, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 122. Dar AA, Majid S, Rittsteuer C, et al: The role of miR-18b in MDM2-p53 pathway signaling and me", 
        "paper": 3, 
        "tag_id": "erb-2cd9ec5c-643e-4d4c-afe6-2e5cb9de2966"
    }
},
{
    "pk": 4224, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 123. Ray-Coquard I, Blay JY, Italiano A, et al: Effect of the MDM2 antagonist RG7112 on the P53 pat", 
        "paper": 3, 
        "tag_id": "erb-58da4727-c47d-4f42-b6d2-f6aee659d0ed"
    }
},
{
    "pk": 4225, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 124. Ji Z, Kumar R, Taylor M, et al: Vemurafenib Synergizes with Nutlin-3 to Deplete Survivin and S", 
        "paper": 3, 
        "tag_id": "erb-db3ea2b0-1764-457f-b8b6-1e1643a0d046"
    }
},
{
    "pk": 4226, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 125. Brown CJ, Quah ST, Jong J, et al: Stapled peptides with improved potency and specificity that ", 
        "paper": 3, 
        "tag_id": "erb-9b4fc9f8-3018-4748-84db-770b5d523025"
    }
},
{
    "pk": 4227, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 126. Chang YS, Graves B, Guerlavais V, et al: Stapled alpha-helical peptide drug development: A pot", 
        "paper": 3, 
        "tag_id": "erb-7ed5125b-7ab3-4815-9f00-1c2feb4b2719"
    }
},
{
    "pk": 4228, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 127. Lu M, Breyssens H, Salter V, et al: Restoring p53 Function in Human Melanoma Cells by Inhibiti", 
        "paper": 3, 
        "tag_id": "erb-a243cf67-f6c9-4238-bd50-378f568def37"
    }
},
{
    "pk": 4229, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 128. Ohanna M, Giuliano S, Bonet C, et al: Senescent cells develop a PARP-1 and nuclear factor-{kap", 
        "paper": 3, 
        "tag_id": "erb-30acf820-5933-457d-89b6-df8d32d8bdba"
    }
},
{
    "pk": 4230, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 129. Gartner JJ, Parker SC, Prickett TD, et al: Whole-genome sequencing identifies a recurrent func", 
        "paper": 3, 
        "tag_id": "erb-a7a66fad-478d-4ab4-8dd9-43b3842f5363"
    }
},
{
    "pk": 4231, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 130. Anvekar RA, Asciolla JJ, Lopez-Rivera E, et al: Sensitization to the mitochondrial pathway of ", 
        "paper": 3, 
        "tag_id": "erb-f1131527-1cb8-4bc4-84e7-e28351882763"
    }
},
{
    "pk": 4232, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 131. Reifenberger J, Knobbe CB, Wolter M, et al: Molecular genetic analysis of malignant melanomas ", 
        "paper": 3, 
        "tag_id": "erb-64a3d3f1-4103-4142-be24-d94ff0e4fa25"
    }
},
{
    "pk": 4233, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 132. Delmas V, Beermann F, Martinozzi S, et al: Beta-catenin induces immortalization of melanocytes", 
        "paper": 3, 
        "tag_id": "erb-38467678-352d-429f-ac21-9fa2740497fe"
    }
},
{
    "pk": 4234, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 133. Grossmann AH, Yoo JH, Clancy J, et al: The Small GTPase ARF6 Stimulates beta-Catenin Transcrip", 
        "paper": 3, 
        "tag_id": "erb-f84d21b2-d1d5-4f12-8e65-81e9824c1289"
    }
},
{
    "pk": 4235, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 134. Damsky WE, Curley DP, Santhanakrishnan M, et al: beta-catenin signaling controls metastasis in", 
        "paper": 3, 
        "tag_id": "erb-f6945e3e-f856-4c07-96af-d10be452eb53"
    }
},
{
    "pk": 4236, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 135. Biechele TL, Kulikauskas RM, Toroni RA, et al: Wnt/beta-catenin signaling and AXIN1 regulate a", 
        "paper": 3, 
        "tag_id": "erb-8f0bf7bd-954e-49b3-8697-940911e3379e"
    }
},
{
    "pk": 4237, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 136. Conrad WH, Swift RD, Biechele TL, et al: Regulating the response to targeted MEK inhibition in", 
        "paper": 3, 
        "tag_id": "erb-1cbd608e-30a4-436d-bea4-30df26955c8e"
    }
},
{
    "pk": 4238, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 137. Jane-Valbuena J, Widlund HR, Perner S, et al: An oncogenic role for ETV1 in melanoma. Cancer R", 
        "paper": 3, 
        "tag_id": "erb-68006ae4-cb09-4c7f-98f3-e834c3578891"
    }
},
{
    "pk": 4239, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 138. Kim M, Gans JD, Nogueira C, et al: Comparative oncogenomics identifies NEDD9 as a melanoma met", 
        "paper": 3, 
        "tag_id": "erb-458d2793-871d-4baa-a1c4-392adf274222"
    }
},
{
    "pk": 4240, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 139. Harbour JW, Onken MD, Roberson ED, et al: Frequent mutation of BAP1 in metastasizing uveal mel", 
        "paper": 3, 
        "tag_id": "erb-18ba2e27-45b2-4045-a319-5c601b3463cf"
    }
},
{
    "pk": 4241, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 140. Wiesner T, Obenauf AC, Murali R, et al: Germline mutations in BAP1 predispose to melanocytic t", 
        "paper": 3, 
        "tag_id": "erb-c7b50b10-cc81-4445-8e86-1567d5dc0823"
    }
},
{
    "pk": 4242, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 141. Njauw CN, Kim I, Piris A, et al: Germline BAP1 inactivation is preferentially associated with ", 
        "paper": 3, 
        "tag_id": "erb-2193cffb-7d85-423e-8ca1-e71bfbf7ef5a"
    }
},
{
    "pk": 4243, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 142. Landreville S, Agapova OA, Matatall KA, et al: Histone deacetylase inhibitors induce growth ar", 
        "paper": 3, 
        "tag_id": "erb-01bb2a8c-ede9-442c-a384-f1ac9c51e15e"
    }
},
{
    "pk": 4244, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 143. Harbour JW, Roberson ED, Anbunathan H, et al: Recurrent mutations at codon 625 of the splicing", 
        "paper": 3, 
        "tag_id": "erb-e935a328-c43b-42db-bb3b-2735036ec818"
    }
},
{
    "pk": 4245, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 144. Martin M, Masshofer L, Temming P, et al: Exome sequencing identifies recurrent somatic mutatio", 
        "paper": 3, 
        "tag_id": "erb-516ff404-fe9d-4d35-b0cf-d18e62c4e8b6"
    }
},
{
    "pk": 4246, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 145. Ghai R, Mobli M, Norwood SJ, et al: Phox homology band 4.1/ezrin/radixin/moesin-like proteins ", 
        "paper": 3, 
        "tag_id": "erb-0aa772f6-9f9c-4b17-bc4c-5adc970c5dc3"
    }
},
{
    "pk": 4247, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 146. Forbes SA, Bindal N, Bamford S, et al: COSMIC: mining complete cancer genomes in the Catalogue", 
        "paper": 3, 
        "tag_id": "erb-477694ac-2da4-4b8b-9db4-a340931c8dce"
    }
},
{
    "pk": 4248, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 147. Liu W, Monahan KB, Pfefferle AD, et al: LKB1/STK11 inactivation leads to expansion of a promet", 
        "paper": 3, 
        "tag_id": "erb-251c58fd-068b-4b7d-9040-b0a9c2e01055"
    }
},
{
    "pk": 4249, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 148. Wei X, Walia V, Lin JC, et al: Exome sequencing identifies GRIN2A as frequently mutated in mel", 
        "paper": 3, 
        "tag_id": "erb-b2425248-3a94-40b4-8ef2-db160d54b2ef"
    }
},
{
    "pk": 4250, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 149. Prickett TD, Wei X, Cardenas-Navia I, et al: Exon capture analysis of G protein-coupled recept", 
        "paper": 3, 
        "tag_id": "erb-db90f2a1-e6a7-4f47-9ebd-1734ef272640"
    }
},
{
    "pk": 4251, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 150. Namkoong J, Shin SS, Lee HJ, et al: Metabotropic glutamate receptor 1 and glutamate signaling ", 
        "paper": 3, 
        "tag_id": "erb-3987ecb6-5469-4a52-b8a0-913864950b27"
    }
},
{
    "pk": 4252, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 151. Locasale JW, Grassian AR, Melman T, et al: Phosphoglycerate dehydrogenase diverts glycolytic f", 
        "paper": 3, 
        "tag_id": "erb-b4b9005d-6cb6-4496-9607-53bc5c910ad8"
    }
},
{
    "pk": 4253, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 152. Magnussen GI, Holm R, Emilsen E, et al: High expression of Wee1 is associated with poor diseas", 
        "paper": 3, 
        "tag_id": "erb-fbc14473-e26a-4bce-a91a-a5eae892c75a"
    }
},
{
    "pk": 4254, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 153. Namiki T, Tanemura A, Valencia JC, et al: AMP kinase-related kinase NUAK2 affects tumor growth", 
        "paper": 3, 
        "tag_id": "erb-dba0a92a-52ee-4ec2-b223-fee9164687ec"
    }
},
{
    "pk": 4255, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 154. van den Hurk K, Niessen HE, Veeck J, et al: Genetics and epigenetics of cutaneous malignant me", 
        "paper": 3, 
        "tag_id": "erb-485511c3-8101-495e-9417-6ec82759c776"
    }
},
{
    "pk": 4256, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 155. Smalley KS, Haass NK, Brafford PA, et al: Multiple signaling pathways must be targeted to over", 
        "paper": 3, 
        "tag_id": "erb-5a4aad7d-1b71-45ba-a221-292777013726"
    }
},
{
    "pk": 4257, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 156. Paraiso KH, Xiang Y, Rebecca VW, et al: PTEN loss confers BRAF inhibitor resistance to melanom", 
        "paper": 3, 
        "tag_id": "erb-83e96752-cdc6-482f-87d3-2264a55bb366"
    }
},
{
    "pk": 4258, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 157. Smalley KS, Lioni M, Dalla Palma M, et al: Increased cyclin D1 expression can mediate BRAF inh", 
        "paper": 3, 
        "tag_id": "erb-cde300b6-03a7-46c0-9d4e-89b2c59c187f"
    }
},
{
    "pk": 4259, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 158. McArthur GA, Puzanov I, Amaravadi R, et al: Marked, homogeneous, and early [18F]fluorodeoxyglu", 
        "paper": 3, 
        "tag_id": "erb-d7a3361d-fd33-45b3-9584-a9a6893d427f"
    }
},
{
    "pk": 4260, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 159. Vergani E, Vallacchi V, Frigerio S, et al: Identification of MET and SRC activation in melanom", 
        "paper": 3, 
        "tag_id": "erb-834a9e14-c8e6-42e3-85c6-eca78f55ee56"
    }
},
{
    "pk": 4261, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 160. Straussman R, Morikawa T, Shee K, et al: Tumour micro-environment elicits innate resistance to", 
        "paper": 3, 
        "tag_id": "erb-5eef0083-624a-47e9-aff0-c457f50e762c"
    }
},
{
    "pk": 4262, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 161. Wroblewski D, Mijatov B, Mohana-Kumaran N, et al: The BH3-mimetic ABT-737 sensitizes human mel", 
        "paper": 3, 
        "tag_id": "erb-0847f466-207f-4a41-8898-c7acb8bf302a"
    }
},
{
    "pk": 4263, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 162. Haq R, Shoag J, Andreu-Perez P, et al: Oncogenic BRAF Regulates Oxidative Metabolism via PGC1a", 
        "paper": 3, 
        "tag_id": "erb-31602756-e765-443a-a10d-344026a56e7d"
    }
},
{
    "pk": 4264, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 163. Basile KJ, Abel EV, Aplin AE: Adaptive upregulation of FOXD3 and resistance to PLX4032/4720-in", 
        "paper": 3, 
        "tag_id": "erb-8f72a52c-5e4c-4144-b5c3-24d7ec60e431"
    }
},
{
    "pk": 4265, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 164. Abel EV, Basile KJ, Kugel CH, 3rd, et al: Melanoma adapts to RAF/MEK inhibitors through FOXD3-", 
        "paper": 3, 
        "tag_id": "erb-0b8a47c2-02cd-4bf3-a58c-7986166b73bb"
    }
},
{
    "pk": 4266, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 165. Paraiso KH, Haarberg HE, Wood E, et al: The HSP90 inhibitor XL888 overcomes BRAF inhibitor res", 
        "paper": 3, 
        "tag_id": "erb-c7a916d4-2716-47a3-ac35-42cf086122aa"
    }
},
{
    "pk": 4267, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 166. Smith MP, Ferguson J, Arozarena I, et al: Effect of SMURF2 Targeting on Susceptibility to MEK ", 
        "paper": 3, 
        "tag_id": "erb-79b32147-60e2-4735-9cce-e50f706651cf"
    }
},
{
    "pk": 4268, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 167. Byron SA, Loch DC, Wellens CL, et al: Sensitivity to the MEK inhibitor E6201 in melanoma cells", 
        "paper": 3, 
        "tag_id": "erb-73b1a6f6-9485-4c21-b0c3-555e7eb4cdaf"
    }
},
{
    "pk": 4269, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 168. Shimizu T, Tolcher AW, Papadopoulos KP, et al: The clinical effect of the dual-targeting strat", 
        "paper": 3, 
        "tag_id": "erb-c4c1a572-1162-461f-9cbc-ba54128d5132"
    }
},
{
    "pk": 4270, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 169. Zmajkovicova K, Jesenberger V, Catalanotti F, et al: MEK1 Is Required for PTEN Membrane Recrui", 
        "paper": 3, 
        "tag_id": "erb-9c035e5a-8971-4411-96c1-85765bf1baf4"
    }
},
{
    "pk": 4271, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 170. Sondergaard JN, Nazarian R, Wang Q, et al: Differential sensitivity of melanoma cell lines wit", 
        "paper": 3, 
        "tag_id": "erb-3e4ccf6f-f030-4eaa-92a9-93e633f43fa7"
    }
},
{
    "pk": 4272, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 171. Wilson TR, Fridlyand J, Yan Y, et al: Widespread potential for growth-factor-driven resistance", 
        "paper": 3, 
        "tag_id": "erb-54b7a631-c3dc-426a-b9ef-0817b3d64bd1"
    }
},
{
    "pk": 4273, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 172. Catalanotti F, Solit DB: Will Hsp90 inhibitors prove effective in BRAF-mutant melanomas? Clin ", 
        "paper": 3, 
        "tag_id": "erb-936a912e-44e0-41f7-8fc3-03a4b6532052"
    }
},
{
    "pk": 4274, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 173. Haarberg HE, Paraiso KH, Wood E, et al: Inhibition of Wee1, AKT and CDK4 underlies the efficac", 
        "paper": 3, 
        "tag_id": "erb-30e09452-5ada-46b7-adae-c1a0f7e13f23"
    }
},
{
    "pk": 4275, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 174. Deng W, Gopal YN, Scott A, et al: Role and therapeutic potential of PI3K-mTOR signaling in de ", 
        "paper": 3, 
        "tag_id": "erb-daeeac5d-72e5-4cb1-86b2-0bf9b0c2403f"
    }
},
{
    "pk": 4276, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 175. Corcoran RB, Rothenberg SM, Hata AN, et al: TORC1 Suppression Predicts Responsiveness to RAF a", 
        "paper": 3, 
        "tag_id": "erb-ab2941d4-2eed-459d-a831-746adb1cba56"
    }
},
{
    "pk": 4277, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 176. Poulikakos PI, Persaud Y, Janakiraman M, et al: RAF inhibitor resistance is mediated by dimeri", 
        "paper": 3, 
        "tag_id": "erb-e6128661-f90e-4989-b975-1ee7e1648013"
    }
},
{
    "pk": 4278, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 177. Shi H, Moriceau G, Kong X, et al: Melanoma whole-exome sequencing identifies (V600E)B-RAF ampl", 
        "paper": 3, 
        "tag_id": "erb-525cd221-5f9e-4b91-b25f-9b43fb9d8576"
    }
},
{
    "pk": 4279, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 178. Girotti MR, Pedersen M, Sanchez-Laorden B, et al: Inhibiting EGF receptor or SRC family kinase", 
        "paper": 3, 
        "tag_id": "erb-20268d79-52de-4f13-bf7b-73b8127c8809"
    }
},
{
    "pk": 4280, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 179. Yadav V, Zhang X, Liu J, et al: Reactivation of mitogen-activated protein kinase (MAPK) pathwa", 
        "paper": 3, 
        "tag_id": "erb-e1b08d18-53f1-44c1-b6c7-5fe552618a57"
    }
},
{
    "pk": 4281, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 180. Villanueva J, Vultur A, Lee JT, et al: Acquired resistance to BRAF inhibitors mediated by a RA", 
        "paper": 3, 
        "tag_id": "erb-120d25bc-8fab-4be5-b6a2-72a5948ee4cb"
    }
},
{
    "pk": 4282, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 181. Nazarian R, Shi H, Wang Q, et al: Melanomas acquire resistance to B-RAF(V600E) inhibition by R", 
        "paper": 3, 
        "tag_id": "erb-5a389de5-d23a-463e-bf4e-cafca62e28db"
    }
},
{
    "pk": 4283, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 182. Johannessen CM, Boehm JS, Kim SY, et al: COT drives resistance to RAF inhibition through MAP k", 
        "paper": 3, 
        "tag_id": "erb-146bafb5-ee16-43d1-915d-c5a84204226d"
    }
},
{
    "pk": 4284, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 183. Wagle N, Emery C, Berger MF, et al: Dissecting therapeutic resistance to RAF inhibition in mel", 
        "paper": 3, 
        "tag_id": "erb-d1d1e8b0-85bf-427f-bbc0-336bc4547355"
    }
},
{
    "pk": 4285, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 184. Trunzer K, Pavlick AC, Schuchter L, et al: Pharmacodynamic Effects and Mechanisms of Resistanc", 
        "paper": 3, 
        "tag_id": "erb-216698bc-0b5b-4a68-bcc8-41ba3ff676fa"
    }
},
{
    "pk": 4286, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 185. Shao Y, Aplin AE: Akt3-mediated resistance to apoptosis in B-RAF-targeted melanoma cells. Canc", 
        "paper": 3, 
        "tag_id": "erb-ee6c94d3-2846-491e-a3d0-bdea66f1391e"
    }
},
{
    "pk": 4287, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 186. Jiang CC, Lai F, Thorne RF, et al: MEK-independent survival of B-RAFV600E melanoma cells selec", 
        "paper": 3, 
        "tag_id": "erb-19bc8e5f-0de2-45fc-99f6-b94da0ad6dc5"
    }
},
{
    "pk": 4288, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 187. Klein RM, Higgins PJ: A switch in RND3-RHOA signaling is critical for melanoma cell invasion f", 
        "paper": 3, 
        "tag_id": "erb-4abf1320-5772-4515-a240-f79d9b310385"
    }
},
{
    "pk": 4289, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 188. Reuveni H, Flashner-Abramson E, Steiner L, et al: Therapeutic destruction of insulin receptor ", 
        "paper": 3, 
        "tag_id": "erb-61663dc8-13e9-48d0-8895-274b88421f3f"
    }
},
{
    "pk": 4290, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 189. Emery CM, Vijayendran KG, Zipser MC, et al: MEK1 mutations confer resistance to MEK and B-RAF ", 
        "paper": 3, 
        "tag_id": "erb-51c564f9-5275-4f76-9cd2-59d578c03e85"
    }
},
{
    "pk": 4291, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 190. Gopal YN, Deng W, Woodman SE, et al: Basal and treatment-induced activation of AKT mediates re", 
        "paper": 3, 
        "tag_id": "erb-5dcd4587-6155-4f80-b668-f9a62a3f7bf8"
    }
},
{
    "pk": 4292, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 191. Sullivan RJ, Flaherty KT: Resistance to BRAF-targeted therapy in melanoma. Eur J Cancer, 2013.", 
        "paper": 3, 
        "tag_id": "erb-b3522226-2ae9-4eab-b9dc-6ae4305eb96f"
    }
},
{
    "pk": 4293, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 192. Morris EJ, Jha S, Restino CR, et al: Discovery of a novel ERK inhibitor with activity in model", 
        "paper": 3, 
        "tag_id": "erb-4b5ea91d-c16a-468f-b530-9bcff532ecf3"
    }
},
{
    "pk": 4294, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 193. Duncan JS, Whittle MC, Nakamura K, et al: Dynamic reprogramming of the kinome in response to t", 
        "paper": 3, 
        "tag_id": "erb-d4dbb7f4-9fea-4d50-8d81-22f7c44d2ed3"
    }
},
{
    "pk": 4295, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 194. Roller DG, Axelrod M, Capaldo BJ, et al: Synthetic lethal screening with small-molecule inhibi", 
        "paper": 3, 
        "tag_id": "erb-cbf9af8c-389f-42b9-a6fa-e8dcfd7d1caf"
    }
},
{
    "pk": 4296, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 195. Kawakami Y, Eliyahu S, Delgado CH, et al: Cloning of the gene coding for a shared human melano", 
        "paper": 3, 
        "tag_id": "erb-42633339-9aca-4a3e-bae2-55e7d264369e"
    }
},
{
    "pk": 4297, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 196. Slingluff CL, Jr., Petroni GR, Yamshchikov GV, et al: Immunologic and clinical outcomes of vac", 
        "paper": 3, 
        "tag_id": "erb-7cab8cfc-9d3b-4819-b20d-7b6d48da6084"
    }
},
{
    "pk": 4298, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 197. Rosenberg SA, Yang JC, Restifo NP: Cancer immunotherapy: moving beyond current vaccines. Nat M", 
        "paper": 3, 
        "tag_id": "erb-23b9518a-0682-4736-a9f5-a724aef25e92"
    }
},
{
    "pk": 4299, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 198. Spranger S, Spaapen RM, Zha Y, et al: Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma T", 
        "paper": 3, 
        "tag_id": "erb-eafb7835-6d15-4f77-8dad-88163f271b9d"
    }
},
{
    "pk": 4300, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 199. van Elsas A, Hurwitz AA, Allison JP: Combination immunotherapy of B16 melanoma using anti-cyto", 
        "paper": 3, 
        "tag_id": "erb-2ee5d480-a424-43c4-8fbc-1837bcb23bc0"
    }
},
{
    "pk": 4301, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 200. Atkins MB, Lotze MT, Dutcher JP, et al: High-dose recombinant interleukin 2 therapy for patien", 
        "paper": 3, 
        "tag_id": "erb-a0c96f00-b081-467d-a858-f6d80ed534c0"
    }
},
{
    "pk": 4302, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 201. Hodi FS, O'Day SJ, McDermott DF, et al: Improved survival with ipilimumab in patients with met", 
        "paper": 3, 
        "tag_id": "erb-0c68e99d-c787-4228-b534-be6a4d6a54f4"
    }
},
{
    "pk": 4303, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 202. Robbins PF, Lu YC, El-Gamil M, et al: Mining exomic sequencing data to identify mutated antige", 
        "paper": 3, 
        "tag_id": "erb-786d30d1-a1ad-4b92-9f2a-edecb80762fa"
    }
},
{
    "pk": 4304, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 203. Ascierto PA, Kalos M, Schaer DA, et al: Biomarkers for Immunostimulatory Monoclonal Antibodies", 
        "paper": 3, 
        "tag_id": "erb-3ce5096f-1602-4f9d-9b5e-eca701d5e34f"
    }
},
{
    "pk": 4305, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 204. Peggs KS, Quezada SA, Chambers CA, et al: Blockade of CTLA-4 on both effector and regulatory T", 
        "paper": 3, 
        "tag_id": "erb-26b7a019-6574-4297-bf99-8b0b0ce89200"
    }
},
{
    "pk": 4306, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 205. Contardi E, Palmisano GL, Tazzari PL, et al: CTLA-4 is constitutively expressed on tumor cells", 
        "paper": 3, 
        "tag_id": "erb-7cdb652b-c634-481a-938c-3be6d723d00b"
    }
},
{
    "pk": 4307, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 206. Shah KV, Chien AJ, Yee C, et al: CTLA-4 is a direct target of Wnt/beta-catenin signaling and i", 
        "paper": 3, 
        "tag_id": "erb-793fa487-9d6f-4b62-aa8f-88dd8fb8aa43"
    }
},
{
    "pk": 4308, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 207. Sapoznik S, Hammer O, Ortenberg R, et al: Novel anti-melanoma immunotherapies: disarming tumor", 
        "paper": 3, 
        "tag_id": "erb-18576e39-9390-4b4b-91a4-2a183e2be907"
    }
},
{
    "pk": 4309, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 208. Hamid O, Schmidt H, Nissan A, et al: A prospective phase II trial exploring the association be", 
        "paper": 3, 
        "tag_id": "erb-f6be598e-8a12-43cf-aeb6-b79360187377"
    }
},
{
    "pk": 4310, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 209. Holmgaard RB, Zamarin D, Munn DH, et al: Indoleamine 2,3-dioxygenase is a critical resistance ", 
        "paper": 3, 
        "tag_id": "erb-9c2b7b63-ea90-4cb6-8944-618dd969afe8"
    }
},
{
    "pk": 4311, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 210. Iwai Y, Ishida M, Tanaka Y, et al: Involvement of PD-L1 on tumor cells in the escape from host", 
        "paper": 3, 
        "tag_id": "erb-308694d1-68b8-4cdb-ad92-c4fee6a8b20d"
    }
},
{
    "pk": 4312, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 211. Freeman GJ, Long AJ, Iwai Y, et al: Engagement of the PD-1 immunoinhibitory receptor by a nove", 
        "paper": 3, 
        "tag_id": "erb-bc51f51a-7fd0-4a7b-964c-281664712c39"
    }
},
{
    "pk": 4313, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 212. Ahmadzadeh M, Johnson LA, Heemskerk B, et al: Tumor antigen-specific CD8 T cells infiltrating ", 
        "paper": 3, 
        "tag_id": "erb-395739a7-1362-4480-b9e4-506acce4cd44"
    }
},
{
    "pk": 4314, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 213. Topalian SL, Hodi FS, Brahmer JR, et al: Safety, activity, and immune correlates of anti-PD-1 ", 
        "paper": 3, 
        "tag_id": "erb-8f70326a-7529-4006-b62d-bdcfaed76499"
    }
},
{
    "pk": 4315, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 214. Lipson EJ, Sharfman WH, Drake CG, et al: Durable Cancer Regression Off-Treatment and Effective", 
        "paper": 3, 
        "tag_id": "erb-69c3fb22-7aad-40c6-90c9-8eac312baf7c"
    }
},
{
    "pk": 4316, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 215. Hamid O, Robert C, Daud A, et al: Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in", 
        "paper": 3, 
        "tag_id": "erb-5b381507-55c2-4cee-9b87-ff61fbdbc36e"
    }
},
{
    "pk": 4317, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 216. Brahmer JR, Tykodi SS, Chow LQ, et al: Safety and activity of anti-PD-L1 antibody in patients ", 
        "paper": 3, 
        "tag_id": "erb-a81522d1-29f0-4241-a233-665092814b02"
    }
},
{
    "pk": 4318, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 217. Curran MA, Montalvo W, Yagita H, et al: PD-1 and CTLA-4 combination blockade expands infiltrat", 
        "paper": 3, 
        "tag_id": "erb-05a04233-ec02-4b8d-b280-05c6e2ae6ab2"
    }
},
{
    "pk": 4319, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 218. Wolchok JD, Kluger H, Callahan MK, et al: Nivolumab plus Ipilimumab in Advanced Melanoma. N En", 
        "paper": 3, 
        "tag_id": "erb-1fc38e37-a15d-4379-8671-2ff462c94ca4"
    }
},
{
    "pk": 4320, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 219. Chacon JA, Wu RC, Sukhumalchandra P, et al: Co-Stimulation through 4-1BB/CD137 Improves the Ex", 
        "paper": 3, 
        "tag_id": "erb-1dcb261a-d6ae-4ba0-9658-a2c5a04b61d7"
    }
},
{
    "pk": 4321, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 220. Vonderheide RH, Flaherty KT, Khalil M, et al: Clinical activity and immune modulation in cance", 
        "paper": 3, 
        "tag_id": "erb-86f9e5a4-90c3-4e05-a7d0-31107dc0a67a"
    }
},
{
    "pk": 4322, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 221. Schwartzentruber DJ, Lawson DH, Richards JM, et al: gp100 peptide vaccine and interleukin-2 in", 
        "paper": 3, 
        "tag_id": "erb-ada060ed-33e4-45c0-86db-d3f408e5f037"
    }
},
{
    "pk": 4323, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 222. Prieto PA, Yang JC, Sherry RM, et al: CTLA-4 blockade with ipilimumab: long-term follow-up of ", 
        "paper": 3, 
        "tag_id": "erb-fb3b2458-2702-44b1-9d91-ca4daad9f446"
    }
},
{
    "pk": 4324, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 223. Petrella TM, Tozer R, Belanger K, et al: Interleukin-21 has activity in patients with metastat", 
        "paper": 3, 
        "tag_id": "erb-8634977f-c091-468e-b977-9d6a743ec966"
    }
},
{
    "pk": 4325, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 224. Galluzzi L, Vacchelli E, Eggermont A, et al: Trial Watch: Adoptive cell transfer immunotherapy", 
        "paper": 3, 
        "tag_id": "erb-60003344-626a-4f53-a42b-8af53028a14b"
    }
},
{
    "pk": 4326, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 225. Itzhaki O, Levy D, Zikich D, et al: Adoptive T-cell transfer in melanoma. Immunotherapy 5:79-9", 
        "paper": 3, 
        "tag_id": "erb-3a3e9b99-cb7a-49a6-9187-e8b154e27037"
    }
},
{
    "pk": 4327, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 226. Rosenberg SA, Yang JC, Sherry RM, et al: Durable complete responses in heavily pretreated pati", 
        "paper": 3, 
        "tag_id": "erb-6db15a52-67e3-492c-a4a4-1d680fa8f92f"
    }
},
{
    "pk": 4328, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 227. Purwar R, Schlapbach C, Xiao S, et al: Robust tumor immunity to melanoma mediated by interleuk", 
        "paper": 3, 
        "tag_id": "erb-af00a660-b4b2-4ac7-b8b0-d620a6a82340"
    }
},
{
    "pk": 4329, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 228. Ellebaek E, Iversen TZ, Junker N, et al: Adoptive cell therapy with autologous tumor infiltrat", 
        "paper": 3, 
        "tag_id": "erb-50be168c-8c12-4d33-80bf-6ae7e8e3d0b0"
    }
},
{
    "pk": 4330, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 229. Hirschhorn-Cymerman D, Budhu S, Kitano S, et al: Induction of tumoricidal function in CD4+ T c", 
        "paper": 3, 
        "tag_id": "erb-990b39cd-ec7e-4865-8f0c-07aeeaef2f23"
    }
},
{
    "pk": 4331, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 230. Wang A, Chandran S, Shah SA, et al: The stoichiometric production of IL-2 and IFN-gamma mRNA d", 
        "paper": 3, 
        "tag_id": "erb-b585c4ef-5c35-459a-a3c1-8bd2de000e19"
    }
},
{
    "pk": 4332, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 231. Landsberg J, Kohlmeyer J, Renn M, et al: Melanomas resist T-cell therapy through inflammation-", 
        "paper": 3, 
        "tag_id": "erb-5db54a51-9d51-4893-8c1e-6d5bccc0e57b"
    }
},
{
    "pk": 4333, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 232. Kodumudi KN, Weber A, Sarnaik AA, et al: Blockade of myeloid-derived suppressor cells after in", 
        "paper": 3, 
        "tag_id": "erb-ef91362d-4b25-4196-af69-322b93c22d29"
    }
},
{
    "pk": 4334, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 233. Lu YC, Yao X, Li YF, et al: Mutated PPP1R3B Is Recognized by T Cells Used To Treat a Melanoma ", 
        "paper": 3, 
        "tag_id": "erb-b22f95f5-80a6-41d5-a24c-671362beb14a"
    }
},
{
    "pk": 4335, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 234. Radvanyi LG, Bernatchez C, Zhang M, et al: Specific lymphocyte subsets predict response to ado", 
        "paper": 3, 
        "tag_id": "erb-5a6ef92e-f331-487a-b30d-f58e71a685cb"
    }
},
{
    "pk": 4336, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 235. Dudley ME, Gross CA, Somerville RP, et al: Randomized Selection Design Trial Evaluating CD8+-E", 
        "paper": 3, 
        "tag_id": "erb-c597e3f6-9180-4208-8150-d76715efefa2"
    }
},
{
    "pk": 4337, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 236. Butler MO, Friedlander P, Milstein MI, et al: Establishment of antitumor memory in humans usin", 
        "paper": 3, 
        "tag_id": "erb-95dbfec0-ba2d-4b6b-9116-400903317bf9"
    }
},
{
    "pk": 4338, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 237. Kershaw MH, Westwood JA, Darcy PK: Gene-engineered T cells for cancer therapy. Nat Rev Cancer ", 
        "paper": 3, 
        "tag_id": "erb-b90c1fd2-37f4-4290-9251-b5a673a3f2b8"
    }
},
{
    "pk": 4339, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 238. Stauss HJ, Morris EC: Immunotherapy with gene-modified T cells: limiting side effects provides", 
        "paper": 3, 
        "tag_id": "erb-d61657d6-fc35-4309-a719-4fd27556aa86"
    }
},
{
    "pk": 4340, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 239. Robbins PF, Morgan RA, Feldman SA, et al: Tumor regression in patients with metastatic synovia", 
        "paper": 3, 
        "tag_id": "erb-98d081c3-3ab7-4bda-acca-55476a3dc766"
    }
},
{
    "pk": 4341, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 240. Hunder NN, Wallen H, Cao J, et al: Treatment of metastatic melanoma with autologous CD4+ T cel", 
        "paper": 3, 
        "tag_id": "erb-d0a6dfa2-9e75-486d-a2d4-21181085457e"
    }
},
{
    "pk": 4342, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 241. Braumuller H, Wieder T, Brenner E, et al: T-helper-1-cell cytokines drive cancer into senescen", 
        "paper": 3, 
        "tag_id": "erb-4ae1c66f-9678-473a-abe4-afc48de981ec"
    }
},
{
    "pk": 4343, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 242. Palucka K, Banchereau J: Cancer immunotherapy via dendritic cells. Nat Rev Cancer 12:265-77, 2", 
        "paper": 3, 
        "tag_id": "erb-375d0845-051b-420c-a319-ec290ff8034f"
    }
},
{
    "pk": 4344, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 243. Nestle FO, Alijagic S, Gilliet M, et al: Vaccination of melanoma patients with peptide- or tum", 
        "paper": 3, 
        "tag_id": "erb-485dca96-e754-4e0b-86e7-382caba1f872"
    }
},
{
    "pk": 4345, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 244. Thurner B, Haendle I, Roder C, et al: Vaccination with mage-3A1 peptide-pulsed mature, monocyt", 
        "paper": 3, 
        "tag_id": "erb-1a266cc6-88ae-4d70-8a9e-0c00a6502ab2"
    }
},
{
    "pk": 4346, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 245. Mackensen A, Herbst B, Chen JL, et al: Phase I study in melanoma patients of a vaccine with pe", 
        "paper": 3, 
        "tag_id": "erb-521ae3a6-10a5-4614-bb85-72b96c3ec426"
    }
},
{
    "pk": 4347, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 246. Romano E, Rossi M, Ratzinger G, et al: Peptide-loaded Langerhans cells, despite increased IL15", 
        "paper": 3, 
        "tag_id": "erb-abaf1312-f63c-48d7-891f-a8eea7767043"
    }
},
{
    "pk": 4348, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 247. Verdijk P, Aarntzen EH, Lesterhuis WJ, et al: Limited amounts of dendritic cells migrate into ", 
        "paper": 3, 
        "tag_id": "erb-7c351349-58ec-4bcc-af24-5fc0aa9f6462"
    }
},
{
    "pk": 4349, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 248. Lesterhuis WJ, de Vries IJ, Schreibelt G, et al: Route of administration modulates the inducti", 
        "paper": 3, 
        "tag_id": "erb-affc4a42-5f3f-4dec-8113-3bef1f144a42"
    }
},
{
    "pk": 4350, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 249. Mitchell DA, Nair SK: RNA-transfected dendritic cells in cancer immunotherapy. J Clin Invest 1", 
        "paper": 3, 
        "tag_id": "erb-9b6e7fbf-b20f-48d8-aa47-6629d57a4602"
    }
},
{
    "pk": 4351, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 250. Aarntzen EH, Schreibelt G, Bol K, et al: Vaccination with mRNA-electroporated dendritic cells ", 
        "paper": 3, 
        "tag_id": "erb-e6a74285-668d-47ce-8303-17b47798d7fd"
    }
},
{
    "pk": 4352, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 251. Dannull J, Haley NR, Archer G, et al: Melanoma immunotherapy using mature DCs expressing the c", 
        "paper": 3, 
        "tag_id": "erb-400d87d8-f89b-4937-8bca-ee73879b77b9"
    }
},
{
    "pk": 4353, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 252. Carreno BM, Becker-Hapak M, Huang A, et al: IL-12p70-producing patient DC vaccine elicits Tc1-", 
        "paper": 3, 
        "tag_id": "erb-420a1c61-a747-4fee-82fc-2ef28b75a18c"
    }
},
{
    "pk": 4354, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 253. Ribas A, Comin-Anduix B, Chmielowski B, et al: Dendritic cell vaccination combined with CTLA4 ", 
        "paper": 3, 
        "tag_id": "erb-bbbb25e6-4b97-469c-9a29-5753142a6b50"
    }
},
{
    "pk": 4355, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 254. Rosenberg SA, Lotze MT, Yang JC, et al: Prospective randomized trial of high-dose interleukin-", 
        "paper": 3, 
        "tag_id": "erb-97678c1f-7669-4788-95ab-3ba6fa447195"
    }
},
{
    "pk": 4356, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 255. Parkhurst MR, Riley JP, Dudley ME, et al: Adoptive transfer of autologous natural killer cells", 
        "paper": 3, 
        "tag_id": "erb-5ca51819-da9d-466d-b60e-b69995abd770"
    }
},
{
    "pk": 4357, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 256. Besser MJ, Shoham T, Harari-Steinberg O, et al: Development of allogeneic NK cell adoptive tra", 
        "paper": 3, 
        "tag_id": "erb-e6e28106-e7f2-4607-a8af-c28c0d0253c2"
    }
},
{
    "pk": 4358, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 257. Gammaitoni L, Giraudo L, Leuci V, et al: Effective Activity of Cytokine Induced Killer Cells a", 
        "paper": 3, 
        "tag_id": "erb-5e05c404-4841-4f32-aa5f-2282c27e9cf0"
    }
},
{
    "pk": 4359, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 258. Sumimoto H, Imabayashi F, Iwata T, et al: The BRAF-MAPK signaling pathway is essential for can", 
        "paper": 3, 
        "tag_id": "erb-8806de99-b7c1-4807-a412-d8ea9dfc9cc4"
    }
},
{
    "pk": 4360, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 259. Kono M, Dunn IS, Durda PJ, et al: Role of the mitogen-activated protein kinase signaling pathw", 
        "paper": 3, 
        "tag_id": "erb-14448a4d-0ba0-4737-97ee-8c848cd48454"
    }
},
{
    "pk": 4361, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 260. Khalili JS, Liu S, Rodriguez-Cruz TG, et al: Oncogenic BRAF(V600E) promotes stromal cell-media", 
        "paper": 3, 
        "tag_id": "erb-615d585f-be2d-4aca-94e6-ab11ad79d31d"
    }
},
{
    "pk": 4362, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 261. Knight DA, Ngiow SF, Li M, et al: Host immunity contributes to the anti-melanoma activity of B", 
        "paper": 3, 
        "tag_id": "erb-e4e30ea9-62ec-4945-a197-2cd104342026"
    }
},
{
    "pk": 4363, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 262. Boni A, Cogdill AP, Dang P, et al: Selective BRAFV600E inhibition enhances T-cell recognition ", 
        "paper": 3, 
        "tag_id": "erb-9fec53e1-51ad-44ca-b803-d4d8fa179141"
    }
},
{
    "pk": 4364, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 263. Wilmott JS, Long GV, Howle JR, et al: Selective BRAF inhibitors induce marked T-cell infiltrat", 
        "paper": 3, 
        "tag_id": "erb-cd48a73c-04fa-4066-8555-c0bdeffac62e"
    }
},
{
    "pk": 4365, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 264. Hong DS, Vence L, Falchook G, et al: BRAF(V600) inhibitor GSK2118436 targeted inhibition of mu", 
        "paper": 3, 
        "tag_id": "erb-65f4d9ff-2384-4835-95aa-121e4e4699b0"
    }
},
{
    "pk": 4366, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 265. Hooijkaas A, Gadiot J, Morrow M, et al: Selective BRAF inhibition decreases tumor-resident lym", 
        "paper": 3, 
        "tag_id": "erb-83d38e19-c842-475c-ab6a-0293c45e2205"
    }
},
{
    "pk": 4367, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 266. Frederick DT, Piris A, Cogdill AP, et al: BRAF Inhibition Is Associated with Enhanced Melanoma", 
        "paper": 3, 
        "tag_id": "erb-d754715b-441f-4f1c-9381-b158f500c321"
    }
},
{
    "pk": 4368, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 267. Koya RC, Mok S, Otte N, et al: BRAF inhibitor vemurafenib improves the antitumor activity of a", 
        "paper": 3, 
        "tag_id": "erb-de471d03-1467-4626-a83d-cda77aee0ca8"
    }
},
{
    "pk": 4369, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 268. Liu C, Peng W, Xu C, et al: BRAF Inhibition Increases Tumor Infiltration by T cells and Enhanc", 
        "paper": 3, 
        "tag_id": "erb-a7ef2912-04b5-4959-9325-5217f4bcc8cf"
    }
},
{
    "pk": 4370, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 269. Ott PA, Henry T, Baranda SJ, et al: Inhibition of both BRAF and MEK in BRAF(V600E) mutant mela", 
        "paper": 3, 
        "tag_id": "erb-53a66a8f-e6bc-47e0-9fd4-a0172e74ca7c"
    }
},
{
    "pk": 4371, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 270. Donia M, Fagone P, Nicoletti F, et al: BRAF inhibition improves tumor recognition by the immun", 
        "paper": 3, 
        "tag_id": "erb-834283ea-0b02-4ea0-82c4-2345e4caa37c"
    }
},
{
    "pk": 4372, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 271. Ribas A, Hodi FS, Callahan M, et al: Hepatotoxicity with combination of vemurafenib and ipilim", 
        "paper": 3, 
        "tag_id": "erb-5970b0f8-5edf-4ad9-8144-2f99467a6795"
    }
},
{
    "pk": 4373, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 272. Joseph RW, Sullivan RJ, Harrell R, et al: Correlation of NRAS mutations with clinical response", 
        "paper": 3, 
        "tag_id": "erb-d34536a1-442f-414d-9ca9-dfcd910b5288"
    }
},
{
    "pk": 4374, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 273. Yaguchi T, Goto Y, Kido K, et al: Immune suppression and resistance mediated by constitutive a", 
        "paper": 3, 
        "tag_id": "erb-dd9a2a4a-726a-48be-a1ac-03ed009f73ba"
    }
},
{
    "pk": 4375, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 274. Gilbert AE, Karagiannis P, Dodev T, et al: Monitoring the systemic human memory B cell compart", 
        "paper": 3, 
        "tag_id": "erb-79b95c00-609c-4ec5-91cb-cdc62394c82c"
    }
},
{
    "pk": 4376, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 275. Carpenter EL, Mick R, Rech AJ, et al: Collapse of the CD27+ B-cell compartment associated with", 
        "paper": 3, 
        "tag_id": "erb-37ff9cb4-cb0f-466d-a92c-565e22c95311"
    }
},
{
    "pk": 4377, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 276. Karagiannis P, Gilbert AE, Josephs DH, et al: IgG4 subclass antibodies impair antitumor immuni", 
        "paper": 3, 
        "tag_id": "erb-638d4036-5620-445a-848f-e3772d4845d9"
    }
},
{
    "pk": 4378, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 277. Jochems C, Schlom J: Tumor-infiltrating immune cells and prognosis: the potential link between", 
        "paper": 3, 
        "tag_id": "erb-d4f8a087-a4a2-453a-8071-cbb33109ebf0"
    }
},
{
    "pk": 4379, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 278. Messina JL, Fenstermacher DA, Eschrich S, et al: 12-Chemokine gene signature identifies lymph ", 
        "paper": 3, 
        "tag_id": "erb-eca88b02-6fa2-40d1-a5bf-acb1224fbbbe"
    }
},
{
    "pk": 4380, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 279. Sonveaux P, Vegran F, Schroeder T, et al: Targeting lactate-fueled respiration selectively kil", 
        "paper": 3, 
        "tag_id": "erb-0d010c01-34eb-45e3-b040-5b97c6755184"
    }
},
{
    "pk": 4381, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 280. O'Day SJ, Eggermont AM, Chiarion-Sileni V, et al: Final Results of Phase III SYMMETRY Study: R", 
        "paper": 3, 
        "tag_id": "erb-55b6bf78-3b21-4f4e-a82a-0b8e3aef2da1"
    }
},
{
    "pk": 4382, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 281. Roesch A, Fukunaga-Kalabis M, Schmidt EC, et al: A temporarily distinct subpopulation of slow-", 
        "paper": 3, 
        "tag_id": "erb-8d4253d8-5185-48bf-9e8a-5e75c89000c6"
    }
},
{
    "pk": 4383, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 282. Roesch A, Vultur A, Bogeski I, et al: Overcoming Intrinsic Multidrug Resistance in Melanoma by", 
        "paper": 3, 
        "tag_id": "erb-7c0bbe05-f37f-4c49-9d0b-d9bdbc95fd35"
    }
},
{
    "pk": 4384, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 283. Kaplon J, Zheng L, Meissl K, et al: A key role for mitochondrial gatekeeper pyruvate dehydroge", 
        "paper": 3, 
        "tag_id": "erb-c5af78ac-eb0e-4a09-b411-67a893d7ff85"
    }
},
{
    "pk": 4385, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 284. Dillon BJ, Prieto VG, Curley SA, et al: Incidence and distribution of argininosuccinate synthe", 
        "paper": 3, 
        "tag_id": "erb-0fad9505-d169-44d4-80f1-f168d9f8a12e"
    }
},
{
    "pk": 4386, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 285. Yoon JK, Frankel AE, Feun LG, et al: Arginine deprivation therapy for malignant melanoma. Clin", 
        "paper": 3, 
        "tag_id": "erb-dc76ae30-0fdc-4f94-9586-94bf9e3adac4"
    }
},
{
    "pk": 4387, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 286. Sheen JH, Zoncu R, Kim D, et al: Defective regulation of autophagy upon leucine deprivation re", 
        "paper": 3, 
        "tag_id": "erb-69fb32b6-e754-474d-ad5b-a83810d11ff2"
    }
},
{
    "pk": 4388, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 287. Tomic T, Botton T, Cerezo M, et al: Metformin inhibits melanoma development through autophagy ", 
        "paper": 3, 
        "tag_id": "erb-151440e9-2035-4af4-bbed-fd2d10f86b8b"
    }
},
{
    "pk": 4389, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 288. Li H, Li Y, Jiao J, et al: Alpha-alumina nanoparticles induce efficient autophagy-dependent cr", 
        "paper": 3, 
        "tag_id": "erb-b00ae624-3b27-487b-8f92-092249591aa3"
    }
},
{
    "pk": 4390, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 289. Li Y, Wang LX, Pang P, et al: Tumor-derived autophagosome vaccine: mechanism of cross-presenta", 
        "paper": 3, 
        "tag_id": "erb-f6e71b4f-a8a4-4a6c-9ee7-e772bc36a0de"
    }
},
{
    "pk": 4391, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 290. Liang X, De Vera ME, Buchser WJ, et al: Inhibiting systemic autophagy during interleukin 2 imm", 
        "paper": 3, 
        "tag_id": "erb-b69da3b0-d636-4fa2-a354-1f57a1bc1ed1"
    }
},
{
    "pk": 4392, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 291. Lotze MT, Buchser WJ, Liang X: Blocking the interleukin 2 (IL2)-induced systemic autophagic sy", 
        "paper": 3, 
        "tag_id": "erb-81a48223-3967-48ca-8aac-2d99a73a20e6"
    }
},
{
    "pk": 4393, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 292. Ireland A, Millward M, Pearce R, et al: Genetic factors in metastatic progression of cutaneous", 
        "paper": 3, 
        "tag_id": "erb-473c4a5f-57e8-4b2c-9825-019bf28fa8a3"
    }
},
{
    "pk": 4394, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 293. Tanaka R, Koyanagi K, Narita N, et al: Prognostic molecular biomarkers for cutaneous malignant", 
        "paper": 3, 
        "tag_id": "erb-ebfc8c62-9690-4c1b-803a-bc54361d155c"
    }
},
{
    "pk": 4395, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 294. Smith B, Selby P, Southgate J, et al: Detection of melanoma cells in peripheral blood by means", 
        "paper": 3, 
        "tag_id": "erb-e37977d8-0cd2-4f4f-9993-9fd71fa76fb1"
    }
},
{
    "pk": 4396, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 295. Mocellin S, Del Fiore P, Guarnieri L, et al: Molecular detection of circulating tumor cells is", 
        "paper": 3, 
        "tag_id": "erb-86653e1d-6c50-4279-b911-658d7e6307e4"
    }
},
{
    "pk": 4397, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 296. Koyanagi K, O'Day SJ, Boasberg P, et al: Serial monitoring of circulating tumor cells predicts", 
        "paper": 3, 
        "tag_id": "erb-7c576888-fdb8-4c62-b3f2-bdde4bf83403"
    }
},
{
    "pk": 4398, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 297. Hoshimoto S, Faries MB, Morton DL, et al: Assessment of prognostic circulating tumor cells in ", 
        "paper": 3, 
        "tag_id": "erb-e2268412-c963-42b6-8035-a352535af5a3"
    }
},
{
    "pk": 4399, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 298. Hoshimoto S, Shingai T, Morton DL, et al: Association between circulating tumor cells and prog", 
        "paper": 3, 
        "tag_id": "erb-58f29b04-078d-4b9d-b869-20181b7f10a9"
    }
},
{
    "pk": 4400, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 299. Reid AL, Millward M, Pearce R, et al: Markers of circulating tumour cells in the peripheral bl", 
        "paper": 3, 
        "tag_id": "erb-1becedd0-cbfd-4198-99dc-de3d12308ab3"
    }
},
{
    "pk": 4401, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 300. Fusi A, Liu Z, Kummerlen V, et al: Expression of chemokine receptors on circulating tumor cell", 
        "paper": 3, 
        "tag_id": "erb-e71b38c3-2f25-49e0-bd29-be88495f10b6"
    }
},
{
    "pk": 4402, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 301. Khoja L, Lorigan P, Zhou C, et al: Biomarker Utility of Circulating Tumor Cells in Metastatic ", 
        "paper": 3, 
        "tag_id": "erb-f63189e0-031e-4ffa-8095-fa2e0a891cb4"
    }
},
{
    "pk": 4403, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 302. Le Rhun E, Tu Q, De Carvalho Bittencourt M, et al: Detection and quantification of CSF maligna", 
        "paper": 3, 
        "tag_id": "erb-35528e3a-38b8-4486-b1bd-859dc1a08f8f"
    }
},
{
    "pk": 4404, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 303. De Giorgi V, Pinzani P, Salvianti F, et al: Application of a filtration- and isolation-by-size", 
        "paper": 3, 
        "tag_id": "erb-2180434e-c695-4224-8247-592672ad9d2e"
    }
},
{
    "pk": 4405, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 304. De Giorgi V, Pinzani P, Salvianti F, et al: Circulating benign nevus cells detected by ISET te", 
        "paper": 3, 
        "tag_id": "erb-cb2cd1bb-4df2-487d-9efe-4defe6f7713a"
    }
},
{
    "pk": 4406, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 305. Galanzha EI, Shashkov EV, Spring PM, et al: In vivo, noninvasive, label-free detection and era", 
        "paper": 3, 
        "tag_id": "erb-5e88fe9c-6721-4eb6-b4a2-239000de73e2"
    }
},
{
    "pk": 4407, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 306. O'Brien CM, Rood KD, Bhattacharyya K, et al: Capture of circulating tumor cells using photoaco", 
        "paper": 3, 
        "tag_id": "erb-72a3b065-6831-4fdb-b632-274fde606356"
    }
},
{
    "pk": 4408, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 307. Hou S, Zhao L, Shen Q, et al: Polymer nanofiber-embedded microchips for detection, isolation, ", 
        "paper": 3, 
        "tag_id": "erb-b0447128-64a4-4643-ba6d-e6d56edac620"
    }
},
{
    "pk": 4409, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 308. Ozkumur E, Shah AM, Ciciliano JC, et al: Inertial focusing for tumor antigen-dependent and -in", 
        "paper": 3, 
        "tag_id": "erb-9d42f9aa-a446-4ec0-a39e-361ddc14cc53"
    }
},
{
    "pk": 4410, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 309. Adebayo Awe J, Xu MC, Wechsler J, et al: Three-Dimensional Telomeric Analysis of Isolated Circ", 
        "paper": 3, 
        "tag_id": "erb-cadfea13-6bd8-4b7f-b13f-fe5e51d279c8"
    }
},
{
    "pk": 4411, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 310. Fusi A, Berdel R, Havemann S, et al: Enhanced detection of BRAF-mutants by pre-PCR cleavage of", 
        "paper": 3, 
        "tag_id": "erb-7da7ed0b-9aab-4d2a-97eb-61e1b0715ff0"
    }
},
{
    "pk": 4412, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 311. Sakaizawa K, Goto Y, Kiniwa Y, et al: Mutation analysis of BRAF and KIT in circulating melanom", 
        "paper": 3, 
        "tag_id": "erb-ddc575b0-ea76-4778-a68d-0b686295e4e5"
    }
},
{
    "pk": 4413, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 312. Dawson SJ, Tsui DW, Murtaza M, et al: Analysis of circulating tumor DNA to monitor metastatic ", 
        "paper": 3, 
        "tag_id": "erb-f3ceef83-603f-46c0-9975-fca24e8d2537"
    }
},
{
    "pk": 4414, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 313. Murtaza M, Dawson SJ, Tsui DW, et al: Non-invasive analysis of acquired resistance to cancer t", 
        "paper": 3, 
        "tag_id": "erb-348094b1-f1b4-4a4d-abd2-b7fd9922d521"
    }
},
{
    "pk": 4415, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 314. Harbour JW, Chen R: The DecisionDx-UM Gene Expression Profile Test Provides Risk Stratificatio", 
        "paper": 3, 
        "tag_id": "erb-76874cf4-0a07-45b6-836f-7fab0baab039"
    }
},
{
    "pk": 4416, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 315. Ohno S, Ishikawa A, Kuroda M: Roles of exosomes and microvesicles in disease pathogenesis. Adv", 
        "paper": 3, 
        "tag_id": "erb-92273fde-003b-49df-8aa7-1f963ee6c7dc"
    }
},
{
    "pk": 4417, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 316. Peinado H, Aleckovic M, Lavotshkin S, et al: Melanoma exosomes educate bone marrow progenitor ", 
        "paper": 3, 
        "tag_id": "erb-d3eb8d62-8311-4119-99b9-3cbc3f21dd65"
    }
},
{
    "pk": 4988, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "The revolutionary discovery of a striking, if temporary, effect that targeted inhibition of BRAF has", 
        "paper": 1, 
        "tag_id": "erb-0e4b22a6-6ce8-45c1-a953-f16b5fb462b0"
    }
},
{
    "pk": 4989, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "The mutational landscape of melanoma was examined in several large studies employing NGS (next-gener", 
        "paper": 1, 
        "tag_id": "erb-c6bef2b1-4f42-42be-bb2b-490911acef68"
    }
},
{
    "pk": 4990, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "In one recent study 1, a wide range of point-mutation rates was observed: they were lowest in melano", 
        "paper": 1, 
        "tag_id": "erb-3e5ffdfd-f72b-495e-adb4-21bdb0370ec5"
    }
},
{
    "pk": 4991, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "The different types of melanoma appear to have distinct sets of relevant somatogenic alterations (Ta", 
        "paper": 1, 
        "tag_id": "erb-f0cbea73-6ed6-4eb6-ad22-4456396e14ef"
    }
},
{
    "pk": 4992, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "This paper describes genetic alterations that are known to occur in melanoma and information about t", 
        "paper": 1, 
        "tag_id": "erb-f2f9cfb7-2384-4a85-9340-8fc891271a64"
    }
},
{
    "pk": 4993, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Multiple cellular pathways have been implicated in melanomagenesis, ranging from signal transduction", 
        "paper": 1, 
        "tag_id": "erb-3821d319-941d-4af8-9899-e66726b4046a"
    }
},
{
    "pk": 4994, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "\n\n\n\n\n\n\n\n\nPATHWAY*\n\n\nCOMPONENTS MUTATED/ACTIVATED\n\n\nTYPE OF ALTERATION\n\n\n\n\n\u00a0\n\u00a0\nReceptor tyrosine kina", 
        "paper": 1, 
        "tag_id": "erb-02709731-4df3-4436-ad37-619c5cf5c169"
    }
},
{
    "pk": 4995, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Table 1 summarizes the molecular pathways involved in melanomagenesis, and Table 2 lists the known d", 
        "paper": 1, 
        "tag_id": "erb-0d16e5de-d11d-486d-a28a-98572f1ecb2c"
    }
},
{
    "pk": 4996, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "\n\n\n\n\n\n\n\n\n\n\n\nPRIMARY SUBTYPES\n\n\nPATHWAY \n\n\nABERRATION\n\n\nFOUND IN TUMORS WITH\u2026\n\n\nFREQUENCY\n\n\nPOSSIBLE ", 
        "paper": 1, 
        "tag_id": "erb-5b68f1b2-a05f-4d0f-83a5-8b4ae9a45126"
    }
},
{
    "pk": 4997, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " BRAF", 
        "paper": 1, 
        "tag_id": "erb-7a3b9a7d-4480-4ec6-bbde-9c2778bf02d8"
    }
},
{
    "pk": 4998, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "BRAF mutations (V600E in 70%-80% of all BRAF mutations in all cancers) occur early in melanomagenesi", 
        "paper": 1, 
        "tag_id": "erb-ce9f76a8-c5e4-4551-9dd8-feda472f170b"
    }
},
{
    "pk": 4999, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Overall, about 50% of melanomas of all clinical types have mutations in BRAF. BRAF mutations are mor", 
        "paper": 1, 
        "tag_id": "erb-f8ead44c-bff2-49c2-a996-276b0148d012"
    }
},
{
    "pk": 5000, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "The reported results of trials with selective oral BRAF inhibitors showed efficacy in melanoma patie", 
        "paper": 1, 
        "tag_id": "erb-c739d91f-58a7-4be5-bcf9-601eecc6d23c"
    }
},
{
    "pk": 5001, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Treatment approaches to BRAF mutations", 
        "paper": 1, 
        "tag_id": "erb-63373e0b-6424-4201-ae7b-bf6f18a4eafb"
    }
},
{
    "pk": 5002, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "The U.S. Food and Drug Administration (FDA) approved the mutant BRAF inhibitor vemurafenib/Zelboraf ", 
        "paper": 1, 
        "tag_id": "erb-2418ebde-7cd5-4eeb-aad8-814cbbcf66d0"
    }
},
{
    "pk": 5003, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Inhibition of MEK has been explored in clinical trials for melanoma patients with mutant BRAF 21,22.", 
        "paper": 1, 
        "tag_id": "erb-8cae2532-fc08-4b77-8286-950c2966813e"
    }
},
{
    "pk": 5004, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Most importantly, it is increasingly clear that combination treatments, such as BRAF and MEK inhibit", 
        "paper": 1, 
        "tag_id": "erb-ef2c64bc-47e3-4d9f-aeda-0d9152add2f4"
    }
},
{
    "pk": 5005, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Targeting ERK1/2, the kinases at the lower end of the MAPK cascade, is an emerging therapeutic strat", 
        "paper": 1, 
        "tag_id": "erb-57d18d6a-2baa-4160-93df-c2069c8a2a91"
    }
},
{
    "pk": 5006, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "BRAF mutations other than V600", 
        "paper": 1, 
        "tag_id": "erb-7b669e2c-f30a-441b-90fa-a675dd659036"
    }
},
{
    "pk": 5007, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "A number of BRAF mutants other than V600 were identified in human cancers 27. Some of these have a r", 
        "paper": 1, 
        "tag_id": "erb-df60f658-712c-4d30-a0fe-27c548fd57fa"
    }
},
{
    "pk": 5008, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Melanomas with BRAF mutations other than V600 have not been specifically targeted in clinical trials", 
        "paper": 1, 
        "tag_id": "erb-4ffc32e9-24d6-4073-82c2-ae0a8433ae31"
    }
},
{
    "pk": 5009, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " NRAS", 
        "paper": 1, 
        "tag_id": "erb-b89a33da-c4c9-4634-9d85-364ff318989b"
    }
},
{
    "pk": 5010, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Approximately 20% of melanomas have mutations in the GTPase NRAS. NRAS and BRAF mutations are almost", 
        "paper": 1, 
        "tag_id": "erb-c2dbe411-6d00-46ad-add7-8d61a8644774"
    }
},
{
    "pk": 5011, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Potential treatment approaches to NRAS mutations", 
        "paper": 1, 
        "tag_id": "erb-31ec429f-45a9-4a30-b4b3-7690826b659b"
    }
},
{
    "pk": 5012, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "The pathways downstream of NRAS that could be targeted simultaneously in NRAS-mutant melanoma includ", 
        "paper": 1, 
        "tag_id": "erb-7cc2f960-8afe-4af9-83b9-6cb80ad58496"
    }
},
{
    "pk": 5013, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Preclinical studies indicate several potential points of intervention:", 
        "paper": 1, 
        "tag_id": "erb-5bdd1d01-c1f4-4533-b6a6-52e593018905"
    }
},
{
    "pk": 5014, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "The combinations of inhibitors to\u00a0target NRAS-activated signaling through MEK and PI3K, MEK and AKT,", 
        "paper": 1, 
        "tag_id": "erb-51453db9-3d17-4a11-9a0d-3f42dab813dd"
    }
},
{
    "pk": 5015, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " GNAQ and GNA11", 
        "paper": 1, 
        "tag_id": "erb-d9e0414a-3515-48c1-a417-809861afe389"
    }
},
{
    "pk": 5016, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Activating mutations in GNAQ and GNA11, encoding members of the G\u03b1(q) family of G protein \u03b1 subunits", 
        "paper": 1, 
        "tag_id": "erb-d4ac2909-fd2b-450b-9226-05a71f5a24a3"
    }
},
{
    "pk": 5017, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Potential treatment approaches to GNAQ and GNA11 mutations", 
        "paper": 1, 
        "tag_id": "erb-e7273fec-770e-4d82-bd83-a43079ad7dd9"
    }
},
{
    "pk": 5018, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "A randomized phase II clinical trial compared the MEK inhibitor selumetinib (AZD6244) with temozolom", 
        "paper": 1, 
        "tag_id": "erb-073e712d-e755-47c1-a91d-adb0b1d32394"
    }
},
{
    "pk": 5019, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Inhibition of both PI3K and MAPK, but neither of them singly, might also work in uveal melanoma as s", 
        "paper": 1, 
        "tag_id": "erb-b09c5847-d0a1-4f7a-88d7-d0f3bf38b0fa"
    }
},
{
    "pk": 5020, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Enzastaurin and AEB071, PKC inhibitors, have shown some activity against uveal melanoma cell lines i", 
        "paper": 1, 
        "tag_id": "erb-88dcaf09-70a7-4cc8-a2de-554aaf2655d4"
    }
},
{
    "pk": 5021, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Recently, it was shown that the guanine nucleotide exchange factor Trio is involved in mitogenic sig", 
        "paper": 1, 
        "tag_id": "erb-5a81201a-d4c1-40b8-91e8-b67d021c5671"
    }
},
{
    "pk": 5022, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " MITF", 
        "paper": 1, 
        "tag_id": "erb-239f381e-e2cf-4c86-96ee-687621279c2e"
    }
},
{
    "pk": 5023, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Microphthalmia-associated transcription factor\u00a0MITF is a lineage survival oncogene, amplified in 20%", 
        "paper": 1, 
        "tag_id": "erb-56aa8edf-0fb1-459e-bf3f-89273acbeb08"
    }
},
{
    "pk": 5024, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Other candidate targets in the MITF program include receptor tyrosine kinase TYRO3, which regulates ", 
        "paper": 1, 
        "tag_id": "erb-d936ecae-262f-4c85-9b93-654d95c0afc3"
    }
},
{
    "pk": 5025, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Hypoxia-inducible factor HIF1\uf061 was also reported to be a transcriptional target of MITF52, and its e", 
        "paper": 1, 
        "tag_id": "erb-9df14086-f884-4ed5-ae88-fa3e0d0a853a"
    }
},
{
    "pk": 5026, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "MITF is regulated by the transcription factor ATF2. Primary melanoma specimens that exhibit a high n", 
        "paper": 1, 
        "tag_id": "erb-3a7e7eb6-a743-4394-99f6-68afeb037026"
    }
},
{
    "pk": 5027, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "SOX10, PAX3, and MITF participate in regulation of MET (HGF receptor), which is expressed at high le", 
        "paper": 1, 
        "tag_id": "erb-19b230ba-e3a4-4fa4-bd4a-a2ab01105e0e"
    }
},
{
    "pk": 5028, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "PPAR-\u03b3 coactivators PGC-1\u03b1 and PGC-1\u03b2 are critical components of the melanogenic system governed by ", 
        "paper": 1, 
        "tag_id": "erb-4593a26a-e92c-4995-97e5-d5794b5227a1"
    }
},
{
    "pk": 5029, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "BCL2A1, a lineage-specific anti-apoptotic protein in the BCL2 family, is amplified and overexpressed", 
        "paper": 1, 
        "tag_id": "erb-147d6a53-f1be-433e-8ad0-6ad23a7e1d2d"
    }
},
{
    "pk": 5030, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "A recent paper proposed targeting of tyrosinase (MITF transcriptional target) by first inducing expr", 
        "paper": 1, 
        "tag_id": "erb-12f09655-0be6-4bfc-a835-e492f02b2ac8"
    }
},
{
    "pk": 5031, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "The crystal structure of MITF was resolved recently, paving the way for the future targeting of MITF", 
        "paper": 1, 
        "tag_id": "erb-7b78a90c-bab1-4602-bb25-a4da2cd6296b"
    }
},
{
    "pk": 5032, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Potential treatment approaches to MITF amplification", 
        "paper": 1, 
        "tag_id": "erb-c5ee4029-b2eb-4585-a0f5-33eba6287546"
    }
},
{
    "pk": 5033, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "These findings on MITF-mediated pathways remain in the domain of preclinical research, although targ", 
        "paper": 1, 
        "tag_id": "erb-020e1f17-1cff-4a83-878a-76f126739c9d"
    }
},
{
    "pk": 5034, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "A new study opened a possibility of targeting the nuclear translocation of ATF2 by inhibiting PKC\u03b5, ", 
        "paper": 1, 
        "tag_id": "erb-d5adc7da-36c2-4855-8a09-3a2a879b7a2f"
    }
},
{
    "pk": 5035, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " KIT ", 
        "paper": 1, 
        "tag_id": "erb-d0bdf58d-ca6e-444f-8d18-afa26d180b73"
    }
},
{
    "pk": 5036, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "KIT is a receptor tyrosine kinase activated by binding of the cytokine stem cell factor (SCF); mutat", 
        "paper": 1, 
        "tag_id": "erb-fa56fd3b-fc8a-4573-945d-22814431cb9f"
    }
},
{
    "pk": 5037, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Treatment approaches to KIT mutations", 
        "paper": 1, 
        "tag_id": "erb-55232cfd-f792-46a3-8e93-78c9e8144cd3"
    }
},
{
    "pk": 5038, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " Targeting KIT with imatinib has demonstrated remarkable efficacy in patients with gastrointestinal ", 
        "paper": 1, 
        "tag_id": "erb-c98c1930-4ffd-4eb7-96a0-25d314df8539"
    }
},
{
    "pk": 5039, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Recently, trials of imatinib and nilotinib have shown promising results in trials where patients wer", 
        "paper": 1, 
        "tag_id": "erb-f1d4d650-64b8-4f27-a229-4baeb9ba4fb9"
    }
},
{
    "pk": 5040, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "At least 10 ongoing trials test the activity of the aforementioned inhibitors in KIT-mutated melanom", 
        "paper": 1, 
        "tag_id": "erb-ac4c6160-a5ba-4382-a875-a192cdef848d"
    }
},
{
    "pk": 5041, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " NF1/neurofibromin", 
        "paper": 1, 
        "tag_id": "erb-00ffdc40-98d4-4ebc-9a1a-3086be30a5ac"
    }
},
{
    "pk": 5042, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "NF1 is a tumor suppressor regulating signaling from RAS; germline mutations in NF1 deregulate both P", 
        "paper": 1, 
        "tag_id": "erb-eef66596-3cd2-4b72-abd4-3d430f97b84c"
    }
},
{
    "pk": 5043, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Potential treatment approaches to NFI mutations", 
        "paper": 1, 
        "tag_id": "erb-cc0d14ae-c5a8-45ea-87fa-4df69c8d8cd5"
    }
},
{
    "pk": 5044, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "In recent studies NF1 could be successfully targeted in mouse models with a combination of MEK and P", 
        "paper": 1, 
        "tag_id": "erb-0228c2a0-fba1-40bc-80be-ceed4fa45fff"
    }
},
{
    "pk": 5045, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " Telomerase", 
        "paper": 1, 
        "tag_id": "erb-248e4516-a0cf-4aed-aa83-e89639717f8c"
    }
},
{
    "pk": 5046, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Two very recent studies\u2014one based on analysis of genomic alterations in a melanoma-prone family, the", 
        "paper": 1, 
        "tag_id": "erb-abc25c8a-8bd1-4e9a-807f-aac2b693d397"
    }
},
{
    "pk": 5047, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Potential treatment options to telomerase mutations", 
        "paper": 1, 
        "tag_id": "erb-d8f7b837-e8e0-4eba-9dcc-3535ae3bf84c"
    }
},
{
    "pk": 5048, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Telomerase inhibitor imetelstat sodium/GRN163L (antisense oligonucleotide) is trialed in breast canc", 
        "paper": 1, 
        "tag_id": "erb-838ebaae-c5b9-4471-984f-7f226db06ff7"
    }
},
{
    "pk": 5049, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Receptor tyrosine kinases and PI3K pathway", 
        "paper": 1, 
        "tag_id": "erb-9879baa1-652a-446a-8030-26b5d1148a14"
    }
},
{
    "pk": 5050, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Activation of the PI3K pathway serves to overcome OIS that is associated with mutant BRAF. PTEN aber", 
        "paper": 1, 
        "tag_id": "erb-ebf678ea-cdf6-4ce4-8589-b5f210d15c6e"
    }
},
{
    "pk": 5051, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " ERBB4. Mutations in this tyrosine kinase receptor are found in 19% of melanomas, based on the resul", 
        "paper": 1, 
        "tag_id": "erb-8a9fe700-5ea3-4229-a1a0-a816abd97f38"
    }
},
{
    "pk": 5052, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " MET. Mutations in MET have not been described in melanoma, but there is strong evidence that this R", 
        "paper": 1, 
        "tag_id": "erb-79724e00-ca39-4ee1-9937-da4ae749ca70"
    }
},
{
    "pk": 5053, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " MERTK. MER, a receptor tyrosine kinase (RTK) sharing a family relationship with TYRO3 and AXL, was ", 
        "paper": 1, 
        "tag_id": "erb-b6f2b62a-0c39-4682-bfe5-2f37e8deffa6"
    }
},
{
    "pk": 5054, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " AKT. Deregulated Akt3 activity was shown to promote development of malignant melanoma; amplificatio", 
        "paper": 1, 
        "tag_id": "erb-83e8396d-5364-4d5d-866c-87a848750c4e"
    }
},
{
    "pk": 5055, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " PTEN is a well-known tumor suppressor affected in approximately 25% to 30% of melanoma, most common", 
        "paper": 1, 
        "tag_id": "erb-56cb8e54-3af5-4f91-88b0-da2a6a09d8e1"
    }
},
{
    "pk": 5056, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Other PI3K pathway mutations. Mutations in other PI3K pathways genes MTOR, IRS4, PIK3R1, PIK3R4, and", 
        "paper": 1, 
        "tag_id": "erb-37473d55-6894-4c8d-b7ae-c9f7902953ec"
    }
},
{
    "pk": 5057, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " MAPK pathway downstream of BRAF", 
        "paper": 1, 
        "tag_id": "erb-1f34f8cd-2472-4371-9d13-050f33474336"
    }
},
{
    "pk": 5058, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "MEK1 and MEK2. Sequencing of seven melanoma cell lines and donor-matched germline cells found MAP2K1", 
        "paper": 1, 
        "tag_id": "erb-29b4e57e-47b2-4137-9d2f-391330b01d7d"
    }
},
{
    "pk": 5059, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "IQGAP1: a scaffold protein in MAPK pathway as a possible target. There are new data indicating that ", 
        "paper": 1, 
        "tag_id": "erb-c865b9c2-a395-4508-8b1d-b0e54c099b14"
    }
},
{
    "pk": 5060, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " RAC pathway. RAC1 is a Rho GTPase, a GTP exchange protein known to affect the cell cytoskeleton and", 
        "paper": 1, 
        "tag_id": "erb-2507e33a-dbf7-4d0f-bc64-f884083acf1b"
    }
},
{
    "pk": 5061, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " MAP3K5 and MAP3K9. These MAP3 kinases are directly downstream of Rac and Rho signaling activated by", 
        "paper": 1, 
        "tag_id": "erb-8d5c6794-1a4e-4e2c-80c4-78c5b33f1e29"
    }
},
{
    "pk": 5062, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " PREX2. Mutations of phosphatidylinositol-3,4,5-trisphosphate-dependent Rac exchange factor 2 were f", 
        "paper": 1, 
        "tag_id": "erb-dd32afd0-8356-42ff-888f-5f3af6c23a63"
    }
},
{
    "pk": 5063, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Cell cycle and apoptosis-related genes", 
        "paper": 1, 
        "tag_id": "erb-0e752c0a-d0ac-4b58-aa67-800530260f85"
    }
},
{
    "pk": 5064, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " CDK4, a cell cycle G1/S kinase, and cyclin D1 (CCND1), were shown to be amplified in melanoma 111. ", 
        "paper": 1, 
        "tag_id": "erb-97e2927a-2e4d-4426-9288-a5aacc416c43"
    }
},
{
    "pk": 5065, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " TP53 pathway. TP53 mutations are found in 19% of melanoma tumors 31, a frequency relatively low com", 
        "paper": 1, 
        "tag_id": "erb-8d3cee48-1465-47bf-9b5a-2bb6313a419f"
    }
},
{
    "pk": 5066, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " CDKN2A locus is frequently deleted in melanoma of all primary subtypes 119-121. Two tumor suppresso", 
        "paper": 1, 
        "tag_id": "erb-f49b36e6-6d5e-4e98-b0f7-3561b96cf1d2"
    }
},
{
    "pk": 5067, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "MDM2. This protein binds to p53 and promotes its degradation and inactivation. MDM2 is considered to", 
        "paper": 1, 
        "tag_id": "erb-cb25dde7-dc30-4592-906d-9b8373eef7b2"
    }
},
{
    "pk": 5068, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " MDM4. In a recent study it was shown that MDM4, a negative regulator of p53, is upregulated in abou", 
        "paper": 1, 
        "tag_id": "erb-fd68e0cd-d3c2-4f6f-b7d9-e7f75e613a55"
    }
},
{
    "pk": 5069, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Potential treatment of melanoma harboring inactivated wild-type p53 would involve inhibition of CDK4", 
        "paper": 1, 
        "tag_id": "erb-1e63ec19-be6b-4e0d-9c05-5f02802eab63"
    }
},
{
    "pk": 5070, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "P63, a protein related to p53, has been reported to have an anti-apoptotic role in melanoma, which i", 
        "paper": 1, 
        "tag_id": "erb-548bfbc1-9744-4042-a74b-0616a916d9c4"
    }
},
{
    "pk": 5071, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "iASPP is a conserved ankyrin repeat protein that shuttles between nuclear and cytoplasmic compartmen", 
        "paper": 1, 
        "tag_id": "erb-910e7562-3a16-4c73-b552-6b9718fb5096"
    }
},
{
    "pk": 5072, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "\u00a0NFkB. As in many, many other tumors, the NFkB pathway is activated in melanoma, but systemic inhibi", 
        "paper": 1, 
        "tag_id": "erb-d3a43b44-6467-4d2b-ac37-7c97a240c6b7"
    }
},
{
    "pk": 5073, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " BCL2. There is abundant literature that documents elevated BCL2 expression in melanoma and its cont", 
        "paper": 1, 
        "tag_id": "erb-0eb540fb-7aca-4928-a763-fe5f86feb587"
    }
},
{
    "pk": 5074, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Attempts to target BCL2 with antisense RNA in melanoma patients have not been successful. Obatoclax,", 
        "paper": 1, 
        "tag_id": "erb-072257b9-814a-4a4e-a65d-9826eb9b1d8b"
    }
},
{
    "pk": 5075, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "\u03b2-catenin and WNT pathway", 
        "paper": 1, 
        "tag_id": "erb-8d8315e8-afe0-45de-9ef0-3bc5e474bb11"
    }
},
{
    "pk": 5076, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "A number of reports have heavily implicated WNT signaling in melanoma progression and metastases. \u03b2-", 
        "paper": 1, 
        "tag_id": "erb-e1285874-a599-4bd0-a8e4-ddd48d97e30c"
    }
},
{
    "pk": 5077, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "In a mouse melanoma model based on PTEN loss and BRAFV600E mutation, \uf062-catenin was shown to be a cen", 
        "paper": 1, 
        "tag_id": "erb-58103a4e-516e-49a5-bab2-2ddf8d1e1bac"
    }
},
{
    "pk": 5078, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Negative regulation of WNT/\uf062-catenin signaling by MAPK pathway was confirmed in an additional study ", 
        "paper": 1, 
        "tag_id": "erb-3094bab2-099a-4613-9efd-7df29395c6d4"
    }
},
{
    "pk": 5079, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Transcriptional factors in melanoma", 
        "paper": 1, 
        "tag_id": "erb-6659576e-f647-471c-b3e7-066f04447e15"
    }
},
{
    "pk": 5080, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " MYC. This universal oncogene and transcriptional master regulator is overexpressed or present at in", 
        "paper": 1, 
        "tag_id": "erb-298b26b9-f61e-4c75-b154-23fce1deeaa5"
    }
},
{
    "pk": 5081, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " ETV1. This transcription factor from the ETS family was implicated as an oncogene in melanoma and c", 
        "paper": 1, 
        "tag_id": "erb-d5b7934b-9072-45ed-9279-a008e19d363f"
    }
},
{
    "pk": 5082, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Other significant genetic abnormalities in melanoma", 
        "paper": 1, 
        "tag_id": "erb-6f7778b4-4ecc-43e3-b35c-dc4e05eb0a36"
    }
},
{
    "pk": 5083, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " NEDD9, an integrin adaptor protein related to P130CAS, and a member of a family implicated in patho", 
        "paper": 1, 
        "tag_id": "erb-66dfcf6c-695a-4eb4-9125-e6640b3d8a0f"
    }
},
{
    "pk": 5084, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " PPP6C is a serine-threonine phosphatase, mutated in 12% of sun-exposed melanomas exclusively with B", 
        "paper": 1, 
        "tag_id": "erb-ad5c7083-6e61-4f05-a094-668be826386c"
    }
},
{
    "pk": 5085, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " TACC1 (transforming acidic coiled-coil containing protein 1) is mutated in 5% of an experimental se", 
        "paper": 1, 
        "tag_id": "erb-281f6400-ece2-41bd-8a86-079197a63b18"
    }
},
{
    "pk": 5086, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " BAP1 (BRCA1-associated protein-1/ubiquitin carboxy-terminal hydrolase) is involved in metastatic pr", 
        "paper": 1, 
        "tag_id": "erb-bb450c96-e0d3-469e-bd47-393cd5010ff7"
    }
},
{
    "pk": 5087, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "SF3B1. Codon 625 of the SF3B1 gene, encoding splicing factor 3B subunit 1, is consistently mutated i", 
        "paper": 1, 
        "tag_id": "erb-28e06d63-5c2f-403e-a1af-9e54ce7b16b3"
    }
},
{
    "pk": 5088, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " SNX31 was identified as one of the 11 new genes mutated in melanoma 31. It encodes a poorly charact", 
        "paper": 1, 
        "tag_id": "erb-a6602eb0-c3c3-493b-8fcf-f35733f49233"
    }
},
{
    "pk": 5089, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " STK19. A 5% mutation rate of this kinase gene with unknown functions is seen in melanoma 31.", 
        "paper": 1, 
        "tag_id": "erb-137b4e60-95db-4bba-897d-7e60bd10d440"
    }
},
{
    "pk": 5090, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "LKB1/STK11. LKB1 might be a central kinase that integrates energy metabolism and tumor growth, in pa", 
        "paper": 1, 
        "tag_id": "erb-32566ff2-661e-4af8-b927-b6f18a470c6d"
    }
},
{
    "pk": 5091, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " ARID2 is a component of the SWI/SNF chromatin-remodeling complex. Loss-of-function mutations were f", 
        "paper": 1, 
        "tag_id": "erb-539cfd4f-2755-462b-9599-dc18fffc7aab"
    }
},
{
    "pk": 5092, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " TRRAP2. Identified mutations occur in 4% of the melanoma set examined. TRRAP functions as part of a", 
        "paper": 1, 
        "tag_id": "erb-50257ede-1f07-40c4-900a-94567efad325"
    }
},
{
    "pk": 5093, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " GRIN2A encodes the glutamate N-methyl-D-aspartic acid (NMDA) receptor subunit \u03b5-1 that is part of t", 
        "paper": 1, 
        "tag_id": "erb-74a95d24-41dc-467d-9cd3-2a22270d602a"
    }
},
{
    "pk": 5094, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " GRM3 is a metabotropic glutamate receptor, a G-protein-coupled receptor (GPCR) that activates phosp", 
        "paper": 1, 
        "tag_id": "erb-5869b252-4210-4b24-889d-190e07c649fd"
    }
},
{
    "pk": 5095, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Phosphoglycerate dehydrogenase PHGDH serves to divert glycolytic carbon into serine and glycine meta", 
        "paper": 1, 
        "tag_id": "erb-d116599e-26a2-4ad3-8bb9-dad4f3684fb0"
    }
},
{
    "pk": 5096, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "WEE1. Cell cycle regulatory kinase Wee1 is upregulated in melanoma and is associated with poor progn", 
        "paper": 1, 
        "tag_id": "erb-ed110c4e-0b8d-430a-b97f-dd04d5f459fe"
    }
},
{
    "pk": 5097, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "NUAK2 (AMPK-related kinase). High levels of expression of NUAK2 were found in patients with acral me", 
        "paper": 1, 
        "tag_id": "erb-4646ca08-554a-4315-b2bd-3e32584ef8a7"
    }
},
{
    "pk": 5098, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Various noncoding RNAs and other epigenetic alterations", 
        "paper": 1, 
        "tag_id": "erb-37090b04-274d-4c2e-81f4-04fd16907d33"
    }
},
{
    "pk": 5099, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "A number of reports found significant roles for miRNA, ncRNA, or ceRNA in pathogenesis of melanoma; ", 
        "paper": 1, 
        "tag_id": "erb-5d7bc483-6997-476e-9125-34ee18086488"
    }
},
{
    "pk": 5100, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Strategies to inhibit or increase expression of ncRNAs in clinical setting are only beginning to eme", 
        "paper": 1, 
        "tag_id": "erb-957ba85d-cdd3-490c-93ae-3bd46a038329"
    }
},
{
    "pk": 5101, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Resistance to BRAF inhibitors could be intrinsic (as in lack of response to selective BRAF inhibitor", 
        "paper": 1, 
        "tag_id": "erb-afe7c337-b1e5-4c18-8416-e2a883ef3c0b"
    }
},
{
    "pk": 5102, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "It is well established that BRAF mutations play a role in melanomagenesis; however, without addition", 
        "paper": 1, 
        "tag_id": "erb-28572f71-516c-451e-abd0-ec37e4f035cf"
    }
},
{
    "pk": 5103, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "\n\n\n\n\n\n\n\n\nMOLECULAR CHANGE\n\n\nCONFIRMED IN PATIENT BIOPSIES?\n\n\nDRUGS TO OVERCOME RESISTANCE\n\n\n\n\nResist", 
        "paper": 1, 
        "tag_id": "erb-6269dc15-0dbb-41c4-8751-2a46e69ab1dc"
    }
},
{
    "pk": 5104, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "PI3K/AKT. Mutations of the PI3K pathway are frequent in the BRAF-mutant setting. These have been sho", 
        "paper": 1, 
        "tag_id": "erb-d8b2489b-e981-4356-b3f5-444b02fd34ea"
    }
},
{
    "pk": 5105, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "A recent study demonstrated an essential role for ERK-phosphorylated MEK1 (pT292) in membrane recrui", 
        "paper": 1, 
        "tag_id": "erb-307987f0-c962-4af3-b1d9-64f67cf1a53f"
    }
},
{
    "pk": 5106, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "CDK4 pathway. Increased cyclin D expression mediates inherent resistance to mutant BRAF inhibition 1", 
        "paper": 1, 
        "tag_id": "erb-584c2e95-20de-4f70-ae8c-9b3c2e070d6f"
    }
},
{
    "pk": 5107, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "NF1 mutations. In a mouse model, NF1 ablation decreases the sensitivity of NF1 wild-type melanoma ce", 
        "paper": 1, 
        "tag_id": "erb-e7c830b2-46df-4816-86cc-52660915f5c0"
    }
},
{
    "pk": 5108, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "MET and SRC. The activation of MET and SRC signaling was detected in two patient-derived melanoma ce", 
        "paper": 1, 
        "tag_id": "erb-68cf2a34-e2a6-4a57-9dfe-3e4efc1e9ac8"
    }
},
{
    "pk": 5109, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Metabolic signature of melanoma sensitive to mutant BRAF inhibition. An interesting study could not ", 
        "paper": 1, 
        "tag_id": "erb-192d69a2-f242-4731-94b0-947f0f712215"
    }
},
{
    "pk": 5110, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "MITF-PGC1a axis in resistance to BRAF inhibition. Inhibition of BRAFV600 and, to a lesser extent of ", 
        "paper": 1, 
        "tag_id": "erb-982f66de-9ea7-4a2d-8144-a9a98fe7dc5b"
    }
},
{
    "pk": 5111, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Tumor stroma influence. An important study demonstrated production of HGF by stromal cells in patien", 
        "paper": 1, 
        "tag_id": "erb-e5e35ea6-896c-4daf-a01a-b8f08df0eab0"
    }
},
{
    "pk": 5112, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "BCL-2. Inhibition of anti-apoptotic protein Bcl-2 might have a potential role in the future studies ", 
        "paper": 1, 
        "tag_id": "erb-e8913150-f47e-4957-83ca-05891cb5143e"
    }
},
{
    "pk": 5113, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "BCL2A1. Amplification of one family member, BCL2A1 in 30% of melanoma, was shown to contribute to re", 
        "paper": 1, 
        "tag_id": "erb-a1e06b5b-a9fe-4253-832d-0b5134a9f149"
    }
},
{
    "pk": 5114, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "FOXD3-ERBB3. Transcription factor FOXD3 was shown to be upregulated when mutant BRAF is inhibited in", 
        "paper": 1, 
        "tag_id": "erb-5631fee9-0f29-4c30-8e02-e2ebab62e2a0"
    }
},
{
    "pk": 5116, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Signaling through TGF-\u03b2/SMURF2/PAX3 and MITF.  In an in vitro study, cells sensitive to MEK inhibiti", 
        "paper": 1, 
        "tag_id": "erb-f0d2d93a-9883-49d2-adb8-0bc096059632"
    }
},
{
    "pk": 5117, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Activation of the PI3K pathway was seen as a factor in resistance of a panel of melanoma cell lines ", 
        "paper": 1, 
        "tag_id": "erb-fc2e7f2e-8696-4fca-b4b8-0d4c431508a2"
    }
},
{
    "pk": 5118, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "\n\n\n\n\n\n\n\n\n\nMOLECULAR CHANGE\n\n\nCONFIRMED IN PATIENT BIOPSIES?\n\n\nDRUGS TO ADD TO OVERCOME RESISTANCE\n\n\n", 
        "paper": 1, 
        "tag_id": "erb-c4701a71-1ae7-4194-9643-389381125674"
    }
},
{
    "pk": 5119, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Mechanistic studies have provided insights into the development of resistance through two major mech", 
        "paper": 1, 
        "tag_id": "erb-8bc889b0-c044-45b7-a9b3-b2c6d6deb5bc"
    }
},
{
    "pk": 5120, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "The identification of mechanisms of acquired resistance to BRAF inhibitors usually involves selectio", 
        "paper": 1, 
        "tag_id": "erb-0e800264-886e-4544-a5a7-4cb54852bdec"
    }
},
{
    "pk": 5121, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "New aberrations in BRAF. Unlike the experiences with other molecularly targeted therapies of oncogen", 
        "paper": 1, 
        "tag_id": "erb-f0996500-f62f-4395-8344-31f82dd8fda1"
    }
},
{
    "pk": 5122, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Analysis of a subset of cells resistant to vemurafenib (PLX4032) in vitro detected the 61-kDa varian", 
        "paper": 1, 
        "tag_id": "erb-0903eb56-1da2-4e31-be5c-efb15cec4a96"
    }
},
{
    "pk": 5123, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Activation of signaling through RTKs", 
        "paper": 1, 
        "tag_id": "erb-99548d8d-e6ea-41ac-baaa-2d1f935d01dc"
    }
},
{
    "pk": 5124, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "EGFR/SFK/STAT3. BRAF inhibitor\u2013mediated activation of EGFR/SRC family kinase/STAT3 signaling was sho", 
        "paper": 1, 
        "tag_id": "erb-c65359c3-f932-461a-a3c6-4f84673f7bb1"
    }
},
{
    "pk": 5125, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "FGFR3-RAS. Upregulation of FGFR3 signaling in selected vemurafenib-resistant cells was described in ", 
        "paper": 1, 
        "tag_id": "erb-96f3781d-3083-472e-b24d-da86db4150b7"
    }
},
{
    "pk": 5126, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "IGF-1R/PI3K pathway.  Mutations in the IGF-1R/PI3K pathway were identified as another way for develo", 
        "paper": 1, 
        "tag_id": "erb-e2c6bd92-b956-4810-967a-4d6aab221cb5"
    }
},
{
    "pk": 5127, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Activation of PDGFR\uf062 signaling was shown to occur during selection for BRAF inhibitor resistance in ", 
        "paper": 1, 
        "tag_id": "erb-1f89b788-7780-4165-b8e7-c3aa54cc1365"
    }
},
{
    "pk": 5128, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "ERBB3 signaling. Enhanced ERBB3 signaling promoted resistance to RAF pathway inhibitors in cultured ", 
        "paper": 1, 
        "tag_id": "erb-0ff6e5a1-dd3c-4f95-8d7d-d8239a601678"
    }
},
{
    "pk": 5129, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "PDGFR\uf062 activation. Induction of PDGFR\uf062 RNA, protein, and tyrosine phosphorylation were detected in a", 
        "paper": 1, 
        "tag_id": "erb-09cafe12-16bd-4759-9504-110e786ff7bb"
    }
},
{
    "pk": 5130, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "NF1 expression is lost in tumors from patients following treatment with BRAF and MEK inhibitors 85. ", 
        "paper": 1, 
        "tag_id": "erb-edeb2a21-15f4-4bab-a12e-42c51c5dce15"
    }
},
{
    "pk": 5131, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "NRAS. Secondary mutations in NRAS were shown to confer resistance to PLX4032 in vitro 183. These acq", 
        "paper": 1, 
        "tag_id": "erb-0154e608-7aa2-4ec2-91f0-a935257234e5"
    }
},
{
    "pk": 5132, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "AKT3. Activation of AKT3 in response to BRAF inhibitor PLX4720 or BRAF siRNA was implicated in the r", 
        "paper": 1, 
        "tag_id": "erb-4c0fb62f-b5f8-45a5-bc36-bac351ee3539"
    }
},
{
    "pk": 5133, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "ERK activation, independent of classical RAF/MEK/ERK pathways, was shown to occur in resistant lines", 
        "paper": 1, 
        "tag_id": "erb-99d5ae0d-0812-4467-8906-826215054172"
    }
},
{
    "pk": 5134, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "MAP3K8/COT. In a massive functional kinome screening study, a kinase known as MAP3K8/COT was implica", 
        "paper": 1, 
        "tag_id": "erb-ea4d73da-44e1-4178-9247-41f8449ceb6a"
    }
},
{
    "pk": 5135, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "MEK1 mutation C121S was identified in a patient treated with vemurafenib 185. This mutation was show", 
        "paper": 1, 
        "tag_id": "erb-6257e971-8375-41c2-b0fd-cf906819d405"
    }
},
{
    "pk": 5136, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "RND3. An in vitro study with a single BRAF-mutant melanoma line showed that BRAF-inhibitor treatment", 
        "paper": 1, 
        "tag_id": "erb-1b90aaf2-bab3-4cb7-8256-168f945fb106"
    }
},
{
    "pk": 5137, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "IRS1. Insulin receptor substrates 1 and 2 (IRS1/2) mediate oncogenic signaling from IGF-1R and are u", 
        "paper": 1, 
        "tag_id": "erb-9370fa6a-524a-46bd-9080-616ee145fe5c"
    }
},
{
    "pk": 5138, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Factors that mediate acquired resistance to MEK inhibitors (Table 4)", 
        "paper": 1, 
        "tag_id": "erb-58763f49-7168-4acd-b1dc-f94069870552"
    }
},
{
    "pk": 5139, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Similar to the adaptation of BRAF-mutant melanoma cells to BRAF inhibition, resistance to MEK inhibi", 
        "paper": 1, 
        "tag_id": "erb-9ffd59e9-9fb3-4338-93f1-6da50337007f"
    }
},
{
    "pk": 5140, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Mutations in MEK1 and MEK2. De novo mutations in MEK1 were strongly implicated in resistance to MEK ", 
        "paper": 1, 
        "tag_id": "erb-0e93d07a-d392-4844-beed-c1eb6da670d7"
    }
},
{
    "pk": 5141, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "PI3K-AKT pathway. A study in vitro has identified basal and treatment-induced activation of the PI3K", 
        "paper": 1, 
        "tag_id": "erb-176caa71-f1b5-44be-8e4f-6514c966b030"
    }
},
{
    "pk": 5142, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Factors that mediate acquired resistance to BRAF and MEK inhibitors (Table 4)", 
        "paper": 1, 
        "tag_id": "erb-363747c7-2caf-4059-9785-0649b9bc2d14"
    }
},
{
    "pk": 5143, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "MEK2 mutation Q60P was identified in a patient that developed resistance to trametinib 192. Interest", 
        "paper": 1, 
        "tag_id": "erb-2db3901c-9414-4d97-8a7a-8d2e5198c513"
    }
},
{
    "pk": 5144, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Inherent resistance, partial and low durability responses, and acquired resistance are major problem", 
        "paper": 1, 
        "tag_id": "erb-f9e66180-1eeb-4aee-b543-8a8f691525ce"
    }
},
{
    "pk": 5145, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Two recent publications examined possible synergistic interactions between targeted therapies. The f", 
        "paper": 1, 
        "tag_id": "erb-cce3f0b2-84f3-4c25-bc73-c91dc7972507"
    }
},
{
    "pk": 5146, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "The second study\u00a038 examined drug interactions between 150 small-molecule inhibitors in a panel of 2", 
        "paper": 1, 
        "tag_id": "erb-cc486c29-7d1c-4dc4-b3b7-cb81ccb641d6"
    }
},
{
    "pk": 5147, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "IMMUNOTHERAPY", 
        "paper": 1, 
        "tag_id": "erb-f5c71d36-dbea-4346-a56a-32d7120f115f"
    }
},
{
    "pk": 5148, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Malignant melanoma is a tumor extensively investigated as target for immunotherapy for reasons inclu", 
        "paper": 1, 
        "tag_id": "erb-823083b6-9431-417c-87e9-1f4b5664de0e"
    }
},
{
    "pk": 5149, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Interleukin-2 was the earliest immunotherapy for metastatic melanoma, approved by the FDA in 1998, f", 
        "paper": 1, 
        "tag_id": "erb-e4c96035-e1a1-483c-b8e5-6fe68ce774ce"
    }
},
{
    "pk": 5150, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "In light of the complexity of the immune response, it is very likely that combining immunotherapies ", 
        "paper": 1, 
        "tag_id": "erb-27ade8df-9cb6-4f10-9074-45d57beb1425"
    }
},
{
    "pk": 5151, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Immunomodulatory antibodies", 
        "paper": 1, 
        "tag_id": "erb-de5c7103-b647-49ae-902d-40d7493c5411"
    }
},
{
    "pk": 5152, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "The use of immune checkpoint inhibitors (antibodies that block proteins inhibiting immune response) ", 
        "paper": 1, 
        "tag_id": "erb-2f6e80bb-2a77-4bf5-8b0d-f445e62e1dc7"
    }
},
{
    "pk": 5153, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "\n\n\n\n\n\n\n\n\n\nTarget\n\n\nDesired effects\n\n\nAntibodies \n\n\nTrials\n\n\n\n\nCTLA-4\n\n\nRelieve the immune checkpoint", 
        "paper": 1, 
        "tag_id": "erb-d65c659d-6353-46d2-b650-73d7256644ab"
    }
},
{
    "pk": 5154, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "CTLA4 is an inhibitory molecule expressed on T cells that is involved in the negative regulation of ", 
        "paper": 1, 
        "tag_id": "erb-f0e0c87c-1cde-4cc7-a0e4-f700c8f30dff"
    }
},
{
    "pk": 5155, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Potential markers that could predict response to ipilimumab are of obvious importance. Clinical tria", 
        "paper": 1, 
        "tag_id": "erb-917d1447-9fea-4df9-afda-0bfcb6737dcd"
    }
},
{
    "pk": 5156, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Trials of ipilimumab and gp100 peptide vaccine\u2014each as a single agent or in combination\u2014showed limit", 
        "paper": 1, 
        "tag_id": "erb-875ab628-23c2-47e7-8d58-eb3a70f610cf"
    }
},
{
    "pk": 5157, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "PD-1, like CTLA-4, is an inhibitory receptor; however, its expression is not limited to T cells and ", 
        "paper": 1, 
        "tag_id": "erb-25bc6e98-1cac-45b0-a497-a3024998f4fa"
    }
},
{
    "pk": 5158, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Humanized antibodies to PD-1 and PD-L1 have been developed and tested in clinical trials for several", 
        "paper": 1, 
        "tag_id": "erb-537b8e01-23e6-4505-9cd8-97da16fc116f"
    }
},
{
    "pk": 5159, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Clinical trials targeting PD-1/ PD-L1 interaction", 
        "paper": 1, 
        "tag_id": "erb-83120be2-c74b-4fe3-81c9-e8f2f6f6a96a"
    }
},
{
    "pk": 5160, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Results from an early-phase clinical trial with anti-PD1 antibody BMS-936558 (MDX-1106, ONO-4538, ni", 
        "paper": 1, 
        "tag_id": "erb-c64a70a1-fe95-4708-95c8-bee27b379874"
    }
},
{
    "pk": 5161, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Two other anti-PD-1 antibodies (CT-011: CureTech Ltd. and MK-3475/Lambrolizumablambrolizumab: Merck)", 
        "paper": 1, 
        "tag_id": "erb-af58c21e-2e9f-48dc-bddf-81d553983d6e"
    }
},
{
    "pk": 5162, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "An anti-PD-L1 antibody (MPDL3280A/BMS-936559/MDX-1105 is being tested as well. Preliminary results w", 
        "paper": 1, 
        "tag_id": "erb-30dd191a-b19f-431a-b5ab-a1cf8af10370"
    }
},
{
    "pk": 5163, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "An important paper has shown that combining blockade of both immune checkpoints (PD-1 and CTLA4) is ", 
        "paper": 1, 
        "tag_id": "erb-e9fa247c-e40d-4e7f-a8be-9f70c3b90dfb"
    }
},
{
    "pk": 5164, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "In general, a concept is emerging that different immune checkpoints might have non-overlapping funct", 
        "paper": 1, 
        "tag_id": "erb-6abcc4f1-0b07-4d7a-97b4-8ccc59174e26"
    }
},
{
    "pk": 5165, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "4-1BB. Also known as CD137, 4-1BB is a member of the TNF receptor superfamily, and is an activation-", 
        "paper": 1, 
        "tag_id": "erb-1293d806-5436-4805-96fe-ddb7b4fc04a1"
    }
},
{
    "pk": 5166, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "GITR is a co-stimulatory receptor expressed after T-cell activation that enhances T-cell function an", 
        "paper": 1, 
        "tag_id": "erb-43588aca-3377-498f-8d41-3c4181b8eefc"
    }
},
{
    "pk": 5167, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "OX40 is not involved in effector T-cell activation, but rather, promotes T-cell survival and expansi", 
        "paper": 1, 
        "tag_id": "erb-7ad2a15c-2ab4-4c1c-b8b4-d1d24c4a806c"
    }
},
{
    "pk": 5168, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "CD40. Unlike the co-stimulatory targets above, CD40 is expressed on APCs, while its ligand is expres", 
        "paper": 1, 
        "tag_id": "erb-1b9c0c60-e3a3-4313-90b2-5121d3018589"
    }
},
{
    "pk": 5169, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "CEACAM1 is a potential new target for the development of targeting antibodies. CEACAM1 is a carcinoe", 
        "paper": 1, 
        "tag_id": "erb-93279be7-ac58-4175-b917-d55b09ed8bc8"
    }
},
{
    "pk": 5170, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Cytokines", 
        "paper": 1, 
        "tag_id": "erb-4601313c-3878-4164-8aab-b497e27115ea"
    }
},
{
    "pk": 5171, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Interleukin-2 (IL-2), a protein produced primarily by CD4+ T-cells that activates and induces prolif", 
        "paper": 1, 
        "tag_id": "erb-dcf15b3a-1e46-4e27-8785-6f6ea67e862c"
    }
},
{
    "pk": 5172, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Interferon-alpha is FDA-approved for the treatment of stage III melanoma in the adjuvant setting. In", 
        "paper": 1, 
        "tag_id": "erb-b087af16-6e14-4438-9d65-e81899886d02"
    }
},
{
    "pk": 5173, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Cytokines under investigation for the treatment of metastatic melanoma include IL-21, which produced", 
        "paper": 1, 
        "tag_id": "erb-cbd24ae9-37ce-4c26-a00c-a93d9583fc17"
    }
},
{
    "pk": 5174, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Adoptive cell transfer", 
        "paper": 1, 
        "tag_id": "erb-d63dfac4-9ac0-4b82-ae2d-65042822be0c"
    }
},
{
    "pk": 5175, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Adoptive cell transfer (ACT) involves the selection of autologous lymphocytes with antitumor activit", 
        "paper": 1, 
        "tag_id": "erb-1d22d4c7-1bdb-4994-aa70-7b3690421dfe"
    }
},
{
    "pk": 5176, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Different aspects of ACT are being examined, among them the role of cytokines such as IL-15 and T-ce", 
        "paper": 1, 
        "tag_id": "erb-254eb6b2-7685-43f1-9f59-288c6b2195a2"
    }
},
{
    "pk": 5177, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Analysis of the repertoire of T cells in the successful ACT treatments of three melanoma patients th", 
        "paper": 1, 
        "tag_id": "erb-45030460-32a2-48b3-b6a1-747133dbf1af"
    }
},
{
    "pk": 5178, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "A recent phase II clinical trial reported objective clinical responses in almost half of the 31 pati", 
        "paper": 1, 
        "tag_id": "erb-609713af-4a52-40ae-a23c-0d9c59e2b740"
    }
},
{
    "pk": 5179, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Failure of the infused CD8 cells to persist in the patients could be a major cause for the limited e", 
        "paper": 1, 
        "tag_id": "erb-99d0d6e3-8556-481a-8feb-388584db20c8"
    }
},
{
    "pk": 5180, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Another approach to ACT therapy is to create tumor-reactive T-cell populations from PBL by retrovira", 
        "paper": 1, 
        "tag_id": "erb-db75d187-397b-4b54-bde4-634ef093d518"
    }
},
{
    "pk": 5181, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Some remarkable responses were observed in individual patients treated with CD4+ T cells. For exampl", 
        "paper": 1, 
        "tag_id": "erb-cfb04485-e0a7-4d85-a7b5-3f3043575dcf"
    }
},
{
    "pk": 5182, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Dendritic cell\u2013based immunotherapy.", 
        "paper": 1, 
        "tag_id": "erb-a91c5f17-805c-4fa0-9dde-712f245b0da6"
    }
},
{
    "pk": 5183, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Dendritic cells (DCs) are the most potent-presenting cells in the immune system; clinical efforts to", 
        "paper": 1, 
        "tag_id": "erb-7c01ddf9-9268-4bdf-9442-a2403c41016e"
    }
},
{
    "pk": 5184, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Stimulation of anti-melanoma responses by DCs involves a number of steps that need better scientific", 
        "paper": 1, 
        "tag_id": "erb-12d84f95-8931-4b00-94c4-807d09f84881"
    }
},
{
    "pk": 5185, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "A number of variables remain to be fully explored in DC vaccination: the source of DCs, the optimal ", 
        "paper": 1, 
        "tag_id": "erb-9c55671a-249d-423f-a02f-4c43660fdbe4"
    }
},
{
    "pk": 5186, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Clinical trials have explored DCs generated by different methods and injected by different routes in", 
        "paper": 1, 
        "tag_id": "erb-026d6c02-e46c-47d6-b891-bcefc55bdc2e"
    }
},
{
    "pk": 5187, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "In a different approach, immature DCs were generated from CD34+ hematopoietic progenitor cells throu", 
        "paper": 1, 
        "tag_id": "erb-e5673e8d-57dc-4e7c-8b21-07a1a05221fb"
    }
},
{
    "pk": 5188, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Langerhans cells were directly compared to monocyte-derived DCs in a clinical trial, and were found ", 
        "paper": 1, 
        "tag_id": "erb-9785c4ed-b003-47c5-9a76-a5d7eddf3800"
    }
},
{
    "pk": 5189, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Stimulation of DCs could be performed not only by exposing them to tumor antigens, but also by trans", 
        "paper": 1, 
        "tag_id": "erb-09a59a75-8f38-4418-9762-8611b4c26c7f"
    }
},
{
    "pk": 5190, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "A recent study reported a further significant improvement on DC maturation ex vivo. Mature DCs (used", 
        "paper": 1, 
        "tag_id": "erb-bbec9ffe-343a-4fe2-80a3-a13810e7e507"
    }
},
{
    "pk": 5191, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Another important component of successful vaccination with DCs is their ability to stimulate CD8+ T ", 
        "paper": 1, 
        "tag_id": "erb-a8c697ae-dcc4-414a-a647-0802c728b0f9"
    }
},
{
    "pk": 5192, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Although combination immunotherapies involving DCs and immunomodulatory antibodies may hold promise ", 
        "paper": 1, 
        "tag_id": "erb-2ea746c1-2752-49b7-8cc6-5e16687d339b"
    }
},
{
    "pk": 5193, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Adoptive transfer of natural killer cells. NK cells are an essential part of the innate immune syste", 
        "paper": 1, 
        "tag_id": "erb-b28b107f-99d3-4d4e-bb6c-01fc5d6ec555"
    }
},
{
    "pk": 5194, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "NK cells can be obtained from PBMC where they comprise 5% to 15 % of the lymphocyte population, expa", 
        "paper": 1, 
        "tag_id": "erb-bc5a2fc9-1278-4cb0-84ca-bc05395bc8a8"
    }
},
{
    "pk": 5195, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Influence of targeted therapies on the responses to immune therapy", 
        "paper": 1, 
        "tag_id": "erb-734f3d55-e577-4b29-8584-c56319b8b1f4"
    }
},
{
    "pk": 5196, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "BRAF/MAPK signaling and TIL. Activated BRAF/MAPK signaling was shown to be essential in the developm", 
        "paper": 1, 
        "tag_id": "erb-264ec0d5-bd68-43d8-9394-4f2ca52a9a53"
    }
},
{
    "pk": 5197, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "There were concerns that treatment with BRAF/MEK inhibitors might have a direct inhibitory effect on", 
        "paper": 1, 
        "tag_id": "erb-d149b695-d28d-4ded-a866-5528871d164b"
    }
},
{
    "pk": 5198, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "A number of subsequent reports have confirmed that inhibition of mutant BRAF could potentiate immune", 
        "paper": 1, 
        "tag_id": "erb-d93d4775-8175-4fca-bee2-321836b37444"
    }
},
{
    "pk": 5199, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "A single report claimed that selective BRAF inhibition decreases tumor-resident lymphocyte frequenci", 
        "paper": 1, 
        "tag_id": "erb-b60705c7-35fa-47f0-b063-6cdb5ad6feb6"
    }
},
{
    "pk": 5200, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "The latest reported analysis of biopsies taken before and after treatment with BRAF or BRAF+MEK inhi", 
        "paper": 1, 
        "tag_id": "erb-1f0f9f9b-f0f4-4011-9064-2fffbd023970"
    }
},
{
    "pk": 5201, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Adoptive cell transfer therapy and targeted therapies. Adoptive cell transfer therapy could also be ", 
        "paper": 1, 
        "tag_id": "erb-ddca8f46-e0d5-4740-8392-9a9c4a547446"
    }
},
{
    "pk": 5202, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "An in vitro study analyzed effects of BRAF and MEK inhibition on function of dendritic cells (DC) in", 
        "paper": 1, 
        "tag_id": "erb-a533c539-5734-43a3-8ce8-c725f6243f82"
    }
},
{
    "pk": 5203, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Another in vitro study examined how vemurafenib affects the ability of the TILs to recognize autolog", 
        "paper": 1, 
        "tag_id": "erb-71e6a9bb-45b4-4a8a-8623-42e6ba355d06"
    }
},
{
    "pk": 5204, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "These studies in general provide a strong rationale for combination therapies involving BRAF inhibit", 
        "paper": 1, 
        "tag_id": "erb-1ae76afc-a762-402d-b1f9-6a7b5c77b56a"
    }
},
{
    "pk": 5205, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Mutant BRAF and/or its inhibition are not expected to influence outcomes of all immune therapies. Fo", 
        "paper": 1, 
        "tag_id": "erb-a34486fe-9657-4c79-be5c-2db30d2eac9c"
    }
},
{
    "pk": 5206, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Other melanoma-related pathways might also play a role in responses to immune therapy. Wnt/\uf062-catenin", 
        "paper": 1, 
        "tag_id": "erb-4a58fbb8-e0ac-4065-8444-937c6ebd1f5a"
    }
},
{
    "pk": 5207, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Tumor microenvironment and immune responses", 
        "paper": 1, 
        "tag_id": "erb-9e5fa267-5536-4272-afab-a0f70b61f4af"
    }
},
{
    "pk": 5208, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "The role of B cells in immune responses in melanoma. An extensive study measured humoral B-cell resp", 
        "paper": 1, 
        "tag_id": "erb-b010b7df-1b63-4db6-a4d5-1eca0d83ff32"
    }
},
{
    "pk": 5209, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Intratumoral IgG-producing B cells have been reported in melanoma, but their functional significance", 
        "paper": 1, 
        "tag_id": "erb-72aa5aad-00c5-42f8-bf01-d0f48af633eb"
    }
},
{
    "pk": 5210, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Immune cell infiltrates in melanoma. The presence of lymph node\u2013like structures in solid tumors has ", 
        "paper": 1, 
        "tag_id": "erb-0f97d5b8-b866-46e9-ac51-a7dedd30b3c7"
    }
},
{
    "pk": 5211, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "There have been few attempts to target melanoma metabolism with the exception of several known metab", 
        "paper": 1, 
        "tag_id": "erb-33c355e4-ef04-4f7a-85e9-34a94a20a7d9"
    }
},
{
    "pk": 5212, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Regarding the possible effects of metabolic preferences of melanoma tumors on the efficacy of target", 
        "paper": 1, 
        "tag_id": "erb-447034fc-cd27-4330-87c7-c5f752c220ad"
    }
},
{
    "pk": 5213, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "The importance of OXPHOS in melanoma resistance to chemotherapy and targeted therapy with vemurafeni", 
        "paper": 1, 
        "tag_id": "erb-5e880437-3022-4da2-a887-a1d3b7115a11"
    }
},
{
    "pk": 5214, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "A most interesting study implicated enzyme PDH (pyruvate dehydrogenase) that links glycolysis to OXP", 
        "paper": 1, 
        "tag_id": "erb-f89548f4-aba3-48ca-8169-8625542bb4fa"
    }
},
{
    "pk": 5215, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "The role of autophagy in tumor development and responses to various treatments remains controversial", 
        "paper": 1, 
        "tag_id": "erb-bc881a70-2dd3-457f-8d83-e2e8256a39d7"
    }
},
{
    "pk": 5216, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Arginine deprivation. Melanoma tumors, along with hepatocellular cancer (HCC) and prostate cancer, f", 
        "paper": 1, 
        "tag_id": "erb-3f5d0737-9b6f-40ea-8122-11a937664de1"
    }
},
{
    "pk": 5217, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Leucine deprivation. Leucine deprivation was also shown to induce apoptotic death in melanoma cells;", 
        "paper": 1, 
        "tag_id": "erb-4794f5f7-0758-4076-8216-71aca2855ef4"
    }
},
{
    "pk": 5218, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Autophagy is a potential target in melanoma. However, drug-induced autophagy could be either suicida", 
        "paper": 1, 
        "tag_id": "erb-891c8456-a442-4f89-a13b-f79243413169"
    }
},
{
    "pk": 5219, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Because autophagy is known to be involved in both innate and adaptive immunity, there is an interest", 
        "paper": 1, 
        "tag_id": "erb-f9d47759-2999-4d78-935e-e46e59cbf50c"
    }
},
{
    "pk": 5220, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Circulating melanoma cells", 
        "paper": 1, 
        "tag_id": "erb-80d4f2bb-ff03-4118-aa2d-7fde5e33686b"
    }
},
{
    "pk": 5221, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Detection of circulating tumor cells (CTCs) in melanoma was explored for at least last 20 years. CTC", 
        "paper": 1, 
        "tag_id": "erb-b4b9e3a2-f78c-44fd-8289-fa9e123c7f0d"
    }
},
{
    "pk": 5222, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "The earlier attempts were directed mostly toward developing a multimarker RT-PCR to detect and monit", 
        "paper": 1, 
        "tag_id": "erb-bed9f8de-beee-4365-bf99-f1947df31ea2"
    }
},
{
    "pk": 5223, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "A different approach involves physical separation of CTCs prior to their analyses. This methodology ", 
        "paper": 1, 
        "tag_id": "erb-4ac26528-5080-430c-8c11-d5b01154e407"
    }
},
{
    "pk": 5224, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "New techniques are being developed, such as isolation by size of epithelial tumor cells (ISET), whic", 
        "paper": 1, 
        "tag_id": "erb-de755a6a-9d18-48f1-8810-defa60f12afc"
    }
},
{
    "pk": 5225, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "The inertial focusing\u2013enhanced microfluidic CTC capture platform, termed \"CTC-iChip\" is capable of r", 
        "paper": 1, 
        "tag_id": "erb-496068ba-a62c-4dc6-9bd3-cbc8b25be804"
    }
},
{
    "pk": 5226, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Molecular profiling of CTC might provide a very valuable representation of a tumor(s) genotype becau", 
        "paper": 1, 
        "tag_id": "erb-6d11fbb6-dd5a-469d-bcd3-ae960234da18"
    }
},
{
    "pk": 5227, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Several clinical trials are ongoing that incorporate CTC detection and analyses prior to and after t", 
        "paper": 1, 
        "tag_id": "erb-2206afcf-8a8a-440f-81f7-0098dc2e7978"
    }
},
{
    "pk": 5228, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Recent studies have addressed the utility of yet another method of \u201cliquid biopsy\u201d, i.e., analysis o", 
        "paper": 1, 
        "tag_id": "erb-6f085264-f9c6-4f9a-b1d4-4c508e96dd1f"
    }
},
{
    "pk": 5229, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Prognostic test for uveal melanoma", 
        "paper": 1, 
        "tag_id": "erb-0c2fc190-4628-4b95-be92-845e47352fa7"
    }
},
{
    "pk": 5230, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Uveal melanoma is a distinct type of melanoma with a clinical course and molecular landscape of its ", 
        "paper": 1, 
        "tag_id": "erb-b8c9e674-e95d-4fd5-bfa2-6851948b51c2"
    }
},
{
    "pk": 5231, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "DecisionDx-UM gene expression profile test was developed as a stand-alone platform, which requires n", 
        "paper": 1, 
        "tag_id": "erb-1e802947-777d-4460-99ce-b6ed29135c37"
    }
},
{
    "pk": 5232, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Exosomes", 
        "paper": 1, 
        "tag_id": "erb-80c936fe-5fde-494d-99fc-714433ddb4e5"
    }
},
{
    "pk": 5233, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Exosomes are small membrane vesicles with an endosome origin that are released by cells into the ext", 
        "paper": 1, 
        "tag_id": "erb-da65341e-cc5c-4f3c-a483-3ce0f6951478"
    }
},
{
    "pk": 5234, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "It is very likely, considering the most recent findings, that the majority of driver mutations in me", 
        "paper": 1, 
        "tag_id": "erb-cb458123-a2bf-4659-9946-77dc75648377"
    }
},
{
    "pk": 5235, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "However, the accumulated knowledge is already sufficient to concentrate on the biological significan", 
        "paper": 1, 
        "tag_id": "erb-f1b3b2b2-1962-48b6-9516-54342ef24974"
    }
},
{
    "pk": 5236, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "The ubiquitous problem of resistance to targeted therapies could only be addressed by dedicated prof", 
        "paper": 1, 
        "tag_id": "erb-a4064fad-042b-4ed3-97a5-5b49408d96dc"
    }
},
{
    "pk": 5237, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 1. Berger MF, Hodis E, Heffernan TP, et al: Melanoma genome sequencing reveals frequent PREX2 mutat", 
        "paper": 1, 
        "tag_id": "erb-73646092-f2ac-4dc3-910c-12f1eff08f57"
    }
},
{
    "pk": 5238, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 2. Furney SJ, Pedersen M, Gentien D, et al: SF3B1 mutations are associated with alternative splicin", 
        "paper": 1, 
        "tag_id": "erb-4efe4637-1e4a-40b5-96c6-6c58b70c757f"
    }
},
{
    "pk": 5239, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 3. Mar VJ, Wong SQ, Li J, et al: BRAF/NRAS wild-type melanomas have a high mutation load correlatin", 
        "paper": 1, 
        "tag_id": "erb-0ee5630d-5381-4372-9457-14f1d484faf5"
    }
},
{
    "pk": 5240, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 4. Furney SJ, Turajlic S, Stamp G, et al: Genome sequencing of mucosal melanomas reveals that they ", 
        "paper": 1, 
        "tag_id": "erb-f368c064-0f6a-458a-bca5-19da9d781e8e"
    }
},
{
    "pk": 5241, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 5. Griewank KG, Westekemper H, Murali R, et al: Conjunctival Melanomas Harbor BRAF and NRAS Mutatio", 
        "paper": 1, 
        "tag_id": "erb-d65ed2aa-0a0e-4e4b-b79e-2ede1fd95596"
    }
},
{
    "pk": 5242, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 6. Pollock PM, Harper UL, Hansen KS, et al: High frequency of BRAF mutations in nevi. Nat Genet 33:", 
        "paper": 1, 
        "tag_id": "erb-8dcccb66-880c-44c6-9948-a560bc0035af"
    }
},
{
    "pk": 5243, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 7. Michaloglou C, Vredeveld LC, Soengas MS, et al: BRAFE600-associated senescence-like cell cycle a", 
        "paper": 1, 
        "tag_id": "erb-74c90f21-654d-4f20-93c1-25710f53e232"
    }
},
{
    "pk": 5244, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 8. Flaherty KT, Hodi FS, Fisher DE: From genes to drugs: targeted strategies for melanoma. Nat Rev ", 
        "paper": 1, 
        "tag_id": "erb-038e7927-04c7-4e58-9c27-4155f9c3a2e1"
    }
},
{
    "pk": 5245, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 9. Flaherty KT, Puzanov I, Kim KB, et al: Inhibition of mutated, activated BRAF in metastatic melan", 
        "paper": 1, 
        "tag_id": "erb-9b09687c-a7e1-4f0f-890a-173c74a7d8b6"
    }
},
{
    "pk": 5246, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 10. Jordan EJ, Kelly CM: Vemurafenib for the treatment of melanoma. Expert Opin Pharmacother 13:253", 
        "paper": 1, 
        "tag_id": "erb-a4574180-ccf3-4e31-b506-ac50c2cd775b"
    }
},
{
    "pk": 5247, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 11. Alloo A, Garibyan L, LeBoeuf N, et al: Photodynamic therapy for multiple eruptive keratoacantho", 
        "paper": 1, 
        "tag_id": "erb-23ad11c9-2641-4281-81d5-ab7f6186151a"
    }
},
{
    "pk": 5248, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 12. Callahan MK, Rampal R, Harding JJ, et al: Progression of RAS-mutant leukemia during RAF inhibit", 
        "paper": 1, 
        "tag_id": "erb-73c6bfd9-8cd3-43e6-8edc-0f3ee6eed610"
    }
},
{
    "pk": 5249, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 13. Gibney GT, Messina JL, Fedorenko IV, et al: Paradoxical oncogenesis-the long-term effects of BR", 
        "paper": 1, 
        "tag_id": "erb-efdc0a24-1250-4590-ba2d-298181a239d9"
    }
},
{
    "pk": 5250, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 14. Poulikakos PI, Zhang C, Bollag G, et al: RAF inhibitors transactivate RAF dimers and ERK signal", 
        "paper": 1, 
        "tag_id": "erb-3b4ef4df-7fec-4390-b2de-1cdae26f3125"
    }
},
{
    "pk": 5251, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 15. Dalle S, Poulalhon N, Debarbieux S, et al: Second primary melanomas under vemurafenib. Br J Der", 
        "paper": 1, 
        "tag_id": "erb-9e1b6d68-24ef-44f1-b30b-a75545e7fdcd"
    }
},
{
    "pk": 5252, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 16. Zimmer L, Hillen U, Livingstone E, et al: Atypical melanocytic proliferations and new primary m", 
        "paper": 1, 
        "tag_id": "erb-430d351e-8e60-4295-917f-c357f4345149"
    }
},
{
    "pk": 5253, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 17. Holderfield M, Merritt H, Chan J, et al: RAF Inhibitors Activate the MAPK Pathway by Relieving ", 
        "paper": 1, 
        "tag_id": "erb-3c74447f-1421-44da-a1e4-78a9d8f1d150"
    }
},
{
    "pk": 5254, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 18. Ascierto PA, Minor D, Ribas A, et al: Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib", 
        "paper": 1, 
        "tag_id": "erb-3c24d781-9f07-406d-a8c0-e23bd84308ef"
    }
},
{
    "pk": 5255, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 19. Le K, Blomain E, Rodeck U, et al: Selective RAF inhibitor impairs ERK1/2 phosphorylation and gr", 
        "paper": 1, 
        "tag_id": "erb-78cd1359-40cc-451f-aa4d-1a99e6c3fe37"
    }
},
{
    "pk": 5256, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 20. Das Thakur M, Salangsang F, Landman AS, et al: Modelling vemurafenib resistance in melanoma rev", 
        "paper": 1, 
        "tag_id": "erb-b7d170c5-26de-47e8-bab5-42a2c2328968"
    }
},
{
    "pk": 5257, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 21. Falchook GS, Lewis KD, Infante JR, et al: Activity of the oral MEK inhibitor trametinib in pati", 
        "paper": 1, 
        "tag_id": "erb-10db8e22-e42e-46c4-8ad4-99d795928f96"
    }
},
{
    "pk": 5258, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 22. Flaherty KT, Robert C, Hersey P, et al: Improved survival with MEK inhibition in BRAF-mutated m", 
        "paper": 1, 
        "tag_id": "erb-eb7496c4-0c77-414b-8abe-34d9c3344585"
    }
},
{
    "pk": 5259, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 23. Robert C, Dummer R, Gutzmer R, et al: Selumetinib plus dacarbazine versus placebo plus dacarbaz", 
        "paper": 1, 
        "tag_id": "erb-3f441d65-68dc-43e3-a591-f34caf2cb5fd"
    }
},
{
    "pk": 5260, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 24. Kim KB, Kefford R, Pavlick AC, et al: Phase II study of the MEK1/MEK2 inhibitor Trametinib in p", 
        "paper": 1, 
        "tag_id": "erb-4722f853-cf86-4f82-aa2b-68383ea8e20e"
    }
},
{
    "pk": 5261, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 25. Flaherty KT, Infante JR, Daud A, et al: Combined BRAF and MEK inhibition in melanoma with BRAF ", 
        "paper": 1, 
        "tag_id": "erb-34e2d298-5986-461f-97bc-0f0976fe98ee"
    }
},
{
    "pk": 5262, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 26. Morris EJ, Jha S, Restaino CR, et al: Discovery of a Novel ERK Inhibitor with Activity in Model", 
        "paper": 1, 
        "tag_id": "erb-fd5644b7-f6de-40d4-847e-3fb4739726e7"
    }
},
{
    "pk": 5263, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 27. Davies H, Bignell GR, Cox C, et al: Mutations of the BRAF gene in human cancer. Nature 417:949-", 
        "paper": 1, 
        "tag_id": "erb-5d02526c-8128-4788-b626-5227940b24d9"
    }
},
{
    "pk": 5264, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 28. Wan PT, Garnett MJ, Roe SM, et al: Mechanism of activation of the RAF-ERK signaling pathway by ", 
        "paper": 1, 
        "tag_id": "erb-79600a8d-8512-46ea-aa23-27a4724dc3b7"
    }
},
{
    "pk": 5265, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 29. Smalley KS, Xiao M, Villanueva J, et al: CRAF inhibition induces apoptosis in melanoma cells wi", 
        "paper": 1, 
        "tag_id": "erb-0e974191-c9a7-4ecf-978b-b5cca36b386c"
    }
},
{
    "pk": 5266, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 30. Dahlman KB, Xia J, Hutchinson K, et al: BRAF(L597) mutations in melanoma are associated with se", 
        "paper": 1, 
        "tag_id": "erb-7da91038-5f0d-4696-9fe4-403616258bc2"
    }
},
{
    "pk": 5267, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 31. Hodis E, Watson IR, Kryukov GV, et al: A landscape of driver mutations in melanoma. Cell 150:25", 
        "paper": 1, 
        "tag_id": "erb-65502735-af42-41df-87ba-4a3bbfd58111"
    }
},
{
    "pk": 5268, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 32. Ascierto PA, Schadendorf D, Berking C, et al: MEK162 for patients with advanced melanoma harbou", 
        "paper": 1, 
        "tag_id": "erb-7c59bfb9-bf3d-4fd0-b4ca-a6862ccab26b"
    }
},
{
    "pk": 5269, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 33. Hatzivassiliou G, Haling JR, Chen H, et al: Mechanism of MEK inhibition determines efficacy in ", 
        "paper": 1, 
        "tag_id": "erb-5e991bf0-1150-4cc7-8320-575a2b31dd20"
    }
},
{
    "pk": 5270, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 34. Roberts PJ, Usary JE, Darr DB, et al: Combined PI3K/mTOR and MEK inhibition provides broad anti", 
        "paper": 1, 
        "tag_id": "erb-c1e4b4bb-0d93-46bc-b353-0f261c7a3fb6"
    }
},
{
    "pk": 5271, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 35. Posch C, Moslehi H, Feeney L, et al: Combined targeting of MEK and PI3K/mTOR effector pathways ", 
        "paper": 1, 
        "tag_id": "erb-d16dd82d-7f24-41bb-acca-ac2ab502659d"
    }
},
{
    "pk": 5272, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 36. Kwong LN, Costello JC, Liu H, et al: Oncogenic NRAS signaling differentially regulates survival", 
        "paper": 1, 
        "tag_id": "erb-31866a57-9297-4248-8ba5-7ee81f7edca8"
    }
},
{
    "pk": 5273, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 37. Barretina J, Caponigro G, Stransky N, et al: The Cancer Cell Line Encyclopedia enables predicti", 
        "paper": 1, 
        "tag_id": "erb-d89cca62-202d-46f5-890c-c3e82015e3a7"
    }
},
{
    "pk": 5274, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 38. Held MA, Langdon CG, Platt JT, et al: Genotype-selective combination therapies for melanoma ide", 
        "paper": 1, 
        "tag_id": "erb-ae1293ce-5982-4c29-90b2-ac7691c6dc03"
    }
},
{
    "pk": 5275, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 39. Van Raamsdonk CD, Bezrookove V, Green G, et al: Frequent somatic mutations of GNAQ in uveal mel", 
        "paper": 1, 
        "tag_id": "erb-0666972a-5743-4da4-9e04-c81fab0e3ada"
    }
},
{
    "pk": 5276, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 40. Van Raamsdonk CD, Griewank KG, Crosby MB, et al: Mutations in GNA11 in uveal melanoma. N Engl J", 
        "paper": 1, 
        "tag_id": "erb-319e21ae-2ea0-44be-9f30-e469d83155b8"
    }
},
{
    "pk": 5277, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 41. Daniels AB, Lee JE, MacConaill LE, et al: High throughput mass spectrometry-based mutation prof", 
        "paper": 1, 
        "tag_id": "erb-0d2f20b9-a85e-4aa0-a51a-2c81cea74bb6"
    }
},
{
    "pk": 5278, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 42. Ho AL, Musi E, Ambrosini G, et al: Impact of combined mTOR and MEK inhibition in uveal melanoma", 
        "paper": 1, 
        "tag_id": "erb-61345bdb-25b2-4899-a3d7-36f6f4b5a292"
    }
},
{
    "pk": 5279, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 43. Khalili JS, Yu X, Wang J, et al: Combination small molecule MEK and PI3K inhibition enhances uv", 
        "paper": 1, 
        "tag_id": "erb-0cc1a925-7daa-41c6-b139-f1fa3533c769"
    }
},
{
    "pk": 5280, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 44. Wu X, Li J, Zhu M, et al: Protein kinase C inhibitor AEB071 targets ocular melanoma harboring G", 
        "paper": 1, 
        "tag_id": "erb-93017992-4d55-4f58-a50d-a7c04c7f9fa4"
    }
},
{
    "pk": 5281, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 45. Wu X, Zhu M, Fletcher JA, et al: The protein kinase C inhibitor enzastaurin exhibits antitumor ", 
        "paper": 1, 
        "tag_id": "erb-60583a8a-31b7-43a8-920d-80ef90e9f11b"
    }
},
{
    "pk": 5282, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 46. Vaque JP, Dorsam RT, Feng X, et al: A Genome-wide RNAi Screen Reveals a Trio-Regulated Rho GTPa", 
        "paper": 1, 
        "tag_id": "erb-048f5b64-f3d1-40c9-804a-2607603d711e"
    }
},
{
    "pk": 5283, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 47. Garraway LA, Widlund HR, Rubin MA, et al: Integrative genomic analyses identify MITF as a linea", 
        "paper": 1, 
        "tag_id": "erb-cd79a28c-cb82-4e07-8df8-3174de2c9c81"
    }
},
{
    "pk": 5284, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 48. Yokoyama S, Woods SL, Boyle GM, et al: A novel recurrent mutation in MITF predisposes to famili", 
        "paper": 1, 
        "tag_id": "erb-b9d3b322-da68-4a7d-a1f5-1d2749f6dc60"
    }
},
{
    "pk": 5285, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 49. Du J, Widlund HR, Horstmann MA, et al: Critical role of CDK2 for melanoma growth linked to its ", 
        "paper": 1, 
        "tag_id": "erb-5a764182-3164-407e-a902-58c159316eb2"
    }
},
{
    "pk": 5286, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 50. Zhu S, Wurdak H, Wang Y, et al: A genomic screen identifies TYRO3 as a MITF regulator in melano", 
        "paper": 1, 
        "tag_id": "erb-21ed2af7-679a-4b06-8023-dabdfc6d7041"
    }
},
{
    "pk": 5287, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 51. Zhao X, Fiske B, Kawakami A, et al: Regulation of MITF stability by the USP13 deubiquitinase. N", 
        "paper": 1, 
        "tag_id": "erb-fd84ecb9-2074-45e4-893d-ab24f8992dd9"
    }
},
{
    "pk": 5288, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 52. Busca R, Berra E, Gaggioli C, et al: Hypoxia-inducible factor 1{alpha} is a new target of micro", 
        "paper": 1, 
        "tag_id": "erb-f1599830-287e-428f-a258-0778e655ac26"
    }
},
{
    "pk": 5289, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 53. Feige E, Yokoyama S, Levy C, et al: Hypoxia-induced transcriptional repression of the melanoma-", 
        "paper": 1, 
        "tag_id": "erb-e6a6cfe9-f2a4-4d8d-8436-8dc25fd47083"
    }
},
{
    "pk": 5290, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 54. Hanna SC, Krishnan B, Bailey ST, et al: HIF1alpha and HIF2alpha independently activate SRC to p", 
        "paper": 1, 
        "tag_id": "erb-ddacf685-43f3-48af-9d51-ddf4e9ddfcdb"
    }
},
{
    "pk": 5291, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 55. Shah M, Bhoumik A, Goel V, et al: A role for ATF2 in regulating MITF and melanoma development. ", 
        "paper": 1, 
        "tag_id": "erb-998c0128-d28e-4813-baea-e690d9e8219d"
    }
},
{
    "pk": 5292, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 56. Shakhova O, Zingg D, Schaefer SM, et al: Sox10 promotes the formation and maintenance of giant ", 
        "paper": 1, 
        "tag_id": "erb-518c4294-ffce-415b-8f06-adc12bf320cd"
    }
},
{
    "pk": 5293, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 57. Puri N, Ahmed S, Janamanchi V, et al: c-Met is a potentially new therapeutic target for treatme", 
        "paper": 1, 
        "tag_id": "erb-e4dafdf8-1356-42b5-bbed-1562b630fbbb"
    }
},
{
    "pk": 5294, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 58. Mascarenhas JB, Littlejohn EL, Wolsky RJ, et al: PAX3 and SOX10 activate MET receptor expressio", 
        "paper": 1, 
        "tag_id": "erb-91b71680-1154-4091-9811-a1ad26515c4e"
    }
},
{
    "pk": 5295, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 59. Vazquez F, Lim JH, Chim H, et al: PGC1alpha Expression Defines a Subset of Human Melanoma Tumor", 
        "paper": 1, 
        "tag_id": "erb-0ef07ee6-9630-4a95-906a-e2538df8fb53"
    }
},
{
    "pk": 5296, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 60. Shoag J, Haq R, Zhang M, et al: PGC-1 Coactivators Regulate MITF and the Tanning Response. Mol ", 
        "paper": 1, 
        "tag_id": "erb-2b47fc23-88e4-4ebd-b7a5-8bb24c601adf"
    }
},
{
    "pk": 5297, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 61. Haq R, Yokoyama S, Hawryluk EB, et al: BCL2A1 is a lineage-specific antiapoptotic melanoma onco", 
        "paper": 1, 
        "tag_id": "erb-2bdd949c-67a1-4d55-8ce0-4d7562892fb2"
    }
},
{
    "pk": 5298, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 62. Saez-Ayala M, Montenegro MF, Sanchez-Del-Campo L, et al: Directed Phenotype Switching as an Eff", 
        "paper": 1, 
        "tag_id": "erb-febbcb7d-a424-44e9-b3f5-05bad6595e46"
    }
},
{
    "pk": 5299, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 63. Pogenberg V, Ogmundsdottir MH, Bergsteinsdottir K, et al: Restricted leucine zipper dimerizatio", 
        "paper": 1, 
        "tag_id": "erb-078dbbe8-ce44-4cd3-ba89-6518e611ec78"
    }
},
{
    "pk": 5300, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 64. Yokoyama S, Feige E, Poling LL, et al: Pharmacologic suppression of MITF expression via HDAC in", 
        "paper": 1, 
        "tag_id": "erb-9f929e08-a8f5-4b55-8e95-5166d0b75441"
    }
},
{
    "pk": 5301, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 65. Varsano T, Lau E, Feng Y, et al: Inhibition of Melanoma Growth by Small Molecules That Promote ", 
        "paper": 1, 
        "tag_id": "erb-18f014e1-6a3c-44fc-9739-5ec3f4eab556"
    }
},
{
    "pk": 5302, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 66. Curtin JA, Busam K, Pinkel D, et al: Somatic activation of KIT in distinct subtypes of melanoma", 
        "paper": 1, 
        "tag_id": "erb-eef0da20-5e6f-4a50-ba0b-f8ac667f45ec"
    }
},
{
    "pk": 5303, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 67. Woodman SE, Davies MA: Targeting KIT in melanoma: a paradigm of molecular medicine and targeted", 
        "paper": 1, 
        "tag_id": "erb-85169388-fd88-4009-aa2e-d3544d77d2dc"
    }
},
{
    "pk": 5304, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 68. Kim KB, Eton O, Davis DW, et al: Phase II trial of imatinib mesylate in patients with metastati", 
        "paper": 1, 
        "tag_id": "erb-ba2b5134-c57d-49c1-b1c1-c32d459d958c"
    }
},
{
    "pk": 5305, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 69. Penel N, Delcambre C, Durando X, et al: O-Mel-Inib: a Cancero-pole Nord-Ouest multicenter phase", 
        "paper": 1, 
        "tag_id": "erb-0f1fc750-a935-47ca-91da-27d9457ea0dc"
    }
},
{
    "pk": 5306, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 70. Wyman K, Atkins MB, Prieto V, et al: Multicenter Phase II trial of high-dose imatinib mesylate ", 
        "paper": 1, 
        "tag_id": "erb-28d72d9b-e623-4625-a7ba-76f0e80cc95f"
    }
},
{
    "pk": 5307, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 71. Kluger HM, Dudek AZ, McCann C, et al: A phase 2 trial of dasatinib in advanced melanoma. Cancer", 
        "paper": 1, 
        "tag_id": "erb-1fe66e75-cd57-41f4-8cb1-e1cec536c9d7"
    }
},
{
    "pk": 5308, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 72. Lutzky J, Bauer J, Bastian BC: Dose-dependent, complete response to imatinib of a metastatic mu", 
        "paper": 1, 
        "tag_id": "erb-4bf2cfec-8372-4cdb-aee2-ecaae6cd9d79"
    }
},
{
    "pk": 5309, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 73. Hodi FS, Friedlander P, Corless CL, et al: Major response to imatinib mesylate in KIT-mutated m", 
        "paper": 1, 
        "tag_id": "erb-0c1ebd14-bdc2-4149-bffc-65edcb8e9b1c"
    }
},
{
    "pk": 5310, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 74. Woodman SE, Trent JC, Stemke-Hale K, et al: Activity of dasatinib against L576P KIT mutant mela", 
        "paper": 1, 
        "tag_id": "erb-a1fcd05d-57ce-4276-a740-bea7080bcdc9"
    }
},
{
    "pk": 5311, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 75. Hofmann UB, Kauczok-Vetter CS, Houben R, et al: Overexpression of the KIT/SCF in uveal melanoma", 
        "paper": 1, 
        "tag_id": "erb-1f4a61b3-0341-41b6-adcb-1202b2bf9125"
    }
},
{
    "pk": 5312, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 76. Mahipal A, Tijani L, Chan K, et al: A pilot study of sunitinib malate in patients with metastat", 
        "paper": 1, 
        "tag_id": "erb-64dae639-4b49-4ae9-9281-a80bf490ba71"
    }
},
{
    "pk": 5313, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 77. Guo J, Si L, Kong Y, et al: Phase II, open-label, single-arm trial of imatinib mesylate in pati", 
        "paper": 1, 
        "tag_id": "erb-24d50dfd-4cc2-4696-bccb-3f99ba961d51"
    }
},
{
    "pk": 5314, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 78. Carvajal RD, Antonescu CR, Wolchok JD, et al: KIT as a therapeutic target in metastatic melanom", 
        "paper": 1, 
        "tag_id": "erb-1c633e18-c66a-44b1-9355-7c7b14172678"
    }
},
{
    "pk": 5315, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 79. Minor DR, Kashani-Sabet M, Garrido M, et al: Sunitinib therapy for melanoma patients with KIT m", 
        "paper": 1, 
        "tag_id": "erb-990480f3-f5f5-455b-8b95-652b0df6698c"
    }
},
{
    "pk": 5316, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 80. Cho JH, Kim KM, Kwon M, et al: Nilotinib in patients with metastatic melanoma harboring KIT gen", 
        "paper": 1, 
        "tag_id": "erb-717932c4-e448-4bb1-9f10-a9fba9fe79b2"
    }
},
{
    "pk": 5317, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 81. Hodi FS, Corless CL, Giobbie-Hurder A, et al: Imatinib for Melanomas Harboring Mutationally Act", 
        "paper": 1, 
        "tag_id": "erb-3df519ba-b4b0-48b5-a54e-42ca908e7986"
    }
},
{
    "pk": 5318, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 82. Carvajal RD: Another Option in Our KIT of Effective Therapies for Advanced Melanoma. J Clin Onc", 
        "paper": 1, 
        "tag_id": "erb-5f8c212c-f227-41e0-8359-63d90686a775"
    }
},
{
    "pk": 5319, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 83. Johnson MR, Look AT, DeClue JE, et al: Inactivation of the NF1 gene in human melanoma and neuro", 
        "paper": 1, 
        "tag_id": "erb-2041a9de-d0ed-4ef2-a679-62aede4196f2"
    }
},
{
    "pk": 5320, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 84. Gutzmer R, Herbst RA, Mommert S, et al: Allelic loss at the neurofibromatosis type 1 (NF1) gene", 
        "paper": 1, 
        "tag_id": "erb-bb05c2be-a9be-4201-9e42-d19c4c27d55f"
    }
},
{
    "pk": 5321, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 85. Maertens O, Johnson B, Hollstein P, et al: Elucidating distinct roles for NF1 in melanomagenesi", 
        "paper": 1, 
        "tag_id": "erb-36bdd25f-5fb0-4865-a595-3f798aa4578e"
    }
},
{
    "pk": 5322, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 86. Whittaker SR, Theurillat JP, Van Allen E, et al: A genome-scale RNA interference screen implica", 
        "paper": 1, 
        "tag_id": "erb-08f22c73-2105-47b7-8e07-08fe34ef8788"
    }
},
{
    "pk": 5323, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 87. Horn S, Figl A, Rachakonda PS, et al: TERT Promoter Mutations in Familial and Sporadic Melanoma", 
        "paper": 1, 
        "tag_id": "erb-7a4c487c-b59a-418f-8ff5-0be53b2e37c8"
    }
},
{
    "pk": 5324, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 88. Huang FW, Hodis E, Xu MJ, et al: Highly Recurrent TERT Promoter Mutations in Human Melanoma. Sc", 
        "paper": 1, 
        "tag_id": "erb-4964f7e5-060b-4700-aac2-0c320326632d"
    }
},
{
    "pk": 5325, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 89. Dankort D, Curley DP, Cartlidge RA, et al: Braf(V600E) cooperates with Pten loss to induce meta", 
        "paper": 1, 
        "tag_id": "erb-209e5cc7-8f1e-456d-9e13-c408e7fbdeed"
    }
},
{
    "pk": 5326, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 90. Vredeveld LC, Possik PA, Smit MA, et al: Abrogation of BRAFV600E-induced senescence by PI3K pat", 
        "paper": 1, 
        "tag_id": "erb-08e50dcf-778b-405e-8adb-5e811d8d78f9"
    }
},
{
    "pk": 5327, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 91. Prickett TD, Agrawal NS, Wei X, et al: Analysis of the tyrosine kinome in melanoma reveals recu", 
        "paper": 1, 
        "tag_id": "erb-9cacb264-2e85-4698-83de-0c4d3eaafba8"
    }
},
{
    "pk": 5328, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 92. Dutton-Regester K, Irwin D, Hunt P, et al: A high-throughput panel for identifying clinically r", 
        "paper": 1, 
        "tag_id": "erb-b6a0797d-ae97-4fb4-8bad-91f5007778dd"
    }
},
{
    "pk": 5329, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 93. Zhou QM, Li W, Guan YX, et al: The absence of the ERBB4 hotspot mutations in melanomas in patie", 
        "paper": 1, 
        "tag_id": "erb-c02b590f-22ef-472a-ace7-19f7c95e3b99"
    }
},
{
    "pk": 5330, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 94. Moore SR, Persons DL, Sosman JA, et al: Detection of copy number alterations in metastatic mela", 
        "paper": 1, 
        "tag_id": "erb-de3221fe-9767-480e-9cad-16bf490dc7df"
    }
},
{
    "pk": 5331, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 95. Kenessey I, Keszthelyi M, Kramer Z, et al: Inhibition of c-Met with the specific small molecule", 
        "paper": 1, 
        "tag_id": "erb-efd4a6b3-d096-4136-974d-2427f84e6ef1"
    }
},
{
    "pk": 5332, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 96. Schlegel J, Sambade MJ, Sather S, et al: MERTK receptor tyrosine kinase is a therapeutic target", 
        "paper": 1, 
        "tag_id": "erb-82b6655c-201a-416a-bc14-b492a08b5f62"
    }
},
{
    "pk": 5333, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 97. Tworkoski KA, Platt JT, Bacchiocchi A, et al: MERTK controls melanoma cell migration and surviv", 
        "paper": 1, 
        "tag_id": "erb-3bf26777-dcf1-43cb-9528-030dbb204912"
    }
},
{
    "pk": 5334, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 98. Stahl JM, Sharma A, Cheung M, et al: Deregulated Akt3 activity promotes development of malignan", 
        "paper": 1, 
        "tag_id": "erb-e7b7d16a-7502-48a6-9190-774fd47da373"
    }
},
{
    "pk": 5335, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 99. Davies MA, Stemke-Hale K, Tellez C, et al: A novel AKT3 mutation in melanoma tumours and cell l", 
        "paper": 1, 
        "tag_id": "erb-d783ea6b-4303-471e-89cb-9850e677cc01"
    }
},
{
    "pk": 5336, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 100. Cheung M, Sharma A, Madhunapantula SV, et al: Akt3 and mutant V600E B-Raf cooperate to promote", 
        "paper": 1, 
        "tag_id": "erb-b273c0ec-ca04-4588-b325-28399a97d03d"
    }
},
{
    "pk": 5337, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 101. Tsao H, Zhang X, Benoit E, et al: Identification of PTEN/MMAC1 alterations in uncultured melan", 
        "paper": 1, 
        "tag_id": "erb-96c96f29-dd2b-4b8d-8759-5599ff12a630"
    }
},
{
    "pk": 5338, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 102. Karreth FA, Tay Y, Perna D, et al: In vivo identification of tumor- suppressive PTEN ceRNAs in", 
        "paper": 1, 
        "tag_id": "erb-3f769a1d-c6a7-4ebe-a32a-a149218bbff2"
    }
},
{
    "pk": 5339, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 103. Nathanson KL, Martin AM, Wubbenhorst B, et al: Tumor genetic analyses of patients with metasta", 
        "paper": 1, 
        "tag_id": "erb-98ed74d5-2668-48f2-bca7-e9c78c0c0eb4"
    }
},
{
    "pk": 5340, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 104. Cao J, Wan L, Hacker E, et al: MC1R Is a Potent Regulator of PTEN after UV Exposure in Melanoc", 
        "paper": 1, 
        "tag_id": "erb-e435e36e-77e1-43d2-9ddc-9becfbb4afc1"
    }
},
{
    "pk": 5341, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 105. Shull AY, Latham-Schwark A, Ramasamy P, et al: Novel somatic mutations to PI3K pathway genes i", 
        "paper": 1, 
        "tag_id": "erb-2cd5fd0a-8400-43c8-af62-3570ba9ee5aa"
    }
},
{
    "pk": 5342, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 106. Nikolaev SI, Rimoldi D, Iseli C, et al: Exome sequencing identifies recurrent somatic MAP2K1 a", 
        "paper": 1, 
        "tag_id": "erb-a0fe05da-2991-47d5-91da-ed6bcb0a44f5"
    }
},
{
    "pk": 5343, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 107. Jameson KL, Mazur PK, Zehnder AM, et al: IQGAP1 scaffold-kinase interaction blockade selective", 
        "paper": 1, 
        "tag_id": "erb-f333dbf8-2d9a-4d67-892b-3ade7351335f"
    }
},
{
    "pk": 5344, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 108. Li A, Ma Y, Jin M, et al: Activated mutant NRas(Q61K) drives aberrant melanocyte signaling, su", 
        "paper": 1, 
        "tag_id": "erb-f831f066-f355-44c5-ba94-4f4efe7786cc"
    }
},
{
    "pk": 5345, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 109. Krauthammer M, Kong Y, Ha BH, et al: Exome sequencing identifies recurrent somatic RAC1 mutati", 
        "paper": 1, 
        "tag_id": "erb-ba330211-ed4d-423b-b043-53c5a4760388"
    }
},
{
    "pk": 5346, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 110. Stark MS, Woods SL, Gartside MG, et al: Frequent somatic mutations in MAP3K5 and MAP3K9 in met", 
        "paper": 1, 
        "tag_id": "erb-c9f5391e-b1c1-45e9-ba83-8eb326b69859"
    }
},
{
    "pk": 5347, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 111. Muthusamy V, Hobbs C, Nogueira C, et al: Amplification of CDK4 and MDM2 in malignant melanoma.", 
        "paper": 1, 
        "tag_id": "erb-e0c0d1e5-7039-4a91-a73d-f391392900ae"
    }
},
{
    "pk": 5348, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 112. Zuo L, Weger J, Yang Q, et al: Germline mutations in the p16INK4a binding domain of CDK4 in fa", 
        "paper": 1, 
        "tag_id": "erb-cf2be9fd-a56b-4430-b964-97c7a1f2c457"
    }
},
{
    "pk": 5349, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 113. Dickson MA, Shah MA, Rathkopf D, et al: A phase I clinical trial of FOLFIRI in combination wit", 
        "paper": 1, 
        "tag_id": "erb-4a224c2b-95bc-44bc-a33a-f8c90528e9f7"
    }
},
{
    "pk": 5350, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 114. Hussussian CJ, Struewing JP, Goldstein AM, et al: Germline p16 mutations in familial melanoma.", 
        "paper": 1, 
        "tag_id": "erb-f3254999-c743-455a-a028-fe6279eb673f"
    }
},
{
    "pk": 5351, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 115. Polsky D, Bastian BC, Hazan C, et al: HDM2 protein overexpression, but not gene amplification,", 
        "paper": 1, 
        "tag_id": "erb-2b779965-8d7d-4737-9a04-d1dfa80f8888"
    }
},
{
    "pk": 5352, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 116. Gembarska A, Luciani F, Fedele C, et al: MDM4 is a key therapeutic target in cutaneous melanom", 
        "paper": 1, 
        "tag_id": "erb-bb5a53f1-1a60-4c3e-8bc8-a656186e1112"
    }
},
{
    "pk": 5353, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 117. Matin RN, Chikh A, Law Pak Chong S, et al: p63 is an alternative p53 repressor in melanoma tha", 
        "paper": 1, 
        "tag_id": "erb-ae4bdf92-46e7-47f6-b788-766d3cc3d130"
    }
},
{
    "pk": 5354, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 118. Bergamaschi D, Samuels Y, Sullivan A, et al: iASPP preferentially binds p53 proline-rich regio", 
        "paper": 1, 
        "tag_id": "erb-9a319d87-655d-4703-a3c6-421d80d04328"
    }
},
{
    "pk": 5355, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 119. Kamb A, Gruis NA, Weaver-Feldhaus J, et al: A cell cycle regulator potentially involved in gen", 
        "paper": 1, 
        "tag_id": "erb-1dacea00-6fc1-4d24-a3f8-0f07d4cbf492"
    }
},
{
    "pk": 5356, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 120. Kamb A, Shattuck-Eidens D, Eeles R, et al: Analysis of the p16 gene (CDKN2) as a candidate for", 
        "paper": 1, 
        "tag_id": "erb-d6666cec-b963-4670-883f-0193e941d244"
    }
},
{
    "pk": 5357, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 121. Ohta M, Berd D, Shimizu M, et al: Deletion mapping of chromosome region 9p21-p22 surrounding t", 
        "paper": 1, 
        "tag_id": "erb-bba42596-edef-4151-8b40-aee9ee2116d6"
    }
},
{
    "pk": 5358, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 122. Dar AA, Majid S, Rittsteuer C, et al: The role of miR-18b in MDM2-p53 pathway signaling and me", 
        "paper": 1, 
        "tag_id": "erb-c1be19c2-63e8-40e1-bfef-a0a72e1e13af"
    }
},
{
    "pk": 5359, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 123. Ray-Coquard I, Blay JY, Italiano A, et al: Effect of the MDM2 antagonist RG7112 on the P53 pat", 
        "paper": 1, 
        "tag_id": "erb-f1cceebc-a833-4d4d-98d1-bcb30c858f17"
    }
},
{
    "pk": 5360, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 124. Ji Z, Kumar R, Taylor M, et al: Vemurafenib Synergizes with Nutlin-3 to Deplete Survivin and S", 
        "paper": 1, 
        "tag_id": "erb-241288f5-3d97-4e0b-9dcc-0eb3a4a0db5d"
    }
},
{
    "pk": 5361, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 125. Brown CJ, Quah ST, Jong J, et al: Stapled peptides with improved potency and specificity that ", 
        "paper": 1, 
        "tag_id": "erb-7c48bacc-0899-487b-8d71-414e0c7641e7"
    }
},
{
    "pk": 5362, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 126. Chang YS, Graves B, Guerlavais V, et al: Stapled alpha-helical peptide drug development: A pot", 
        "paper": 1, 
        "tag_id": "erb-2a457cc2-a2df-46bf-8682-1d071e00c61c"
    }
},
{
    "pk": 5363, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 127. Lu M, Breyssens H, Salter V, et al: Restoring p53 Function in Human Melanoma Cells by Inhibiti", 
        "paper": 1, 
        "tag_id": "erb-903f38fc-0256-456d-9ede-6fc66da1a9e1"
    }
},
{
    "pk": 5364, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 128. Ohanna M, Giuliano S, Bonet C, et al: Senescent cells develop a PARP-1 and nuclear factor-{kap", 
        "paper": 1, 
        "tag_id": "erb-5d64fbcc-3e54-4869-8c46-797db4585ce5"
    }
},
{
    "pk": 5365, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 129. Gartner JJ, Parker SC, Prickett TD, et al: Whole-genome sequencing identifies a recurrent func", 
        "paper": 1, 
        "tag_id": "erb-5e2f119f-007e-4bc6-9900-eb363986a8a7"
    }
},
{
    "pk": 5366, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 130. Anvekar RA, Asciolla JJ, Lopez-Rivera E, et al: Sensitization to the mitochondrial pathway of ", 
        "paper": 1, 
        "tag_id": "erb-0ee34898-282c-4185-81b5-f21907109398"
    }
},
{
    "pk": 5367, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 131. Reifenberger J, Knobbe CB, Wolter M, et al: Molecular genetic analysis of malignant melanomas ", 
        "paper": 1, 
        "tag_id": "erb-8e30d039-44af-477e-af05-dccbf72cb953"
    }
},
{
    "pk": 5368, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 132. Delmas V, Beermann F, Martinozzi S, et al: Beta-catenin induces immortalization of melanocytes", 
        "paper": 1, 
        "tag_id": "erb-474e44be-c5e7-4e2b-936f-7efcaaab3e7c"
    }
},
{
    "pk": 5369, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 133. Grossmann AH, Yoo JH, Clancy J, et al: The Small GTPase ARF6 Stimulates beta-Catenin Transcrip", 
        "paper": 1, 
        "tag_id": "erb-57a696d5-75ff-4427-8ba1-d49005bdb495"
    }
},
{
    "pk": 5370, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 134. Damsky WE, Curley DP, Santhanakrishnan M, et al: beta-catenin signaling controls metastasis in", 
        "paper": 1, 
        "tag_id": "erb-6f8c6f16-daa9-4dd7-91c4-017bd571bd5c"
    }
},
{
    "pk": 5371, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 135. Biechele TL, Kulikauskas RM, Toroni RA, et al: Wnt/beta-catenin signaling and AXIN1 regulate a", 
        "paper": 1, 
        "tag_id": "erb-27fe5f21-398d-40ec-8333-75081cdcba70"
    }
},
{
    "pk": 5372, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 136. Conrad WH, Swift RD, Biechele TL, et al: Regulating the response to targeted MEK inhibition in", 
        "paper": 1, 
        "tag_id": "erb-fd055581-8a50-42f8-8d20-81409e98da46"
    }
},
{
    "pk": 5373, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 137. Jane-Valbuena J, Widlund HR, Perner S, et al: An oncogenic role for ETV1 in melanoma. Cancer R", 
        "paper": 1, 
        "tag_id": "erb-7566355c-3856-4cdd-9805-29e73c12fb0a"
    }
},
{
    "pk": 5374, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 138. Kim M, Gans JD, Nogueira C, et al: Comparative oncogenomics identifies NEDD9 as a melanoma met", 
        "paper": 1, 
        "tag_id": "erb-4c1e01c8-bb5c-46cf-98ff-0366c7b8ff86"
    }
},
{
    "pk": 5375, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 139. Harbour JW, Onken MD, Roberson ED, et al: Frequent mutation of BAP1 in metastasizing uveal mel", 
        "paper": 1, 
        "tag_id": "erb-ed75fac2-6101-4abc-a240-92128c5e067c"
    }
},
{
    "pk": 5376, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 140. Wiesner T, Obenauf AC, Murali R, et al: Germline mutations in BAP1 predispose to melanocytic t", 
        "paper": 1, 
        "tag_id": "erb-5782fbad-9afa-484e-a304-6b5c31d52b9e"
    }
},
{
    "pk": 5377, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 141. Njauw CN, Kim I, Piris A, et al: Germline BAP1 inactivation is preferentially associated with ", 
        "paper": 1, 
        "tag_id": "erb-f99ab359-77ce-4ed2-bd99-ace13c1512fd"
    }
},
{
    "pk": 5378, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 142. Landreville S, Agapova OA, Matatall KA, et al: Histone deacetylase inhibitors induce growth ar", 
        "paper": 1, 
        "tag_id": "erb-6d4df9e9-dfd2-4e07-a7ca-bfecf2853945"
    }
},
{
    "pk": 5379, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 143. Harbour JW, Roberson ED, Anbunathan H, et al: Recurrent mutations at codon 625 of the splicing", 
        "paper": 1, 
        "tag_id": "erb-16990d1b-cc10-4160-b35d-aea65c3a9a84"
    }
},
{
    "pk": 5380, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 144. Martin M, Masshofer L, Temming P, et al: Exome sequencing identifies recurrent somatic mutatio", 
        "paper": 1, 
        "tag_id": "erb-068e0264-cf27-4590-b65d-a6390a740966"
    }
},
{
    "pk": 5381, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 145. Ghai R, Mobli M, Norwood SJ, et al: Phox homology band 4.1/ezrin/radixin/moesin-like proteins ", 
        "paper": 1, 
        "tag_id": "erb-b51251c0-5bb5-437a-a25b-83eaa11b94bd"
    }
},
{
    "pk": 5382, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 146. Forbes SA, Bindal N, Bamford S, et al: COSMIC: mining complete cancer genomes in the Catalogue", 
        "paper": 1, 
        "tag_id": "erb-f1fb8ee8-728c-48b4-af5c-b74bb5f8b09a"
    }
},
{
    "pk": 5383, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 147. Liu W, Monahan KB, Pfefferle AD, et al: LKB1/STK11 inactivation leads to expansion of a promet", 
        "paper": 1, 
        "tag_id": "erb-08bccc0f-d9b0-4c9e-b50b-b890ff0a75eb"
    }
},
{
    "pk": 5384, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 148. Wei X, Walia V, Lin JC, et al: Exome sequencing identifies GRIN2A as frequently mutated in mel", 
        "paper": 1, 
        "tag_id": "erb-a6aec49f-6715-44e6-a291-c2019a6ef960"
    }
},
{
    "pk": 5385, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 149. Prickett TD, Wei X, Cardenas-Navia I, et al: Exon capture analysis of G protein-coupled recept", 
        "paper": 1, 
        "tag_id": "erb-8607d3b8-cb6e-4be0-af90-21fa1070f032"
    }
},
{
    "pk": 5386, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 150. Namkoong J, Shin SS, Lee HJ, et al: Metabotropic glutamate receptor 1 and glutamate signaling ", 
        "paper": 1, 
        "tag_id": "erb-6c511563-fb71-4d4c-aa32-63313ceafcb3"
    }
},
{
    "pk": 5387, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 151. Locasale JW, Grassian AR, Melman T, et al: Phosphoglycerate dehydrogenase diverts glycolytic f", 
        "paper": 1, 
        "tag_id": "erb-fc0a2aa1-21a6-4c1d-b81b-b551bbc64249"
    }
},
{
    "pk": 5388, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 152. Magnussen GI, Holm R, Emilsen E, et al: High expression of Wee1 is associated with poor diseas", 
        "paper": 1, 
        "tag_id": "erb-b854395a-8e57-4075-8294-def4f1d2b92b"
    }
},
{
    "pk": 5389, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 153. Namiki T, Tanemura A, Valencia JC, et al: AMP kinase-related kinase NUAK2 affects tumor growth", 
        "paper": 1, 
        "tag_id": "erb-3bbc93fd-aa78-4b74-9ccd-1fdf70faab2a"
    }
},
{
    "pk": 5390, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 154. van den Hurk K, Niessen HE, Veeck J, et al: Genetics and epigenetics of cutaneous malignant me", 
        "paper": 1, 
        "tag_id": "erb-0dc6fbcc-5309-4003-9e2f-cc5607a59e2c"
    }
},
{
    "pk": 5391, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 155. Smalley KS, Haass NK, Brafford PA, et al: Multiple signaling pathways must be targeted to over", 
        "paper": 1, 
        "tag_id": "erb-27c6f35b-1ea0-4e6d-82d0-875a04560315"
    }
},
{
    "pk": 5392, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 156. Paraiso KH, Xiang Y, Rebecca VW, et al: PTEN loss confers BRAF inhibitor resistance to melanom", 
        "paper": 1, 
        "tag_id": "erb-8f74b63b-581f-4984-bc7e-e881a2dae2aa"
    }
},
{
    "pk": 5393, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 157. Smalley KS, Lioni M, Dalla Palma M, et al: Increased cyclin D1 expression can mediate BRAF inh", 
        "paper": 1, 
        "tag_id": "erb-3a2305de-6ecf-4e24-8385-90fda923976d"
    }
},
{
    "pk": 5394, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 158. McArthur GA, Puzanov I, Amaravadi R, et al: Marked, homogeneous, and early [18F]fluorodeoxyglu", 
        "paper": 1, 
        "tag_id": "erb-5efa0e2f-d575-43d8-9732-5341386df617"
    }
},
{
    "pk": 5395, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 159. Vergani E, Vallacchi V, Frigerio S, et al: Identification of MET and SRC activation in melanom", 
        "paper": 1, 
        "tag_id": "erb-b04b1359-7944-4021-8cb2-c2487c12bf09"
    }
},
{
    "pk": 5396, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 160. Straussman R, Morikawa T, Shee K, et al: Tumour micro-environment elicits innate resistance to", 
        "paper": 1, 
        "tag_id": "erb-8b0a6870-6477-47e6-b5cb-1e693de432d5"
    }
},
{
    "pk": 5397, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 161. Wroblewski D, Mijatov B, Mohana-Kumaran N, et al: The BH3-mimetic ABT-737 sensitizes human mel", 
        "paper": 1, 
        "tag_id": "erb-fb3bf95b-b30f-41db-98d7-215a42ff4dbb"
    }
},
{
    "pk": 5398, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 162. Haq R, Shoag J, Andreu-Perez P, et al: Oncogenic BRAF Regulates Oxidative Metabolism via PGC1a", 
        "paper": 1, 
        "tag_id": "erb-8a955a05-7c47-4338-93aa-2af6eb3bf7c5"
    }
},
{
    "pk": 5399, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 163. Basile KJ, Abel EV, Aplin AE: Adaptive upregulation of FOXD3 and resistance to PLX4032/4720-in", 
        "paper": 1, 
        "tag_id": "erb-ed78e7d7-4ae1-43e4-a604-e81ad735c1f4"
    }
},
{
    "pk": 5400, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 164. Abel EV, Basile KJ, Kugel CH, 3rd, et al: Melanoma adapts to RAF/MEK inhibitors through FOXD3-", 
        "paper": 1, 
        "tag_id": "erb-24c7acce-07a8-4e24-b210-dc9036cbbf7d"
    }
},
{
    "pk": 5401, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 165. Paraiso KH, Haarberg HE, Wood E, et al: The HSP90 inhibitor XL888 overcomes BRAF inhibitor res", 
        "paper": 1, 
        "tag_id": "erb-c74ee03a-2b26-4506-b124-fed63bd2a591"
    }
},
{
    "pk": 5402, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 166. Deng W, Gopal YN, Scott A, et al: Role and therapeutic potential of PI3K-mTOR signaling in de ", 
        "paper": 1, 
        "tag_id": "erb-483602dc-fc6b-4a55-bde0-54245b427323"
    }
},
{
    "pk": 5403, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 167. Corcoran RB, Rothenberg SM, Hata AN, et al: TORC1 Suppression Predicts Responsiveness to RAF a", 
        "paper": 1, 
        "tag_id": "erb-da796d99-575b-4d34-afe4-85834b3d48e4"
    }
},
{
    "pk": 5404, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 168. Smith MP, Ferguson J, Arozarena I, et al: Effect of SMURF2 Targeting on Susceptibility to MEK ", 
        "paper": 1, 
        "tag_id": "erb-598ea424-d26e-4018-80fc-e821adfe8593"
    }
},
{
    "pk": 5405, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 169. Byron SA, Loch DC, Wellens CL, et al: Sensitivity to the MEK inhibitor E6201 in melanoma cells", 
        "paper": 1, 
        "tag_id": "erb-dc8ceab9-21db-4ada-b07a-dbbd8761664f"
    }
},
{
    "pk": 5406, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 170. Shimizu T, Tolcher AW, Papadopoulos KP, et al: The clinical effect of the dual-targeting strat", 
        "paper": 1, 
        "tag_id": "erb-af7eafe8-57db-45f3-b655-f3f52f258d6f"
    }
},
{
    "pk": 5407, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 171. Zmajkovicova K, Jesenberger V, Catalanotti F, et al: MEK1 Is Required for PTEN Membrane Recrui", 
        "paper": 1, 
        "tag_id": "erb-1eea30bb-6431-4910-9c8c-5d8373f4b819"
    }
},
{
    "pk": 5408, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 172. Sondergaard JN, Nazarian R, Wang Q, et al: Differential sensitivity of melanoma cell lines wit", 
        "paper": 1, 
        "tag_id": "erb-57b288d9-394a-4094-848e-3038fc9fa75f"
    }
},
{
    "pk": 5409, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 173. Wilson TR, Fridlyand J, Yan Y, et al: Widespread potential for growth-factor-driven resistance", 
        "paper": 1, 
        "tag_id": "erb-75d90816-6828-410b-92f6-bcf7b6061d23"
    }
},
{
    "pk": 5410, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 174. Catalanotti F, Solit DB: Will Hsp90 inhibitors prove effective in BRAF-mutant melanomas? Clin ", 
        "paper": 1, 
        "tag_id": "erb-50bae73a-e5f7-45ac-8221-c4bd4a676378"
    }
},
{
    "pk": 5411, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 175. Haarberg HE, Paraiso KH, Wood E, et al: Inhibition of Wee1, AKT and CDK4 underlies the efficac", 
        "paper": 1, 
        "tag_id": "erb-4eda61d4-d9fd-446b-8ff0-e98f084c58d1"
    }
},
{
    "pk": 5412, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 176. Poulikakos PI, Persaud Y, Janakiraman M, et al: RAF inhibitor resistance is mediated by dimeri", 
        "paper": 1, 
        "tag_id": "erb-7918ab7e-2df2-4f1a-8fb4-0820e8318f74"
    }
},
{
    "pk": 5413, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 177. Romano E, Pradervand S, Paillusson A, et al: Identification of Multiple Mechanisms of Resistan", 
        "paper": 1, 
        "tag_id": "erb-27f0b360-3509-4c84-a4c2-3fe8c42782e3"
    }
},
{
    "pk": 5414, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 178. Shi H, Moriceau G, Kong X, et al: Melanoma whole-exome sequencing identifies (V600E)B-RAF ampl", 
        "paper": 1, 
        "tag_id": "erb-6957e100-0207-4cf5-bc75-42f2f359d7b4"
    }
},
{
    "pk": 5415, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 179. Girotti MR, Pedersen M, Sanchez-Laorden B, et al: Inhibiting EGF receptor or SRC family kinase", 
        "paper": 1, 
        "tag_id": "erb-a375cea9-460d-449c-b034-3398cf186b54"
    }
},
{
    "pk": 5416, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 180. Yadav V, Zhang X, Liu J, et al: Reactivation of mitogen-activated protein kinase (MAPK) pathwa", 
        "paper": 1, 
        "tag_id": "erb-95f77362-d2f2-46fb-b787-5e4e694693cc"
    }
},
{
    "pk": 5417, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 181. Villanueva J, Vultur A, Lee JT, et al: Acquired resistance to BRAF inhibitors mediated by a RA", 
        "paper": 1, 
        "tag_id": "erb-847a97d0-19f3-4081-8612-254256aa904d"
    }
},
{
    "pk": 5418, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 182. Fattore L, Marra E, Pisanu ME, et al: Activation of an early feedback survival loop involving ", 
        "paper": 1, 
        "tag_id": "erb-f16fcba2-183f-4b97-a55a-995b677db2ea"
    }
},
{
    "pk": 5419, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 183. Nazarian R, Shi H, Wang Q, et al: Melanomas acquire resistance to B-RAF(V600E) inhibition by R", 
        "paper": 1, 
        "tag_id": "erb-4bc74b28-6f42-4e0e-a224-9ded4b551ac3"
    }
},
{
    "pk": 5420, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 184. Johannessen CM, Boehm JS, Kim SY, et al: COT drives resistance to RAF inhibition through MAP k", 
        "paper": 1, 
        "tag_id": "erb-fa554ebb-e85a-44dd-9d03-d5c553de712b"
    }
},
{
    "pk": 5421, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 185. Wagle N, Emery C, Berger MF, et al: Dissecting therapeutic resistance to RAF inhibition in mel", 
        "paper": 1, 
        "tag_id": "erb-d32254c1-0775-4f56-9ba1-b394a693bca8"
    }
},
{
    "pk": 5422, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 186. Trunzer K, Pavlick AC, Schuchter L, et al: Pharmacodynamic Effects and Mechanisms of Resistanc", 
        "paper": 1, 
        "tag_id": "erb-a06be7bc-f7be-4af3-98c7-59e0c0a45d2f"
    }
},
{
    "pk": 5423, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 187. Emery CM, Vijayendran KG, Zipser MC, et al: MEK1 mutations confer resistance to MEK and B-RAF ", 
        "paper": 1, 
        "tag_id": "erb-83016b6e-d11a-41ee-b67b-9ff86d19245e"
    }
},
{
    "pk": 5424, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 188. Shao Y, Aplin AE: Akt3-mediated resistance to apoptosis in B-RAF-targeted melanoma cells. Canc", 
        "paper": 1, 
        "tag_id": "erb-6f880c6c-506f-4e58-9af1-6c041cd4820f"
    }
},
{
    "pk": 5425, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 189. Jiang CC, Lai F, Thorne RF, et al: MEK-independent survival of B-RAFV600E melanoma cells selec", 
        "paper": 1, 
        "tag_id": "erb-109b755b-d32d-4080-b5fd-fff5238095f7"
    }
},
{
    "pk": 5426, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 190. Klein RM, Higgins PJ: A switch in RND3-RHOA signaling is critical for melanoma cell invasion f", 
        "paper": 1, 
        "tag_id": "erb-a392aa18-3e23-425e-8f99-8c9a403ce070"
    }
},
{
    "pk": 5427, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 191. Reuveni H, Flashner-Abramson E, Steiner L, et al: Therapeutic destruction of insulin receptor ", 
        "paper": 1, 
        "tag_id": "erb-021a617e-27bb-4813-bb30-bed376bef1ec"
    }
},
{
    "pk": 5428, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 192. Villanueva J, Infante JR, Krepler C, et al: Concurrent MEK2 Mutation and BRAF Amplification Co", 
        "paper": 1, 
        "tag_id": "erb-7e042c80-eacf-4879-857e-c5cbf2759948"
    }
},
{
    "pk": 5429, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 193. Sullivan RJ, Flaherty KT: Resistance to BRAF-targeted therapy in melanoma. Eur J Cancer, 2013.", 
        "paper": 1, 
        "tag_id": "erb-508af8b0-2e40-4d4c-8156-68ac7d8e1250"
    }
},
{
    "pk": 5430, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 194. Morris EJ, Jha S, Restino CR, et al: Discovery of a novel ERK inhibitor with activity in model", 
        "paper": 1, 
        "tag_id": "erb-83225385-3195-4adc-bd58-a806efa784eb"
    }
},
{
    "pk": 5431, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 195. Duncan JS, Whittle MC, Nakamura K, et al: Dynamic reprogramming of the kinome in response to t", 
        "paper": 1, 
        "tag_id": "erb-ff6e88cc-b08a-4181-9b27-a4c64ca1ca17"
    }
},
{
    "pk": 5432, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 196. Gopal YN, Deng W, Woodman SE, et al: Basal and treatment-induced activation of AKT mediates re", 
        "paper": 1, 
        "tag_id": "erb-201df5b1-9fbe-4fee-812d-0ed5a51f7fa6"
    }
},
{
    "pk": 5433, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 197. Roller DG, Axelrod M, Capaldo BJ, et al: Synthetic lethal screening with small-molecule inhibi", 
        "paper": 1, 
        "tag_id": "erb-1165f917-dfb9-47df-8353-95bcdb794e02"
    }
},
{
    "pk": 5434, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 198. Kawakami Y, Eliyahu S, Delgado CH, et al: Cloning of the gene coding for a shared human melano", 
        "paper": 1, 
        "tag_id": "erb-c788b2f9-b20a-4d60-bd40-4c11c1a1c0e2"
    }
},
{
    "pk": 5435, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 199. Slingluff CL, Jr., Petroni GR, Yamshchikov GV, et al: Immunologic and clinical outcomes of vac", 
        "paper": 1, 
        "tag_id": "erb-c79e0e5a-6873-4132-837f-e7f72467fca6"
    }
},
{
    "pk": 5436, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 200. Rosenberg SA, Yang JC, Restifo NP: Cancer immunotherapy: moving beyond current vaccines. Nat M", 
        "paper": 1, 
        "tag_id": "erb-b6982816-5499-4df8-bd6e-2518927cfa6c"
    }
},
{
    "pk": 5437, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 201. Spranger S, Spaapen RM, Zha Y, et al: Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma T", 
        "paper": 1, 
        "tag_id": "erb-1e7ef0bd-7a6d-45eb-9e71-12e6d7d03f2f"
    }
},
{
    "pk": 5438, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 202. van Elsas A, Hurwitz AA, Allison JP: Combination immunotherapy of B16 melanoma using anti-cyto", 
        "paper": 1, 
        "tag_id": "erb-d85bd2e4-0067-46b5-9de9-dd494780a735"
    }
},
{
    "pk": 5439, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 203. Atkins MB, Lotze MT, Dutcher JP, et al: High-dose recombinant interleukin 2 therapy for patien", 
        "paper": 1, 
        "tag_id": "erb-156093c5-7858-4faa-83ec-064f30254bba"
    }
},
{
    "pk": 5440, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 204. Hodi FS, O'Day SJ, McDermott DF, et al: Improved survival with ipilimumab in patients with met", 
        "paper": 1, 
        "tag_id": "erb-2dad7f69-4dec-43ce-814a-9d47611e4a6a"
    }
},
{
    "pk": 5441, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 205. Robbins PF, Lu YC, El-Gamil M, et al: Mining exomic sequencing data to identify mutated antige", 
        "paper": 1, 
        "tag_id": "erb-12f60fea-9f8a-46ed-8dda-5ea278d63bce"
    }
},
{
    "pk": 5442, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 206. Ascierto PA, Kalos M, Schaer DA, et al: Biomarkers for Immunostimulatory Monoclonal Antibodies", 
        "paper": 1, 
        "tag_id": "erb-49de2a6d-1d4a-4e5e-bc14-9266bf34df25"
    }
},
{
    "pk": 5443, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 207. Peggs KS, Quezada SA, Chambers CA, et al: Blockade of CTLA-4 on both effector and regulatory T", 
        "paper": 1, 
        "tag_id": "erb-1de2387d-3f6a-43c0-a082-cf94cce8b012"
    }
},
{
    "pk": 5444, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 208. Contardi E, Palmisano GL, Tazzari PL, et al: CTLA-4 is constitutively expressed on tumor cells", 
        "paper": 1, 
        "tag_id": "erb-87a62682-2cf3-4ede-92a1-9c8f312139dc"
    }
},
{
    "pk": 5445, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 209. Shah KV, Chien AJ, Yee C, et al: CTLA-4 is a direct target of Wnt/beta-catenin signaling and i", 
        "paper": 1, 
        "tag_id": "erb-7ea9ef92-9eab-428c-8859-7b49185c67f1"
    }
},
{
    "pk": 5446, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 210. Sapoznik S, Hammer O, Ortenberg R, et al: Novel anti-melanoma immunotherapies: disarming tumor", 
        "paper": 1, 
        "tag_id": "erb-9daa6cfe-ce0e-4c0b-9516-243fe3f8d5ab"
    }
},
{
    "pk": 5447, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 211. Hamid O, Schmidt H, Nissan A, et al: A prospective phase II trial exploring the association be", 
        "paper": 1, 
        "tag_id": "erb-640c0067-2cb2-4cb5-a7db-25a399f748f8"
    }
},
{
    "pk": 5448, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 212. Holmgaard RB, Zamarin D, Munn DH, et al: Indoleamine 2,3-dioxygenase is a critical resistance ", 
        "paper": 1, 
        "tag_id": "erb-8532a23c-d441-403e-91ec-c450840ed39a"
    }
},
{
    "pk": 5449, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 213. Iwai Y, Ishida M, Tanaka Y, et al: Involvement of PD-L1 on tumor cells in the escape from host", 
        "paper": 1, 
        "tag_id": "erb-3b58d6d5-508a-4fce-98c0-ccc01eb76058"
    }
},
{
    "pk": 5450, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 214. Freeman GJ, Long AJ, Iwai Y, et al: Engagement of the PD-1 immunoinhibitory receptor by a nove", 
        "paper": 1, 
        "tag_id": "erb-f1c2b71c-569c-406b-b0ac-67f038fddd69"
    }
},
{
    "pk": 5451, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 215. Ahmadzadeh M, Johnson LA, Heemskerk B, et al: Tumor antigen-specific CD8 T cells infiltrating ", 
        "paper": 1, 
        "tag_id": "erb-b7830649-bee1-4651-996d-806adb21e99d"
    }
},
{
    "pk": 5452, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 216. Topalian SL, Hodi FS, Brahmer JR, et al: Safety, activity, and immune correlates of anti-PD-1 ", 
        "paper": 1, 
        "tag_id": "erb-db829523-64d6-4f0e-8449-6b5c812e02b6"
    }
},
{
    "pk": 5453, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 217. Lipson EJ, Sharfman WH, Drake CG, et al: Durable Cancer Regression Off-Treatment and Effective", 
        "paper": 1, 
        "tag_id": "erb-cd1279cd-b21b-4266-b715-9ce25e21c83a"
    }
},
{
    "pk": 5454, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 218. Hamid O, Robert C, Daud A, et al: Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in", 
        "paper": 1, 
        "tag_id": "erb-1751fdb8-aa02-4a32-af21-3b9b33cadd82"
    }
},
{
    "pk": 5455, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 219. Brahmer JR, Tykodi SS, Chow LQ, et al: Safety and activity of anti-PD-L1 antibody in patients ", 
        "paper": 1, 
        "tag_id": "erb-29d0c219-e4b5-4584-97f1-ff89bd890e3d"
    }
},
{
    "pk": 5456, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 220. Curran MA, Montalvo W, Yagita H, et al: PD-1 and CTLA-4 combination blockade expands infiltrat", 
        "paper": 1, 
        "tag_id": "erb-bddaca63-1854-4c64-9c89-e3c56bd02953"
    }
},
{
    "pk": 5457, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 221. Wolchok JD, Kluger H, Callahan MK, et al: Nivolumab plus Ipilimumab in Advanced Melanoma. N En", 
        "paper": 1, 
        "tag_id": "erb-838e5445-3df4-4c5b-b10c-2337d359c254"
    }
},
{
    "pk": 5458, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 222. Chacon JA, Wu RC, Sukhumalchandra P, et al: Co-Stimulation through 4-1BB/CD137 Improves the Ex", 
        "paper": 1, 
        "tag_id": "erb-7155ca63-e7ae-4210-96d8-e35c680f0f52"
    }
},
{
    "pk": 5459, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 223. Vonderheide RH, Flaherty KT, Khalil M, et al: Clinical activity and immune modulation in cance", 
        "paper": 1, 
        "tag_id": "erb-6e8999a4-ce11-4ff5-9887-d63d1edda935"
    }
},
{
    "pk": 5460, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 224. Schwartzentruber DJ, Lawson DH, Richards JM, et al: gp100 peptide vaccine and interleukin-2 in", 
        "paper": 1, 
        "tag_id": "erb-aa738bac-b47d-49af-becd-7909883d14ea"
    }
},
{
    "pk": 5461, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 225. Prieto PA, Yang JC, Sherry RM, et al: CTLA-4 blockade with ipilimumab: long-term follow-up of ", 
        "paper": 1, 
        "tag_id": "erb-1b4a2fe2-f297-4530-8018-da419c916090"
    }
},
{
    "pk": 5462, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 226. Petrella TM, Tozer R, Belanger K, et al: Interleukin-21 has activity in patients with metastat", 
        "paper": 1, 
        "tag_id": "erb-06fe3599-2bdd-434a-a013-60798dea5e3b"
    }
},
{
    "pk": 5463, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 227. Galluzzi L, Vacchelli E, Eggermont A, et al: Trial Watch: Adoptive cell transfer immunotherapy", 
        "paper": 1, 
        "tag_id": "erb-b9899058-3c2f-4836-94c6-4fa2bb69c1c4"
    }
},
{
    "pk": 5464, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 228. Itzhaki O, Levy D, Zikich D, et al: Adoptive T-cell transfer in melanoma. Immunotherapy 5:79-9", 
        "paper": 1, 
        "tag_id": "erb-0a3b28d1-ddd7-47d0-bbbb-988ce2cdecd2"
    }
},
{
    "pk": 5465, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 229. Rosenberg SA, Yang JC, Sherry RM, et al: Durable complete responses in heavily pretreated pati", 
        "paper": 1, 
        "tag_id": "erb-2b3d215a-f0e0-4302-b9a6-025ce01fed3c"
    }
},
{
    "pk": 5466, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 230. Purwar R, Schlapbach C, Xiao S, et al: Robust tumor immunity to melanoma mediated by interleuk", 
        "paper": 1, 
        "tag_id": "erb-6c3056b9-ed2e-4a1b-acb8-8bc06955f7ab"
    }
},
{
    "pk": 5467, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 231. Ellebaek E, Iversen TZ, Junker N, et al: Adoptive cell therapy with autologous tumor infiltrat", 
        "paper": 1, 
        "tag_id": "erb-b84b4adc-7228-4a88-9784-46c005c36970"
    }
},
{
    "pk": 5468, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 232. Hirschhorn-Cymerman D, Budhu S, Kitano S, et al: Induction of tumoricidal function in CD4+ T c", 
        "paper": 1, 
        "tag_id": "erb-7f480719-47a5-4a67-ae1f-6f25b3448177"
    }
},
{
    "pk": 5469, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 233. Wang A, Chandran S, Shah SA, et al: The stoichiometric production of IL-2 and IFN-gamma mRNA d", 
        "paper": 1, 
        "tag_id": "erb-22012e34-8f30-46dc-b524-1ff0f5872a46"
    }
},
{
    "pk": 5470, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 234. Landsberg J, Kohlmeyer J, Renn M, et al: Melanomas resist T-cell therapy through inflammation-", 
        "paper": 1, 
        "tag_id": "erb-e182d41a-eaa7-448f-9c13-e305400441aa"
    }
},
{
    "pk": 5471, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 235. Kodumudi KN, Weber A, Sarnaik AA, et al: Blockade of myeloid-derived suppressor cells after in", 
        "paper": 1, 
        "tag_id": "erb-cefcce02-77bd-42f3-8850-ab4757b73dfd"
    }
},
{
    "pk": 5472, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 236. Lu YC, Yao X, Li YF, et al: Mutated PPP1R3B Is Recognized by T Cells Used To Treat a Melanoma ", 
        "paper": 1, 
        "tag_id": "erb-9d69739a-4b4f-4549-aa0f-020b2f81b954"
    }
},
{
    "pk": 5473, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 237. Radvanyi LG, Bernatchez C, Zhang M, et al: Specific lymphocyte subsets predict response to ado", 
        "paper": 1, 
        "tag_id": "erb-7fa39f51-06dd-4e4e-909b-3a3202f741fd"
    }
},
{
    "pk": 5474, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 238. Dudley ME, Gross CA, Somerville RP, et al: Randomized Selection Design Trial Evaluating CD8+-E", 
        "paper": 1, 
        "tag_id": "erb-067d11f9-810e-40ff-9c5a-fc1e3352b6c7"
    }
},
{
    "pk": 5475, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 239. Butler MO, Friedlander P, Milstein MI, et al: Establishment of antitumor memory in humans usin", 
        "paper": 1, 
        "tag_id": "erb-318b5ca1-fd36-444a-810b-f65700ec0093"
    }
},
{
    "pk": 5476, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 240. Kershaw MH, Westwood JA, Darcy PK: Gene-engineered T cells for cancer therapy. Nat Rev Cancer ", 
        "paper": 1, 
        "tag_id": "erb-c0a45c4c-7a4a-4e5a-9af6-922f5c9f9b0f"
    }
},
{
    "pk": 5477, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 241. Stauss HJ, Morris EC: Immunotherapy with gene-modified T cells: limiting side effects provides", 
        "paper": 1, 
        "tag_id": "erb-2dd069bd-c75c-48c5-a563-ea7524d2bd5f"
    }
},
{
    "pk": 5478, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 242. Robbins PF, Morgan RA, Feldman SA, et al: Tumor regression in patients with metastatic synovia", 
        "paper": 1, 
        "tag_id": "erb-e7f508e6-c9fc-4c2e-8d2c-d4303827bd6e"
    }
},
{
    "pk": 5479, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 243. Hunder NN, Wallen H, Cao J, et al: Treatment of metastatic melanoma with autologous CD4+ T cel", 
        "paper": 1, 
        "tag_id": "erb-630307e6-44d2-42dc-a2c6-8cc64b6231ad"
    }
},
{
    "pk": 5480, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 244. Braumuller H, Wieder T, Brenner E, et al: T-helper-1-cell cytokines drive cancer into senescen", 
        "paper": 1, 
        "tag_id": "erb-ba02d7ec-635f-4770-826f-1e1a7890cda9"
    }
},
{
    "pk": 5481, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 245. Palucka K, Banchereau J: Cancer immunotherapy via dendritic cells. Nat Rev Cancer 12:265-77, 2", 
        "paper": 1, 
        "tag_id": "erb-b939b558-b8a2-491a-a0b1-6467fac08794"
    }
},
{
    "pk": 5482, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 246. Nestle FO, Alijagic S, Gilliet M, et al: Vaccination of melanoma patients with peptide- or tum", 
        "paper": 1, 
        "tag_id": "erb-606f4b9b-5e66-4cc1-bbbe-8a5dd3556151"
    }
},
{
    "pk": 5483, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 247. Thurner B, Haendle I, Roder C, et al: Vaccination with mage-3A1 peptide-pulsed mature, monocyt", 
        "paper": 1, 
        "tag_id": "erb-dff5daf3-71d3-44f9-94e5-984a7a9a80d1"
    }
},
{
    "pk": 5484, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 248. Mackensen A, Herbst B, Chen JL, et al: Phase I study in melanoma patients of a vaccine with pe", 
        "paper": 1, 
        "tag_id": "erb-f92dac1f-6d3f-419d-ae54-43b6dae62d7d"
    }
},
{
    "pk": 5485, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 249. Romano E, Rossi M, Ratzinger G, et al: Peptide-loaded Langerhans cells, despite increased IL15", 
        "paper": 1, 
        "tag_id": "erb-1a27532c-9b89-46c6-907c-b7c746b55fd4"
    }
},
{
    "pk": 5486, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 250. Verdijk P, Aarntzen EH, Lesterhuis WJ, et al: Limited amounts of dendritic cells migrate into ", 
        "paper": 1, 
        "tag_id": "erb-ea041668-8069-4df6-9841-62386b9163f5"
    }
},
{
    "pk": 5487, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 251. Lesterhuis WJ, de Vries IJ, Schreibelt G, et al: Route of administration modulates the inducti", 
        "paper": 1, 
        "tag_id": "erb-3353e706-0d95-4cb7-9d13-10ff94940518"
    }
},
{
    "pk": 5488, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 252. Mitchell DA, Nair SK: RNA-transfected dendritic cells in cancer immunotherapy. J Clin Invest 1", 
        "paper": 1, 
        "tag_id": "erb-930b1eaa-6665-4f35-9391-84adb5f122f2"
    }
},
{
    "pk": 5489, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 253. Aarntzen EH, Schreibelt G, Bol K, et al: Vaccination with mRNA-electroporated dendritic cells ", 
        "paper": 1, 
        "tag_id": "erb-6e2386a9-a0ad-4b8f-9c88-fb66655f21d7"
    }
},
{
    "pk": 5490, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 254. Dannull J, Haley NR, Archer G, et al: Melanoma immunotherapy using mature DCs expressing the c", 
        "paper": 1, 
        "tag_id": "erb-18630e88-47d5-4312-b554-d5389d1181c9"
    }
},
{
    "pk": 5491, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 255. Carreno BM, Becker-Hapak M, Huang A, et al: IL-12p70-producing patient DC vaccine elicits Tc1-", 
        "paper": 1, 
        "tag_id": "erb-d386cac8-124a-415e-bdfd-164bdf75d45b"
    }
},
{
    "pk": 5492, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 256. Ribas A, Comin-Anduix B, Chmielowski B, et al: Dendritic cell vaccination combined with CTLA4 ", 
        "paper": 1, 
        "tag_id": "erb-4dc0dbf6-4ac1-451a-8394-09ee7313b76c"
    }
},
{
    "pk": 5493, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 257. Rosenberg SA, Lotze MT, Yang JC, et al: Prospective randomized trial of high-dose interleukin-", 
        "paper": 1, 
        "tag_id": "erb-ec66febc-56a2-4ec7-997d-c26efa921583"
    }
},
{
    "pk": 5494, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 258. Parkhurst MR, Riley JP, Dudley ME, et al: Adoptive transfer of autologous natural killer cells", 
        "paper": 1, 
        "tag_id": "erb-1f6d231a-b344-42ba-a15f-060a738dfb38"
    }
},
{
    "pk": 5495, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 259. Besser MJ, Shoham T, Harari-Steinberg O, et al: Development of allogeneic NK cell adoptive tra", 
        "paper": 1, 
        "tag_id": "erb-85809f2d-66ae-4c30-9ee3-437e10ff99a0"
    }
},
{
    "pk": 5496, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 260. Gammaitoni L, Giraudo L, Leuci V, et al: Effective Activity of Cytokine Induced Killer Cells a", 
        "paper": 1, 
        "tag_id": "erb-123cdc9d-d164-4d1b-9d9d-83c103f3178d"
    }
},
{
    "pk": 5497, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 261. Sumimoto H, Imabayashi F, Iwata T, et al: The BRAF-MAPK signaling pathway is essential for can", 
        "paper": 1, 
        "tag_id": "erb-4329de9e-47d9-47a2-89d6-9b8b786a0351"
    }
},
{
    "pk": 5498, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 262. Kono M, Dunn IS, Durda PJ, et al: Role of the mitogen-activated protein kinase signaling pathw", 
        "paper": 1, 
        "tag_id": "erb-dff60bf4-053b-4757-8c06-3adb8be69f88"
    }
},
{
    "pk": 5499, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 263. Khalili JS, Liu S, Rodriguez-Cruz TG, et al: Oncogenic BRAF(V600E) promotes stromal cell-media", 
        "paper": 1, 
        "tag_id": "erb-5755b1ff-ed19-4849-b5ff-e0bd71d65c43"
    }
},
{
    "pk": 5500, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 264. Knight DA, Ngiow SF, Li M, et al: Host immunity contributes to the anti-melanoma activity of B", 
        "paper": 1, 
        "tag_id": "erb-65c43fd3-6d4c-4a15-b1d8-d64258ddb9bb"
    }
},
{
    "pk": 5501, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 265. Boni A, Cogdill AP, Dang P, et al: Selective BRAFV600E inhibition enhances T-cell recognition ", 
        "paper": 1, 
        "tag_id": "erb-ffda7d30-286e-4beb-8ca4-24e1c8ba026e"
    }
},
{
    "pk": 5502, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 266. Wilmott JS, Long GV, Howle JR, et al: Selective BRAF inhibitors induce marked T-cell infiltrat", 
        "paper": 1, 
        "tag_id": "erb-db5de006-69d5-41ee-b5a2-c67235098ca6"
    }
},
{
    "pk": 5503, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 267. Hong DS, Vence L, Falchook G, et al: BRAF(V600) inhibitor GSK2118436 targeted inhibition of mu", 
        "paper": 1, 
        "tag_id": "erb-a5ef7f5b-5f1b-4ec5-9def-eab637b30d33"
    }
},
{
    "pk": 5504, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 268. Hooijkaas A, Gadiot J, Morrow M, et al: Selective BRAF inhibition decreases tumor-resident lym", 
        "paper": 1, 
        "tag_id": "erb-d3b52ffc-d126-4c85-be79-076d60f320d0"
    }
},
{
    "pk": 5505, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 269. Frederick DT, Piris A, Cogdill AP, et al: BRAF Inhibition Is Associated with Enhanced Melanoma", 
        "paper": 1, 
        "tag_id": "erb-f19061da-0ebb-4b30-a8cc-d6fef976e2f9"
    }
},
{
    "pk": 5506, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 270. Koya RC, Mok S, Otte N, et al: BRAF inhibitor vemurafenib improves the antitumor activity of a", 
        "paper": 1, 
        "tag_id": "erb-a7f989c2-a776-4ff3-b0ea-549e1fa284d3"
    }
},
{
    "pk": 5507, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 271. Liu C, Peng W, Xu C, et al: BRAF Inhibition Increases Tumor Infiltration by T cells and Enhanc", 
        "paper": 1, 
        "tag_id": "erb-d4015ccd-2de4-4bde-b8f9-edf79baa687a"
    }
},
{
    "pk": 5508, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 272. Ott PA, Henry T, Baranda SJ, et al: Inhibition of both BRAF and MEK in BRAF(V600E) mutant mela", 
        "paper": 1, 
        "tag_id": "erb-195bb76d-7372-44c9-9968-045422cb2462"
    }
},
{
    "pk": 5509, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 273. Donia M, Fagone P, Nicoletti F, et al: BRAF inhibition improves tumor recognition by the immun", 
        "paper": 1, 
        "tag_id": "erb-42de41bd-d2a5-4c1d-98ec-088b2ba96936"
    }
},
{
    "pk": 5510, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 274. Ribas A, Hodi FS, Callahan M, et al: Hepatotoxicity with combination of vemurafenib and ipilim", 
        "paper": 1, 
        "tag_id": "erb-074ea502-286b-4a72-b867-132aee20ff5a"
    }
},
{
    "pk": 5511, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 275. Joseph RW, Sullivan RJ, Harrell R, et al: Correlation of NRAS mutations with clinical response", 
        "paper": 1, 
        "tag_id": "erb-36a2a5ae-9b3f-414f-b05a-dce0b2493563"
    }
},
{
    "pk": 5512, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 276. Yaguchi T, Goto Y, Kido K, et al: Immune suppression and resistance mediated by constitutive a", 
        "paper": 1, 
        "tag_id": "erb-687dbd10-f1e5-4e8b-a89d-60beb963e6b7"
    }
},
{
    "pk": 5513, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 277. Gilbert AE, Karagiannis P, Dodev T, et al: Monitoring the systemic human memory B cell compart", 
        "paper": 1, 
        "tag_id": "erb-95c47ca0-a68b-47be-9628-eec75dd5dbc1"
    }
},
{
    "pk": 5514, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 278. Carpenter EL, Mick R, Rech AJ, et al: Collapse of the CD27+ B-cell compartment associated with", 
        "paper": 1, 
        "tag_id": "erb-c224ed7f-d2f1-4a9d-bdcf-d23502a936fe"
    }
},
{
    "pk": 5515, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 279. Karagiannis P, Gilbert AE, Josephs DH, et al: IgG4 subclass antibodies impair antitumor immuni", 
        "paper": 1, 
        "tag_id": "erb-5a7b3085-b4a0-4903-aa20-797b1e9a6779"
    }
},
{
    "pk": 5516, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 280. Jochems C, Schlom J: Tumor-infiltrating immune cells and prognosis: the potential link between", 
        "paper": 1, 
        "tag_id": "erb-678004c2-c698-44c6-8398-6eab9e798999"
    }
},
{
    "pk": 5517, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 281. Messina JL, Fenstermacher DA, Eschrich S, et al: 12-Chemokine gene signature identifies lymph ", 
        "paper": 1, 
        "tag_id": "erb-3e0dd15e-3e20-4b7a-bb3b-be4e15a7b87a"
    }
},
{
    "pk": 5518, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 282. Sonveaux P, Vegran F, Schroeder T, et al: Targeting lactate-fueled respiration selectively kil", 
        "paper": 1, 
        "tag_id": "erb-ad5d0f8f-1fdb-404e-bf34-a3394d3995f3"
    }
},
{
    "pk": 5519, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 283. O'Day SJ, Eggermont AM, Chiarion-Sileni V, et al: Final Results of Phase III SYMMETRY Study: R", 
        "paper": 1, 
        "tag_id": "erb-567a41a4-d187-48ab-97c0-ee028f42e770"
    }
},
{
    "pk": 5520, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 284. Roesch A, Fukunaga-Kalabis M, Schmidt EC, et al: A temporarily distinct subpopulation of slow-", 
        "paper": 1, 
        "tag_id": "erb-69d77047-618f-46ec-ab0f-a349e78a5c4b"
    }
},
{
    "pk": 5521, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 285. Roesch A, Vultur A, Bogeski I, et al: Overcoming Intrinsic Multidrug Resistance in Melanoma by", 
        "paper": 1, 
        "tag_id": "erb-37c56535-b2ca-4940-bacb-ab95ecb841ef"
    }
},
{
    "pk": 5522, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 286. Kaplon J, Zheng L, Meissl K, et al: A key role for mitochondrial gatekeeper pyruvate dehydroge", 
        "paper": 1, 
        "tag_id": "erb-923d232e-c0da-4c5e-a800-30a55f5e24a4"
    }
},
{
    "pk": 5523, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 287. Dillon BJ, Prieto VG, Curley SA, et al: Incidence and distribution of argininosuccinate synthe", 
        "paper": 1, 
        "tag_id": "erb-9643b46c-8360-4f03-bb06-f45904ef643c"
    }
},
{
    "pk": 5524, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 288. Yoon JK, Frankel AE, Feun LG, et al: Arginine deprivation therapy for malignant melanoma. Clin", 
        "paper": 1, 
        "tag_id": "erb-7847b3a5-fed7-49c7-8a92-79c8500f57b6"
    }
},
{
    "pk": 5525, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 289. Ott PA, Carvajal RD, Pandit-Taskar N, et al: Phase I/II study of pegylated arginine deiminase ", 
        "paper": 1, 
        "tag_id": "erb-7a8b2a3c-76e7-4127-a2e3-622c9ccd3fa0"
    }
},
{
    "pk": 5526, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 290. Sheen JH, Zoncu R, Kim D, et al: Defective regulation of autophagy upon leucine deprivation re", 
        "paper": 1, 
        "tag_id": "erb-6fd0d2a2-eda1-43ef-804d-efd6ff5b32f4"
    }
},
{
    "pk": 5527, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 291. Tomic T, Botton T, Cerezo M, et al: Metformin inhibits melanoma development through autophagy ", 
        "paper": 1, 
        "tag_id": "erb-92698907-429f-4f1c-bb61-9b804e8ee9e6"
    }
},
{
    "pk": 5528, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 292. Li H, Li Y, Jiao J, et al: Alpha-alumina nanoparticles induce efficient autophagy-dependent cr", 
        "paper": 1, 
        "tag_id": "erb-a8fa7629-0782-4cfe-9b75-045f3455f04a"
    }
},
{
    "pk": 5529, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 293. Li Y, Wang LX, Pang P, et al: Tumor-derived autophagosome vaccine: mechanism of cross-presenta", 
        "paper": 1, 
        "tag_id": "erb-32b942a5-02e0-4643-95cd-c0803a468f71"
    }
},
{
    "pk": 5530, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 294. Liang X, De Vera ME, Buchser WJ, et al: Inhibiting systemic autophagy during interleukin 2 imm", 
        "paper": 1, 
        "tag_id": "erb-ec92a317-ef61-4ab5-ae08-5e9f024b5561"
    }
},
{
    "pk": 5531, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 295. Lotze MT, Buchser WJ, Liang X: Blocking the interleukin 2 (IL2)-induced systemic autophagic sy", 
        "paper": 1, 
        "tag_id": "erb-5602e782-0638-42f5-a98f-496b7fff0864"
    }
},
{
    "pk": 5532, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 296. Ireland A, Millward M, Pearce R, et al: Genetic factors in metastatic progression of cutaneous", 
        "paper": 1, 
        "tag_id": "erb-e63d88e5-d885-4b57-bc89-2ad453e8add8"
    }
},
{
    "pk": 5533, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 297. Tanaka R, Koyanagi K, Narita N, et al: Prognostic molecular biomarkers for cutaneous malignant", 
        "paper": 1, 
        "tag_id": "erb-e760ebaf-0a61-4d3a-8b56-09a27928ea38"
    }
},
{
    "pk": 5534, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 298. Smith B, Selby P, Southgate J, et al: Detection of melanoma cells in peripheral blood by means", 
        "paper": 1, 
        "tag_id": "erb-12c7e762-f24b-48a8-8fcd-c6c89daba911"
    }
},
{
    "pk": 5535, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 299. Mocellin S, Del Fiore P, Guarnieri L, et al: Molecular detection of circulating tumor cells is", 
        "paper": 1, 
        "tag_id": "erb-6cd717ab-abec-4d75-9aa5-f3ac7a83c8e1"
    }
},
{
    "pk": 5536, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 300. Koyanagi K, O'Day SJ, Boasberg P, et al: Serial monitoring of circulating tumor cells predicts", 
        "paper": 1, 
        "tag_id": "erb-49f644c3-1c90-4f16-9178-4e0569697a8f"
    }
},
{
    "pk": 5537, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 301. Hoshimoto S, Faries MB, Morton DL, et al: Assessment of prognostic circulating tumor cells in ", 
        "paper": 1, 
        "tag_id": "erb-f1a06011-bac2-4334-8a7b-7711377ef823"
    }
},
{
    "pk": 5538, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 302. Hoshimoto S, Shingai T, Morton DL, et al: Association between circulating tumor cells and prog", 
        "paper": 1, 
        "tag_id": "erb-55ba7bdc-bde2-4c36-9f98-d7de53a95acc"
    }
},
{
    "pk": 5539, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 303. Reid AL, Millward M, Pearce R, et al: Markers of circulating tumour cells in the peripheral bl", 
        "paper": 1, 
        "tag_id": "erb-467c29e6-34f3-477e-af05-9f01389b8485"
    }
},
{
    "pk": 5540, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 304. Fusi A, Liu Z, Kummerlen V, et al: Expression of chemokine receptors on circulating tumor cell", 
        "paper": 1, 
        "tag_id": "erb-76874611-a15d-4f57-82c7-564306d1230f"
    }
},
{
    "pk": 5541, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 305. Khoja L, Lorigan P, Zhou C, et al: Biomarker Utility of Circulating Tumor Cells in Metastatic ", 
        "paper": 1, 
        "tag_id": "erb-86e71e09-a10a-4462-a32a-8096d876ed3e"
    }
},
{
    "pk": 5542, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 306. Le Rhun E, Tu Q, De Carvalho Bittencourt M, et al: Detection and quantification of CSF maligna", 
        "paper": 1, 
        "tag_id": "erb-23ede70c-15a0-4eeb-8966-df15cf1cbeb1"
    }
},
{
    "pk": 5543, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 307. De Giorgi V, Pinzani P, Salvianti F, et al: Application of a filtration- and isolation-by-size", 
        "paper": 1, 
        "tag_id": "erb-edad9c6f-a1e0-4a19-ad3a-87ed381527d0"
    }
},
{
    "pk": 5544, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 308. De Giorgi V, Pinzani P, Salvianti F, et al: Circulating benign nevus cells detected by ISET te", 
        "paper": 1, 
        "tag_id": "erb-d68e66a7-8cb6-49a9-8b5f-24bf67419adc"
    }
},
{
    "pk": 5545, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 309. Galanzha EI, Shashkov EV, Spring PM, et al: In vivo, noninvasive, label-free detection and era", 
        "paper": 1, 
        "tag_id": "erb-0f3203db-6426-4ea9-af66-ec72bd9685d6"
    }
},
{
    "pk": 5546, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 310. O'Brien CM, Rood KD, Bhattacharyya K, et al: Capture of circulating tumor cells using photoaco", 
        "paper": 1, 
        "tag_id": "erb-fe3e5b7c-6607-4b3b-b5cf-0843094bb408"
    }
},
{
    "pk": 5547, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 311. Hou S, Zhao L, Shen Q, et al: Polymer nanofiber-embedded microchips for detection, isolation, ", 
        "paper": 1, 
        "tag_id": "erb-5bfe48b3-6dd0-40fb-9061-419ac0d4fe4b"
    }
},
{
    "pk": 5548, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 312. Ozkumur E, Shah AM, Ciciliano JC, et al: Inertial focusing for tumor antigen-dependent and -in", 
        "paper": 1, 
        "tag_id": "erb-b6664c95-121b-4cc6-8d60-dfa0df96b52b"
    }
},
{
    "pk": 5549, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 313. Adebayo Awe J, Xu MC, Wechsler J, et al: Three-Dimensional Telomeric Analysis of Isolated Circ", 
        "paper": 1, 
        "tag_id": "erb-4c61c16e-49bb-4c32-b1a3-f665d3af3694"
    }
},
{
    "pk": 5550, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 314. Fusi A, Berdel R, Havemann S, et al: Enhanced detection of BRAF-mutants by pre-PCR cleavage of", 
        "paper": 1, 
        "tag_id": "erb-48f0224a-e7a4-48a0-8554-188102d6fcb3"
    }
},
{
    "pk": 5551, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 315. Sakaizawa K, Goto Y, Kiniwa Y, et al: Mutation analysis of BRAF and KIT in circulating melanom", 
        "paper": 1, 
        "tag_id": "erb-1bb46d58-078b-48c9-95b0-a261d81c87af"
    }
},
{
    "pk": 5552, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 316. Dawson SJ, Tsui DW, Murtaza M, et al: Analysis of circulating tumor DNA to monitor metastatic ", 
        "paper": 1, 
        "tag_id": "erb-08299af8-a24b-4f20-87d3-c98f48c82c13"
    }
},
{
    "pk": 5553, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 317. Murtaza M, Dawson SJ, Tsui DW, et al: Non-invasive analysis of acquired resistance to cancer t", 
        "paper": 1, 
        "tag_id": "erb-bba2420a-a207-4532-b6a1-2aef7c6aa709"
    }
},
{
    "pk": 5554, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 318. Harbour JW, Chen R: The DecisionDx-UM Gene Expression Profile Test Provides Risk Stratificatio", 
        "paper": 1, 
        "tag_id": "erb-55b6195d-650d-4ad4-b81a-eaf308076c11"
    }
},
{
    "pk": 5555, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 319. Ohno S, Ishikawa A, Kuroda M: Roles of exosomes and microvesicles in disease pathogenesis. Adv", 
        "paper": 1, 
        "tag_id": "erb-e9ba2891-279a-4183-b6a6-3b1a353df9a9"
    }
},
{
    "pk": 5556, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": " 320. Peinado H, Aleckovic M, Lavotshkin S, et al: Melanoma exosomes educate bone marrow progenitor ", 
        "paper": 1, 
        "tag_id": "erb-60ccf06f-ad35-4c38-b5f3-25416312b10b"
    }
},
{
    "pk": 5557, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "Chaperone Hsp90 is required for the stability of several of the oncoproteins that mediate RAF inhibi", 
        "paper": 1, 
        "tag_id": "erb-60130f4e-e3e4-4b44-97f7-577e1a1be17a"
    }
},
{
    "pk": 5559, 
    "model": "er.paperblock", 
    "fields": {
        "position": 0, 
        "preview_text": "mTORC1. Activity of mTORC1 after treatment of melanoma cells in vitro was found to be a faithful pre", 
        "paper": 1, 
        "tag_id": "erb-f23716a5-5cbf-4405-a2bb-f1d715223c25"
    }
},
{
    "pk": 152, 
    "model": "er.papersection", 
    "fields": {
        "position": 0, 
        "paper": 3, 
        "header_text": "INTRODUCTION", 
        "tag_id": "erh-d7a3a627-f300-439d-a4c2-2dba622ca151"
    }
},
{
    "pk": 153, 
    "model": "er.papersection", 
    "fields": {
        "position": 1, 
        "paper": 3, 
        "header_text": "MOLECULAR SUBTYPES", 
        "tag_id": "erh-2d16e0e7-a1a2-49ac-9448-14d3713ceb70"
    }
},
{
    "pk": 154, 
    "model": "er.papersection", 
    "fields": {
        "position": 2, 
        "paper": 3, 
        "header_text": "INTRINSIC RESISTANCE TO BRAF AND MEK INHIBITORS (Table 3)", 
        "tag_id": "erh-00582ad2-5f80-4391-9ebc-6ba1b87ae4d3"
    }
},
{
    "pk": 155, 
    "model": "er.papersection", 
    "fields": {
        "position": 3, 
        "paper": 3, 
        "header_text": "ACQUIRED RESISTANCE TO BRAF AND MEK INHIBITORS (Table 4)", 
        "tag_id": "erh-68694966-6f5e-413b-a797-00bdc8787221"
    }
},
{
    "pk": 156, 
    "model": "er.papersection", 
    "fields": {
        "position": 4, 
        "paper": 3, 
        "header_text": "COMBINATORIAL THERAPIES", 
        "tag_id": "erh-5dd71168-f58a-4e7d-a99f-65f8ba5abc3c"
    }
},
{
    "pk": 157, 
    "model": "er.papersection", 
    "fields": {
        "position": 5, 
        "paper": 3, 
        "header_text": "IMMUNOTHERAPY", 
        "tag_id": "erh-b87d6198-db29-485a-be6c-a9351795c717"
    }
},
{
    "pk": 158, 
    "model": "er.papersection", 
    "fields": {
        "position": 6, 
        "paper": 3, 
        "header_text": "METABOLISM AND AUTOPHAGY AS TARGETS IN MELANOMA THERAPY", 
        "tag_id": "erh-125b182c-3834-45f0-86c1-f58065a0a247"
    }
},
{
    "pk": 159, 
    "model": "er.papersection", 
    "fields": {
        "position": 7, 
        "paper": 3, 
        "header_text": "NEW PROGNOSTIC MARKERS", 
        "tag_id": "erh-406b93a9-9d6c-47e9-b0bf-3ce042f2f20f"
    }
},
{
    "pk": 160, 
    "model": "er.papersection", 
    "fields": {
        "position": 8, 
        "paper": 3, 
        "header_text": "CONCLUDING REMARKS", 
        "tag_id": "erh-bea4a42a-fd00-4aa3-b71e-331bb7aca6fe"
    }
},
{
    "pk": 161, 
    "model": "er.papersection", 
    "fields": {
        "position": 9, 
        "paper": 3, 
        "header_text": "REFERENCES", 
        "tag_id": "erh-63096cf1-4daf-4b19-916c-09012502806d"
    }
},
{
    "pk": 173, 
    "model": "er.papersection", 
    "fields": {
        "position": 0, 
        "paper": 1, 
        "header_text": "Introduction", 
        "tag_id": "erh-1f63a7a2-7eb8-4c7d-b68f-e742b0c448fe"
    }
},
{
    "pk": 174, 
    "model": "er.papersection", 
    "fields": {
        "position": 1, 
        "paper": 1, 
        "header_text": "Molecular subtypes", 
        "tag_id": "erh-2869d8e5-6721-401b-81b8-f35a96487ad7"
    }
},
{
    "pk": 175, 
    "model": "er.papersection", 
    "fields": {
        "position": 2, 
        "paper": 1, 
        "header_text": "Intrinsic resistance to BRAF and MEK inhibitors", 
        "tag_id": "erh-885f8fad-b845-4050-aef0-c4ea92f6c88a"
    }
},
{
    "pk": 178, 
    "model": "er.papersection", 
    "fields": {
        "position": 4, 
        "paper": 1, 
        "header_text": "Acquired resistance to BRAF and MEK inhibitors", 
        "tag_id": "erh-1790630e-e1a9-4921-a099-a554732ba516"
    }
},
{
    "pk": 179, 
    "model": "er.papersection", 
    "fields": {
        "position": 5, 
        "paper": 1, 
        "header_text": "Combinatorial Therapies", 
        "tag_id": "erh-a4edbefd-752d-4839-bb51-0fd43b105df4"
    }
},
{
    "pk": 180, 
    "model": "er.papersection", 
    "fields": {
        "position": 6, 
        "paper": 1, 
        "header_text": "Metabolism and Autophagy\u00a0as Targets in Melanoma Therapy", 
        "tag_id": "erh-27f0edbc-2f21-4059-bf29-4c1b1fd718db"
    }
},
{
    "pk": 181, 
    "model": "er.papersection", 
    "fields": {
        "position": 7, 
        "paper": 1, 
        "header_text": "New Prognostic Markers", 
        "tag_id": "erh-956508a6-47cf-4328-9937-6f384f3787be"
    }
},
{
    "pk": 182, 
    "model": "er.papersection", 
    "fields": {
        "position": 8, 
        "paper": 1, 
        "header_text": "Concluding Remarks", 
        "tag_id": "erh-97bb2e49-2845-4170-a3f7-f62698a70d7e"
    }
},
{
    "pk": 183, 
    "model": "er.papersection", 
    "fields": {
        "position": 9, 
        "paper": 1, 
        "header_text": "References", 
        "tag_id": "erh-c60edfd5-81b9-4717-9196-7a8d28b6fa28"
    }
},
{
    "pk": 184, 
    "model": "er.papersection", 
    "fields": {
        "position": 3, 
        "paper": 1, 
        "header_text": "Intrinsic resistance to MEK inhibitors", 
        "tag_id": "erh-d0af1f47-8119-4057-beb9-bea7b3e46beb"
    }
},
{
    "pk": 31, 
    "model": "er.papertable", 
    "fields": {
        "caption": "Table 1. Pathways Involved In Melanomagenesis", 
        "paper": 3, 
        "tag_id": "erb-87dc1858-b815-4ba2-acc9-2b25f873ee99", 
        "position": 0
    }
},
{
    "pk": 32, 
    "model": "er.papertable", 
    "fields": {
        "caption": "Table\u00a02. Genes Known To Be Altered in Melanoma", 
        "paper": 3, 
        "tag_id": "erb-20be40f0-a1de-4767-88e7-973c6a6dd7ab", 
        "position": 1
    }
},
{
    "pk": 33, 
    "model": "er.papertable", 
    "fields": {
        "caption": "Table 3. Intrinsic Resistance to BRAF and MEK Inhibitors", 
        "paper": 3, 
        "tag_id": "erb-f0991301-5283-4c8b-8344-7ae28f545e0f", 
        "position": 2
    }
},
{
    "pk": 34, 
    "model": "er.papertable", 
    "fields": {
        "caption": "Table 4. Acquired Resistance to BRAF and MEK Inhibitors", 
        "paper": 3, 
        "tag_id": "erb-d00f18de-2707-4a7b-acac-d161399fdd74", 
        "position": 3
    }
},
{
    "pk": 35, 
    "model": "er.papertable", 
    "fields": {
        "caption": "Table 5. Antibody-based immunotherapy of melanoma", 
        "paper": 3, 
        "tag_id": "erb-04f9c5c6-780c-45ca-bc93-beb24a211ae1", 
        "position": 4
    }
},
{
    "pk": 36, 
    "model": "er.papertable", 
    "fields": {
        "caption": "Table 1. Pathways Involved In Melanomagenesis", 
        "paper": 1, 
        "tag_id": "erb-02709731-4df3-4436-ad37-619c5cf5c169", 
        "position": 0
    }
},
{
    "pk": 37, 
    "model": "er.papertable", 
    "fields": {
        "caption": "Table\u00a02. Genes Known To Be Altered in Melanoma", 
        "paper": 1, 
        "tag_id": "erb-5b68f1b2-a05f-4d0f-83a5-8b4ae9a45126", 
        "position": 1
    }
},
{
    "pk": 38, 
    "model": "er.papertable", 
    "fields": {
        "caption": "Table 3. Intrinsic Resistance to BRAF and MEK Inhibitors", 
        "paper": 1, 
        "tag_id": "erb-6269dc15-0dbb-41c4-8751-2a46e69ab1dc", 
        "position": 2
    }
},
{
    "pk": 39, 
    "model": "er.papertable", 
    "fields": {
        "caption": "Table 4. Acquired Resistance to BRAF and MEK Inhibitors", 
        "paper": 1, 
        "tag_id": "erb-c4701a71-1ae7-4194-9643-389381125674", 
        "position": 3
    }
},
{
    "pk": 40, 
    "model": "er.papertable", 
    "fields": {
        "caption": "Table 5. Antibody-based immunotherapy of melanoma", 
        "paper": 1, 
        "tag_id": "erb-d65c659d-6353-46d2-b650-73d7256644ab", 
        "position": 4
    }
},
{
    "pk": 1, 
    "model": "er.author", 
    "fields": {
        "author_without_user": "E. Shtivelman", 
        "author": null
    }
},
{
    "pk": 2, 
    "model": "er.author", 
    "fields": {
        "author_without_user": "K.T. Flaherty", 
        "author": null
    }
},
{
    "pk": 3, 
    "model": "er.author", 
    "fields": {
        "author_without_user": "D.E. Fisher", 
        "author": null
    }
},
{
    "pk": 6, 
    "model": "er.author", 
    "fields": {
        "author_without_user": "M. A. Davies", 
        "author": null
    }
},
{
    "pk": 7, 
    "model": "er.author", 
    "fields": {
        "author_without_user": "P. Hwu", 
        "author": null
    }
},
{
    "pk": 8, 
    "model": "er.author", 
    "fields": {
        "author_without_user": "J. Yang", 
        "author": null
    }
},
{
    "pk": 9, 
    "model": "er.author", 
    "fields": {
        "author_without_user": "M. Lotem", 
        "author": null
    }
},
{
    "pk": 10, 
    "model": "er.author", 
    "fields": {
        "author_without_user": "M. Oren", 
        "author": null
    }
},
{
    "pk": 1, 
    "model": "er.paperauthorship", 
    "fields": {
        "position": 1, 
        "paper": 3, 
        "author": 1
    }
},
{
    "pk": 2, 
    "model": "er.paperauthorship", 
    "fields": {
        "position": 7, 
        "paper": 3, 
        "author": 2
    }
},
{
    "pk": 3, 
    "model": "er.paperauthorship", 
    "fields": {
        "position": 8, 
        "paper": 3, 
        "author": 3
    }
},
{
    "pk": 4, 
    "model": "er.paperauthorship", 
    "fields": {
        "position": 2, 
        "paper": 3, 
        "author": 6
    }
},
{
    "pk": 5, 
    "model": "er.paperauthorship", 
    "fields": {
        "position": 3, 
        "paper": 3, 
        "author": 7
    }
},
{
    "pk": 6, 
    "model": "er.paperauthorship", 
    "fields": {
        "position": 4, 
        "paper": 3, 
        "author": 8
    }
},
{
    "pk": 7, 
    "model": "er.paperauthorship", 
    "fields": {
        "position": 5, 
        "paper": 3, 
        "author": 9
    }
},
{
    "pk": 8, 
    "model": "er.paperauthorship", 
    "fields": {
        "position": 6, 
        "paper": 3, 
        "author": 10
    }
},
{
    "pk": 9, 
    "model": "er.paperauthorship", 
    "fields": {
        "position": 1, 
        "paper": 1, 
        "author": 1
    }
},
{
    "pk": 10, 
    "model": "er.paperauthorship", 
    "fields": {
        "position": 2, 
        "paper": 1, 
        "author": 6
    }
},
{
    "pk": 11, 
    "model": "er.paperauthorship", 
    "fields": {
        "position": 3, 
        "paper": 1, 
        "author": 7
    }
},
{
    "pk": 12, 
    "model": "er.paperauthorship", 
    "fields": {
        "position": 4, 
        "paper": 1, 
        "author": 8
    }
},
{
    "pk": 13, 
    "model": "er.paperauthorship", 
    "fields": {
        "position": 5, 
        "paper": 1, 
        "author": 9
    }
},
{
    "pk": 14, 
    "model": "er.paperauthorship", 
    "fields": {
        "position": 6, 
        "paper": 1, 
        "author": 10
    }
},
{
    "pk": 15, 
    "model": "er.paperauthorship", 
    "fields": {
        "position": 7, 
        "paper": 1, 
        "author": 2
    }
},
{
    "pk": 16, 
    "model": "er.paperauthorship", 
    "fields": {
        "position": 8, 
        "paper": 1, 
        "author": 3
    }
},
{
    "pk": 2, 
    "model": "er.defaultdocument", 
    "fields": {
        "timestamp": "2013-09-29T18:15:50Z", 
        "document": 1
    }
}
]
